Clustering O 0 5.73566057937569e-06
of O 0 3.162902260100964e-07
missense O 0 3.5721157018997474e-06
mutations O 0 2.7045874162467953e-07
in O 0 5.50148868683209e-08
the O 0 5.947777481196681e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 2.4480959837092087e-06
in O 0 2.761667161621517e-08
a O 0 2.9140934998395096e-08
sporadic B-Disease 0 0.00015983340563252568
T I-Disease 1 0.9999922513961792
- I-Disease 0 0.4350823163986206
cell I-Disease 0 0.0032386297825723886
leukaemia I-Disease 0 0.006243987008929253
. O 0 1.7373043874613359e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999994039535522
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.360013315998003e-08
is O 0 1.8474334284590554e-09
a O 0 4.579170820306899e-09
recessive B-Disease 0 1.28943665913539e-05
multi I-Disease 0 0.0006929476512596011
- I-Disease 0 6.553421553689986e-05
system I-Disease 0 1.184093321171531e-06
disorder I-Disease 0 1.9683977825479815e-06
caused O 0 5.820676829415561e-09
by O 0 5.214593756797115e-10
mutations O 0 1.4913535961724733e-09
in O 0 9.230540776172802e-10
the O 0 8.872392598391343e-09
ATM O 0 9.238102620656718e-07
gene O 0 2.4067528414661865e-08
at O 0 1.970917651306081e-07
11q22 O 0 1.1238388424317236e-06
- O 0 5.863602723366057e-07
q23 O 0 1.3155793112673564e-06
( O 0 2.662757481175504e-08
ref O 0 5.222064487497846e-07
. O 0 1.2310628072498275e-08
3 O 0 3.7867368973820703e-07
) O 0 4.7493781352159203e-08
. O 0 8.589943263359601e-07

The O 0 1.2581474493345013e-06
risk O 0 6.027877361702849e-07
of O 0 5.505392550730903e-07
cancer B-Disease 0 3.181632564519532e-05
, O 0 3.867171827209859e-08
especially O 0 1.5378770967799937e-07
lymphoid B-Disease 0 0.3559161424636841
neoplasias I-Disease 0 0.0010701504070311785
, O 0 1.4699198302992045e-08
is O 0 1.8976504811973882e-09
substantially O 0 8.789454497559746e-09
elevated O 0 2.15313278317808e-07
in O 0 1.6006520553446535e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5747642123642436e-07
and O 0 4.236357487030773e-09
has O 0 6.91038948286149e-10
long O 0 4.987877333384461e-10
been O 0 5.761964794182006e-10
associated O 0 1.1966991841916297e-08
with O 0 2.1538633987461253e-08
chromosomal O 1 0.9999997615814209
instability O 1 0.9999997615814209
. O 0 5.642949327011593e-05

By O 0 5.687969633072498e-07
analysing O 0 1.2339056411292404e-05
tumour B-Disease 1 0.9999996423721313
DNA O 0 4.3973520291729074e-07
from O 0 5.801247926484621e-09
patients O 0 2.9596831652156652e-09
with O 0 2.0254320443058305e-09
sporadic B-Disease 0 6.476593171100831e-06
T I-Disease 1 0.976887583732605
- I-Disease 0 0.0002936126256827265
cell I-Disease 0 6.705163104925305e-05
prolymphocytic I-Disease 0 6.200826464919373e-05
leukaemia I-Disease 0 0.23555399477481842
( O 0 1.427418396815483e-07
T B-Disease 0 4.4330081436783075e-05
- I-Disease 0 1.896739718176832e-06
PLL I-Disease 0 7.247839675983414e-06
) O 0 2.635943907591809e-09
, O 0 7.486491426789144e-10
a O 0 2.5362585365229506e-09
rare O 0 1.2762118473119699e-08
clonal B-Disease 0 1.0971364190481836e-06
malignancy I-Disease 0 1.392513240716653e-06
with O 0 1.6816934511609816e-09
similarities O 0 7.657734890642587e-09
to O 0 2.1921289228288288e-09
a O 0 2.032363966009143e-08
mature B-Disease 0 7.916440154076554e-06
T I-Disease 0 0.020580094307661057
- I-Disease 0 1.1482513400551397e-05
cell I-Disease 0 6.579474757018033e-06
leukaemia I-Disease 0 3.376809399924241e-05
seen O 0 2.0579884463245435e-08
in O 0 6.537950181240149e-09
A B-Disease 1 0.9999626874923706
- I-Disease 1 0.8550404906272888
T I-Disease 1 0.9999973773956299
, O 0 2.2417694367504737e-09
we O 0 7.219986275508461e-10
demonstrate O 0 1.082499201388032e-09
a O 0 4.144294629693235e-10
high O 0 8.813141327834728e-09
frequency O 0 2.4008061316749263e-08
of O 0 1.159210505363717e-08
ATM O 0 6.98326914516656e-07
mutations O 0 7.76057689222398e-08
in O 0 9.448147153534592e-08
T B-Disease 0 0.00022819446166977286
- I-Disease 0 1.713678466330748e-05
PLL I-Disease 0 0.00013449463585857302
. O 0 2.0693737496912945e-06

In O 0 2.695482237413671e-07
marked O 0 1.4440598761211731e-07
contrast O 0 1.758877665736236e-08
to O 0 2.8736175661236985e-09
the O 0 1.534500881916756e-08
ATM O 0 1.7667072143012774e-06
mutation O 0 3.1271593314841084e-08
pattern O 0 9.206266327055346e-08
in O 0 2.0565522618198884e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 7.764778153784846e-09
the O 0 7.667317891701941e-10
most O 0 8.479711377518129e-11
frequent O 0 1.4680634485841892e-10
nucleotide O 0 1.0369824998690547e-09
changes O 0 6.070301483696028e-10
in O 0 2.1446579234751795e-10
this O 0 3.259477410200162e-10
leukaemia B-Disease 0 3.376905794993945e-07
were O 0 4.162741618074506e-08
missense O 0 1.7635861695453059e-06
mutations O 0 3.2638595257594716e-06
. O 0 5.314028385328129e-06

These O 0 2.6894943516708736e-07
clustered O 0 3.1247836318470945e-07
in O 0 3.3025144841047904e-09
the O 0 4.566375721992699e-09
region O 0 2.8228137605168513e-09
corresponding O 0 3.284623462107561e-09
to O 0 2.501456375370026e-09
the O 0 9.32728205782496e-09
kinase O 0 3.8069995156320147e-08
domain O 0 4.13673095778222e-09
, O 0 1.9075964419190683e-10
which O 0 1.4803623604731087e-10
is O 0 1.0546872403205398e-10
highly O 0 1.1442894409796622e-09
conserved O 0 4.912377171706339e-09
in O 0 2.5173325646221656e-09
ATM O 0 1.2657220622713794e-06
- O 0 4.69024250548955e-08
related O 0 1.4659292668639523e-09
proteins O 0 2.0329318783929295e-10
in O 0 6.53637588499123e-10
mouse O 0 1.2692109585543676e-08
, O 0 3.0279403429034346e-09
yeast O 0 2.2961899048823398e-07
and O 0 1.0766604674472546e-07
Drosophila O 0 1.9621459159679944e-06
. O 0 1.3670692169398535e-06

The O 0 1.4456928738582064e-06
resulting O 0 1.305004047935654e-06
amino O 0 5.673899750036071e-07
- O 0 1.3881719951314153e-07
acid O 0 1.2509024038820371e-08
substitutions O 0 3.8327474527477534e-08
are O 0 2.138756505232209e-09
predicted O 0 6.122328954916156e-08
to O 0 7.517173550297684e-09
interfere O 0 7.164339166365608e-08
with O 0 7.86188358858908e-09
ATP O 0 7.666354576940648e-06
binding O 0 4.318142998727126e-08
or O 0 1.021876272488953e-08
substrate O 0 4.8963464394091716e-08
recognition O 0 6.89652992491574e-08
. O 0 9.310015229857527e-07

Two O 0 2.623381760713528e-07
of O 0 2.504029055216961e-07
seventeen O 0 1.2480591067287605e-06
mutated O 0 1.2425722388798022e-06
T B-Disease 0 4.5141605369281024e-05
- I-Disease 0 2.1099665445944993e-06
PLL I-Disease 0 5.3473982006835286e-06
samples O 0 7.849012995109206e-09
had O 0 3.949766735900084e-09
a O 0 2.1574146913394543e-09
previously O 0 4.29168736104657e-08
reported O 0 2.1037068620444188e-07
A B-Disease 1 0.999935507774353
- I-Disease 1 0.9990296363830566
T I-Disease 1 0.9999996423721313
allele O 0 7.50180843169801e-05
. O 0 6.191123702592449e-06

In O 0 9.920022847609289e-08
contrast O 0 4.4934310494681995e-08
, O 0 4.6711794432496845e-09
no O 0 2.8098197102366385e-09
mutations O 0 1.2686010464335595e-08
were O 0 4.099656170097887e-09
detected O 0 2.7587701012521393e-09
in O 0 8.118097860609907e-10
the O 0 1.554446127371989e-09
p53 O 0 5.596452190559376e-09
gene O 0 5.930195001724314e-09
, O 0 1.0144071138640243e-09
suggesting O 0 3.5934646369639722e-09
that O 0 4.058497149461715e-10
this O 0 2.9666744616463347e-09
tumour B-Disease 1 1.0
suppressor O 0 1.6199319361476228e-05
is O 0 1.053827136665575e-09
not O 0 4.495912808710756e-10
frequently O 0 1.3011612898239378e-09
altered O 0 1.1380649311831803e-08
in O 0 2.478380389803192e-09
this O 0 1.0490706969790153e-08
leukaemia B-Disease 0 2.5080371415242553e-05
. O 0 1.6896636907404172e-06

Occasional O 0 5.032802164350869e-06
missense O 0 1.041656196321128e-05
mutations O 0 3.616484036683687e-07
in O 0 3.451692265343809e-08
ATM O 0 1.7980844859266654e-05
were O 0 5.284769244440213e-08
also O 0 1.9719124111361452e-09
found O 0 2.1587853726856565e-09
in O 0 5.0182351607475084e-09
tumour B-Disease 1 0.9999973773956299
DNA O 0 8.001642015642574e-08
from O 0 2.3975652574392825e-09
patients O 0 1.3257595021798352e-09
with O 0 1.587598053021111e-09
B B-Disease 0 2.9525426725740544e-05
- I-Disease 0 5.861137196916388e-06
cell I-Disease 0 1.2044332834193483e-05
non I-Disease 0 6.24727617832832e-05
- I-Disease 0 6.0308640968287364e-05
Hodgkins I-Disease 1 0.9999539852142334
lymphomas I-Disease 0 8.83431584952632e-06
( O 0 8.378641780382168e-09
B B-Disease 0 2.175540032567369e-07
- I-Disease 0 1.303952057440938e-08
NHL I-Disease 0 7.271513879913982e-08
) O 0 4.468691805481484e-10
and O 0 3.6972847006211396e-10
a O 0 2.1948483031053456e-09
B B-Disease 0 4.0507026710656646e-07
- I-Disease 0 1.6870779973032768e-07
NHL I-Disease 0 2.8748308977810666e-06
cell O 0 1.9575143141992157e-06
line O 0 9.331020009994972e-07
. O 0 1.0234923593088752e-06

The O 0 1.328481715745511e-07
evidence O 0 6.199698532327602e-08
of O 0 4.983097046107332e-09
a O 0 6.273155883640413e-10
significant O 0 8.279728569426936e-10
proportion O 0 3.151912730814388e-09
of O 0 1.4676449389128265e-08
loss O 0 4.979166874363727e-07
- O 0 1.440189691948035e-07
of O 0 7.940493418345795e-08
- O 0 6.103510941102286e-08
function O 0 6.9348859987883316e-09
mutations O 0 4.045183743528469e-09
and O 0 6.754895531813077e-10
a O 0 5.240557987562511e-10
complete O 0 6.051727119427142e-09
absence O 0 2.4043623980674056e-08
of O 0 6.114974748783197e-09
the O 0 9.080937113381538e-10
normal O 0 1.6085258680575976e-09
copy O 0 5.6194275899201784e-09
of O 0 3.0304132536684847e-09
ATM O 0 8.145620711275114e-08
in O 0 1.2003539273663932e-09
the O 0 1.7526983198123958e-09
majority O 0 1.7936704344023724e-09
of O 0 2.7501975807808776e-08
mutated O 0 1.2764122629960184e-06
tumours B-Disease 1 1.0
establishes O 0 1.8153551195609907e-07
somatic O 0 2.850403291176917e-07
inactivation O 0 3.299803097434051e-07
of O 0 1.3261673537101615e-08
this O 0 1.173335206772208e-09
gene O 0 2.7301108040944655e-09
in O 0 1.837158869477662e-09
the O 0 8.73313865668024e-09
pathogenesis O 0 2.5208014449162874e-06
of O 0 1.4323806851734844e-07
sporadic B-Disease 0 0.00040817484841682017
T I-Disease 1 0.9999831914901733
- I-Disease 0 0.008093294687569141
PLL I-Disease 0 2.1372776245698333e-05
and O 0 4.617163540387992e-09
suggests O 0 4.197933556326916e-09
that O 0 4.083562377132921e-10
ATM O 0 1.8037754045963084e-07
acts O 0 9.36939859030872e-09
as O 0 8.521794825355755e-09
a O 0 4.854278401467127e-08
tumour B-Disease 1 1.0
suppressor O 0 0.0006327003939077258
. O 0 6.900556400069036e-06

As O 0 2.578530882146879e-07
constitutional O 0 7.665335601814149e-07
DNA O 0 8.02028310431524e-08
was O 0 8.26537416287465e-09
not O 0 4.2156800272863393e-10
available O 0 1.2901716361923832e-09
, O 0 1.5581091972194372e-09
a O 0 7.624534781314196e-09
putative O 0 7.485141395591199e-07
hereditary O 0 0.000765958393458277
predisposition O 0 2.4455139282508753e-05
to O 0 4.3610366446955595e-06
T B-Disease 1 0.9999998807907104
- I-Disease 1 0.9998180270195007
PLL I-Disease 0 0.0010919403284788132
will O 0 9.828469593742284e-09
require O 0 4.080605631173739e-09
further O 0 1.005914640472838e-08
investigation O 0 3.4673966808895784e-08
. O 0 1.346267985979921e-08
. O 0 2.7220562515140045e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 3.3176587749039754e-05
kinase O 0 1.2077445035174605e-06
is O 0 7.090150133670647e-10
involved O 0 5.171724715147263e-10
in O 0 1.1199027122321681e-10
the O 0 6.691662779445551e-10
modulation O 0 7.967372539496864e-09
of O 0 9.273209977678221e-10
the O 0 1.1947121070221556e-09
Ca2 O 0 3.122915259723413e-08
+ O 0 1.031940399798259e-07
homeostasis O 0 5.209877826928277e-07
in O 0 2.1732212474034895e-08
skeletal O 0 1.5477244232897647e-05
muscle O 0 3.6485630516835954e-06
cells O 0 1.4231533896236215e-05
. O 0 2.1673697574442485e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999810457229614
DM B-Disease 1 1.0
) O 0 2.401473295776668e-07
, O 0 4.720206003838712e-09
the O 0 3.5269058784592744e-09
most O 0 4.148527743552677e-09
prevalent O 0 2.100532037729863e-05
muscular B-Disease 1 0.9999983310699463
disorder I-Disease 0 0.0770663172006607
in O 0 7.814267455330537e-09
adults O 0 1.0061621757984085e-08
, O 0 5.947580206111525e-10
is O 0 2.055483422358506e-10
caused O 0 7.704939797292809e-09
by O 0 7.093549303505142e-09
( O 0 1.868302490493079e-08
CTG O 0 4.271575562597718e-06
) O 0 8.117265082319136e-09
n O 0 9.195930772420979e-08
- O 0 1.3708426394032358e-08
repeat O 0 4.330488412307432e-09
expansion O 0 3.7205465375222957e-09
in O 0 3.563268291539856e-10
a O 0 8.056704192682673e-10
gene O 0 1.7067075530619036e-09
encoding O 0 2.222246919814097e-08
a O 0 1.3744031690521297e-08
protein O 0 1.1904936059181637e-07
kinase O 0 6.621375518989225e-07
( O 0 6.82318130884596e-08
DM B-Disease 1 0.9969757795333862
protein O 0 4.888713078798901e-08
kinase O 0 3.153537875277834e-08
; O 0 2.2321522408219607e-09
DMPK O 0 1.5063493492561975e-06
) O 0 1.340172417485519e-09
and O 0 5.992969454027275e-10
involves O 0 1.0497267499687268e-09
changes O 0 2.2228476836971822e-09
in O 0 2.7734952112723477e-09
cytoarchitecture O 0 5.368513598114077e-07
and O 0 4.6010075749336465e-08
ion O 0 1.970629637071397e-05
homeostasis O 0 0.0001649936893954873
. O 0 7.0805463110446e-06

To O 0 6.161068455412533e-08
obtain O 0 9.996815464319297e-08
clues O 0 2.0604339567853458e-07
to O 0 1.875825050845492e-09
the O 0 2.179205482732982e-09
normal O 0 5.055269092224535e-09
biological O 0 1.1269578159556204e-08
role O 0 9.129620615055956e-09
of O 0 2.823590605771642e-08
DMPK O 0 1.0072558325191494e-05
in O 0 4.4114145225648826e-08
cellular O 0 4.7195334218486096e-07
ion O 0 2.4396058506681584e-06
homeostasis O 0 7.236009423650103e-06
, O 0 4.218320359683503e-09
we O 0 2.785726316290038e-09
have O 0 6.91786683493234e-10
compared O 0 2.199630255717011e-09
the O 0 1.9791472904984175e-09
resting O 0 4.301365663650358e-08
[ O 0 9.928196043063053e-09
Ca2 O 0 6.305055144650851e-09
+ O 0 1.12265849949722e-08
] O 0 6.380204364830888e-09
i O 0 2.0314678828015076e-09
, O 0 3.0451463572944704e-10
the O 0 4.89706997175432e-10
amplitude O 0 9.164234704428509e-09
and O 0 4.2019529522541177e-10
shape O 0 2.5165801886828376e-08
of O 0 2.069482007982515e-08
depolarization O 0 9.368597631009834e-08
- O 0 4.9218893849456435e-08
induced O 0 1.665440407805363e-08
Ca2 O 0 2.690222267176523e-08
+ O 0 6.324895451825796e-08
transients O 0 6.186680678865741e-08
, O 0 7.354303277473662e-10
and O 0 3.9147685093610107e-10
the O 0 8.990303501654751e-10
content O 0 2.3579780350502233e-09
of O 0 1.0029949315537579e-08
ATP O 0 1.5643909136997536e-06
- O 0 1.7195398882563495e-08
driven O 0 6.052015333324334e-09
ion O 0 1.039708621419777e-07
pumps O 0 5.302024419506779e-08
in O 0 1.8608339757975045e-08
cultured O 0 4.794142682840175e-07
skeletal O 0 9.495350923316437e-07
muscle O 0 2.3334566279231694e-08
cells O 0 3.498873724083751e-08
of O 0 2.1030142960398734e-08
wild O 0 6.930284346395865e-09
- O 0 4.244526508045965e-09
type O 0 4.443688528255052e-09
and O 0 4.8454507073358855e-09
DMPK O 0 9.521207175566815e-06
[ O 0 2.7355054044164717e-07
- O 0 2.492400312803511e-07
/ O 0 7.544193749708938e-07
- O 0 4.037943881485262e-07
] O 0 7.547842528765614e-07
knockout O 0 0.0009391892817802727
mice O 0 1.5666348190279678e-05
. O 0 3.3575145153008634e-06

In O 0 4.037268809042871e-06
vitro O 0 7.312485195143381e-06
- O 0 2.850704731827136e-06
differentiated O 0 3.0713745218236e-06
DMPK O 0 3.433165329624899e-05
[ O 0 2.175030886064633e-06
- O 0 2.4256905817310326e-06
/ O 0 3.297951479908079e-06
- O 0 8.640390660730191e-07
] O 0 2.3157045347943495e-07
myotubes O 0 9.357503927276412e-07
exhibit O 0 1.3470642379331821e-08
a O 0 5.422467808102738e-09
higher O 0 6.581869627098058e-08
resting O 0 2.1047002007890114e-07
[ O 0 4.798145170070711e-08
Ca2 O 0 2.9217851249541127e-08
+ O 0 2.451910319223316e-08
] O 0 1.9688167540721224e-08
i O 0 5.300454297696433e-09
than O 0 8.692718211911199e-10
do O 0 2.8523428063920164e-09
wild O 0 1.0504361824814623e-08
- O 0 1.1238924457757093e-08
type O 0 1.178530339984718e-08
myotubes O 0 1.4871537246108346e-07
because O 0 8.421817687676025e-10
of O 0 1.7620904735338172e-09
an O 0 1.4024158223602257e-10
altered O 0 2.6232744865239965e-09
open O 0 9.768310604840735e-09
probability O 0 1.2153937412051619e-08
of O 0 1.7453798406563692e-08
voltage O 0 1.0399660368420882e-06
- O 0 1.613368283415184e-07
dependent O 0 2.7421572568187003e-08
l O 0 6.749968406438711e-08
- O 0 6.962479925931575e-09
type O 0 6.812761910168774e-09
Ca2 O 0 1.3576397783765515e-08
+ O 0 2.543114163700011e-08
and O 0 1.3355925254643353e-08
Na O 0 5.983598043712846e-07
+ O 0 8.267474527201557e-08
channels O 0 2.4047483293543337e-07
. O 0 2.4185385427699657e-07

The O 0 1.8076739252137486e-06
mutant O 0 5.626091933663702e-06
myotubes O 0 4.698238626588136e-06
exhibit O 0 4.5812612370355055e-08
smaller O 0 1.7859049350477108e-08
and O 0 1.0939654515595976e-08
slower O 0 5.861858198841219e-08
Ca2 O 0 4.23151433892599e-08
+ O 0 1.3641081153537016e-08
responses O 0 6.68130717418336e-10
upon O 0 1.886902190051387e-09
triggering O 0 1.3871392923192616e-08
by O 0 1.13675835411442e-09
acetylcholine O 0 1.8802570167508748e-08
or O 0 8.316293431676058e-09
high O 0 3.301351014783904e-08
external O 0 2.1073252298720035e-07
K O 0 7.841936167096719e-07
+ O 0 3.973419495650887e-07
. O 0 4.760324827657314e-07

In O 0 9.419070323701817e-08
addition O 0 1.2964403772741662e-08
, O 0 2.390843079069782e-09
we O 0 1.5589950441707856e-09
observed O 0 9.684305579682473e-10
that O 0 6.397928714596546e-11
these O 0 3.156314654084724e-10
Ca2 O 0 5.005561831694649e-08
+ O 0 1.4679451965093904e-07
transients O 0 9.741224005210825e-08
partially O 0 4.361040861766696e-09
result O 0 9.520207955304727e-10
from O 0 2.3513346825154713e-10
an O 0 8.223677988583589e-11
influx O 0 1.0654565008039185e-09
of O 0 7.561593129423727e-09
extracellular O 0 2.88142363302768e-08
Ca2 O 0 2.2107055741571457e-08
+ O 0 1.1111229269999967e-08
through O 0 9.798235556246482e-10
the O 0 1.9515131732816826e-09
l O 0 2.1284453310954632e-08
- O 0 2.651413977261541e-09
type O 0 4.154854682525411e-09
Ca2 O 0 6.508776095870417e-08
+ O 0 9.202141626474258e-08
channel O 0 2.702681740629487e-07
. O 0 2.611544402952859e-07

Neither O 0 4.4358598643157165e-06
the O 0 9.95592444041904e-08
content O 0 1.724558806870391e-08
nor O 0 3.007990656556103e-08
the O 0 3.0312630183715328e-09
activity O 0 7.1764945097640975e-09
of O 0 1.6643671330029974e-08
Na O 0 1.6425364037786494e-06
+ O 0 2.490917552222527e-07
/ O 0 3.1255137855623616e-07
K O 0 5.20059018072061e-07
+ O 0 3.507012422687694e-07
ATPase O 0 1.8892891375799081e-06
and O 0 8.37423570487772e-08
sarcoplasmic O 0 1.8637415450939443e-06
reticulum O 0 6.976226814003894e-07
Ca2 O 0 1.1878323675773572e-06
+ O 0 1.6107790088426555e-06
- O 0 2.511244190372963e-07
ATPase O 0 2.6841388489629026e-07
are O 0 1.341520228237414e-09
affected O 0 6.810306985016723e-09
by O 0 9.018577884489787e-09
DMPK O 0 3.239460420445539e-05
absence O 0 8.157689990184736e-06
. O 0 6.011779078107793e-06

In O 0 1.985917350566524e-07
conclusion O 0 4.4064449866709765e-07
, O 0 6.6335021919883275e-09
our O 0 5.96545435271878e-09
data O 0 2.321062231303017e-09
suggest O 0 3.115304680889608e-09
that O 0 5.91180604470054e-10
DMPK O 0 1.4772408576391172e-06
is O 0 1.882312083978377e-09
involved O 0 3.0539364370696376e-09
in O 0 2.141658850263184e-09
modulating O 0 1.0920832949068426e-07
the O 0 3.646609014751334e-09
initial O 0 1.2051651232525273e-08
events O 0 5.800429025981657e-09
of O 0 2.520624953206152e-08
excitation O 0 4.7822861233726144e-05
- O 0 7.328123047045665e-06
contraction O 0 2.1629496416153415e-07
coupling O 0 2.3269461735253572e-07
in O 0 4.294930278092579e-08
skeletal O 0 3.4772885555867106e-05
muscle O 0 1.1430148560975795e-06
. O 0 2.0881022066987498e-07
. O 0 9.60546572059684e-07

Constitutional O 0 0.0006674400647170842
RB1 O 0 0.16563138365745544
- O 0 1.2253382919880096e-05
gene O 0 5.3077712891536066e-08
mutations O 0 4.054477642512211e-08
in O 0 4.956914434472992e-09
patients O 0 1.1043682413003353e-08
with O 0 1.1230867791311994e-08
isolated O 0 1.1176460930073517e-06
unilateral B-Disease 0 7.21463147783652e-05
retinoblastoma I-Disease 1 0.9999938011169434
. O 0 0.0011987139005213976

In O 0 5.501357236425974e-07
most O 0 1.59225077567271e-08
patients O 0 5.819811299545563e-09
with O 0 9.454952376586334e-10
isolated O 0 3.5466459991084776e-08
unilateral B-Disease 0 1.5302401834560442e-06
retinoblastoma I-Disease 1 0.9997435212135315
, O 0 1.6221065379795618e-07
tumor B-Disease 0 4.007512416137615e-06
development O 0 5.667880742521447e-08
is O 0 6.795926044134148e-10
initiated O 0 7.902475118726215e-09
by O 0 4.380521501090584e-10
somatic O 0 2.8487884051742185e-08
inactivation O 0 8.079548763362254e-08
of O 0 7.469920682012798e-09
both O 0 1.8536420176573642e-09
alleles O 0 2.6801682651012015e-08
of O 0 5.0490854164308985e-08
the O 0 1.7121116968610295e-07
RB1 O 0 5.897215669392608e-05
gene O 0 2.4810622107906966e-06
. O 0 7.2985089900612365e-06

However O 0 8.443383876510779e-07
, O 0 2.3632876988699536e-08
some O 0 1.2231371471216335e-09
of O 0 2.6953568266208094e-09
these O 0 7.714773819778031e-10
patients O 0 2.8136810659162848e-09
can O 0 3.3067819593668446e-09
transmit O 0 2.227858004744121e-07
retinoblastoma B-Disease 0 2.2659643946099095e-05
predisposition O 0 2.843349875547574e-07
to O 0 1.3478095084451525e-08
their O 0 5.116696399909415e-08
offspring O 0 6.665655973847606e-07
. O 0 1.9135770799039165e-06

To O 0 1.0650408910350961e-07
determine O 0 9.495063579834095e-08
the O 0 7.429949988591034e-09
frequency O 0 8.890080493983987e-08
and O 0 3.3139166966122957e-09
nature O 0 8.402904150273116e-09
of O 0 1.5076478732112264e-08
constitutional O 0 1.9038474192711874e-06
RB1 O 0 0.00010087663395097479
- O 0 2.1037087094555318e-07
gene O 0 3.147442972917247e-09
mutations O 0 3.0653277693915015e-09
in O 0 8.990372335482277e-10
patients O 0 1.0261120841903448e-09
with O 0 4.905895134577065e-10
isolated O 0 2.3497587875453974e-08
unilateral B-Disease 0 3.9562306142215675e-07
retinoblastoma I-Disease 0 0.010257040150463581
, O 0 1.1691850154704753e-08
we O 0 3.548268123765297e-09
analyzed O 0 3.149652982870066e-09
DNA O 0 6.136005037404857e-09
from O 0 1.528975501763341e-09
peripheral O 0 2.1269178773763997e-07
blood O 0 5.668800184821521e-08
and O 0 4.4971010026984004e-08
from O 0 2.7782354194982872e-08
tumor B-Disease 0 1.2600995432876516e-05
tissue O 0 3.913886394002475e-05
. O 0 4.8050460463855416e-06

The O 0 2.9989968197696726e-07
analysis O 0 1.1318913095692551e-07
of O 0 1.6324405294199096e-07
tumors B-Disease 1 0.9999994039535522
from O 0 4.020141730620708e-08
54 O 0 1.9360565772785776e-07
( O 0 9.44178424333586e-09
71 O 0 3.251080116228877e-08
% O 0 1.905103186317092e-09
) O 0 1.5593519808732026e-09
of O 0 8.432317954998325e-09
76 O 0 1.1286898882190144e-07
informative O 0 4.848541124147232e-08
patients O 0 3.14561265923885e-09
showed O 0 1.1136329192140693e-08
loss O 0 9.013834301185852e-08
of O 0 1.4543563509050728e-07
constitutional O 0 2.7941738153458573e-05
heterozygosity O 0 0.11481468379497528
( O 0 4.192121650703484e-06
LOH O 0 0.2866847515106201
) O 0 1.0869608502162009e-07
at O 0 9.873045883068698e-07
intragenic O 0 2.3580687411595136e-05
loci O 0 2.8875398129457608e-05
. O 0 1.4541729797201697e-05

Three O 0 5.555953634939215e-07
of O 0 6.36676816156978e-07
13 O 0 3.1457757359021343e-06
uninformative O 0 0.00032912069582380354
patients O 0 6.103837222326547e-07
had O 0 4.50485316605409e-07
constitutional O 0 1.327318386756815e-05
deletions O 0 5.5434502428397536e-05
. O 0 1.7508551536593586e-05

For O 0 4.625477743047668e-07
39 O 0 7.703546316406573e-07
randomly O 0 1.6347961206975015e-07
selected O 0 7.564798352177604e-07
tumors B-Disease 1 1.0
, O 0 5.649984586852952e-07
SSCP O 0 0.0011967197060585022
, O 0 3.0296291697595734e-07
hetero O 0 1.043485553964274e-05
- O 0 3.283354317318299e-07
duplex O 0 3.3104473118328315e-07
analysis O 0 4.182357127291425e-09
, O 0 1.154789708301962e-09
sequencing O 0 3.940570980631719e-09
, O 0 9.639706810560256e-10
and O 0 2.352546824013757e-09
Southern O 0 3.238497825464037e-08
blot O 0 1.5406544662255328e-07
analysis O 0 6.849569800237987e-09
were O 0 2.6509789918804927e-09
used O 0 1.0503875547129837e-09
to O 0 6.309602618159715e-09
identify O 0 3.743533909528196e-07
mutations O 0 5.693945695384173e-06
. O 0 8.340015483554453e-06

Mutations O 0 4.65905401370037e-07
were O 0 4.016791876892967e-08
detected O 0 1.3671608734000529e-08
in O 0 2.302367185791354e-09
21 O 0 8.319660338429458e-08
( O 0 5.085064369581005e-09
91 O 0 2.5708153827963542e-08
% O 0 2.5234665468332196e-09
) O 0 3.951393878764975e-09
of O 0 5.359092014600719e-08
23 O 0 2.2646981960861012e-05
tumors B-Disease 1 1.0
with O 0 4.019211701233871e-05
LOH O 1 0.9999995231628418
. O 0 3.5635581298265606e-05

In O 0 1.7333478297132388e-07
6 O 0 1.0326309620722895e-06
( O 0 1.1848322323260163e-08
38 O 0 3.403549797553751e-08
% O 0 1.8252589439882172e-09
) O 0 2.6904669603311504e-09
of O 0 2.6492518401255438e-08
16 O 0 5.630981831927784e-06
tumors B-Disease 1 1.0
without O 0 0.0004807933291886002
LOH O 1 0.999963641166687
, O 0 4.0870706818907365e-09
one O 0 1.4029223338596353e-09
mutation O 0 1.8342422025696692e-09
was O 0 4.583810664371413e-09
detected O 0 2.5866071506897015e-09
, O 0 5.746872977496764e-10
and O 0 4.117301499739767e-10
in O 0 7.954507053042903e-10
9 O 0 6.150888509637298e-08
( O 0 1.4695490380134402e-09
56 O 0 7.243093236297682e-09
% O 0 5.567712957343929e-10
) O 0 1.3219516592499758e-09
of O 0 1.6127383872799328e-08
the O 0 2.469857633968786e-07
tumors B-Disease 1 1.0
without O 0 0.050201259553432465
LOH O 1 0.9999963045120239
, O 0 4.362912697786214e-09
both O 0 2.147368949323436e-09
mutations O 0 2.1954313922378788e-08
were O 0 2.7592557572120313e-08
found O 0 7.261147061399242e-08
. O 0 1.445676275579899e-06

Thus O 0 6.056244501451147e-07
, O 0 7.2681691776210755e-09
a O 0 7.471898100241958e-10
total O 0 2.586443281771267e-10
of O 0 1.73672176639883e-09
45 O 0 4.059536706790823e-09
mutations O 0 1.0367378955322692e-08
were O 0 1.0531866934115897e-08
identified O 0 3.643315693580007e-08
in O 0 2.730653925198112e-08
tumors B-Disease 1 1.0
of O 0 0.00017055828357115388
36 O 0 2.4861095880623907e-05
patients O 0 2.290198381160735e-06
. O 0 5.912246251682518e-06

Thirty O 0 2.2833004550193436e-05
- O 0 1.1107013051514514e-06
nine O 0 8.142793461729525e-08
of O 0 1.1428854307382608e-08
the O 0 5.928080692996218e-09
mutations O 0 3.5580494994746914e-08
- O 0 9.696582203844173e-09
including O 0 1.166780672079426e-09
34 O 0 1.918570902148531e-08
small O 0 1.866969245867267e-09
mutations O 0 1.410578054361622e-08
, O 0 3.451578578506087e-09
2 O 0 8.728896716547752e-08
large O 0 6.997200596714492e-09
structural O 0 1.9407179934205487e-06
alterations O 0 9.625098300602986e-07
, O 0 1.0907110770119743e-08
and O 0 1.0529215721533092e-08
hypermethylation O 0 3.25052087646327e-06
in O 0 3.9690714714879505e-08
3 O 0 2.2324922611005604e-05
tumors O 1 1.0
- O 0 1.0012212214860483e-06
were O 0 5.10672926168354e-09
not O 0 1.05754416335202e-09
detected O 0 8.77247163799666e-09
in O 0 1.0793180793555734e-09
the O 0 4.70137306862739e-09
corresponding O 0 3.233757439602414e-08
peripheral O 0 9.351598464490962e-07
blood O 0 1.4354425559304218e-07
DNA O 0 8.169283773895586e-07
. O 0 1.044797272697906e-06

In O 0 3.3296853985120833e-07
6 O 0 2.4746652798057767e-06
( O 0 1.89937505723492e-08
17 O 0 1.9266787276706054e-08
% O 0 8.667321860222899e-10
) O 0 6.857959755635079e-10
of O 0 1.3810902421695914e-09
the O 0 2.012738864465291e-09
36 O 0 1.5453714752311498e-08
patients O 0 5.28627586149355e-10
, O 0 4.443957424271616e-10
a O 0 8.207933777093501e-10
mutation O 0 2.6620501358820547e-09
was O 0 4.706486755878814e-09
detected O 0 6.432121946176039e-09
in O 0 8.48704495570729e-10
constitutional O 0 4.846849321893387e-08
DNA O 0 1.7316189371285873e-08
, O 0 7.970286097780388e-10
and O 0 6.046450562458006e-10
1 O 0 5.898957766703461e-09
of O 0 9.479474982754255e-10
these O 0 2.0634378927741892e-10
mutations O 0 3.828668049266071e-09
is O 0 1.4484216603882771e-10
known O 0 2.307795760048137e-10
to O 0 2.7800348134654485e-10
be O 0 1.9384400751221165e-09
associated O 0 1.3094201278818218e-08
with O 0 4.926648866643291e-09
reduced O 0 6.473089229075413e-07
expressivity O 0 9.12100076675415e-05
. O 0 3.645175638666842e-06

The O 0 7.990386308165398e-08
presence O 0 8.719324817718643e-09
of O 0 9.126035038775626e-09
a O 0 1.4208056953179948e-09
constitutional O 0 3.2159814367105355e-08
mutation O 0 1.2616371058982168e-08
was O 0 4.896791860886651e-09
not O 0 3.4670891158050665e-10
associated O 0 1.246055814085878e-09
with O 0 1.1446402853332316e-10
an O 0 1.744076966181396e-10
early O 0 2.7169487992750874e-08
age O 0 9.593346561587168e-08
at O 0 2.2512534769703052e-07
treatment O 0 2.3682383698542253e-07
. O 0 1.0279646858180058e-06

In O 0 2.6072345349348325e-07
1 O 0 9.036942856255337e-07
patient O 0 9.308482162850851e-08
, O 0 1.3797429865292088e-08
somatic O 0 2.6598850126902107e-06
mosaicism O 0 8.842357601679396e-06
was O 0 7.281326475094829e-08
demonstrated O 0 1.2813753613727386e-08
by O 0 5.96433624711068e-10
molecular O 0 5.973070926756918e-09
analysis O 0 1.0749605650062222e-09
of O 0 9.556722080361624e-10
DNA O 0 7.268862844966861e-09
and O 0 2.0768202713128403e-09
RNA O 0 2.7907374189339862e-08
from O 0 1.029180207723357e-08
peripheral O 0 1.9567714844015427e-06
blood O 0 1.6479448277095798e-06
. O 0 3.0931500987207983e-06

In O 0 3.1742189321448677e-07
2 O 0 9.170652788270672e-07
patients O 0 7.268585289210705e-09
without O 0 2.1785113712979864e-09
a O 0 1.05283459728156e-09
detectable O 0 5.089510679567866e-08
mutation O 0 3.9924699102300565e-09
in O 0 1.0198391020566078e-09
peripheral O 0 7.671552992860597e-08
blood O 0 3.3304502267128555e-08
, O 0 4.39828928833208e-09
mosaicism O 0 1.8341053191761603e-06
was O 0 1.0476109757462382e-08
suggested O 0 1.973323504600444e-09
because O 0 4.786696039538185e-10
1 O 0 1.0677884354493017e-08
of O 0 3.5109855023307546e-09
the O 0 5.298392391495099e-09
patients O 0 1.4629497613327658e-08
showed O 0 9.426975680071337e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 6.648692192356975e-07
the O 0 3.929959646598036e-08
other O 0 2.5618516197312147e-09
later O 0 1.984530939580509e-08
developed O 0 9.644791276741671e-08
bilateral B-Disease 0 3.5774000934907235e-06
retinoblastoma I-Disease 0 0.06993191689252853
. O 0 3.677452468764386e-06

In O 0 1.5494805438720505e-07
conclusion O 0 2.0664300848238781e-07
, O 0 5.280595072321148e-09
our O 0 5.871904296128605e-09
results O 0 6.983293943108038e-09
emphasize O 0 2.6765960559060886e-09
that O 0 1.4776824208695416e-10
the O 0 1.2609171484712078e-09
manifestation O 0 5.356455901051049e-08
and O 0 4.7823545124003886e-09
transmissibility O 0 4.999683937967347e-07
of O 0 4.63841196562953e-08
retinoblastoma B-Disease 0 1.7363056485919515e-06
depend O 0 1.1005012900966449e-08
on O 0 8.168705711852908e-09
the O 0 8.501578330211146e-10
nature O 0 1.9855899147103173e-09
of O 0 1.8027490611416397e-09
the O 0 8.496585102157894e-10
first O 0 1.4068612941287029e-09
mutation O 0 1.4748364751682175e-09
, O 0 3.9093961401448496e-10
its O 0 2.0289844804288748e-10
time O 0 1.6157210014355883e-09
in O 0 6.062849666754744e-10
development O 0 4.312610268897288e-09
, O 0 5.261480140461572e-10
and O 0 3.8416503311822225e-10
the O 0 3.7726169410667865e-10
number O 0 1.2683698535909116e-10
and O 0 1.6650067435897142e-10
types O 0 1.2968773832611191e-09
of O 0 2.3792792180898914e-09
cells O 0 2.2954480538572852e-09
that O 0 2.221202388685839e-10
are O 0 3.5317374025289894e-10
affected O 0 2.7592226281569765e-09
. O 0 1.5714389789422967e-08
. O 0 4.294799396120652e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
of I-Disease 0 0.050957970321178436
the I-Disease 0 2.6820332550414605e-06
fifth I-Disease 0 1.317208898399258e-06
component I-Disease 0 4.993070490399987e-08
of I-Disease 0 2.315156422127984e-08
complement I-Disease 0 3.476415955105949e-08
in O 0 6.900872762116705e-08
man O 0 4.194248958810931e-06
. O 0 1.8649755020305747e-06

I O 0 0.0028173322789371014
. O 0 9.08602523850277e-05

Clinical O 0 0.00022463129425887018
, O 0 3.253586555729271e-07
immunochemical O 0 1.8386326701147482e-05
, O 0 3.894589539754634e-08
and O 0 3.553823901825126e-08
family O 0 3.90430336949521e-08
studies O 0 1.329526071458531e-07
. O 0 1.0090537898577168e-06

The O 0 5.813379289065779e-07
first O 0 8.181916655303212e-08
recognized O 0 6.300525257074696e-08
human O 0 1.5316783219532226e-07
kindred O 0 1.2521084499894641e-05
with O 0 3.4573662333059474e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
of I-Disease 1 0.9636738300323486
the I-Disease 0 4.192441338091157e-06
fifth I-Disease 0 9.021562732414168e-07
component I-Disease 0 3.2821514395209306e-08
of I-Disease 0 6.393399587523163e-08
complement I-Disease 0 2.50432748316598e-07
( O 0 1.937397371420957e-07
C5 O 0 0.12582890689373016
) O 0 2.118106223747418e-08
is O 0 5.793717505753193e-09
described O 0 1.3202959792124602e-07
. O 0 8.329479328494926e-07

The O 0 4.0068744056043215e-06
proband O 0 2.9848508347640745e-05
, O 0 3.720300156828671e-08
a O 0 1.3679225752127877e-08
20 O 0 1.1476478789518296e-07
- O 0 6.694821763630898e-08
year O 0 8.691529274074128e-09
- O 0 6.541919361779946e-08
old O 0 2.0414985613115277e-07
black O 0 6.431707078036197e-08
female O 0 4.9078654029699464e-08
with O 0 1.3531239062558598e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.5320392847061157
age O 0 0.00012017336848657578
11 O 0 1.7380518784193555e-06
, O 0 1.234227386959219e-08
lacked O 0 1.7065901829482755e-06
serum O 0 5.424321329883242e-07
hemolytic O 0 3.7928584788460284e-05
complement O 0 5.7866849090260075e-08
activity O 0 6.431130827877496e-08
, O 0 3.9107557192608056e-09
even O 0 4.846633760990926e-09
during O 0 7.334683971293998e-08
remission O 0 4.4515510921883106e-07
. O 0 3.151926932787319e-07

C5 O 1 0.9463105797767639
was O 0 4.368179816083284e-06
undetectable O 0 2.071923063340364e-06
in O 0 3.812418380988447e-09
her O 0 1.3261084452764749e-09
serum O 0 1.0386299820197564e-08
by O 0 1.4382804947032923e-09
both O 0 1.4848148488511015e-08
immunodiffusion O 0 8.183645149983931e-06
and O 0 5.298647920426447e-07
hemolytic O 1 0.9769080877304077
assays O 0 4.2995347030228004e-05
. O 0 8.165232429746538e-06

Other O 0 2.953019517804023e-08
complement O 0 2.320620851037347e-08
components O 0 4.3416637396376245e-08
were O 0 9.17358988772321e-09
normal O 0 1.6126184831932733e-08
during O 0 6.952447506591852e-09
remission O 0 1.8087945363731706e-08
of O 0 1.2580542829709884e-08
lupus O 0 1.1481123465273413e-06
, O 0 7.031288440373373e-09
but O 0 1.7066595248138583e-08
C1 O 0 8.239306771429256e-05
, O 0 7.138776680903902e-08
C4 O 0 0.0011976798996329308
, O 0 3.342879750789507e-08
C2 O 0 6.700482572341571e-06
, O 0 2.5807839421077006e-08
and O 0 5.988496099007534e-08
C3 O 0 0.013423114083707333
levels O 0 2.370607035118155e-06
fell O 0 1.4906148862792179e-05
during O 0 1.090721411856066e-06
exacerbations O 0 0.00015517622523475438
. O 0 3.3754065498214914e-06

A O 0 8.507743586960714e-06
younger O 0 1.0573798135737889e-05
half O 0 1.3259783600005903e-06
- O 0 1.9026186919290922e-06
sister O 0 1.9041002019548614e-07
, O 0 5.891558796378149e-09
who O 0 5.09654141112037e-09
had O 0 9.689501645482324e-09
no O 0 3.6167143946386204e-08
underlying O 0 0.4523967206478119
disease O 1 0.8993109464645386
, O 0 1.4708901652227269e-08
was O 0 7.773717669579128e-08
also O 0 1.7527717055543235e-09
found O 0 2.615405891859268e-09
to O 0 5.493181465254793e-09
lack O 0 2.1153864508960396e-06
immunochemically O 0 0.0011473114136606455
detectable O 0 0.09432154893875122
C5 O 1 0.9940802454948425
. O 0 1.1254046512476634e-05

By O 0 1.4591007584385807e-06
hemolytic O 0 0.14725057780742645
assay O 0 7.61738010623958e-06
, O 0 3.267067683054847e-08
she O 0 6.3648046833009175e-09
exhibited O 0 2.3447356056749413e-08
1 O 0 9.692998759192051e-08
- O 0 1.1806115196577593e-08
2 O 0 1.3780650398587113e-08
% O 0 2.8433624899015797e-10
of O 0 9.042497861599941e-10
the O 0 1.5678516263051279e-09
normal O 0 2.225623418894429e-08
serum O 0 5.8979932049396666e-08
C5 O 0 7.145763447624631e-06
level O 0 1.0284898621648608e-07
and O 0 1.4762042699345557e-09
normal O 0 1.991571352277788e-09
concentrations O 0 3.080843136160638e-09
of O 0 1.682697647886755e-09
other O 0 6.501734151065364e-10
complement O 0 2.3008933425217037e-08
components O 0 3.03562160297588e-07
. O 0 5.001577392249601e-07

C5 O 0 0.00142299837898463
levels O 0 5.075043532087875e-07
of O 0 4.143286957969394e-08
other O 0 1.5060922509135821e-09
family O 0 7.076639829683984e-10
members O 0 3.73702346845306e-10
were O 0 1.6059722440786572e-09
either O 0 3.747510746165972e-09
normal O 0 4.045146795306209e-08
or O 0 8.30266344564734e-09
approximately O 0 8.383342020579221e-09
half O 0 1.763207535532274e-08
- O 0 2.633156270803738e-08
normal O 0 1.1667879107335466e-08
, O 0 1.4464291986371336e-09
consistent O 0 1.9827073316491806e-08
with O 0 2.0912174214515744e-09
autosomal O 0 3.793264511386951e-07
codominant O 0 4.416710623900144e-07
inheritance O 0 2.6343066394929338e-08
of O 0 1.819760697685524e-08
the O 0 2.8571795596121774e-08
gene O 0 2.951142903384607e-07
determining O 0 5.073762440588325e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00014114435180090368

Normal O 0 0.00011426884157117456
hemolytic O 1 0.9256139397621155
titers O 0 5.3579344239551574e-05
were O 0 7.340744190287296e-08
restored O 0 1.2450686881493311e-07
to O 0 2.778191676711117e-09
both O 0 2.2276577027469102e-08
homozygous O 0 1.4274144632508978e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
deficient I-Disease 1 1.0
( O 0 4.334839559305692e-06
C5D B-Disease 1 1.0
) O 0 1.9462765621369726e-08
sera O 0 1.171416528222835e-07
by O 0 3.049441255065233e-10
addition O 0 2.0401966782657155e-09
of O 0 9.837003211998763e-09
highly O 0 8.493935865772073e-08
purified O 0 4.5857370878366055e-07
human O 0 1.1625227216427447e-06
C5 O 0 0.07206364721059799
. O 0 6.143834070826415e-06

In O 0 1.3049542531007319e-06
specific O 0 1.2230302672833204e-06
C5 O 0 0.1265212595462799
titrations O 0 1.5561159671051428e-05
, O 0 1.1252287990259902e-08
however O 0 3.889569555326489e-09
, O 0 1.3218860450692205e-09
it O 0 2.849464830756432e-10
was O 0 3.464829978483408e-09
noted O 0 4.5250600488877524e-10
that O 0 5.88849732863217e-11
when O 0 3.3571637136908805e-10
limited O 0 6.476090219642572e-10
amounts O 0 1.7460682899539393e-09
of O 0 2.155848477514155e-08
C5 O 0 5.364637036109343e-05
were O 0 4.4052512748748995e-08
assayed O 0 1.308891199869322e-07
in O 0 8.29199320317997e-10
the O 0 8.342185275900249e-10
presence O 0 7.796860379549742e-10
of O 0 4.938211173310947e-09
low O 0 1.1143174560857005e-07
dilutions O 0 2.206860926889931e-06
of O 0 7.836136717287445e-08
either O 0 3.9843746435508365e-07
C5D B-Disease 1 1.0
serum O 0 7.565396913378208e-07
, O 0 1.4064650777356746e-08
curving O 0 1.002513343451028e-07
rather O 0 6.259521789786504e-09
than O 0 2.4506983109517932e-09
linear O 0 6.291374887723578e-08
dose O 0 1.7671473528935167e-07
- O 0 1.6834817984090478e-08
response O 0 1.3692479372551247e-09
plots O 0 5.932491387028449e-09
were O 0 1.9713635168727706e-09
consistently O 0 1.983962327756217e-09
obtained O 0 4.071587067500104e-09
, O 0 7.630844844896956e-10
suggesting O 0 5.603383979035925e-09
some O 0 2.034771684478187e-09
inhibitory O 0 2.460784571667318e-07
effect O 0 4.655615839510574e-07
. O 0 7.764172664792568e-07

Further O 0 3.360229925419844e-07
studies O 0 2.619955630223103e-08
suggested O 0 8.937068862735487e-09
that O 0 7.606257845793607e-10
low O 0 7.592089446006867e-08
dilutions O 0 5.801139195682481e-06
of O 0 7.895312705841206e-07
C5D B-Disease 1 1.0
serum O 0 4.8191850510193035e-08
contain O 0 3.95048971313372e-09
a O 0 1.1007987854583234e-09
factor O 0 5.56536949858355e-09
( O 0 7.141003899313603e-10
or O 0 8.235078174934074e-10
factors O 0 7.627152243117052e-09
) O 0 3.3592149062400267e-09
interfering O 0 1.5540379649792158e-08
at O 0 1.0665326399816877e-08
some O 0 3.2947741757105575e-10
step O 0 2.1004767702947902e-08
in O 0 3.551910987553697e-09
the O 0 2.360620676711278e-08
hemolytic O 0 0.00023495318600907922
assay O 0 2.6856801014218945e-06
of O 0 1.5216091924230568e-06
C5 O 1 0.995669960975647
, O 0 9.326678096499563e-09
rather O 0 2.5617832299928978e-09
than O 0 1.3124599185232455e-09
a O 0 3.7427461130334905e-09
true O 0 1.1551332335102416e-07
C5 O 0 0.0007729826611466706
inhibitor O 0 3.4983015666512074e-06
or O 0 3.278173039689136e-07
inactivator O 0 2.3966895241755992e-05
. O 0 3.511819159029983e-06

Of O 0 1.3746360991717665e-06
clinical O 0 4.557000011118362e-06
interest O 0 5.1009006796221e-08
are O 0 2.502773543966441e-09
( O 0 1.3527355902098748e-09
a O 0 4.781914308971125e-10
) O 0 1.8680831881390247e-10
the O 0 4.284322063785595e-10
documentation O 0 1.6303021155295028e-08
of O 0 5.5378205132683433e-08
membranous O 1 0.999984860420227
glomerulonephritis B-Disease 1 1.0
, O 1 0.53895503282547
vasculitis B-Disease 1 1.0
, O 0 0.0003098025335930288
and O 0 0.05729857087135315
arthritis B-Disease 1 1.0
in O 0 1.637867370618551e-07
an O 0 1.8897294840058976e-09
individual O 0 5.913241896138288e-09
lacking O 0 5.938151298323646e-05
C5 O 1 0.9999676942825317
( O 0 1.7610799929457244e-08
and O 0 2.5258695135477183e-09
its O 0 8.883156987771201e-10
biologic O 0 3.189767738831506e-08
functions O 0 3.73036668221971e-09
) O 0 2.2865195847820985e-10
, O 0 1.493504764304987e-10
and O 0 7.494792564344266e-10
( O 0 1.1114933418099326e-09
b O 0 1.7209506708582012e-08
) O 0 7.052667894136277e-10
a O 0 8.648661231624999e-10
remarkable O 0 8.974922138804686e-09
propensity O 0 1.4379979518253094e-07
to O 0 5.4234632784755377e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.232157569892479e-08
the O 0 2.2138451072351018e-08
proband O 0 7.555756837973604e-07
, O 0 7.544043167939662e-10
even O 0 6.222509174591551e-10
during O 0 1.4199171838313873e-09
periods O 0 5.682133430440217e-09
of O 0 1.799087323561821e-09
low O 0 2.002275323320646e-08
- O 0 3.6665905867039328e-09
dose O 0 1.84712796169606e-08
or O 0 6.2868257266757155e-09
alternate O 0 1.31628169697251e-07
- O 0 2.023377589921438e-07
day O 0 8.370275850211328e-08
corticosteroid O 0 9.370878615300171e-06
therapy O 0 2.102462303810171e-06
. O 0 9.56181338551687e-07

Other O 0 8.803333884088715e-08
observations O 0 9.506661768909908e-08
indicate O 0 1.3631614059761432e-08
that O 0 1.4256023028735854e-09
the O 0 1.1984053749358736e-08
C5D B-Disease 1 0.9999990463256836
state O 0 1.3968824985610695e-09
is O 0 2.0245119469741724e-10
compatible O 0 6.0987610517315716e-09
with O 0 2.9021926528649544e-10
normal O 0 4.994324953599971e-09
coagulation O 0 2.0155328073201417e-08
function O 0 6.53403597894453e-09
and O 0 8.584369326491981e-10
the O 0 1.0281711038118146e-09
capacity O 0 1.3210827098930622e-08
to O 0 2.724991787772524e-09
mount O 0 1.3598810255643912e-06
a O 0 5.298809355736012e-07
neutrophilic O 0 0.08673323690891266
leukocytosis O 0 0.005020680837333202
during O 0 2.6384501325082965e-05
pyogenic B-Disease 0 0.0014607954071834683
infection I-Disease 0 4.2436342482687905e-05
. O 0 4.844187060371041e-07
. O 0 3.4447782581992215e-06

Susceptibility O 0 0.003895792178809643
to O 0 7.640220428584144e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 9.905472325044684e-06
twins O 0 1.066617869582842e-06
: O 0 1.0939773531504215e-09
the O 0 1.822975659315773e-10
role O 0 4.784669882518244e-10
of O 0 7.755494024763721e-10
genes O 0 1.5374063133677396e-09
, O 0 2.679926947024569e-09
HLA O 0 4.1395395555809955e-07
, O 0 4.103223538720613e-09
and O 0 1.3015070798871875e-08
the O 0 6.438101962658038e-08
environment O 0 1.208042817779642e-06
. O 0 9.499462407802639e-07

OBJECTIVE O 0 1.5441004507010803e-05
To O 0 4.062598435439213e-08
determine O 0 6.07751289294356e-08
the O 0 3.4197640275124286e-09
relative O 0 4.166872002997479e-08
effects O 0 2.4210305582528235e-07
of O 0 2.5848629903180154e-08
genetic O 0 5.008541492657059e-08
and O 0 2.7420408166278776e-09
environmental O 0 7.457905404351095e-09
factors O 0 5.419324100586209e-09
in O 0 2.3639896706839636e-09
susceptibility O 0 1.0886597010539845e-06
to O 0 3.769269369513495e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.009076249785721302
AS B-Disease 1 0.9999969005584717
) O 0 4.478235737792602e-08
. O 0 1.913867606617714e-07

METHODS O 0 1.8421182176098228e-05
Twins O 0 8.117429388221353e-06
with O 0 3.6885596799152154e-09
AS B-Disease 1 0.9645769000053406
were O 0 8.052100319844158e-09
identified O 0 2.767191586983131e-09
from O 0 4.821441579316854e-10
the O 0 3.489341704465687e-09
Royal O 0 1.8384781697022845e-06
National O 0 1.0758064490801189e-05
Hospital O 0 6.835139356553555e-05
for O 0 1.698839753316861e-07
Rheumatic B-Disease 1 0.9999995231628418
Diseases I-Disease 1 0.9999997615814209
database O 0 3.81747759092832e-06
. O 0 6.631368705711793e-06

Clinical O 0 3.8399524783017114e-05
and O 0 8.083478775233743e-08
radiographic O 0 3.4055674404953606e-06
examinations O 0 2.652490820764797e-06
were O 0 8.748043178741227e-09
performed O 0 1.1274560174356907e-09
to O 0 3.516586744023442e-10
establish O 0 1.8038539550957466e-08
diagnoses O 0 7.481475677195704e-06
, O 0 3.487121347234279e-08
and O 0 6.973247081987211e-07
disease O 1 0.860296368598938
severity O 0 3.6810764868278056e-05
was O 0 2.224554549457025e-07
assessed O 0 1.9688430441533455e-08
using O 0 8.223761116532557e-10
a O 0 7.196791496077992e-10
combination O 0 5.6112021695753356e-09
of O 0 1.1237874630865008e-08
validated O 0 2.0798307787117665e-07
scoring O 0 3.7320626233849907e-07
systems O 0 8.366395150005701e-07
. O 0 5.485875362865045e-07

HLA O 0 0.000287973991362378
typing O 0 1.220056219608523e-05
for O 0 2.0455482285797189e-07
HLA O 0 8.659934792376589e-06
- O 0 5.856761617906159e-07
B27 O 0 8.026332807276049e-07
, O 0 2.0869348915653063e-08
HLA O 0 6.756698098797642e-07
- O 0 4.170577483364468e-08
B60 O 0 5.8929558122144954e-08
, O 0 2.7974722538459673e-09
and O 0 1.1581453129849706e-08
HLA O 0 1.7426358454031288e-06
- O 0 2.83655197108601e-07
DR1 O 0 1.5836900274734944e-05
was O 0 2.8320046752128292e-08
performed O 0 1.6182376549878086e-09
by O 0 9.547957979805233e-10
polymerase O 0 4.2978314240826876e-08
chain O 0 5.08368724894126e-09
reaction O 0 1.7159841325664615e-09
with O 0 8.475365409488234e-10
sequence O 0 5.68203573081405e-09
- O 0 4.7130268576722756e-09
specific O 0 4.996609237473137e-10
primers O 0 1.0918767223699888e-08
, O 0 1.0171854469831487e-09
and O 0 1.921052428244252e-09
zygosity O 0 2.734269060056249e-07
was O 0 4.484475368826679e-08
assessed O 0 7.591944495288772e-08
using O 0 4.0316752603075656e-08
microsatellite O 0 6.626841695833718e-06
markers O 0 3.7176089335844154e-06
. O 0 7.086653567967005e-06

Genetic O 0 7.898349394963589e-06
and O 0 7.006978819390497e-08
environmental O 0 2.0070892503554205e-08
variance O 0 2.099251261711288e-08
components O 0 7.070993035540596e-08
were O 0 1.6227293286874556e-08
assessed O 0 1.9496537717600404e-08
with O 0 3.7937450403369155e-10
the O 0 1.963059936826994e-09
program O 0 3.792589353679432e-09
Mx O 0 4.5470747522813326e-07
, O 0 3.1656477439412356e-10
using O 0 5.290573534821874e-10
data O 0 9.090728725347219e-10
from O 0 6.225640836188262e-11
this O 0 6.435096899792825e-11
and O 0 3.295666795022356e-10
previous O 0 3.1156195401393916e-09
studies O 0 3.2924891701924253e-09
of O 0 5.658318702472798e-09
twins O 0 1.810254985912252e-07
with O 0 9.281867718868853e-09
AS B-Disease 1 0.9998711347579956
. O 0 3.4578677059471374e-06

RESULTS O 0 9.354459507449064e-06
Six O 0 6.611323897232069e-07
of O 0 1.453915245974713e-07
8 O 0 5.801643055747263e-06
monozygotic O 0 9.79307951638475e-05
( O 0 3.6945786519027024e-07
MZ O 0 0.11186302453279495
) O 0 9.260262601173963e-08
twin O 0 1.379061131956405e-06
pairs O 0 4.840834932906546e-08
were O 0 7.875541996327229e-07
disease O 0 8.567478653276339e-05
concordant O 0 5.441987013909966e-06
, O 0 9.877613393882712e-09
compared O 0 2.2297268476023646e-09
with O 0 3.014224980724123e-10
4 O 0 3.9469668422498216e-08
of O 0 9.643132514725039e-09
15 O 0 4.9362835596866717e-08
B27 O 0 3.202484606390499e-07
- O 0 5.791709156710567e-08
positive O 0 1.6435089733590758e-08
dizygotic O 0 8.105083907139488e-06
( O 0 5.982604989185347e-08
DZ O 0 1.0154287338082213e-05
) O 0 1.5591981039619895e-08
twin O 0 1.1265176880215222e-07
pairs O 0 3.1593401228491302e-09
( O 0 4.0065444295578345e-09
27 O 0 3.006017834650265e-08
% O 0 1.2815605243687855e-09
) O 0 4.4669876131386843e-10
and O 0 1.2421618178493077e-09
4 O 0 3.637677181700383e-08
of O 0 7.003117730164377e-08
32 O 0 2.3071240775607293e-06
DZ O 0 0.0002800833317451179
twin O 0 9.11705797079776e-07
pairs O 0 3.958024574757246e-09
overall O 0 3.6244834689114214e-08
( O 0 3.884943033938271e-09
12 O 0 8.237470261462931e-09
. O 0 9.992842109340927e-10
5 O 0 1.165951513115715e-08
% O 0 1.3074255011957803e-09
) O 0 1.0212509060636421e-08
. O 0 3.9809066265661386e-07

Nonsignificant O 0 0.0001710385549813509
increases O 0 1.1053084847389982e-07
in O 0 4.041312173796996e-09
similarity O 0 4.297386446694418e-09
with O 0 2.240797825070473e-10
regard O 0 9.068145678803319e-10
to O 0 2.440602442366213e-10
age O 0 5.121236412719554e-08
at O 0 6.193623676153948e-07
disease O 0 1.842777010097052e-06
onset O 0 3.3977426028286573e-06
and O 0 2.658888886841737e-09
all O 0 3.7657371665389405e-10
of O 0 1.4523949820599569e-09
the O 0 2.707640778254472e-09
disease O 0 6.964594234659671e-08
severity O 0 7.233653320781741e-08
scores O 0 3.531841841208916e-08
assessed O 0 2.7783201517195266e-08
were O 0 2.2788493314607194e-09
noted O 0 3.87816134761465e-09
in O 0 1.2378816194313913e-08
disease O 0 6.9630921643693e-05
- O 0 9.549170499667525e-06
concordant O 0 0.00021961303718853742
MZ O 1 0.9991044402122498
twins O 0 3.1019119433040032e-06
compared O 0 3.713834217933254e-08
with O 0 3.542346505014393e-08
concordant O 0 0.0003120244655292481
DZ O 1 0.9888074994087219
twins O 0 0.00019609251467045397
. O 0 8.696333679836243e-06

HLA O 0 0.0027157498989254236
- O 0 1.1901129255420528e-05
B27 O 0 1.4470447240455542e-06
and O 0 1.1743567895905471e-08
B60 O 0 3.4721756492217537e-07
were O 0 8.376021654044052e-09
associated O 0 4.449778323589726e-09
with O 0 8.382090577185863e-10
the O 0 1.1925203935447826e-08
disease O 0 2.5770265210667276e-07
in O 0 2.1477499778654874e-09
probands O 0 1.5498072798436624e-06
, O 0 1.6350192311165301e-09
and O 0 9.452717497637764e-10
the O 0 9.355107799535745e-10
rate O 0 5.616973552946547e-09
of O 0 8.935090889394814e-09
disease O 0 1.8654044708910078e-07
concordance O 0 7.06923941606874e-08
was O 0 1.0973132624769733e-08
significantly O 0 4.405980469357473e-09
increased O 0 1.0010379192237906e-08
among O 0 3.6519214319241655e-08
DZ O 0 0.000201165588805452
twin O 0 8.998054568110092e-07
pairs O 0 1.9102883719313013e-09
in O 0 9.316609705933843e-10
which O 0 8.126556094723014e-10
the O 0 7.090437570411723e-09
co O 0 2.5842646778073686e-07
- O 0 3.910608370460977e-08
twin O 0 4.501434602843801e-08
was O 0 6.52651310772967e-09
positive O 0 7.85975062811417e-10
for O 0 1.0397235294945517e-09
both O 0 1.0172402475916442e-08
B27 O 0 1.7816253148339456e-06
and O 0 3.205418011020811e-07
DR1 O 0 0.0014053949853405356
. O 0 3.627122850957676e-06

Additive O 0 1.8511151438360685e-06
genetic O 0 2.9943703339085914e-07
effects O 0 3.01772018929114e-07
were O 0 1.1316944714678812e-08
estimated O 0 9.061230099582929e-10
to O 0 2.1350257672914097e-10
contribute O 0 7.263758483588845e-10
97 O 0 1.588880316205632e-08
% O 0 4.202610204284696e-10
of O 0 1.1799827781544536e-09
the O 0 1.7374937044678518e-09
population O 0 3.9428169062993845e-10
variance O 0 3.923907954117567e-08
. O 0 4.7439954187211697e-07

CONCLUSION O 0 9.891718036669772e-06
Susceptibility O 0 4.9134196160594e-06
to O 0 5.2603819966634546e-08
AS B-Disease 1 0.999950647354126
is O 0 1.4406855708415378e-09
largely O 0 2.923093544993094e-09
genetically O 0 2.3992807740569333e-09
determined O 0 1.2850394526253694e-08
, O 0 2.5662529878900386e-09
and O 0 3.1960813995368653e-09
the O 0 6.886564207775336e-09
environmental O 0 1.757459244799975e-08
trigger O 0 5.2498474900630754e-08
for O 0 8.532984985265557e-09
the O 0 8.773446324994438e-08
disease O 0 1.0863004717975855e-05
is O 0 2.531160170349267e-09
probably O 0 8.972324394562747e-08
ubiquitous O 0 9.228856470144819e-07
. O 0 1.3574102695201873e-06

HLA O 0 0.0019837466534227133
- O 0 1.3430178114504088e-05
B27 O 0 2.2757546958018793e-06
accounts O 0 1.0155304153158795e-08
for O 0 1.218515066625514e-09
a O 0 1.5368932793080603e-09
minority O 0 2.0459602900757545e-09
of O 0 5.094908495095751e-09
the O 0 3.5640312923135298e-09
overall O 0 1.967728024965254e-08
genetic O 0 7.165705540046474e-08
susceptibility O 0 3.7901909877291473e-07
to O 0 1.2099701507395366e-07
AS B-Disease 1 1.0
. O 0 4.743940371554345e-05

Cell O 0 0.00014857501082587987
cycle O 0 4.3628670027828775e-06
- O 0 4.177671542038297e-07
dependent O 0 3.73071742387765e-08
colocalization O 0 1.083804249901732e-06
of O 0 1.1200067717709317e-07
BARD1 O 0 1.3403846423898358e-05
and O 0 3.718157870480354e-08
BRCA1 O 0 9.055519001321954e-08
proteins O 0 3.366873668753101e-09
in O 0 5.188494078822714e-09
discrete O 0 1.8687074998524622e-07
nuclear O 0 1.0596020274533657e-06
domains O 0 1.689244754743413e-06
. O 0 2.3527848043158883e-06

Germ O 0 0.0055043697357177734
- O 0 2.6330884793424048e-05
line O 0 2.9748758834102773e-07
mutations O 0 2.7226240817412872e-08
of O 0 1.619238965133718e-08
the O 0 1.3620178762607793e-08
BRCA1 O 0 1.356902572524632e-07
gene O 0 3.102492129869461e-08
predispose O 0 1.7550115671838284e-07
women O 0 7.410616564840211e-09
to O 0 2.2239079466856992e-09
early O 0 1.8625529264681973e-05
- O 1 0.5743106603622437
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.0303812132406165e-06
compromising O 0 2.309389174115495e-06
the O 0 1.9988753763300338e-08
genes O 0 7.076035757336285e-09
presumptive O 0 1.186650990803173e-07
function O 0 2.954343436556428e-08
as O 0 5.91833071439396e-09
a O 0 1.2237258317782107e-08
tumor B-Disease 0 1.841384005274449e-06
suppressor O 0 6.713243783451617e-05
. O 0 1.2881204384029843e-05

Although O 0 4.38972648453273e-07
the O 0 4.051231172752523e-08
biochemical O 0 1.6518265510967467e-07
properties O 0 8.503580772867281e-08
of O 0 8.724286004735404e-08
BRCA1 O 0 2.6596416091706487e-07
polypeptides O 0 5.604861996744148e-08
are O 0 6.733966162464355e-10
not O 0 6.16506012907081e-10
understood O 0 6.271053454298681e-09
, O 0 5.806082281623048e-10
their O 0 3.49187651016436e-10
expression O 0 6.190502777059237e-09
pattern O 0 3.283842175960672e-08
and O 0 7.538667468054427e-09
subcellular O 0 1.6713837567294831e-06
localization O 0 8.247753839896177e-07
suggest O 0 2.2376140051960647e-08
a O 0 6.007232489224634e-09
role O 0 3.046909569093259e-08
in O 0 3.1279945744699944e-08
cell O 0 3.406241012271494e-05
- O 0 6.209406365087489e-06
cycle O 0 1.5878932799751055e-06
regulation O 0 2.952053591798176e-06
. O 0 2.094832780130673e-06

When O 0 3.98815973312594e-06
resting O 0 1.0726715117925778e-05
cells O 0 2.3317601005601318e-07
are O 0 3.910583856736594e-09
induced O 0 2.4566009670934363e-08
to O 0 1.223510515124815e-09
proliferate O 0 3.8214476916209605e-08
, O 0 2.543214749906042e-09
the O 0 5.9772196081553375e-09
steady O 0 4.057278246705209e-08
- O 0 2.7236666255703312e-09
state O 0 9.134837331004064e-11
levels O 0 1.1505223440622103e-09
of O 0 9.007278811701269e-10
BRCA1 O 0 2.4537805121127576e-09
increase O 0 1.5745096892949562e-10
in O 0 9.97669280522473e-10
late O 0 1.4993852914813033e-07
G1 O 0 3.835373263427755e-07
and O 0 1.6714700734610233e-09
reach O 0 6.445741718152931e-09
a O 0 1.168036556364882e-09
maximum O 0 3.398742620674966e-08
during O 0 6.502063598645691e-08
S O 0 2.3803258955013007e-06
phase O 0 7.6234846346778795e-06
. O 0 1.2632234529519337e-06

Moreover O 0 1.9982937828899594e-06
, O 0 5.027338545460225e-08
in O 0 8.370176551864006e-09
S O 0 5.299800136526756e-07
phase O 0 1.2159894140495453e-06
cells O 0 8.558073716358194e-08
, O 0 1.0718899545736349e-08
BRCA1 O 0 2.1307306496964884e-07
polypeptides O 0 5.487749277222065e-08
are O 0 4.073902104551053e-09
hyperphosphorylated O 0 2.6907102324003063e-07
and O 0 4.695162481027637e-09
accumulate O 0 1.538366234399291e-08
into O 0 1.3641654028617722e-08
discrete O 0 4.2187011217720283e-07
subnuclear O 0 3.4314266486035194e-06
foci O 0 4.3844397623615805e-06
termed O 0 9.090785511034483e-07
" O 0 1.2362168035906507e-06
BRCA1 O 0 7.239114893309306e-06
nuclear O 0 2.10646576306317e-05
dots O 0 3.64779079973232e-05
. O 0 7.486007689294638e-06

" O 0 1.6875614164746366e-05
BRCA1 O 0 3.476986967143603e-05
associates O 0 4.5852743824070785e-06
in O 0 6.045694789236222e-08
vivo O 0 4.927201189275365e-07
with O 0 5.2032902431164985e-09
a O 0 3.40768089301946e-08
structurally O 0 1.7728084458212834e-06
related O 0 1.388989289807796e-06
protein O 0 4.864204129262362e-06
termed O 0 7.4461854637775104e-06
BARD1 O 0 0.004014296922832727
. O 0 7.180048669397365e-06

Here O 0 9.311560233982163e-07
we O 0 2.5005990167414893e-08
show O 0 5.990150597767752e-09
that O 0 2.1739444966417665e-10
the O 0 2.068415660971823e-09
steady O 0 3.404867854328586e-08
- O 0 3.701569717406983e-09
state O 0 2.966616396982147e-10
levels O 0 8.196017198258687e-09
of O 0 7.689055614434892e-09
BARD1 O 0 3.975670551881194e-06
, O 0 8.30012558683535e-10
unlike O 0 8.017032593343743e-10
those O 0 2.0091209251837938e-10
of O 0 1.9339050361111276e-09
BRCA1 O 0 2.3250779079830863e-08
, O 0 8.372280091428763e-10
remain O 0 3.173302731696026e-09
relatively O 0 2.7994417894916523e-09
constant O 0 1.824549933360231e-08
during O 0 1.1779701480918447e-07
cell O 0 1.394069158777711e-06
cycle O 0 6.338264029182028e-07
progression O 0 1.7504276002000552e-06
. O 0 9.166376457869774e-07

However O 0 3.1275164928956656e-06
, O 0 4.532104185273056e-07
immunostaining O 0 5.6916437642939854e-06
revealed O 0 3.8949579561631253e-07
that O 0 1.3447949420708483e-08
BARD1 O 0 1.1578697012737393e-05
resides O 0 1.4087274280427664e-07
within O 0 6.294759913316739e-08
BRCA1 O 0 1.793803505734104e-07
nuclear O 0 8.055665148276603e-07
dots O 0 2.710417561502254e-07
during O 0 8.121589445408972e-08
S O 0 2.403686778507108e-07
phase O 0 2.383557671237213e-07
of O 0 4.946827392160458e-09
the O 0 2.1137542827176503e-09
cell O 0 1.0724994226052331e-08
cycle O 0 1.9542472085021245e-09
, O 0 1.4918308255396084e-10
but O 0 3.0485225455123555e-10
not O 0 5.912539347008305e-10
during O 0 1.4738417597470743e-08
the O 0 3.3006333666207865e-08
G1 O 0 1.185708515549777e-05
phase O 0 5.771644737251336e-06
. O 0 2.0799864159926074e-06

Nevertheless O 0 1.5831252312636934e-05
, O 0 4.5810426740899857e-07
BARD1 O 0 2.1007404939155094e-05
polypeptides O 0 1.7754956616045092e-07
are O 0 1.9996371225516896e-09
found O 0 2.7768034538411257e-09
exclusively O 0 1.207375532885635e-09
in O 0 5.560433224971462e-10
the O 0 1.3570539136864568e-09
nuclear O 0 2.4242185148182216e-08
fractions O 0 3.37565886354696e-08
of O 0 1.2441210728297847e-08
both O 0 1.0116059989684345e-08
G1 O 0 2.307539944013115e-06
- O 0 3.098080725294494e-08
and O 0 5.267517977358693e-09
S O 0 5.394389859247894e-07
- O 0 1.5383272966573713e-07
phase O 0 1.218954821524676e-06
cells O 0 6.551253477482533e-07
. O 0 5.219644663156942e-07

Therefore O 0 1.1524389265105128e-06
, O 0 4.599788283599082e-08
progression O 0 8.782638616366967e-08
to O 0 2.386423947342564e-09
S O 0 2.6746897674456704e-07
phase O 0 7.984678518369037e-07
is O 0 7.550607916684271e-10
accompanied O 0 1.6506519484593696e-09
by O 0 2.7014079861942264e-10
the O 0 1.2405517724189963e-09
aggregation O 0 6.263701557429613e-09
of O 0 7.494653786466188e-09
nuclear O 0 5.317793352332956e-07
BARD1 O 0 2.4125400159391575e-05
polypeptides O 0 4.817512717636419e-07
into O 0 7.024883785788916e-08
BRCA1 O 0 8.926226655603386e-07
nuclear O 0 1.0944894711428788e-05
dots O 0 2.4328204744961113e-05
. O 0 6.609435786231188e-06

This O 0 4.844155228056479e-07
cell O 0 2.195688693973352e-06
cycle O 0 2.3054626296925562e-07
- O 0 7.532001689014578e-08
dependent O 0 1.6932297342009406e-08
colocalization O 0 4.5585548491544614e-07
of O 0 4.5411812976681176e-08
BARD1 O 0 1.653170693316497e-05
and O 0 2.3933036885637193e-08
BRCA1 O 0 1.0660367166792639e-07
indicates O 0 5.9824203368918916e-09
a O 0 2.1019423979140583e-09
role O 0 5.581027640033653e-09
for O 0 1.911082847527723e-09
BARD1 O 0 3.940452643291792e-06
in O 0 5.152481463710501e-08
BRCA1 O 0 7.730077413725667e-06
- O 0 3.877182734868256e-06
mediated O 0 4.717805495602079e-06
tumor B-Disease 0 1.0463734724908136e-05
suppression O 0 0.00011418148642405868
. O 0 1.1858939615194686e-05

Ethnic O 0 1.2855317663706955e-06
differences O 0 1.1012540426236228e-06
in O 0 7.930458423288655e-08
the O 0 1.1980721126292337e-07
HFE O 0 7.620181713718921e-05
codon O 0 4.653534688259242e-06
282 O 0 3.2921252568485215e-06
( O 0 1.0371907137596281e-06
Cys O 1 0.5183773040771484
/ O 0 0.000148428458487615
Tyr O 0 0.0002275133883813396
) O 0 2.533615770516917e-07
polymorphism O 0 3.5772907267528353e-06
. O 0 2.1984374143357854e-06

Recent O 0 8.128935746753996e-08
studies O 0 1.9739605505719737e-08
have O 0 2.169525892270485e-09
shown O 0 1.0424027863109586e-08
that O 0 1.0568090402784946e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9531815052032471
HH B-Disease 1 0.9999998807907104
) O 0 7.399656443141112e-09
is O 0 1.7583461076053908e-10
likely O 0 8.891056779702922e-10
to O 0 5.161702731903972e-10
be O 0 2.6117119578117354e-09
caused O 0 2.7622940379501415e-08
by O 0 6.057027768235912e-09
homozygosity O 0 6.747677048224432e-07
for O 0 4.20805035261651e-09
a O 0 9.313326998494631e-09
Cys282Tyr O 0 6.653157242908492e-07
mutation O 0 1.5109238304944483e-08
in O 0 4.617621840452557e-09
the O 0 2.1437605468577203e-08
HFE O 0 9.05862634681398e-06
gene O 0 1.1910716324337045e-07
located O 0 1.4297836514742812e-07
4 O 0 3.5502848731994163e-06
. O 0 3.4316262826905586e-06

5 O 0 6.62072779959999e-05
Mb O 0 0.001215837663039565
telomeric O 0 9.31297690840438e-05
to O 0 9.885426379696582e-07
HLA O 0 0.00015424948651343584
- O 0 5.796356617793208e-06
A O 0 1.0005684316638508e-06
. O 0 1.9316389625601005e-06

Population O 0 3.35531069595163e-08
studies O 0 1.0903345781798635e-08
of O 0 8.89411388982353e-09
this O 0 1.2260007453690491e-09
polymorphism O 0 3.86534324547938e-08
are O 0 9.712273207895805e-10
facilitated O 0 5.352398524394175e-09
by O 0 3.6178976481338054e-10
the O 0 4.634931605185244e-10
fact O 0 3.567770245904711e-10
that O 0 1.752072237293234e-10
the O 0 4.5892609712439025e-09
Cys282Tyr O 0 1.8507868162487284e-06
mutation O 0 1.0808413719587406e-07
creates O 0 5.2926576898926214e-08
a O 0 3.8714524919214455e-08
Rsal O 0 4.141536010138225e-06
restriction O 0 3.721091843544855e-07
site O 0 4.997777409698756e-07
. O 0 1.5302533711292199e-06

We O 0 1.8121862410680478e-07
have O 0 8.32553048724094e-09
studied O 0 8.663198514113901e-08
the O 0 1.7363847248930142e-08
codon O 0 3.656571152532706e-07
282 O 0 9.345411058347963e-07
( O 0 3.5951876498074853e-07
Cys O 1 0.520570695400238
/ O 0 5.482832420966588e-05
Tyr O 0 3.83600672648754e-05
) O 0 1.7427717935447617e-08
polymorphism O 0 1.8852519545475843e-08
in O 0 4.3414272177244584e-10
different O 0 9.04061825401925e-10
ethnic O 0 4.304088196960265e-09
groups O 0 1.3256792108506943e-08
. O 0 4.03986604169404e-07

In O 0 1.353934635517362e-07
agreement O 0 1.0280662365858007e-07
with O 0 1.5883977466657484e-09
previous O 0 1.3500016216028143e-08
observations O 0 4.268177278277108e-08
the O 0 9.99683180680222e-09
Tyr O 0 2.2239064492168836e-06
allele O 0 7.671889790117348e-08
appeared O 0 1.0234660230423742e-08
to O 0 2.8876323554527517e-10
be O 0 4.0468872697374536e-10
rare O 0 1.0131232519583477e-09
or O 0 3.225359979097675e-09
absent O 0 2.7730894913702286e-08
in O 0 2.7758293441593196e-09
Asiatic O 0 1.1869011018461606e-07
( O 0 2.512569263757314e-09
Indian O 0 5.145927683969376e-09
, O 0 1.5323796676014467e-09
Chinese O 0 7.729035189640854e-09
) O 0 7.2122410266217685e-09
populations O 0 4.520785523709492e-08
. O 0 7.455184345417365e-07

The O 0 5.290563649396063e-07
highest O 0 3.4763539247251174e-07
allele O 0 1.470791204383204e-07
frequency O 0 8.230799153352564e-08
( O 0 1.5276608866798824e-09
7 O 0 5.856770179946125e-09
. O 0 3.1115796050862343e-10
5 O 0 3.761123412715506e-09
% O 0 3.228626255236122e-10
) O 0 5.398255731314805e-10
was O 0 7.1960544190119435e-09
found O 0 4.583312840367171e-09
in O 0 1.5696116406616056e-08
Swedes O 0 1.4471479516942054e-05
. O 0 1.047444766300032e-05

Saamis O 0 0.00021074315009173006
( O 0 2.2654032250102318e-07
2 O 0 3.707705502620229e-07
% O 0 6.0260987311266945e-09
) O 0 1.9900943115658265e-09
and O 0 4.189486979555568e-09
Mordvinians O 0 7.305782219191315e-07
( O 0 1.8090557940553254e-09
1 O 0 5.470451203137827e-09
. O 0 4.909320727719546e-10
8 O 0 9.331411199298145e-09
% O 0 6.329499147028628e-10
) O 0 7.090136810994352e-10
had O 0 2.4950472798934697e-09
significantly O 0 6.9852523765234764e-09
lower O 0 4.2192159099840865e-08
frequencies O 0 1.1690973167333141e-07
of O 0 1.6061138197187574e-08
the O 0 2.190069814389517e-08
Tyr O 0 1.0868528988794424e-05
allele O 0 2.0340585251688026e-06
. O 0 7.022759973551729e-07

Comparisons O 0 1.12637633264967e-06
with O 0 6.491926285434602e-08
allele O 0 6.323278967101942e-07
frequencies O 0 4.1092567926170886e-07
based O 0 5.338797404164097e-09
on O 0 1.2247299174816817e-08
prevalence O 0 5.344209697000224e-08
estimates O 0 6.45525277676029e-09
of O 0 2.5021735794439337e-08
HH B-Disease 1 0.7607758045196533
showed O 0 8.209867274899807e-08
some O 0 6.125060014738892e-09
disagreements O 0 2.4513170160389564e-07
with O 0 2.7033320026959018e-09
the O 0 1.2233641655257088e-08
RFLP O 0 7.458761501766276e-07
data O 0 1.2035181740088774e-08
, O 0 2.4299853240705716e-09
particularly O 0 1.1987665970991657e-08
in O 0 2.359607798041452e-08
Finns O 0 9.333421076007653e-06
. O 0 4.622444521373836e-06

The O 0 1.6044964468164835e-06
newly O 0 4.697015356214251e-06
described O 0 7.247420512612734e-07
HFE O 0 0.0006244286778382957
marker O 0 1.180055278382497e-06
provides O 0 1.1651288822633887e-08
a O 0 1.7984904676637825e-09
new O 0 2.999143822179917e-09
approach O 0 5.042951833900133e-09
to O 0 6.022384813064718e-10
the O 0 8.627440428732314e-10
screening O 0 3.034392515033346e-09
of O 0 5.019192617083945e-09
HH B-Disease 0 0.00012440946011338383
as O 0 1.4229726286174582e-09
well O 0 4.0486936025985187e-10
as O 0 3.4818739558239997e-10
studies O 0 3.8208167185693753e-10
of O 0 6.214384562497344e-10
the O 0 1.6601559016393708e-09
relationship O 0 4.383022389475855e-09
between O 0 1.82897856859654e-08
the O 0 6.838425292698957e-08
HFE O 0 0.00018045799515675753
Tyr O 0 3.643146555987187e-05
allele O 0 1.0541682513576234e-06
and O 0 7.336181084838245e-08
different O 0 1.1739064120774856e-06
disorders O 1 0.9998903274536133
including O 0 1.4060115063330159e-05
cancer B-Disease 1 0.9998736381530762

Autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9936224818229675
associated O 0 2.200143853769987e-07
with O 0 7.600286622277963e-09
a O 0 4.4715783076298976e-08
missense O 0 1.86689032943832e-06
mutation O 0 1.8858567329971265e-07
encoding O 0 1.0069436484627659e-06
Gly23 O 0 3.6940633435733616e-05
- O 0 6.643496362812584e-06
- O 0 8.548241794414935e-07
> O 0 6.838293984401389e-07
Val O 0 7.569821036668145e-07
in O 0 3.294922024110747e-08
neurophysin O 0 5.495706773217535e-06
II O 0 0.0009681290248408914
. O 0 5.175048954697559e-06

Autosomal B-Disease 1 0.9999995231628418
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 3.2000665669329464e-05
ADNDI B-Disease 1 0.999954342842102
) O 0 7.14169132720599e-08
is O 0 3.712954166346094e-09
an O 0 6.1962204256360565e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.001778312842361629
by O 0 1.5173981182670104e-07
progressive O 1 0.999972939491272
degeneration O 1 0.9999998807907104
of O 0 2.5425199055462144e-05
the O 0 6.755287245141517e-07
magnocellular O 0 5.737916944781318e-05
neurons O 0 4.3845426489497186e-07
of O 0 1.0410501261048921e-07
the O 0 1.0521932125584499e-07
hypothalamus O 0 4.013583918549557e-07
leading O 0 1.2097717672077124e-07
to O 0 4.652595197995879e-09
decreased O 0 3.416747063056391e-08
ability O 0 7.868918849851525e-09
to O 0 2.2414530231884555e-09
produce O 0 2.4792706554421784e-08
the O 0 1.4737861420144327e-07
hormone O 0 7.586298806927516e-07
arginine O 0 2.220615215264843e-06
vasopressin O 0 1.0858952919079456e-06
( O 0 5.2724459465025575e-08
AVP O 0 6.3649017647549044e-06
) O 0 4.689088584086676e-08
. O 0 6.806212127230538e-07

Affected O 0 2.141773848052253e-06
individuals O 0 7.571941296191653e-09
are O 0 1.7453124501187744e-09
not O 0 1.7766491611226343e-09
symptomatic O 0 9.421370350537472e-08
at O 0 3.5724998070918446e-08
birth O 0 9.062410377680408e-09
, O 0 9.049174742870036e-10
but O 0 3.55042106825465e-09
usually O 0 7.463059858991983e-08
develop O 0 6.015323378960602e-06
diabetes B-Disease 1 0.855354368686676
insipidus I-Disease 0 0.00019089887791778892
at O 0 3.0091325697867433e-06
1 O 0 1.968191327250679e-06
- O 0 4.2785370624187635e-07
6 O 0 6.427194421121385e-07
yr O 0 6.560202109540114e-06
of O 0 4.330217961978633e-08
age O 0 5.055223937233677e-07
. O 0 9.463971082368516e-07

The O 0 7.622020916642214e-07
genetic O 0 1.4230431588657666e-07
locus O 0 2.4345197857655876e-07
of O 0 1.0870313360555883e-07
the O 0 9.90848789683696e-08
disease O 0 4.448348136065761e-06
is O 0 5.884079889995064e-09
the O 0 8.61600355506198e-08
AVP O 0 4.2518939153524116e-05
- O 0 1.5308722822737764e-06
neurophysin O 0 3.865631242661038e-06
II O 1 0.9998319149017334
( O 0 8.222968972404487e-08
NPII O 0 1.5437795809702948e-05
) O 0 3.74615316545146e-09
gene O 0 7.732795737069864e-09
, O 0 1.5222884064414188e-09
and O 0 2.375714958091635e-09
mutations O 0 1.2360271917088994e-08
that O 0 5.069876185537225e-10
cause O 0 1.2695299744791555e-07
ADNDI B-Disease 0 0.009399980306625366
have O 0 4.413507781464432e-09
been O 0 1.6041628025931232e-09
found O 0 3.163215245294282e-10
in O 0 2.4834898026959706e-10
both O 0 7.284430836307365e-10
the O 0 2.6669442210192074e-09
signal O 0 3.773542189833279e-08
peptide O 0 9.908842635297788e-09
of O 0 1.1488168638607021e-08
the O 0 2.7920895817601377e-08
prepro O 0 8.90718638402177e-06
- O 0 1.134423837356735e-05
AVP O 0 6.330575706670061e-05
- O 0 1.7788663626561174e-06
NPII O 0 7.915081368992105e-06
precursor O 0 4.64722319293287e-07
and O 0 4.512566675884955e-08
within O 0 2.4515182417417236e-07
NPII O 0 4.4135329517303035e-05
itself O 0 4.266574080702412e-07
. O 0 1.813100311665039e-06

An O 0 3.323654595988046e-07
affected O 0 3.321556789614988e-07
girl O 0 2.9662723477485997e-07
who O 0 1.7415789699271045e-08
presented O 0 1.1849320458168222e-07
at O 0 1.3280624955314124e-07
9 O 0 9.373781040267204e-08
months O 0 4.89344964549332e-09
of O 0 2.335566406941325e-09
age O 0 1.2220092493464563e-08
and O 0 1.3962857536853335e-09
her O 0 6.1184013411264e-10
similarly O 0 2.0833148539622925e-09
affected O 0 3.235927747979872e-09
younger O 0 1.0496074054344717e-07
brother O 0 1.5368800632131752e-07
and O 0 5.548580706005168e-09
father O 0 2.115659292201144e-08
were O 0 4.678062381913151e-09
all O 0 5.626717980433682e-10
found O 0 1.9293061592762228e-10
to O 0 2.0044130244478708e-10
have O 0 5.863283747409298e-10
a O 0 4.268166708953913e-09
novel O 0 9.154612001793794e-08
missense O 0 3.1409044822794385e-06
mutation O 0 5.10485733684618e-07
( O 0 1.1864246829418335e-07
G1758 O 0 1.5711924561401247e-06
- O 0 7.307956479962741e-07
- O 0 3.193176780769136e-07
> O 0 5.568126653088257e-07
T O 0 6.134773116173164e-07
) O 0 6.172534927628703e-09
encoding O 0 2.1180333931170026e-08
the O 0 1.4023157746123616e-08
amino O 0 2.243669783297264e-08
acid O 0 4.4626635720135255e-09
substitution O 0 6.385673145814508e-08
Gly23 O 0 3.659725052784779e-06
- O 0 1.7663921880739508e-06
- O 0 4.4145460265099246e-07
> O 0 7.377983024525747e-07
Val O 0 2.5038430067070294e-06
within O 0 2.623381760713528e-07
NPII O 0 0.00010785346239572391
. O 0 3.4652989597816486e-06

The O 0 1.2681083489951561e-06
mutation O 0 5.417982720246073e-07
was O 0 1.0834916963631258e-07
confirmed O 0 5.082012677348757e-08
by O 0 6.883897896159397e-09
restriction O 0 7.155134795766571e-08
endonuclease O 0 4.2178667172265705e-06
analysis O 0 1.094086428565788e-06
. O 0 4.9872160161612555e-06

A O 0 8.15485545899719e-05
T1 O 0 0.002564075170084834
- O 0 2.5841882234090008e-06
weighted O 0 1.9062387934809522e-07
magnetic O 0 3.457979289578361e-07
resonance O 0 4.2656097321014386e-07
imaging O 0 1.9864792193402536e-06
of O 0 1.872267887392809e-07
the O 0 4.0663007894181646e-07
fathers O 0 9.482587302045431e-06
pituitary O 0 3.91656685678754e-05
gland O 0 3.917009507858893e-06
demonstrates O 0 3.581670000585291e-07
an O 0 5.746737130607471e-08
attenuated O 0 2.7673475415213034e-05
posterior O 0 0.003500621300190687
pituitary O 1 0.9992430210113525
bright O 1 0.9998528957366943
spot O 1 0.9270690083503723
. O 0 7.360235758824274e-05

This O 0 6.446543210358868e-08
mutation O 0 2.1626155444209871e-07
may O 0 4.1890736213190394e-08
be O 0 7.94321675101628e-09
valuable O 0 5.227465393886632e-08
for O 0 1.565457985464036e-09
developing O 0 6.171439803637213e-09
models O 0 1.6067389196905424e-08
of O 0 2.2113466613404853e-08
dominantly B-Disease 0 1.632633757253643e-05
inherited I-Disease 0 0.0041004023514688015
neurodegeneration I-Disease 1 1.0
, O 0 9.606930362338062e-09
as O 0 5.949440939900796e-10
the O 0 3.3342542615777404e-10
early O 0 2.459187520287287e-09
age O 0 2.4955186805897256e-09
of O 0 4.1729784072686016e-09
onset O 0 2.7154803319717757e-05
of O 0 3.395273608930438e-07
symptoms O 0 8.064088433457073e-06
suggests O 0 1.0970705233148692e-08
that O 0 1.9158116759676602e-10
this O 0 2.009416105730466e-10
mutation O 0 2.4141491028473183e-09
may O 0 3.1762092955744947e-09
be O 0 3.823836802752112e-09
particularly O 0 5.030732275201899e-09
deleterious O 0 5.370838493945485e-07
to O 0 1.6839409866520327e-08
the O 0 1.4935410774796765e-07
magnocellular O 0 2.665968168003019e-05
neuron O 0 3.279059228589176e-06
. O 0 1.6594069052189298e-07
. O 0 1.9849906038871268e-06

Frequent O 0 1.6173117955986527e-06
inactivation O 0 4.193252607365139e-05
of O 0 1.8139158783014864e-05
PTEN O 1 0.9997476935386658
/ O 1 0.9640563130378723
MMAC1 O 0 0.17847183346748352
in O 0 4.899864052276826e-07
primary O 1 0.9992103576660156
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004704056482296437

Sporadic B-Disease 1 0.9999990463256836
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 2.20165611608536e-06
the O 0 6.613821312839718e-08
most O 0 2.304876067782402e-09
common O 0 1.636814239702744e-08
male B-Disease 0 1.2599729259932246e-08
cancer I-Disease 0 2.342554061840474e-08
in O 0 1.91192128795592e-09
the O 0 7.379655997397094e-09
Western O 0 2.065496005343448e-07
world O 0 2.0598065475496696e-08
, O 0 2.467827331376071e-10
yet O 0 1.5379744700005915e-10
many O 0 1.3054082120822486e-11
of O 0 1.6037950134606405e-10
the O 0 1.4688840421772653e-10
major O 0 1.5878010017900124e-09
genetic O 0 3.805226356234925e-09
events O 0 9.65918012241218e-10
involved O 0 1.0890536250585114e-09
in O 0 5.441092576496942e-10
the O 0 2.7076509923062986e-09
progression O 0 1.0802087047068198e-07
of O 0 8.140274232459888e-09
this O 0 1.4059600150773122e-09
often O 0 5.102992872707546e-08
fatal O 0 0.00027909010532312095
cancer B-Disease 0 7.248379461088916e-06
remain O 0 2.890876373840001e-07
to O 0 4.462427227736043e-08
be O 0 2.5300712991338514e-07
elucidated O 0 8.271157275885344e-05
. O 0 4.007237293990329e-06

Numerous O 0 1.6230442270170897e-06
cytogenetic O 0 8.824079850455746e-05
and O 0 2.4944833398876654e-07
allelotype O 0 1.3195954124967102e-05
studies O 0 7.014160274820824e-08
have O 0 6.890321646579878e-09
reported O 0 1.0381031145811903e-08
frequent O 0 5.970451244508013e-09
loss O 0 2.539721890570945e-07
of O 0 1.332003762399836e-06
heterozygosity O 0 0.033735353499650955
on O 0 9.686466000857763e-06
chromosomal O 0 0.0003163997898809612
arm O 0 6.795196532038972e-05
10q O 0 7.118281064322218e-05
in O 0 1.5169524658631417e-06
sporadic B-Disease 1 0.9999966621398926
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.002143104560673237

Deletion O 0 6.577889871550724e-05
mapping O 0 9.119580113292614e-07
studies O 0 6.479420022742488e-08
have O 0 8.1890476621993e-09
unambiguously O 0 6.121698703509537e-08
identified O 0 3.476250398648517e-08
a O 0 1.2564548512727924e-08
region O 0 2.2094200247124718e-08
of O 0 1.658733026488335e-07
chromosome O 0 3.224014903935313e-07
10q23 O 0 1.8023189340965473e-07
to O 0 1.453761333536363e-09
be O 0 2.4311908042307095e-09
the O 0 2.8683715402877397e-09
minimal O 0 1.000511389293024e-07
area O 0 2.5522934876676118e-08
of O 0 6.238641248046406e-08
loss O 0 2.727187847995083e-06
. O 0 3.106287067566882e-06

A O 0 1.0238486538582947e-06
new O 0 7.120336675825456e-08
tumor B-Disease 0 2.7111079248243186e-07
suppressor O 0 6.838900503680634e-07
gene O 0 3.6162109751103344e-08
, O 0 5.409650327692361e-08
PTEN O 0 0.0005609459476545453
/ O 0 0.0003237243217881769
MMAC1 O 0 0.049482762813568115
, O 0 2.7716511752373663e-08
was O 0 1.0450130361050469e-07
isolated O 0 3.045271412815964e-08
recently O 0 1.0177876319517054e-08
at O 0 1.56138835194497e-08
this O 0 3.3377159369685216e-10
region O 0 3.095421252652386e-09
of O 0 1.0992132537523958e-08
chromosome O 0 6.272922092875888e-08
10q23 O 0 1.1288923218444324e-07
and O 0 3.106777723971277e-09
found O 0 8.726274147718982e-10
to O 0 3.669254344806916e-10
be O 0 6.397492535725746e-10
inactivated O 0 1.521978632013088e-08
by O 0 7.960851977628636e-10
mutation O 0 1.3574119606118984e-08
in O 0 2.3871216114912386e-08
three O 0 5.141122073837323e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.05416807532310486
lines O 0 5.37480809725821e-06
. O 0 4.245882792019984e-06

We O 0 6.428214419429423e-06
screened O 0 5.967555352981435e-06
80 O 0 5.6237531680380926e-06
prostate B-Disease 1 0.726331353187561
tumors I-Disease 1 1.0
by O 0 5.424197624392946e-08
microsatellite O 0 1.6159812048499589e-06
analysis O 0 4.637766082282724e-08
and O 0 1.266357685381081e-08
found O 0 1.691025275363245e-08
chromosome O 0 1.55884492869518e-07
10q23 O 0 3.94600789377364e-07
to O 0 1.174825037253413e-08
be O 0 1.4871389453219308e-08
deleted O 0 6.486158810048437e-08
in O 0 5.958335602684883e-09
23 O 0 3.1941638667376537e-07
cases O 0 1.8264184120653226e-07
. O 0 1.2997676321901963e-06

We O 0 2.9651465638380614e-07
then O 0 3.644559498638955e-08
proceeded O 0 4.505540118771023e-08
with O 0 1.8036011573130395e-10
sequence O 0 1.875191779632246e-09
analysis O 0 1.5567012123796076e-09
of O 0 2.1904320579579917e-09
the O 0 6.890347847843259e-09
entire O 0 4.057356193243322e-07
PTEN O 0 0.0002578534185886383
/ O 0 4.595024438458495e-05
MMAC1 O 0 0.00011919553799089044
coding O 0 2.5450344764976762e-06
region O 0 5.522357326981364e-08
and O 0 8.771467996382398e-09
tested O 0 1.3354752859129349e-08
for O 0 4.110649598487726e-09
homozygous O 0 5.040204342776633e-08
deletion O 0 3.756235855689738e-08
with O 0 9.928210475962373e-10
new O 0 1.3770376838806442e-08
intragenic O 0 4.747729462906136e-07
markers O 0 1.9120971472830206e-08
in O 0 1.2083570810617061e-09
these O 0 1.2378880143160131e-09
23 O 0 3.000415560450165e-08
cases O 0 4.029758748913537e-09
with O 0 2.238573104662578e-09
10q23 O 0 4.7542630454699975e-07
loss O 0 3.8556683534807235e-07
of O 0 1.4508682397718076e-06
heterozygosity O 0 0.0007505710236728191
. O 0 1.7100903278333135e-05

The O 0 1.2855915088039183e-07
identification O 0 1.1647694009297993e-07
of O 0 4.5191988817805395e-08
the O 0 2.8495438897380154e-08
second O 0 8.659976913349965e-08
mutational O 0 7.991625921022205e-07
event O 0 4.88993485703304e-08
in O 0 5.680356185422397e-09
10 O 0 3.037046170106805e-08
( O 0 5.25123677874717e-09
43 O 0 2.902594253839652e-08
% O 0 1.059204013387216e-08
) O 0 1.3561405864948028e-07
tumors B-Disease 1 1.0
establishes O 0 3.2045008993009105e-05
PTEN O 1 0.8922134041786194
/ O 0 0.00010051012941403314
MMAC1 O 0 3.055999695789069e-05
as O 0 6.95926694049831e-09
a O 0 3.3633116292008935e-09
main O 0 1.2437081586824661e-08
inactivation O 0 1.1087924889352507e-07
target O 0 3.170811879726898e-08
of O 0 2.3374392199571048e-08
10q O 0 8.797658210824011e-07
loss O 0 2.4838743684085784e-07
in O 0 6.65412187572656e-08
sporadic B-Disease 1 0.9993600249290466
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.2001262297853827e-06
. O 0 4.555818122753408e-06

Risk O 0 2.1188321625231765e-05
reversals O 0 4.12814461014932e-06
in O 0 2.652776132094914e-08
predictive O 0 1.1815034213213949e-06
testing O 0 8.867166343407007e-07
for O 0 2.485891627657111e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.890472337137908e-05

The O 0 5.865235266355739e-07
first O 0 5.944569281268741e-08
predictive O 0 2.2999725501904322e-07
testing O 0 7.693225256844016e-08
for O 0 1.421658168965223e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.411313625496405e-08
HD B-Disease 0 0.0001246810716111213
) O 0 2.0420265478549027e-09
was O 0 2.400585286110868e-09
based O 0 3.607575349562353e-10
on O 0 1.0481900902803432e-09
analysis O 0 1.776818581156192e-09
of O 0 4.7220427568106516e-09
linked O 0 9.46001250667905e-08
polymorphic O 0 1.1570527647108975e-07
DNA O 0 4.4129464527031814e-08
markers O 0 2.1592805765635603e-08
to O 0 2.896244133410164e-09
estimate O 0 1.657416603961792e-08
the O 0 2.349632044484906e-09
likelihood O 0 2.0379342657861343e-08
of O 0 2.1016630213921417e-08
inheriting O 0 9.170148018711188e-08
the O 0 2.0258077881862846e-08
mutation O 0 2.887178141008917e-08
for O 0 2.232068219143457e-08
HD B-Disease 0 0.00044242083095014095
. O 0 3.6868214010610245e-06

Limits O 0 3.188201844750438e-07
to O 0 2.2686371892177704e-08
accuracy O 0 2.807090027090453e-07
included O 0 1.7249897510396295e-08
recombination O 0 2.5924961732926022e-08
between O 0 4.554415511393017e-09
the O 0 2.8641402582962883e-09
DNA O 0 6.70967370552944e-09
markers O 0 3.5165215184207455e-09
and O 0 2.121286923895127e-09
the O 0 6.670512586737232e-09
mutation O 0 1.799554993908714e-08
, O 0 3.4774223500733115e-09
pedigree O 0 1.94280129761637e-08
structure O 0 6.256635032286795e-08
, O 0 1.153739548342969e-09
and O 0 4.637168704579864e-10
whether O 0 5.276907244500251e-10
DNA O 0 1.661422888155073e-09
samples O 0 5.089738630559282e-10
were O 0 1.7532465479419557e-09
available O 0 2.488569350589387e-09
from O 0 2.95414470663502e-09
family O 0 9.656385024925385e-09
members O 0 4.938929620834642e-08
. O 0 8.732474725547945e-07

With O 0 3.960495575938694e-08
direct O 0 1.2913589308993778e-08
tests O 0 6.297374621766494e-09
for O 0 5.777768818937545e-10
the O 0 1.4950303217631244e-09
HD B-Disease 0 1.28646513530839e-06
mutation O 0 1.9444907906063236e-09
, O 0 2.550188671346376e-10
we O 0 2.902557916240056e-10
have O 0 2.5296095773619243e-10
assessed O 0 5.228470101314997e-09
the O 0 4.61727572842463e-10
accuracy O 0 1.1696667634453206e-08
of O 0 2.266369536485513e-09
results O 0 9.253902533146174e-09
obtained O 0 8.538910911681796e-09
by O 0 7.811209457031509e-10
linkage O 0 1.4979454121544222e-08
approaches O 0 1.4156263716813555e-08
when O 0 1.8548516056426934e-09
requested O 0 1.749238420778454e-09
to O 0 3.765033007585572e-10
do O 0 6.805342955829019e-10
so O 0 3.1868149785729827e-10
by O 0 2.6127669472408854e-10
the O 0 2.159106449184378e-09
test O 0 3.8568593652144045e-08
individuals O 0 1.321924525399254e-08
. O 0 6.653442596871173e-07

For O 0 1.860245362195201e-07
six O 0 2.1511741721269573e-08
such O 0 3.482146238020789e-10
individuals O 0 3.850747221090245e-10
, O 0 4.5061290809833565e-10
there O 0 5.169081829237143e-10
was O 0 3.2067855038064863e-09
significant O 0 5.6887046184783685e-09
disparity O 0 2.9209660468154652e-08
between O 0 1.4635468836843302e-08
the O 0 2.2670885613251812e-08
tests O 0 1.6089799714791297e-07
. O 0 6.165712989059102e-07

Three O 0 1.3930086879554437e-06
went O 0 3.350572228555393e-07
from O 0 7.882785091339883e-09
a O 0 7.577301452954543e-09
decreased O 0 9.452545413068947e-08
risk O 0 9.799045130876038e-09
to O 0 6.078167968937009e-10
an O 0 2.0264744049480754e-10
increased O 0 1.5660971408593127e-09
risk O 0 9.336128314885173e-09
, O 0 7.786397637765674e-10
while O 0 5.125276314466021e-10
in O 0 1.4395175329529053e-10
another O 0 5.841316319532552e-10
three O 0 2.077793909149861e-10
the O 0 1.4436564166331323e-09
risk O 0 1.2890063239012761e-08
was O 0 1.009008769869979e-07
decreased O 0 7.594108524244803e-07
. O 0 2.04672028303321e-06

Knowledge O 0 5.244271051196847e-06
of O 0 1.9653261063012906e-07
the O 0 8.066672663176178e-09
potential O 0 6.627115745061474e-09
reasons O 0 3.853262153796777e-09
for O 0 2.6488750082265256e-10
these O 0 1.062403845453197e-10
changes O 0 9.347206342269487e-10
in O 0 7.412789826410915e-10
results O 0 9.769912878709874e-09
and O 0 1.3765694140133178e-09
impact O 0 8.738037848843305e-09
of O 0 1.2882117594870124e-09
these O 0 7.8303025174975e-10
risk O 0 4.523146746038265e-09
reversals O 0 3.0659553118539407e-08
on O 0 6.183033640638769e-09
both O 0 6.917892925173419e-10
patients O 0 1.488085876744094e-09
and O 0 9.597310723918895e-10
the O 0 5.005005299096865e-09
counseling O 0 4.4966181889094514e-09
team O 0 2.696107559430061e-09
can O 0 3.562486972086276e-10
assist O 0 2.7076563213768168e-09
in O 0 5.725538376744055e-10
the O 0 2.451857605834107e-09
development O 0 5.353715248901381e-09
of O 0 1.8885153441061675e-09
strategies O 0 8.213105751053718e-09
for O 0 3.305430651412422e-10
the O 0 9.347312923679851e-10
prevention O 0 1.3297995593575251e-08
and O 0 2.3058686904331438e-10
, O 0 1.589512271804594e-10
where O 0 3.5274222431880276e-10
necessary O 0 1.2910880364813693e-08
, O 0 4.6135717468587245e-09
management O 0 2.249119823716228e-08
of O 0 4.3018064666000555e-09
a O 0 3.863189323993765e-09
risk O 0 1.9035677922829564e-08
reversal O 0 4.700102351762325e-08
in O 0 2.355357464622898e-09
any O 0 5.076632891842792e-09
predictive O 0 1.9359806913143984e-07
testing O 0 2.3911180591085213e-08
program O 0 1.9863600542180393e-08
. O 0 2.9739673834683344e-08
. O 0 5.123503115100903e-07

A O 0 2.1429118532978464e-06
novel O 0 3.747627488337457e-07
common O 0 1.9953162677666114e-07
missense O 0 3.431210870985524e-06
mutation O 0 1.5072058090481733e-07
G301C O 0 5.109206995257409e-07
in O 0 8.768256343216763e-09
the O 0 2.4092560835242693e-08
N O 0 1.6319205542458803e-06
- O 0 3.414461104966904e-07
acetylgalactosamine O 0 9.632967703510076e-07
- O 0 2.51708740961476e-07
6 O 0 8.928670354180213e-07
- O 0 1.4871935150040372e-07
sulfate O 0 1.451155924314662e-07
sulfatase O 0 4.385627107694745e-06
gene O 0 3.345992638514872e-08
in O 0 3.8727968387775036e-08
mucopolysaccharidosis B-Disease 0 2.4817654775688425e-05
IVA I-Disease 0 0.08723458647727966
. O 0 2.5952775104087777e-05

Mucopolysaccharidosis B-Disease 0 0.009402057155966759
IVA I-Disease 1 0.9999991655349731
( O 0 7.1734692028258e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.7752812431790517e-07
is O 0 1.3455209391111111e-08
an O 0 1.6038150363328896e-08
autosomal B-Disease 1 0.9996846914291382
recessive I-Disease 1 0.9999996423721313
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.0005048664752393961
by O 0 1.3959888178760593e-07
a O 0 1.1389746532586287e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999984502792358
in O 0 8.16345846033073e-07
N O 0 0.0001540499069960788
- O 0 1.0954512617900036e-05
acetylgalactosamine O 0 4.603720753948437e-06
- O 0 6.643760457336612e-07
6 O 0 1.9841675111820223e-06
- O 0 6.277159059209225e-07
sulfate O 0 7.842706395422283e-07
sulfatase O 0 4.128773070988245e-05
( O 0 6.366190774542702e-08
GALNS O 0 2.0007417333545163e-05
) O 0 9.610983653374205e-08
. O 0 1.02663818779547e-06

In O 0 2.1733232813403447e-07
previous O 0 9.644865883728926e-08
studies O 0 1.0738319566883092e-08
, O 0 1.0350184043161903e-09
we O 0 1.0766266766992771e-09
have O 0 2.8642915816945447e-10
found O 0 4.6424164512615107e-10
two O 0 3.1112354359486005e-10
common O 0 7.491476883281223e-10
mutations O 0 5.874783326476063e-09
in O 0 2.589964243071563e-09
Caucasians O 0 1.3325674785846786e-07
and O 0 6.745898950555329e-09
Japanese O 0 1.6477673625558964e-07
, O 0 3.749106980421857e-08
respectively O 0 4.349264486336324e-07
. O 0 9.638949904910987e-07

To O 0 1.5928786751828738e-06
characterize O 0 5.5626724133617245e-06
the O 0 1.8162053549986013e-07
mutational O 0 3.909589850081829e-06
spectrum O 0 1.9637431591945642e-07
in O 0 1.2921810288446522e-09
various O 0 3.662974923379636e-10
ethnic O 0 2.456237713222009e-10
groups O 0 5.5214641886403015e-11
, O 0 9.016762336777617e-11
mutations O 0 4.9234527566e-10
in O 0 2.4633220463421424e-10
the O 0 3.2036004959934417e-09
GALNS O 0 5.512948177965882e-07
gene O 0 5.783879597487385e-09
in O 0 5.160277982696471e-09
Colombian O 0 9.2621843350571e-07
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 5.778765057584678e-07
were O 0 4.878671333585771e-08
investigated O 0 1.3191922221267305e-07
, O 0 2.7061384244575493e-09
and O 0 2.658903985874872e-09
genetic O 0 2.6231708361024175e-08
backgrounds O 0 6.686858711191235e-08
were O 0 2.128108356203029e-08
extensively O 0 6.437350208443604e-09
analyzed O 0 9.221042596152529e-09
to O 0 6.100898120031673e-10
identify O 0 1.4414560212117067e-08
racial O 0 1.7978567967702475e-08
origin O 0 4.886808291360012e-09
, O 0 1.0496105096180486e-09
based O 0 8.335234169543071e-10
on O 0 7.106332411410676e-09
mitochondrial O 0 3.498179523830913e-08
DNA O 0 4.28591242496168e-08
( O 0 6.0597775686233035e-09
mtDNA O 0 2.4561744638162963e-08
) O 0 1.4677653759065379e-08
lineages O 0 3.610635701534193e-07
. O 0 1.295456058869604e-06

Three O 0 8.755072258281871e-07
novel O 0 4.6327886593644507e-07
missense O 0 7.671488674532156e-06
mutations O 0 3.1716618309474143e-07
never O 0 9.718397109281796e-08
identified O 0 3.753786259608205e-08
previously O 0 8.09299471882241e-09
in O 0 6.34959584910888e-10
other O 0 1.934527538161035e-10
populations O 0 3.222406508296416e-10
and O 0 5.416335158159313e-10
found O 0 8.356246250507127e-10
in O 0 7.100502963375277e-10
16 O 0 1.1509771802309388e-08
out O 0 6.086416926009974e-10
of O 0 2.683691713301073e-09
19 O 0 1.4533024739193934e-07
Colombian O 0 8.638124882054399e-07
MPS B-Disease 1 0.9999136924743652
IVA I-Disease 1 1.0
unrelated O 0 3.569833779692999e-07
alleles O 0 6.031712018739199e-08
account O 0 9.627622254981816e-09
for O 0 1.9624019742536802e-08
84 O 0 1.5593577700201422e-06
. O 0 2.789907739497721e-06

2 O 0 1.9855567643389804e-06
% O 0 2.2060259396994297e-08
of O 0 2.7178662875826376e-08
the O 0 1.0871635147680081e-08
alleles O 0 3.5831657640983394e-08
in O 0 3.735913800539947e-09
this O 0 5.159352944872353e-09
study O 0 2.1834670960174662e-08
. O 0 3.120736380424205e-07

The O 0 2.5896058559737867e-06
G301C O 0 7.01390399626689e-06
and O 0 8.543737095578763e-08
S162F O 0 1.1308733292025863e-06
mutations O 0 4.6163293632162095e-08
account O 0 8.391612738023468e-09
for O 0 2.475901439424888e-08
68 O 0 1.8353002815274522e-06
. O 0 2.0454324385354994e-06

4 O 0 6.3061675064091105e-06
% O 0 1.6811691239126958e-07
and O 0 1.3100301998747454e-07
10 O 0 1.008723756967811e-06
. O 0 1.9962824353569886e-06

5 O 0 8.813260592432925e-07
% O 0 1.4476277954145189e-08
of O 0 1.8871912033091576e-08
mutations O 0 3.2127623228461744e-08
, O 0 3.60679974775735e-09
respectively O 0 1.716937703122312e-08
, O 0 9.055062255569624e-10
whereas O 0 4.3410981476199595e-09
the O 0 4.56749971178283e-09
remaining O 0 5.910899147920645e-08
F69V O 0 1.780662159944768e-06
is O 0 4.453495072720415e-10
limited O 0 9.614147256087335e-10
to O 0 7.131421564388063e-10
a O 0 5.714849038440661e-09
single O 0 2.2605512128848204e-08
allele O 0 1.424876586497703e-06
. O 0 1.1499238325995975e-06

The O 0 1.2750314226650517e-06
skewed O 0 4.1591312083255616e-07
prevalence O 0 2.8895809123241634e-07
of O 0 3.2181965536892676e-08
G301C O 0 1.434377878695159e-07
in O 0 1.5702936728700934e-09
only O 0 2.075952965086003e-09
Colombian O 0 5.009525239074719e-08
patients O 0 2.5597024500001453e-09
and O 0 5.505159439422869e-09
haplotype O 0 5.590320739656818e-08
analysis O 0 2.9011535396250565e-09
by O 0 5.196246211092159e-10
restriction O 0 1.7237093974387108e-09
fragment O 0 1.4006610093986183e-08
length O 0 3.3340781246948836e-09
polymorphisms O 0 9.070796558319216e-09
in O 0 9.45287959019936e-10
the O 0 4.877524606428096e-09
GALNS O 0 2.0964196210115915e-06
gene O 0 1.0468080624548293e-08
suggest O 0 3.835978201749413e-09
that O 0 1.107603564420856e-09
G301C O 0 1.3051854352852388e-07
originated O 0 9.456508465177649e-09
from O 0 1.92350180228118e-09
a O 0 4.9131640977861935e-09
common O 0 3.4646596702714305e-08
ancestor O 0 7.527628440584522e-07
. O 0 1.6449348549940623e-06

Investigation O 0 4.682600774685852e-06
of O 0 1.7673345098501159e-07
the O 0 2.17500844001961e-08
genetic O 0 9.674303136364415e-09
background O 0 3.541405391160879e-09
by O 0 6.207798164403755e-10
means O 0 1.2037224550454084e-08
of O 0 2.365993800879096e-08
mtDNA O 0 1.3376856955460426e-08
lineages O 0 6.0880451790978896e-09
indicate O 0 2.1710657716056403e-09
that O 0 4.2793893428871854e-10
all O 0 1.0533628413966767e-09
our O 0 1.5823591326125097e-09
patients O 0 5.06757524831869e-10
are O 0 9.697312397527469e-11
probably O 0 3.2783835646199577e-09
of O 0 7.3553034773965464e-09
native O 0 2.3378850855237943e-08
American O 0 2.8368441462589544e-07
descent O 0 4.1192473872797564e-05

Low O 0 4.1609387153584976e-06
frequency O 0 8.81390803897375e-07
of O 0 1.310136354959468e-07
BRCA1 O 0 8.158111768352683e-07
germline O 0 1.9681351659528445e-06
mutations O 0 3.4757665190454645e-08
in O 0 5.279517267808842e-09
45 O 0 1.4059398267818324e-07
German O 1 0.9999997615814209
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.3258942241664045e-06
. O 0 1.4336997992359102e-05

In O 0 1.6762029986239213e-07
this O 0 7.093603038299534e-09
study O 0 4.728117009022981e-09
we O 0 2.9999160933158464e-09
investigated O 0 3.931264558332259e-08
45 O 0 3.474560017480144e-08
German O 1 0.9997443556785583
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.056399317496016e-08
for O 0 7.647020794365744e-09
germline O 0 8.450706445728429e-07
mutations O 0 1.6392512236507173e-08
in O 0 3.3402840493579333e-09
the O 0 2.4626434225183402e-08
BRCA1 O 0 4.979110030944867e-07
gene O 0 7.342879371208255e-07
. O 0 3.150988050037995e-06

We O 0 1.4733857369719772e-06
identified O 0 7.908244015197852e-07
four O 0 2.004612582595655e-07
germline O 0 1.0110031325893942e-05
mutations O 0 2.096830655773374e-07
in O 0 2.4289578348657415e-08
three O 0 1.059689438420719e-07
breast B-Disease 0 1.3601090358861256e-05
cancer I-Disease 0 6.559670055139577e-06
families O 0 3.3419536027423646e-09
and O 0 2.7013593140168268e-08
in O 0 1.395294049189033e-07
one O 0 0.0977722555398941
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.173210305045359e-06
. O 0 7.529097345582159e-09
among O 0 5.437232886151833e-10
these O 0 2.5824306582045153e-10
were O 0 2.526418629855698e-09
one O 0 1.5440654310694413e-09
frameshift O 0 1.931716724357102e-07
mutation O 0 6.126333662592742e-09
, O 0 1.40344147414595e-09
one O 0 1.4574094153729789e-09
nonsense O 0 7.718151806557216e-08
mutation O 0 1.8858562711443483e-08
, O 0 3.348467947361655e-09
one O 0 2.6820439202879243e-09
novel O 0 1.2576343522141542e-08
splice O 0 2.3758393297157454e-07
site O 0 2.5990612328996576e-08
mutation O 0 2.821437306010921e-08
, O 0 1.0360934332709348e-08
and O 0 3.076792509659754e-08
one O 0 7.84962992383953e-08
missense O 0 1.3330444744497072e-05
mutation O 0 1.1196207196917385e-05
. O 0 3.1792726076673716e-05

The O 0 1.1417979521866073e-06
missense O 0 9.246446097677108e-06
mutation O 0 3.7208860703685787e-07
was O 0 9.287857238859942e-08
also O 0 2.0049149007661526e-09
found O 0 2.2935924270939267e-09
in O 0 1.0423232943423955e-08
2 O 0 2.4390822090936126e-06
. O 0 1.6169663012988167e-06

8 O 0 3.269086619184236e-06
% O 0 1.8822950309527187e-08
of O 0 1.4225284061808452e-08
the O 0 4.455026569871734e-09
general O 0 5.36837907461063e-09
population O 0 1.4525383673635872e-10
, O 0 1.89883719858841e-10
suggesting O 0 1.0555007978751973e-09
that O 0 1.56770429970976e-10
it O 0 3.367315315472297e-10
is O 0 4.3103542957112495e-10
not O 0 1.0914769532632818e-08
disease O 0 2.4812657102302182e-06
associated O 0 9.909997515933355e-07
. O 0 4.560669367492665e-06

The O 0 4.0787446664580784e-07
average O 0 7.203637153452291e-08
age O 0 1.3150119571037067e-07
of O 0 1.5461417035567138e-07
disease O 0 2.2627638827543706e-05
onset O 0 8.577881089877337e-06
in O 0 4.88225282424537e-09
those O 0 1.647663783188591e-09
families O 0 1.6503119981692294e-09
harbouring O 0 4.070409431733424e-07
causative O 0 1.1975866698321624e-07
mutations O 0 1.6793103441159474e-07
was O 0 3.3621466855038307e-07
between O 0 4.714908357073e-07
32 O 0 1.282914945477387e-05
. O 0 9.059447620529681e-06

3 O 0 1.427089318895014e-05
and O 0 8.486808269481116e-07
37 O 0 6.850226782262325e-06
. O 0 5.033276920585195e-06

4 O 0 5.069976850791136e-06
years O 0 7.552415581812966e-08
, O 0 5.191552965300161e-09
whereas O 0 1.4406039916536884e-08
the O 0 7.034226534585741e-09
family O 0 7.798574230832855e-09
harbouring O 0 4.599551175488159e-07
the O 0 3.5658008101790983e-08
missense O 0 2.9234129215183202e-06
mutation O 0 1.5429716881953937e-07
had O 0 3.7698082877568595e-08
an O 0 1.9224160041630967e-09
average O 0 7.1295347403577125e-09
age O 0 4.8628688631424666e-08
of O 0 6.002584740372185e-08
onset O 0 0.00022036732116248459
of O 0 4.529098077910021e-06
51 O 0 7.311536592169432e-06
. O 0 4.577165782393422e-06

2 O 0 3.7013272958574817e-05
years O 0 3.3159212762257084e-06
. O 0 5.6079802561725955e-06

These O 0 3.6006778714181564e-07
findings O 0 1.517188366051414e-07
show O 0 8.215502944608488e-09
that O 0 3.5925669106262603e-09
BRCA1 O 0 4.119914649436396e-07
is O 0 6.184955658739e-09
implicated O 0 4.5953594707270895e-08
in O 0 1.5295764654865707e-09
a O 0 1.0312113385424482e-09
small O 0 1.2205643162843671e-09
fraction O 0 1.2176584185397132e-08
of O 0 4.792599429492839e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.0979437560272345e-08
suggesting O 0 2.956790012831334e-08
the O 0 9.961770075506138e-09
involvement O 0 1.2886179234783413e-08
of O 0 1.050762765686386e-08
another O 0 5.806661373952693e-09
susceptibility O 0 1.6995804230646172e-07
gene O 0 2.8848668875980366e-07
( O 0 5.607689672615379e-07
s O 0 2.02284318220336e-05
) O 0 7.758512765576597e-06

Paternal O 0 8.960094419308007e-05
transmission O 1 0.9999817609786987
of O 1 0.9999997615814209
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999979734420776

We O 0 1.2413664762789267e-06
report O 0 3.130889325575481e-08
a O 0 3.735001641302915e-09
rare O 0 6.458761969696525e-09
case O 0 2.974404189615143e-08
of O 0 1.9527321626355842e-07
paternally O 1 0.99897301197052
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999994039535522
DM B-Disease 1 1.0
) O 0 2.299596189914155e-06
. O 0 2.8161955469840905e-06

The O 0 7.596201498927257e-07
proband O 0 4.7922690100676846e-06
is O 0 3.0648543702938014e-09
a O 0 1.6740255848191055e-09
23 O 0 2.063137038987861e-08
year O 0 2.5960078531284125e-09
old O 0 2.170541506529844e-07
, O 0 2.528440745663829e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 7.656359230168164e-06
who O 0 1.1404190445318818e-06
suffers O 1 0.9990215301513672
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999997615814209

He O 0 2.375923486397369e-06
presented O 0 1.5844489098526537e-06
with O 0 2.955888760425296e-07
respiratory O 1 0.9999736547470093
and O 0 1.8687711644815863e-06
feeding O 0 1.3238910696600215e-06
difficulties O 0 8.129181878757663e-06
at O 0 4.612004431692185e-06
birth O 0 1.0171770554734394e-06
. O 0 2.099104449371225e-06

His O 0 7.484123216272565e-06
two O 0 1.5853891000006115e-06
sibs O 0 0.01641610637307167
suffer O 0 7.359020855801646e-06
from O 0 6.91464038027334e-07
childhood O 0 0.0032722747419029474
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.002273263642564416

Their O 0 2.3748174271531752e-07
late O 0 2.1839352939423406e-06
father O 0 1.2809984184514178e-07
had O 0 9.576707427072506e-09
the O 0 1.9604520229421496e-09
adult O 0 2.572584811844081e-09
type O 0 1.4556849947666706e-08
of O 0 4.198996919058118e-07
DM B-Disease 1 1.0
, O 0 3.678023574593681e-08
with O 0 4.212603599285103e-09
onset O 0 4.921555955661461e-05
around O 0 3.288367622644728e-08
30 O 0 1.0106460024417174e-07
years O 0 8.237929449705916e-08
. O 0 5.349176603886008e-07

Only O 0 2.4148786792466126e-07
six O 0 5.167776251369105e-08
other O 0 4.89391360769531e-10
cases O 0 6.359656135046521e-10
of O 0 1.5742281922470625e-09
paternal O 0 5.4673137128702365e-08
transmission O 0 0.06213444098830223
of O 1 0.9963207244873047
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 9.920115553541109e-05
been O 0 2.7808391678263433e-07
reported O 0 6.863801615963894e-08
recently O 0 3.520469817885896e-07
. O 0 1.972524614757276e-06

We O 0 1.0184846814809134e-06
review O 0 1.6062892882473534e-07
the O 0 8.063103962285822e-09
sex O 0 8.64446025872212e-09
related O 0 8.572021314989797e-09
effects O 0 9.505283316002533e-08
on O 0 1.4219131116988137e-07
transmission O 0 0.01896728202700615
of O 0 0.01892704702913761
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.7020630836486816

Decreased O 0 8.08271397545468e-06
fertility O 0 4.7381087142639444e-07
of O 0 3.0047164756297207e-08
males O 0 2.197974779960532e-08
with O 0 5.048177431632439e-09
adult O 0 6.877508553770895e-07
onset O 1 0.999639630317688
DM B-Disease 1 1.0
and O 0 6.135124408501724e-07
contraction O 0 1.2378053781958442e-07
of O 0 8.565483433642385e-09
the O 0 1.7600079171842253e-09
repeat O 0 7.703176763129704e-09
upon O 0 3.663850112189948e-09
male O 0 5.405057734719776e-09
transmission O 0 1.3701419554479344e-08
contribute O 0 4.602091208116832e-10
to O 0 7.262594969859038e-10
the O 0 2.4694668532276864e-09
almost O 0 5.206387321265993e-09
absent O 0 2.2597923532430286e-08
occurrence O 0 4.974797018775234e-09
of O 0 5.319819695870365e-09
paternal O 0 2.745418328231608e-07
transmission O 0 0.0001618635724298656
of O 0 0.00033996780985035
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.616055428981781

Also O 0 4.79735831504513e-07
the O 0 8.079702951135914e-08
fathers O 0 2.105945071662063e-07
of O 0 1.8693789627377555e-08
the O 0 1.743549837840419e-08
reported O 0 1.205556401373542e-07
congenitally O 0 1.3813401892548427e-05
affected O 0 1.0360187019387013e-07
children O 0 1.7510350502902838e-08
showed O 0 4.312274981543851e-08
, O 0 1.1102755159697608e-08
on O 0 5.7451035928579586e-08
average O 0 2.8601020218843587e-08
, O 0 1.3447205127192774e-08
shorter O 0 6.738069942002767e-07
CTG O 0 6.16540783084929e-05
repeat O 0 1.3277170864967047e-06
lengths O 0 1.4330669273476815e-06
and O 0 4.974180178862753e-09
hence O 0 2.3889709765967382e-08
less O 0 6.3310485742817946e-09
severe O 0 1.1685193612720468e-06
clinical O 0 3.036848283954896e-05
symptoms O 0 1.3494808115410706e-07
than O 0 1.4485715960077528e-09
the O 0 2.8702979992800692e-09
mothers O 0 1.2565117835094952e-09
of O 0 1.942348282213402e-09
children O 0 9.298648073752247e-09
with O 0 1.0754987300742869e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.009025187231600285

We O 0 5.003022920391231e-07
conclude O 0 5.181451001590176e-07
that O 0 2.09706518816688e-09
paternal O 0 1.8200563545178738e-07
transmission O 0 0.0009985193610191345
of O 1 0.9501782655715942
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.4918329043211997e-06
rare O 0 1.9097937453693703e-08
and O 0 4.81581974298706e-09
preferentially O 0 8.627198511135248e-09
occurs O 0 1.2510544822319503e-09
with O 0 6.351873471643898e-10
onset O 0 2.5347276277898345e-06
of O 0 8.830136835058511e-07
DM B-Disease 1 1.0
past O 0 3.655329194884871e-08
30 O 0 3.7371394867591334e-09
years O 0 7.669805346388614e-10
in O 0 2.097716028659491e-10
the O 0 1.5005754416819173e-09
father O 0 7.2291945762970045e-09
. O 0 1.69293574714402e-08
. O 0 4.072560386703117e-07

The O 0 2.4907706119847717e-06
RB1 O 0 5.4512340284418315e-05
gene O 0 8.910689786034709e-08
mutation O 0 4.6734989211927314e-08
in O 0 7.1712817906188775e-09
a O 0 3.806287907082151e-08
child O 0 1.359783937004977e-06
with O 0 1.001179271042929e-06
ectopic B-Disease 1 0.9999845027923584
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.1287245750427246

The O 0 3.1638571726944065e-06
RB1 O 0 8.225537021644413e-05
gene O 0 3.641947046162386e-07
mutation O 0 2.176914080109782e-07
was O 0 2.0178374882107164e-07
investigated O 0 3.630600247106486e-07
in O 0 7.646001165539928e-09
a O 0 2.397566412071228e-08
child O 0 3.635173584370932e-07
with O 0 1.0206962741676762e-07
ectopic B-Disease 0 0.013284971006214619
intracranial I-Disease 1 0.99989914894104
retinoblastoma I-Disease 0 0.4665055274963379
using O 0 4.309569945348812e-08
DNA O 0 3.861415720507466e-08
obtained O 0 9.988808002958649e-09
from O 0 6.677904895724396e-10
both O 0 3.7106462347225033e-09
the O 0 3.447310348292376e-08
pineal B-Disease 0 2.9981674742884934e-05
and I-Disease 0 1.5411923470765032e-07
retinal I-Disease 1 0.8009556531906128
tumours I-Disease 1 1.0
of O 0 2.287367169628851e-05
the O 0 1.3100043361191638e-06
patient O 0 1.2402990705595585e-06
. O 0 2.2359663489623927e-06

A O 0 2.165541218346334e-06
nonsense O 0 2.2361264200299047e-06
mutation O 0 1.9488177827042819e-07
in O 0 3.672989734582188e-08
exon O 0 1.0492747151147341e-06
17 O 0 4.0564822256783373e-07
( O 0 2.4312290847205986e-08
codon O 0 1.9922531180327496e-07
556 O 0 1.4037748030659714e-07
) O 0 2.7741673402914557e-09
of O 0 7.992425388181346e-09
the O 0 3.002149995268155e-08
RB1 O 0 1.6044952644733712e-05
gene O 0 3.8665746160404524e-08
was O 0 3.2694927654119965e-08
found O 0 1.4168303197337195e-09
to O 0 5.603049690883211e-10
be O 0 1.2822084505259568e-09
present O 0 2.757076345005771e-09
homozygously O 0 1.9016087549061922e-07
in O 0 1.6917470757604747e-09
both O 0 2.2243578090552774e-09
the O 0 1.800461291168176e-08
retinal B-Disease 0 3.3198164146597264e-06
and I-Disease 0 1.1488908313594948e-07
the I-Disease 0 1.811230390558194e-06
pineal I-Disease 1 0.5135433077812195
tumours I-Disease 1 1.0
. O 0 3.2727912184782326e-05

The O 0 2.4272682708215143e-07
same O 0 2.4712257129522186e-08
mutation O 0 4.783013807241332e-08
was O 0 3.2259830362590947e-08
present O 0 5.678558512300924e-09
heterozygously O 0 6.657397477738414e-08
in O 0 7.499525445098243e-10
the O 0 4.844505907541929e-10
DNA O 0 1.5968242284003509e-09
from O 0 2.0798478217454175e-10
the O 0 8.867143130864008e-10
constitutional O 0 2.7178819195228243e-08
cells O 0 7.064344220708563e-09
of O 0 6.341949632115984e-09
the O 0 3.3319100811723956e-09
patient O 0 5.717335049837402e-09
, O 0 1.3651407781978264e-09
proving O 0 1.6560736781912055e-08
it O 0 1.9697087016989911e-10
to O 0 3.0449195942416907e-10
be O 0 2.1488519852397303e-09
of O 0 4.198144054612385e-08
germline O 0 1.0627407391439192e-05
origin O 0 7.86751684245246e-07
. O 0 2.6755033104564063e-06

The O 0 1.4264522008033964e-07
initial O 0 8.762225434111315e-08
mutation O 0 2.6995616408953538e-08
was O 0 1.5184904000875576e-08
shown O 0 1.2005210159315993e-09
to O 0 9.301250880611178e-10
have O 0 1.2661081072451452e-09
occurred O 0 6.369518956717002e-08
in O 0 3.685978633427567e-09
the O 0 3.452660024549914e-08
paternally O 0 1.2676307505898876e-06
derived O 0 8.057601235123002e-07
RB1 O 0 0.00015297284699045122
allele O 0 3.3663473004708067e-05
. O 0 9.550983122608159e-06

The O 0 4.93593461214914e-07
mutation O 0 8.186146516209192e-08
is O 0 1.2996655973651627e-09
in O 0 3.1551108947702744e-10
an O 0 1.6398624125280037e-10
area O 0 6.923014383986015e-10
of O 0 1.3032377399468942e-09
the O 0 1.5652519280706656e-09
gene O 0 1.2879488586747811e-09
that O 0 4.25261992287318e-10
encodes O 0 3.818625859963731e-09
the O 0 3.8019325465654674e-09
protein O 0 1.9383005422923816e-08
- O 0 4.308435563871171e-08
binding O 0 2.4953770605407044e-08
region O 0 2.304538782027521e-08
known O 0 9.870344541695886e-09
as O 0 3.2625204759995086e-09
the O 0 3.1312996640053825e-09
pocket O 0 7.749407586743473e-07
region O 0 2.012072108925622e-08
and O 0 4.051353030831706e-09
has O 0 7.138171165266272e-10
been O 0 5.900102628686454e-10
detected O 0 1.7308915412073134e-09
in O 0 1.8599166651256382e-10
other O 0 2.1305471276100718e-10
cases O 0 1.2649736813585832e-09
of O 0 1.3359747086383322e-08
retinoblastoma B-Disease 0 4.712400823336793e-06
. O 0 9.424461211438029e-08
. O 0 9.975841521736584e-07

Low O 0 6.324470177787589e-06
levels O 0 2.584205276434659e-07
of O 0 6.978756061926106e-08
beta O 0 7.503080610149482e-07
hexosaminidase O 0 9.675641194917262e-07
A O 0 1.4995405805962037e-08
in O 0 1.5633871974785052e-09
healthy O 0 5.85704951205912e-09
individuals O 0 3.6522243562764345e-10
with O 0 6.340023506190562e-10
apparent O 0 3.211453758922289e-06
deficiency O 0 0.0033533491659909487
of O 0 1.6375970517401583e-06
this O 0 1.9542628848512322e-08
enzyme O 0 3.611214367538196e-07
. O 0 5.47602724054741e-07

Appreciable O 0 8.797789632808417e-05
beta O 0 2.4685683456482366e-05
hexosaminidase O 0 5.114549276186153e-05
A O 0 1.0041703717433847e-06
( O 0 9.613825824317246e-08
hex O 0 2.0646446046157507e-06
A O 0 7.075445296322869e-08
) O 0 2.418758082711747e-09
activity O 0 8.880417290413334e-09
has O 0 4.950818088822473e-10
been O 0 8.555502417628702e-10
detected O 0 1.0011658169162274e-08
in O 0 1.242186176142468e-08
cultured O 0 3.676487904158421e-05
skin O 1 0.7420899868011475
fibroblasts O 0 4.703762169810943e-05
and O 0 7.265205681505904e-07
melanoma B-Disease 1 0.9993414282798767
tissue O 0 2.889370762204635e-06
from O 0 1.3112645191881711e-08
healthy O 0 4.9848107863681435e-08
individuals O 0 1.0753009593855722e-09
previously O 0 1.3296093115400254e-08
reported O 0 5.7024802657679174e-09
as O 0 4.118222651783299e-09
having O 0 2.3638111201762513e-07
deficiency B-Disease 0 2.330990719201509e-05
of I-Disease 0 7.496443004129105e-07
hex I-Disease 0 2.6176187475357438e-06
A I-Disease 0 1.641979707756036e-08
activity O 0 1.0992761367845105e-08
indistinguishable O 0 6.402989249920665e-09
from O 0 1.4925906344220863e-10
that O 0 6.123605095220697e-11
of O 0 9.909008058528457e-10
patients O 0 3.3525580089843743e-09
with O 0 1.6740287378524954e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.817845026787836e-06
TSD B-Disease 0 0.2467888742685318
) O 0 1.9123676509025245e-07
. O 0 7.443533149853465e-07

Identification O 0 2.924941099990974e-06
and O 0 2.928729827544885e-07
quantitation O 0 0.00012028136552544311
of O 0 3.97326766687911e-06
hex O 0 2.315230085514486e-05
A O 0 2.2333655635975447e-07
, O 0 1.0994669175090621e-08
amounting O 0 3.7261656871123705e-08
to O 0 1.450103770395117e-08
3 O 0 1.9155470454279566e-06
. O 0 2.0495465378189692e-06

5 O 0 5.139043423696421e-06
% O 0 3.478671999346261e-07
- O 0 2.5096881017816486e-06
6 O 0 5.169115411263192e-06
. O 0 1.8179240441895672e-06

9 O 0 3.356362185513717e-06
% O 0 2.2270205235486173e-08
of O 0 1.4147301108380361e-08
total O 0 9.326375227658446e-09
beta O 0 1.3992223557579564e-07
hexosaminidase O 0 2.628535469284543e-07
activity O 0 6.680137776271522e-09
, O 0 5.277461245789539e-10
has O 0 1.520894798989758e-10
been O 0 3.2571900732136783e-10
obtained O 0 2.5258597435851016e-09
by O 0 2.935183651686657e-09
cellulose O 0 4.257120167494577e-07
acetate O 0 9.863121874786884e-08
gel O 0 4.869087320003018e-07
electrophoresis O 0 4.411103589063714e-07
, O 0 7.578836402899469e-08
DEAE O 0 3.291621396783739e-05
- O 0 9.984217967939912e-07
cellulose O 0 1.097316385312297e-06
ion O 0 4.9485847739560995e-06
- O 0 4.2119754084524175e-07
exchange O 0 7.684338498847865e-08
chromatography O 0 3.0390688721126935e-07
, O 0 4.7918504719746124e-09
radial O 0 2.5662109237600816e-07
immunodiffusion O 0 8.618745823696372e-07
, O 0 1.2816809835669574e-08
and O 0 8.770753368025908e-08
radioimmunoassay O 0 1.3110017789585982e-05
. O 0 2.4072455744317267e-06

Previous O 0 1.884209268609993e-05
family O 0 8.064984058364644e-08
studies O 0 1.2180717767762417e-08
suggested O 0 1.0386854043531457e-08
that O 0 2.2557251899701924e-10
these O 0 2.9460969774852686e-10
individuals O 0 1.502757224214335e-10
may O 0 1.5288180721384492e-09
be O 0 2.519493946806506e-09
compound O 0 3.195948750089883e-08
heterozygotes O 0 4.187906910146921e-08
for O 0 1.0972457387126155e-09
the O 0 3.019785310698353e-09
common O 0 1.1642403485723207e-08
mutant O 0 3.2558588713982317e-07
TSD B-Disease 0 6.2734520724916365e-06
gene O 0 2.423127654083146e-08
and O 0 8.289387842808082e-09
a O 0 9.616940133128082e-09
rare O 0 4.631057137771677e-08
( O 0 3.7676013420195886e-08
allelic O 0 1.6263537645500037e-06
) O 0 5.3743033134878715e-08
mutant O 0 1.485749180574203e-06
gene O 0 1.369139909002115e-06
. O 0 5.82127358939033e-06

Thus O 0 2.6645566322258674e-06
, O 0 5.923833157339686e-08
the O 0 1.836000329547005e-08
postulated O 0 2.971235346649337e-07
rate O 0 1.148050188248817e-08
mutant O 0 2.22145040140731e-08
gene O 0 4.665178021667771e-09
appears O 0 4.1828918107000845e-09
to O 0 5.337419950457445e-10
code O 0 6.830441212635208e-10
for O 0 1.4193937691864278e-10
the O 0 5.106483014216678e-10
expression O 0 1.7047554479177052e-09
of O 0 1.76849446198446e-09
low O 0 7.7914528162637e-09
amounts O 0 2.2512303132771194e-09
of O 0 3.4590737385542525e-08
hex O 0 2.8796575861633755e-06
A O 0 2.9382945854194986e-07
. O 0 7.896456963862875e-07

Heterozygotes O 0 0.00019419020100031048
for O 0 1.198970664972876e-07
the O 0 2.9318055538851695e-08
rare O 0 1.0661806548739605e-08
mutant O 0 9.799590117154366e-08
may O 0 4.360067418218705e-09
be O 0 1.8666133083655723e-09
indistinguishable O 0 7.2313595111950235e-09
from O 0 8.547493823840568e-10
heterozygotes O 0 9.193544769914297e-08
for O 0 4.010520360253622e-09
the O 0 1.9353597835447545e-08
common O 0 3.493216524930176e-07
TSD B-Disease 0 0.00012829549086745828
mutant O 0 1.4123063010629267e-05
. O 0 3.931627816200489e-06

However O 0 5.395701805355202e-07
, O 0 2.0888824892040248e-08
direct O 0 2.3603460519439068e-08
visualization O 0 3.056846651361411e-07
and O 0 2.2231967378161244e-08
quantitation O 0 2.564886017353274e-05
of O 0 6.646707788604544e-07
hex O 0 2.79360574495513e-06
A O 0 1.375326252883724e-08
by O 0 4.099161565740417e-10
the O 0 7.361966036789624e-10
methods O 0 1.4962235894699916e-08
described O 0 7.3697390412519326e-09
may O 0 2.119682207535334e-08
prevent O 0 5.149003357018955e-08
false O 0 3.151971839088219e-07
- O 0 1.542049403724377e-07
positive O 0 1.400244364901937e-08
prenatal O 0 1.2269047999780014e-07
diagnosis O 0 5.835575507262547e-07
of O 0 1.837170771068486e-07
TSD B-Disease 0 0.006267594639211893
in O 0 6.571283250877968e-08
fetuses O 0 5.517434829016565e-07
having O 0 2.185467096182947e-08
the O 0 1.575196151293312e-08
incomplete O 0 3.419746690269676e-07
hex B-Disease 0 2.9218992494861595e-05
A I-Disease 0 8.917769491745275e-07
deficiency I-Disease 0 5.053203040006338e-06
of O 0 2.0860960603386047e-07
the O 0 1.9157733177621594e-08
type O 0 1.167388859357743e-06
described O 0 3.314487173611269e-08
in O 0 7.166645943357253e-09
the O 0 6.690213893989494e-08
four O 0 3.751088684111892e-07
healthy O 0 2.6600321234582225e-06
individuals O 0 1.157979340860038e-06

The O 0 1.1662982615234796e-06
tumor B-Disease 0 2.8711510822176933e-06
suppressor O 0 1.2192269423394464e-05
gene O 0 6.755583399353782e-07
Smad4 O 0 0.00015851660282351077
/ O 0 4.270525823812932e-05
Dpc4 O 0 8.789625098870602e-06
is O 0 2.23902585361202e-09
required O 0 2.774146024009383e-09
for O 0 9.414302670762709e-10
gastrulation O 0 2.5463134534220444e-07
and O 0 3.2819620354729295e-09
later O 0 2.5616037291342764e-08
for O 0 4.192148850279409e-09
anterior O 0 2.490492363449448e-07
development O 0 6.01679843725833e-08
of O 0 6.037145539039557e-08
the O 0 9.907505216233403e-08
mouse O 0 4.1000421902026574e-07
embryo O 0 4.780368954016012e-07
. O 0 1.1277887779215234e-06

Mutations O 0 3.6062695016880753e-06
in O 0 1.273287324465855e-07
the O 0 2.8657490247496753e-07
SMAD4 O 0 0.0009801489068195224
/ O 0 2.503522773622535e-05
DPC4 O 0 2.3634382159798406e-05
tumor B-Disease 0 8.678957783558872e-07
suppressor O 0 1.5775074189150473e-06
gene O 0 3.434669793023204e-08
, O 0 7.977469351772015e-09
a O 0 1.13899005782514e-08
key O 0 3.919461448731454e-07
signal O 0 5.752542620029999e-07
transducer O 0 4.6563351929762575e-07
in O 0 7.818367286915873e-09
most O 0 7.433096360642821e-09
TGFbeta O 0 1.5741121387691237e-05
- O 0 2.6929950536214164e-07
related O 0 1.312132713593428e-08
pathways O 0 1.193123289056075e-08
, O 0 5.087661403280208e-10
are O 0 1.3695919398593048e-10
involved O 0 7.168310389715771e-10
in O 0 8.721349753493257e-10
50 O 0 6.025776766449553e-09
% O 0 7.43499617428256e-09
of O 0 9.723530638439115e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
. O 0 0.0001665031595621258

Homozygous O 0 5.711254561902024e-05
Smad4 O 0 0.00018482103769201785
mutant O 0 1.2073727702954784e-05
mice O 0 1.986630650208099e-06
die O 0 3.3216658721357817e-06
before O 0 9.809929224502412e-07
day O 0 5.531633178179618e-07
7 O 0 3.64525908480573e-06
. O 0 1.7433857237847405e-06

5 O 0 1.4176916920405347e-05
of O 0 4.696993528341409e-06
embryogenesis O 0 0.00011204204929526895
. O 0 1.1613299648161046e-05

Mutant O 0 3.398526814635261e-06
embryos O 0 1.605431663165291e-07
have O 0 5.088673482589456e-09
reduced O 0 1.7330991752828595e-08
size O 0 9.050836524693295e-09
, O 0 1.8081072195030856e-09
fail O 0 5.83071404491875e-08
to O 0 5.714456907668364e-09
gastrulate O 0 9.417055935045937e-07
or O 0 8.207969415252592e-09
express O 0 2.0607133777161835e-09
a O 0 2.0135222378314666e-09
mesodermal O 0 2.1816693163145828e-07
marker O 0 1.6033659733238892e-07
, O 0 7.972327686900371e-09
and O 0 1.3674164911492426e-08
show O 0 1.1255491472184076e-07
abnormal O 0 2.9425364118651487e-06
visceral O 0 3.402968650334515e-05
endoderm O 0 0.010146494954824448
development O 0 8.307152711495291e-06
. O 0 2.021077989411424e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 2.8605984425666975e-06
the O 0 3.173625771069055e-07
Smad4 O 0 0.00013735437823925167
- O 0 5.350370315682085e-07
deficient O 0 5.1050761840087944e-08
embryos O 0 5.430354388380465e-09
results O 0 1.0454392018743874e-08
from O 0 1.1462882865131974e-09
reduced O 0 2.940497090264671e-08
cell O 0 5.544711356719745e-08
proliferation O 0 2.1578765441176984e-08
rather O 0 1.8600773143973015e-09
than O 0 1.0357590340959177e-09
increased O 0 1.3533428599998842e-08
apoptosis O 0 1.3922211792305461e-06
. O 0 5.036994821239205e-07

Aggregation O 0 3.0157400487951236e-06
of O 0 5.837779895045969e-07
mutant O 0 2.130802613464766e-06
Smad4 O 0 2.590510484878905e-05
ES O 0 1.6405187125201337e-05
cells O 0 7.905750010195334e-08
with O 0 6.6765584172401304e-09
wild O 0 1.2669379145791027e-07
- O 0 1.7764001825071318e-07
type O 0 8.370481054953416e-07
tetraploid O 0 0.0002889935567509383
morulae O 0 0.00023397759650833905
rescues O 0 6.527033747261157e-06
the O 0 3.0241849913181795e-07
gastrulation B-Disease 0 4.92178623971995e-05
defect I-Disease 0 1.3265400411910377e-05
. O 0 5.910841991862981e-06

These O 0 9.673882317429161e-08
results O 0 1.448208308829635e-07
indicate O 0 1.330433807567033e-08
that O 0 8.64841420700202e-10
Smad4 O 0 2.222807182761244e-07
is O 0 4.5541440063523453e-10
initially O 0 1.9037482701378394e-09
required O 0 8.185515043557245e-10
for O 0 2.9593202888200665e-10
the O 0 4.2222869645058836e-10
differentiation O 0 7.309835847735258e-09
of O 0 3.563841000087109e-09
the O 0 2.726608716585588e-09
visceral O 0 1.350730940430367e-07
endoderm O 0 1.528978373244172e-06
and O 0 3.851182484027049e-09
that O 0 6.350673875665791e-10
the O 0 1.0432998465148557e-08
gastrulation B-Disease 0 2.0435020360309863e-06
defect I-Disease 0 1.5804391750862123e-07
in O 0 8.611301005601035e-09
the O 0 3.839075901623801e-08
epiblast O 0 5.0486219151935074e-06
is O 0 2.1318733445241378e-09
secondary O 0 1.211866305084186e-07
and O 0 1.2755402956088346e-08
non O 0 1.6732910808059387e-06
- O 0 1.761216253726161e-06
cell O 0 3.145085656797164e-06
autonomous O 0 7.156990591283829e-07
. O 0 2.230216523457784e-06

Rescued O 0 1.7749447579262778e-05
embryos O 0 4.123975543279812e-07
show O 0 2.576969961864961e-07
severe O 0 2.7911242796108127e-05
anterior O 0 0.0028370062354952097
truncations O 1 0.9987492561340332
, O 0 1.30582407109614e-07
indicating O 0 1.83444313961445e-07
a O 0 1.1818866774149228e-08
second O 0 3.197948927891048e-08
important O 0 9.3274596935089e-09
role O 0 9.89894477498865e-09
for O 0 6.139118546855116e-09
Smad4 O 0 3.123170699836919e-06
in O 0 5.664973556918085e-08
anterior O 0 1.174625867861323e-05
patterning O 0 2.5752606234163977e-05
during O 0 4.0352360883844085e-06
embryogenesis O 0 5.6004315410973504e-05
. O 0 8.381813131563831e-06

Prevalence O 0 2.5705568987177685e-05
of O 0 1.4148995433060918e-06
p16 O 0 7.370118055405328e-06
and O 0 6.505958367597486e-07
CDK4 O 0 0.00033414887730032206
germline O 0 6.081525134504773e-05
mutations O 0 4.269089401987003e-07
in O 0 8.597847056535102e-08
48 O 0 1.0141977327293716e-05
melanoma B-Disease 1 0.9999995231628418
- O 0 0.016391819342970848
prone O 0 1.4385507711267564e-05
families O 0 2.6973740574476324e-08
in O 0 5.295949989658766e-08
France O 0 3.4988868719665334e-05
. O 0 2.4819122700137086e-05

The O 0 4.920969331578817e-06
French O 0 0.0004883977817371488
Familial B-Disease 1 0.9913139939308167
Melanoma I-Disease 1 0.9999997615814209
Study O 0 4.692193670052802e-06
Group O 0 2.614774302855949e-06
. O 0 5.130699264555005e-06

Germline O 0 0.000749237893614918
mutations O 0 1.7215160141859087e-06
in O 0 5.957407012147087e-08
the O 0 4.559389310543338e-08
p16 O 0 3.2820958040247206e-07
and O 0 2.3783094604823418e-08
CDK4 O 0 1.2119686289224774e-05
genes O 0 1.2101059709834772e-08
have O 0 1.1795102672351732e-09
been O 0 1.7596453183443828e-09
reported O 0 1.8776038501755465e-09
in O 0 5.035702410616238e-10
a O 0 1.8383260469434504e-09
subset O 0 4.0769979392507594e-08
of O 0 8.737275436487835e-08
melanoma B-Disease 0 0.07702969759702682
pedigrees O 0 1.3758356942616956e-07
, O 0 2.9799562817345304e-09
but O 0 7.64028174060627e-10
their O 0 1.1809847544341778e-09
prevalence O 0 3.4492046552259126e-08
is O 0 2.182590497223913e-10
not O 0 5.352068788155862e-10
well O 0 5.233848021646281e-09
known O 0 6.152390596980695e-08
. O 0 1.0861231203307398e-06

We O 0 5.02003274505114e-07
searched O 0 1.7440444821659185e-07
for O 0 1.6845571604306997e-09
such O 0 4.03330391307577e-09
germline O 0 1.533046201984689e-06
mutations O 0 5.041252393311879e-08
in O 0 9.422803870506868e-09
48 O 0 8.001715627869999e-07
French O 1 0.9218465089797974
melanoma B-Disease 1 1.0
- O 0 0.3729231655597687
prone O 0 3.4982381293957587e-06
families O 0 1.963823992312541e-09
selected O 0 3.6481186960202194e-09
according O 0 5.086497334438889e-10
to O 0 2.897927731115857e-10
two O 0 8.0614392938827e-10
major O 0 5.179110917907792e-09
criteria O 0 1.6079743758723453e-08
families O 0 3.528175807065992e-10
with O 0 2.3284130179490603e-10
at O 0 1.1816748468618243e-08
least O 0 1.473177690947125e-09
three O 0 1.1257627052785324e-09
affected O 0 2.0459718363952106e-09
members O 0 1.7124561768611102e-09
( O 0 1.7984251865499346e-09
n O 0 2.6615591508516445e-08
= O 0 4.5328736320016105e-08
20 O 0 7.102483934318116e-09
) O 0 2.7134403057793577e-10
or O 0 1.9233906134452639e-10
families O 0 6.369048344279093e-11
with O 0 7.031402543544729e-11
two O 0 4.081638638187002e-10
affected O 0 1.47866430211252e-09
members O 0 4.574611245367066e-10
, O 0 2.6023672106134654e-10
one O 0 1.9761435543497186e-10
of O 0 6.733349433574176e-10
them O 0 4.3947648298292563e-10
affected O 0 9.688776447802638e-10
before O 0 1.6755142828728253e-09
the O 0 4.718546664506107e-10
age O 0 1.7168386712285155e-09
of O 0 1.353422152128303e-09
50 O 0 5.361441068885142e-09
( O 0 1.905259505718959e-09
n O 0 2.1603433708605735e-08
= O 0 6.087200432602913e-08
28 O 0 2.430209100623415e-08
) O 0 8.235438997417077e-10
, O 0 4.160133904029806e-10
and O 0 3.614835097920377e-10
one O 0 2.1027996011113714e-10
additional O 0 3.038944873523519e-09
minor O 0 2.2025348300758196e-07
criterion O 0 3.9547094274894334e-06
. O 0 1.4666217111880542e-06

Sixteen O 0 1.4057259249966592e-05
different O 0 2.394536977590178e-07
p16 O 0 2.7632063392957207e-06
germline O 0 4.035116944578476e-06
mutations O 0 6.400195928790708e-08
were O 0 7.766170817546936e-09
found O 0 1.2798432313942953e-09
in O 0 8.448847177433549e-10
21 O 0 3.021641603595526e-08
families O 0 3.724272279459484e-10
, O 0 9.27267929107245e-10
while O 0 1.63567115407659e-09
one O 0 5.3454609627578975e-09
germline O 0 1.0591635373202735e-06
mutation O 0 1.7882227254517602e-08
, O 0 9.050387106412927e-09
Arg24His O 0 4.075554898008704e-06
, O 0 1.2850810193754114e-08
was O 0 4.4367798324174146e-08
detected O 0 2.8778536886875372e-08
in O 0 9.589867566717203e-09
the O 0 1.4788294322443107e-07
CDK4 O 0 0.00012885319301858544
gene O 0 3.062018549826462e-06
. O 0 4.460714990273118e-06

The O 0 3.6616691545532376e-07
frequency O 0 3.705906408413284e-07
of O 0 4.298970779359479e-08
p16 O 0 8.754824420975638e-08
gene O 0 3.6006548853606546e-09
mutation O 0 1.9616226420993144e-09
in O 0 6.089574955403521e-10
our O 0 7.25074722485175e-10
sample O 0 2.819411648591341e-10
( O 0 4.2902098540409384e-10
44 O 0 1.3048345737232125e-09
% O 0 5.129628388722551e-10
) O 0 6.171236299756799e-10
is O 0 1.800995186318488e-10
among O 0 3.834469131103191e-10
the O 0 1.0307354969540938e-09
highest O 0 9.218510399477964e-09
rates O 0 2.933616460865096e-09
yet O 0 1.6682627501651837e-09
reported O 0 2.3121280445792536e-09
and O 0 1.4674623738386572e-09
the O 0 5.059378249683277e-09
CDK4 O 0 8.313480179822363e-07
mutation O 0 7.066446539027993e-09
is O 0 5.190025631485184e-10
the O 0 1.0663103733321577e-09
second O 0 5.994847729340336e-09
mutation O 0 5.059648255922866e-09
detected O 0 5.303002481582553e-09
in O 0 8.762316983101925e-10
this O 0 1.6445679262844237e-09
gene O 0 5.529492597133867e-08
worldwide O 0 2.58371272821023e-07
. O 0 2.69492443294439e-06

In O 0 1.1276737268417492e-06
summary O 0 9.691048944659997e-06
, O 0 1.351140177519028e-08
our O 0 1.0596648003513565e-08
results O 0 1.5669494146663965e-08
show O 0 2.46695308625533e-09
frequent O 0 2.0604105088750657e-09
involvement O 0 2.5519332425005814e-08
of O 0 2.1383781856343376e-08
the O 0 1.8792745137830025e-08
p16 O 0 8.960729047657878e-08
gene O 0 3.7079381343119167e-08
in O 0 1.2810479788072371e-08
familial B-Disease 0 4.98161125506158e-06
melanoma I-Disease 0 0.07507903128862381
and O 0 2.3657456438286317e-08
confirm O 0 5.553157222948357e-08
the O 0 1.1244242870134258e-08
role O 0 1.7882397784774184e-08
of O 0 5.29269819082856e-08
the O 0 6.121045004192638e-08
CDK4 O 0 0.0003583338111639023
gene O 0 9.90138389056483e-08
as O 0 3.1491861562926715e-08
a O 0 8.800429895927664e-08
melanoma B-Disease 0 0.10135217756032944
- O 0 4.793155767401913e-06
predisposing O 0 9.26305006032635e-07
gene O 0 1.2383307534946653e-07
. O 0 1.9429758424394095e-07
. O 0 2.866956720026792e-06

Progression O 0 6.591548299184069e-05
of O 0 3.945359821955208e-06
somatic O 0 7.334969996009022e-05
CTG O 0 7.949989230837673e-05
repeat O 0 4.1224456026611733e-07
length O 0 1.13637739218575e-08
heterogeneity O 0 7.260856449420316e-08
in O 0 1.9899348835394903e-09
the O 0 2.195585269149092e-09
blood O 0 1.4249506463670514e-08
cells O 0 1.3075504057269427e-06
of O 0 0.00015816632367204875
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0011819492792710662
. O 0 1.3137490896042436e-05

The O 0 2.052680940778373e-07
genetic O 0 9.915748222510956e-08
basis O 0 3.6771822919945407e-07
of O 0 0.00024526752531528473
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999485015869141
DM B-Disease 1 1.0
) O 0 2.549369426674275e-08
is O 0 2.7145996561728225e-10
the O 0 2.6439486711105076e-10
expansion O 0 2.534788379193742e-09
of O 0 2.3402484394807743e-09
an O 0 1.0605822886589067e-09
unstable O 0 3.213973513993551e-07
CTG O 0 5.564041202887893e-06
repeat O 0 7.658848488745207e-08
in O 0 4.788981211589771e-09
the O 0 7.458744732957712e-09
34 O 0 5.0281631303050744e-08
UTR O 0 4.412472662806977e-06
of O 0 8.414904328901684e-08
the O 0 2.7266759161648224e-07
DM B-Disease 1 0.9999967813491821
protein O 0 1.992226401625885e-07
kinase O 0 1.8315571992388868e-07
gene O 0 1.5188959423539927e-08
on O 0 4.465543668175087e-08
chromosome O 0 3.3293108003817906e-07
19 O 0 1.7299933006142965e-06
. O 0 4.7430999075004365e-06

One O 0 2.883557499444578e-07
of O 0 6.043873668204469e-08
the O 0 1.521418546701625e-08
principal O 0 6.985094813671822e-08
features O 0 8.678956220364853e-09
of O 0 1.5972331013358598e-08
the O 0 1.6835228677791747e-07
DM B-Disease 1 1.0
mutation O 0 1.2281563499527692e-07
is O 0 1.322236653500397e-09
an O 0 9.827622049485285e-10
extraordinarily O 0 3.407615878359138e-08
high O 0 1.2146387007305748e-07
level O 0 6.960211180739861e-07
of O 0 8.890657454685424e-08
somatic O 0 7.887036190368235e-06
mosaicism O 0 1.0027435564552434e-05
, O 0 1.9415111740528346e-09
due O 0 4.886603566234271e-09
to O 0 6.095605686873284e-10
an O 0 1.9492875369397922e-10
extremely O 0 1.9953281249485144e-09
high O 0 8.55862403170704e-09
degree O 0 8.32388309390808e-08
of O 0 1.5353295523823363e-08
somatic O 0 4.2669157096497656e-07
instability O 0 2.057682202405431e-08
both O 0 1.998104348643892e-09
within O 0 2.991180192424281e-09
and O 0 1.1723420012543784e-09
between O 0 4.418486021506851e-09
different O 0 7.500574383811909e-09
tissues O 0 6.799691618653014e-07
. O 0 5.98384929162421e-07

This O 0 3.274948028320068e-07
instability O 0 9.017700790536765e-07
appears O 0 2.320541092615258e-08
to O 0 5.696628169182816e-10
be O 0 5.038056083428444e-10
biased O 0 6.861155199544555e-09
towards O 0 3.272592197234303e-09
further O 0 1.1256446885710147e-09
expansion O 0 4.538286635380473e-09
and O 0 4.0245334842481384e-10
continuous O 0 3.313436414131843e-09
throughout O 0 6.950759967594422e-10
the O 0 8.740650425664853e-10
life O 0 2.814092847636118e-10
of O 0 1.8053908368287352e-10
an O 0 3.496653314116749e-11
individual O 0 8.802598927548644e-11
, O 0 2.384488995144096e-10
features O 0 5.062455454840631e-10
that O 0 4.6156883870551724e-11
could O 0 1.7574944277676252e-10
be O 0 2.9775912291363227e-10
associated O 0 1.4411390969470972e-09
with O 0 4.915129969695897e-10
the O 0 5.057101404304376e-09
progressive O 0 1.8389604292678996e-06
nature O 0 4.0557463165669105e-08
of O 0 1.1968091939706937e-07
the O 0 3.364010012774088e-07
disease O 0 3.122641282971017e-05
. O 0 1.765740307746455e-06

Although O 0 4.27712961936777e-07
increasing O 0 1.0958893170709416e-07
measured O 0 1.8130711509911634e-07
allele O 0 1.034403567246045e-07
size O 0 1.5299301381332953e-08
between O 0 7.533047075014565e-09
patients O 0 4.676581344398301e-09
clearly O 0 3.7209442194097164e-09
correlates O 0 2.3973456553250116e-09
with O 0 2.9105398646755987e-11
an O 0 4.29795574130587e-11
increased O 0 5.21188980862064e-10
severity O 0 2.1831283447681926e-07
of O 0 5.170270611642991e-08
symptoms O 0 3.260096548274305e-07
and O 0 1.0338365719064768e-09
an O 0 1.195899351769114e-10
earlier O 0 1.1110694586591308e-09
age O 0 3.1991307380963008e-09
of O 0 3.27131255417612e-09
onset O 0 1.8353706821017113e-07
, O 0 7.459367568074526e-10
this O 0 1.14732445766208e-10
correlation O 0 1.3488298256092435e-09
is O 0 6.56453363889753e-11
not O 0 9.824936697544473e-11
precise O 0 1.3553473898753055e-08
and O 0 1.5352232818344191e-09
measured O 0 8.995848510551241e-09
allele O 0 2.0035320957845215e-08
length O 0 1.5321897084419334e-09
cannot O 0 7.407164881456652e-10
be O 0 1.7099162363809484e-10
used O 0 1.533542737242044e-10
as O 0 1.1048347653419555e-10
an O 0 1.9237491807877483e-11
accurate O 0 3.2660072424306463e-09
predictor O 0 9.961736679997557e-08
of O 0 6.3683383011436945e-09
age O 0 7.215518138536936e-08
of O 0 3.143752280720946e-07
onset O 0 0.0007305858889594674
. O 0 4.6983645916043315e-06

In O 0 1.0839381303640039e-07
order O 0 3.407356174989218e-08
to O 0 3.270426818247074e-09
further O 0 1.1531306576273437e-08
characterize O 0 9.095609243559011e-08
the O 0 3.01749487618963e-08
dynamics O 0 1.2588315030370723e-06
of O 0 3.0973537832323927e-06
DM B-Disease 1 1.0
CTG O 0 0.006385089363902807
repeat O 0 1.218050670104276e-06
somatic O 0 1.7876041056297254e-06
instability O 0 8.912866178434342e-08
, O 0 1.7288063203224624e-09
we O 0 1.5598844438358128e-09
have O 0 5.937560443314283e-10
studied O 0 1.8268970336521306e-08
repeat O 0 1.1132549104786449e-08
length O 0 1.349007350270881e-09
changes O 0 1.6410397485344674e-09
over O 0 8.174375065728157e-10
time O 0 1.3726394465507497e-09
in O 0 2.6794668706031644e-09
111 O 0 1.3558274076785892e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.018582172056085e-08
with O 0 1.8186980810241948e-09
varying O 0 2.5600455089147545e-08
clinical O 0 9.098747568714316e-07
severity O 0 8.89098600964644e-07
and O 0 4.035021561321628e-08
CTG O 0 3.4891252198576694e-06
repeat O 0 3.4273796245543053e-08
size O 0 4.7520938295519954e-09
over O 0 1.3348940841595436e-09
time O 0 1.8998198569875058e-09
intervals O 0 6.760634718716574e-09
of O 0 1.8533061751924151e-09
1 O 0 7.263793122547213e-08
- O 0 2.3908352630996887e-08
7 O 0 6.955182385581793e-08
years O 0 7.56930234047104e-08
. O 0 6.081804144741909e-07

We O 0 2.4434422130070743e-07
have O 0 3.868365183734568e-09
found O 0 1.349635292413609e-09
a O 0 6.229100013577238e-10
direct O 0 1.7589641965187752e-09
progression O 0 3.3840265700746386e-08
of O 0 6.577023370368806e-09
the O 0 1.4925914948449304e-09
size O 0 2.9272890778031524e-09
heterogeneity O 0 2.577782787227534e-08
over O 0 2.547127619934031e-09
time O 0 2.7876982944263773e-09
related O 0 1.89210647150162e-09
to O 0 7.445593586119514e-10
initial O 0 2.322356706940809e-08
CTG O 0 1.4006525361764943e-06
repeat O 0 2.3910040169994318e-08
size O 0 4.236349493424996e-09
and O 0 5.217897225406887e-10
the O 0 9.414500290461092e-10
time O 0 2.031839807514757e-09
interval O 0 1.297655050080948e-08
and O 0 4.899610717146174e-10
always O 0 2.221139938640704e-09
biased O 0 2.217039707375079e-08
towards O 0 2.0769004294152182e-08
further O 0 3.503908985180715e-08
expansion O 0 7.989934260876908e-07
. O 0 1.3129409808243508e-06

Attempts O 0 1.2016117807434057e-06
to O 0 3.61940593052168e-08
mathematically O 0 4.848388925893232e-07
model O 0 8.13346474615173e-08
the O 0 2.8057028700345654e-08
dynamics O 0 5.078185267848312e-07
have O 0 3.0205742351796516e-09
proved O 0 9.976415782375625e-08
only O 0 2.1016097750958807e-09
partially O 0 1.6128645086155302e-08
successful O 0 4.19934309547898e-09
suggesting O 0 2.2420816314649983e-09
that O 0 1.1224774582041519e-10
individual O 0 2.3274450422494652e-10
specific O 0 7.715274530362137e-10
genetic O 0 2.7379501332802647e-08
and O 0 3.2719007947434875e-08
/ O 0 1.6843136108946055e-05
or O 0 3.126455538904338e-08
environmental O 0 1.3538953069769377e-08
factors O 0 6.7191376906805544e-09
also O 0 1.4489198729705777e-09
play O 0 8.505344872844489e-09
a O 0 2.266698384545407e-09
role O 0 5.038231609688637e-09
in O 0 6.889769643692034e-09
somatic O 0 1.626421862965799e-06
mosaicism O 0 1.374184648739174e-05
. O 0 2.2825375367574452e-07
. O 0 1.8801547412294894e-06

Aspartylglucosaminuria B-Disease 1 0.9999949932098389
among O 0 2.544718881836161e-06
Palestinian O 0 5.6274297094205394e-05
Arabs O 0 3.7657126085832715e-05
. O 0 6.334315457934281e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9943477511405945
AGU B-Disease 1 1.0
) O 0 1.320574369856331e-07
is O 0 3.5526563912924303e-09
a O 0 5.781023215689629e-09
rare O 0 2.605139286515623e-07
disorder B-Disease 1 0.9978681802749634
of I-Disease 0 0.009557337500154972
glycoprotein I-Disease 0 0.025876188650727272
metabolism I-Disease 0 0.0005656228167936206
caused O 0 4.402303375172778e-07
by O 0 6.68064759068443e-09
the O 0 9.531662925610362e-08
deficiency B-Disease 0 0.002232744824141264
of I-Disease 0 6.521844625240192e-06
the I-Disease 0 7.599441573802324e-07
lysosomal I-Disease 0 9.842660801950842e-05
enzyme I-Disease 0 2.1579718634257006e-07
aspartylglucosaminidase I-Disease 0 2.5086640107474523e-06
( O 0 2.4509517970727757e-08
AGA O 0 4.675488071370637e-06
) O 0 8.901177750431088e-08
. O 0 7.649861117897672e-07

AGU B-Disease 1 1.0
is O 0 1.0959201972582377e-06
inherited O 0 1.6062836948549375e-05
as O 0 7.52063229469968e-08
an O 0 1.6682889736330253e-08
autosomal O 0 7.031707355054095e-05
recessive O 0 0.0008161915466189384
trait O 0 1.5424552657350432e-06
and O 0 4.759824889788433e-08
occurs O 0 1.3250168962031239e-08
with O 0 7.241749977460188e-10
a O 0 2.80418732678811e-09
high O 0 7.351757602691578e-08
frequency O 0 3.382275224339537e-07
in O 0 3.163404205253073e-09
Finland O 0 2.067509541348045e-08
because O 0 1.6718176842900334e-09
of O 0 5.904833955128197e-09
a O 0 5.341689757187851e-09
founder O 0 3.9128062212512305e-07
effect O 0 4.732459331080463e-07
. O 0 9.54142706177663e-07

While O 0 9.871606607703143e-07
very O 0 7.297955306739823e-08
few O 0 2.745428062667088e-08
patients O 0 1.4598890096806372e-08
with O 0 1.3844537072316143e-08
AGU B-Disease 1 1.0
have O 0 1.3460522474417758e-08
been O 0 5.4257678350211336e-09
reported O 0 1.91553484185647e-09
from O 0 8.898996539663528e-10
non O 0 1.1007767142245939e-07
- O 0 4.232781591895218e-08
Finnish O 0 1.3889638239561464e-07
origin O 0 1.8277649616038616e-08
, O 0 5.202476671684053e-09
we O 0 2.5672433068280043e-08
diagnosed O 0 1.4520129525408265e-06
the O 0 1.797976700856907e-08
disorder O 0 1.0687235771911219e-06
in O 0 5.475158548762238e-09
8 O 0 1.0828532737150454e-07
patients O 0 1.787478498549433e-09
originating O 0 1.789074777214239e-09
from O 0 1.5533496711128691e-09
3 O 0 3.799237546786571e-08
unrelated O 0 6.457284040806144e-09
families O 0 1.502691304722248e-10
, O 0 2.0028537162097848e-10
all O 0 3.363085365748475e-10
Palestinian O 0 9.134118528209001e-08
Arabs O 0 3.781135760050347e-08
from O 0 1.4719391261408532e-09
the O 0 3.209422727579181e-09
region O 0 1.3665717446542658e-08
of O 0 7.253921552319298e-08
Jerusalem O 0 1.2443852028809488e-05
. O 0 3.337705265948898e-06

The O 0 6.072143037272326e-07
clinical O 0 1.0693643162085209e-05
diagnosis O 1 0.9499949216842651
of O 0 0.2931957542896271
AGU B-Disease 1 1.0
is O 0 9.306618409254952e-08
often O 0 2.6308355494109037e-09
difficult O 0 1.105915359289611e-08
, O 0 6.707763788860177e-10
in O 0 2.366004892007112e-10
particular O 0 8.28769164407106e-10
early O 0 9.392962851961784e-09
in O 0 5.130382230156272e-10
the O 0 1.2703122997947958e-09
course O 0 3.130045778121371e-09
of O 0 1.7961798715049326e-09
the O 0 4.9094173171226885e-09
disease O 0 1.076695426149854e-07
, O 0 6.48758768928559e-10
and O 0 6.161862131648377e-10
most O 0 2.2416571376915329e-10
of O 0 2.7066080487969657e-09
the O 0 3.5237122109066377e-09
patients O 0 4.022164379335891e-09
are O 0 1.3805503407127162e-09
diagnosed O 0 1.7890675962917157e-07
after O 0 1.2727454645755643e-08
the O 0 2.713286262334691e-09
age O 0 9.373473552898304e-09
of O 0 1.2150390915621756e-08
5 O 0 1.1886501027902341e-07
years O 0 4.1490437752145226e-08
. O 0 4.379523375064309e-07

However O 0 6.638187528551498e-07
, O 0 1.4081667387699781e-08
since O 0 6.880104486128857e-09
these O 0 1.4127717884448998e-09
patients O 0 7.375008936882921e-10
excrete O 0 1.1712719683032446e-08
early O 0 5.21874587988691e-09
large O 0 1.02711861238447e-09
amounts O 0 1.4298560113701342e-09
of O 0 4.310077184044303e-09
aspartylglucosamine O 0 8.375130988724777e-08
in O 0 1.996413034888178e-09
urine O 0 6.2287588420417705e-09
, O 0 2.0492565422358666e-09
biochemical O 0 5.2590078070124946e-08
screening O 0 2.1536497030183455e-08
is O 0 1.3471972426515322e-09
easy O 0 8.210051305468369e-09
by O 0 3.939534032326719e-09
urine O 0 4.926529229010157e-08
chromatography O 0 9.633197350922273e-07
. O 0 1.7889158243633574e-07
. O 0 7.462340363417752e-07

Detection O 0 2.7459172997623682e-05
of O 0 5.925109576310206e-07
heterozygous O 0 2.838094417256798e-07
carriers O 0 3.8613936936826576e-08
of O 0 1.2641102387078718e-07
the O 0 7.1043273237592075e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.2639290768420324e-05
ATM O 0 3.2602310966467485e-05
) O 0 5.361686206128979e-09
gene O 0 5.030942773487368e-09
by O 0 3.6222080890269126e-09
G2 O 0 7.028024811006617e-06
phase O 0 3.498171508908854e-06
chromosomal O 0 1.4341442238219315e-06
radiosensitivity O 0 2.1120504243299365e-06
of O 0 3.241075035020913e-07
peripheral O 0 1.197428719024174e-05
blood O 0 2.2541742055182112e-06
lymphocytes O 0 1.373027862427989e-05
. O 0 5.237263849267038e-06

In O 0 0.00012980413157492876
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.634536594963265e-08
patients O 0 1.7873013069547028e-09
, O 0 1.659414133881043e-10
mutations O 0 2.9484692465331364e-10
in O 0 9.155489560930263e-11
a O 0 1.7407568442262544e-10
single O 0 3.488155597697329e-10
gene O 0 1.0542854367301402e-09
, O 0 7.845760707780869e-10
ATM O 0 1.3974086243706552e-07
, O 0 5.70324953930168e-10
result O 0 2.550228916931019e-09
in O 0 2.9299425108320065e-09
an O 0 1.4279480353707186e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 7.76799424784258e-07
embraces O 0 1.6362749022391654e-07
a O 0 4.449218327096105e-09
variety O 0 5.1086090913088356e-09
of O 0 2.8151802666798176e-08
clinical O 0 6.140620598671376e-07
features O 0 1.6794729162938893e-08
and O 0 9.24354726095089e-09
manifests O 0 4.3700023155679446e-08
extreme O 0 3.8676412827953754e-07
radiosensitivity O 0 8.89460807229625e-06
and O 0 1.313705322303349e-08
a O 0 1.8419070713093788e-08
strong O 0 1.3464816106534272e-07
pre O 0 3.463606844889e-05
- O 0 6.648165822298324e-07
disposition O 0 8.741089914110489e-07
to O 0 3.878947296698243e-08
malignancy B-Disease 0 0.00011525977606652305
. O 0 5.231582690612413e-06

Heterozygotes O 0 7.956204171932768e-06
for O 0 2.584034852759487e-08
the O 0 1.9103111981166876e-08
ATM O 0 6.168959316710243e-07
gene O 0 3.1195559468955025e-09
have O 0 2.345439953366224e-10
no O 0 5.829117744049483e-10
clinical O 0 1.9865305844746217e-08
expression O 0 1.1398484822677801e-08
of O 0 2.138044266075667e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.2348152722552186e-07
may O 0 1.999053296231068e-07
be O 0 4.890830140880098e-08
cancer B-Disease 0 1.5768637240398675e-06
prone O 0 3.8786438949500734e-08
with O 0 3.3009950328732884e-10
a O 0 1.4561006844715507e-09
moderate O 0 1.1504048558208524e-07
increase O 0 4.636215855668979e-09
in O 0 8.495486980564237e-09
in O 0 2.9522537303705576e-08
vitro O 0 1.2378671954138554e-06
radiosensitivity O 0 6.2433118728222325e-06
. O 0 1.276900434277195e-06

We O 0 6.438452260226768e-07
performed O 0 1.6854939133281732e-07
a O 0 6.199864088785034e-08
blind O 0 6.744126039848197e-07
chromosomal O 0 6.775637189093686e-07
analysis O 0 1.619251861484372e-07
on O 0 4.27735415087227e-07
G2 O 0 2.322859836567659e-05
- O 0 1.7706226174141193e-07
phase O 0 3.6818457260778814e-07
lymphocytes O 0 4.063427283540477e-08
from O 0 2.029875822984195e-09
7 O 0 1.8143425961625326e-07
unrelated O 0 2.9636399290211557e-07
A B-Disease 1 0.9999920129776001
- I-Disease 1 0.9999853372573853
T I-Disease 1 1.0
patients O 0 7.49276978240232e-08
, O 0 9.142585355448318e-09
13 O 0 9.400906719747582e-08
obligate O 0 1.6763181065471144e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999971389770508
T I-Disease 1 1.0
heterozygotes O 0 3.704570644913474e-06
( O 0 3.2169920061164703e-09
parents O 0 3.481096799706762e-10
of O 0 6.093548998720166e-10
the O 0 6.41868669326584e-10
patients O 0 2.382434249881271e-10
) O 0 3.025595052275065e-10
, O 0 3.7478448122740815e-10
and O 0 1.6556180870708204e-09
14 O 0 5.8292794591352504e-08
normal O 0 3.503828693851574e-08
controls O 0 3.265391868012557e-08
following O 0 2.7324409401785488e-08
X O 0 1.2778226619047928e-06
- O 0 2.6185968948766458e-08
irradiation O 0 9.604291584253133e-09
with O 0 5.02263730606245e-10
1 O 0 6.55258389770097e-08
Gy O 0 1.4393756373465294e-06
in O 0 4.985261647938444e-10
order O 0 2.3957138495234176e-09
to O 0 6.47565778777448e-10
evaluate O 0 1.0073739176164054e-08
this O 0 4.921790752732136e-10
cytogenetic O 0 2.022440099835876e-07
method O 0 1.797565296612902e-08
as O 0 1.3707451840261342e-09
a O 0 1.1933843913070064e-09
tool O 0 2.244286001484852e-08
for O 0 1.106993163801917e-09
detection O 0 7.057195716697606e-08
of O 0 6.642202521334184e-08
ATM O 0 3.5703278626897372e-06
carriers O 0 1.5709078127201792e-07
. O 0 1.0593231536404346e-06

Both O 0 1.1328495929774363e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.00032768238452263176
and O 0 2.5615602794459846e-07
heterozygotes O 0 2.3965574200701667e-06
showed O 0 6.153282328114074e-08
significantly O 0 6.4186895798457044e-09
increased O 0 3.874834231254454e-09
levels O 0 1.2831877782559786e-08
of O 0 9.209179197000594e-09
radiation O 0 2.5911725970217958e-05
- O 0 4.512592965966178e-07
induced O 0 2.3208559696286102e-07
chromatid O 0 7.416706466756295e-07
damage O 0 6.09396124673367e-08
relative O 0 1.8449590299951524e-08
to O 0 1.1813025002638256e-09
that O 0 6.11875161649067e-10
of O 0 8.250726324376956e-09
normal O 0 2.018738314291113e-07
controls O 0 1.077477577382524e-06
. O 0 1.6498869399583782e-06

These O 0 9.02424162063653e-08
results O 0 1.155354709680978e-07
show O 0 7.97179566802697e-09
that O 0 1.342605471243985e-09
the O 0 1.346421996117897e-08
G2 O 0 9.794637662707828e-06
- O 0 2.3169572216374945e-07
phase O 0 1.2997242038181867e-06
chromosomal O 0 9.761261026142165e-07
radiosensitivity O 0 5.559791134146508e-07
assay O 0 6.930947904493223e-08
can O 0 1.1029404056728254e-09
be O 0 3.914126522897021e-10
used O 0 3.6395261804322843e-10
for O 0 4.117333141095969e-10
the O 0 4.383363116922112e-10
detection O 0 7.167892590587144e-08
of O 0 1.04557123847826e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 0.0006077575380913913
. O 0 9.18461137189297e-06

In O 0 2.3844191332500486e-07
combination O 0 3.690655603350024e-07
with O 0 5.2361843749793024e-09
molecular O 0 8.459777518510236e-07
genetic O 0 2.2924476539287753e-08
analyses O 0 7.523986766955204e-09
, O 0 6.029130528162341e-10
this O 0 1.3605754023426897e-10
test O 0 2.4285675692681252e-09
may O 0 3.6240374590157387e-10
be O 0 9.004800377576672e-11
of O 0 1.5009754550376897e-10
value O 0 1.121099602041653e-10
in O 0 3.7197838559377416e-11
studies O 0 1.9518360538928192e-10
of O 0 4.6149248311699864e-10
familial B-Disease 0 1.6256105794809628e-08
and I-Disease 0 7.769815901781385e-09
sporadic I-Disease 0 2.71067074208986e-06
cancers I-Disease 0 0.06237034872174263
aimed O 0 1.7352147096971748e-06
at O 0 2.437825799006532e-07
determination O 0 2.851484914856428e-08
of O 0 1.782199277045038e-08
the O 0 3.3239313523836245e-09
potential O 0 6.6678920163099065e-09
involvement O 0 1.4249994961801349e-08
of O 0 4.5774790180530545e-08
ATM O 0 3.6360995636641746e-06
mutations O 0 1.1980355907326157e-07
in O 0 1.1385968612387387e-08
tumor B-Disease 0 2.9637812986038625e-05
risk O 0 5.363939976632537e-07
or O 0 1.7842170052517758e-07
development O 0 1.424925386572795e-07
. O 0 5.0365333237323284e-08
. O 0 7.768698537802265e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.1847449741253513e-06
identification O 0 6.339509184272174e-08
and O 0 3.536079873356357e-09
detection O 0 2.240065697378668e-07
of O 0 9.930113264999818e-08
founder O 0 2.0309437331889058e-06
- O 0 9.162543079810348e-08
effect O 0 1.1109005271237038e-08
mutations O 0 1.0281967499636835e-09
in O 0 9.787551880080514e-10
the O 0 3.4886895594610223e-09
ATM O 0 1.2621021028280666e-07
gene O 0 1.8204332485893815e-09
in O 0 1.2466954135703645e-09
ethnic O 0 6.5684484518158115e-09
populations O 0 6.265484842060687e-08
. O 0 1.1380343494238332e-06

To O 0 1.585652285029937e-07
facilitate O 0 1.1735981075844393e-07
the O 0 1.1940885613626051e-08
evaluation O 0 4.5640533130608674e-08
of O 0 4.7952266157835766e-08
ATM O 0 2.3076801880961284e-05
heterozygotes O 0 1.018383613882179e-06
for O 0 7.735657447938138e-09
susceptibility O 0 2.9683099000976654e-07
to O 0 8.671459994502584e-09
other O 0 1.8005607671511825e-08
diseases O 1 0.9346907138824463
, O 0 5.963414762000241e-10
such O 0 5.783060696984421e-10
as O 0 1.6288103310557744e-08
breast B-Disease 0 9.047817002283409e-07
cancer I-Disease 0 1.5507342254750256e-07
, O 0 2.0005028744662923e-09
we O 0 2.3517661151828406e-09
have O 0 3.1954824897262313e-10
attempted O 0 4.619753468659837e-09
to O 0 2.83020357150221e-10
define O 0 6.6172387569451985e-09
the O 0 1.0301950403857063e-09
most O 0 1.8685715474919817e-10
common O 0 4.304956391365522e-10
mutations O 0 7.80702336111716e-10
and O 0 3.152103300596565e-10
their O 0 1.167807073265692e-09
frequencies O 0 1.4249104651753441e-07
in O 0 9.130565103987465e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6066473126411438
A B-Disease 1 1.0
- I-Disease 1 0.9999939203262329
T I-Disease 1 0.9999997615814209
) O 0 1.250191683510593e-08
homozygotes O 0 7.113604283404129e-08
from O 0 6.632044358134692e-10
10 O 0 3.5786631435996696e-09
ethnic O 0 4.845949863607757e-09
populations O 0 1.9995464839439592e-08
. O 0 2.577085638222343e-07

Both O 0 2.564087537848536e-07
genomic O 0 2.6907000005849113e-07
mutations O 0 6.958261167255841e-08
and O 0 5.193434571282296e-09
their O 0 2.008826882615722e-09
effects O 0 5.86977968453084e-08
on O 0 4.3839111896204486e-08
cDNA O 0 1.6283793513593992e-07
were O 0 1.4808982484737498e-07
characterized O 0 9.9574981504702e-07
. O 0 3.979915618401719e-06

Protein O 0 7.456843832187587e-06
- O 0 1.1047073940062546e-06
truncation O 0 4.279785628114041e-07
testing O 0 3.388716152130655e-08
of O 0 8.288043140680657e-09
the O 0 6.40487041181359e-09
entire O 0 3.943024040609089e-08
ATM O 0 2.4006331500459055e-07
cDNA O 0 5.4813678929122034e-08
detected O 0 2.49566269872048e-08
92 O 0 2.4690214672773436e-07
( O 0 1.0778949288692274e-08
66 O 0 9.277446366695585e-08
% O 0 9.139657031198567e-09
) O 0 6.517854700405223e-09
truncating O 0 3.3650144359853584e-07
mutations O 0 2.7598556329166968e-08
in O 0 5.471713748761431e-09
140 O 0 4.115484131261837e-08
mutant O 0 2.856106959825411e-07
alleles O 0 6.067887738936406e-07
screened O 0 7.551377052550379e-07
. O 0 2.2557117063115584e-06

The O 0 4.440731572685763e-06
haplotyping O 0 6.44168394501321e-05
of O 0 5.139084464644839e-07
patients O 0 3.1586488091761566e-08
with O 0 1.985840158980068e-09
identical O 0 1.1072624062080649e-07
mutations O 0 6.459664092517414e-08
indicates O 0 1.8648703914436737e-08
that O 0 4.777173656655975e-10
almost O 0 9.306255766006188e-10
all O 0 1.0687408596998793e-10
of O 0 1.6603704522388796e-10
these O 0 5.4835556234644756e-11
represent O 0 2.0754767349195902e-10
common O 0 2.159823209169076e-09
ancestry O 0 1.7708640109859175e-09
and O 0 1.0237506398169671e-09
that O 0 6.557604459445088e-10
very O 0 4.574360445985803e-09
few O 0 1.4669230274932943e-08
spontaneously O 0 1.39373938168319e-07
recurring O 0 1.6052663909249532e-07
ATM O 0 3.4134295674448367e-06
mutations O 0 5.234145419308334e-07
exist O 0 7.313407763831492e-07
. O 0 2.149504553017323e-06

Assays O 0 8.625837836007122e-06
requiring O 0 1.1953149225973903e-07
minimal O 0 8.867861822636769e-08
amounts O 0 9.23297616139962e-09
of O 0 4.207841630687881e-09
genomic O 0 4.937777742242133e-09
DNA O 0 4.3982053554714184e-09
were O 0 6.225157056505282e-10
designed O 0 1.6864957208539977e-09
to O 0 2.699471479683524e-10
allow O 0 1.3379732877183415e-09
rapid O 0 1.1357815132839733e-08
screening O 0 4.693649469089678e-09
for O 0 8.047105759523276e-10
common O 0 1.2982095398683668e-08
ethnic O 0 3.131922454713276e-08
mutations O 0 5.249327159617678e-07
. O 0 8.192822633645847e-07

These O 0 1.834569189895774e-07
rapid O 0 2.682352828742296e-07
assays O 0 9.360113750744858e-08
detected O 0 6.473895641789795e-09
mutations O 0 2.1653627779727458e-09
in O 0 4.5886108801518333e-10
76 O 0 7.515323474649449e-09
% O 0 5.866684360533725e-10
of O 0 5.3910551578439936e-09
Costa O 0 1.2398834314808482e-07
Rican O 0 3.293740746812546e-08
patients O 0 8.244051552530607e-10
( O 0 5.252786539067245e-10
3 O 0 6.748884562313151e-09
) O 0 4.924645136128447e-10
, O 0 1.6382055434416287e-10
50 O 0 4.967607436512367e-10
% O 0 2.2364382568085261e-10
of O 0 3.024287043018603e-09
Norwegian O 0 1.6060259611094807e-07
patients O 0 2.022853218264231e-09
( O 0 7.71096408946903e-10
1 O 0 1.0338607303594927e-08
) O 0 2.43043835057577e-10
, O 0 1.4284705363021288e-10
25 O 0 1.3559492417769548e-09
% O 0 2.513243779755925e-10
of O 0 2.1936850114201434e-09
Polish O 0 3.5671757814270677e-07
patients O 0 7.39095273871726e-09
( O 0 1.6715848705217695e-09
4 O 0 2.2354340600827527e-08
) O 0 5.041930206672873e-10
, O 0 4.5656420311068757e-10
and O 0 7.249544298204569e-10
14 O 0 1.0631772795477445e-08
% O 0 4.169690426270023e-10
of O 0 3.1426079516450045e-09
Italian O 0 4.987768988939933e-07
patients O 0 3.5721980928826724e-09
( O 0 1.5284623566813593e-09
1 O 0 3.5800166386934507e-08
) O 0 7.866559070812684e-10
, O 0 1.305446306609781e-10
as O 0 3.2905916880210384e-10
well O 0 3.2535887872775504e-10
as O 0 4.503920847387377e-10
in O 0 3.983104679416982e-10
patients O 0 1.3272749566084485e-09
of O 0 1.3939661869244446e-08
Amish O 0 3.830135028692894e-06
/ O 0 4.1830080590443686e-06
Mennonite O 0 1.6399944797740318e-06
and O 0 2.7690937542956817e-08
Irish O 0 5.81619644890452e-07
English O 0 2.726818593146163e-06
backgrounds O 0 6.919680799910566e-06
. O 0 4.213058673485648e-06

Additional O 0 4.987673491996247e-07
mutations O 0 1.463971983639567e-07
were O 0 2.9750964358754572e-08
observed O 0 1.634664492655702e-08
in O 0 2.445403213258146e-09
Japanese O 0 2.6164949318285835e-08
, O 0 5.293644633752592e-09
Utah O 0 3.506550072529535e-08
Mormon O 0 1.0151257612278641e-08
, O 0 2.657606135159085e-09
and O 0 4.529224106875063e-09
African O 0 2.1086479762288945e-07
American O 0 5.981122086495816e-08
patients O 0 1.3032139634105988e-07
. O 0 1.8741577605396742e-06

These O 0 1.0640216174806483e-07
assays O 0 2.124043589901703e-07
should O 0 1.0062831456991717e-08
facilitate O 0 2.424833489556022e-08
screening O 0 1.683170403055101e-08
for O 0 7.63169261119856e-09
A B-Disease 1 0.999996542930603
- I-Disease 1 0.9999701976776123
T I-Disease 1 0.9999998807907104
heterozygotes O 0 5.133720719641133e-07
in O 0 1.7088997994463284e-09
the O 0 2.096744999846578e-09
populations O 0 8.052587485707363e-10
studied O 0 2.003157639762776e-08
. O 0 2.084480499320307e-08
. O 0 5.458185796669568e-07

The O 0 7.34277136871242e-06
von B-Disease 1 0.999586284160614
Hippel I-Disease 1 0.9999912977218628
- I-Disease 1 0.9503756165504456
Lindau I-Disease 0 0.0008367110858671367
tumor I-Disease 0 5.1227880248916335e-06
suppressor O 0 1.4276105275712325e-06
gene O 0 2.1586423315511638e-08
is O 0 1.7266181817632287e-09
required O 0 1.265442506337422e-08
for O 0 7.290592574094035e-09
cell O 0 3.06865558741265e-07
cycle O 0 3.4783194990950506e-08
exit O 0 4.358257399417198e-08
upon O 0 1.833396723327496e-08
serum O 0 8.62815667801442e-08
withdrawal O 0 5.324857283994788e-07
. O 0 2.439240461171721e-06

The O 0 1.2808558267352055e-06
inactivation O 0 1.1648281542875338e-05
of O 0 4.4601728177440236e-07
the O 0 2.6710469569479756e-07
von B-Disease 1 0.9993316531181335
Hippel I-Disease 1 0.9999995231628418
- I-Disease 1 0.9999923706054688
Lindau I-Disease 1 0.9999845027923584
( I-Disease 0 2.1064702195872087e-06
VHL I-Disease 0 0.0021074311807751656
) I-Disease 0 1.4423338257074647e-07
tumor I-Disease 0 3.968325472669676e-06
suppressor O 0 3.522553379298188e-05
gene O 0 7.583709020764218e-07
predisposes O 0 2.1454331999848364e-06
affected O 0 5.7272703912758516e-08
individuals O 0 2.8712507926798025e-09
to O 0 7.17678227957208e-09
the O 0 2.2065316329644702e-07
human O 1 0.9870448708534241
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.6166718808108271e-07
is O 0 2.9484592545259147e-09
associated O 0 7.795793344200774e-09
with O 0 5.286379778368655e-09
sporadic B-Disease 0 0.0005344217643141747
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.000740578630939126
RCC B-Disease 1 0.9999971389770508
) O 0 8.532304462960383e-08
and O 0 1.439067887076817e-07
brain B-Disease 0 0.0040535833686590195
hemangioblastomas I-Disease 0 0.0001545099075883627
. O 0 7.782997272443026e-06

VHL O 0 0.261515736579895
- O 0 8.350057032657787e-05
negative O 0 1.7745456943885074e-06
786 O 0 1.5809600881766528e-05
- O 0 2.7351322842150694e-06
0 O 0 7.571351829938067e-07
RCC B-Disease 0 3.786894740187563e-05
cells O 0 7.98171839733186e-08
are O 0 2.0442243453544506e-09
tumorigenic O 0 5.011977464164374e-07
in O 0 1.2691963924282845e-08
nude O 0 2.0241901665940532e-07
mice O 0 9.848585946770072e-09
which O 0 2.7672852898064093e-10
is O 0 2.6675381348262306e-10
suppressed O 0 5.911572564798462e-09
by O 0 5.597121655043225e-10
the O 0 3.1923221843754845e-09
reintroduction O 0 7.901196852344583e-08
of O 0 2.2860908188704343e-07
VHL B-Disease 0 0.0013503655791282654
. O 0 1.612767118785996e-05

Remarkably O 0 1.9857667211908847e-05
, O 0 1.4256356983821661e-08
this O 0 9.697909142403205e-10
occurs O 0 4.546881982037121e-09
without O 0 6.5992900033506885e-09
affecting O 0 1.4708116502504254e-08
the O 0 9.53256362734578e-10
growth O 0 3.003299609005694e-09
rate O 0 3.3345548544616577e-09
and O 0 1.7144627939558177e-09
cell O 0 3.115775726314496e-08
cycle O 0 5.422084559114637e-09
profile O 0 2.3514072911012818e-09
of O 0 8.995106881570791e-10
these O 0 3.3888675199378326e-10
cells O 0 3.673709780827039e-09
in O 0 2.095841500349138e-09
culture O 0 3.920676050483962e-08
. O 0 2.231434592658843e-07

The O 0 3.065270448132651e-06
786 O 0 5.278309799905401e-06
- O 0 5.899647135265695e-07
0 O 0 1.6690965765064902e-07
cell O 0 1.784177783292762e-07
line O 0 3.83644831458696e-08
, O 0 1.8984722682802158e-09
like O 0 1.0046985465805847e-09
many O 0 5.376717404637077e-10
cancer B-Disease 0 1.4313792817688409e-08
cells O 0 7.471801843905723e-09
, O 0 1.2708041285947047e-09
fails O 0 8.310902188668479e-09
to O 0 2.4559250189071236e-09
exit O 0 1.233254636190395e-07
the O 0 1.936009574876607e-08
cell O 0 1.935083702164775e-07
cycle O 0 2.0942680478697184e-08
upon O 0 1.2496814250084753e-08
serum O 0 7.060346263187967e-08
withdrawal O 0 4.755601139549981e-07
. O 0 1.871842755463149e-06

Here O 0 7.250055205076933e-07
, O 0 6.647371098011945e-09
it O 0 4.3317005538057174e-10
is O 0 1.333239491030369e-10
shown O 0 2.0806890932423272e-10
that O 0 4.8421013726374085e-11
reintroduction O 0 5.4501940738305166e-09
of O 0 2.5241067014292184e-09
the O 0 4.26571711287238e-09
wild O 0 1.725183906842176e-08
- O 0 3.1378302622897536e-08
type O 0 1.0804539130049307e-07
VHL B-Disease 0 4.692131915362552e-05
gene O 0 7.373792243470234e-08
restores O 0 2.4553509092584136e-07
the O 0 6.122981233147584e-09
ability O 0 9.200225470351597e-09
of O 0 1.9475822909953422e-07
VHL O 1 0.9911617040634155
- O 0 1.1707441444741562e-05
negative O 0 3.128096182081208e-07
RCC B-Disease 0 0.12639302015304565
cancer I-Disease 0 9.089956165553303e-08
cells O 0 4.0793759481516645e-09
to O 0 8.180769950349998e-10
exit O 0 2.715332669822601e-08
the O 0 7.68263497263888e-09
cell O 0 4.1765716218833404e-08
cycle O 0 1.5372576100958213e-08
and O 0 5.665856672720793e-09
enter O 0 1.5369944605936325e-07
G0 O 0 0.0014815982431173325
/ O 0 6.402798589988379e-06
quiescence O 0 4.796923803951358e-06
in O 0 6.497934634808189e-08
low O 0 2.9949208055768395e-06
serum O 0 3.053276259379345e-06
. O 0 2.6236693884129636e-06

Both O 0 1.3806763490720186e-05
VHL O 1 0.9803050756454468
- O 0 1.1614905815804377e-05
positive O 0 1.0459223176439991e-07
and O 0 1.9955199093146803e-07
VHL O 0 0.038062527775764465
- O 0 1.8358027773501817e-06
negative O 0 1.1432935309585446e-07
RCC B-Disease 0 2.1496609406312928e-05
cells O 0 6.057907597778467e-08
exit O 0 6.045118539077521e-08
the O 0 1.4083225252647935e-08
cell O 0 9.800263001125131e-08
cycle O 0 2.615930938532074e-08
by O 0 4.645093643063092e-09
contact O 0 2.636466263084003e-07
inhibition O 0 9.161612979369238e-06
. O 0 4.771606199938105e-06

The O 0 7.792645192239434e-06
cyclin O 0 5.866366336704232e-05
- O 0 1.5171679024206242e-06
dependent O 0 1.909535711774879e-07
kinase O 0 1.0062822184409015e-06
inhibitor O 0 6.725005619045987e-07
, O 0 6.55509424518641e-09
p27 O 0 4.9440001248513e-07
, O 0 4.915170048747086e-09
accumulates O 0 6.568648736049454e-09
upon O 0 1.279921391095229e-09
serum O 0 1.4934771197516739e-09
withdrawal O 0 3.6681293558160633e-09
, O 0 2.992684988711858e-10
only O 0 1.437084201638683e-10
in O 0 1.036088437267324e-10
the O 0 1.8477003260741753e-10
presence O 0 1.1204203120840361e-09
of O 0 1.1171644942464809e-08
VHL B-Disease 0 7.876852032495663e-05
, O 0 2.7701698712689904e-09
as O 0 4.903276118461974e-10
a O 0 3.1345848139352483e-10
result O 0 1.9181929378220275e-09
of O 0 3.589655905855693e-09
the O 0 3.0434694764380765e-09
stabilization O 0 5.1091188169039015e-08
of O 0 3.7652885254146895e-08
the O 0 6.201295121854855e-08
protein O 0 4.042860837216722e-07
. O 0 7.689775998187542e-07

We O 0 2.1729586308083526e-07
propose O 0 5.546170811498996e-08
that O 0 4.0463313255578726e-10
the O 0 2.0718904369942948e-09
loss O 0 1.4796073699585577e-08
of O 0 1.8472089635679367e-08
wild O 0 2.257875131306264e-08
- O 0 5.690466053920318e-08
type O 0 2.977515691782173e-07
VHL B-Disease 0 0.005723849404603243
gene O 0 1.2228758805576945e-07
results O 0 1.172897654555527e-07
in O 0 3.5568534784147232e-09
a O 0 2.3568043072685896e-09
specific O 0 3.9950140973132875e-09
cellular O 0 2.788660538044496e-07
defect O 0 3.124136682686185e-08
in O 0 5.504603439732136e-09
serum O 0 1.2421618578173366e-07
- O 0 3.662696030914958e-07
dependent O 0 6.141812392002066e-09
growth O 0 2.1963475482777994e-09
control O 0 6.355730164386841e-09
, O 0 5.198565466990601e-10
which O 0 4.682541576706001e-10
may O 0 5.118304002849072e-09
initiate O 0 5.920806245285348e-08
tumor B-Disease 0 4.939457198815944e-07
formation O 0 9.847357205217122e-07
. O 0 1.2724512998829596e-06

This O 0 1.0216155743592026e-07
is O 0 9.698283953696318e-09
corrected O 0 7.450132244457564e-08
by O 0 1.0546374884512488e-09
the O 0 3.105823820348519e-09
reintroduction O 0 7.374720212283137e-08
of O 0 1.740609079092792e-08
wild O 0 5.64994202534308e-08
- O 0 1.3797935594084265e-07
type O 0 2.5033630208781688e-06
VHL B-Disease 1 0.9999966621398926
, O 0 1.4731258488609456e-06
implicating O 0 0.00027606444200500846
VHL B-Disease 0 0.005203179083764553
as O 0 1.6669467584051745e-08
the O 0 7.332359608369643e-09
first O 0 7.618210950965931e-09
tumor B-Disease 0 7.318320882632179e-08
suppressor O 0 4.110699478587776e-07
involved O 0 1.2138554161822412e-08
in O 0 3.1949234369221813e-09
the O 0 1.0708519404545314e-08
regulation O 0 8.743126755916819e-08
of O 0 4.0885694829739805e-08
cell O 0 2.546242967582657e-07
cycle O 0 3.130250192384665e-08
exit O 0 4.903056094462954e-08
, O 0 1.491433199163339e-09
which O 0 7.514201483260763e-10
is O 0 6.746191383300015e-10
consistent O 0 4.353054361416753e-09
with O 0 1.7722451284285512e-10
its O 0 2.249513464391839e-09
gatekeeper O 0 7.849509842117186e-08
function O 0 1.6279562586873908e-08
in O 0 1.9972890008546074e-09
the O 0 1.0165692287955608e-08
kidney O 0 1.2171972230134998e-06
. O 0 7.598449514034655e-08
. O 0 7.911766601864656e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0001610395120223984
deafness B-Disease 1 1.0
: O 0 1.8470298357442516e-07
molecular O 0 3.2323734444617003e-07
evidence O 0 3.1199800076819884e-08
for O 0 1.8474792806699725e-09
an O 0 2.472308802126122e-09
expanded O 0 4.1292997821074096e-07
syndrome O 1 0.9679825305938721
. O 0 2.0426707123988308e-05

In O 0 2.0910813702812447e-07
a O 0 4.0768114217826223e-08
South O 0 3.7894534443694283e-07
African O 0 1.2543257525976514e-06
girl O 0 2.6106056338903727e-07
of O 0 1.145161689919405e-07
Xhosa O 0 7.784022272971924e-06
stock O 0 4.5019756811370826e-08
with O 0 2.1698776109246865e-09
severe O 0 4.460774107428733e-06
piebaldism B-Disease 0 0.0012777899391949177
and O 0 5.42275211046217e-06
profound O 1 0.9999997615814209
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.909558159240987e-05
identified O 0 1.1778667641237917e-07
a O 0 4.6060280034510015e-09
novel O 0 1.9224609459911335e-08
missense O 0 4.3949626160610933e-07
substitution O 0 1.438058205849302e-07
at O 0 1.6628732169010618e-07
a O 0 8.689175601261923e-09
highly O 0 1.5810474707222966e-08
conserved O 0 5.2512692860773313e-08
residue O 0 3.9851983046901296e-08
in O 0 5.36805133677376e-09
the O 0 9.790918298335782e-09
intracellular O 0 1.0697335994791501e-07
kinase O 0 7.896843357002581e-08
domain O 0 1.507495461794406e-08
of O 0 9.155917801706437e-09
the O 0 2.640922325269912e-08
KIT O 0 1.5250902833940927e-05
proto O 0 0.00022229997557587922
- O 0 5.221872925176285e-06
oncogene O 0 1.0855135769816115e-05
, O 0 1.1967817670210934e-07
R796G O 0 1.6213938579312526e-05
. O 0 3.832415131910238e-06

Though O 0 3.14896942654741e-06
auditory B-Disease 0 0.0014218620490282774
anomalies I-Disease 0 1.7432761524105445e-05
have O 0 8.46541770016529e-09
been O 0 5.9001616925513645e-09
observed O 0 1.5217784365972875e-08
in O 0 3.6394727231936486e-09
mice O 0 3.2012991368901567e-08
with O 0 3.130809833606918e-09
dominant O 0 0.0006689248257316649
white O 0 1.1232516499148915e-06
spotting O 0 9.043745194503572e-06
( O 0 9.880292850539263e-08
W O 0 2.033329838013742e-05
) O 0 4.068466452622488e-09
due O 0 1.458775678031543e-08
to O 0 6.104894367808811e-09
KIT O 0 8.082947169896215e-05
mutations O 0 1.3852027223038021e-05
, O 0 1.69688030382531e-06
deafness B-Disease 1 1.0
is O 0 3.5956997379571476e-09
not O 0 1.6670986813238642e-09
typical O 0 1.3586060276793432e-08
in O 0 6.3164056207654085e-09
human O 0 1.0180131226888989e-07
piebaldism B-Disease 0 5.9045264606538694e-06
. O 0 2.631896904858877e-06

Thus O 0 4.6592359126407246e-07
, O 0 1.1816455369739742e-08
the O 0 8.897541370345152e-09
occurrence O 0 1.6776392897099868e-07
of O 0 6.200808002176927e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.34882145125448e-07
this O 0 1.0495470270655005e-08
patient O 0 2.6265000840908215e-08
extends O 0 9.751406793157003e-09
considerably O 0 1.382485237400033e-08
the O 0 6.903976945693557e-09
phenotypic O 0 2.5131728875749104e-07
range O 0 3.2623667323150585e-08
of O 0 1.3532138076755018e-08
piebaldism B-Disease 0 3.7114554629624763e-07
due O 0 3.7587010837114576e-08
to O 0 6.287485643241553e-09
KIT O 0 1.1601304095165688e-06
gene O 0 1.9883728441527637e-08
mutation O 0 2.4504283047122044e-08
in O 0 3.870416875884075e-09
humans O 0 2.1832672558730337e-08
and O 0 1.1475992600651352e-08
tightens O 0 7.391873424467121e-08
the O 0 4.787574781062176e-09
clinical O 0 4.204979831001765e-08
similarity O 0 2.550103950227367e-08
between O 0 4.2088874607770776e-08
piebaldism B-Disease 0 1.3873583384338417e-06
and O 0 5.203439457091008e-09
the O 0 2.5204216491658826e-09
various O 0 1.212237532577376e-09
forms O 0 3.029582629210381e-08
of O 0 1.2139940963606932e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.96293705701828
. O 0 5.379594085752615e-07
. O 0 3.206596602467471e-06

Cycloheximide O 0 0.00011909260501852259
facilitates O 0 2.431392260859866e-07
the O 0 1.2982591002241861e-08
identification O 0 2.529409570684038e-08
of O 0 5.975158501314581e-08
aberrant O 0 5.942936240899144e-07
transcripts O 0 5.748188414145261e-07
resulting O 0 4.3393622917164976e-08
from O 0 6.444488054313524e-09
a O 0 1.4068567644187624e-08
novel O 0 6.562027010659222e-08
splice O 0 3.3071071356971515e-06
- O 0 1.8809245716511214e-07
site O 0 1.9517001348390295e-08
mutation O 0 1.765381263396648e-08
in O 0 9.522428179309372e-09
COL17A1 O 0 5.109084668220021e-05
in O 0 1.33346969022341e-08
a O 0 1.411431149733744e-08
patient O 0 4.8285148324112015e-08
with O 0 6.780835093422866e-08
generalized O 1 0.9876002073287964
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999696016311646
. O 0 0.00012495611736085266

Patients O 0 9.90496209851699e-06
with O 0 5.597009362645622e-07
generalized O 1 0.8895384073257446
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999215602874756
often O 0 7.794651679660092e-08
show O 0 1.7986833356076204e-08
decreased O 0 3.4754350508592324e-08
expression O 0 1.2219042666572477e-08
of O 0 1.120762860296054e-08
type O 0 2.660212317096011e-07
XVII O 0 0.00018209640984423459
collagen O 0 2.486996208972414e-07
, O 0 9.562961977849227e-09
a O 0 1.4117488511544707e-08
transmembrane O 0 1.711504467039049e-07
hemidesmosomal O 0 4.988030468666693e-07
protein O 0 1.8199134643737125e-08
encoded O 0 1.0818227202946673e-08
by O 0 1.3415463406829531e-08
COL17A1 O 0 3.860690776491538e-05
. O 0 4.817393346456811e-06

This O 0 3.9939311591297155e-07
report O 0 1.1249459674900208e-07
documents O 0 1.1264382493436642e-07
a O 0 1.80941217564623e-08
novel O 0 1.2044750974382623e-07
splice O 0 3.9435090002371e-06
- O 0 1.1813124700665867e-07
site O 0 2.1060287735963357e-08
mutation O 0 1.7187725021017286e-08
in O 0 7.52266693382353e-09
COL17A1 O 0 2.839406079147011e-05
in O 0 1.1607348859854483e-08
a O 0 1.21055379054269e-08
patient O 0 8.694932063235683e-08
with O 0 1.1363236751549266e-07
generalized O 1 0.9996980428695679
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999988079071045
, O 0 2.646396524141892e-07
and O 0 3.20826174515787e-08
applies O 0 2.654238784316476e-08
a O 0 2.664107379146685e-09
new O 0 2.7550997039327285e-09
methodology O 0 8.729875489166261e-09
to O 0 5.893916465993243e-10
define O 0 1.9799259121100476e-08
and O 0 5.539687375488711e-09
characterize O 0 4.148355614574939e-08
the O 0 1.0454930254866213e-08
resulting O 0 2.423844058796476e-08
mRNA O 0 7.062433269311441e-07
splice O 0 4.773280579684069e-06
variants O 0 4.681064638134558e-06
. O 0 5.593863079411676e-06

Mutational O 0 0.00010767424828372896
analysis O 0 1.1051457704525092e-06
of O 0 2.279142790939659e-06
COL17A1 O 0 0.005214906297624111
identified O 0 1.8083948134517414e-06
a O 0 1.8819474689735216e-07
maternally O 0 2.3858440272306325e-06
inherited O 0 1.1204121619812213e-05
G O 0 0.00015287281712517142
- O 0 3.5036315239267424e-05
to O 0 2.581407159141236e-07
- O 0 0.0007337112911045551
T O 0 7.232762436615303e-05
transversion O 0 5.362893261917634e-06
at O 0 1.292922036100208e-07
the O 0 5.748553189022232e-09
- O 0 4.544393306105121e-09
1 O 0 5.921763079896891e-09
position O 0 2.9858860273179744e-08
of O 0 2.8009868202616417e-08
exon O 0 5.216191425461147e-07
32 O 0 7.4594089483071e-07
. O 0 2.0972556740161963e-06

This O 0 4.905596142634749e-07
acceptor O 0 6.522259923258389e-07
splice O 0 6.482747721747728e-06
- O 0 2.0813386925055966e-07
site O 0 9.153368729641898e-09
mutation O 0 5.484397824773168e-09
led O 0 4.049437229980413e-09
to O 0 1.1104740460510243e-09
the O 0 6.06005512437946e-09
formation O 0 1.099870061693764e-07
of O 0 1.7549244546444243e-07
aberrant O 0 3.071102980811702e-07
transcripts O 0 5.339884410204832e-07
present O 0 3.6673615255722325e-08
at O 0 6.100008818066271e-07
extremely O 0 6.431695283026784e-07
low O 0 1.0581626156636048e-05
levels O 0 1.10717119241599e-05
. O 0 5.736032562708715e-06

Based O 0 6.176047122607997e-07
on O 0 1.7079857173030177e-07
our O 0 3.0018465935199856e-08
recent O 0 4.92084506475976e-09
finding O 0 1.9198484579874275e-08
that O 0 2.5804673953189194e-09
cycloheximide O 0 7.312675620596565e-07
stabilized O 0 1.1768387366828392e-06
mutant O 0 4.733718697025324e-07
COL17A1 O 0 5.796461209683912e-06
transcripts O 0 2.0156294056050683e-07
in O 0 5.6837374806661956e-09
keratinocytes O 0 1.3514241459233745e-07
homozygous O 0 1.921713099761746e-08
for O 0 2.139478594287425e-09
a O 0 8.915990612479163e-09
frameshift O 0 1.1790338021455682e-06
mutation O 0 5.2184400800570074e-08
, O 0 5.308619321908736e-09
the O 0 5.883799225614439e-09
effects O 0 1.303915269090794e-07
of O 0 1.201926522753638e-07
the O 0 5.80462611310395e-08
splice O 0 8.092625307654089e-07
- O 0 3.24520073036183e-08
site O 0 4.1043977105914564e-09
mutation O 0 2.2444859304471265e-09
on O 0 1.02450909977847e-08
splicing O 0 3.653579483398062e-08
of O 0 2.8453021272412116e-08
COL17A1 O 0 5.14586054123356e-06
transcripts O 0 1.417211308307742e-07
were O 0 2.866359150033304e-09
determined O 0 6.864244728177482e-09
using O 0 7.183437844560103e-09
reverse O 0 2.1299952379649767e-07
transcriptase O 0 5.076935849501751e-07
polymerase O 0 5.808790959349608e-08
chain O 0 7.124600021057859e-09
reaction O 0 2.4683226573785078e-09
of O 0 8.067503109998597e-09
total O 0 4.156582633640937e-09
RNA O 0 1.4016579008568897e-08
from O 0 2.4034763068669918e-09
keratinocytes O 0 1.95189059581935e-07
incubated O 0 5.544796266576668e-08
for O 0 2.65109023622756e-09
2 O 0 4.2860921212195535e-07
. O 0 6.594372621293587e-07

5 O 0 2.860412905647536e-06
h O 0 4.7454255991397076e-07
in O 0 2.5561213146119144e-09
the O 0 1.5733035985121546e-09
presence O 0 2.469598969767617e-09
or O 0 3.792458791451736e-09
absence O 0 3.585435592867725e-08
of O 0 4.932199004770155e-08
10 O 0 2.6730472768576874e-07
microg O 0 8.975815035228152e-06
cycloheximide O 0 7.72544171923073e-06
per O 0 4.54153621376463e-07
ml O 0 1.3568545000453014e-05
. O 0 3.6117555737291696e-06

Using O 0 6.744357250454414e-08
this O 0 2.8312363564708676e-09
approach O 0 9.182676841135162e-09
, O 0 2.0080761498064703e-09
an O 0 1.3054071157370117e-09
abnormally O 0 9.196772765562855e-08
spliced O 0 4.996714437766059e-07
transcript O 0 5.850453703715175e-07
was O 0 2.0029284897304933e-08
identified O 0 3.0698212860613694e-09
that O 0 1.5039988698895002e-10
contains O 0 5.732903596289418e-10
an O 0 3.0037622389400553e-10
extra O 0 7.60843832381397e-09
264 O 0 2.1262298588453632e-08
bases O 0 5.323290697134553e-09
upstream O 0 1.9804923923061324e-08
from O 0 3.946852178415838e-09
exon O 0 1.2099874879822892e-07
32 O 0 3.560567662930225e-08
, O 0 1.8618698804928613e-09
resulting O 0 6.156731569006979e-09
in O 0 2.73825695451535e-09
a O 0 1.3828042710883892e-08
premature O 0 4.107783979634405e-07
termination O 0 1.7561611684868694e-06
codon O 0 5.679926744051045e-06
27 O 0 3.26776512338256e-06
bp O 0 1.9288427210994996e-06
downstream O 0 1.701294536360365e-07
from O 0 2.3046442976237813e-08
the O 0 1.635446409409269e-07
cryptic O 0 4.004949005320668e-06
splice O 0 9.358393981528934e-06
site O 0 1.3784667771687964e-06
. O 0 4.804093350685434e-06

Three O 0 3.095417184795224e-07
other O 0 1.471967880917191e-08
splice O 0 4.3824982753903896e-07
variants O 0 3.64458720980565e-08
, O 0 1.5381367290956405e-09
including O 0 3.651283997374577e-10
one O 0 3.200642806344689e-10
derived O 0 5.221770238428292e-10
from O 0 6.137523267391032e-10
the O 0 1.785437464540962e-09
skipping O 0 1.1071141337026802e-08
of O 0 1.2511266689330114e-08
exon O 0 1.0337271305616014e-07
32 O 0 3.334384857112127e-08
, O 0 4.197541425554618e-09
were O 0 1.0994270382980176e-08
also O 0 1.2330650278613575e-08
identified O 0 5.321313665263006e-07
. O 0 2.9852765237592394e-06

These O 0 2.8247524141988833e-07
results O 0 1.205646071866795e-07
indicate O 0 2.4598406866971345e-08
the O 0 6.081963377368993e-09
usefulness O 0 1.6233849464697414e-07
of O 0 2.023309342291668e-08
cycloheximide O 0 4.0228343323178706e-07
treatment O 0 8.315595323438174e-09
in O 0 2.3440411833774988e-09
evaluating O 0 2.993630232595024e-08
the O 0 5.886133802590621e-09
abnormal O 0 2.333078441552061e-08
processing O 0 1.9727298905536372e-08
of O 0 1.2450706243782861e-08
mRNA O 0 2.3689423755968164e-08
due O 0 3.309111917815244e-08
to O 0 6.657852491542826e-09
splice O 0 6.28521036105667e-07
- O 0 4.37655067742071e-08
site O 0 4.180491064431635e-09
mutations O 0 3.2232136959464697e-09
, O 0 1.2575043228935101e-09
because O 0 2.1407766670478168e-09
( O 0 8.439010379390766e-09
i O 0 5.037263406393322e-08
) O 0 1.0757403856587189e-08
aberrant O 0 9.994070637731056e-08
splicing O 0 1.7004947494569933e-07
often O 0 2.372517959869924e-09
generates O 0 4.444518975077472e-09
a O 0 4.425444455335992e-09
premature O 0 9.098542363972228e-08
termination O 0 1.655433266023465e-07
codon O 0 2.3701045392954256e-07
, O 0 1.3692747380389392e-08
( O 0 6.847571842882871e-09
ii O 0 1.2037072565362905e-06
) O 0 2.0805639877607973e-08
transcripts O 0 1.9343345059041894e-07
with O 0 1.947883632169578e-09
premature O 0 9.287538205171586e-08
termination O 0 1.4894119715336274e-07
codons O 0 1.6709503825040883e-07
can O 0 6.9900236709941055e-09
occur O 0 2.132610532612489e-08
at O 0 1.607175050821752e-07
low O 0 2.54768337981659e-07
or O 0 1.394391624387481e-08
undetectable O 0 1.5248907914156007e-07
levels O 0 4.816278931230045e-09
due O 0 5.622708521002551e-09
to O 0 1.8574360938217183e-09
nonsense O 0 1.481177918094545e-07
- O 0 7.756134401404324e-09
mediated O 0 1.0042507270213719e-08
mRNA O 0 1.951129702248977e-09
decay O 0 8.858932254440788e-09
, O 0 1.2698102291874847e-10
and O 0 3.225228972780769e-10
( O 0 2.5237012479806253e-10
iii O 0 5.130700486688511e-08
) O 0 6.007412900466136e-10
the O 0 3.6040470607900943e-10
levels O 0 1.518171033332294e-09
of O 0 1.1185754544840165e-09
these O 0 2.426714384995421e-10
transcripts O 0 5.935548053059847e-09
can O 0 1.5234320749346608e-10
be O 0 3.510956803065568e-10
increased O 0 2.1147665840715035e-09
by O 0 1.1379302833347538e-08
cycloheximide O 0 7.513186574215069e-06
. O 0 2.1688128981622867e-06

A O 0 3.5977161587652517e-06
deletion O 0 3.01984982797876e-06
mutation O 0 3.607916596592986e-07
in O 0 5.4672721461201945e-08
COL17A1 O 0 4.504803291638382e-05
in O 0 1.4809908854829246e-08
five O 0 1.5258299512765916e-08
Austrian O 0 3.437724558352784e-07
families O 0 8.349512192751263e-09
with O 0 2.4293749234516326e-08
generalized O 0 0.09130904823541641
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997236132621765
represents O 0 8.658215620016563e-07
propagation O 0 2.599399067548802e-06
of O 0 1.6337565966750844e-07
an O 0 2.1741582756362732e-08
ancestral O 0 1.4478702041742508e-06
allele O 0 1.1278456440777518e-05
. O 0 5.2652130761998706e-06

Patients O 0 1.8351993276155554e-05
with O 0 4.766561687574722e-07
generalized O 1 0.9645227789878845
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
, O 0 1.1568133118089463e-07
a O 0 1.4309753382235613e-08
usually O 0 1.6244387168740104e-08
nonlethal O 0 2.3900206542748492e-06
form O 0 5.494399033523223e-07
of O 0 1.812338814488612e-05
junctional B-Disease 1 0.999995231628418
epidermolysis I-Disease 1 0.9999983310699463
bullosa I-Disease 1 0.9985098242759705
, O 0 1.3325420411547384e-07
have O 0 2.572753032836772e-08
generalized O 0 2.051171577477362e-06
blistering B-Disease 0 2.6506968424655497e-05
, O 0 2.039588707702933e-06
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 0.00014354579616338015
patchy B-Disease 1 1.0
alopecia I-Disease 1 0.9999998807907104
, O 0 1.1533852557477076e-05
and O 0 0.0006565373623743653
dental B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999998807907104
. O 0 0.0005771324504166842

Skin B-Disease 1 0.9999995231628418
fragility I-Disease 0 0.0038155813235789537
in O 0 8.73627570285862e-08
most O 0 3.7231944194360267e-09
cases O 0 1.7740147129075012e-09
is O 0 1.6436985106338398e-10
due O 0 2.6463717883729032e-09
to O 0 5.147171577846166e-10
mutations O 0 2.3301067741954284e-09
in O 0 6.614736536292298e-10
the O 0 2.880718552589201e-09
gene O 0 3.6184997220800597e-09
encoding O 0 3.8821298176117125e-08
type O 0 4.639884991775034e-07
XVII O 0 0.0022949830163270235
collagen O 0 2.053120851996937e-06
( O 0 4.9619686137702956e-08
COL17A1 O 0 1.601079202373512e-05
) O 0 1.6128591084907384e-07
. O 0 1.069814743459574e-06

Recently O 0 3.450357780820923e-06
, O 0 6.051325129874385e-08
we O 0 3.325188302483184e-08
reported O 0 2.1182112064366265e-08
five O 0 4.330421798925954e-09
Austrian O 0 9.344968532332132e-08
families O 0 7.499229681684483e-09
with O 0 2.912587859782434e-08
generalized O 0 0.1071106567978859
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
who O 0 5.876786417502444e-07
share O 0 8.43373655357027e-08
the O 0 5.643641642905095e-08
same O 0 1.0850965281861136e-07
COL17A1 O 0 6.5411782998126e-05
mutation O 0 4.151825578446733e-06
. O 0 3.7843649351998465e-06

Affected O 0 2.357494850002695e-06
individuals O 0 1.0990769183649718e-08
in O 0 3.944617077422663e-09
three O 0 2.4948045851402867e-09
families O 0 3.5989225488641807e-10
are O 0 3.098343248630897e-10
homozygous O 0 1.0440005304701572e-08
for O 0 1.586553666221846e-09
4003delTC O 0 1.4882334653520957e-07
, O 0 2.610596183671987e-09
whereas O 0 6.352991466229696e-09
those O 0 7.18270776189911e-10
in O 0 6.677128294718671e-10
two O 0 1.0300692521170163e-09
others O 0 1.3022363187786823e-09
are O 0 2.0837243042137743e-09
compound O 0 2.487619781277317e-07
heterozygotes O 0 3.955520696763415e-06
. O 0 3.5404391383053735e-06

To O 0 7.468000973176459e-08
determine O 0 8.248085947570871e-08
if O 0 8.613534774326581e-09
the O 0 7.678152336154653e-09
occurrence O 0 3.8995473516934e-08
of O 0 1.2674643556920273e-08
4003delTC O 0 2.508721195226826e-07
in O 0 1.5641538064770089e-09
these O 0 1.0781575632279328e-09
unrelated O 0 1.060528198593147e-08
families O 0 3.759378641721156e-10
signifies O 0 4.074228510120292e-09
propagation O 0 7.354338293907858e-08
of O 0 8.831651854279698e-09
an O 0 1.5872407832517865e-09
ancestral O 0 7.607687280142272e-08
allele O 0 3.6904899047840445e-07
or O 0 3.388703007090044e-08
a O 0 1.864511212090747e-08
mutational O 0 2.6586526473693084e-06
hot O 0 7.311292392842006e-06
spot O 0 5.9494059314602055e-06
, O 0 1.8579470406621112e-08
haplotypes O 0 6.94359769681796e-08
were O 0 2.8652713535137764e-09
determined O 0 8.288076003282185e-09
for O 0 1.436755936445877e-09
polymorphisms O 0 1.733565291317518e-08
both O 0 6.4724883230837804e-09
within O 0 3.695462780228809e-08
and O 0 8.426886211054807e-08
flanking O 0 2.2120328139862977e-05
COL17A1 O 0 0.0010653913486748934
. O 0 6.526610832224833e-06

Five O 0 1.1962941243837122e-05
intragenic O 0 2.41886136791436e-05
polymorphisms O 0 8.051271720432851e-07
were O 0 2.1110638570576157e-08
chosen O 0 3.996791875238159e-08
based O 0 7.856186812205124e-09
on O 0 3.4568905959986296e-08
their O 0 1.0530283134357887e-07
informativeness O 0 2.6070603780681267e-05
. O 0 4.2408851186337415e-06

One O 0 1.0253754112454772e-07
of O 0 1.3927941466818083e-08
these O 0 6.276710262653751e-10
, O 0 5.095780464259292e-10
not O 0 4.244111451168209e-10
previously O 0 8.9959684146379e-09
reported O 0 4.007056464416792e-09
, O 0 2.5248145796297194e-09
was O 0 4.6303064493713464e-08
2988 O 0 8.863581228979456e-07
A O 0 5.101075828406465e-08
or O 0 2.796945608452006e-08
C O 0 1.327928544014867e-06
that O 0 9.76096647953284e-10
introduces O 0 3.4723983688422777e-09
a O 0 8.853149879861633e-10
new O 0 2.1477375433676116e-09
restriction O 0 3.112762492207821e-09
site O 0 6.2870300077122465e-09
for O 0 2.32015029411059e-09
Eco0109 O 0 1.0929998097708449e-06
I O 0 7.06374612491345e-06
. O 0 2.5799206468946068e-06

All O 0 2.0332602446160308e-07
the O 0 5.9283550513100636e-08
4003delTC O 0 9.030799787979049e-07
alleles O 0 6.345958070141933e-08
showed O 0 1.5966513444709562e-08
the O 0 4.684375110031169e-09
same O 0 3.0324542876769556e-09
haplotype O 0 5.1717698568154447e-08
for O 0 2.0771331321611797e-09
these O 0 4.119738772345727e-09
five O 0 2.6773072647756635e-08
polymorphic O 0 1.5472184031750658e-06
markers O 0 1.8964233277074527e-06
. O 0 3.6594040011550533e-06

Fourteen O 0 4.2123068851651624e-05
microsatellite O 0 5.592768138740212e-05
polymorphisms O 0 9.986626992031233e-07
were O 0 9.567581571445771e-08
selected O 0 4.6388542784825404e-08
based O 0 9.365431097307919e-09
on O 0 1.957658035678378e-08
their O 0 1.0767504221576019e-08
high O 0 3.2445944952996797e-07
heterozygosity O 0 1.1753179478546372e-06
and O 0 5.887716980623736e-09
their O 0 4.338913228707497e-09
location O 0 3.751982546873478e-08
within O 0 5.8853849793649715e-08
10q23 O 0 3.1971003409125842e-06
- O 0 7.781525823702395e-07
q25 O 0 4.8671367949282285e-06
near O 0 4.6673753786308225e-06
COL17A1 O 0 0.0003640230861492455
. O 0 1.1668785191432107e-05

Three O 0 4.774436774823698e-07
families O 0 1.884396461093729e-08
shared O 0 5.2854748133768226e-08
microsatellite O 0 1.261526904272614e-05
polymorphisms O 0 2.2796689336246345e-06
covering O 0 1.1358636129443767e-06
at O 0 2.952578483927937e-07
most O 0 5.4497264478925445e-09
19 O 0 7.437779458996374e-08
cM O 0 2.3249853597917536e-07
, O 0 2.1411277195682032e-09
whereas O 0 5.446567197253671e-09
the O 0 3.35257088757146e-09
others O 0 1.2547489713909954e-09
shared O 0 9.943541545709422e-10
smaller O 0 1.4978475126881108e-09
regions O 0 2.263337073316052e-09
consistent O 0 1.4886005317293893e-08
with O 0 1.7505866756195587e-09
cross O 0 4.3798241478043565e-08
- O 0 3.444766960569723e-08
over O 0 7.476617103208127e-10
events O 0 4.037981615745423e-10
during O 0 4.70117333950526e-10
passage O 0 4.936419606416109e-10
of O 0 1.8134561907690028e-10
this O 0 4.461229649588283e-11
mutation O 0 1.927100257148595e-09
through O 0 1.8744907848144976e-09
several O 0 4.590775315449491e-09
generations O 0 2.4655344077473274e-07
. O 0 1.2904204140795628e-06

These O 0 4.3095369051115995e-07
results O 0 3.8674676261507557e-07
indicate O 0 3.0752143942436305e-08
that O 0 2.025092316060295e-09
4003delTC O 0 2.1752933321295131e-07
occurs O 0 4.855599922137799e-09
on O 0 4.409443921105094e-09
a O 0 1.4055068220386602e-09
single O 0 2.8327704626462946e-09
ancestral O 0 3.98741875073938e-08
allele O 0 4.025366990845214e-07
. O 0 9.698010217107367e-08
. O 0 1.0597365189823904e-06

The O 0 5.668254289048491e-06
haptoglobin O 0 0.0001160082538262941
- O 0 3.3000972052832367e-06
gene O 0 6.488880899269134e-08
deletion O 0 2.976970563395298e-07
responsible O 0 1.4428759698148497e-07
for O 0 7.210180541505906e-08
anhaptoglobinemia B-Disease 0 0.00012629572302103043
. O 0 1.2676437108893879e-05

We O 0 5.998270466989197e-07
have O 0 1.179510888960067e-08
found O 0 5.480696341209068e-09
an O 0 1.3755616645738655e-09
allelic O 0 2.555377704993589e-07
deletion O 0 2.9529192602240073e-07
of O 0 1.1853650505599944e-07
the O 0 1.8522158029554703e-07
haptoglobin O 0 3.4914173738798127e-05
( O 0 6.039724809170366e-08
Hp O 0 1.0716885299189016e-06
) O 0 4.213302595701407e-09
gene O 0 2.862731163233434e-09
from O 0 9.778818865768812e-10
an O 0 4.4004519472728987e-10
individual O 0 3.3638440921635038e-09
with O 0 1.180064401751224e-08
anhaptoglobinemia B-Disease 0 1.7868604118120857e-05
. O 0 4.056469151691999e-06

The O 0 3.2846364774741232e-06
Hp O 0 1.057609733834397e-05
gene O 0 4.490055616201971e-08
cluster O 0 3.0213283253033296e-07
consists O 0 2.8041835520298264e-08
of O 0 3.2515885095563135e-08
coding O 0 1.1317769832430713e-07
regions O 0 1.1229817964419908e-08
of O 0 3.919008406683133e-08
the O 0 2.9367305032224067e-08
alpha O 0 3.690497010211402e-07
chain O 0 1.0103795133886706e-08
and O 0 2.7130897528593323e-09
beta O 0 5.120416091131119e-08
chain O 0 2.239555652039371e-09
of O 0 3.5267109232961502e-09
the O 0 5.0595230227656884e-09
haptoglobin O 0 7.64372771300259e-07
gene O 0 2.0749443052636707e-08
( O 0 8.365595327575193e-09
Hp O 0 4.255577721323789e-07
) O 0 2.812409416463879e-09
and O 0 2.975577118036199e-09
of O 0 1.0974912534322812e-08
the O 0 2.1677649897355877e-08
alpha O 0 3.0934342021282646e-07
chain O 0 9.886774066103499e-09
and O 0 4.817115151212192e-09
beta O 0 9.870969108760619e-08
chain O 0 1.4546968962747542e-08
of O 0 1.3320792469073695e-08
the O 0 2.3815324823317496e-08
haptoglobin O 0 2.0388381472002948e-06
- O 0 9.308375581440487e-08
related O 0 1.1415585809970707e-08
gene O 0 2.842129021018991e-08
( O 0 1.875736366230285e-08
Hpr O 0 1.05934134353447e-06
) O 0 7.615001074157135e-09
, O 0 2.668837373320798e-09
in O 0 2.71776134930235e-09
tandem O 0 8.074972868143959e-08
from O 0 6.289896603561829e-09
the O 0 4.094610162042045e-08
5 O 0 9.356674581795232e-07
side O 0 3.5971738725493196e-06
. O 0 1.5917489690764342e-06

Southern O 0 1.0617894986353349e-05
blot O 0 1.3195021892897785e-05
and O 0 8.60956319570505e-08
PCR O 0 2.152328022475558e-07
analyses O 0 2.0612883844250973e-08
have O 0 6.680644371037658e-10
indicated O 0 3.321231734076946e-09
that O 0 9.427685021545784e-11
the O 0 4.386650209742271e-10
individual O 0 1.8252441225108385e-10
with O 0 2.7534172164500603e-10
anhaptoglobinemia B-Disease 0 7.716415240111019e-08
was O 0 1.002434579788769e-08
homozygous O 0 2.3732105169926854e-09
for O 0 4.758277105665343e-10
the O 0 9.810727785719564e-10
gene O 0 1.885330114248518e-09
deletion O 0 8.169110721212292e-09
and O 0 5.722394225138316e-10
that O 0 1.93855723140679e-10
the O 0 1.7190930901023194e-09
gene O 0 6.421542853018991e-09
deletion O 0 6.835504251512248e-08
was O 0 3.4690042838292356e-08
included O 0 7.819142666676271e-09
at O 0 5.114539902706383e-08
least O 0 2.8988249578532077e-09
from O 0 2.0108203990787388e-09
the O 0 9.740625195320263e-09
promoter O 0 4.0473008766639396e-07
region O 0 9.115217380895047e-08
of O 0 1.546558934251152e-07
Hp O 0 5.725020400859648e-06
to O 0 3.267684789420855e-08
Hpr O 0 2.3838424567657057e-06
alpha O 0 2.4996126057885704e-07
but O 0 1.9097454728722596e-09
not O 0 1.121072235044096e-09
to O 0 4.258514429977822e-09
Hpr O 0 1.7598579233890632e-06
beta O 0 1.216239866153046e-06
( O 0 5.6375416335185946e-08
Hpdel O 0 5.1702791097341105e-06
) O 0 9.17564122460135e-08
. O 0 8.869068892636278e-07

In O 0 1.0274055739500909e-07
addition O 0 2.948112154399496e-08
, O 0 2.6073867509524007e-09
we O 0 1.999484355863501e-09
found O 0 1.6618063591877785e-09
seven O 0 1.4370794554352528e-09
individuals O 0 8.101418841333086e-11
with O 0 2.0858784144373033e-10
hypohaptoglobinemia B-Disease 0 7.298331894389776e-08
in O 0 1.4167925721508823e-09
three O 0 1.1755214579523e-09
families O 0 9.531649775018636e-11
, O 0 2.377209540327385e-10
and O 0 2.6305080336186393e-10
the O 0 1.5002721287515897e-09
genotypes O 0 1.448385091862292e-07
of O 0 1.4645214818642671e-08
six O 0 5.582613926691238e-09
of O 0 3.6160987537670053e-09
the O 0 2.709014790269748e-09
seven O 0 2.9522577715823672e-09
individuals O 0 1.6513060363543275e-10
were O 0 1.5067244119038037e-09
found O 0 9.607291628910275e-10
to O 0 2.0497137320774073e-09
be O 0 4.536826381240644e-08
Hp2 O 0 0.0007014597649686038
/ O 0 0.0008062468841671944
Hpdel O 0 0.0008469384047202766
. O 0 1.0165101230086293e-05

The O 0 6.877181135678256e-07
phenotypes O 0 9.93782236946572e-07
and O 0 1.5459551860885767e-08
genotypes O 0 3.1960499313754553e-07
in O 0 1.7951283792783101e-09
one O 0 3.6637781697379523e-10
of O 0 5.681762282883085e-10
these O 0 1.6485493525841832e-10
three O 0 4.1116668403340384e-10
families O 0 1.7926263251588637e-10
showed O 0 2.2368147334361765e-09
the O 0 2.181430369674331e-09
father O 0 3.955420879719895e-09
to O 0 1.458007159449437e-09
be O 0 1.2573106111801735e-08
hypohaptoglobinemic B-Disease 0 1.6997292959786137e-06
( O 0 6.426581222740424e-08
Hp2 O 0 3.2239611300610704e-06
) O 0 1.0035498654303865e-08
and O 0 2.7364935206719565e-08
Hp2 O 0 3.2580155675532296e-05
/ O 0 4.487312708079116e-06
Hpdel O 0 6.489527550002094e-06
, O 0 6.299849975022198e-09
the O 0 2.72620304109239e-09
mother O 0 1.4194513342502546e-09
to O 0 4.2106740316683045e-10
be O 0 6.622162818104016e-09
Hp2 O 0 1.7899513977681636e-06
- O 0 8.311555887985378e-08
1 O 0 8.9917520540439e-08
and O 0 1.174061203812471e-08
Hp1 O 0 1.3314538591657765e-05
/ O 0 1.6133865301526384e-06
Hp2 O 0 2.1960570393275702e-06
, O 0 1.50944556853716e-09
one O 0 3.552031446751869e-10
of O 0 1.2678020855361183e-09
the O 0 1.343097300043894e-09
two O 0 6.847216127425781e-10
children O 0 2.2723635473287374e-10
to O 0 2.765659923298358e-10
be O 0 4.7483790233116e-09
hypohaptoglobinemic B-Disease 0 1.4917518456059042e-06
( O 0 4.102153638996242e-08
Hp2 O 0 4.246458047418855e-06
) O 0 1.1589341042395063e-08
and O 0 1.7513789529743917e-08
Hp2 O 0 2.745906931522768e-05
/ O 0 1.0017170097853523e-05
Hpdel O 0 2.1802643459523097e-05
, O 0 8.589418065696464e-09
and O 0 3.24317550592923e-09
the O 0 3.46193651523663e-09
other O 0 6.064896918012153e-10
child O 0 2.251938857611435e-09
to O 0 3.2713920461446833e-10
be O 0 3.6583753804109165e-09
Hp1 O 0 2.1164155441510957e-06
and O 0 6.304816935198687e-08
Hp1 O 0 0.0007138871005736291
/ O 0 2.8325066523393616e-05
Hpdel O 0 2.361214683332946e-05
, O 0 6.649565342797814e-09
showing O 0 1.1765494356552608e-08
an O 0 2.4009882970688068e-09
anomalous O 0 1.5158128974235296e-07
inheritance O 0 2.2332440607897297e-07
of O 0 5.366676418816496e-07
Hp O 0 4.136813004151918e-05
phenotypes O 0 1.5835668136787717e-06
in O 0 1.7379717220933344e-08
the O 0 3.819094018808755e-08
child O 0 9.058732075573062e-08
with O 0 2.4815367538622013e-08
Hp1 O 0 0.000128707688418217
. O 0 9.738920198287815e-06

The O 0 5.928099199081771e-06
Hp2 O 0 0.07516632974147797
/ O 0 0.0011299879988655448
Hpdel O 0 0.00014165793254505843
individuals O 0 7.816518987624477e-09
had O 0 7.3509553999429045e-09
an O 0 1.2015817230093262e-09
extremely O 0 1.8220390529677388e-08
low O 0 2.853425087323558e-07
level O 0 2.2894428184372373e-06
of O 0 1.4750403920515964e-07
Hp O 0 5.186090675124433e-06
( O 0 1.9576680276855996e-09
mean O 0 6.333923163737154e-09
+ O 0 2.2614223382788623e-08
/ O 0 2.605976057168391e-08
- O 0 6.49014086917532e-09
SD O 0 1.4505747003568104e-07
= O 0 1.5145392495696797e-08
0 O 0 5.765716348804517e-09
. O 0 1.7622988623955393e-09
049 O 0 3.1481116025133815e-07
+ O 0 5.459664720319779e-08
/ O 0 8.770636128474507e-08
- O 0 1.3298629752966917e-08
0 O 0 2.4401302312071493e-08
. O 0 1.0244152193195077e-08
043 O 0 2.602313770694309e-06
mg O 0 2.492894964234438e-06
/ O 0 2.871685751415498e-07
ml O 0 1.3886142369301524e-07
; O 0 2.559741529850612e-09
n O 0 2.880522487203052e-08
= O 0 4.0699276837585785e-08
6 O 0 2.1046794529411272e-08
) O 0 3.1418395662896614e-10
, O 0 1.2819975636624292e-10
compared O 0 2.6875165981543603e-10
with O 0 7.276442642867309e-11
the O 0 4.5614292898399356e-10
level O 0 1.6798477275870027e-08
( O 0 2.760063566586979e-10
1 O 0 1.660076742737715e-09
. O 0 3.0035102183134654e-10
64 O 0 5.820810056178516e-09
+ O 0 1.5391293572974973e-08
/ O 0 2.266837739739458e-08
- O 0 2.8939082241663527e-09
1 O 0 5.120227353216933e-09
. O 0 1.1692736778812218e-09
07 O 0 1.3089449169001455e-07
mg O 0 6.426103595913446e-07
/ O 0 1.0539687167465672e-07
ml O 0 7.410110924865876e-08
) O 0 4.322992797067826e-10
obtained O 0 4.289999466777772e-09
from O 0 1.3090948325356067e-09
52 O 0 4.8243446570950255e-08
healthy O 0 6.738391533644972e-08
volunteers O 0 8.244782634392323e-08
having O 0 1.5940565845085075e-07
phenotype O 0 1.816509893615148e-06
Hp2 O 0 1.0831609870365355e-05
, O 0 2.1664504856744315e-08
whereas O 0 2.757603745351389e-08
the O 0 2.5721446306192775e-08
serum O 0 7.564885606825555e-08
Hp O 0 6.798628646720317e-07
level O 0 1.4835302408755524e-07
of O 0 5.28136068211893e-09
an O 0 2.0855642213213343e-10
individual O 0 5.148968473811522e-10
with O 0 1.6739235553231424e-09
Hp1 O 0 7.670530067116488e-06
/ O 0 2.9360417101997882e-06
Hpdel O 0 5.803613021271303e-06
was O 0 3.2152397011486755e-07
0 O 0 9.094046049540339e-07
. O 0 7.546654501311423e-07

50 O 0 4.351522875367664e-06
mg O 0 0.0002058004611171782
/ O 0 2.0179264538455755e-05
ml O 0 2.24224663725181e-06
, O 0 1.6096582955427152e-09
which O 0 3.049470398419629e-10
was O 0 2.6079138848444927e-09
approximately O 0 7.483736408353536e-10
half O 0 5.598104202420018e-10
the O 0 4.067129966145444e-10
level O 0 1.4670544778994099e-08
of O 0 3.1394689070651793e-09
Hp O 0 1.2820433425986266e-07
in O 0 1.007354200055488e-09
control O 0 3.929480030251398e-08
sera O 0 5.054317853137036e-07
from O 0 3.0154510000102164e-09
the O 0 1.232944946139014e-08
Hp1 O 0 1.0461133115313714e-06
phenotype O 0 1.4256062286222004e-07
( O 0 3.1568221370292804e-09
1 O 0 1.3751977334663934e-08
. O 0 1.0707001951715256e-09
26 O 0 2.2055800741327403e-08
+ O 0 3.8397789836608354e-08
/ O 0 3.766610134903203e-08
- O 0 3.881062138333391e-09
0 O 0 3.4966838313721382e-09
. O 0 8.91901386079752e-10
33 O 0 1.6269225966425438e-08
mg O 0 5.84727445129829e-07
/ O 0 1.0783436010797232e-07
ml O 0 4.912801188083904e-08
; O 0 1.0871525901734458e-09
n O 0 1.1201302108077016e-08
= O 0 1.8397125600699837e-08
9 O 0 3.028877415545139e-08
) O 0 9.239805587313299e-10
, O 0 5.846822470623181e-10
showing O 0 1.233700164249285e-08
a O 0 1.513182112944378e-08
gene O 0 7.508749888529564e-08
- O 0 1.8194836570728512e-07
dosage O 0 1.312228732786025e-06
effect O 0 1.2747420896630501e-06
. O 0 1.50217624650395e-06

The O 0 3.5341810189493117e-07
other O 0 1.3903708406814985e-08
allele O 0 2.52934285072115e-07
( O 0 2.8918625716300994e-08
Hp2 O 0 1.7750026017893106e-06
) O 0 3.113053370640273e-09
of O 0 3.547746985077538e-09
individuals O 0 8.871711143498828e-10
with O 0 3.883787069725031e-09
Hp2 O 0 0.0022508855909109116
/ O 0 0.0005595677066594362
Hpdel O 0 9.295275958720595e-05
was O 0 4.865429303890778e-08
found O 0 7.319276851269763e-10
to O 0 1.9039289589350972e-10
have O 0 2.994021142121994e-10
, O 0 3.0726962640947875e-10
in O 0 2.665468123996817e-10
all O 0 8.750593027961884e-10
exons O 0 1.8348519148503328e-08
, O 0 5.184781493028368e-10
no O 0 1.1377431219372625e-09
mutation O 0 3.794586422856128e-09
, O 0 1.7770219740143034e-09
by O 0 3.521877678380747e-09
DNA O 0 1.372582971725933e-07
sequencing O 0 6.675007284684398e-07
. O 0 2.295389322171104e-06

On O 0 5.450830258268979e-07
the O 0 5.219920495846964e-09
basis O 0 5.160494254141668e-09
of O 0 2.3272506144422778e-09
the O 0 9.7074037697098e-10
present O 0 1.3132762655132524e-09
study O 0 8.362703862729859e-10
, O 0 3.710234064424611e-10
the O 0 8.148441366095938e-10
mechanism O 0 3.149282079561999e-08
of O 0 2.005091914725199e-08
anhaptoglobinemia B-Disease 0 1.055986558640143e-06
and O 0 7.241877320041112e-09
the O 0 9.327851380191987e-09
mechanism O 0 1.6459659946121974e-07
of O 0 2.0681643064790478e-08
anomalous O 0 4.2651993226172635e-07
inheritance O 0 1.3834393541856116e-07
of O 0 2.19268244450177e-07
Hp O 0 1.4144397027848754e-05
phenotypes O 0 2.416328243270982e-06
were O 0 1.6208957731578266e-07
well O 0 4.7365318778247456e-08
explained O 0 1.499551217420958e-06
. O 0 2.7148671506438404e-06

However O 0 8.552310077902803e-07
, O 0 3.073103727047055e-08
the O 0 7.654668010559362e-09
mechanism O 0 1.5387192320304166e-07
of O 0 9.462936390036703e-08
hypohaptoglobinemia B-Disease 0 4.8555370995018166e-06
remains O 0 2.023801471295883e-06
unknown O 0 3.64181942131836e-05

ATM O 0 5.495636287378147e-05
mutations O 0 1.0261888974127942e-06
and O 0 1.0652522064447112e-07
phenotypes O 0 1.6896356100915e-05
in O 0 5.600252279691631e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.6822693282847467e-07
in O 0 4.800880137878494e-09
the O 0 6.603533275750806e-09
British O 0 2.9015094327178304e-08
Isles O 0 2.4719193447708676e-07
: O 0 1.3692740274962034e-09
expression O 0 1.3107963603431472e-09
of O 0 2.1578139275391095e-09
mutant O 0 3.2333876021084507e-08
ATM O 0 2.749828524883924e-07
and O 0 1.9165544706822857e-09
the O 0 1.350552003565042e-09
risk O 0 6.158739740413921e-09
of O 0 8.261532258302395e-08
leukemia B-Disease 1 1.0
, O 1 0.5027070641517639
lymphoma B-Disease 1 1.0
, O 1 0.9999945163726807
and O 1 0.9999939203262329
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 1 0.7960787415504456

We O 0 9.653170991441584e-07
report O 0 3.8370920663055585e-08
the O 0 3.716156715682928e-09
spectrum O 0 3.5507746076746116e-08
of O 0 8.99845620239148e-09
59 O 0 3.9426254261343274e-08
ATM O 0 3.508758652515098e-07
mutations O 0 4.866644687240296e-08
observed O 0 8.658143002548968e-08
in O 0 4.021848667434824e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.6788442514534836e-08
patients O 0 4.451925939008561e-09
in O 0 2.1207731126793306e-09
the O 0 1.6155862425648593e-08
British O 0 4.2808758848877915e-07
Isles O 0 1.4310579899756704e-05
. O 0 2.2023448309482774e-06

Of O 0 6.621030024689389e-06
51 O 0 5.046489604865201e-06
ATM O 0 1.0975468285323586e-05
mutations O 0 2.259168212503937e-07
identified O 0 6.568338761780979e-08
in O 0 6.917632688896447e-09
families O 0 2.3466983911646366e-09
native O 0 1.7580015221341228e-09
to O 0 1.1903517060929403e-09
the O 0 8.486336966484487e-09
British O 0 2.0850637838520925e-07
Isles O 0 1.4871709481667494e-06
, O 0 7.60394058829661e-09
11 O 0 3.4233419654583486e-08
were O 0 1.3634005924245685e-08
founder O 0 9.199403905313375e-08
mutations O 0 1.5099933747819705e-08
, O 0 3.474624588051256e-09
and O 0 3.6820855253694162e-09
2 O 0 6.455969270291462e-08
of O 0 9.685289015237686e-09
these O 0 2.2810495714509216e-09
11 O 0 3.826582073429563e-08
conferred O 0 8.125866202135512e-08
a O 0 1.3507331253492794e-08
milder O 0 3.6830152794209425e-07
clinical O 0 2.002037149395619e-07
phenotype O 0 6.438482813564406e-08
with O 0 4.704923117770932e-10
respect O 0 5.18450748998589e-09
to O 0 4.967467770455869e-09
both O 0 1.2076645816705422e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.8162153310186113e-06
cellular O 0 5.655253062286647e-06
features O 0 4.818697902919666e-07
. O 0 1.435880903954967e-06

We O 0 7.905823622422758e-07
report O 0 6.306608923978274e-08
, O 0 5.599794405952707e-09
in O 0 3.1700784219879097e-09
two O 0 1.097554047646554e-08
A B-Disease 1 0.9671363234519958
- I-Disease 0 0.25962990522384644
T I-Disease 1 0.9999995231628418
families O 0 5.641259903654827e-09
, O 0 1.4393644054422339e-09
an O 0 1.389932502426916e-09
ATM O 0 3.0960077879171877e-07
mutation O 0 4.289993427164518e-08
( O 0 1.864479060031954e-08
7271T O 0 4.668816870889714e-07
- O 0 4.0397850398221635e-07
- O 0 1.3954483790712402e-07
> O 0 9.159555247606477e-08
G O 0 1.2395713611113024e-07
) O 0 4.865499114714567e-10
that O 0 4.059594327365801e-11
may O 0 4.4757378359072675e-10
be O 0 3.9966127629575965e-10
associated O 0 9.8075103593942e-10
with O 0 7.361162374097674e-11
an O 0 7.168046711747422e-11
increased O 0 9.573359882608656e-10
risk O 0 6.5250212344381e-08
of O 0 1.5566773754471797e-06
breast B-Disease 0 0.0005489123286679387
cancer I-Disease 0 9.60964371188311e-07
in O 0 8.035928367178258e-09
both O 0 2.6034571831701214e-08
homozygotes O 0 8.706995231477777e-07
and O 0 1.1506765318358703e-08
heterozygotes O 0 2.1693247731491283e-07
( O 0 2.559214173913915e-09
relative O 0 9.48722078675246e-09
risk O 0 7.061555784559914e-09
12 O 0 7.306211635693671e-09
. O 0 1.0047962462067517e-09
7 O 0 3.128519310280353e-08
; O 0 4.009931053872151e-09
P O 0 1.3260746527521405e-06
= O 0 1.3365767870254786e-07
. O 0 5.492332810774769e-09
0025 O 0 1.691341822152026e-06
) O 0 5.305225148077852e-10
, O 0 1.8233581311477565e-10
although O 0 3.984548524460507e-10
there O 0 4.4314391045574553e-10
is O 0 2.7718441431012764e-10
a O 0 1.7032507626524307e-09
less O 0 2.600454784840167e-08
severe O 1 0.9090943336486816
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 5.789124770672061e-07
in O 0 4.319456736734395e-10
terms O 0 1.1955554324316608e-09
of O 0 4.694667987692469e-10
the O 0 6.026245613632852e-10
degree O 0 9.72010241184762e-08
of O 0 2.4004657461773604e-07
cerebellar B-Disease 1 0.9999991655349731
degeneration I-Disease 1 0.9999998807907104
. O 0 3.162019493174739e-05

This O 0 2.959194489449146e-07
mutation O 0 3.927828231553576e-07
( O 0 8.635318238248146e-08
7271T O 0 1.4268919130699942e-06
- O 0 2.953344448997086e-07
- O 0 5.139819592159256e-08
> O 0 7.229046161683073e-08
G O 0 1.1048764037013825e-07
) O 0 7.842619331732692e-10
also O 0 1.4987498742069505e-10
allows O 0 8.136416540516223e-11
expression O 0 2.7378532774235964e-10
of O 0 6.318522927095671e-10
full O 0 4.308795098495466e-09
- O 0 2.2355268747276114e-09
length O 0 8.782747307201078e-10
ATM O 0 3.6650959600592614e-08
protein O 0 4.199967928997239e-09
at O 0 5.882239140220236e-09
a O 0 2.3948537597462405e-10
level O 0 6.195428614574894e-09
comparable O 0 1.5196428559960395e-09
with O 0 6.799319440808915e-11
that O 0 1.2353588985103414e-10
in O 0 1.5189183244501692e-09
unaffected O 0 8.133837070545269e-08
individuals O 0 1.23747083691228e-08
. O 0 3.595832254177367e-07

In O 0 2.06880613973226e-07
addition O 0 1.9285833374738104e-08
, O 0 2.5889173027593415e-09
we O 0 2.783214325674521e-09
have O 0 5.249682355490393e-10
studied O 0 4.841702860858277e-08
18 O 0 1.9479500679153716e-07
A B-Disease 1 0.9999488592147827
- I-Disease 1 0.9984064698219299
T I-Disease 1 0.9999998807907104
patients O 0 1.9647353965979164e-08
, O 0 8.972624865322132e-10
in O 0 5.905743116763063e-10
15 O 0 6.897487914159228e-09
families O 0 1.4297570072319132e-10
, O 0 8.708682663893796e-10
who O 0 1.1149585699143927e-09
developed O 0 9.517020771454554e-08
leukemia B-Disease 1 0.9999580383300781
, O 0 4.577069830702385e-06
lymphoma B-Disease 1 1.0
, O 0 1.217661611008225e-05
preleukemic O 0 0.093129463493824
T O 0 0.08131281286478043
- O 0 1.6674530343152583e-06
cell O 0 2.5441241291446204e-07
proliferation O 0 4.09602478157467e-07
, O 0 9.763839514675965e-09
or O 0 2.3972287976903317e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.8298946997674648e-06
mostly O 0 1.0503980796272572e-08
in O 0 1.3238877549781591e-08
childhood O 0 7.937787813716568e-07
. O 0 1.6535414033569396e-06

A O 0 2.5287688458774937e-06
wide O 0 3.9033170651237015e-07
variety O 0 3.7958695742190685e-08
of O 0 6.456560441847614e-08
ATM O 0 2.3032614535622997e-06
mutation O 0 7.96190313678835e-09
types O 0 2.6209738823723683e-09
, O 0 5.24583876337914e-10
including O 0 1.0766143532237038e-09
missense O 0 2.2590970161218138e-07
mutations O 0 4.189561053635771e-08
and O 0 1.38837004115544e-08
in O 0 2.4397392550667973e-08
- O 0 1.7513676766611752e-06
frame O 0 2.2094004634709563e-06
deletions O 0 7.632351639585977e-08
, O 0 3.479585286569886e-09
were O 0 1.0048140097751457e-08
seen O 0 1.0626156843329682e-08
in O 0 2.5948889703641953e-09
these O 0 7.370006382956262e-09
patients O 0 4.7967905203449845e-08
. O 0 8.669097155689087e-07

We O 0 2.7624949439086777e-07
also O 0 4.041474266358591e-09
show O 0 8.181362809445147e-10
that O 0 1.0441727343879492e-10
25 O 0 2.337705584665173e-09
% O 0 5.081280951557687e-10
of O 0 3.898489531195537e-09
all O 0 2.0942040990235e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
patients O 0 7.76541853042545e-08
carried O 0 3.104025125821863e-08
in O 0 1.7174748734305467e-08
- O 0 2.2224891438327177e-07
frame O 0 3.7392166518657177e-07
deletions O 0 4.70108858507956e-08
or O 0 6.7012453364156954e-09
missense O 0 1.1919454578901423e-07
mutations O 0 2.1580330411552495e-08
, O 0 1.1828987789286316e-09
many O 0 1.268379568042377e-10
of O 0 1.1498312302293812e-09
which O 0 3.2347161060819474e-10
were O 0 1.9586130495241605e-09
also O 0 2.7307395233933107e-10
associated O 0 1.2396790260993384e-09
with O 0 3.209629229061761e-10
expression O 0 9.271605705407637e-09
of O 0 6.19096596210511e-08
mutant O 0 7.813598585926229e-07
ATM O 0 1.0369442861701827e-05
protein O 0 1.6801205902083893e-06
. O 0 2.1393097995314747e-06

The O 0 1.0209021183982259e-06
DMPK O 0 8.167728083208203e-05
gene O 0 2.2814909073076706e-07
of O 0 6.222645652087522e-07
severely O 1 0.9999268054962158
affected O 1 0.9999958276748657
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8094830513000488
is O 0 1.556257416268636e-07
hypermethylated O 0 9.513963959761895e-06
proximal O 0 2.0617246718757087e-06
to O 0 1.2164582230411725e-08
the O 0 2.031333146135239e-08
largely O 0 3.825918071242995e-08
expanded O 0 1.5537955277977744e-07
CTG O 0 4.2023559217341244e-05
repeat O 0 4.887873274128651e-06
. O 0 2.8031490728608333e-06

Using O 0 1.752492039486242e-06
methylation O 0 5.349734692572383e-06
- O 0 3.7707254705310334e-06
sensitive O 0 1.5553047205685289e-07
restriction O 0 1.6589506657282982e-08
enzymes O 0 1.662247761657909e-08
, O 0 1.8801986634287005e-09
we O 0 2.3549890926233275e-09
characterized O 0 2.6977637901381968e-09
the O 0 3.073747034676444e-09
methylation O 0 3.3609598659722906e-08
pattern O 0 3.161698813869407e-08
on O 0 9.976259818245126e-09
the O 0 3.0636211345580477e-09
5 O 0 1.904697199961447e-08
side O 0 1.8769819476460725e-08
of O 0 1.7889561831907486e-08
the O 0 3.0857197685918436e-08
CTG O 0 4.181440544925863e-06
repeat O 0 2.5334363940032745e-08
in O 0 2.6811282083372134e-09
the O 0 4.987470880735145e-09
DMPK O 0 7.974671234478592e-07
gene O 0 2.7267437197053823e-09
of O 0 3.5302372136669646e-09
normal O 0 1.1410535627476293e-08
individuals O 0 2.247299568658434e-10
and O 0 6.231524185551507e-10
of O 0 7.1603198925629385e-09
patients O 0 1.4420335148201957e-08
affected O 0 6.610404312823448e-08
with O 0 2.51230758294696e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 5.452993150356633e-07
showing O 0 3.572881368540948e-08
expansions O 0 3.618336208432993e-08
of O 0 1.0634510161366961e-08
the O 0 1.3485244032551691e-08
repetitive O 0 2.3339805466093821e-07
sequence O 0 7.579038907579161e-08
. O 0 6.333345368148002e-07

The O 0 2.5558849756635027e-06
gene O 0 6.073022973396291e-07
segment O 0 1.8721947014910256e-07
analyzed O 0 3.830028916240735e-08
corresponds O 0 2.4617934357706872e-08
to O 0 5.238062428247758e-09
the O 0 2.1262623661755242e-08
genomic O 0 7.164522912717075e-07
SacI O 0 6.173378642415628e-05
- O 0 1.6580860346948612e-06
HindIII O 0 5.2161640269332565e-06
fragment O 0 6.405996941794001e-07
carrying O 0 3.192506881077861e-07
exons O 0 3.264749693698832e-06
11 O 0 2.0793320345546817e-06
- O 0 1.2237419468874577e-06
15 O 0 1.117266606343037e-06
. O 0 1.7459879018133506e-06

There O 0 8.410313512285938e-07
is O 0 4.2270613676009816e-08
constitutive O 0 1.910039827635046e-06
methylation O 0 2.2297795965187106e-07
in O 0 2.23095746321178e-08
intron O 0 4.36061100117513e-07
12 O 0 1.7236320104530023e-07
at O 0 4.4232947971067915e-08
restriction O 0 2.925391484609463e-09
sites O 0 2.6188551327521736e-09
of O 0 4.205531034529031e-09
SacII O 0 1.0395950766906026e-06
and O 0 1.0362199098779001e-08
HhaI O 0 1.1898074490090949e-06
, O 0 2.9327884565333306e-09
localized O 0 2.3976898688715664e-08
1 O 0 8.105078563858115e-08
, O 0 4.1970373843014386e-09
159 O 0 3.386415770023632e-08
- O 0 2.5474786724544174e-08
1 O 0 3.216815613882318e-08
, O 0 1.2647547897870481e-08
232 O 0 1.0865732491538438e-07
bp O 0 1.2862659559687017e-07
upstream O 0 2.9591316064170314e-08
of O 0 3.214625721170705e-08
the O 0 6.10362747011095e-08
CTG O 0 1.979893568204716e-05
repeat O 0 2.548174222738453e-07
, O 0 3.2349463108261034e-09
whereas O 0 2.0342438844522803e-09
most O 0 2.6156390942055907e-10
, O 0 1.048949538340338e-10
if O 0 9.533777239889574e-11
not O 0 1.5987555723739888e-10
all O 0 2.1527810090127275e-10
, O 0 2.287596917449619e-10
of O 0 4.796181785060583e-10
the O 0 2.5481367016411127e-10
other O 0 4.9927964540508185e-11
sites O 0 8.632856096646435e-10
of O 0 3.737780751578157e-09
SacII O 0 1.1771833214879734e-06
, O 0 1.0523311999577345e-08
HhaI O 0 1.3572743000622722e-06
, O 0 6.751382564118558e-09
and O 0 5.807857306194819e-09
HpaII O 0 5.941627136962779e-07
in O 0 1.0063900823809036e-09
this O 0 4.802058750641436e-10
region O 0 6.54176757208802e-09
are O 0 1.1063452376447458e-09
unmethylated O 0 5.655731882825421e-08
, O 0 4.6413986543036856e-10
in O 0 3.124544512012051e-10
normal O 0 3.2344218414692705e-09
individuals O 0 1.3185262603965242e-10
and O 0 5.373190781199355e-10
most O 0 4.4726994330446246e-10
of O 0 2.8692634934657235e-09
the O 0 2.5987739959987266e-08
patients O 0 5.730657903768588e-08
. O 0 6.207413321135391e-07

In O 0 5.6796444880546915e-08
a O 0 9.2061407386268e-09
number O 0 5.960938853633024e-09
of O 0 2.3041694774406096e-08
young O 0 2.3810970617432758e-07
and O 0 5.4387946590850333e-08
severely O 0 1.9968283595517278e-05
affected O 0 2.298783385867864e-08
patients O 0 3.2595537380331052e-09
, O 0 6.602510205233614e-10
however O 0 2.7696838156288095e-09
, O 0 6.502429150678779e-10
complete O 0 3.2500182545192047e-09
methylation O 0 5.7052433888316045e-09
of O 0 1.231625801345615e-09
these O 0 8.656975136744904e-11
restriction O 0 5.327330243609651e-10
sites O 0 1.4431086325927822e-09
was O 0 3.807418824663955e-09
found O 0 9.72089186923597e-10
in O 0 1.1749162753815767e-09
the O 0 2.121793762910329e-08
mutated O 0 4.07132574764546e-07
allele O 0 5.2094032980676275e-06
. O 0 3.3479384455858963e-06

In O 0 1.010881192087254e-07
most O 0 2.981252356093478e-09
of O 0 3.1614015849612542e-09
these O 0 3.6358557831128735e-10
patients O 0 5.977193184847351e-10
, O 0 3.1797961486113024e-10
the O 0 9.737444184310107e-10
onset O 0 9.499852353656024e-07
of O 0 8.309130095085493e-08
the O 0 6.46262776626827e-07
disease O 1 0.9969913959503174
was O 0 7.12208347977139e-05
congenital O 1 1.0
. O 0 0.00020780260092578828

Preliminary O 0 1.992271063500084e-05
in O 0 3.754940109956806e-07
vivo O 0 5.468666131491773e-06
footprinting O 0 9.63285219768295e-06
data O 0 9.259184707843815e-08
gave O 0 2.4250095265188065e-08
evidence O 0 5.599594032901223e-08
for O 0 3.2534728244826283e-09
protein O 0 2.2410565847508224e-08
- O 0 2.7674410318923037e-08
DNA O 0 1.5797001040596115e-08
contact O 0 6.116969597513844e-09
in O 0 1.139465299893061e-09
normal O 0 1.3574792845361117e-08
genes O 0 2.9831523917778213e-09
at O 0 1.1989999215700209e-08
an O 0 6.368978677784298e-10
Sp1 O 0 4.411894565237162e-07
consensus O 0 1.2138038130160567e-07
binding O 0 3.289810379669689e-08
site O 0 3.990050956304003e-08
upstream O 0 2.873153448490484e-08
of O 0 1.623181411503083e-08
the O 0 4.089661587158844e-08
CTG O 0 1.1354411981301382e-05
repeat O 0 8.114528782243724e-08
and O 0 2.114593167235057e-09
for O 0 3.438513918041508e-10
a O 0 3.101891243861843e-10
significant O 0 6.133685226394903e-10
reduction O 0 2.934724685488277e-09
of O 0 1.9562087505420322e-09
this O 0 1.7287593578885208e-10
interaction O 0 1.1911898134542298e-09
in O 0 1.9989533639463986e-10
cells O 0 1.2945788885332377e-09
with O 0 2.4927582220612976e-10
a O 0 3.9565075660163984e-09
hypermethylated O 0 6.523342221953499e-07
DMPK O 0 4.861482011619955e-06
gene O 0 6.262305873860896e-08
. O 0 4.7668024194535974e-08
. O 0 7.854255272832233e-07

The O 0 7.076487236190587e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.7238453981226485e-07
product O 0 3.236200996070693e-08
complexes O 0 4.341614001646121e-08
with O 0 3.329438946764185e-09
the O 0 4.9638050114708676e-08
transferrin O 0 9.710038284538314e-07
receptor O 0 1.1146066469791549e-07
and O 0 8.591990230399915e-09
lowers O 0 2.120078512746204e-08
its O 0 7.09860725756073e-10
affinity O 0 2.026780743236145e-09
for O 0 1.7472542301888438e-09
ligand O 0 3.831629058481667e-08
binding O 0 1.262497022480602e-07
. O 0 3.182065881901508e-07

We O 0 1.8132144532501115e-06
recently O 0 3.5956404076387116e-07
reported O 0 3.163460249311356e-08
the O 0 4.137622244826389e-09
positional O 0 3.4527661796346365e-07
cloning O 0 1.9673379370033217e-08
of O 0 5.001007163940585e-09
a O 0 2.309730184890668e-09
candidate O 0 5.874786168647006e-08
gene O 0 9.122920232584875e-07
for O 0 5.481082553160377e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9998595714569092
HFE O 1 0.9999885559082031
. O 0 5.212367250351235e-05

The O 0 2.2756258033496124e-07
gene O 0 1.7572380883734695e-08
product O 0 6.12337824890119e-09
, O 0 4.46404246901011e-09
a O 0 2.5287232308102148e-09
member O 0 1.0194020738651943e-08
of O 0 2.063711690425407e-08
the O 0 2.3064384180315756e-08
major O 0 2.0598660910309263e-07
histocompatibility O 0 9.09418158698827e-05
complex O 0 7.748255370643164e-07
class O 0 6.464162538577511e-08
I O 0 8.772389605837816e-07
- O 0 6.216963299721101e-08
like O 0 8.321398570210192e-10
family O 0 5.497465260795309e-10
, O 0 3.699154038638852e-10
was O 0 1.6820496107072813e-09
found O 0 3.881341081868328e-10
to O 0 2.4582574864595585e-10
have O 0 8.529904560461432e-10
a O 0 7.082733066710034e-09
mutation O 0 9.30752364070031e-08
, O 0 1.4853253560431767e-07
Cys O 0 0.016999581828713417
- O 0 2.7901234716409817e-05
282 O 0 4.287231149646686e-06
- O 0 7.389972779492382e-06
- O 0 2.458350309098023e-06
> O 0 2.649924454090069e-06
Tyr O 0 3.671824015327729e-05
( O 0 1.3799561493499368e-08
C282Y O 0 1.395878257426375e-07
) O 0 4.6328460512334857e-10
, O 0 2.1275867179149088e-10
in O 0 2.3147125882694297e-10
85 O 0 5.362668087371958e-09
% O 0 1.8408770063871316e-09
of O 0 3.158775285783122e-08
patient O 0 3.0184108368302986e-07
chromosomes O 0 2.487959591235267e-06
. O 0 5.184661858947948e-06

This O 0 1.6019446036352747e-07
mutation O 0 2.955175659735687e-07
eliminates O 0 4.1386672933185764e-07
the O 0 1.2647138447619e-08
ability O 0 1.4129610370616774e-08
of O 0 5.956441384569189e-08
HFE O 0 1.0427615052321926e-05
to O 0 7.389021838832832e-09
associate O 0 8.767123915731645e-08
with O 0 5.5775473128960584e-09
beta2 O 0 5.674479780282127e-06
- O 0 5.3940843827149365e-06
microglobulin O 0 9.35044590733014e-06
( O 0 4.56215580868502e-08
beta2m O 0 1.388944383506896e-06
) O 0 6.840639610317112e-09
and O 0 9.00159857764038e-09
prevents O 0 2.8141172947471205e-08
cell O 0 1.0409335118310992e-06
- O 0 1.304167653870536e-07
surface O 0 2.907920304551226e-07
expression O 0 1.1097133665316505e-06
. O 0 3.347852043589228e-06

A O 0 1.5292598618543707e-06
second O 0 1.2260252901796775e-07
mutation O 0 1.54855221978778e-08
that O 0 4.939037512308175e-10
has O 0 2.1388328608207274e-10
no O 0 1.142566596890049e-09
effect O 0 3.01644753619712e-08
on O 0 6.676064856492303e-08
beta2m O 0 3.866276529151946e-06
association O 0 1.3783463259642303e-08
, O 0 6.9062688901055935e-09
H63D O 0 2.3264078663487453e-06
, O 0 3.2266829208538184e-09
was O 0 1.0117931381614653e-08
found O 0 7.231328869039544e-10
in O 0 1.0421895568768491e-09
eight O 0 6.917513672988207e-09
out O 0 2.3827262385367476e-09
of O 0 1.2019122586082176e-08
nine O 0 7.433950344193363e-08
patients O 0 6.966398125030082e-09
heterozygous O 0 1.3777285978733289e-08
for O 0 8.186158417800016e-09
the O 0 6.251995188222281e-08
C282Y O 0 3.7258075735735474e-06
mutant O 0 7.299309800146148e-06
. O 0 4.4509242798085324e-06

In O 0 2.829985987773398e-07
this O 0 9.724512750608483e-09
report O 0 1.0550283313648379e-08
, O 0 1.774410729460385e-09
we O 0 2.777815311105769e-09
demonstrate O 0 1.155078788173114e-08
in O 0 7.147221037229201e-09
cultured O 0 4.499022736581537e-07
293 O 0 1.6171192385172617e-07
cells O 0 2.741096523095621e-07
overexpressing O 0 2.2607207483815728e-06
wild O 0 8.230736625591817e-08
- O 0 7.102785559709446e-08
type O 0 6.192182411268732e-08
or O 0 1.870941268578008e-08
mutant O 0 1.20630048172643e-07
HFE O 0 1.255884285455977e-06
proteins O 0 7.9566619959337e-10
that O 0 1.2116890824032112e-10
both O 0 9.435118242251406e-10
the O 0 3.3893994277889306e-09
wild O 0 1.5141347731173482e-08
- O 0 2.7408761482661248e-08
type O 0 6.891573178791077e-08
and O 0 4.929029628897297e-08
H63D O 0 0.00025420510792173445
HFE O 0 4.1720013541635126e-05
proteins O 0 5.730075081089581e-09
form O 0 1.1799923704813864e-08
stable O 0 4.414377485773002e-08
complexes O 0 1.0672020600566157e-08
with O 0 1.3591806569124287e-09
the O 0 1.3872767823386312e-08
transferrin O 0 6.366780098687741e-07
receptor O 0 4.091300525033148e-07
( O 0 3.346618271393709e-08
TfR O 0 3.3061169233405963e-06
) O 0 7.590018924474862e-08
. O 0 1.089347165361687e-06

The O 0 4.787609668710502e-06
C282Y O 0 1.6482750652357936e-05
mutation O 0 4.403831894705945e-07
nearly O 0 4.049678281603519e-08
completely O 0 6.114463957374028e-08
prevents O 0 1.0835697672462175e-08
the O 0 7.0509633687265705e-09
association O 0 3.1353637464093254e-09
of O 0 8.04184718816714e-09
the O 0 1.4504246692581546e-08
mutant O 0 4.773193609253212e-07
HFE O 0 1.4623138667957392e-05
protein O 0 9.278065959961168e-08
with O 0 1.5018533972011028e-08
the O 0 2.6392009999653965e-07
TfR O 0 6.434960960177705e-05
. O 0 5.541208338399883e-06

Studies O 0 1.5848493148951093e-06
on O 0 7.518394795624772e-07
cell O 0 2.9837169677193742e-06
- O 0 1.9050847299695306e-07
associated O 0 1.991994125205565e-08
transferrin O 0 3.2364297908316075e-07
at O 0 1.7113934802637232e-07
37 O 0 2.0993672578129008e-08
degrees O 0 8.097228487713437e-08
C O 0 2.486811183644022e-07
suggest O 0 3.880736176853361e-09
that O 0 2.5104410217302586e-10
the O 0 3.9151513142599015e-09
overexpressed O 0 2.4298785206156026e-07
wild O 0 3.5635437711789564e-08
- O 0 4.246075135938554e-08
type O 0 6.378199657319783e-08
HFE O 0 6.021728040650487e-06
protein O 0 3.118915259392452e-08
decreases O 0 6.508103389535336e-09
the O 0 6.94051927041528e-10
affinity O 0 3.4145755112291454e-09
of O 0 1.2808744287440277e-08
the O 0 2.5054207597463574e-08
TfR O 0 1.1081366437792894e-06
for O 0 1.9749208490793535e-08
transferrin O 0 4.450597316463245e-06
. O 0 2.485057166268234e-06

The O 0 9.59851786319632e-06
overexpressed O 0 8.886397699825466e-05
H63D O 0 6.685427797492594e-05
protein O 0 3.3477800087666765e-08
does O 0 1.0163632158111113e-09
not O 0 1.8877906182712678e-10
have O 0 3.4233234302849525e-11
this O 0 2.0094226629852052e-11
effect O 0 9.994234329013807e-10
, O 0 1.1275716471637054e-10
providing O 0 2.816047395270971e-10
the O 0 1.0744945905249992e-10
first O 0 1.80706505314987e-10
direct O 0 2.4974983192649347e-10
evidence O 0 2.6824222842947165e-09
for O 0 1.6810833280977988e-10
a O 0 9.883752705164284e-10
functional O 0 5.466385744057334e-08
consequence O 0 1.0481210921398088e-07
of O 0 3.523249958448105e-08
the O 0 7.71447261627145e-08
H63D O 0 2.56128787441412e-05
mutation O 0 1.3616460137200193e-06
. O 0 1.5401710697915405e-06

Addition O 0 9.808319418880274e-07
of O 0 6.579415980922931e-07
soluble O 0 1.9748999875446316e-06
wild O 0 1.294430802545321e-07
- O 0 1.7654224393481854e-07
type O 0 1.889970349111536e-06
HFE O 1 0.9999822378158569
/ O 0 0.017528317868709564
beta2m O 0 1.1790983080572914e-05
heterodimers O 0 2.0474408302106895e-06
to O 0 6.765304316758147e-09
cultured O 0 4.910674533675774e-08
cells O 0 1.071771382754605e-08
also O 0 6.375907024569472e-10
decreased O 0 4.466112368817221e-09
the O 0 8.41200831214195e-10
apparent O 0 7.501776089213763e-09
affinity O 0 5.584573248285096e-09
of O 0 2.0166440961588705e-08
the O 0 8.812973462113405e-09
TfR O 0 1.8214488761714165e-07
for O 0 3.65616231734478e-10
its O 0 4.141394727152914e-10
ligand O 0 1.607477706500049e-08
under O 0 1.4280251647846853e-08
steady O 0 1.8505984655803331e-07
- O 0 1.7747670000289872e-08
state O 0 4.946617560008804e-10
conditions O 0 5.545152781394336e-09
, O 0 4.3194239851551686e-10
both O 0 3.587887764666675e-10
in O 0 9.63011337340447e-10
293 O 0 3.2713001196782443e-09
cells O 0 1.9630936876069427e-09
and O 0 2.4084001459812043e-09
in O 0 1.1114642539666875e-08
HeLa O 0 4.781404641107656e-06
cells O 0 9.531823934594286e-07
. O 0 9.762351282915915e-07

Furthermore O 0 2.2013496163708623e-06
, O 0 6.976253530410759e-08
at O 0 1.0381055659536287e-07
4 O 0 3.751796384676709e-08
degrees O 0 2.0502255893006804e-07
C O 0 5.389484272200207e-07
, O 0 2.8562137099896745e-09
the O 0 2.9275348811808044e-09
added O 0 1.695731199902184e-08
soluble O 0 2.0773521569594777e-08
complex O 0 2.4351832550451036e-08
of O 0 2.453000291779972e-08
HFE O 0 0.00016505725216120481
/ O 0 3.779755388677586e-06
beta2m O 0 3.0471821901301155e-06
inhibited O 0 1.1645894204548313e-07
binding O 0 3.8194510665334747e-08
of O 0 4.124993324694515e-08
transferrin O 0 9.624546919440036e-07
to O 0 5.970362337848201e-08
HeLa O 0 1.5162961972237099e-05
cell O 0 2.3229472390084993e-06
TfR O 0 8.694515827301075e-07
in O 0 2.904774865086779e-09
a O 0 5.487997611908213e-09
concentration O 0 3.944672073430411e-07
- O 0 2.3054450082327094e-07
dependent O 0 2.550687661084794e-08
manner O 0 7.0812967578604e-07
. O 0 1.1613834658419364e-06

Scatchard O 0 4.339784572948702e-05
plots O 0 1.0573005511105293e-06
of O 0 7.838767857037965e-08
these O 0 2.893759232236448e-09
data O 0 6.374937466802066e-09
indicate O 0 8.833842102262679e-09
that O 0 2.9132916079532833e-09
the O 0 2.580616431657745e-08
added O 0 7.161019510704136e-08
heterodimer O 0 2.0239063758253906e-07
substantially O 0 2.7749942788091175e-08
reduced O 0 1.6363770782845677e-08
the O 0 4.294403943561065e-09
affinity O 0 1.5276848230882933e-08
of O 0 3.960012051607009e-08
TfR O 0 2.0151080661889864e-06
for O 0 5.9593276091618463e-08
transferrin O 0 1.1974538210779428e-05
. O 0 3.4653321563382633e-06

These O 0 9.152988411642582e-08
results O 0 2.0423864555141336e-07
establish O 0 4.819212762185998e-08
a O 0 4.9715622729706865e-09
molecular O 0 1.0778892090002046e-07
link O 0 1.1488820206295713e-07
between O 0 7.891844688856509e-08
HFE O 0 0.0010254179360345006
and O 0 2.1634319224972387e-08
a O 0 1.0590908594565462e-08
key O 0 1.8164598714065505e-07
protein O 0 1.3738318926925785e-08
involved O 0 2.4532984532754654e-09
in O 0 1.2208437594196653e-09
iron O 0 3.481981138975243e-07
transport O 0 1.1983075864918646e-07
, O 0 5.607585507050317e-09
the O 0 1.2346959010756109e-08
TfR O 0 1.8756596773528145e-06
, O 0 3.5756337890546774e-09
and O 0 2.3611643751308975e-09
raise O 0 2.645549113111656e-09
the O 0 1.2972929397392363e-09
possibility O 0 8.389308803202766e-09
that O 0 1.2986441089157807e-10
alterations O 0 4.318684965198827e-09
in O 0 1.5710957534942338e-10
this O 0 1.372426616796929e-10
regulatory O 0 5.2203885658741456e-09
mechanism O 0 3.45659394440645e-08
may O 0 3.1813871537167415e-09
play O 0 6.981882183509924e-09
a O 0 6.186934853324999e-10
role O 0 1.800477655855559e-09
in O 0 8.766730674736323e-10
the O 0 1.0978702391639672e-08
pathogenesis O 0 0.00020951639453414828
of O 0 7.373125845333561e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 6.228194251889363e-05
. O 0 7.707802069489844e-06

Genomic O 0 2.7647561182675418e-06
organization O 0 2.511085881451436e-07
of O 0 1.6843995354065555e-07
the O 0 2.3047854824653768e-07
UBE3A O 0 0.0006983161438256502
/ O 0 0.00036358521902002394
E6 O 0 0.00024587861844338477
- O 0 8.625516784377396e-06
AP O 0 1.2190908819320612e-05
gene O 0 7.483372144179157e-08
and O 0 3.207680521200018e-08
related O 0 4.458990758848813e-07
pseudogenes O 0 1.2808674910047557e-05
. O 0 3.364229314684053e-06

The O 0 3.872538854921004e-06
UBE3A O 0 7.58482565288432e-05
gene O 0 1.893804864039339e-07
encodes O 0 1.7442840771764168e-07
the O 0 7.909807209216524e-08
E6 O 0 2.4151733668986708e-05
- O 0 6.152476544230012e-06
AP O 0 0.0002429581800242886
ubiquitin O 0 8.370262548851315e-06
- O 0 1.7326120769212139e-06
protein O 0 3.3777652674871206e-08
ligase O 0 4.9640508592574406e-08
and O 0 4.073000603455057e-09
has O 0 1.0240259751270742e-09
recently O 0 1.9050487853888853e-09
been O 0 3.6145661463926615e-10
shown O 0 2.542621668766287e-10
to O 0 2.369355822651187e-10
be O 0 1.7470743740588546e-09
mutated O 0 3.862116102482105e-07
in O 0 1.386843678119476e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.626318160371738e-07
who O 0 1.5622402926851464e-08
lack O 0 2.8093290893593803e-07
15q11 O 0 1.992410034290515e-06
- O 0 3.951317637529428e-07
q13 O 0 4.2330242422394804e-07
deletions O 0 1.2406108851337194e-07
or O 0 5.847297046557287e-08
chromosome O 0 7.715398169239052e-07
15 O 0 2.0414197479112772e-06
paternal O 0 2.269015385536477e-05
uniparental B-Disease 0 0.01658099703490734
disomy I-Disease 0 0.005175473168492317
. O 0 7.919609197415411e-05

Previous O 0 2.1733018002123572e-05
UBE3A O 0 8.979503036243841e-05
cDNA O 0 6.624792945331137e-07
analysis O 0 5.809810232904056e-08
has O 0 1.9995607392075954e-09
shown O 0 3.7325662560760975e-09
a O 0 6.1902434289606845e-09
coding O 0 1.3633828643833112e-07
region O 0 1.830912133016227e-08
of O 0 4.197743663780784e-08
approximately O 0 5.6561418659839546e-08
2 O 0 5.716769919672515e-07
. O 0 7.039261618047021e-07

6 O 0 7.495172030758113e-05
kb O 0 7.964277028804645e-05
and O 0 1.0709666042885146e-07
a O 0 5.208744724427561e-08
3 O 0 6.015559392835712e-07
- O 0 4.671894657803932e-07
untranslated O 0 1.3043872968410142e-05
region O 0 1.0205931033624438e-07
( O 0 3.297971673532629e-08
UTR O 0 8.669561793794855e-06
) O 0 6.290676424214325e-09
of O 0 2.7862963491998016e-08
< O 0 1.1410381830501137e-06
50 O 0 9.916882959259965e-08
bp O 0 9.782521459555937e-08
, O 0 2.3245712021946474e-09
whereas O 0 7.538149660035742e-09
Northern O 0 3.353391164750974e-08
analysis O 0 1.1213423078970663e-08
has O 0 8.656946270946264e-10
indicated O 0 5.681461967554924e-09
mRNA O 0 5.20444176643764e-09
sizes O 0 7.399119983375613e-09
of O 0 6.561486465272992e-09
5 O 0 1.01777629879507e-07
- O 0 9.300105574538975e-08
8 O 0 3.06551100948127e-07
kb O 0 1.8223423467134126e-05
. O 0 1.039180801853945e-06

We O 0 4.408731797411747e-07
have O 0 6.9624666032552796e-09
analyzed O 0 2.0203939854468445e-08
additional O 0 4.032695954947485e-09
cDNA O 0 1.9538008544373042e-08
clones O 0 3.7381607143061046e-08
and O 0 1.7503763993786947e-09
provide O 0 8.644719384776067e-10
evidence O 0 2.72273692480951e-09
for O 0 2.5834998029772294e-10
an O 0 1.3313233848677442e-10
additional O 0 2.360943662793602e-09
0 O 0 2.586308482932509e-07
. O 0 3.5646593232740997e-07

5 O 0 9.338746167486534e-06
kb O 0 4.026135866297409e-05
of O 0 3.3839629054455145e-07
5 O 0 1.2574109859997407e-06
- O 0 2.848729536708561e-07
UTR O 0 7.772094249958172e-06
and O 0 1.5466216751747197e-08
> O 0 1.4888013311065151e-07
2 O 0 1.38651813585966e-07
kb O 0 9.423101232641784e-07
of O 0 5.429145488733411e-08
3 O 0 1.3414897921393276e-06
- O 0 1.9375040665181587e-06
UTR O 0 0.00013940432108938694
. O 0 2.4535931970603997e-06

We O 0 1.1093721496990838e-07
have O 0 1.8272653390383198e-09
established O 0 2.901900941765234e-09
the O 0 6.527181573012797e-10
genomic O 0 3.641500212481219e-09
organization O 0 2.4760509198529235e-09
of O 0 1.0343262246692575e-08
UBE3A O 0 3.1031336220621597e-06
and O 0 1.3597751369331945e-08
the O 0 8.284044561435167e-09
sequence O 0 9.412278956233422e-09
of O 0 7.094999432410987e-08
intron O 0 5.0185335567221045e-06
- O 0 1.2327366675890516e-05
exon O 0 4.051663381687831e-06
borders O 0 8.947499168243667e-07
. O 0 7.560278845630819e-06

We O 0 1.787614451131958e-06
have O 0 3.32591127971682e-08
also O 0 1.8348170982562806e-08
mapped O 0 3.41803101377991e-08
two O 0 1.8941610502309913e-09
highly O 0 8.894249781121744e-09
homologous O 0 1.6377635247977196e-08
processed O 0 1.8573306448388394e-08
pseudogenes O 0 2.1199294053531048e-07
, O 0 1.6600363750285396e-08
UBE3AP1 O 0 3.0328692446346395e-06
and O 0 1.5693931487703594e-08
UBE3AP2 O 0 1.8231100966659142e-06
, O 0 9.229959574419411e-10
to O 0 1.6713258554901245e-10
chromosomes O 0 1.9182844201992566e-09
2 O 0 8.904399884102077e-09
and O 0 7.98230537224498e-10
21 O 0 2.0101465381117123e-08
, O 0 1.674635652371137e-09
respectively O 0 1.1580149283929586e-08
, O 0 7.908728671957022e-10
and O 0 1.2371161872692937e-09
determined O 0 1.0914936510175721e-08
their O 0 5.786671142260502e-09
genomic O 0 1.0192643884465724e-07
organization O 0 2.2013379918917053e-07
. O 0 1.1976190990026225e-06

These O 0 4.4827650924617046e-08
results O 0 5.825566873340904e-08
will O 0 1.3623705497067817e-09
form O 0 1.1719484271921488e-09
the O 0 2.829410039595359e-10
basis O 0 4.634949091197882e-10
for O 0 1.3851858896019031e-11
studies O 0 5.894295468378274e-11
of O 0 2.5251023494377023e-10
mutation O 0 2.42008235673552e-09
and O 0 3.218544764038711e-09
imprinting O 0 8.81434516486479e-07
of O 0 9.325717655883636e-07
UBE3A O 0 0.0015031647635623813
. O 0 2.024529931077268e-05

Mutation O 0 1.9287605027784593e-05
spectrum O 0 1.4192853086569812e-05
and O 0 6.350237526930869e-07
genotype O 0 1.9527373297023587e-05
- O 0 4.203390290058451e-06
phenotype O 0 5.673580858456262e-07
analyses O 0 7.663874868057974e-08
in O 0 3.187949104699328e-08
Cowden B-Disease 1 0.996408998966217
disease I-Disease 0 0.03928723558783531
and O 0 1.368749508401379e-06
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999986886978149
, O 0 1.6051330931077246e-07
two O 0 5.786044425803993e-07
hamartoma B-Disease 1 0.5876200199127197
syndromes I-Disease 0 0.00018467623158358037
with O 0 1.7511522401036927e-06
germline O 1 0.9990187883377075
PTEN O 0 0.37503984570503235
mutation O 0 5.893201887374744e-05
. O 0 4.075951437698677e-05

The O 0 1.0250854757032357e-05
tumour B-Disease 1 1.0
suppressor O 0 0.0003888039500452578
gene O 0 1.284174118154624e-06
PTEN O 0 3.5129356547258794e-05
, O 0 5.3128864863083436e-08
which O 0 8.147885033338298e-09
maps O 0 5.632221089513223e-08
to O 0 6.450959233461617e-08
10q23 O 0 2.2628890292253345e-05
. O 0 8.076780432020314e-06

3 O 0 5.908446837565862e-06
and O 0 1.7583302280854696e-07
encodes O 0 7.654598732642626e-08
a O 0 2.3835591278498214e-08
403 O 0 3.088805300421882e-08
amino O 0 4.578771140018034e-08
acid O 0 4.259572961018421e-08
dual O 0 7.75465650804108e-07
specificity O 0 5.774078090325929e-06
phosphatase O 0 0.0006265314295887947
( O 0 1.8936134438263252e-07
protein O 0 2.0616722906652285e-07
tyrosine O 0 3.524978353652841e-07
phosphatase O 0 3.733094899871503e-07
; O 0 2.314386904345156e-09
PTPase O 0 4.035141500935424e-07
) O 0 1.0255388760427309e-09
, O 0 5.426241123096531e-10
was O 0 2.1735890864960083e-09
shown O 0 1.015223904943241e-09
recently O 0 1.642680547142561e-09
to O 0 4.863531799514931e-10
play O 0 9.338782192003237e-09
a O 0 2.5614312892940916e-09
broad O 0 3.960080263709642e-08
role O 0 3.968632356077251e-08
in O 0 2.0521127908068593e-08
human O 0 3.7851086176488025e-07
malignancy B-Disease 0 4.1249513742513955e-05
. O 0 5.185645477467915e-06

Somatic O 0 0.0012634852901101112
PTEN O 0 0.00018821025150828063
deletions O 0 1.0764854323497275e-06
and O 0 1.434391005972202e-08
mutations O 0 2.575836610674287e-08
were O 0 7.725394546298503e-09
observed O 0 7.476307573028862e-09
in O 0 2.4882800264691696e-09
sporadic B-Disease 0 4.546403943095356e-06
breast I-Disease 1 0.9842113852500916
, I-Disease 0 9.277228855353314e-06
brain I-Disease 1 1.0
, I-Disease 0 4.010344491689466e-05
prostate I-Disease 1 0.9999998807907104
and I-Disease 0 0.05675628408789635
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9997909665107727
cell O 0 0.11779589205980301
lines O 0 4.0407365986538935e-07
and O 0 9.279548685015016e-09
in O 0 2.2940080945943464e-09
several O 0 1.764821622174395e-09
primary O 0 1.225131541104929e-06
tumours B-Disease 1 1.0
such O 0 2.0260010558104113e-08
as O 0 7.794040470798791e-07
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999922513961792
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9999686479568481

In O 0 8.617449509529251e-08
addition O 0 3.333227382995574e-08
, O 0 2.8720355871314496e-08
PTEN O 0 6.5632930272840895e-06
was O 0 2.8130923368507865e-08
identified O 0 2.6020856580544205e-09
as O 0 3.187295427586889e-10
the O 0 7.681897895572831e-10
susceptibility O 0 1.307757901969353e-08
gene O 0 1.3949289723313996e-08
for O 0 8.755788982739432e-09
two O 0 8.668783380016976e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999690055847168
( O 0 2.82299367881933e-07
CD B-Disease 0 5.30953002453316e-06
; O 0 1.6651091527819517e-07
MIM O 0 2.9036658816039562e-05
158350 O 0 2.3570587472931948e-06
) O 0 2.1647650783052086e-08
and O 0 3.946507476371153e-08
Bannayan B-Disease 0 0.00010547653073444963
- I-Disease 0 6.302692781900987e-05
Zonana I-Disease 0 0.07126407325267792
( I-Disease 0 4.214446676087391e-07
BZS I-Disease 0 9.016630792757496e-05
) I-Disease 0 9.422448954410356e-08
or I-Disease 0 1.9940550544106372e-07
Ruvalcaba I-Disease 0 9.904235776048154e-05
- I-Disease 0 2.1311530872480944e-05
Riley I-Disease 0 0.00027205058722756803
- I-Disease 0 0.05578388273715973
Smith I-Disease 1 0.9271465539932251
syndrome I-Disease 1 0.9999998807907104
( O 0 7.338025170611218e-06
MIM O 0 0.003927268087863922
153480 O 0 2.318878068763297e-05
) O 0 5.004473564440559e-07
. O 0 3.6242704481992405e-06

Constitutive O 0 1.9010400137631223e-05
DNA O 0 6.108309662522515e-07
from O 0 2.5514999890674517e-08
37 O 0 1.734462244940005e-07
CD B-Disease 0 6.552422178174311e-07
families O 0 3.170592455248311e-09
and O 0 1.4607079990014427e-08
seven O 0 6.73912410320554e-08
BZS B-Disease 0 1.3329630746738985e-05
families O 0 9.901833131209514e-09
was O 0 5.6242669188577565e-08
screened O 0 6.220379589194636e-08
for O 0 9.334262074389699e-08
germline O 0 0.00021118084259796888
PTEN O 0 0.0009947512298822403
mutations O 0 4.6997542085591704e-05
. O 0 2.4764765839790925e-05

PTEN O 0 0.0003208728739991784
mutations O 0 1.6439828414149815e-06
were O 0 1.0322671073481615e-07
identified O 0 2.7837996796620246e-08
in O 0 2.405072141442588e-09
30 O 0 1.4691293515056714e-08
of O 0 1.5630629235374727e-08
37 O 0 1.0874419587025841e-07
( O 0 5.88794168976392e-09
81 O 0 3.329535758211932e-08
% O 0 1.3407399634957073e-09
) O 0 1.0314552545409583e-09
CD B-Disease 0 3.905591583475143e-08
families O 0 3.4050071096025647e-10
, O 0 3.506566426114688e-10
including O 0 4.578976364744136e-10
missense O 0 5.205655639883844e-08
and O 0 4.2592862570245416e-09
nonsense O 0 1.4425539518470032e-07
point O 0 9.601181716334395e-08
mutations O 0 4.396027009079262e-08
, O 0 4.761175453893429e-09
deletions O 0 6.62620891489496e-08
, O 0 1.0897067248549774e-08
insertions O 0 1.8237223287087545e-07
, O 0 1.6976924754885658e-08
a O 0 3.61676981697201e-08
deletion O 0 2.122378191415919e-06
/ O 0 9.113266969507094e-06
insertion O 0 1.006153752314276e-06
and O 0 8.420634571848495e-07
splice O 0 1.9682009224197827e-05
site O 0 1.165056573881884e-06
mutations O 0 3.7902918847976252e-06
. O 0 8.551334758521989e-06

These O 0 8.67814904381703e-08
mutations O 0 1.4773225132103107e-07
were O 0 1.9585840504987573e-08
scattered O 0 2.578235402950213e-08
over O 0 7.209627561621801e-09
the O 0 3.019163141715353e-09
entire O 0 9.630817032757477e-09
length O 0 2.0170316528123067e-09
of O 0 8.170824905562313e-09
PTEN O 0 1.5067703316162806e-06
, O 0 1.02808883628569e-09
with O 0 8.873991125257774e-11
the O 0 3.7013139775332604e-10
exception O 0 8.639791104769756e-10
of O 0 9.231931330511145e-10
the O 0 1.0198838440445002e-09
first O 0 3.4234903800722805e-09
, O 0 1.0261982374970557e-09
fourth O 0 2.3374258972808093e-08
and O 0 8.95915430731975e-09
last O 0 2.5818283688749943e-07
exons O 0 6.96473352945759e-06
. O 0 2.907057250922662e-06

A O 0 8.841378985380288e-06
hot O 0 9.95109076029621e-06
spot O 0 2.526811385905603e-06
for O 0 3.158799444236138e-08
PTEN O 0 4.030232958029956e-06
mutation O 0 1.5893077076611917e-08
in O 0 2.2962141077442766e-09
CD B-Disease 0 1.5546952170097939e-07
was O 0 2.058742332167185e-08
identified O 0 6.408194419549318e-09
in O 0 1.4642135282016966e-09
exon O 0 3.017046168451998e-08
5 O 0 1.1266741317683682e-08
that O 0 3.78916731325063e-10
contains O 0 1.4743808396389113e-09
the O 0 6.6343375237920554e-09
PTPase O 0 7.806389135112113e-07
core O 0 1.4859317332138744e-07
motif O 0 1.706871088913431e-08
, O 0 3.5616917748448884e-10
with O 0 1.1865905480412664e-10
13 O 0 4.822051202779676e-09
of O 0 2.9480655694413826e-09
30 O 0 1.6018155690744607e-08
( O 0 1.868251775505314e-09
43 O 0 5.394964475158304e-09
% O 0 5.940992697794911e-10
) O 0 8.843732968166762e-10
CD B-Disease 0 7.125689904796673e-08
mutations O 0 2.601918325240149e-08
identified O 0 2.7908171773560753e-08
in O 0 7.1527850309394125e-09
this O 0 2.8888967662510368e-08
exon O 0 4.528934368863702e-06
. O 0 1.8835825130736339e-06

Seven O 0 9.62441845331341e-07
of O 0 7.100712906549234e-08
30 O 0 1.1842057290323282e-07
( O 0 3.860022079749115e-09
23 O 0 1.7397727702928023e-08
% O 0 7.869170315366603e-10
) O 0 7.10288716732066e-10
were O 0 1.8547525737488968e-09
within O 0 4.580682055888019e-09
the O 0 2.473407922920501e-09
core O 0 4.479671034118837e-08
motif O 0 6.5727343567800744e-09
, O 0 4.099419692593642e-10
the O 0 4.829145416884728e-10
majority O 0 1.0120996263296433e-09
( O 0 1.152230866274806e-09
five O 0 1.7651313743982655e-09
of O 0 2.529490172875626e-09
seven O 0 2.746846305967665e-09
) O 0 1.316247250082725e-10
of O 0 3.7200692526440093e-10
which O 0 1.2193816789629608e-10
were O 0 7.344732821934485e-09
missense O 0 3.5972249179394566e-07
mutations O 0 1.1256006615667502e-07
, O 0 1.1614103456736302e-08
possibly O 0 1.4582282403807767e-07
pointing O 0 6.919957939999222e-08
to O 0 3.1010942702636157e-09
the O 0 4.275034992673454e-09
functional O 0 7.280466007841824e-08
significance O 0 4.4124075060381074e-08
of O 0 9.197382411230137e-09
this O 0 4.200560788092389e-09
region O 0 1.075230073865896e-07
. O 0 1.2854189890276757e-06

Germline O 0 0.008779390715062618
PTEN O 0 0.00015311817696783692
mutations O 0 6.748513783350063e-07
were O 0 4.161280386938415e-08
identified O 0 2.3282286321091306e-08
in O 0 2.7579336592253867e-09
four O 0 6.607186797680242e-09
of O 0 1.692248119411488e-08
seven O 0 3.3406742261377076e-08
( O 0 5.387529977696204e-09
57 O 0 7.062528339929486e-08
% O 0 9.186599925214978e-09
) O 0 6.60543832964322e-08
BZS B-Disease 0 4.296899351174943e-05
families O 0 2.3648686919841566e-07
studied O 0 8.21356752567226e-06
. O 0 6.96622146278969e-06

Interestingly O 0 2.321822194062406e-06
, O 0 1.3998491255051704e-08
none O 0 1.2410494854009357e-08
of O 0 4.415385834732888e-09
these O 0 5.585870654911673e-10
mutations O 0 6.918332129401961e-09
was O 0 1.9283405094938644e-08
observed O 0 8.958521924284923e-09
in O 0 3.845325391438337e-09
the O 0 6.042375133574751e-08
PTPase O 0 1.988396979868412e-05
core O 0 1.4800350982113741e-05
motif O 0 4.577157142193755e-06
. O 0 1.8925062477137544e-06

It O 0 1.0210039391722603e-07
is O 0 4.619717941523049e-09
also O 0 9.971498071692508e-10
worthy O 0 2.1899944968595264e-08
of O 0 4.352340265967314e-09
note O 0 4.372509909700284e-09
that O 0 2.3650484348713974e-10
a O 0 1.6605359309807e-09
single O 0 4.295428013278979e-09
nonsense O 0 1.7265308827063564e-07
point O 0 1.4634861145168543e-07
mutation O 0 4.0978758164555984e-08
, O 0 7.906877819152669e-09
R233X O 0 2.2585477665870712e-07
, O 0 3.3878675420595528e-09
was O 0 1.1634678109828656e-08
observed O 0 2.9894746678138517e-09
in O 0 6.002899843871035e-10
the O 0 2.842436730432496e-09
germline O 0 4.813834380001936e-07
DNA O 0 2.9125098777171843e-08
from O 0 1.8272584556555671e-09
two O 0 5.1981219328922634e-09
unrelated O 0 4.0784758681411404e-08
CD B-Disease 0 3.925030966911436e-07
families O 0 4.858786706307683e-09
and O 0 1.7955674280756284e-08
one O 0 8.622875924402251e-08
BZS B-Disease 0 0.00011729320976883173
family O 0 1.0392263902758714e-06
. O 0 5.7287288655061275e-06

Genotype O 0 0.00017003362881951034
- O 0 6.969876267248765e-06
phenotype O 0 1.106818956486677e-07
studies O 0 5.2361248670251825e-09
were O 0 1.8462006368125117e-09
not O 0 2.6085544835297014e-10
performed O 0 5.903513233818103e-10
on O 0 2.1301660435568692e-09
this O 0 2.4361099248970675e-10
small O 0 2.0434369751853865e-09
group O 0 5.106300271506825e-09
of O 0 1.7677442087915551e-07
BZS B-Disease 0 0.00018701457884162664
families O 0 7.032813300611451e-07
. O 0 4.634053311747266e-06

However O 0 7.799334866831487e-07
, O 0 1.55133477619529e-07
genotype O 0 2.7748440061259316e-06
- O 0 3.6953855442334316e-07
phenotype O 0 1.3334192772163078e-07
analysis O 0 3.225478550916705e-08
inthe O 0 9.56095618676045e-07
group O 0 8.122655437148296e-09
of O 0 1.7996304890743886e-08
CD B-Disease 0 1.3712397048948333e-06
families O 0 6.895001902762488e-09
revealed O 0 4.6234934103495107e-08
two O 0 1.7934685958564955e-09
possible O 0 2.004525967436166e-08
associations O 0 6.071288805031827e-09
worthy O 0 2.528796905210129e-08
of O 0 2.1531691984932877e-08
follow O 0 4.337558223710403e-08
- O 0 3.913159929425092e-08
up O 0 4.963698341242662e-09
in O 0 2.591338033042234e-09
independent O 0 1.6744639452781485e-08
analyses O 0 1.799641324851109e-07
. O 0 1.3732759498452651e-06

The O 0 4.190132472103869e-07
first O 0 5.381791368108679e-08
was O 0 5.32924673279922e-08
an O 0 1.5790697638351503e-09
association O 0 6.7682597304496994e-09
noted O 0 2.765334405907538e-09
in O 0 9.96203119996153e-10
the O 0 4.240391593413051e-09
group O 0 2.021680600705622e-09
of O 0 1.1591176019010163e-08
CD B-Disease 0 2.7370160751161166e-06
families O 0 1.6350604425952042e-08
with O 0 2.6875048320107453e-07
breast B-Disease 1 0.9999945163726807
disease I-Disease 1 0.9999679327011108
. O 0 0.0001514688483439386

A O 0 2.042099367827177e-06
correlation O 0 6.921778776813881e-07
was O 0 1.4109741641732398e-07
observed O 0 1.619881473402529e-08
between O 0 5.141689296550567e-09
the O 0 1.8823731462447313e-09
presence O 0 9.411667889480668e-09
/ O 0 5.238674702923163e-07
absence O 0 6.57336443055101e-08
of O 0 3.244594282136859e-08
a O 0 1.8597411610699055e-08
PTEN O 0 2.36952200793894e-06
mutation O 0 3.3093705553710606e-08
and O 0 5.408522962824236e-09
the O 0 2.1738171263052664e-09
type O 0 7.037301941181795e-08
of O 0 5.431143108580727e-07
breast O 0 0.0025422521866858006
involvement O 0 1.3235590813565068e-05
( O 0 4.668883661906875e-07
unaffected O 0 3.3525648177601397e-06
versus O 0 0.00032052031019702554
benign O 0 0.044156186282634735
versus O 0 0.011602221988141537
malignant O 0 0.39130958914756775
) O 0 1.0379823152106837e-06
. O 0 5.923730896029156e-06

Specifically O 0 2.7831819693346915e-07
and O 0 1.8845581095661146e-08
more O 0 8.462604506043192e-10
directly O 0 6.708020250378866e-10
, O 0 6.490731285779816e-10
an O 0 5.227240862382132e-10
association O 0 3.1070621631101858e-09
was O 0 1.3659514408459472e-08
also O 0 6.041379063681518e-10
observed O 0 1.9341483969981255e-09
between O 0 4.6040229961796797e-10
the O 0 3.2501029645359836e-10
presence O 0 5.304031103214868e-10
of O 0 5.036492556342864e-09
a O 0 3.100758760865574e-08
PTEN O 0 0.0005228486261330545
mutation O 0 2.563061934779398e-05
and O 0 8.19102642708458e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0013841076288372278

Secondly O 0 1.6668500393279828e-05
, O 0 4.566473776890234e-08
there O 0 5.451004980727703e-09
appeared O 0 1.1757351536800797e-08
to O 0 8.629053582787094e-10
be O 0 2.4113051555474385e-09
an O 0 2.7924877965546102e-09
interdependent O 0 1.3555383020502632e-06
association O 0 6.29377305827461e-09
between O 0 1.918739123141222e-08
mutations O 0 6.997389334628679e-08
upstream O 0 2.8436637933282327e-08
and O 0 3.367015111166438e-09
within O 0 1.303579022504664e-08
the O 0 9.722806559864239e-09
PTPase O 0 1.6002574056983576e-06
core O 0 2.2777254571337835e-07
motif O 0 3.264377212985892e-08
, O 0 1.2544475458398097e-09
the O 0 1.4131760206481658e-09
core O 0 4.042879098165031e-08
motif O 0 4.254187668806253e-09
containing O 0 7.052546879826593e-10
the O 0 4.2356362861539765e-10
majority O 0 6.083143433421867e-10
of O 0 3.636121403971515e-09
missense O 0 1.755269209979815e-07
mutations O 0 2.37680399806095e-08
, O 0 2.8597297863086624e-09
and O 0 1.8580668115220078e-09
the O 0 3.722065544664588e-09
involvement O 0 1.0193029531535558e-08
of O 0 8.565598008658526e-09
all O 0 1.6189848350833813e-09
major O 0 1.0032168873408409e-08
organ O 0 4.74251191917574e-06
systems O 0 0.01796744577586651
( O 0 5.877363378203881e-07
central O 0 2.1828564058523625e-05
nervous O 0 7.358810307778185e-06
system O 0 0.00015000822895672172
, O 0 4.466755399334943e-06
thyroid O 1 1.0
, O 0 0.00010888507677009329
breast O 1 0.9999992847442627
, O 0 0.004410609137266874
skin O 1 1.0
and O 1 0.9992733597755432
gastrointestinal O 1 1.0
tract O 1 0.9668492078781128
) O 0 4.363815605756827e-06
. O 0 9.796366612135898e-06

However O 0 1.6555658248762484e-06
, O 0 1.6905254085486376e-08
these O 0 9.6318775177906e-10
observations O 0 6.835071175714802e-09
would O 0 5.096781330315991e-10
need O 0 1.1314327252875955e-09
to O 0 2.9653207667124093e-10
be O 0 4.4173797952851146e-10
confirmed O 0 4.0273304691140765e-09
by O 0 3.1720001625323846e-10
studying O 0 4.336778491875748e-09
a O 0 4.34784153124923e-10
larger O 0 1.5717648294000242e-09
number O 0 3.398008319166479e-09
of O 0 2.0743192052918857e-08
CD B-Disease 0 1.0186225836150697e-06
families O 0 9.129938405294524e-08
. O 0 6.354508172989881e-07

Molecular O 1 0.9998279809951782
defects O 1 0.9992934465408325
leading O 0 1.6652647900627926e-06
to O 0 1.544908734274486e-08
human O 0 8.70306209321825e-08
complement B-Disease 0 3.538521923474036e-06
component I-Disease 1 0.9999992847442627
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3548667077145637e-08
an O 0 1.561298312857673e-09
African O 0 8.935726469871952e-08
- O 0 3.28087459422477e-08
American O 0 8.730740574947049e-09
family O 0 2.5335667785952865e-08
. O 0 5.243803116172785e-07

Complement B-Disease 0 0.0001691176585154608
component I-Disease 1 0.999688982963562
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.0617322914185934e-06
C6D B-Disease 0 0.0003230383154004812
) O 0 2.4173848700570488e-08
was O 0 5.8219015386384854e-08
diagnosed O 0 1.6916825984480965e-07
in O 0 3.6839544748090702e-09
a O 0 6.764362403544055e-09
16 O 0 1.240136526803326e-07
- O 0 4.017397259303834e-08
year O 0 5.654380963449057e-09
- O 0 2.066366278086207e-08
old O 0 1.5854692492212052e-07
African O 0 4.40129184653415e-07
- O 0 3.386699987117936e-08
American O 0 4.558091681872156e-09
male O 0 6.742454417008048e-08
with O 0 3.413093736526207e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.002417336218059063

The O 0 3.471417642231245e-07
patients O 0 2.477838201286886e-08
father O 0 2.584123315330089e-08
and O 0 1.0032762176592769e-08
two O 0 1.86259523360377e-08
brothers O 0 1.6329201457665476e-07
also O 0 7.301029114614721e-09
had O 0 6.144017561382498e-08
C6D B-Disease 0 6.1022288718959317e-05
, O 0 3.546434701462431e-09
but O 0 1.7981919286924608e-09
gave O 0 5.98903104886972e-09
no O 0 2.1509638514771723e-09
history O 0 9.192910432886947e-09
of O 0 6.193197776838133e-08
meningitis B-Disease 1 1.0
or O 0 2.3734612852877035e-07
other O 0 3.048979380082528e-08
neisserial B-Disease 0 3.920184099115431e-05
infection I-Disease 0 0.0002823986578732729
. O 0 4.197641828795895e-06

By O 0 3.1491867957811337e-07
using O 0 2.6052759949379833e-07
exon O 0 1.0658410474206903e-06
- O 0 7.480775110479954e-08
specific O 0 4.532318076400088e-09
polymerase O 0 6.893321824463783e-08
chain O 0 1.3911506613339952e-08
reaction O 0 5.435618177784818e-09
( O 0 4.040225487500493e-09
PCR O 0 3.6491783816927637e-08
) O 0 3.4832774442605796e-09
/ O 0 5.090093324611189e-08
single O 0 9.20273546256567e-09
- O 0 3.329326148104883e-08
strand O 0 3.7032382493862315e-08
conformation O 0 2.5054389674039612e-09
polymorphism O 0 5.076361997424783e-09
as O 0 2.764979634140019e-10
a O 0 2.010957372844402e-10
screening O 0 1.0664608085519944e-09
step O 0 2.260946763144034e-09
and O 0 1.4751319055150702e-09
nucleotide O 0 5.3840061298160435e-09
sequencing O 0 2.165862600378432e-09
of O 0 1.7358373627374135e-09
target O 0 2.512905972196222e-08
exons O 0 2.1638079772401397e-07
, O 0 3.786156721474754e-09
we O 0 2.2668451560292624e-09
determined O 0 6.787975515010203e-09
that O 0 3.634809120356408e-10
the O 0 5.574654959872305e-09
proband O 0 3.4355781508565997e-07
was O 0 1.91509030855741e-08
a O 0 4.504781880854125e-09
compound O 0 5.0861434175430986e-08
heterozygote O 0 3.947524476188846e-07
for O 0 2.2376095643039662e-08
two O 0 1.4896862410296308e-07
C6 O 0 0.0003020101576112211
gene O 0 1.5393076182590448e-06
mutations O 0 4.859053206018871e-06
. O 0 9.095364475797396e-06

The O 0 6.276691806306189e-07
first O 0 9.04466190831954e-08
, O 0 1.2059286014221016e-08
1195delC O 0 2.510408307898615e-07
located O 0 6.683324116352196e-09
in O 0 1.7926887752039988e-09
exon O 0 4.7267672442785624e-08
7 O 0 5.107930078906975e-08
, O 0 1.2851809616520882e-09
is O 0 2.0094237385137603e-10
a O 0 3.245630431081281e-10
novel O 0 8.607224377676914e-10
mutation O 0 1.4280516769105134e-09
, O 0 5.989359008751194e-10
while O 0 1.010005412638293e-09
the O 0 1.6445239614526486e-09
second O 0 6.945555242054979e-09
, O 0 1.139171978969955e-09
1936delG O 0 3.080921118225888e-08
in O 0 2.2108816999377723e-09
exon O 0 7.000513591037816e-08
12 O 0 2.8329663948056805e-08
, O 0 1.148732997613422e-09
has O 0 4.095832006889566e-10
been O 0 5.349017340172679e-10
described O 0 2.209819216503206e-09
before O 0 4.567028977220389e-09
to O 0 1.0400071914773434e-09
cause O 0 4.062420089212537e-08
C6D B-Disease 0 3.985772127634846e-05
in O 0 8.988336297477417e-09
an O 0 2.830388590169264e-09
unrelated O 0 7.11105343498275e-08
African O 0 4.649014329061174e-07
- O 0 1.2457101661311754e-07
American O 0 1.8598901974087312e-08
individual O 0 7.301436255602312e-08
. O 0 1.3755985719399177e-06

Both O 0 8.697177804606326e-07
mutations O 0 9.781138032849412e-07
result O 0 1.516926459999013e-07
in O 0 2.414007482798297e-08
premature O 0 3.7132539887352323e-07
termination O 0 6.76766831020359e-07
codons O 0 1.5910189858914237e-06
and O 0 3.423747614306194e-07
C6 O 0 0.0004966874257661402
null O 0 4.510503276833333e-05
alleles O 0 1.0035337254521437e-05
. O 0 5.388659701566212e-06

Allele O 0 3.107475640717894e-05
- O 0 5.214609473114251e-07
specific O 0 7.180314565147228e-09
PCR O 0 3.2044454201241024e-08
indicated O 0 6.344732739194114e-09
that O 0 3.576320906084618e-10
the O 0 5.086645327168071e-09
probands O 0 5.68996597394289e-07
two O 0 9.918183607737774e-09
brothers O 0 5.18670582039249e-08
also O 0 3.7158023324934675e-09
inherited O 0 5.80896823976218e-08
the O 0 2.0340353401593347e-08
1195delC O 0 1.64625177490052e-07
mutation O 0 7.692957382232635e-09
from O 0 1.1572879321519736e-09
their O 0 2.944154919859443e-09
heterozygous O 0 1.9336072298870022e-08
mother O 0 6.232133920036631e-09
and O 0 2.306384416783658e-09
the O 0 7.40747951866183e-09
1936delG O 0 8.135248918961224e-08
mutation O 0 3.1083069451653955e-09
from O 0 7.598051077195578e-10
their O 0 5.7469637937401785e-09
homozygous O 0 1.0758044766134844e-07
father O 0 1.26501348063357e-07
. O 0 3.030339996712428e-07
. O 0 4.23238407165627e-06

PAX6 O 0 0.017490142956376076
mutations O 0 0.0001394190767314285
reviewed O 0 3.8116333598736674e-05
. O 0 1.3380308701016475e-05

Mutations O 0 4.992212325305445e-06
in O 0 1.6775592825979402e-07
PAX6 O 0 0.0018430986674502492
are O 0 1.3006410171101379e-08
responsible O 0 5.529661706304978e-08
for O 0 6.273182862059912e-09
human O 0 1.8547858360307146e-07
aniridia B-Disease 1 1.0
and O 0 2.9434374937409302e-08
have O 0 1.5703983669013155e-09
also O 0 4.3707568120332496e-10
been O 0 4.645906714895176e-10
found O 0 2.922188879761478e-10
in O 0 2.6123583851678234e-10
patients O 0 1.929748583151536e-09
with O 0 5.436675998282681e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 4.814908720618405e-07
with O 0 0.0004782831238117069
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.00011834104952868074
with O 0 3.0829367005935637e-06
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 2.8460465273383306e-07
and O 0 8.768595449737404e-08
with O 0 1.340137743000014e-07
isolated B-Disease 0 0.0006070542149245739
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0021165311336517334

No O 0 8.904537480702857e-07
locus O 0 4.470776673315413e-07
other O 0 5.2365041192103945e-09
than O 0 6.380618255974468e-09
chromosome O 0 8.221165614941128e-08
11p13 O 0 5.253353378975589e-07
has O 0 3.701343898043774e-09
been O 0 1.0463648614233989e-08
implicated O 0 2.0851392434906302e-07
in O 0 2.0997596550387243e-08
aniridia B-Disease 1 0.9999998807907104
, O 0 4.3510976155403114e-08
and O 0 4.396462927047651e-08
PAX6 O 0 0.009874995797872543
is O 0 2.6965139010570738e-09
clearly O 0 3.1309832504433643e-09
the O 0 1.5458658797484759e-09
major O 0 3.840040729841121e-09
, O 0 1.953593953274435e-10
if O 0 1.8147675029389632e-10
not O 0 1.1262969723535576e-10
only O 0 4.2950568102106956e-10
, O 0 3.188026509448605e-09
gene O 0 7.195864526465812e-08
responsible O 0 4.5390464720185264e-07
. O 0 1.7803735090637929e-06

Twenty O 0 2.4987668439280242e-05
- O 0 1.2017493418170488e-06
eight O 0 7.411340163798741e-08
percent O 0 4.9045598693453485e-09
of O 0 1.3220632588684111e-08
identified O 0 1.580580857307723e-07
PAX6 O 0 1.8811586414813064e-05
mutations O 0 2.392738167600328e-07
are O 0 2.2934623089554407e-08
C O 0 0.00011572871153475717
- O 0 8.39655058371136e-06
T O 0 7.750826966912427e-07
changes O 0 4.450714286008406e-08
at O 0 1.0150002083264553e-07
CpG O 0 9.858645455551596e-08
dinucleotides O 0 5.852675144524255e-08
, O 0 6.897116211490584e-10
20 O 0 1.2334077093001383e-09
% O 0 1.1764203500241877e-10
are O 0 2.514744801285218e-10
splicing O 0 3.1544342249389956e-08
errors O 0 9.333442818615367e-08
, O 0 1.485054856864565e-09
and O 0 2.525926134921974e-10
more O 0 2.946449334517709e-11
than O 0 8.789949323961821e-11
30 O 0 1.346447064953793e-09
% O 0 5.535322755712002e-10
are O 0 9.551345270253364e-10
deletion O 0 5.7400217912118023e-08
or O 0 1.1212268447025053e-08
insertion O 0 1.1544427280796299e-07
events O 0 2.6398151931061875e-07
. O 0 1.6903533150980365e-06

There O 0 2.1034661301655433e-07
is O 0 1.3401449727723502e-08
a O 0 1.4858518859739434e-08
noticeably O 0 2.7996202334179543e-07
elevated O 0 9.491557193541666e-07
level O 0 2.46907802647911e-07
of O 0 5.634270383580997e-09
mutation O 0 3.9160101827917515e-09
in O 0 1.3887322403149938e-09
the O 0 4.678669451863016e-09
paired O 0 5.4659659021183415e-09
domain O 0 8.5540055039246e-09
compared O 0 1.0127174654428472e-09
with O 0 1.4643775081424337e-10
the O 0 7.277209945755203e-10
rest O 0 4.2997805316247195e-09
of O 0 4.354300031650382e-09
the O 0 2.3717861452610123e-08
gene O 0 1.7595732515474083e-07
. O 0 1.1163868975927471e-06

Increased O 0 4.799477437700261e-07
mutation O 0 1.4892202671035193e-07
in O 0 1.1110932618407787e-08
the O 0 1.9778347848387057e-08
homeodomain O 0 1.06875211258739e-06
is O 0 1.2444858477067555e-09
accounted O 0 4.4486410111233e-09
for O 0 5.187135720952085e-10
by O 0 9.010079349280886e-10
the O 0 3.6968021532857165e-08
hypermutable O 0 7.155337243602844e-06
CpG O 0 2.0526611478999257e-05
dinucleotide O 0 1.4916799955244642e-05
in O 0 4.794933943230717e-07
codon O 0 9.696041161078028e-06
240 O 0 5.224343567533651e-06
. O 0 4.47959928351338e-06

Very O 0 4.723337667655869e-07
nearly O 0 5.035649408569043e-08
all O 0 3.455023600551499e-09
mutations O 0 1.0484385803977148e-08
appear O 0 4.737098713292198e-09
to O 0 8.392969097492653e-10
cause O 0 1.6149762416262092e-08
loss O 0 7.30815159499798e-08
of O 0 1.4525841862678135e-08
function O 0 1.1691671630842393e-08
of O 0 3.902499656760483e-09
the O 0 2.2539283772715635e-09
mutant O 0 1.5950472942449778e-08
allele O 0 2.5128963798692894e-08
, O 0 7.8026474170656e-10
and O 0 3.8915784483783966e-10
more O 0 6.451626732850713e-11
than O 0 1.2919906811070803e-10
80 O 0 5.834924765579785e-10
% O 0 2.4694707390082726e-10
of O 0 3.212926369400293e-09
exonic O 0 1.97883153418843e-07
substitutions O 0 2.061999992974961e-08
result O 0 2.8333985824247065e-08
in O 0 2.3620259526069276e-08
nonsense O 0 2.098063987432397e-06
codons O 0 7.81557446316583e-06
. O 0 2.0557579318847274e-06

In O 0 1.790783130672935e-07
a O 0 4.067242542760141e-08
gene O 0 8.927238503986246e-09
with O 0 4.1499342851025744e-10
such O 0 2.032847445931907e-09
extraordinarily O 0 1.7180637712499447e-07
high O 0 6.046398226544625e-08
sequence O 0 3.2651474857203766e-09
conservation O 0 8.128416273400774e-10
throughout O 0 1.8107568222625048e-10
evolution O 0 1.9855899147103173e-09
, O 0 1.8391457801136823e-10
there O 0 1.7331833190858958e-10
are O 0 1.9039506082840774e-10
presumed O 0 9.193369265858564e-08
undiscovered O 0 7.545531843788922e-07
missense O 0 1.0177049034609809e-06
mutations O 0 9.716561777395327e-08
, O 0 4.9664352630429676e-09
these O 0 1.5548851095559257e-09
are O 0 9.284572000112234e-10
hypothesized O 0 6.534996099816226e-09
to O 0 3.0206476209215793e-10
exist O 0 2.6451858481379986e-09
in O 0 1.7196111201656095e-09
as O 0 4.767254591087067e-09
- O 0 3.4273796245543053e-08
yet O 0 8.331376477599406e-09
unidentified O 0 1.0182617415921413e-07
phenotypes O 0 2.574633697349782e-07
. O 0 6.830694587733888e-08
. O 0 1.6572259937674971e-06

Genetic O 0 6.927855338290101e-06
heterogeneity O 0 9.25506537896581e-06
and O 0 1.0190233723506026e-07
penetrance O 0 4.175455615040846e-06
analysis O 0 5.063116859105321e-08
of O 0 4.598357961071997e-08
the O 0 4.78046011664901e-08
BRCA1 O 0 4.296577458262618e-07
and O 0 1.6081699527603632e-07
BRCA2 O 0 1.7669227645455976e-06
genes O 0 3.7862096746721363e-07
in O 0 9.220058814207732e-07
breast B-Disease 1 0.6595820188522339
cancer I-Disease 0 0.0015880579594522715
families O 0 6.379208912221657e-07
. O 0 1.8974338672705926e-05

The O 0 0.0049621365033090115
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0005970590864308178
Consortium O 0 1.2745810636261012e-05
. O 0 5.68084760743659e-06

The O 0 1.8059733974951087e-07
contribution O 0 9.404995893191881e-08
of O 0 9.786216992324626e-08
BRCA1 O 0 7.372687491624674e-07
and O 0 7.466135087952352e-08
BRCA2 O 0 3.332952837808989e-05
to O 0 2.5392521365574794e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.915429949760437
assessed O 0 4.597209510848188e-07
by O 0 2.508125929168159e-09
linkage O 0 2.8822757514035402e-08
and O 0 2.4801773967908503e-09
mutation O 0 4.928923491576143e-09
analysis O 0 3.5590113078853847e-09
in O 0 1.16209653011623e-09
237 O 0 8.587190514219856e-09
families O 0 2.4172533419353215e-10
, O 0 2.4119292674207315e-10
each O 0 9.204937506668287e-11
with O 0 1.914452901763397e-10
at O 0 1.9156308539436395e-08
least O 0 2.0841375292235398e-09
four O 0 1.7062291579605926e-09
cases O 0 1.7228416471226637e-09
of O 0 3.4622484434976286e-08
breast B-Disease 0 7.807998372300062e-06
cancer I-Disease 0 6.26609391929378e-07
, O 0 3.834405237768124e-09
collected O 0 1.8146301128396658e-09
by O 0 2.3666109072451036e-09
the O 0 3.157344963256037e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 7.112899766070768e-05
Consortium O 0 6.055405719962437e-06
. O 0 2.6578109100228176e-06

Families O 0 1.4097233247412078e-07
were O 0 3.4594762610140606e-08
included O 0 8.485139701974731e-09
without O 0 7.528896617259306e-09
regard O 0 4.19022194719787e-09
to O 0 7.944969682149861e-10
the O 0 3.607033560726336e-09
occurrence O 0 9.141682966173903e-08
of O 0 2.349670239709667e-06
ovarian B-Disease 1 0.9999995231628418
or I-Disease 0 0.0010446287924423814
other I-Disease 0 3.4940335353894625e-06
cancers I-Disease 1 0.9999866485595703
. O 0 4.344870103523135e-05

Overall O 0 7.581101090181619e-05
, O 0 3.1075610422703903e-06
disease O 0 0.05903298780322075
was O 0 5.782988523606036e-07
linked O 0 6.254428086549524e-08
to O 0 2.5114768043010827e-09
BRCA1 O 0 5.073876963024304e-08
in O 0 2.341570048969288e-09
an O 0 2.2877758021344619e-10
estimated O 0 9.3515395427346e-10
52 O 0 6.222655279941591e-09
% O 0 4.39508374139308e-10
of O 0 3.067333942396999e-09
families O 0 7.025869330767875e-10
, O 0 7.054390405158983e-10
to O 0 1.1059991811279701e-09
BRCA2 O 0 7.861167006240066e-08
in O 0 4.734470149259096e-09
32 O 0 3.444641905048229e-08
% O 0 1.0430089014690225e-09
of O 0 2.7798665591660665e-09
families O 0 1.5876155945449e-10
, O 0 1.8656227951385773e-10
and O 0 1.9936036155243642e-10
to O 0 1.877116101445253e-10
neither O 0 1.5205067205315004e-09
gene O 0 7.121974121560015e-10
in O 0 7.139900892738638e-10
16 O 0 9.182046234457175e-09
% O 0 4.942468101454267e-10
( O 0 4.1098396907912615e-10
95 O 0 1.738953336882787e-08
% O 0 1.5135392938958603e-09
confidence O 0 1.3942192822469224e-07
interval O 0 4.931008561470662e-07
[ O 0 2.6375099082542874e-07
CI O 0 2.5027040919667343e-06
] O 0 7.703179960572015e-08
6 O 0 4.8906155569738985e-08
% O 0 1.5185503965398084e-09
- O 0 5.8033395866630144e-09
28 O 0 8.153543618050207e-09
% O 0 9.448607452000601e-10
) O 0 1.230538670959902e-09
, O 0 1.3932504039360083e-09
suggesting O 0 2.0710537285140163e-08
other O 0 9.817153312496885e-09
predisposition O 0 6.992933094807086e-07
genes O 0 1.735522573653725e-06
. O 0 3.854032456729328e-06

The O 0 3.052581689644285e-07
majority O 0 4.2409759259953717e-08
( O 0 1.116103831577675e-08
81 O 0 6.024767884582616e-08
% O 0 3.879603749368243e-09
) O 0 3.06237102343232e-09
of O 0 3.460485942241576e-08
the O 0 6.307983767328551e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.123742414208209e-08
were O 0 1.7759656856242145e-08
due O 0 3.445377672051109e-08
to O 0 1.6501986443984151e-09
BRCA1 O 0 8.09983902172462e-08
, O 0 1.7682718622680227e-09
with O 0 1.6617643372462965e-10
most O 0 4.83758089142583e-10
others O 0 1.6292819315921747e-09
( O 0 1.4630884281885415e-09
14 O 0 1.1416370071515303e-08
% O 0 7.387947476011902e-10
) O 0 1.2711193209113958e-09
due O 0 6.230567350939964e-08
to O 0 1.7371242222452565e-07
BRCA2 O 0 7.179684325819835e-05
. O 0 1.731433076201938e-05

Conversely O 0 3.861555796902394e-06
, O 0 1.821993933504018e-08
the O 0 4.409065557098302e-09
majority O 0 2.428011791621998e-09
of O 0 5.564276595038109e-09
families O 0 8.598609047005823e-10
with O 0 1.0735344835310912e-09
male B-Disease 0 4.07615488029478e-07
and I-Disease 0 2.7889659577340353e-06
female I-Disease 0 0.05759550258517265
breast I-Disease 1 0.995489776134491
cancer I-Disease 1 0.7665340304374695
were O 0 2.315656956852763e-06
due O 0 2.227050754299853e-05
to O 0 1.5851880164063914e-07
BRCA2 O 0 6.595394097530516e-06
( O 0 7.179632888210108e-08
76 O 0 4.5000439286013716e-07
% O 0 2.295558587661617e-08
) O 0 5.4326363851942006e-08
. O 0 1.6504660607097321e-06

The O 0 4.2206568195979344e-07
largest O 0 3.396597492155706e-08
proportion O 0 2.5407723924786296e-08
( O 0 3.81534270843531e-09
67 O 0 1.2980362562586834e-08
% O 0 7.835681548051809e-10
) O 0 4.514792428800263e-10
of O 0 1.339111932452397e-09
families O 0 1.219286338560721e-10
due O 0 2.7355788745353493e-09
to O 0 4.672549014372862e-10
other O 0 2.261307807671642e-10
genes O 0 1.8095908105308922e-09
was O 0 3.2544471562090393e-09
found O 0 5.173185213536158e-10
in O 0 3.415316640609234e-10
families O 0 1.3522653830033704e-10
with O 0 2.3186406961084316e-10
four O 0 3.752882449248318e-09
or O 0 6.514027095505526e-09
five O 0 3.9719472155752555e-09
cases O 0 5.819899673298323e-09
of O 0 1.8098079124229116e-07
female O 0 2.8705664590233937e-05
breast B-Disease 0 0.003027224913239479
cancer I-Disease 0 9.397207031724975e-05
only O 0 2.0309707906562835e-06
. O 0 1.3884456166124437e-05

These O 0 2.608535396575462e-07
estimates O 0 8.356844460877255e-08
were O 0 9.894281838285224e-09
not O 0 3.143992843845922e-09
substantially O 0 2.4806091403206665e-08
affected O 0 2.2769766072627817e-09
either O 0 2.105116081452252e-09
by O 0 4.804056041862736e-10
changing O 0 5.675926839643353e-09
the O 0 8.380843241617697e-10
assumed O 0 1.591507015064053e-08
penetrance O 0 7.824606740314266e-08
model O 0 6.7100445200196646e-09
for O 0 1.4447858465160834e-09
BRCA1 O 0 1.9353043612113652e-08
or O 0 1.1697867119409011e-09
by O 0 2.0148811785691834e-10
including O 0 7.373643917674144e-10
or O 0 1.2191317289023118e-08
excluding O 0 9.182539884022844e-08
BRCA1 O 0 6.894214834574086e-07
mutation O 0 4.5788240754518483e-07
data O 0 1.2365433121885872e-06
. O 0 2.9641532819368877e-06

Among O 0 9.542172847432084e-07
those O 0 3.540482040875759e-08
families O 0 6.274762487379348e-09
with O 0 4.112861162752779e-09
disease O 0 5.210120548326813e-07
due O 0 9.676724488372201e-08
to O 0 6.2479634799217365e-09
BRCA1 O 0 4.3669281524216785e-08
that O 0 6.131860574853931e-10
were O 0 2.616603156369024e-09
tested O 0 2.8138420482548554e-09
by O 0 3.6808339709537563e-10
one O 0 2.678545718559633e-10
of O 0 6.752615133720496e-10
the O 0 4.964008093466532e-10
standard O 0 1.9450323573977357e-09
screening O 0 5.435678018805845e-10
methods O 0 2.1509309888756434e-09
, O 0 2.9241292720527667e-10
mutations O 0 1.9688195518341445e-09
were O 0 2.898498774328573e-09
detected O 0 7.199870921681395e-09
in O 0 9.9362051919627e-10
the O 0 8.256834327369234e-09
coding O 0 4.8886196424291484e-08
sequence O 0 4.249297358427384e-09
or O 0 1.720930287163469e-09
splice O 0 1.6730338003867473e-08
sites O 0 1.2800971394000271e-09
in O 0 1.5333115332971659e-10
an O 0 8.186838013068964e-11
estimated O 0 6.92088886200537e-10
63 O 0 1.0811626260931462e-08
% O 0 1.4038697981888504e-09
( O 0 3.0206954715339407e-09
95 O 0 4.550276244685847e-08
% O 0 9.68261026912387e-09
CI O 0 3.390747906450997e-06
51 O 0 1.1490846674178101e-07
% O 0 6.289620824162512e-09
- O 0 4.200146364041757e-08
77 O 0 2.0942200862350546e-08
% O 0 3.598094044932054e-09
) O 0 2.0343380313647685e-08
. O 0 4.228198520195292e-07

The O 0 3.796507144215866e-07
estimated O 0 2.6206153691532563e-08
sensitivity O 0 4.4263156695478756e-08
was O 0 1.6053819607009245e-08
identical O 0 2.086340877838211e-09
for O 0 2.2284502021463481e-10
direct O 0 1.4689829352931838e-09
sequencing O 0 5.440348171958931e-09
and O 0 2.0247215015700704e-09
other O 0 2.195342352351304e-09
techniques O 0 9.016041531140218e-07
. O 0 6.829534413554939e-07

The O 0 1.726030177451321e-06
penetrance O 0 8.336771134054288e-05
of O 0 2.040139179371181e-06
BRCA2 O 0 4.725324743048986e-06
was O 0 1.008310448469274e-07
estimated O 0 2.3233743817741015e-09
by O 0 9.683880364264041e-10
maximizing O 0 2.660188869185731e-08
the O 0 7.858165673724216e-09
LOD O 0 3.3459657515777508e-06
score O 0 8.377016058602749e-08
in O 0 1.8270746693360707e-08
BRCA2 O 0 1.688917677711288e-06
- O 0 3.917551794074825e-07
mutation O 0 1.3669314569142443e-08
families O 0 1.3672567522604595e-09
, O 0 1.2705254626155238e-09
over O 0 3.5586651403463065e-09
all O 0 3.0282987228957836e-09
possible O 0 4.161153555060082e-08
penetrance O 0 5.968950063106604e-06
functions O 0 1.539225422675372e-06
. O 0 1.4463755633187247e-06

The O 0 5.715374413739482e-07
estimated O 0 5.165874128465475e-08
cumulative O 0 1.5054877167131053e-07
risk O 0 1.0113999593386325e-07
of O 0 3.7964420585012704e-07
breast B-Disease 0 6.865274826850509e-06
cancer I-Disease 0 9.711612847240758e-07
reached O 0 6.068223683541873e-07
28 O 0 1.203013795247898e-07
% O 0 1.395548232530075e-09
( O 0 1.0351171031430795e-09
95 O 0 1.2127168602660277e-08
% O 0 1.96594518442339e-09
CI O 0 8.583867838751758e-07
9 O 0 1.467130630317115e-07
% O 0 2.72540234824703e-09
- O 0 4.402746167642135e-09
44 O 0 1.2032512763937575e-09
% O 0 2.427075207478424e-10
) O 0 1.2596497456218714e-10
by O 0 9.882465679122987e-11
age O 0 1.339837574221292e-09
50 O 0 7.173630578449774e-10
years O 0 2.041924268558759e-10
and O 0 2.6638621863916967e-10
84 O 0 3.6069098818813927e-09
% O 0 2.312258995385008e-10
( O 0 4.334626269031361e-10
95 O 0 8.266177964344479e-09
% O 0 2.1701382912908684e-09
CI O 0 7.54759071242006e-07
43 O 0 2.5837142203499752e-08
% O 0 1.6728031182466907e-09
- O 0 7.640067245517912e-09
95 O 0 4.66049998593121e-09
% O 0 3.403637094390177e-10
) O 0 1.8851782634943248e-10
by O 0 3.5186595304104173e-10
age O 0 8.614652102778564e-09
70 O 0 1.9188854949447887e-08
years O 0 2.9264979772847255e-08
. O 0 4.6478527337967535e-07

The O 0 1.2753166629408952e-05
corresponding O 1 0.9676670432090759
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 2.0358349502203055e-05
were O 0 1.2169360843472532e-06
0 O 0 4.22251923737349e-06
. O 0 1.6318955431415816e-06

4 O 0 1.908242666104343e-06
% O 0 3.215883026541633e-08
( O 0 7.688146119733119e-09
95 O 0 4.6838859901754404e-08
% O 0 8.348730595741927e-09
CI O 0 1.039357243826089e-06
0 O 0 5.70246143638542e-08
% O 0 1.6808372471643906e-09
- O 0 3.8325040918607556e-09
1 O 0 2.383639952086014e-09
% O 0 1.3356625527816135e-10
) O 0 4.069781664450822e-11
by O 0 3.6988419271910544e-11
age O 0 8.206493817830562e-10
50 O 0 4.2287745527502807e-10
years O 0 2.772124196859238e-10
and O 0 3.673294446393527e-10
27 O 0 8.80937633951362e-09
% O 0 5.421089688262271e-10
( O 0 4.275261256125873e-10
95 O 0 1.121663206760104e-08
% O 0 2.3372062063486965e-09
CI O 0 8.464870120405976e-07
0 O 0 8.207534563098307e-08
% O 0 4.6794723651544246e-09
- O 0 1.0770339287091701e-08
47 O 0 6.3896425928078315e-09
% O 0 4.0101738596476366e-10
) O 0 2.1186130627626198e-10
by O 0 1.7179384304011336e-10
age O 0 7.413076374973571e-09
70 O 0 1.2134758087256614e-08
years O 0 2.432806134322618e-08
. O 0 3.9873586388239346e-07

The O 0 1.2081650311301928e-06
lifetime O 0 2.2681927021039883e-06
risk O 0 8.655501005705446e-06
of O 0 0.006506066303700209
breast B-Disease 1 0.9999978542327881
cancer I-Disease 0 0.2694454491138458
appears O 0 1.7050075484803529e-07
similar O 0 5.276386438879399e-09
to O 0 3.350065114204881e-09
the O 0 5.032382510705702e-09
risk O 0 1.3875149029729528e-08
in O 0 2.7669699864674158e-09
BRCA1 O 0 5.970692740220329e-08
carriers O 0 1.2779796110251596e-09
, O 0 4.846992252005577e-10
but O 0 3.4839067741820884e-10
there O 0 3.680714621978609e-10
was O 0 1.9056665134797868e-09
some O 0 1.0653970067275864e-10
suggestion O 0 5.384910295447298e-09
of O 0 3.880824994695331e-09
a O 0 6.454771828146022e-09
lower O 0 8.12101674796395e-08
risk O 0 6.454540368849848e-08
in O 0 1.8579790150852205e-08
BRCA2 O 0 5.095980668556876e-07
carriers O 0 3.926378155938437e-08
< O 0 6.432688905988471e-07
50 O 0 3.8132785817879267e-08
years O 0 1.6709895689359655e-08
of O 0 3.4457720232694555e-08
age O 0 8.83295911080495e-07
. O 0 1.7060157233572681e-06

Eye B-Disease 1 0.9999964237213135
movement I-Disease 0 0.0004010279953945428
abnormalities I-Disease 0 0.001226853346452117
correlate O 0 1.4231422085231316e-07
with O 0 6.406983832363267e-09
genotype O 0 1.2773365369866951e-06
in O 0 7.466690732371717e-08
autosomal O 1 0.9187989830970764
dominant O 1 0.9999898672103882
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999998807907104
I I-Disease 1 0.9999991655349731
. O 0 4.66184392280411e-05

We O 0 9.759781960383407e-07
compared O 0 1.8725948791598057e-07
horizontal O 0 3.5501325328368694e-05
eye O 0 0.001005998463369906
movements O 0 7.976854590197036e-07
( O 0 3.219319921754504e-08
visually O 0 4.354883742507809e-08
guided O 0 2.1037830322256923e-07
saccades O 0 2.577051191110513e-06
, O 0 1.2273490668235354e-08
antisaccades O 0 4.270522708793578e-07
, O 0 2.740310200977092e-09
and O 0 2.2036279467840814e-09
smooth O 0 2.115025843352214e-08
pursuit O 0 2.8837879639809216e-08
) O 0 1.2210673583368248e-09
in O 0 5.797760049830458e-10
control O 0 1.1862975490828376e-08
subjects O 0 6.425515408636784e-08
( O 0 5.104947131684412e-09
n O 0 5.436803007796698e-08
= O 0 1.086044818521259e-07
14 O 0 2.4696332090456963e-08
) O 0 4.6229417516308047e-10
and O 0 4.0997011341303846e-10
patients O 0 3.971763196108924e-10
with O 0 8.560248343503218e-11
three O 0 3.821626071154327e-10
forms O 0 2.7705346905548822e-09
of O 0 2.8141119656766023e-08
autosomal O 0 2.02387946046656e-05
dominant O 0 0.0001025224119075574
cerebellar B-Disease 1 0.9999854564666748
ataxias I-Disease 0 0.0004080211801920086
type I-Disease 0 1.7045818822225556e-05
I I-Disease 0 3.755319630727172e-05
spinocerebellar B-Disease 0 6.732361362082884e-05
ataxias I-Disease 0 4.2360788938822225e-06
1 I-Disease 0 3.5030012668357813e-07
and I-Disease 0 1.744547795112794e-08
2 I-Disease 0 3.8567276305911946e-07
( O 0 1.1391443344166419e-08
SCA1 B-Disease 0 1.1284687388979364e-06
, O 0 6.3272338479691825e-09
n O 0 4.419272059408286e-08
= O 0 4.478543402797186e-08
11 O 0 1.8127629175523907e-08
; O 0 1.926335979618443e-09
SCA2 B-Disease 0 4.37401808994764e-07
, O 0 2.530962106561674e-09
n O 0 3.619564736823122e-08
= O 0 7.669753898653653e-08
10 O 0 1.553643791396553e-08
) O 0 3.974766293879384e-09
and O 0 3.812303717154464e-08
SCA3 B-Disease 1 1.0
/ O 0 1.1680586794682313e-05
Machado B-Disease 0 1.4936535990273114e-06
- I-Disease 0 3.030556854355382e-07
Joseph I-Disease 0 1.3476930689648725e-05
disease I-Disease 0 1.7919526726473123e-05
( O 0 1.3246433638869348e-07
MJD B-Disease 1 1.0
) O 0 4.7961506766114326e-08
( O 0 1.0091547153479041e-08
n O 0 1.7798612361730193e-07
= O 0 5.204494755162159e-07
16 O 0 4.043385217755713e-07
) O 0 6.585059253438885e-08
. O 0 5.86314399697585e-07

In O 0 2.403052576482878e-06
SCA1 B-Disease 0 0.00017165482859127223
, O 0 1.7817751540860627e-07
saccade O 0 4.314613306632964e-06
amplitude O 0 8.138079010677757e-07
was O 0 4.835261080415876e-08
significantly O 0 8.689175601261923e-09
increased O 0 7.640344357184858e-09
, O 0 3.993932295998093e-09
resulting O 0 3.460472797200964e-08
in O 0 3.044563001708411e-08
hypermetria B-Disease 0 1.0982871572196018e-05
. O 0 2.402543714197236e-06

The O 0 2.615991661514272e-06
smooth O 0 4.572030775307212e-06
pursuit O 0 4.2876031329797115e-06
gain O 0 3.3632861686783144e-06
was O 0 3.102062692050822e-06
decreased O 0 4.102524144400377e-06
. O 0 2.9320124212972587e-06

In O 0 1.7138414705186733e-06
SCA2 B-Disease 0 0.00012442690785974264
, O 0 1.5093260685716814e-07
saccade O 0 4.247721790306969e-06
velocity O 0 2.2239319150685333e-06
was O 0 1.0437934179208241e-06
markedly O 0 3.884459147229791e-06
decreased O 0 4.198406713840086e-06
. O 0 3.0641920147900237e-06

The O 0 4.281353369606222e-07
percentage O 0 9.437430747993858e-08
of O 0 2.560719636335307e-08
errors O 0 6.708633009111509e-07
in O 0 1.2893727863172444e-08
antisaccades O 0 1.1504831718411879e-06
was O 0 3.4384058267278306e-08
greatly O 0 4.631195871240834e-09
increased O 0 2.8919660000070735e-09
and O 0 2.5127897540500044e-09
was O 0 9.154556224189037e-09
significantly O 0 2.614642724552141e-09
correlated O 0 3.0470592715658995e-09
with O 0 2.6193183733091985e-10
age O 0 1.0434813901838424e-07
at O 0 5.891555474590859e-07
disease O 0 2.72375700660632e-06
onset O 0 1.2903643437311985e-05
. O 0 7.350936925831775e-07

In O 0 1.9763137970585376e-07
addition O 0 4.16369445588316e-08
, O 0 7.370639210080299e-09
a O 0 2.1560448981716718e-09
correlation O 0 1.3889872363392897e-08
between O 0 6.657141060628646e-09
smooth O 0 4.632567751627903e-08
pursuit O 0 5.707063976956306e-08
gain O 0 5.735709507348474e-08
and O 0 2.1206274514184997e-09
the O 0 1.630139911945605e-09
number O 0 1.099101587520579e-09
of O 0 1.862822784914897e-08
trinucleotide O 0 3.130709501419915e-06
repeats O 0 2.3715834629456367e-07
was O 0 2.1070619027341309e-07
found O 0 1.940531717536942e-07
. O 0 1.350948991785117e-06

In O 0 8.139451892930083e-06
SCA3 B-Disease 1 1.0
, O 0 1.3549722552852472e-06
gaze B-Disease 0 0.00787239708006382
- I-Disease 0 3.63280123565346e-05
evoked I-Disease 0 1.3793504649584065e-06
nystagmus I-Disease 0 6.607810064451769e-05
was O 0 3.0793934513440036e-08
often O 0 7.363567533502646e-10
present O 0 7.02389979512219e-10
as O 0 1.437106877943961e-09
was O 0 2.8212056690790632e-08
saccade O 0 9.86614736575575e-07
hypometria O 0 9.454994938096206e-07
and O 0 4.315014834332942e-08
smooth O 0 7.140280899875506e-07
pursuit O 0 8.4098962815915e-07
gain O 0 2.1450750864460133e-06
was O 0 2.170780817323248e-06
markedly O 0 2.7817991394840647e-06
decreased O 0 1.9418807823967654e-06
. O 0 1.41697239541827e-06

Three O 0 4.899022769677686e-07
major O 0 9.828080038687403e-08
criteria O 0 1.5734205760509212e-07
, O 0 2.4530283582180346e-08
saccade O 0 1.2094030807929812e-06
amplitude O 0 2.522152442452352e-07
, O 0 9.225617603192404e-09
saccade O 0 3.775583650167391e-07
velocity O 0 2.2321709991501848e-07
, O 0 5.728468810417553e-09
and O 0 3.1466147465408767e-09
presence O 0 9.920227306281504e-09
of O 0 3.3319886938443233e-07
gaze B-Disease 0 0.03136538714170456
- I-Disease 0 4.8572448577033356e-05
evoked I-Disease 0 1.9629433154477738e-06
nystagmus I-Disease 0 1.0711688446463086e-05
, O 0 3.9388279304830576e-09
permitted O 0 5.613535858373098e-09
the O 0 1.7545078723202323e-09
correct O 0 8.469940304678403e-09
assignment O 0 4.990030610940721e-09
of O 0 1.7602496127366862e-09
90 O 0 2.922770248048323e-09
% O 0 6.773461236342371e-10
of O 0 3.241202861659076e-09
the O 0 8.504549953158858e-09
SCA1 B-Disease 0 1.80110578185122e-06
, O 0 1.7939953966816802e-09
90 O 0 3.687799843277162e-09
% O 0 5.294126248500675e-10
of O 0 2.8241224914182794e-09
the O 0 7.6069293086789e-09
SCA2 B-Disease 0 1.6063061138993362e-06
, O 0 1.515015224384797e-09
and O 0 7.864398576806764e-10
93 O 0 6.352288473010503e-09
% O 0 3.623249755779767e-10
of O 0 2.3851589592283062e-09
the O 0 3.195362197061513e-09
patients O 0 2.6217139570405834e-09
with O 0 3.4687048788839547e-09
SCA3 B-Disease 1 1.0
to O 0 4.624972849143205e-09
their O 0 1.7532432172728818e-09
genetically O 0 1.038376407080932e-08
confirmed O 0 2.2497291141121423e-08
patient O 0 2.3630892798109926e-08
group O 0 2.485192274193082e-09
and O 0 2.0276895718041033e-09
, O 0 8.446575106013654e-10
therefore O 0 3.0899354186431083e-09
, O 0 1.6965391314016642e-09
may O 0 4.863914160324612e-09
help O 0 1.068181632035703e-08
orient O 0 1.5974486586856074e-06
diagnoses O 0 2.319462026889596e-07
of O 0 3.133063586346907e-08
SCA1 B-Disease 0 6.730942004651297e-06
, O 0 1.5282941134842076e-08
SCA2 B-Disease 0 4.797633209818741e-06
, O 0 7.356846687400775e-09
and O 0 2.3953770522666673e-08
SCA3 B-Disease 1 1.0
at O 0 1.2848927610775718e-07
early O 0 2.4117433383707976e-08
clinical O 0 5.8082591181118914e-08
stages O 0 6.4010620803856e-08
of O 0 2.256536468792092e-08
the O 0 4.891902705139728e-08
diseases O 0 2.014337269429234e-06
. O 0 6.334191482437745e-08
. O 0 1.5175095313679776e-06

Genetic O 0 7.416119274239463e-07
basis O 0 1.0600169275676308e-07
and O 0 9.719320459566916e-09
molecular O 0 4.938802362630668e-07
mechanism O 0 4.450015694601461e-06
for O 0 7.635771908098832e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.83244389295578

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999990463256836
causes O 0 1.1127040124847554e-05
more O 0 9.194190297989735e-09
than O 0 3.3572165047957014e-09
300 O 0 5.417463810886147e-09
, O 0 9.083102048279557e-10
000 O 0 1.6861779528198895e-08
sudden O 0 1.983709729813654e-08
deaths O 0 4.048834600922646e-09
each O 0 5.36950262031155e-10
year O 0 7.472112373285711e-10
in O 0 1.0163109243066515e-09
the O 0 1.5170313005796743e-08
USA O 0 1.8401446766347362e-07
alone O 0 1.1695958335167234e-07
. O 0 6.375973384820099e-07

In O 0 2.3091330092483986e-07
approximately O 0 6.199142887908238e-08
5 O 0 1.2843794650052587e-07
- O 0 3.217257216192593e-08
12 O 0 5.1878115137071745e-09
% O 0 1.9623963565251756e-10
of O 0 4.0518455257654296e-10
these O 0 1.2247661218545147e-10
cases O 0 1.9414841956333362e-10
, O 0 6.25655499630895e-11
there O 0 7.515889299813949e-11
are O 0 7.05928579480819e-11
no O 0 2.2083699313668603e-09
demonstrable O 0 2.6562195216683904e-06
cardiac O 0 0.00048305324162356555
or O 0 9.252261179426569e-07
non O 1 0.956951916217804
- O 0 0.014315503649413586
cardiac O 0 0.0016181853134185076
causes O 0 7.394692858042617e-08
to O 0 1.5512769957481964e-09
account O 0 1.0198157873730906e-09
for O 0 6.575565092425961e-10
the O 0 3.2373661529305764e-09
episode O 0 6.249322392903878e-09
, O 0 3.1966160274343736e-10
which O 0 7.373796018228518e-11
is O 0 4.1896507096961244e-11
therefore O 0 7.62867602421835e-10
classified O 0 7.288659897852767e-09
as O 0 2.2004201127856504e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9545560479164124
IVF B-Disease 1 1.0
) O 0 2.2044841898605227e-06
. O 0 6.7013961597695015e-06

A O 0 1.7949190578292473e-06
distinct O 0 2.3482628819238016e-07
group O 0 5.296242733265899e-08
of O 0 1.409853894074331e-06
IVF B-Disease 1 1.0
patients O 0 1.0264262328973928e-07
has O 0 4.5470441301098674e-10
been O 0 3.8645431299499933e-10
found O 0 1.1397103399923836e-10
to O 0 9.893536684346671e-11
present O 0 1.1054720472358781e-09
with O 0 6.401947860723567e-10
a O 0 9.810546153232735e-09
characteristic O 0 4.686532520281617e-06
electrocardiographic O 0 6.15923127043061e-05
pattern O 0 1.382829577778466e-05
. O 0 3.3618175621086266e-06

Because O 0 1.600822230329868e-07
of O 0 1.3321697167612e-07
the O 0 8.454718702921582e-09
small O 0 1.0150283946686045e-09
size O 0 1.4750193289003732e-09
of O 0 4.61272708918159e-09
most O 0 1.188527831708086e-09
pedigrees O 0 2.3922128278286436e-08
and O 0 1.6547688774792846e-09
the O 0 2.1280950335267335e-09
high O 0 1.1806344701881244e-07
incidence O 0 9.779723342262514e-08
of O 0 6.216581471818472e-09
sudden B-Disease 0 6.768610916196849e-08
death I-Disease 0 2.6111263196071377e-07
, O 0 1.3782561758546308e-09
however O 0 1.669039351170909e-09
, O 0 6.36031116663105e-10
molecular O 0 1.1046168424400093e-08
genetic O 0 1.73694358895915e-09
studies O 0 2.2884099060149765e-09
of O 0 1.8523069300613315e-08
IVF B-Disease 1 0.9999819993972778
have O 0 2.1600623512085804e-09
not O 0 1.8344030738859374e-09
yet O 0 9.305886727872803e-09
been O 0 1.6879253550428075e-08
done O 0 1.1366141450253053e-07
. O 0 6.703676831421035e-07

Because O 0 2.232623273812351e-06
IVF B-Disease 1 0.9999998807907104
causes O 0 2.1993306290823966e-05
cardiac O 1 0.9997484087944031
rhythm O 1 0.9995669722557068
disturbance O 1 0.971197783946991
, O 0 3.752097299525303e-08
we O 0 1.9655374217109056e-08
investigated O 0 4.996490687858568e-08
whether O 0 4.067953973674321e-09
malfunction O 0 1.163982574325928e-06
of O 0 2.2756317719085928e-08
ion O 0 1.4200743407855043e-06
channels O 0 1.5726571689356206e-07
could O 0 8.914647686708577e-09
cause O 0 6.123894280563036e-08
the O 0 1.3505192519858156e-08
disorder O 0 8.708558141279354e-08
by O 0 2.744650340336108e-10
studying O 0 1.4543742876682586e-09
mutations O 0 1.4950275462055629e-09
in O 0 3.6732525354743473e-10
the O 0 3.774533574585348e-09
cardiac O 0 2.1012225204231072e-07
sodium O 0 2.740874265327875e-07
channel O 0 8.276489893432881e-07
gene O 0 3.3710850289025984e-07
SCN5A O 0 6.123622733866796e-05
. O 0 3.867124178213999e-06

We O 0 5.180546622796101e-07
have O 0 9.269800926858807e-09
now O 0 8.851264610143517e-09
identified O 0 1.832837170923085e-08
a O 0 8.023997466466426e-09
missense O 0 8.418771813012427e-07
mutation O 0 8.07257123369709e-08
, O 0 1.1534056376660828e-08
a O 0 2.082946259918117e-08
splice O 0 4.119886796161154e-07
- O 0 4.451495527746374e-08
donor O 0 2.106895546916121e-09
mutation O 0 9.49746858935896e-09
, O 0 1.619293699128832e-09
and O 0 2.2284472045441817e-09
a O 0 6.8931744756639546e-09
frameshift O 0 4.5411377413984155e-07
mutation O 0 1.6645511635715593e-08
in O 0 3.022447403466799e-09
the O 0 8.789555749899591e-09
coding O 0 1.4611907772632549e-07
region O 0 1.1987848935746115e-08
of O 0 3.626993816396862e-08
SCN5A O 0 1.3615962416224647e-05
in O 0 1.969703156134983e-08
three O 0 5.7024177380071706e-08
IVF B-Disease 0 0.027743341401219368
families O 0 5.723120466427645e-08
. O 0 6.104058911660104e-07

We O 0 2.6458715751687123e-07
show O 0 8.018352204430812e-09
that O 0 3.253595171059942e-10
sodium O 0 9.59497281627364e-09
channels O 0 5.113181433813452e-09
with O 0 2.440481428056529e-10
the O 0 2.680765165408161e-09
missense O 0 4.851987114307121e-07
mutation O 0 3.1653250687213585e-08
recover O 0 7.062528339929486e-08
from O 0 5.187366092229695e-09
inactivation O 0 6.483140850832569e-07
more O 0 1.1139361655310154e-09
rapidly O 0 1.0153851981442585e-08
than O 0 5.054862084463707e-10
normal O 0 1.702484153653927e-09
and O 0 2.5410898385480607e-10
that O 0 1.2506960744840256e-10
the O 0 1.9674117890389198e-09
frameshift O 0 2.591861516521021e-07
mutation O 0 3.489341704465687e-09
causes O 0 3.105059542818367e-09
the O 0 1.5070578118780986e-09
sodium O 0 5.59928148291533e-09
channel O 0 3.867443254534919e-09
to O 0 2.5754409715972315e-10
be O 0 2.4536541687325553e-09
non O 0 1.1659452070489351e-07
- O 0 1.191617045037674e-07
functional O 0 7.482258297386579e-07
. O 0 7.685773084631364e-07

Our O 0 1.1684313676596503e-06
results O 0 1.3124785880336276e-07
indicate O 0 1.6095823340833704e-08
that O 0 1.506666902351128e-09
mutations O 0 1.502397672936695e-08
in O 0 4.316049295738367e-09
cardiac O 0 3.990043921930919e-07
ion O 0 1.5717254427727312e-05
- O 0 9.557016164762899e-05
channel O 0 4.707360190536747e-08
genes O 0 1.2236809343590949e-09
contribute O 0 2.5585150664753087e-10
to O 0 2.755198291737315e-10
the O 0 1.424830253782261e-09
risk O 0 6.84819889684718e-09
of O 0 2.3622781952781224e-08
developing O 0 1.3528984936783672e-06
IVF B-Disease 1 0.996090829372406
. O 0 6.714886779946028e-08
. O 0 4.3594880594355345e-07

Molecular O 0 8.834484106046148e-06
heterogeneity O 0 3.6258709315006854e-06
in O 0 8.931551320756626e-08
mucopolysaccharidosis B-Disease 0 1.457986218156293e-05
IVA I-Disease 0 0.0005118005792610347
in O 0 1.9505874249148292e-08
Australia O 0 2.24018048555763e-08
and O 0 3.3859102188671386e-09
Northern O 0 2.8122929762730564e-08
Ireland O 0 9.06943427025908e-08
: O 0 3.613492616239e-09
nine O 0 4.813762277677824e-09
novel O 0 1.8089730824399908e-09
mutations O 0 3.89140275558475e-09
including O 0 1.0381937531889207e-09
T312S O 0 1.957753710257748e-07
, O 0 3.004949844509497e-09
a O 0 1.5058998492634146e-09
common O 0 6.742888913890965e-09
allele O 0 4.996042690663671e-08
that O 0 5.087613108578637e-10
confers O 0 9.205108142396057e-08
a O 0 4.3374257074901834e-08
mild O 0 1.7641783415456302e-05
phenotype O 0 4.54644177807495e-05
. O 0 6.491471140179783e-06

Mucopolysaccharidosis B-Disease 0 0.012619315646588802
IVA I-Disease 1 0.9999992847442627
( O 0 7.484758680220693e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.711632589580404e-07
is O 0 6.251789752553805e-09
an O 0 1.7635505500379622e-08
autosomal B-Disease 1 0.9998146891593933
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 0.9999998807907104
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.003402714617550373
by O 0 2.2255052556374721e-07
a O 0 1.8178166101279203e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999910593032837
in O 0 7.399291916954098e-07
N O 0 0.0008310758857987821
- O 0 4.286674811737612e-05
acetylgalactosamine O 0 7.608007308590459e-06
- O 0 9.86468990049616e-07
6 O 0 2.2768726921640337e-06
- O 0 5.297925440572726e-07
sulfate O 0 4.0794952838041354e-07
sulfatase O 0 3.6791214370168746e-05
( O 0 5.095951038924795e-08
GALNS O 0 2.2961727154324763e-05
) O 0 1.3906988272083254e-07
. O 0 1.1284569154668134e-06

Previous O 0 1.5309014997910708e-06
studies O 0 5.724900375980724e-08
of O 0 1.88490325570001e-08
patients O 0 3.775829426899691e-09
from O 0 1.3481481486721236e-09
a O 0 3.5153073785210154e-09
British O 0 2.0364136332773342e-07
- O 0 6.731397093062697e-07
Irish O 0 7.774325183618203e-08
population O 0 4.5010267735179355e-10
showed O 0 1.3032203094454076e-09
that O 0 1.792841708425641e-10
the O 0 1.9802346429287354e-09
I113F O 0 7.180126004868725e-08
mutation O 0 5.685732773486052e-09
is O 0 1.2450360187266085e-10
the O 0 1.7367042526306165e-10
most O 0 3.552855926125531e-11
common O 0 3.3452365877373325e-10
single O 0 5.66410363056491e-10
mutation O 0 1.8260747580711723e-08
among O 0 3.001131076985075e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.225317419084604e-06
and O 0 3.628744593697775e-08
produces O 0 3.220462119202239e-08
a O 0 2.591942482865761e-08
severe O 0 2.2912839995115064e-05
clinical O 0 2.907628550019581e-05
phenotype O 0 2.1138632291695103e-05
. O 0 3.288062089268351e-06

We O 0 6.146919417915342e-07
studied O 0 5.663206366079976e-07
mutations O 0 2.4900092654434047e-08
in O 0 3.954772065384304e-09
the O 0 1.2169618202051424e-08
GALNS O 0 2.297075525348191e-06
gene O 0 6.1470748491387894e-09
from O 0 2.8993611955741017e-09
23 O 0 7.907846111265826e-08
additional O 0 8.854053845652743e-08
MPS B-Disease 1 0.9999979734420776
IVA I-Disease 1 1.0
patients O 0 7.5656792830614e-08
( O 0 5.092071653223229e-09
15 O 0 8.522557770618278e-09
from O 0 3.6876501852134425e-10
Australia O 0 2.1042128039994168e-09
, O 0 3.2609570599362314e-10
8 O 0 3.3510236807643423e-09
from O 0 2.3613389021903686e-10
Northern O 0 6.755594306184776e-09
Ireland O 0 1.5733643721205226e-08
) O 0 6.496924664922687e-10
, O 0 2.1756825507868172e-10
with O 0 5.7314139545461273e-11
various O 0 1.5177569201441088e-09
clinical O 0 7.075639700815373e-07
phenotypes O 0 1.7059626770787872e-05
( O 0 4.094781758112731e-08
severe O 0 2.776893097689026e-06
, O 0 1.6580933959176036e-08
16 O 0 4.681045950860607e-08
cases O 0 8.357409764236934e-10
; O 0 3.6970734806907046e-10
intermediate O 0 3.424034034082979e-08
, O 0 8.242888593912312e-10
4 O 0 1.3342838833807491e-08
cases O 0 1.0216926193962195e-09
; O 0 8.053079314507272e-10
mild O 0 4.9750273234394626e-08
, O 0 4.410234399898627e-09
3 O 0 1.0100099956389386e-07
cases O 0 1.5343546877488734e-08
) O 0 1.0443012676830676e-08
. O 0 4.091874359346548e-07

We O 0 2.8593936463039427e-07
found O 0 2.202162718845102e-08
two O 0 1.3779827279236656e-09
common O 0 2.424809242285164e-09
mutations O 0 4.841940182132021e-09
that O 0 2.6635063599123043e-10
together O 0 4.188781543845721e-10
accounted O 0 1.6439030137149757e-09
for O 0 1.9449980515062748e-10
32 O 0 7.445981164977411e-09
% O 0 9.012176005462891e-10
of O 0 6.590195944511379e-09
the O 0 6.818001274666585e-09
44 O 0 1.9267266893052692e-08
unrelated O 0 1.0146978368652526e-08
alleles O 0 1.1211905182051396e-08
in O 0 1.852330844265282e-09
these O 0 4.385556362507259e-09
patients O 0 3.7233100158573507e-08
. O 0 4.5149172933633963e-07

One O 0 5.288117108648294e-07
is O 0 8.230229830985536e-09
the O 0 1.0223013546806214e-08
T312S O 0 5.518987222785654e-07
mutation O 0 3.455881980585218e-08
, O 0 2.0877581885514473e-09
a O 0 1.9020569563821255e-09
novel O 0 1.546928629636568e-08
mutation O 0 4.843272805032939e-08
found O 0 1.0036302455773694e-08
exclusively O 0 2.7704565752628696e-08
in O 0 4.039449308379517e-08
milder O 0 5.3368126827990636e-05
patients O 0 4.205680397717515e-06
. O 0 1.285978578380309e-05

The O 0 7.524534453295928e-07
other O 0 9.948402990289651e-09
is O 0 1.3247585251008331e-09
the O 0 2.075473792828575e-09
previously O 0 8.552015984264472e-09
described O 0 1.1771869701249216e-08
I113F O 0 1.9968372555467795e-07
that O 0 2.9801212608759897e-09
produces O 0 5.565595273537838e-08
a O 0 7.244975108733342e-08
severe O 0 7.726538024144247e-05
phenotype O 0 0.00046486174687743187
. O 0 1.7390852008247748e-05

The O 0 1.291575244977139e-06
I113F O 0 2.5097983780142386e-06
and O 0 3.570544393483033e-08
T312S O 0 4.5793129288540513e-07
mutations O 0 1.173255270714435e-08
accounted O 0 7.052362249737598e-09
for O 0 8.35380820074505e-10
8 O 0 3.971827666759964e-08
( O 0 1.2918065506184462e-09
18 O 0 2.706716406564169e-09
% O 0 1.5916906681567866e-10
) O 0 1.56551993590881e-10
and O 0 7.119420608603377e-10
6 O 0 6.215517345253829e-08
( O 0 7.802156143377204e-10
14 O 0 3.2102553948476498e-09
% O 0 1.919835401764658e-10
) O 0 1.767090918036729e-10
of O 0 2.0479709039733507e-09
44 O 0 1.6059271246149365e-08
unrelated O 0 4.169814005194894e-08
alleles O 0 1.0282191453825362e-07
, O 0 4.409597309518176e-08
respectively O 0 9.558312967783422e-07
. O 0 3.3895257729454897e-06

The O 0 9.948272463589092e-07
relatively O 0 1.704209324771e-07
high O 0 4.00762843355551e-07
residual O 0 1.5870984952925937e-06
GALNS O 0 1.8401167835691012e-05
activity O 0 6.554759579557867e-08
seen O 0 1.5010458653819114e-08
when O 0 1.7069321511797853e-09
the O 0 2.68747690768123e-09
T312S O 0 3.232240430861566e-08
mutant O 0 3.0284500240895795e-08
cDNA O 0 1.798065873970245e-08
is O 0 8.345272251020219e-10
overexpressed O 0 3.767673462107268e-08
in O 0 1.5821055576736853e-09
mutant O 0 9.239761311619077e-08
cells O 0 2.7564466265062038e-08
provides O 0 2.8771660609550054e-09
an O 0 1.9471582679564392e-10
explanation O 0 3.573138673829135e-09
for O 0 1.636376367741832e-09
the O 0 9.030247660746227e-09
mild O 0 1.532099190626468e-06
phenotype O 0 2.1674449612874014e-07
in O 0 2.0350512386357877e-09
patients O 0 6.884012804242445e-10
with O 0 4.179603885212657e-10
this O 0 2.8022466569410653e-09
mutation O 0 3.2971010455185024e-07
. O 0 1.1168064020239399e-06

The O 0 1.6212715081564966e-07
distribution O 0 1.3281594490877069e-08
and O 0 2.5478272824841497e-09
relative O 0 1.7643042582449198e-08
frequencies O 0 4.2783163678450364e-08
of O 0 3.2274460881609457e-09
the O 0 3.721689401103845e-09
I113F O 0 6.694489940173298e-08
and O 0 4.346889959094824e-09
T312S O 0 9.168049075469753e-08
mutations O 0 1.3588055125524079e-08
in O 0 2.3063493337360796e-09
Australia O 0 6.3320144683132185e-09
corresponded O 0 5.165811778340412e-09
to O 0 7.385580480523402e-10
those O 0 6.388518047906189e-10
observed O 0 5.593293384009712e-09
in O 0 6.443402478240046e-10
Northern O 0 3.4504811452507056e-08
Ireland O 0 1.2416609251886257e-07
and O 0 2.9851274785386295e-09
are O 0 3.117805458252576e-10
unique O 0 2.7482230380293515e-10
to O 0 8.997538131216842e-11
these O 0 9.616453466865238e-11
two O 0 1.0914071729706265e-10
populations O 0 6.754054954205557e-11
, O 0 6.946064556867526e-11
suggesting O 0 2.9190194705819295e-10
that O 0 5.24547558167221e-11
both O 0 2.143586419478538e-10
mutations O 0 4.438809320106429e-09
were O 0 2.3019630646103906e-09
probably O 0 4.813633935896178e-09
introduced O 0 5.100567079807661e-09
to O 0 8.444481225389211e-10
Australia O 0 2.8793893935841197e-09
by O 0 8.777823468086865e-10
Irish O 0 2.121041120517475e-08
migrants O 0 2.649725550085691e-09
during O 0 2.889633643476941e-09
the O 0 4.7341361941732885e-09
19th O 0 1.7457502110573841e-07
century O 0 1.049063598657085e-06
. O 0 1.677971795288613e-06

Haplotype O 0 1.777495890564751e-05
analysis O 0 2.683557909222145e-07
using O 0 1.0679110573619255e-07
6 O 0 3.0769388104090467e-06
RFLPs O 0 5.932736712566111e-06
provides O 0 1.023345053141611e-08
additional O 0 3.333804565741616e-09
data O 0 1.741355504236708e-09
that O 0 7.132261448106192e-11
the O 0 9.318245064449115e-10
I113F O 0 5.715691742125273e-08
mutation O 0 4.7722221729884495e-09
originated O 0 2.4274977583615964e-09
from O 0 5.967988880861697e-10
a O 0 4.325972469132466e-09
common O 0 4.607348103036202e-08
ancestor O 0 1.622230229259003e-06
. O 0 4.058419563079951e-06

The O 0 3.2767289326329774e-07
other O 0 7.272343172104456e-09
9 O 0 1.2848217068039958e-07
novel O 0 1.0205595479817475e-08
mutations O 0 1.0057113364325687e-08
identified O 0 3.765459055671272e-09
in O 0 4.677587206458611e-10
these O 0 4.4615039440643045e-10
23 O 0 4.2318450965694865e-08
patients O 0 1.9357946356990396e-09
were O 0 2.126236964272721e-09
each O 0 3.6839456485360245e-10
limited O 0 1.1580606473771127e-09
to O 0 1.0957712515136109e-09
a O 0 6.213594083703811e-09
single O 0 3.877194387769123e-08
family O 0 8.150531272121952e-08
. O 0 7.444435254910786e-07

These O 0 1.3020090250392968e-07
data O 0 6.479988456931096e-08
provide O 0 3.6294556249316656e-09
further O 0 4.2144119305476124e-09
evidence O 0 8.630802739162391e-09
for O 0 8.921906546888181e-10
extensive O 0 9.782815446612858e-09
allelic O 0 4.0986739691106777e-07
heterogeneity O 0 4.3906308633268054e-07
in O 0 6.886606485068114e-08
MPS B-Disease 1 0.9999947547912598
IVA I-Disease 1 1.0
in O 0 3.75910289562853e-08
British O 0 8.247753839896177e-07
- O 0 1.4100676253292477e-06
Irish O 0 7.453955674918689e-08
patients O 0 1.6505449229597957e-09
and O 0 5.545593984024322e-10
provide O 0 6.073034852782655e-10
evidence O 0 4.86679097022602e-09
for O 0 4.462303859753547e-10
their O 0 1.1170872005195065e-09
transmission O 0 7.361705911534955e-08
to O 0 9.839925541044181e-10
Australia O 0 6.307689481843681e-09
by O 0 7.853546146741053e-10
British O 0 7.963804904420613e-08
- O 0 1.0406728989664771e-07
Irish O 0 5.004492820148698e-08
migrants O 0 1.2636938606647163e-08
. O 0 1.4485005195297163e-08
. O 0 3.703793538534228e-07

Identification O 0 2.5158371954603354e-06
of O 0 8.400365913985297e-07
constitutional O 0 3.665079202619381e-05
WT1 O 0 0.0016825894126668572
mutations O 0 7.768579735056846e-07
, O 0 1.0457703147892516e-08
in O 0 5.238571798571456e-09
patients O 0 8.31131430345522e-09
with O 0 4.21767687441843e-09
isolated O 0 6.340843356156256e-06
diffuse B-Disease 1 0.9999994039535522
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.543833090840053e-07
and O 0 7.875120111577871e-09
analysis O 0 9.716206506027447e-09
of O 0 1.9805906248393512e-08
genotype O 0 1.3564227856477373e-06
/ O 0 9.436618029212696e-07
phenotype O 0 7.540339197475987e-08
correlations O 0 7.967448034662539e-09
by O 0 1.8616984343022835e-10
use O 0 5.927828783391931e-10
of O 0 6.0515539246353e-09
a O 0 8.163207887434965e-09
computerized O 0 3.5049393432018405e-07
mutation O 0 2.4295007960972725e-07
database O 0 2.8063351464879815e-07
. O 0 2.260811243104399e-06

Constitutional O 0 6.4498422034375835e-06
mutations O 0 1.6628541743557435e-07
of O 0 1.1830464785589356e-07
the O 0 8.69829932526045e-08
WT1 O 0 8.319640073750634e-06
gene O 0 5.723404328250581e-08
, O 0 1.4347659060831575e-08
encoding O 0 2.584336016298039e-07
a O 0 6.904375027261267e-08
zinc O 0 2.7636806407826953e-06
- O 0 3.999837645096704e-06
finger O 0 6.034371722307696e-07
transcription O 0 2.0129594702211762e-07
factor O 0 5.8731171037607055e-08
involved O 0 8.412301077953543e-09
in O 0 9.754867136280154e-09
renal O 1 0.999977707862854
and O 0 8.340949761986849e-07
gonadal O 1 0.9999933242797852
development O 0 2.414207074252772e-06
, O 0 2.78397349617876e-09
are O 0 2.456073677770121e-10
found O 0 6.004205466147994e-10
in O 0 4.062787883896135e-10
most O 0 4.6485570948107124e-10
patients O 0 1.5956946874950972e-09
with O 0 3.6851561802109245e-09
Denys B-Disease 1 0.9999943971633911
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.2029324100003578e-05
DDS B-Disease 1 1.0
) O 0 2.0622085372679066e-08
, O 0 6.16596862457186e-09
or O 0 8.93088696329869e-08
diffuse B-Disease 1 0.6673265099525452
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.8783989768708125e-05
DMS B-Disease 1 0.9912505149841309
) O 0 1.414244543695986e-08
associated O 0 1.6177231998426578e-08
with O 0 8.99229757322928e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.669891546247527e-05
/ O 1 0.9315826892852783
or O 0 3.2397017548646545e-06
Wilms B-Disease 1 0.9995903372764587
tumor I-Disease 0 4.712463851319626e-05
( O 0 8.689318065080442e-07
WT B-Disease 1 0.9999996423721313
) O 0 1.28795409182203e-06
. O 0 4.501530384004582e-06

Most O 0 6.763351052541111e-07
mutations O 0 1.2174097037132015e-06
in O 0 3.2365193192163133e-07
DDS B-Disease 1 1.0
patients O 0 6.016500151417858e-07
lie O 0 3.3593133252907137e-07
in O 0 1.6560420590394642e-08
exon O 0 2.833183145867224e-07
8 O 0 1.5506068962167774e-07
or O 0 1.504849755917803e-08
exon O 0 1.2850203745529143e-07
9 O 0 1.3077706739750283e-07
, O 0 9.502379327841481e-09
encoding O 0 4.1285164797955076e-07
zinc O 0 4.871794772043359e-07
finger O 0 1.1125957826152444e-06
2 O 0 4.66162327938946e-06
or O 0 2.3153160100264358e-07
zinc O 0 3.580942689040967e-07
finger O 0 2.775455527626036e-07
3 O 0 4.318275159675977e-07
, O 0 5.991944274086336e-09
respectively O 0 2.906394591661865e-08
, O 0 1.314762521076318e-09
with O 0 5.346406650730273e-10
a O 0 3.476295029614107e-09
hot O 0 1.2254137971012824e-07
spot O 0 5.881882998437504e-07
( O 0 1.0938443928409924e-08
R394W O 0 2.4651370722494903e-07
) O 0 2.708043789212411e-09
in O 0 6.526027718223304e-09
exon O 0 4.949822027811024e-07
9 O 0 1.7355954469167045e-06
. O 0 2.0881311684206594e-06

We O 0 4.727758948774863e-07
analyzed O 0 8.411021212850756e-08
a O 0 3.3821279110668456e-09
series O 0 9.106942755465752e-09
of O 0 5.800085745022443e-09
24 O 0 3.824378680405971e-08
patients O 0 8.488793556971075e-10
, O 0 4.211959114819308e-10
10 O 0 2.6800290875428345e-09
with O 0 1.5468569758425588e-09
isolated B-Disease 0 2.640953198351781e-07
DMS I-Disease 1 0.9989626407623291
( O 0 1.4780002288716787e-07
IDMS B-Disease 0 2.0046856661792845e-05
) O 0 5.499901423178244e-09
, O 0 2.095889461983802e-09
10 O 0 7.78061171047284e-09
with O 0 2.8302806764912702e-09
DDS B-Disease 1 1.0
, O 0 6.053562984220662e-09
and O 0 6.186159584586903e-09
4 O 0 2.797490594730334e-07
with O 0 1.773515023728578e-08
urogenital B-Disease 1 0.9951390027999878
abnormalities I-Disease 1 0.9957142472267151
and O 0 3.1589916034135967e-06
/ O 0 0.4497387409210205
or O 0 3.2450327125843614e-05
WT B-Disease 1 1.0
. O 0 1.9689370674313977e-05

We O 0 6.225124707270879e-06
report O 0 1.1354454727552366e-06
WT1 O 0 3.969093813793734e-05
heterozygous O 0 4.942473310620699e-07
mutations O 0 7.366256937757498e-08
in O 0 1.3723756353556382e-08
16 O 0 1.8544180591106851e-07
patients O 0 5.060160290781823e-09
, O 0 2.4549366983706022e-09
4 O 0 9.107953502507371e-08
of O 0 2.292395251402013e-08
whom O 0 9.532789846389278e-08
presented O 0 3.4457792708053603e-07
with O 0 1.48967330915184e-07
IDMS B-Disease 0 0.0022528632543981075
. O 0 1.5595227523590438e-05

One O 0 6.61599131035473e-07
male O 0 1.811272056784219e-07
and O 0 2.8571029986323992e-08
two O 0 4.8026222998487356e-08
female O 0 2.7487587317409634e-07
IDMS B-Disease 0 0.03401870280504227
patients O 0 3.1727361715638835e-07
with O 0 1.7340786939712416e-07
WT1 O 1 0.9999122619628906
mutations O 0 0.00026860085199587047
underwent O 0 0.0001470191782573238
normal O 0 4.340678788139485e-05
puberty O 0 0.00114616216160357
. O 0 3.36993230121152e-06

Two O 0 5.639325877382362e-07
mutations O 0 4.2337711647633114e-07
associated O 0 1.1420229384384584e-07
with O 0 1.5561914423756207e-08
IDMS B-Disease 0 0.09416691958904266
are O 0 2.3425885675720792e-09
different O 0 8.880887136797355e-10
from O 0 5.282204118550737e-10
those O 0 7.822003045276915e-10
described O 0 9.898775132910487e-09
in O 0 3.8187373263554036e-08
DDS B-Disease 1 1.0
patients O 0 1.1434673297117115e-06
. O 0 2.4166117782442598e-06

No O 0 5.234677246335195e-06
WT1 O 0 0.00013157229113858193
mutations O 0 7.268962463058415e-07
were O 0 7.369320798034096e-08
detected O 0 4.3491066747947116e-08
in O 0 3.3791101028413095e-09
the O 0 1.8255732925354096e-08
six O 0 5.892337284763016e-08
other O 0 9.884510987490103e-09
IDMS B-Disease 1 0.7804297208786011
patients O 0 8.340633428360889e-08
, O 0 4.1779162351929244e-09
suggesting O 0 1.7846314648295447e-08
genetic O 0 3.510806223516738e-08
heterogeneity O 0 1.2043165042996407e-07
of O 0 2.678347357232269e-07
this O 0 8.971913700861478e-08
disease O 0 0.0005881469114683568
. O 0 4.646842626243597e-06

We O 0 4.084122338099405e-06
analyzed O 0 3.44815043717972e-06
genotype O 0 6.093780029914342e-06
/ O 0 2.9295808872120688e-06
phenotype O 0 2.9077983754177694e-07
correlations O 0 1.1191824711431764e-07
, O 0 3.1073110751123068e-09
on O 0 2.7451125816924105e-09
the O 0 3.97886029679384e-10
basis O 0 1.917154213160188e-09
of O 0 7.579784022659908e-10
the O 0 8.364474668454136e-10
constitution O 0 4.149374621675861e-09
of O 0 4.753997639994623e-09
a O 0 1.0525380567116827e-08
WT1 O 0 2.243906692456221e-06
mutation O 0 4.8834007060349904e-08
database O 0 3.2713202813283715e-08
of O 0 3.3293513723720025e-08
84 O 0 5.640154085995164e-07
germ O 0 0.001540477736853063
- O 0 0.00013176952779758722
line O 0 6.02342993261118e-07
mutations O 0 3.763048539440206e-08
, O 0 1.3169435542081942e-09
to O 0 4.591027003009174e-10
compare O 0 2.2176940284168722e-09
the O 0 1.0243873527215897e-09
distribution O 0 8.064268697260957e-10
and O 0 2.100891405287797e-10
type O 0 6.35878549815061e-09
of O 0 6.789399709106192e-09
mutations O 0 7.284935321649755e-09
, O 0 5.309011008591824e-10
according O 0 3.4287361838636343e-10
to O 0 4.297433242594906e-10
the O 0 3.445323359940744e-09
different O 0 2.2339676775118278e-08
symptoms O 0 1.4472004295384977e-05
. O 0 2.089740746669122e-06

This O 0 7.03868536788832e-08
demonstrated O 0 2.0366039166219707e-07
( O 0 1.1114663855948947e-08
1 O 0 4.5453752761659416e-08
) O 0 1.1034074764992852e-09
the O 0 8.439972609686208e-10
association O 0 6.017297771165886e-10
between O 0 5.747727849225726e-10
mutations O 0 1.4209736720616206e-09
in O 0 7.186873873799016e-10
exons O 0 3.1306804260111676e-08
8 O 0 2.197723247832073e-08
and O 0 2.964943401906339e-09
9 O 0 1.519596395382905e-07
and O 0 1.9795709960135355e-08
DMS B-Disease 0 1.4346626812766772e-05
; O 0 8.085404346047653e-09
( O 0 3.029644757290839e-09
2 O 0 4.865420066835213e-08
) O 0 6.650792139240025e-10
among O 0 2.9266791767845746e-10
patients O 0 1.430900842258609e-09
with O 0 2.266979270970637e-09
DMS B-Disease 0 0.00011142653238493949
, O 0 2.9552664759791014e-09
a O 0 1.0711924680606444e-09
higher O 0 3.92928312109575e-09
frequency O 0 9.147294477429568e-09
of O 0 4.769292072381859e-09
exon O 0 3.342968923902845e-08
8 O 0 1.0837144515107866e-08
mutations O 0 3.761812195079983e-09
among O 0 7.473266450119809e-10
46 O 0 1.330273846633645e-08
, O 0 8.884890156934944e-09
XY O 0 4.5611803216161206e-05
patients O 0 1.4833995365393093e-08
with O 0 1.6431820348827841e-09
female O 0 2.9419389591112122e-08
phenotype O 0 5.718363027540363e-08
than O 0 2.239226803979477e-09
among O 0 1.8972234894221174e-09
46 O 0 5.048228501891572e-08
, O 0 2.8299744769810786e-08
XY O 0 0.0032782801426947117
patients O 0 1.677427263757636e-08
with O 0 5.984140405423943e-10
sexual O 0 3.046781671400822e-08
ambiguity O 0 7.61809815230663e-08
or O 0 2.1935772309689128e-08
male O 0 4.835221112386989e-09
phenotype O 0 7.640154287003043e-09
; O 0 8.535747109128522e-10
and O 0 3.43776784816896e-09
( O 0 2.0972972247790267e-09
3 O 0 1.2997555920435389e-08
) O 0 1.464545151819152e-10
statistically O 0 2.4060617387355876e-10
significant O 0 1.796809367959895e-10
evidence O 0 2.4644322138556163e-09
that O 0 1.454928399979849e-10
mutations O 0 2.425484479928741e-09
in O 0 2.3735680088066147e-09
exons O 0 8.990071620473827e-08
8 O 0 7.953771330448944e-08
and O 0 6.352372849960375e-09
9 O 0 1.2978944141650572e-07
preferentially O 0 4.917104234891667e-08
affect O 0 7.134366342143039e-08
amino O 0 1.8440758253746026e-08
acids O 0 2.0740096307036993e-09
with O 0 2.6723048773824587e-10
different O 0 1.0671811212503712e-09
functions O 0 1.296991847254958e-08
. O 0 8.334745338345328e-09
. O 0 1.270679348408521e-07

The O 0 3.394342456886079e-06
185delAG O 0 1.655979394854512e-05
BRCA1 O 0 1.4285420775195234e-06
mutation O 0 4.71106993416015e-08
originated O 0 8.448287402984533e-09
before O 0 1.496323420724366e-08
the O 0 1.2775458468894385e-09
dispersion O 0 2.9628475672893728e-08
of O 0 3.79617892676265e-09
Jews O 0 9.852362481410637e-09
in O 0 1.53155566007257e-09
the O 0 1.4208408893878754e-09
diaspora O 0 1.055438292318911e-09
and O 0 1.0513576675919012e-09
is O 0 4.735298819724676e-10
not O 0 1.3157784861661526e-09
limited O 0 1.3508026697195419e-08
to O 0 7.014815395223195e-08
Ashkenazim O 0 0.000327210669638589
. O 0 1.1778372936532833e-05

The O 0 2.519691179259098e-06
185delAG O 0 9.042416422744282e-06
mutation O 0 2.195785953063023e-07
in O 0 1.4098679557150717e-08
BRCA1 O 0 9.105226439487524e-08
is O 0 1.5668649711031435e-09
detected O 0 3.762500977444461e-09
in O 0 1.0029849173420757e-09
Ashkenazi O 0 8.874122414681551e-08
Jews O 0 2.5953955429258713e-08
both O 0 3.4595009079652073e-09
in O 0 1.5773668593510592e-08
familial B-Disease 0 0.006425170227885246
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.017980903387069702
in O 0 1.760503067771424e-07
the O 0 9.133125189464408e-08
general O 0 1.0250273874135019e-07
population O 0 1.3841368939893073e-08
. O 0 5.414278803073103e-07

All O 0 2.4668424885021523e-06
tested O 0 2.1617054244416067e-06
Ashkenazi O 0 4.386865384731209e-06
mutation O 0 3.9365918524936205e-08
carriers O 0 8.443889143450178e-09
share O 0 5.158585114628522e-09
the O 0 5.431245231335424e-09
same O 0 5.55737145191415e-09
allelic O 0 8.326770739586209e-07
pattern O 0 2.8024146558891516e-07
at O 0 1.9057134181821311e-07
the O 0 9.070160444935027e-08
BRCA1 O 0 2.1363719042710727e-06
locus O 0 4.812682163901627e-06
. O 0 3.661840537461103e-06

Our O 0 2.5127055778284557e-06
previous O 0 3.23629393506053e-07
study O 0 1.8298822013207428e-08
showed O 0 4.026777578047813e-09
that O 0 4.4262946086170984e-10
this O 0 9.976539594447331e-10
Ashkenazi O 0 2.3314287034281733e-07
mutation O 0 1.3528059561451755e-08
also O 0 1.3760654837824404e-09
occurs O 0 1.5504251216214016e-09
in O 0 9.401347478288358e-10
Iraqi O 0 7.859188144720974e-08
Jews O 0 3.2514460457377936e-08
with O 0 1.2434419049967005e-09
a O 0 5.842789807530835e-09
similar O 0 3.2906196878457195e-08
allelic O 0 2.9509099476854317e-05
pattern O 0 3.579371696105227e-05
. O 0 1.2837949725508224e-05

We O 0 1.212028678310162e-06
extended O 0 1.4126436553851818e-07
our O 0 1.99215755003479e-08
analysis O 0 2.6163886612806664e-09
to O 0 7.488348274797829e-10
other O 0 9.385705546094414e-10
non O 0 6.89329553438256e-08
- O 0 3.224912248356304e-08
Ashkenazi O 0 1.0221496182793999e-07
subsets O 0 7.280242897422795e-08
354 O 0 2.6672610786704354e-08
of O 0 2.786650910024946e-09
Moroccan O 0 1.4487442001609452e-07
origin O 0 4.285370724943505e-09
, O 0 6.210193692623989e-09
200 O 0 3.641752144289967e-08
Yemenites O 0 3.4804813822120195e-06
and O 0 3.046003271833797e-08
150 O 0 8.88096352014145e-08
Iranian O 0 4.5232093270897167e-07
Jews O 0 1.363954311273119e-06
. O 0 2.3511227027483983e-06

Heteroduplex O 0 8.057781815296039e-05
analysis O 0 2.610389060464513e-07
complemented O 0 5.159266791565642e-08
by O 0 6.705486721436671e-10
direct O 0 2.163967227630792e-09
DNA O 0 7.075361185826523e-09
sequencing O 0 8.438044929448552e-09
of O 0 1.4322476538097817e-08
abnormally O 0 8.344292723450053e-08
migrating O 0 1.0828136609575267e-08
bands O 0 5.0198938339462984e-08
were O 0 6.455673684513386e-08
employed O 0 2.613243736959703e-07
. O 0 6.268072070270136e-07

Four O 0 1.0477268688191543e-06
of O 0 1.814664472021832e-07
Moroccan O 0 3.649648760983837e-06
origin O 0 1.3706334733853964e-08
( O 0 1.6358833176965959e-09
1 O 0 3.21802895442147e-09
. O 0 2.081109590212904e-10
1 O 0 2.19801976619749e-09
% O 0 1.5947627940438025e-10
) O 0 3.114204172316448e-10
and O 0 3.242097701416924e-10
none O 0 4.327425084937886e-09
of O 0 6.737643332144216e-09
the O 0 1.1164636326554955e-08
Yemenites O 0 2.4539233436371433e-06
or O 0 9.950452906082319e-09
Iranians O 0 8.68727383362966e-08
was O 0 3.2946893213647854e-08
a O 0 4.410436460489109e-09
carrier O 0 8.747242041806658e-09
of O 0 5.991581275566205e-08
the O 0 1.7710209476717864e-07
185delAG O 0 1.1095409718109295e-05
mutation O 0 3.700718025356764e-06
. O 0 3.7733084354840685e-06

BRCA1 O 0 0.0001088997014448978
allelic O 0 4.7960009396774694e-05
patterns O 0 6.328460813165293e-07
were O 0 2.818511291025061e-08
determined O 0 2.9210218244202224e-08
for O 0 1.976012686810691e-09
four O 0 1.9540347118152113e-09
of O 0 8.638308401920369e-10
these O 0 1.1282642875531934e-10
individuals O 0 6.174765559974205e-11
and O 0 2.530043952120309e-10
for O 0 2.7801408397643e-10
12 O 0 7.197056284269365e-09
additional O 0 5.229457311628494e-09
non O 0 1.31420094362511e-07
- O 0 6.727039192355733e-08
Ashkenazi O 0 9.734778672054745e-08
185delAG O 0 1.1114688902580383e-07
mutation O 0 1.4126996461527597e-08
carriers O 0 1.4306314355394534e-08
who O 0 7.908781185506086e-08
had O 0 0.0001230066700372845
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9637681245803833

Six O 0 1.7189096979564056e-05
non O 0 5.458583837025799e-05
- O 0 3.809836243817699e-06
Ashkenazi O 0 8.194924703275319e-07
individuals O 0 1.2043304131736932e-09
shared O 0 4.776647521964605e-09
the O 0 1.8342493079970268e-09
common O 0 1.127275961465557e-08
Ashkenazi O 0 8.059330411924748e-07
haplotype O 0 2.0769209641002817e-07
, O 0 8.412943230950987e-09
four O 0 1.0382259496566348e-08
had O 0 1.5494059368847957e-08
a O 0 1.054314147097557e-08
closely O 0 1.51540895387825e-08
related O 0 2.985066061000907e-08
pattern O 0 6.462892798708708e-08
, O 0 1.856281461876108e-09
and O 0 1.5668023545245546e-09
the O 0 4.924948449058775e-09
rest O 0 1.0471934430711372e-08
( O 0 2.5783812862556488e-09
n O 0 2.343291427564509e-08
= O 0 3.910481538582644e-08
6 O 0 2.0909951103931235e-08
) O 0 3.3249378250665984e-10
displayed O 0 2.2464432536395407e-09
a O 0 7.674169744120718e-09
distinct O 0 1.3327047554412275e-07
BRCA1 O 0 2.8967956495762337e-06
allelic O 0 2.755775858531706e-05
pattern O 0 1.1357336006767582e-05
. O 0 1.0468685104569886e-05

We O 0 5.597073595708935e-07
conclude O 0 8.145890433297609e-07
that O 0 3.990246799645547e-09
the O 0 1.8067533247290157e-08
185delAG O 0 1.3011033388465876e-06
BRCA1 O 0 4.3909992086810234e-07
mutation O 0 3.5890003857730335e-08
occurs O 0 7.434457494071012e-09
in O 0 1.5032425304539743e-09
some O 0 1.3768111095657787e-09
non O 0 4.31311406146051e-07
- O 0 2.543731056903198e-07
Ashkenazi O 0 2.76775608654134e-07
populations O 0 2.3787347647186152e-09
at O 0 2.317718994504503e-08
rates O 0 4.5920627300688466e-09
comparable O 0 4.224899097238222e-09
with O 0 3.0043753596054046e-10
that O 0 1.0727955190859007e-09
of O 0 8.828169484331738e-08
Ashkenazim O 0 0.00014378223568201065
. O 0 2.983028480230132e-06

The O 0 3.8660220980091253e-07
majority O 0 2.798722675834142e-08
of O 0 2.6227054306104947e-08
Jewish O 0 1.7623543158151733e-07
185delAG O 0 7.32512091872195e-07
mutation O 0 6.798265417273797e-08
carriers O 0 1.0559362273454553e-08
have O 0 4.00164124059188e-09
a O 0 9.966636405067675e-09
common O 0 7.550672620482146e-08
allelic O 0 1.9007373339263722e-05
pattern O 0 1.1189375754838693e-06
, O 0 9.17042353165698e-09
supporting O 0 2.0205172646114988e-08
the O 0 2.6614575432404308e-08
founder O 0 1.5872484482315485e-07
effect O 0 1.7359376158765372e-08
notion O 0 9.29212351508113e-09
, O 0 5.801078506451063e-10
but O 0 3.5568989420475816e-10
dating O 0 2.152457767579108e-09
the O 0 3.3011654521075684e-10
mutations O 0 1.2989123110429546e-09
origin O 0 1.1599617932844808e-09
to O 0 7.807767765655171e-10
an O 0 4.2998848925890343e-10
earlier O 0 6.711426969729928e-09
date O 0 8.062153966648111e-08
than O 0 7.253184719502315e-09
currently O 0 1.7617551861803804e-08
estimated O 0 1.241631224502271e-07
. O 0 1.6234807844739407e-06

However O 0 6.157175107546209e-07
, O 0 1.0282658280402757e-08
the O 0 6.476414959877275e-09
different O 0 4.03031208406901e-09
allelic O 0 5.785978487438115e-07
pattern O 0 1.8646414901013486e-07
at O 0 1.3264929066281184e-07
the O 0 1.2344156807841955e-08
BRCA1 O 0 6.835634280832892e-08
locus O 0 3.740600007517969e-08
even O 0 1.8241139709829213e-09
in O 0 5.043487849576422e-10
some O 0 3.319431396420214e-10
Jewish O 0 1.4309589069227968e-08
mutation O 0 1.1628687346387778e-08
carriers O 0 2.0027821623358477e-09
, O 0 1.4754807375894075e-09
might O 0 3.334847509250949e-09
suggest O 0 6.860265244768016e-09
that O 0 7.071957464077627e-10
the O 0 5.5753139882597225e-09
mutation O 0 2.0394274713453342e-08
arose O 0 6.869420587918285e-08
independently O 0 4.023662469876399e-08
. O 0 5.97163776205889e-08
. O 0 1.4623883544118144e-06

Crystal O 0 0.0004907451220788062
structure O 0 9.502701686869841e-06
of O 0 4.119735876884079e-06
the O 0 6.63637911202386e-06
hemochromatosis B-Disease 1 1.0
protein O 0 6.3589736782887485e-06
HFE O 0 0.0019486119272187352
and O 0 1.0404422212673126e-08
characterization O 0 1.9675816531616874e-08
of O 0 1.4106023016324798e-08
its O 0 3.5485390181833054e-09
interaction O 0 1.9879708546000074e-08
with O 0 1.788273884528735e-08
transferrin O 0 4.244530828145798e-06
receptor O 0 4.5056449380354024e-06
. O 0 1.7543666217534337e-06

HFE O 0 0.01224509160965681
is O 0 2.918577877153439e-07
an O 0 4.85719553466879e-08
MHC O 0 3.1135805329540744e-05
- O 0 3.166709211654961e-05
related O 0 1.7964656251479028e-07
protein O 0 1.743659616693094e-08
that O 0 2.9698263293020943e-10
is O 0 2.0422591395785616e-10
mutated O 0 3.76765685317082e-09
in O 0 1.6573304950640022e-09
the O 0 3.0770920034228766e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9987204074859619

HFE O 0 0.0005351924919523299
binds O 0 9.736169204188627e-07
to O 0 9.413287216375466e-08
transferrin O 0 3.701914920384297e-06
receptor O 0 1.5294845070457086e-06
( O 0 5.5985793778745574e-08
TfR O 0 1.1605841336859157e-06
) O 0 3.444173835021047e-09
and O 0 1.849774666773385e-09
reduces O 0 6.656735163090843e-09
its O 0 1.2659584491814257e-09
affinity O 0 1.0010608342270189e-08
for O 0 9.937460632158945e-09
iron O 0 6.8856206780765206e-06
- O 0 9.149825928034261e-07
loaded O 0 7.595102857749225e-08
transferrin O 0 1.2842585874750512e-06
, O 0 8.65470894950704e-08
implicating O 0 1.7000525986077264e-05
HFE O 0 0.0015585501678287983
in O 0 1.4905003808962647e-06
iron O 0 0.4207986891269684
metabolism O 0 0.12539666891098022
. O 0 8.179565156751778e-06

The O 0 5.961713668511948e-06
2 O 0 4.1217113903257996e-05
. O 0 7.936410838738084e-06

6 O 0 0.0001203614374389872
A O 0 3.1721717732580146e-06
crystal O 0 4.558905857265927e-05
structure O 0 5.204263743507909e-06
of O 0 7.368785759354068e-07
HFE O 0 0.0021810741163790226
reveals O 0 1.4086965904880344e-07
the O 0 4.337936676535037e-09
locations O 0 1.6638718847161726e-08
of O 0 5.787821919511771e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0002313548611709848
and O 0 6.565782655343355e-07
a O 0 1.7265686835798988e-07
patch O 0 5.696585503756069e-06
of O 0 2.2915442059456836e-06
histidines O 0 1.9564880858524702e-05
that O 0 1.8415968749962985e-09
could O 0 7.555466474684636e-09
be O 0 5.517332368754069e-09
involved O 0 1.1394940990783198e-08
in O 0 2.7591820384031962e-08
pH O 0 4.537012500804849e-05
- O 0 2.439831405354198e-06
dependent O 0 1.0646387238466559e-07
interactions O 0 2.9334427154026343e-07
. O 0 1.258948032045737e-06

We O 0 9.98307541522081e-07
also O 0 2.0800481337346355e-08
demonstrate O 0 8.678016172325442e-08
that O 0 1.5997791535937722e-08
soluble O 0 1.053110281645786e-06
TfR O 0 4.63490187030402e-06
and O 0 6.881301573002929e-08
HFE O 0 1.998952757276129e-05
bind O 0 8.169456577888923e-08
tightly O 0 6.43526618659962e-08
at O 0 5.4149872141806554e-08
the O 0 5.31772981204881e-09
basic O 0 3.560825945214674e-08
pH O 0 2.16217429738208e-07
of O 0 1.641816993469547e-08
the O 0 4.574038037219452e-09
cell O 0 1.5755928117755502e-08
surface O 0 8.20563705872246e-09
, O 0 9.022857461182809e-10
but O 0 1.1889925710661942e-09
not O 0 1.838178831370385e-09
at O 0 5.133450997618638e-08
the O 0 1.8980497173970434e-08
acidic O 0 4.863314302383515e-07
pH O 0 3.520829295666772e-06
of O 0 9.934581157722278e-07
intracellular O 0 5.989974852127489e-06
vesicles O 0 1.1282522791589145e-05
. O 0 4.089009507879382e-06

TfR O 0 0.0009376272791996598
HFE O 0 0.00028344307793304324
stoichiometry O 0 2.8471426958276425e-06
( O 0 1.1918204734229221e-07
2 O 0 4.3792309156742704e-07
1 O 0 2.0904414554934192e-07
) O 0 4.055836999583562e-09
differs O 0 1.0977005970858045e-08
from O 0 7.81017028828046e-09
TfR O 0 9.953167818821385e-07
transferrin O 0 1.4607753939799295e-07
stoichiometry O 0 1.1538901389940293e-07
( O 0 3.764748068846302e-09
2 O 0 4.061149638800998e-08
2 O 0 3.5923765295819976e-08
) O 0 1.1016473289160444e-09
, O 0 6.842619804103833e-10
implying O 0 6.435214139344225e-09
a O 0 1.3761600747841385e-09
different O 0 3.827790306942802e-10
mode O 0 6.031793020611076e-08
of O 0 4.588726731924453e-09
binding O 0 1.7837907151374566e-08
for O 0 1.2300253260377758e-08
HFE O 0 1.7325824956060387e-05
and O 0 4.1797193262027577e-08
transferrin O 0 5.950518584540987e-07
to O 0 1.1236352293053642e-08
TfR O 0 1.1471219067971106e-06
, O 0 1.4094584388502085e-09
consistent O 0 8.899883496837901e-09
with O 0 5.41639677553718e-10
our O 0 4.432312294966323e-09
demonstration O 0 4.313763923846636e-08
that O 0 1.4375015622292153e-09
HFE O 0 7.3687265285116155e-06
, O 0 1.0065134503633999e-08
transferrin O 0 2.0804139921892784e-07
, O 0 6.663492868597132e-09
and O 0 7.906862720119534e-09
TfR O 0 6.584776315321506e-07
form O 0 2.635286655561231e-08
a O 0 3.230021761169155e-08
ternary O 0 3.12459474116622e-06
complex O 0 3.906615802407032e-06
. O 0 1.7406111965101445e-06

Identification O 0 9.669452083471697e-07
of O 0 1.6771016930761107e-07
three O 0 1.594332488252803e-08
novel O 0 7.17568715558059e-09
mutations O 0 1.835023333285335e-08
and O 0 2.63323030047502e-09
a O 0 3.3231706275671513e-09
high O 0 4.474973991364095e-08
frequency O 0 9.019166213874996e-08
of O 0 1.0579401354959828e-08
the O 0 1.1397158772297189e-08
Arg778Leu O 0 2.3830923510104185e-06
mutation O 0 2.1678683737036408e-08
in O 0 6.079434733408107e-09
Korean O 0 2.5412336412955483e-07
patients O 0 2.7760847842728253e-08
with O 0 2.1168540698113247e-08
Wilson B-Disease 0 7.477945473510772e-05
disease I-Disease 0 0.022027261555194855
. O 0 8.363480446860194e-06

Four O 0 4.348789389041485e-06
mutations O 0 1.953927721842774e-06
- O 0 1.953564378709416e-06
- O 0 1.6508944611359766e-07
R778L O 0 3.5130980791109323e-07
, O 0 7.806029600487818e-09
A874V O 0 1.7247305095224874e-07
, O 0 5.1723980654116986e-09
L1083F O 0 1.2317408959461318e-07
, O 0 2.311872471238985e-09
and O 0 4.5126768988268395e-09
2304delC O 0 2.6540419639786705e-07
- O 0 3.876565912719343e-08
- O 0 7.949263469697598e-09
in O 0 1.3815039112685668e-09
the O 0 5.317303486407354e-09
copper O 0 1.1084034667874221e-07
- O 0 7.478320895870638e-08
transporting O 0 2.9068933926623686e-08
enzyme O 0 1.4238693779589084e-08
, O 0 7.415622338413641e-09
P O 0 6.9959273787389975e-06
- O 0 2.6454904400452506e-07
type O 0 2.479841327840404e-07
ATPase O 0 6.453343303292058e-06
( O 0 1.652325387624387e-08
ATP7B O 0 1.744975747897115e-06
) O 0 9.535163769669452e-10
, O 0 4.895481797717594e-10
were O 0 2.086349093488593e-09
identified O 0 1.2702014551280172e-08
in O 0 4.1665839667359705e-09
Korean O 0 4.784948259839439e-07
Patients O 0 1.5447797352408088e-07
with O 0 8.291778641478231e-08
Wilson B-Disease 0 0.0017030062153935432
disease I-Disease 1 0.9917083382606506
. O 0 2.8508367904578336e-05

Arg778Leu O 0 0.0005706691299565136
, O 0 9.12866724434025e-08
the O 0 1.2654594705452382e-08
most O 0 5.105275646677399e-10
frequently O 0 5.896885202361091e-10
reported O 0 1.0697489560840268e-09
mutation O 0 6.043015532419815e-10
of O 0 1.025116436181861e-09
this O 0 1.9415026530911206e-10
enzyme O 0 2.0657426880177354e-09
, O 0 7.42585160029563e-10
was O 0 4.532758612896259e-09
found O 0 8.810397966740879e-10
in O 0 1.2674201688156472e-09
six O 0 8.616821922657891e-09
of O 0 1.4546968962747542e-08
eight O 0 3.886493615823383e-08
unrelated O 0 1.727894094472049e-08
patients O 0 1.3211953753256012e-09
studied O 0 2.296079770758297e-08
, O 0 1.3031681289632502e-09
an O 0 4.991027591216834e-10
allele O 0 4.142994569633629e-08
frequency O 0 1.5536058128873265e-07
of O 0 1.0816374640398863e-07
37 O 0 1.1268759863014566e-06
. O 0 2.30080695473589e-06

5 O 0 1.566999458191276e-06
% O 0 2.7394021273607905e-08
, O 0 3.0990718880019585e-09
which O 0 4.180496782080212e-10
is O 0 1.2773720969860847e-10
considerably O 0 9.853711180340952e-10
higher O 0 1.2433494234187492e-09
than O 0 7.771081694807336e-11
those O 0 4.146537974092368e-11
in O 0 1.6420251269799735e-10
other O 0 4.608943227069062e-10
Asian O 0 1.713747899145801e-08
populations O 0 9.221325036889993e-09
. O 0 1.8619101638250868e-07

The O 0 3.5607760651146236e-07
novel O 0 7.911663146842329e-08
single O 0 4.4593051029551134e-08
nucleotide O 0 1.3733973958096612e-07
deletion O 0 1.8309546589989623e-07
, O 0 8.270309770352924e-09
2304delC O 0 5.696405764865631e-07
, O 0 9.453443361451264e-09
was O 0 4.587985458215371e-08
found O 0 8.416763286334117e-09
in O 0 7.682868563563261e-09
one O 0 3.754058397476001e-08
patient O 0 4.2570391656227e-07
. O 0 3.7733263980044285e-06

Since O 0 4.1950985973926436e-07
a O 0 6.055504542246126e-08
mutation O 0 4.8484302794804535e-08
at O 0 1.6465342866922583e-07
cDNA O 0 5.94183120483649e-07
nucleotide O 0 1.0054131962533575e-06
2302 O 0 9.288790170103312e-05
( O 0 4.3196422438995796e-08
2302insC O 0 4.322791085087374e-07
) O 0 4.412944232257132e-09
had O 0 4.4601193849302945e-09
been O 0 3.266623860298523e-09
previously O 0 6.6425802636160824e-09
described O 0 4.997288360897301e-09
, O 0 1.0972457387126155e-09
this O 0 5.105489919721151e-10
region O 0 3.6675487091741843e-09
of O 0 9.461164296453717e-09
the O 0 1.7650750194775355e-08
ATP7B O 0 1.2074257028871216e-05
gene O 0 1.2641711677474632e-08
may O 0 5.1838546788474105e-09
be O 0 3.0394087247032076e-09
susceptible O 0 6.378357397807122e-08
to O 0 9.262360656236979e-09
gene O 0 1.1626025298028253e-06
rearrangements O 0 0.005208555143326521
causing O 1 0.9781995415687561
Wilson B-Disease 1 0.9653893709182739
disease I-Disease 1 0.9999265670776367
. O 0 3.090751124545932e-05

Disruption O 0 8.380442159250379e-05
of O 0 1.3202851505411672e-06
splicing O 0 8.66700531787501e-07
regulated O 0 2.400966536697524e-08
by O 0 2.004830967905491e-09
a O 0 1.111744118986735e-08
CUG O 0 6.8841432039334904e-06
- O 0 1.322889886523626e-07
binding O 0 5.139378345120349e-08
protein O 0 4.060399021454941e-07
in O 0 4.399348654260393e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 5.878945012227632e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999958276748657
DM B-Disease 1 1.0
) O 0 3.0058114930398006e-07
is O 0 2.7411675151967074e-09
caused O 0 1.4114446500457234e-08
by O 0 3.0030933295677187e-09
a O 0 9.650105603498105e-09
CTG O 0 1.5036611102914321e-06
expansion O 0 2.217703709561647e-08
in O 0 1.4981789142609614e-09
the O 0 3.197861975223759e-09
3 O 0 6.069947744435922e-08
untranslated O 0 1.5480848105653422e-06
region O 0 1.5743189862860163e-08
of O 0 4.438473055756731e-08
the O 0 3.4317011454731983e-07
DM B-Disease 1 1.0
gene O 0 2.8663660032179905e-06
. O 0 4.687931323132943e-06

One O 0 4.581558243899053e-07
model O 0 1.431894702363934e-06
of O 0 2.8530491817946313e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.013667065650224686
suggests O 0 1.796536963638573e-08
that O 0 5.741428443784002e-10
RNAs O 0 4.621394822379443e-08
from O 0 2.7658935142227392e-09
the O 0 2.480645910907242e-09
expanded O 0 7.647196653692845e-09
allele O 0 3.403932780088326e-08
create O 0 3.419268201909631e-09
a O 0 2.085282613251138e-09
gain O 0 4.376132878292083e-08
- O 0 5.967345373392163e-08
of O 0 2.164633094992041e-08
- O 0 3.049467878213363e-08
function O 0 5.289163329535995e-09
mutation O 0 8.817693797347204e-10
by O 0 1.564997437197846e-10
the O 0 5.405612069075971e-10
inappropriate O 0 1.4239119883185936e-09
binding O 0 1.5416082854713409e-09
of O 0 2.4538224785430884e-09
proteins O 0 2.7658184076351233e-10
to O 0 8.808078710842437e-10
the O 0 2.0575880554929427e-08
CUG O 0 5.1828308642143384e-05
repeats O 0 4.223312316753436e-06
. O 0 2.209906142525142e-06

Data O 0 4.3229742914263625e-06
presented O 0 7.00640384820872e-07
here O 0 1.5478434534088592e-08
indicate O 0 9.345589191411818e-09
that O 0 6.587264622659461e-10
the O 0 4.694482136358147e-09
conserved O 0 3.785616797813418e-08
heterogeneous O 0 1.59695204615673e-07
nuclear O 0 2.0834886527154595e-06
ribonucleoprotein O 0 6.091618161008228e-06
, O 0 7.622328013212609e-08
CUG O 0 1.3367669453145936e-05
- O 0 1.3850103641743772e-07
binding O 0 4.2042820780352486e-08
protein O 0 3.2027099194920083e-08
( O 0 1.131860649650207e-08
CUG O 0 1.0028400538431015e-05
- O 0 2.7711286065823515e-07
BP O 0 3.4527730008449e-07
) O 0 3.1674673994785962e-09
, O 0 2.2623876105853924e-09
may O 0 1.808701455274786e-08
mediate O 0 3.7441193967424624e-07
the O 0 1.419812889480454e-07
trans O 0 4.952366907673422e-07
- O 0 7.820876390951526e-08
dominant O 0 5.886698062340656e-08
effect O 0 2.3816777883212126e-08
of O 0 1.1752687711918952e-08
the O 0 1.246643677177417e-08
RNA O 0 2.644981123012258e-07
. O 0 4.4358876039041206e-07

CUG O 1 0.9911242723464966
- O 0 0.0012836012756451964
BP O 0 8.027329386095516e-06
was O 0 1.219833478671717e-07
found O 0 2.3372863644510744e-09
to O 0 4.252295182638477e-10
bind O 0 1.328597232230777e-09
to O 0 2.2256776421869517e-09
the O 0 1.100725910418987e-08
human O 0 2.4572997858740564e-07
cardiac O 0 0.00019719122792594135
troponin O 0 0.0006637279875576496
T O 0 8.51292279548943e-05
( O 0 3.950860616441787e-08
cTNT O 0 4.449780988124985e-07
) O 0 3.672385728847871e-09
pre O 0 1.9746691748423473e-07
- O 0 3.51934765774331e-08
messenger O 0 3.1022022284332706e-08
RNA O 0 2.6291264276778747e-08
and O 0 1.5981618251004193e-09
regulate O 0 2.0132033817787942e-09
its O 0 1.8589956241044092e-09
alternative O 0 1.1605614957943544e-07
splicing O 0 1.2171706202934729e-06
. O 0 9.440498160984134e-07

Splicing O 0 9.540341125102714e-06
of O 0 9.657812825025758e-07
cTNT O 0 1.3003097592445556e-05
was O 0 6.885797461109178e-07
disrupted O 0 5.509539278136799e-06
in O 0 4.4250205633034057e-07
DM B-Disease 1 1.0
striated O 0 5.281158155412413e-05
muscle O 0 1.062755472958088e-06
and O 0 3.136561588235054e-08
in O 0 4.763819116959667e-09
normal O 0 1.6978153993818523e-08
cells O 0 7.077439967417831e-09
expressing O 0 1.195220367122829e-09
transcripts O 0 1.1216354067755674e-08
that O 0 2.2028702473253503e-10
contain O 0 2.08102441945357e-08
CUG O 0 1.42082362799556e-05
repeats O 0 1.8086310547005269e-06
. O 0 6.77717537200806e-07

Altered O 0 3.640193881437881e-06
expression O 0 3.4660683922993485e-07
of O 0 2.7732198759622406e-07
genes O 0 7.021829873110619e-08
regulated O 0 9.896739783243902e-08
posttranscriptionally O 0 8.921044809540035e-07
by O 0 5.489759047350162e-08
CUG O 0 0.0008786394610069692
- O 0 7.637107046321034e-06
BP O 0 1.4375044656844693e-06
therefore O 0 6.027055121649028e-08
may O 0 2.530191167693374e-08
contribute O 0 1.8143955671234835e-08
to O 0 8.846069476931007e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.031053615733981133
. O 0 1.0063218525147022e-07
. O 0 3.6636183153859747e-07

Identification O 0 1.2403700111462967e-06
of O 0 1.5305846545743407e-07
a O 0 1.4819685034694885e-08
novel O 0 3.3118205067239614e-08
nonsense O 0 3.6676283343695104e-07
mutation O 0 3.2924468484907266e-08
and O 0 6.083100245746209e-09
a O 0 6.831799126416627e-09
missense O 0 2.894269357511803e-07
substitution O 0 7.972088411634104e-08
in O 0 9.227605346495693e-09
the O 0 4.347713300489886e-08
vasopressin O 0 3.7925411788819474e-07
- O 0 5.45472076396436e-08
neurophysin O 0 8.468715861909004e-08
II O 0 1.1792677696575993e-06
gene O 0 1.6879051489837593e-09
in O 0 3.3963740153630795e-10
two O 0 9.091317698661783e-10
Spanish O 0 2.3420741968038783e-07
kindreds O 0 1.7953898350242525e-06
with O 0 4.732937597395903e-08
familial B-Disease 0 0.03187500685453415
neurohypophyseal I-Disease 1 0.9999986886978149
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999938011169434
. O 0 0.0008505794103257358

Familial B-Disease 1 0.999985933303833
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.948058009147644
FNDI B-Disease 1 1.0
) O 0 1.6171546235455025e-07
is O 0 2.1994832621885507e-09
an O 0 2.0499093533743462e-09
autosomal B-Disease 1 0.9994035959243774
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0009248690912500024
by O 0 2.4994696445901354e-07
deficiency O 0 0.32711589336395264
in O 0 2.0373596498757252e-07
the O 0 4.825071755476529e-06
antidiuretic O 0 0.0001434230653103441
hormone O 0 6.722191301378189e-07
arginine O 0 1.9045538692807895e-06
vasopressin O 0 9.143781198872603e-07
( O 0 5.436585581719555e-08
AVP O 0 1.6351874592146487e-06
) O 0 4.492426430857677e-09
encoded O 0 2.984421376694968e-09
by O 0 2.938947973873951e-09
the O 0 3.617266486344306e-08
AVP O 0 1.5298348444048315e-05
- O 0 1.1127771131214104e-06
neurophysin O 0 4.704121238319203e-06
II O 1 0.9993884563446045
( O 0 1.0715873486333294e-06
AVP O 0 3.6175348213873804e-05
- O 0 4.869918370786763e-07
NPII O 0 4.90739694214426e-06
) O 0 1.8827401859766724e-08
gene O 0 6.68151685090379e-08
on O 0 3.56749552565816e-07
chromosome O 0 5.201896783546545e-06
20p13 O 0 4.74426633445546e-05
. O 0 1.7541160559630953e-05

In O 0 6.371899985424534e-08
this O 0 2.6629896066054926e-09
study O 0 1.9435340004037016e-09
, O 0 8.222349467956747e-10
we O 0 3.1008695611234316e-09
analyzed O 0 1.0788472337708299e-08
two O 0 1.318217646151254e-09
families O 0 6.10323791505607e-10
with O 0 1.93597182729377e-09
FNDI B-Disease 1 0.9999631643295288
using O 0 2.168972557115012e-08
direct O 0 1.973817553846402e-08
automated O 0 3.378516453267366e-07
fluorescent O 0 7.285605363449577e-08
, O 0 1.0140821515847165e-09
solid O 0 1.4220129074260512e-08
phase O 0 9.220377705787541e-08
, O 0 6.216697157057638e-10
single O 0 1.0156403495997779e-09
- O 0 1.9951262864026376e-09
stranded O 0 1.6981773764968011e-09
DNA O 0 2.536776122497031e-09
sequencing O 0 4.070158432512017e-09
of O 0 1.1477086836464423e-08
PCR O 0 2.142343873856589e-06
- O 0 3.1012789349915693e-06
amplified O 0 2.9527095648518298e-06
AVP O 0 6.410228525055572e-05
- O 0 3.939975158573361e-06
NPII O 0 4.226639066473581e-05
DNA O 0 1.8049573782263906e-06
. O 0 1.1435993201303063e-06

In O 0 1.7640390126416605e-07
one O 0 9.036863701794573e-09
of O 0 1.2725148046399681e-08
the O 0 2.6071329539689714e-09
families O 0 5.80596015709034e-10
, O 0 8.947655949498312e-10
affected O 0 1.4505789902585775e-09
individuals O 0 5.566662131251121e-10
presented O 0 1.6792551349453788e-08
a O 0 3.1225089180964005e-09
novel O 0 1.3785067309868282e-08
nonsense O 0 7.486041653237407e-08
mutation O 0 6.14769612994337e-09
in O 0 2.3966049145229817e-09
exon O 0 3.7218825355012086e-08
3 O 0 2.0388906563084674e-08
of O 0 2.608525839775666e-09
the O 0 1.698786333825808e-09
gene O 0 1.569715579741171e-09
, O 0 9.458542837847972e-10
consisting O 0 2.391062015050238e-09
in O 0 9.167429593226473e-10
a O 0 4.607134673761948e-09
G O 0 2.578363762495428e-07
to O 0 2.738576831973205e-08
T O 0 4.865990831603995e-06
transition O 0 9.866053005680442e-07
at O 0 2.3077943467342266e-07
nucleotide O 0 6.665860041721317e-08
2101 O 0 1.2501509445428383e-06
, O 0 2.5843092110733323e-09
which O 0 7.517599320827628e-10
produces O 0 1.6083386844556458e-09
a O 0 1.3020674538566368e-09
stop O 0 1.2603287302681565e-08
signal O 0 1.0403235961575774e-07
in O 0 1.4859255159649365e-08
codon O 0 4.106537971892976e-07
82 O 0 7.574471396765148e-07
( O 0 1.4498665734663518e-07
Glu O 0 0.00011277382145635784
) O 0 6.807140806586176e-08
of O 0 4.835431468563911e-07
NPII O 0 0.0004206804442219436
. O 0 9.97374900180148e-06

The O 0 3.1940712688083295e-06
premature O 0 4.393672952573979e-06
termination O 0 2.0623047021217644e-06
eliminates O 0 7.480388717340247e-07
part O 0 1.9697708353305643e-08
of O 0 3.4563960582545405e-08
the O 0 1.2910510882591097e-08
C O 0 3.12769839183602e-06
- O 0 6.745104030869697e-08
terminal O 0 3.035077256186014e-08
domain O 0 1.3492936545844714e-08
of O 0 1.5506625317129874e-08
NPII O 0 3.8611692616541404e-06
, O 0 1.7102953497882822e-09
including O 0 1.034688779100179e-09
a O 0 2.4125379471939823e-09
cysteine O 0 7.76855646478225e-09
residue O 0 2.334761184386025e-08
in O 0 1.0431461250348661e-09
position O 0 3.192007369534622e-08
85 O 0 2.119746866924288e-08
, O 0 7.65488339382614e-10
which O 0 1.9610194024188843e-10
could O 0 8.230884862570065e-10
be O 0 9.107284926201942e-10
involved O 0 2.678475663486779e-09
in O 0 1.7000635343933368e-09
the O 0 1.0641307390812926e-08
correct O 0 3.3798795584516483e-07
folding O 0 2.556226263550343e-06
of O 0 1.42588916673958e-07
the O 0 2.62937788875206e-07
prohormone O 0 0.00022937545145396143
. O 0 5.459484327730024e-06

In O 0 2.7356227860764193e-07
the O 0 6.007716280009845e-08
second O 0 7.072260643781192e-08
family O 0 3.44418027431459e-09
, O 0 1.5477836790012134e-09
a O 0 2.9836872972310857e-09
G279A O 0 5.7593446456394304e-08
substitution O 0 4.0683520552420305e-08
at O 0 3.362896094927237e-08
position O 0 3.4898558709528515e-08
- O 0 1.2902362733768769e-08
1 O 0 1.262450766148504e-08
of O 0 2.610188065688135e-09
the O 0 2.6999000812821805e-09
signal O 0 2.8791658834848022e-08
peptide O 0 1.1959849999243488e-08
was O 0 6.948086106461915e-09
observed O 0 2.229646023366172e-09
in O 0 8.302438181395644e-10
all O 0 3.0506936976593124e-09
affected O 0 9.293399827470239e-09
individuals O 0 1.2130106696872645e-08
. O 0 3.07690470435773e-07

This O 0 1.210562317055519e-07
missense O 0 1.9935580439778278e-06
mutation O 0 7.534789148166965e-08
, O 0 1.44123886158809e-08
which O 0 8.044946042673473e-09
replaces O 0 2.4457962354063056e-05
Ala O 0 2.8925334845553152e-05
with O 0 1.598873033969994e-08
Thr O 0 8.434487426711712e-06
, O 0 5.97042859595831e-09
is O 0 1.106383207272188e-09
frequent O 0 6.195358004390528e-09
among O 0 3.3385148867637326e-08
FNDI B-Disease 1 1.0
patients O 0 1.9682278207255877e-07
and O 0 1.395674154025528e-08
is O 0 9.896674590947896e-10
thought O 0 2.3084794076311255e-09
to O 0 7.343720631602935e-10
reduce O 0 6.4795284693275335e-09
the O 0 4.128281272386403e-09
efficiency O 0 6.208858138734286e-08
of O 0 2.2931342158472034e-08
cleavage O 0 6.295515930787587e-08
by O 0 6.3937628524968204e-09
signal O 0 3.383617581675935e-07
peptidases O 0 3.3055744097509887e-06
. O 0 1.0287703133826653e-07
. O 0 7.15329861122882e-07

Genetic O 0 6.810362265241565e-06
heterogeneity O 0 2.2705067749484442e-05
of O 0 1.3403348020801786e-05
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
, O 0 3.5052192259854564e-08
due O 0 1.4753273092082964e-07
to O 0 8.180820465497618e-09
TWIST O 0 5.7372963055968285e-06
and O 0 1.582402830990759e-07
FGFR O 0 0.0001911012368509546
mutations O 0 1.7395873328496236e-06
. O 0 1.317291776103957e-06

Thirty O 0 0.0006752479821443558
- O 0 1.9887989765265957e-05
two O 0 1.9467181644472475e-08
unrelated O 0 3.731564390818676e-08
patients O 0 1.7597259205359705e-09
with O 0 2.417179512104184e-10
features O 0 1.0206862022243968e-08
of O 0 7.27234578334901e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.184233131672045e-08
a O 0 2.3591262277022906e-08
common O 0 4.5298182271835685e-07
autosomal B-Disease 0 0.003877640701830387
dominant I-Disease 0 0.1727946251630783
condition I-Disease 0 0.00047438355977647007
of O 0 0.0012770388275384903
craniosynostosis B-Disease 1 0.9999998807907104
and O 0 0.0036732663866132498
limb B-Disease 1 0.9999990463256836
anomalies I-Disease 0 0.0006491686799563468
, O 0 3.74173438899561e-08
were O 0 6.142635555761444e-08
screened O 0 2.9586121996771908e-08
for O 0 2.6988755674750564e-09
mutations O 0 1.8098884169148732e-08
in O 0 1.1746121408862109e-08
TWIST O 0 1.349223566649016e-05
, O 0 9.885383178698248e-08
FGFR2 O 0 4.0070262912195176e-05
, O 0 4.76722092912496e-08
and O 0 2.1790907567265094e-07
FGFR3 O 0 0.00017404774553142488
. O 0 5.2409609452297445e-06

Nine O 0 5.9072299336548895e-06
novel O 0 1.7769067994777288e-07
and O 0 4.210766491041795e-08
three O 0 2.5423041449812445e-08
recurrent O 0 2.442324102958082e-07
TWIST O 0 2.1073324205644894e-06
mutations O 0 1.6202281472033064e-07
were O 0 2.9575401683246128e-08
found O 0 7.514750599568742e-09
in O 0 1.880934696885106e-08
12 O 0 6.408006925084919e-07
families O 0 1.389822443798039e-07
. O 0 3.42924158758251e-06

Seven O 0 1.3911314908909844e-06
families O 0 6.778311245625446e-09
were O 0 9.59473389627874e-09
found O 0 1.4885344068460427e-09
to O 0 1.329431120744573e-09
have O 0 2.660512254948344e-09
the O 0 2.934238985119464e-08
FGFR3 O 0 2.842085450538434e-05
P250R O 0 6.80119626395026e-07
mutation O 0 2.851816738314028e-08
, O 0 2.738491877707361e-09
and O 0 1.7692738385477469e-09
one O 0 7.224972842223565e-10
individual O 0 3.351712518639971e-10
was O 0 4.956924204435609e-09
found O 0 6.116044337645121e-10
to O 0 1.1238404651336964e-09
have O 0 2.3425617001748833e-09
an O 0 8.079175550790296e-09
FGFR2 O 0 1.5716865163994953e-05
VV269 O 0 1.0437443961563986e-05
- O 0 3.334669827381731e-06
270 O 0 7.180597663136723e-07
deletion O 0 2.7236453661316773e-06
. O 0 3.4113666060875403e-06

To O 0 1.1387135145923821e-07
date O 0 6.945981567696435e-07
, O 0 1.535499372096183e-08
our O 0 1.07750235400772e-08
detection O 0 6.493561244269586e-08
rate O 0 5.653108203773627e-09
for O 0 1.6918149103872793e-09
TWIST O 0 5.566910772358824e-07
or O 0 2.7580192352161248e-08
FGFR O 0 2.222909870397416e-06
mutations O 0 1.5728424784811068e-08
is O 0 8.641620752314338e-10
68 O 0 7.595895468170966e-09
% O 0 7.579639138555194e-10
in O 0 1.7280348263426504e-09
our O 0 8.460611411464924e-08
Saethre B-Disease 1 0.9976319074630737
- I-Disease 1 0.9994542002677917
Chotzen I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9996696710586548
patients O 0 4.423859678581721e-08
, O 0 3.6400835679017973e-09
including O 0 3.7112761752666756e-09
our O 0 1.6417763148979247e-08
five O 0 8.079545921191311e-09
patients O 0 2.3408377458622454e-09
elsewhere O 0 9.531695432940523e-09
reported O 0 1.3791982667044067e-08
with O 0 1.2592618503504127e-08
TWIST O 0 2.4417435270152055e-05
mutations O 0 7.351025033131009e-06
. O 0 3.411015086385305e-06

More O 0 4.5486185484833186e-08
than O 0 6.2803779954379024e-09
35 O 0 1.2200249699390042e-08
different O 0 2.4533313158769943e-09
TWIST O 0 1.394192707948605e-07
mutations O 0 6.089845072665412e-09
are O 0 4.3172249108991423e-10
now O 0 6.582768219409729e-10
known O 0 9.893202923549893e-10
in O 0 9.720910743027389e-10
the O 0 8.11355072016795e-09
literature O 0 1.248177596835376e-07
. O 0 8.422538257946144e-07

The O 0 4.5564598849523463e-07
most O 0 9.586319293930501e-09
common O 0 2.209588600976531e-08
phenotypic O 0 6.110908543632831e-07
features O 0 1.721594244941116e-08
, O 0 1.0433550690081006e-09
present O 0 5.737311736808692e-10
in O 0 3.4647820723598954e-10
more O 0 1.0582256598778983e-10
than O 0 1.686443346082811e-10
a O 0 2.951563715658523e-10
third O 0 2.114996622282206e-09
of O 0 1.1233903807195134e-09
our O 0 2.7988704687231802e-09
patients O 0 7.555649994550606e-10
with O 0 4.6347017890191466e-10
TWIST O 0 4.0418080970994197e-07
mutations O 0 5.347543918787778e-08
, O 0 8.950545193897597e-09
are O 0 7.282336955682922e-09
coronal B-Disease 0 4.245172385708429e-05
synostosis I-Disease 0 7.17739885658375e-06
, O 0 2.8577899158221953e-08
brachycephaly B-Disease 0 1.7656898307905067e-06
, O 0 3.2149507944723155e-08
low B-Disease 0 2.633470285218209e-05
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 4.0355880628339946e-05
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9990975856781006
, O 0 1.6923663679335732e-06
ptosis B-Disease 1 0.9995623230934143
, O 0 5.547915975512296e-07
hypertelorism B-Disease 0 0.007740755565464497
, O 0 1.930862225663077e-07
broad B-Disease 0 1.5274279576260597e-05
great I-Disease 0 0.0007662844145670533
toes I-Disease 0 0.001100583584047854
, O 0 1.714533368613047e-07
and O 0 3.916662763003842e-07
clinodactyly B-Disease 0 7.710771751590073e-05
. O 0 8.51111144584138e-06

Significant O 0 1.9467985111987218e-05
intra O 0 0.004333789460361004
- O 0 2.119786040566396e-05
and O 0 6.807361074834262e-08
interfamilial O 0 6.7166047301725484e-06
phenotypic O 0 3.626541683843243e-06
variability O 0 4.3770435809165065e-07
is O 0 3.6267758241059767e-10
present O 0 4.969597511284007e-10
for O 0 2.6216026571823647e-10
either O 0 5.061009389351057e-09
TWIST O 0 1.8099026419804431e-06
mutations O 0 2.2953884126764024e-07
or O 0 1.4892655997300608e-07
FGFR O 0 5.790874638478272e-05
mutations O 0 7.134330189728644e-06
. O 0 5.3553289944829885e-06

The O 0 4.44247916675522e-07
overlap O 0 7.550672620482146e-08
in O 0 2.0623331931091116e-09
clinical O 0 6.44364206436876e-08
features O 0 3.403560988601839e-09
and O 0 9.739171691336423e-10
the O 0 7.498910936654113e-10
presence O 0 7.374446053809436e-10
, O 0 3.998061326448976e-10
in O 0 9.915696042028799e-11
the O 0 2.61233840115338e-10
same O 0 1.1429932000872611e-10
genes O 0 5.154550120067825e-10
, O 0 1.628790158303417e-10
of O 0 8.173549059797836e-10
mutations O 0 2.559516820710428e-09
for O 0 1.9718814081581826e-10
more O 0 6.451601752832659e-11
than O 0 2.2618082406999918e-10
one O 0 8.213399405043731e-10
craniosynostotic B-Disease 0 1.954371668944077e-07
condition I-Disease 0 4.251521090736787e-08
- O 0 5.731638275108253e-09
such O 0 3.651903779378074e-10
as O 0 4.85343321088294e-09
Saethre B-Disease 0 3.2253358313028002e-06
- I-Disease 0 2.1496242652574438e-07
Chotzen I-Disease 0 1.554911818857363e-06
, I-Disease 0 1.0011123485753615e-08
Crouzon I-Disease 0 3.359388301760191e-06
, I-Disease 0 2.676944710344742e-08
and I-Disease 0 3.973282503011433e-08
Pfeiffer I-Disease 0 9.765151480678469e-05
syndromes I-Disease 0 1.2195398085168563e-05
- O 0 1.5574896394809912e-07
support O 0 4.99835595135778e-09
the O 0 1.2124901971333202e-08
hypothesis O 0 3.110384483306916e-08
that O 0 6.398712670829809e-10
TWIST O 0 3.0219246127671795e-07
and O 0 2.2182494063827107e-08
FGFRs O 0 1.0714524023569538e-06
are O 0 5.498765887068657e-10
components O 0 3.814033089355462e-09
of O 0 1.540503169472629e-09
the O 0 6.513215522474525e-10
same O 0 3.5545386078972285e-10
molecular O 0 8.884584623558567e-09
pathway O 0 1.563434937068564e-09
involved O 0 1.6710260952734757e-10
in O 0 1.0303909808717648e-10
the O 0 1.013581329978308e-09
modulation O 0 2.8169964139124204e-07
of O 0 2.8252347306079173e-07
craniofacial O 1 0.9999974966049194
and O 0 1.6702695575077087e-05
limb O 1 0.9999717473983765
development O 0 3.139685304631712e-06
in O 0 1.8671340029641215e-08
humans O 0 6.15808417592234e-08
. O 0 4.470196657280212e-08
. O 0 1.152756567535107e-06

Mutation O 0 1.2931022865814157e-06
analysis O 0 2.2591035531149828e-07
of O 0 9.110400469580782e-07
UBE3A O 1 0.9999626874923706
in O 0 0.12836135923862457
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.003928965888917446
. O 0 6.000426219543442e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.3926200270652771
AS B-Disease 1 1.0
) O 0 2.3639730173385942e-08
is O 0 1.9624197822309952e-09
caused O 0 3.540833048987224e-08
by O 0 1.6097420285632325e-08
chromosome O 0 7.988882657627983e-07
15q11 O 0 3.374360403540777e-06
- O 0 7.225061722238024e-07
q13 O 0 4.860550575358502e-07
deletions O 0 3.416649008158856e-08
of O 0 9.493267505433778e-09
maternal O 0 2.4348814520180895e-08
origin O 0 1.4028588068981662e-08
, O 0 6.112362616050859e-09
by O 0 7.925812006703836e-09
paternal O 0 1.4869979167997371e-06
uniparental B-Disease 1 0.8650399446487427
disomy I-Disease 1 0.999482274055481
( O 0 0.0001487866829847917
UPD B-Disease 1 1.0
) O 0 1.7613997727039532e-07
15 O 0 1.5412025788918982e-07
, O 0 5.347143616774019e-09
by O 0 9.861161665014606e-09
imprinting O 0 1.874311055871658e-05
defects O 0 3.826350803137757e-05
, O 0 9.545850332415284e-09
and O 0 4.312067147793641e-09
by O 0 1.7998630363891266e-09
mutations O 0 1.2300933605047248e-08
in O 0 7.58048201987549e-09
the O 0 1.2004201721538266e-07
UBE3A O 0 9.477760613663122e-05
gene O 0 1.6514579783688532e-06
. O 0 3.009620286320569e-06

UBE3A O 0 0.005019115749746561
encodes O 0 1.4539760741172358e-05
a O 0 1.3135271501596435e-06
ubiquitin O 0 1.2580042493937071e-05
- O 0 3.8036098430893617e-06
protein O 0 2.53951355944082e-07
ligase O 0 1.210090090353333e-07
and O 0 3.0147454310736066e-08
shows O 0 1.3855004965535045e-07
brain O 0 0.0010357566643506289
- O 0 1.5206952639346127e-06
specific O 0 1.1124741661205917e-07
imprinting O 0 1.378905199089786e-05
. O 0 5.744254849560093e-06

Here O 0 1.6168121419468662e-06
we O 0 2.953730415811151e-07
describe O 0 6.839995876362082e-07
UBE3A O 0 0.00020419730572029948
coding O 0 1.305009482166497e-05
- O 0 1.269578547180572e-06
region O 0 7.601044416105651e-08
mutations O 0 1.614082378864623e-07
detected O 0 5.746879594425991e-08
by O 0 4.482728854782181e-09
SSCP O 0 3.205881057510851e-06
analysis O 0 1.2576776065031936e-08
in O 0 2.635114348947809e-09
13 O 0 1.0094938573956824e-07
AS B-Disease 1 0.9801803827285767
individuals O 0 2.018055278441011e-09
or O 0 8.990753919135841e-09
families O 0 7.846093552643651e-09
. O 0 3.347384733842773e-07

Two O 0 3.939859709589655e-07
identical O 0 8.792230801191181e-07
de O 0 1.5172233361226972e-05
novo O 0 3.453151975918445e-06
5 O 0 1.8334686728849192e-06
- O 0 4.4855019609713054e-07
bp O 0 2.624037165332993e-07
duplications O 0 7.396624823741149e-07
in O 0 1.9188927780078302e-08
exon O 0 3.2736272714828374e-07
16 O 0 2.5645059054113517e-07
were O 0 1.2170065133432217e-07
found O 0 2.1477760014931846e-07
. O 0 1.7798573708205367e-06

Among O 0 4.1847371790026955e-07
the O 0 1.9985094468211173e-08
other O 0 1.4438216178191965e-09
11 O 0 9.896131913933459e-09
unique O 0 9.977035864139339e-10
mutations O 0 2.656374675780171e-09
, O 0 1.6360548471539005e-09
8 O 0 3.718505325878141e-08
were O 0 6.2976632797528964e-09
small O 0 3.5592693237163076e-09
deletions O 0 5.974269612352145e-08
or O 0 2.036904511726334e-08
insertions O 0 1.2562803419768898e-07
predicted O 0 1.2773507762631198e-07
to O 0 9.463076544591331e-09
cause O 0 2.4937935449997894e-07
frameshifts O 0 8.66319805936655e-06
, O 0 8.230889747551373e-09
1 O 0 1.0335280364870414e-07
was O 0 9.478267948281882e-09
a O 0 4.884019855211363e-10
mutation O 0 5.996079743830762e-10
to O 0 3.5594915903658375e-10
a O 0 1.1621055229227295e-09
stop O 0 5.3021529389241095e-09
codon O 0 3.60576954960834e-08
, O 0 4.094076633265331e-09
1 O 0 3.074194054875079e-08
was O 0 8.857986344423807e-09
a O 0 2.942532217886651e-09
missense O 0 9.043471038694406e-08
mutation O 0 8.934426531936879e-09
, O 0 3.5109317675363627e-09
and O 0 2.504387586199641e-09
1 O 0 8.969757914201182e-08
was O 0 2.7473399555333344e-08
predicted O 0 2.507113272542938e-08
to O 0 1.1556225976150358e-09
cause O 0 5.719320128605432e-09
insertion O 0 3.6880408060824266e-08
of O 0 6.896109994158905e-08
an O 0 1.3318936176176521e-08
isoleucine O 0 1.8893828155341907e-06
in O 0 2.0675489764698796e-08
the O 0 6.937879248880563e-08
hect O 0 8.82520396316977e-07
domain O 0 2.51742022783219e-08
of O 0 1.0114844073427776e-08
the O 0 1.8228595521918578e-08
UBE3A O 0 1.7682308453004225e-06
protein O 0 1.6720289153226986e-08
, O 0 1.1129146493260578e-09
which O 0 6.383645834162621e-10
functions O 0 9.320027416492849e-09
in O 0 4.2769272567966254e-09
E2 O 0 1.6940072100624093e-06
binding O 0 1.298210037248282e-07
and O 0 7.545835245537091e-08
ubiquitin O 0 1.5590100019835518e-06
transfer O 0 2.7346625302016037e-06
. O 0 2.240023832200677e-06

Eight O 0 1.5521738987445133e-06
of O 0 5.265230385020914e-08
the O 0 5.275551551164881e-09
cases O 0 4.698988309570495e-09
were O 0 3.86453802292408e-09
familial O 0 2.4589400737795586e-08
, O 0 3.822203886727493e-09
and O 0 5.260469837509163e-09
five O 0 3.338877974101706e-08
were O 0 6.60028689480896e-08
sporadic O 0 3.6652818380389363e-06
. O 0 4.470172825676855e-06

In O 0 2.544895778555656e-07
two O 0 2.524715014828871e-08
familial O 0 6.335550324365613e-07
cases O 0 1.5546072873462435e-08
and O 0 3.7094289861983043e-09
one O 0 1.3147174460215183e-09
sporadic O 0 6.387877959923571e-08
case O 0 2.8332365786809532e-08
, O 0 6.065281610290185e-09
mosaicism O 0 1.28757835682336e-06
for O 0 1.9772954829022638e-08
UBE3A O 0 7.121917860786198e-06
mutations O 0 7.969427429088682e-08
was O 0 1.4086610988783832e-08
detected O 0 4.500153139019858e-09
in O 0 6.729445889419594e-10
the O 0 1.9556267716325237e-09
mother O 0 1.877869193478432e-09
of O 0 8.313834953810328e-09
three O 0 4.371401018943288e-09
AS B-Disease 1 0.9999755620956421
sons O 0 1.1047748103010235e-06
, O 0 2.569485735293142e-09
in O 0 6.885154668623272e-10
the O 0 1.9170263154677514e-09
maternal O 0 8.452075483944554e-09
grandfather O 0 2.912721086545389e-08
of O 0 5.063116859105321e-08
two O 0 1.5316148349597825e-08
AS B-Disease 1 0.9999995231628418
first O 0 1.3806517529246776e-07
cousins O 0 1.0788620841140073e-07
, O 0 3.336730669545318e-09
and O 0 1.650028669253345e-09
in O 0 2.0409751666505827e-09
the O 0 7.728666595596678e-09
mother O 0 6.31577945497952e-09
of O 0 3.433713402500871e-08
an O 0 9.273957601863003e-09
AS B-Disease 1 0.9999998807907104
daughter O 0 7.433650171151385e-05
. O 0 3.0344252081704326e-05

The O 0 1.869088777084471e-07
frequencies O 0 8.303965159939253e-08
with O 0 3.350338340091241e-10
which O 0 1.4567111406016409e-10
we O 0 2.7419713721776873e-10
detected O 0 7.546691049853393e-10
mutations O 0 5.861024998665698e-10
were O 0 1.1224009499599674e-09
5 O 0 6.45030473478414e-09
( O 0 3.3161026702366314e-10
14 O 0 1.8327909190318792e-09
% O 0 1.2182797826110203e-10
) O 0 9.858688171382468e-11
of O 0 2.576040214474773e-10
35 O 0 1.315801134715855e-09
in O 0 1.786690240201949e-10
sporadic O 0 8.97396468246825e-09
cases O 0 1.2652656700140597e-09
and O 0 8.026947440065157e-10
8 O 0 2.9432746018187572e-08
( O 0 3.9771755333539716e-10
80 O 0 8.789953209742407e-10
% O 0 1.701107033014182e-10
) O 0 2.369604512608703e-10
of O 0 1.671543459202951e-09
10 O 0 5.6463949071883235e-09
in O 0 2.431450374373867e-09
familial O 0 1.582562703106305e-07
cases O 0 4.907659345576576e-08
. O 0 8.794758343810827e-08
. O 0 1.268165192414017e-06

The O 0 6.579427281394601e-05
hemochromatosis B-Disease 1 1.0
845 O 0 8.88672802830115e-05
G O 0 2.8455837309593335e-05
- O 0 3.6625842767534778e-06
- O 0 3.8071632957326074e-07
> O 0 6.59144347991969e-08
A O 0 7.195999796039132e-09
and O 0 2.102752416632825e-09
187 O 0 6.508562577778321e-09
C O 0 1.996079532773365e-07
- O 0 5.1840949311099394e-08
- O 0 2.0380587884005763e-08
> O 0 6.630987314792947e-08
G O 0 8.197959289191203e-08
mutations O 0 6.638615879239751e-09
: O 0 7.677035118724973e-10
prevalence O 0 1.0270525763189653e-08
in O 0 2.1216997048156827e-09
non O 0 1.7479825942245952e-07
- O 0 1.3844463353507308e-07
Caucasian O 0 1.4552288973845862e-07
populations O 0 1.2181618558315677e-07
. O 0 1.4072948033572175e-06

Hemochromatosis B-Disease 1 0.9999890327453613
, O 0 8.298580951304757e-07
the O 0 2.294531441293657e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999891519546509
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999991655349731
, O 0 3.2835390584295965e-07
leads O 0 1.8071052920731745e-07
, O 0 7.584850081343575e-09
if O 0 1.3854046798655872e-08
untreated O 0 1.9131955468765227e-06
, O 0 4.656803831437628e-09
to O 0 2.431307954964268e-08
progressive O 1 0.9999016523361206
iron B-Disease 1 0.9999998807907104
overload I-Disease 1 0.999607264995575
and O 0 3.1169283829513006e-06
premature B-Disease 0 4.597259248839691e-05
death I-Disease 0 3.839000783045776e-05
. O 0 5.782944299426163e-06

The O 0 5.6295873946510255e-05
hemochromatosis B-Disease 1 1.0
gene O 0 4.6221716729633044e-06
, O 0 2.578565556632384e-07
HFE O 1 0.9241655468940735
, O 0 6.689218423616694e-08
recently O 0 1.8891576303303736e-08
has O 0 7.109718369591178e-10
been O 0 6.092641946509048e-10
identified O 0 2.7813302772017323e-09
, O 0 6.44857889309236e-10
and O 0 6.952722286790447e-10
characterization O 0 1.125649617961244e-08
of O 0 9.895943620108483e-09
this O 0 1.1775995734097933e-09
gene O 0 4.068916759081276e-09
has O 0 4.022177590989884e-10
shown O 0 4.2649422882234944e-10
that O 0 5.528882907057664e-11
it O 0 4.696653829738828e-11
contains O 0 1.5109541395830206e-10
two O 0 9.66872276686459e-11
mutations O 0 6.518821038525857e-10
that O 0 1.4627304922854023e-10
result O 0 4.6459978086943465e-09
in O 0 6.476538416677613e-09
amino O 0 2.4965816081135017e-08
acid O 0 1.555787854101709e-08
substitutions O 0 1.3084543581953767e-07
- O 0 1.0447080711628587e-07
cDNA O 0 1.410551675462557e-07
nucleotides O 0 8.234709270027452e-08
845 O 0 2.4995219405354874e-07
G O 0 4.458803459783667e-07
- O 0 2.218106089912908e-07
- O 0 6.410139974377671e-08
> O 0 6.649592876328825e-08
A O 0 2.0627238583870167e-08
( O 0 2.5178750195919974e-09
C282Y O 0 5.2024699215280634e-08
) O 0 6.854546374945869e-10
and O 0 1.1724269333157622e-09
187 O 0 5.932220048521231e-09
C O 0 3.3871140203700634e-07
- O 0 6.250766659832152e-08
- O 0 2.7419373438419825e-08
> O 0 1.0181879872561694e-07
G O 0 6.045799523235473e-07
( O 0 2.899362705477415e-08
H63D O 0 1.456429799873149e-05
) O 0 8.739608858832071e-08
. O 0 7.062143367875251e-07

Although O 0 0.00028978430782444775
hemochromatosis B-Disease 1 1.0
is O 0 2.8940366547658414e-08
common O 0 9.507401088626466e-09
in O 0 5.181936657550068e-09
Caucasians O 0 1.047305744350524e-07
, O 0 9.060958205964198e-09
affecting O 0 3.969593365127366e-08
> O 0 1.7224752468791849e-07
= O 0 1.0990396503984812e-07
1 O 0 8.734426160117437e-08
/ O 0 3.9466055312686876e-08
300 O 0 1.1511567254984811e-09
individuals O 0 9.970257258684612e-11
of O 0 1.1596432702987158e-09
northern O 0 6.629012450076743e-09
European O 0 2.342420124534783e-08
origin O 0 2.855478298258163e-09
, O 0 3.5445188450999865e-10
it O 0 6.170480099099152e-11
has O 0 2.3502347637482934e-11
not O 0 4.573501299898197e-11
been O 0 9.964345321078483e-11
recognized O 0 3.2408734029765185e-10
in O 0 6.938679630863476e-10
other O 0 1.5949004339432804e-09
populations O 0 2.272014754112206e-08
. O 0 5.203422688282444e-07

The O 0 2.9731063477811404e-07
present O 0 1.863142529145989e-08
study O 0 3.225280043039902e-09
used O 0 1.2583296626900164e-09
PCR O 0 3.9891226322197326e-08
and O 0 8.589450928297993e-09
restriction O 0 3.4414505023505626e-08
- O 0 2.1244421333221908e-08
enzyme O 0 1.6605231634159168e-09
digestion O 0 9.83482184579998e-10
to O 0 1.5119169805011268e-10
analyze O 0 2.007685573346407e-09
the O 0 5.832410110429009e-10
frequency O 0 9.475539464176563e-09
of O 0 4.264220532235186e-09
the O 0 5.317181805963855e-09
845 O 0 5.921709700373867e-08
G O 0 1.2209099509163934e-07
- O 0 4.7074589559770175e-08
- O 0 9.280575419268189e-09
> O 0 1.3056419057022595e-08
A O 0 3.4551486116640717e-09
and O 0 9.811439438678349e-10
187 O 0 3.4440423846149315e-09
C O 0 6.181573297681098e-08
- O 0 1.2219416589687171e-08
- O 0 8.035315524068665e-09
> O 0 2.488575390202641e-08
G O 0 3.5826534627858564e-08
mutations O 0 9.979361337286718e-09
in O 0 5.930409940901882e-09
HLA O 0 3.3086516282310185e-07
- O 0 3.163653161664115e-08
typed O 0 1.2109810043625657e-08
samples O 0 4.297859845792118e-10
from O 0 3.2516034309537645e-10
non O 0 3.7783383532996595e-08
- O 0 2.217090333545002e-08
Caucasian O 0 2.1672025951602336e-08
populations O 0 3.868689812946968e-09
, O 0 5.282791093463857e-09
comprising O 0 3.817870464217776e-08
Australian O 0 3.0080025226197904e-07
Aboriginal O 0 1.3668577025782724e-07
, O 0 3.313050944697693e-09
Chinese O 0 9.286488911186552e-09
, O 0 7.586470118781108e-09
and O 0 7.406917035268634e-08
Pacific O 0 3.6605661080102436e-06
Islanders O 0 6.750175089109689e-05
. O 0 4.5750971366942395e-06

Results O 0 1.212054121424444e-05
showed O 0 3.047578616133251e-07
that O 0 1.2079843791923395e-08
the O 0 4.1241118964308043e-08
845 O 0 8.041863566177199e-07
G O 0 5.063260687165894e-06
- O 0 4.494615495787002e-06
- O 0 3.5563570577323844e-07
> O 0 5.487320109409666e-08
A O 0 7.2233095060880714e-09
mutation O 0 2.605999638305434e-09
was O 0 1.3545249366586631e-09
present O 0 1.741945893085628e-10
in O 0 6.163117238777716e-11
these O 0 6.172704708484744e-11
populations O 0 1.5054367474842678e-10
( O 0 1.6944362579707217e-10
allele O 0 2.557164924255062e-09
frequency O 0 3.585646002335352e-09
0 O 0 2.3254891345914075e-09
. O 0 1.0851943649248241e-10
32 O 0 1.2941198113125552e-09
% O 0 1.1634289365236583e-10
) O 0 2.6357915849928304e-10
, O 0 2.3818663708041754e-10
and O 0 7.149890124402702e-10
, O 0 4.451066459854047e-10
furthermore O 0 2.4438551182726087e-09
, O 0 4.752762072790517e-10
it O 0 2.456134740036475e-10
was O 0 4.487193727698013e-09
always O 0 4.00910504794183e-09
seen O 0 1.2248094094502449e-08
in O 0 1.8542360979978412e-09
conjunction O 0 2.6718335988107356e-08
with O 0 1.0120112747813437e-08
HLA O 0 6.863886483188253e-06
haplotypes O 0 3.74627660448823e-07
common O 0 2.8266136098409333e-08
in O 0 7.3532833155809385e-09
Caucasians O 0 1.56968127384971e-07
, O 0 4.174578460691691e-09
suggesting O 0 1.6235064848046932e-08
that O 0 4.077213233699695e-09
845 O 0 3.765159704016696e-07
G O 0 4.61880927105085e-06
- O 0 7.3801893449854106e-06
- O 0 1.0833609849214554e-06
> O 0 1.2817450567581545e-07
A O 0 5.862325291872139e-09
may O 0 1.1828219514953275e-09
have O 0 2.0861806726557575e-10
been O 0 1.5897516636442788e-10
introduced O 0 4.6485659765949094e-10
into O 0 9.096308428713229e-11
these O 0 3.8667014035098646e-11
populations O 0 2.0981041903844755e-10
by O 0 1.338910315951125e-09
Caucasian O 0 5.528553401745739e-07
admixture O 0 6.395134278136538e-06
. O 0 4.2942360778397415e-06

187 O 0 2.895787247325643e-06
C O 0 1.0950532669085078e-05
- O 0 8.873129786479694e-07
- O 0 1.638132829384631e-07
> O 0 1.3619637684314512e-07
G O 0 9.746055695813993e-08
was O 0 1.1047831982580192e-08
present O 0 1.0273909500924105e-09
at O 0 4.506818918059707e-09
an O 0 7.67616734065335e-11
allele O 0 4.001496467509469e-09
frequency O 0 3.259897241036924e-08
of O 0 2.5526050606572426e-08
2 O 0 6.649655688306666e-07
. O 0 6.037203661435342e-07

68 O 0 3.3226035611733096e-06
% O 0 2.7867587348850975e-08
in O 0 4.857637847521801e-09
the O 0 3.5835059364330846e-09
two O 0 1.4067726983313378e-09
populations O 0 7.576488325611308e-10
analyzed O 0 1.0952515339113233e-08
( O 0 6.4077663175510224e-09
Australian O 0 3.409128055409383e-07
Aboriginal O 0 1.1891546591868973e-07
and O 0 1.2579895347641923e-08
Chinese O 0 5.188358542795868e-08
) O 0 7.786999134395955e-08
. O 0 1.1843462743854616e-06

In O 0 5.099563509247673e-07
the O 0 1.8648975697033165e-07
Australian O 0 9.671979341874248e-07
Aboriginal O 0 8.471963042211428e-08
samples O 0 2.3965638362710706e-09
, O 0 2.2296036128466312e-09
187 O 0 2.367311857653931e-08
C O 0 4.732599450107955e-07
- O 0 1.4095054723384237e-07
- O 0 6.033000943261868e-08
> O 0 1.2807895188871044e-07
G O 0 1.0678174078293523e-07
was O 0 8.723516131681208e-09
found O 0 2.8296909260205894e-10
to O 0 1.0632999342119476e-10
be O 0 8.5704299213063e-10
associated O 0 9.770173114986846e-09
with O 0 9.92802640098489e-09
HLA O 0 3.273814945714548e-05
haplotypes O 0 8.343543527189468e-07
common O 0 4.8128285357051936e-08
in O 0 1.2017519424034617e-08
Caucasians O 0 2.7657057444230304e-07
, O 0 2.648250063685964e-09
suggesting O 0 3.5097333928035823e-09
that O 0 1.5941210851355692e-10
it O 0 1.3671072607301937e-10
was O 0 2.050057901215041e-09
introduced O 0 3.867546283231604e-09
by O 0 1.6712564665510854e-09
recent O 0 1.8609618734899414e-08
admixture O 0 1.932086661327048e-06
. O 0 2.747044845818891e-06

In O 0 3.452726673458528e-07
the O 0 4.383442586686215e-08
Chinese O 0 1.0043962994643607e-08
samples O 0 2.339730853506694e-09
analyzed O 0 1.0110041692712457e-08
, O 0 1.387990833379149e-09
187 O 0 8.178589361307331e-09
C O 0 1.6072624475782504e-07
- O 0 4.174206580387363e-08
- O 0 2.425476530731885e-08
> O 0 3.8686771119955665e-08
G O 0 6.182552425570975e-08
was O 0 8.276843210808238e-09
present O 0 1.4607685061562847e-09
in O 0 1.1498685337230086e-09
association O 0 1.5654370022488706e-09
with O 0 2.657396802607792e-10
a O 0 9.961841351824319e-10
wide O 0 1.2308842833874678e-08
variety O 0 9.994733929374888e-09
of O 0 1.0562448693463011e-07
HLA O 0 6.422779279091628e-06
haplotypes O 0 1.1409071731804943e-07
, O 0 1.505558122616435e-09
showing O 0 1.3127228193354767e-09
this O 0 1.0588434296021632e-10
mutation O 0 7.449300620798738e-10
to O 0 1.0894644908443496e-10
be O 0 4.1752054591448484e-10
widespread O 0 6.0867333395719925e-09
and O 0 2.689810152389782e-09
likely O 0 1.2143787309071286e-08
to O 0 4.095951577909318e-09
predate O 0 2.361051372190559e-07
the O 0 9.951667045982049e-09
more O 0 1.0183540677388692e-09
genetically O 0 1.1338745942168771e-08
restricted O 0 1.565697616001671e-08
845 O 0 2.9171698656682565e-07
G O 0 1.6532511608602363e-06
- O 0 2.0331879113655305e-06
- O 0 2.2753893347271514e-07
> O 0 1.390732080608359e-07
A O 0 5.47035980957844e-08
mutation O 0 2.0132664246830245e-07
. O 0 3.7881130765526905e-07

Genotype O 0 0.00016110400611069053
- O 0 2.143478559446521e-05
phenotype O 0 2.0523846160358516e-06
correlations O 0 3.974445917265257e-06
in O 0 9.61549176281551e-07
attenuated B-Disease 1 0.9902303814888
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.00447183707728982

Germ O 1 0.9572857618331909
- O 0 0.0001549526787130162
line O 0 7.951273914841295e-07
mutations O 0 6.575520927754042e-08
of O 0 1.7658191353575603e-08
the O 0 1.0875347733474428e-08
tumor B-Disease 0 2.6272047648490116e-07
suppressor O 0 3.666446218630881e-06
APC O 0 6.606446163459623e-07
are O 0 1.1739783367659129e-08
implicated O 0 4.991156856704038e-07
in O 0 1.4296472272690153e-07
attenuated B-Disease 1 0.998846173286438
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999974966049194
AAPC B-Disease 1 1.0
) O 0 1.1879962613647876e-07
, O 0 5.377847944743053e-09
a O 0 4.976600020967226e-09
variant O 0 1.4646858517153305e-06
of O 0 0.00011952925706282258
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.04426456242799759
FAP B-Disease 0 0.00029028704739175737
) O 0 1.4767971379114897e-06
. O 0 8.234140295826364e-06

AAPC B-Disease 1 1.0
is O 0 7.333886742344475e-08
recognized O 0 1.8727764228287924e-08
by O 0 1.9544632579027166e-09
the O 0 2.0108126275175664e-09
occurrence O 0 1.0614853884760578e-08
of O 0 1.3039843871354151e-08
< O 0 8.055864668676804e-07
100 O 0 1.0080277945689886e-07
colonic B-Disease 0 8.662933396408334e-06
adenomas I-Disease 0 4.570108558255015e-06
and O 0 6.991090373276165e-09
a O 0 3.7012801712421606e-09
later O 0 4.6072955228737555e-08
onset O 0 0.009025992825627327
of O 1 0.9997683167457581
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.3294385325934854e-07
age O 0 8.639568704893463e-08
> O 0 1.3632815409891919e-07
40 O 0 1.2056617926248236e-08
years O 0 1.1092701868165022e-08
) O 0 1.1124482668378732e-08
. O 0 2.3733844045636943e-07

The O 0 3.3667029697426187e-07
aim O 0 3.5808946563520294e-07
of O 0 1.71992358133366e-08
this O 0 6.011745545819736e-10
study O 0 1.0930534255493285e-09
was O 0 2.7140729663699403e-09
to O 0 2.2961617052175143e-09
assess O 0 2.6881480152951553e-07
genotype O 0 6.426522759284126e-06
- O 0 5.67451752431225e-06
phenotype O 0 1.7399357830072404e-06
correlations O 0 4.614507815858815e-06
in O 0 1.176154341919755e-06
AAPC B-Disease 1 0.9999998807907104
families O 0 1.0422356808703626e-06
. O 0 4.614503268385306e-06

By O 0 6.509073955385247e-07
protein O 0 7.513233981626399e-07
- O 0 4.7264697400350997e-07
truncation O 0 1.8576691900307196e-06
test O 0 4.904356387669395e-07
( O 0 4.957711396968989e-08
PTT O 0 2.381029389653122e-06
) O 0 2.9958677760788532e-09
assay O 0 2.906095097898742e-08
, O 0 9.231280184707202e-10
the O 0 2.4164525935788106e-09
entire O 0 1.4846960105785456e-08
coding O 0 1.9849624166567992e-08
region O 0 6.508400929305935e-09
of O 0 7.657617651091186e-09
the O 0 9.200312511836728e-09
APC B-Disease 0 6.839182020712542e-08
gene O 0 1.0646890480359161e-08
was O 0 2.6807818187535304e-08
screened O 0 1.6300036875804835e-08
in O 0 2.1328494526073882e-09
affected O 0 8.3526021654734e-09
individuals O 0 1.2502816559845087e-09
from O 0 2.5484700572064867e-08
11 O 0 3.442719025770202e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.00024082533491309732
, O 0 6.952159026241134e-08
and O 0 1.6947675263168094e-08
their O 0 2.0049389704013265e-08
phenotypic O 0 5.574037004407728e-06
differences O 0 1.6986015225484152e-06
were O 0 1.1105424846391543e-06
examined O 0 4.835067102249013e-06
. O 0 2.314431867489475e-06

Five O 0 4.308108600525884e-06
novel O 0 6.559073426615214e-07
germ O 0 8.584824536228552e-05
- O 0 6.52677863399731e-06
line O 0 6.088257009650988e-07
APC B-Disease 0 4.0309987525688484e-07
mutations O 0 3.823401328872933e-08
were O 0 2.0296639036132547e-08
identified O 0 2.199194959473516e-08
in O 0 3.258169201103556e-08
seven O 0 1.0854355423361994e-06
kindreds O 0 0.00019803819304797798
. O 0 9.47897024161648e-06

Mutations O 0 6.264179319259711e-06
were O 0 3.1403752132064255e-07
located O 0 1.9034732900991003e-08
in O 0 9.350006324737592e-10
three O 0 4.595600566759117e-10
different O 0 2.5047972029845766e-10
regions O 0 9.989488125583534e-10
of O 0 5.002390501829268e-09
the O 0 3.273465942754683e-09
APC B-Disease 0 7.298968984770227e-09
gene O 0 9.943484924335166e-10
( O 0 4.364234251763577e-10
1 O 0 9.435933812085295e-09
) O 0 5.130773583772452e-10
at O 0 2.8413416064410058e-09
the O 0 1.1282068612672447e-09
5 O 0 9.594624650333117e-09
end O 0 1.4370280965181337e-08
spanning O 0 2.8817972008710058e-08
exons O 0 1.8748171015658954e-08
4 O 0 7.928806056156645e-09
and O 0 6.082760406478371e-10
5 O 0 7.217580311191796e-09
, O 0 9.286166280375596e-10
( O 0 6.960271803357898e-10
2 O 0 7.510194244275681e-09
) O 0 3.323150088441196e-10
within O 0 2.735657256280888e-09
exon O 0 1.3170949664242926e-08
9 O 0 1.9708608078872203e-08
, O 0 4.860814528662161e-10
and O 0 9.56246526406801e-10
( O 0 1.4810014326016585e-09
3 O 0 2.0427403768508157e-08
) O 0 1.9047543542427547e-09
at O 0 1.3160627254649171e-08
the O 0 3.6227951749623344e-09
3 O 0 8.847317900517737e-08
distal O 0 2.5620491328481876e-07
end O 0 8.061139311621446e-08
of O 0 5.728078633637779e-08
the O 0 4.548219578737189e-08
gene O 0 3.890733069056296e-07
. O 0 2.3780203264323063e-06

Variability O 0 1.530954432382714e-05
in O 0 3.882863097715017e-08
the O 0 1.502214352910869e-08
number O 0 2.2255980169916256e-08
of O 0 0.00011329162953188643
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 2.6394072847324423e-06
most O 0 9.295416658616773e-10
apparent O 0 1.012439820868849e-08
in O 0 6.747285508090783e-10
individuals O 0 1.6202010566512826e-10
with O 0 1.9580928545259724e-10
mutations O 0 4.007996601274044e-09
in O 0 2.2233650476266575e-09
region O 0 1.2521843117951903e-08
1 O 0 3.7438339859363623e-06
, O 0 1.1363275653764049e-08
and O 0 9.426762659359156e-08
upper O 1 0.9996991157531738
- O 1 0.9065645933151245
gastrointestinal O 0 0.00017180237045977265
manifestations O 0 0.00024176997249014676
were O 0 2.629031214951283e-08
more O 0 1.2410819039132548e-09
severe O 0 2.303432040662301e-07
in O 0 2.0685231305606067e-08
them O 0 7.034323346033489e-08
. O 0 1.4023686389919021e-06

In O 0 1.5505611372645944e-07
individuals O 0 2.600597071023003e-09
with O 0 5.071346120821829e-10
mutations O 0 3.600105324963465e-09
in O 0 4.757587657167051e-10
either O 0 3.279327698280099e-09
region O 0 1.1064977378794083e-08
2 O 0 1.072784172606589e-07
or O 0 2.6959841026297227e-09
region O 0 1.44760214926265e-09
3 O 0 2.662813258780261e-08
, O 0 6.602711710712583e-10
the O 0 4.84598472461073e-10
average O 0 1.0843776987456977e-09
number O 0 2.648866459509236e-09
of O 0 1.6968247251725188e-08
adenomas B-Disease 0 4.124264251004206e-06
tended O 0 3.144474547411846e-08
to O 0 2.402939847101493e-09
be O 0 2.215618133405428e-09
lower O 0 9.296413416848281e-09
than O 0 3.5800812314690234e-10
those O 0 3.869645229248597e-11
in O 0 4.913815188078985e-11
individuals O 0 1.4274618813370221e-11
with O 0 2.4758691624660045e-11
mutations O 0 1.0061617095047382e-09
in O 0 3.117936464569482e-10
region O 0 2.0509183240591256e-09
1 O 0 2.1852045506420836e-08
, O 0 5.380533796284226e-10
although O 0 1.1492808926760745e-09
age O 0 1.4469762277258269e-08
at O 0 2.084969530358194e-08
diagnosis O 0 5.3603088190357084e-08
was O 0 1.4326630548566754e-08
similar O 0 2.9667098999652808e-08
. O 0 6.986733183111937e-07

In O 0 1.94785684470844e-06
all O 0 3.0178114229784114e-06
AAPC B-Disease 1 1.0
kindreds O 0 6.604559894185513e-05
, O 0 1.955202577619275e-08
a O 0 4.5870902631861554e-09
predominance O 0 2.399227696514572e-07
of O 0 7.910725798865315e-07
right O 1 0.9520207643508911
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999958276748657
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999265670776367
sparing O 0 6.83714779370348e-06
was O 0 1.21146592846344e-06
observed O 0 1.6026810953917447e-06
. O 0 3.5531809317035368e-06

No O 0 3.0711475119460374e-05
desmoid B-Disease 1 0.5504977703094482
tumors I-Disease 1 1.0
were O 0 6.209722300809517e-07
found O 0 1.959413786778441e-08
in O 0 8.880383539633385e-09
these O 0 2.5398517067287685e-08
kindreds O 0 2.938119723694399e-05
. O 0 5.465584763442166e-06

Our O 0 1.1492845715110889e-06
data O 0 6.84655603322426e-08
suggest O 0 1.299408580734962e-08
that O 0 4.723085256230775e-10
, O 0 5.568469685357513e-09
in O 0 2.790290309917509e-08
AAPC B-Disease 1 1.0
families O 0 5.593581597906905e-09
, O 0 2.1268209415836736e-09
the O 0 1.8598785844758936e-09
location O 0 8.548297181221187e-09
of O 0 1.8862197137536896e-08
the O 0 6.029319621347895e-08
APC B-Disease 0 7.552976057922933e-07
mutation O 0 2.409261128377693e-07
may O 0 2.072651028584005e-07
partially O 0 1.1448879604358808e-06
predict O 0 4.921378149447264e-07
specific O 0 2.554514821895282e-07
phenotypic O 0 5.627655264106579e-05
expression O 0 1.0660184670996387e-05
. O 0 7.251103397720726e-06

This O 0 8.235573289994136e-08
should O 0 2.1736854094456248e-08
help O 0 4.605008818714396e-09
in O 0 1.7855225076246484e-09
the O 0 1.3364098716550643e-09
design O 0 2.0760012375831138e-08
of O 0 1.8484213271108274e-08
tailored O 0 1.4707308082506643e-07
clinical O 0 4.1506973502691835e-06
- O 0 7.322229862438689e-07
management O 0 1.4965289452106845e-08
protocols O 0 4.3265441007633854e-08
in O 0 1.9436147136175919e-10
this O 0 6.137895053326403e-11
subset O 0 5.099662914176406e-09
of O 0 3.138475035413535e-09
FAP B-Disease 0 1.3921480501721817e-07
patients O 0 8.398354012228992e-09
. O 0 5.7382262497185366e-08
. O 0 1.1646621942418278e-06

Wilms B-Disease 1 0.9934176206588745
' I-Disease 0 7.952336090966128e-06
tumor I-Disease 0 1.6601619563516579e-06
1 O 0 1.4018859246789361e-06
and O 0 1.1894007911905646e-07
Dax O 0 0.0002777938498184085
- O 0 4.108324276330677e-07
1 O 0 1.767299124821875e-07
modulate O 0 9.951025958798709e-08
the O 0 1.3111745467142555e-08
orphan O 0 3.502051626469438e-08
nuclear O 0 2.236645997300002e-07
receptor O 0 3.0644150683656335e-07
SF O 0 2.457322261761874e-05
- O 0 6.148449216425433e-08
1 O 0 1.1728995552573451e-08
in O 0 1.1578574765636063e-09
sex O 0 5.176345574398056e-09
- O 0 2.081027350442355e-09
specific O 0 6.206034575129138e-10
gene O 0 8.232632353610825e-09
expression O 0 2.05567047828481e-07
. O 0 1.2874469348389539e-06

Products O 0 8.625866598777066e-07
of O 0 6.182021934364457e-07
steroidogenic O 0 5.494438482855912e-06
factor O 0 1.4176723084347032e-07
1 O 0 3.4730831544038665e-07
( O 0 1.5747694703804882e-08
SF O 0 6.789791768824216e-06
- O 0 3.837223871983042e-08
1 O 0 3.397167702701154e-08
) O 0 1.2535624760445785e-09
and O 0 1.1332216054427136e-08
Wilms B-Disease 0 1.0906822353717871e-05
tumor I-Disease 0 4.1745570911189134e-07
1 O 0 8.829766215967538e-07
( O 0 1.7458360090927272e-08
WT1 O 0 1.6681129864082322e-06
) O 0 8.917686589171581e-10
genes O 0 6.54548304446223e-10
are O 0 1.3416576183367113e-10
essential O 0 3.582583341099621e-09
for O 0 2.4289845690361744e-09
mammalian O 0 5.505776243808214e-07
gonadogenesis O 0 5.383371330935915e-07
prior O 0 5.10297368805368e-08
to O 0 7.254333134198987e-09
sexual O 0 1.6098179855816852e-07
differentiation O 0 2.2348940547090024e-06
. O 0 2.3456805138266645e-06

In O 0 4.605318792982871e-07
males O 0 4.700443128058396e-07
, O 0 1.7207678126851533e-07
SF O 0 0.0012150370748713613
- O 0 1.956687583515304e-06
1 O 0 2.1718668108405836e-07
participates O 0 8.293167041983907e-09
in O 0 3.631649148072569e-10
sexual O 0 4.772149342358034e-09
development O 0 9.708162052035618e-10
by O 0 1.705775937166365e-10
regulating O 0 1.7123876761004908e-09
expression O 0 2.0385086951790754e-09
of O 0 1.0035231312599535e-08
the O 0 4.575130674311367e-08
polypeptide O 0 1.2272095091248048e-06
hormone O 0 2.745132974268927e-07
Mullerian O 0 1.1834377801278606e-05
inhibiting O 0 6.129042731117806e-07
substance O 0 6.43821863377525e-07
( O 0 2.528349227759463e-07
MIS O 0 0.00011158113920828328
) O 0 1.973810697109002e-07
. O 0 2.4039807158260373e-06

Here O 0 1.4930568568161107e-06
, O 0 3.4584665797865455e-08
we O 0 1.25088810420948e-08
show O 0 6.69222766092048e-09
that O 0 4.210820581107555e-09
WT1 O 0 5.804242755402811e-05
- O 0 5.622288881568238e-06
KTS O 0 7.366990757873282e-05
isoforms O 0 2.0230527297826484e-06
associate O 0 4.025290536446846e-07
and O 0 1.508007407835521e-08
synergize O 0 1.0408758726043743e-06
with O 0 2.1645174541617962e-08
SF O 0 0.0008072651689872146
- O 0 6.40249766092893e-07
1 O 0 9.241118448244379e-08
to O 0 1.1899278895555199e-08
promote O 0 1.6939054603426484e-07
MIS O 0 0.00010175899660680443
expression O 0 8.57684653965407e-07
. O 0 2.0144257177889813e-06

In O 0 4.095313670404721e-07
contrast O 0 3.21107847867097e-07
, O 0 1.7048157019416976e-07
WT1 O 0 0.0001273049711016938
missense O 0 4.301655280869454e-06
mutations O 0 1.8799094902988145e-07
, O 0 1.2372584734521297e-08
associated O 0 2.918994290723731e-08
with O 0 7.452999994939091e-09
male B-Disease 0 1.1257782261964167e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 2.7482526547828456e-06
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.149150415993063e-07
fail O 0 2.0847664927714504e-06
to O 0 5.34798267892711e-08
synergize O 0 4.207950951240491e-06
with O 0 1.8015714431385277e-07
SF O 1 0.9999392032623291
- O 0 5.1769678975688294e-05
1 O 0 5.320417585608084e-06
. O 0 1.2657233128265943e-06

Additionally O 0 4.759602688864106e-06
, O 0 6.930353180223392e-08
the O 0 3.184217689522484e-08
X O 0 3.1348296033684164e-05
- O 0 2.443065341140027e-06
linked O 0 6.51330864798183e-08
, O 0 2.245145402923754e-09
candidate O 0 3.8739639052209895e-08
dosage O 0 2.4765965918049915e-06
- O 0 3.87633377840757e-07
sensitive O 0 7.313995098456871e-08
sex O 0 1.2992772191466884e-08
- O 0 1.505119584521708e-08
reversal O 0 2.4127601250256703e-08
gene O 0 1.3190255998551947e-08
, O 0 3.9099891324667624e-08
Dax O 0 0.00037583697121590376
- O 0 8.023624218367331e-07
1 O 0 2.6523264295974514e-07
, O 0 1.3918699970361104e-08
antagonizes O 0 6.495592401734029e-07
synergy O 0 9.479338558548989e-08
between O 0 9.444651993817388e-08
SF O 0 0.00018693419406190515
- O 0 1.7174970423639024e-07
1 O 0 4.1502470793375323e-08
and O 0 8.875693069398949e-09
WT1 O 0 6.867579941172153e-06
, O 0 2.260782894225599e-09
most O 0 2.950427124837063e-10
likely O 0 1.665582560761436e-09
through O 0 2.7060181873039824e-10
a O 0 5.68804059408734e-10
direct O 0 1.9435490994368365e-09
interaction O 0 3.09565315603777e-08
with O 0 1.309694841467035e-08
SF O 0 0.06747764348983765
- O 0 7.341440777963726e-06
1 O 0 1.5329950429077144e-06
. O 0 8.761721232986019e-07

We O 0 1.8101391106029041e-06
propose O 0 8.725665452402609e-07
that O 0 3.163544448625544e-08
WT1 O 0 5.243375926511362e-05
and O 0 4.909850304102292e-07
Dax O 0 0.06545894593000412
- O 0 8.567306508666661e-07
1 O 0 8.828169484331738e-08
functionally O 0 9.12922004658867e-09
oppose O 0 1.6921730683350233e-09
each O 0 4.718456736441112e-10
other O 0 6.914648298383952e-10
in O 0 3.37171934816638e-09
testis O 0 3.738931013685942e-07
development O 0 2.5944254744558748e-08
by O 0 5.619406273638106e-09
modulating O 0 7.620844257871795e-07
SF O 0 9.342168050352484e-05
- O 0 6.735602937624208e-07
1 O 0 7.30023828054982e-07
- O 0 3.352598696437781e-07
mediated O 0 7.357108415817493e-07
transactivation O 0 4.391645688883727e-06
. O 0 1.0196727373568137e-07
. O 0 9.516918453300605e-07

A O 0 9.37418644753052e-06
mouse O 0 1.3281539850140689e-06
model O 0 6.998216122156009e-07
for O 0 1.798251560103381e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999997615814209
- O 1 0.9995433688163757
centre O 0 0.0004238220863044262
mutations O 0 2.698213165786001e-06
. O 0 2.27566783905786e-06

Imprinting O 0 5.9349924413254485e-05
in O 0 2.495639535027294e-07
the O 0 1.4817091198437993e-07
15q11 O 0 6.588196356460685e-06
- O 0 9.367933557768993e-07
q13 O 0 7.218732207547873e-07
region O 0 1.7268595442487822e-08
involves O 0 1.0739650946334223e-08
an O 0 1.011950967466646e-09
imprinting O 0 2.845422386599239e-07
centre O 0 1.7059186575352214e-05
( O 0 4.978957335310952e-08
IC O 0 8.0368108683615e-06
) O 0 6.122525597618278e-09
, O 0 1.072764876930421e-09
mapping O 0 3.862496544826399e-09
in O 0 3.5007927112751247e-10
part O 0 4.884466719978775e-10
to O 0 7.228984078011536e-10
the O 0 4.380749096810632e-09
promoter O 0 1.300004157656076e-07
and O 0 9.681945911665935e-09
first O 0 5.0725315503541424e-08
exon O 0 5.121031563248835e-07
of O 0 7.485440960408596e-07
SNRPN O 0 0.000376302283257246
. O 0 1.256478026334662e-05

Deletion O 0 2.2919135517440736e-05
of O 0 4.4721326730723376e-07
this O 0 6.21461566652215e-08
IC O 0 5.6957425840664655e-05
abolishes O 0 2.1128219032107154e-06
local O 0 6.357854687166764e-08
paternally O 0 9.517310672890744e-08
derived O 0 4.096873507108967e-09
gene O 0 2.334920479185598e-09
expression O 0 4.8355905946095845e-09
and O 0 4.5811101578863145e-09
results O 0 7.64046390600015e-08
in O 0 6.5402974769313e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999912977218628
PWS B-Disease 1 1.0
) O 0 7.408834790112451e-06
. O 0 5.1849388000846375e-06

We O 0 2.95947671702379e-07
have O 0 4.412464171821284e-09
created O 0 8.265232054327498e-09
two O 0 2.201644866417496e-09
deletion O 0 4.1435317399418636e-08
mutations O 0 2.8472076252228362e-08
in O 0 9.21283316301924e-09
mice O 0 4.0456406225075625e-08
to O 0 6.886367032166163e-09
understand O 0 2.4227244921348756e-06
PWS B-Disease 1 1.0
and O 0 4.407663709571352e-07
the O 0 3.4478695454254193e-08
mechanism O 0 1.3830739931108837e-07
of O 0 1.0487306134621122e-08
this O 0 4.373519324474273e-09
IC O 0 2.4358732844120823e-05
. O 0 2.1330311028577853e-06

Mice O 0 0.0005183528992347419
harbouring O 0 0.0005181590095162392
an O 0 2.785941148886195e-07
intragenic O 0 1.5971827451721765e-05
deletion O 0 1.5228940810629865e-06
in O 0 8.762559389197122e-08
Snrpn O 0 0.00014966874732635915
are O 0 6.305021571506586e-08
phenotypically O 0 3.7626859921147116e-06
normal O 0 1.9366123638064892e-07
, O 0 3.248456392768162e-09
suggesting O 0 7.1935843948267575e-09
that O 0 4.761563920929746e-10
mutations O 0 7.578819349873811e-09
of O 0 6.767808091723282e-09
SNRPN O 0 1.920720251291641e-06
are O 0 5.552060478031251e-10
not O 0 1.093497625781481e-09
sufficient O 0 5.117028223367015e-08
to O 0 5.0535462037260004e-08
induce O 0 3.7834841350559145e-05
PWS B-Disease 1 1.0
. O 0 0.00017716390721034259

Mice O 0 1.1718142559402622e-05
with O 0 2.0422691093813228e-08
a O 0 1.0532187566525408e-08
larger O 0 3.068113585413812e-08
deletion O 0 3.131185621896293e-07
involving O 0 2.5467256747901956e-08
both O 0 8.966436482182871e-09
Snrpn O 0 4.159069703746354e-06
and O 0 2.7568674454414577e-08
the O 0 9.700582381810818e-08
putative O 0 2.217844121332746e-05
PWS O 1 1.0
- O 0 0.008384905755519867
IC O 0 0.0001207577224704437
lack O 0 4.826976578442554e-07
expression O 0 5.4701509100141266e-08
of O 0 3.4859109376839115e-08
the O 0 1.2393178927538884e-08
imprinted O 0 4.711420587000248e-08
genes O 0 2.3430052564776815e-08
Zfp127 O 0 4.877201263298048e-06
( O 0 3.9750183589148946e-08
mouse O 0 1.3023480960328015e-07
homologue O 0 4.555547263862536e-07
of O 0 9.874264605969074e-08
ZNF127 O 0 9.304755803896114e-05
) O 0 5.7267460107368606e-08
, O 0 3.8239264199546597e-08
Ndn O 0 3.483405816950835e-05
and O 0 1.0715898923763234e-07
Ipw O 0 2.378918907197658e-05
, O 0 2.7741581476448118e-08
and O 0 1.5911153283809654e-08
manifest O 0 1.472152462156373e-07
several O 0 2.4732488057566115e-08
phenotypes O 0 4.6978398131614085e-06
common O 0 1.1429953019614914e-06
to O 0 3.089164465563954e-06
PWS B-Disease 1 1.0
infants O 1 0.9999898672103882
. O 0 6.13774755038321e-05

These O 0 9.320598337581032e-08
data O 0 3.089052924565294e-08
demonstrate O 0 1.0689866769553191e-08
that O 0 1.8113441302425315e-10
both O 0 5.934707170140996e-10
the O 0 1.1561693824546637e-09
position O 0 1.678928462922613e-08
of O 0 5.027566363224878e-09
the O 0 3.825047834027373e-09
IC O 0 3.5502810646903527e-07
and O 0 7.800504131516561e-10
its O 0 1.7571491484069668e-10
role O 0 7.001588753219323e-10
in O 0 1.6676607317300807e-10
the O 0 3.7823436049855275e-10
coordinate O 0 1.6112802203593901e-09
expression O 0 1.268266491827319e-09
of O 0 1.958751161268424e-09
genes O 0 8.551798713618552e-10
is O 0 1.6225699950300765e-10
conserved O 0 4.202564074518023e-09
between O 0 5.277876358178446e-09
mouse O 0 2.513068864118395e-08
and O 0 1.2253227321679105e-09
human O 0 1.1372874864079563e-09
, O 0 1.4784351520802375e-10
and O 0 1.6162317317824915e-10
indicate O 0 1.1039380520827535e-09
that O 0 3.670948267586738e-10
the O 0 8.481062074849888e-09
mouse O 0 1.903350010934446e-08
is O 0 5.007199099793525e-10
a O 0 2.4630400496938876e-10
suitable O 0 8.481578994690153e-09
model O 0 1.0573349307207991e-08
system O 0 8.620191671582234e-09
in O 0 6.533820706700055e-10
which O 0 2.886338112961795e-10
to O 0 5.659718804729152e-10
investigate O 0 1.5085884541576888e-08
the O 0 1.4965509942399535e-09
molecular O 0 3.906195189529171e-08
mechanisms O 0 7.36419210056738e-08
of O 0 7.761905784775536e-09
imprinting O 0 1.0007939010847622e-07
in O 0 9.743668094586155e-10
this O 0 2.3983964814178194e-10
region O 0 2.3217308076084464e-09
of O 0 4.444527856861669e-09
the O 0 4.958673471833208e-09
genome O 0 3.913150692369527e-09
. O 0 9.382183918660303e-09
. O 0 3.2756418022472644e-07

Mutations O 0 2.0706136183434865e-06
of O 0 3.3055164294637507e-07
the O 0 1.1709195035791709e-07
ATM O 0 1.4001102499605622e-06
gene O 0 1.5481534276773345e-08
detected O 0 2.152614797523711e-08
in O 0 2.1123851112747616e-08
Japanese O 1 0.9999055862426758
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.000381630816264078
: O 0 4.89481211118914e-09
possible O 0 1.1079104744737833e-08
preponderance O 0 6.164935939523275e-08
of O 0 6.120237205919921e-09
the O 0 3.216169774944433e-09
two O 0 8.827895747742787e-09
founder O 0 1.984266475574259e-07
mutations O 0 1.8950370872516942e-07
4612del165 O 0 1.7870007695819368e-06
and O 0 3.5209197335461795e-07
7883del5 O 0 2.446925464028027e-05
. O 0 5.0900048336188775e-06

The O 0 4.5159822548157535e-06
ATM O 0 0.004275184590369463
( O 0 3.211297325833584e-06
A O 1 0.9999990463256836
- O 1 0.9995680451393127
T O 1 0.9999994039535522
, O 0 7.837000381982762e-09
mutated O 0 1.779980784988311e-08
) O 0 1.6563193039331736e-09
gene O 0 4.009143683703087e-09
on O 0 3.139242821248445e-08
human O 0 6.31195220535119e-08
chromosome O 0 8.844979220157256e-07
11q22 O 0 8.406781489611603e-06
. O 0 4.2854162529692985e-06

3 O 0 6.037737421138445e-06
has O 0 1.127731863448389e-08
recently O 0 6.288396914300165e-09
been O 0 1.269578331353216e-09
identified O 0 1.933296411849028e-09
as O 0 2.608738502996033e-10
the O 0 3.842757223537774e-10
gene O 0 1.5772276817926922e-09
responsible O 0 1.5479991732902931e-09
for O 0 4.848443868610275e-10
the O 0 7.494682208175618e-09
human O 0 7.210282092273701e-06
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6597867897871765e-06
. O 0 1.8215163208878948e-06

In O 0 8.356397529496462e-08
order O 0 4.131922537453647e-08
to O 0 1.1576719582961914e-09
define O 0 1.0039308051545959e-08
the O 0 2.743793414694551e-09
types O 0 1.6506589872733457e-08
of O 0 1.6584324669111083e-07
disease O 0 0.0010807299986481667
- O 0 4.4245354047234287e-07
causing O 0 1.0612711776047945e-07
ATM O 0 2.6435123800183646e-05
mutations O 0 2.708117463612325e-08
in O 0 2.959130052104797e-09
Japanese O 0 3.395248768356396e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3864858594558882e-08
as O 0 5.019065163480718e-10
well O 0 1.6988697948416842e-10
as O 0 1.455017217821819e-10
to O 0 8.474197038532694e-11
look O 0 1.047414710519945e-09
for O 0 2.780554397840973e-10
possible O 0 1.1397288446346465e-08
mutational O 0 6.053865604371822e-07
hotspots O 0 1.4623783783918043e-07
, O 0 3.985918706206348e-09
reverse O 0 5.827989468798478e-08
- O 0 4.024690980486412e-08
transcribed O 0 7.929350509527922e-09
RNA O 0 1.6842229833002875e-09
derived O 0 6.684901521225584e-10
from O 0 4.039082956985851e-10
ten O 0 5.872721864363939e-09
patients O 0 6.938203345185912e-10
belonging O 0 3.4735776477390345e-09
to O 0 3.2906810609745207e-09
eight O 0 4.509675832764515e-08
unrelated O 0 1.8500372789276298e-07
Japanese O 0 2.6094037366419798e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 8.432108344891276e-09
was O 0 1.2331802246023926e-08
analyzed O 0 1.8415757807588307e-09
for O 0 1.5437849609778453e-10
mutations O 0 8.900456482940911e-10
by O 0 2.6340979397687647e-10
the O 0 1.7030524768202326e-09
restriction O 0 7.70558639118235e-09
endonuclease O 0 4.4232695017853985e-07
fingerprinting O 0 1.8721573269431246e-07
method O 0 5.948833745605953e-07
. O 0 1.3295974667926203e-06

As O 0 5.269832286103338e-07
has O 0 5.045510675927289e-09
been O 0 1.7042255384680516e-09
reported O 0 1.7068083613125395e-09
by O 0 3.443863250129908e-10
others O 0 1.5468510916605283e-09
, O 0 7.619195274699564e-10
mutations O 0 5.010392545301556e-09
that O 0 4.3042994168907e-10
lead O 0 1.8577983595946534e-08
to O 0 1.3185577962815387e-08
exon O 0 1.4615212649005116e-06
skipping O 0 2.948433746041701e-07
or O 0 6.489524650987732e-08
premature O 0 1.522094095207649e-07
protein O 0 5.510593936719488e-08
truncation O 0 1.6478473980896524e-06
were O 0 4.284318322334002e-08
also O 0 6.43499342700693e-09
predominant O 0 1.7218445691469242e-07
in O 0 1.9052386335260962e-08
our O 0 2.3053372899539681e-07
mutants O 0 5.017399416828994e-06
. O 0 1.277792307519121e-06

Six O 0 4.4247417463338934e-07
different O 0 3.595041375703545e-09
mutations O 0 1.4473681808624406e-08
were O 0 5.388002488615484e-09
identified O 0 8.123259398473692e-09
on O 0 9.459450112103696e-09
12 O 0 3.0770333836471764e-08
of O 0 1.2922212633270647e-08
the O 0 2.3660119197188578e-08
16 O 0 5.531812803383218e-07
alleles O 0 8.305713663503411e-07
examined O 0 4.169896328676259e-06
. O 0 3.558695198080386e-06

Four O 0 1.8244267039335682e-06
were O 0 2.833142787039833e-07
deletions O 0 1.237569676959538e-06
involving O 0 1.179567519216107e-07
a O 0 9.776996989785403e-09
loss O 0 1.2259316406471044e-07
of O 0 1.6046402606662014e-07
a O 0 2.7897581134084248e-08
single O 0 3.242861623675708e-08
exon O 0 4.253317626989883e-07
exon O 0 3.8958089021434716e-07
7 O 0 3.617653305809654e-07
, O 0 1.7621719194949037e-08
exon O 0 2.845666529083246e-07
16 O 0 1.9680176421843498e-07
, O 0 1.8899216414069997e-08
exon O 0 3.8572059679609083e-07
33 O 0 2.1776034486720164e-07
or O 0 9.597519579074287e-08
exon O 0 1.8243065369460965e-06
35 O 0 7.984975809449679e-07
. O 0 2.1706380266550696e-06

The O 0 5.683842800863204e-07
others O 0 8.416751029471925e-08
were O 0 4.992251589897023e-08
minute O 0 2.726574450662156e-07
deletions O 0 1.236706879126359e-07
, O 0 1.7291830189947177e-08
4649delA O 0 4.527857413449965e-07
in O 0 2.02947028071776e-08
exon O 0 3.612227033045201e-07
33 O 0 1.475479365353749e-07
and O 0 3.236842616161084e-08
7883del5 O 0 1.776963927113684e-06
in O 0 1.0845482023569275e-07
exon O 0 4.097511464351555e-06
55 O 0 1.6067014030340943e-06
. O 0 3.964607458328828e-06

The O 0 1.1555699757082039e-06
mutations O 0 8.166098268702626e-07
4612del165 O 0 1.0558344456512714e-06
and O 0 1.0375449832622508e-08
7883del5 O 0 2.1403290872967773e-07
were O 0 6.05176175838551e-09
found O 0 6.032443433667822e-10
in O 0 1.7195381230017404e-10
more O 0 3.681148094680786e-11
than O 0 1.173659225361945e-10
two O 0 1.2991892284208717e-10
unrelated O 0 1.4553233063097082e-09
families O 0 5.5910907847955826e-11
; O 0 1.3722643854574557e-10
44 O 0 1.2521383929708918e-09
% O 0 5.021411064731751e-10
( O 0 1.7969611354473614e-09
7 O 0 3.1955892154655885e-08
of O 0 5.6543916215900936e-09
16 O 0 4.2356003149279786e-08
) O 0 5.629927635197873e-10
of O 0 7.921123201803937e-10
the O 0 5.720168227973943e-10
mutant O 0 1.488915657432699e-08
alleles O 0 8.287980080012858e-09
had O 0 1.8376705712697117e-09
one O 0 5.373129163821488e-10
of O 0 2.340833304970147e-09
the O 0 7.792433365239049e-09
two O 0 1.7713244204742296e-08
mutations O 0 7.201514335974935e-07
. O 0 2.8133499654359184e-06

The O 0 8.918390790313424e-07
4612del165 O 0 1.5592804629704915e-06
mutations O 0 4.10850375942573e-08
in O 0 1.2906686830405079e-09
three O 0 7.403930246674406e-10
different O 0 1.9416397656346618e-10
families O 0 1.754416611987608e-10
were O 0 8.593084022123776e-10
all O 0 2.2897184148717997e-10
ascribed O 0 5.836596983499476e-09
to O 0 6.177737210677492e-10
the O 0 3.3216625006105005e-09
same O 0 1.146033135057678e-08
T O 0 4.0198419810622e-06
- O 0 4.824505595024675e-07
- O 0 5.508313449809066e-08
> O 0 4.307515411028362e-08
A O 0 6.4003762290099075e-09
substitution O 0 9.450594973259285e-09
at O 0 2.1169872965742798e-08
the O 0 1.9171688681041132e-09
splice O 0 5.690509397027199e-08
donor O 0 4.4846610869342385e-09
site O 0 1.6854254880627195e-08
in O 0 1.2767620738429741e-08
intron O 0 9.665939160186099e-07
33 O 0 6.541759830724914e-06
. O 0 1.1199592336197384e-05

Microsatellite O 0 0.00035294226836413145
genotyping O 0 8.907379378797486e-05
around O 0 3.312879357508791e-07
the O 0 6.676510366787625e-08
ATM O 0 4.651036761060823e-06
locus O 0 2.3023997641757887e-07
also O 0 2.061177228895872e-09
indicated O 0 7.017649572560458e-09
that O 0 4.867884428882974e-10
a O 0 1.9334145395788482e-09
common O 0 1.1036206615244737e-08
haplotype O 0 1.8284244163169205e-07
was O 0 2.2852399084172248e-08
shared O 0 1.7143190200741287e-09
by O 0 3.9129621764999456e-10
the O 0 6.027567334143669e-10
mutant O 0 1.3106619789482465e-08
alleles O 0 9.782815446612858e-09
in O 0 2.929467557422072e-09
both O 0 2.8455843903429923e-08
mutations O 0 1.5324263813454309e-06
. O 0 2.648257122928044e-06

This O 0 1.0025744501263034e-07
suggests O 0 5.665902946816459e-08
that O 0 1.014430317525239e-09
these O 0 1.507535096756385e-09
two O 0 1.3588877800785326e-09
founder O 0 3.843926421609467e-08
mutations O 0 1.7356365233922588e-08
may O 0 2.3465864806837544e-09
be O 0 3.5112937002423905e-09
predominant O 0 7.406154622913164e-08
among O 0 5.6514801727303166e-09
Japanese O 0 9.709152237746821e-08
ATM O 0 3.6175263176119188e-06
mutant O 0 1.2389407402224606e-06
alleles O 0 2.0441239030333236e-06
. O 0 1.9087267446593614e-06

W474C O 0 0.00012037384294671938
amino O 0 2.0765617136930814e-06
acid O 0 1.0945816342200487e-07
substitution O 0 6.502521898710256e-08
affects O 0 9.963119218525662e-09
early O 0 8.668499695829723e-09
processing O 0 3.4121019343302805e-09
of O 0 1.2300200857850996e-09
the O 0 1.2173280161675848e-09
alpha O 0 2.563598044957871e-08
- O 0 1.2270418014992401e-09
subunit O 0 2.0980051029795277e-09
of O 0 1.055190823606722e-09
beta O 0 6.420259524020366e-08
- O 0 1.2008811722807877e-08
hexosaminidase O 0 3.24726876499426e-08
A O 0 4.083517524122726e-09
and O 0 1.2356988765560573e-09
is O 0 6.683116282601986e-10
associated O 0 8.018322006364542e-09
with O 0 1.0546379769493797e-08
subacute O 0 0.00038918497739359736
G B-Disease 0 0.0029812694992870092
( I-Disease 0 7.942202273625298e-07
M2 I-Disease 0 8.74876495799981e-05
) I-Disease 0 3.3548758437973447e-07
gangliosidosis I-Disease 0 1.7282096450799145e-05
. O 0 4.441845248948084e-06

Mutations O 0 2.0243689959897893e-06
in O 0 9.53304422068868e-08
the O 0 1.9641232995581959e-07
HEXA O 0 2.0213892639731057e-05
gene O 0 2.5000650438755656e-08
, O 0 6.8772965100549754e-09
encoding O 0 1.8466382201154374e-08
the O 0 1.0166894881535882e-08
alpha O 0 6.253020501389983e-08
- O 0 4.01369604219326e-09
subunit O 0 1.1731612126197888e-08
of O 0 6.003051389313896e-09
beta O 0 1.7270974694838515e-07
- O 0 3.5094874561991674e-08
hexosaminidase O 0 3.190948518749792e-07
A O 0 5.287612481197357e-08
( O 0 1.1930777255031444e-08
Hex O 0 1.1776021437981399e-06
A O 0 2.1020397866777785e-08
) O 0 1.861053200435947e-09
, O 0 9.550653601309023e-10
that O 0 7.107304744735643e-10
abolish O 0 2.506604630525544e-07
Hex O 0 2.459900542817195e-06
A O 0 6.969550980784334e-08
enzyme O 0 5.209728115573853e-08
activity O 0 1.4249619084694132e-07
cause O 0 0.0004157338698860258
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.798193210968748e-05
TSD B-Disease 1 0.9999830722808838
) O 0 2.9303631521315765e-08
, O 0 2.773775875652973e-09
the O 0 7.3461898786320035e-09
fatal O 0 9.60464035415498e-07
infantile B-Disease 0 3.0706550546710787e-07
form I-Disease 0 2.879385441190152e-08
of I-Disease 0 3.5493434324962436e-07
G I-Disease 0 1.806840555218514e-05
( I-Disease 0 4.1065689515562553e-08
M2 I-Disease 0 5.1087176871078555e-06
) I-Disease 0 2.6193658797524222e-08
gangliosidosis I-Disease 0 4.4082145223001135e-07
, I-Disease 0 5.703197913931035e-09
Type I-Disease 0 3.240512569391285e-07
1 I-Disease 0 2.4216665224230383e-06
. O 0 1.4115382782620145e-06

Less O 0 7.796399586368352e-06
severe O 1 0.8443077802658081
, O 0 1.7212927332366235e-06
subacute O 1 0.999992847442627
( O 0 8.421855568485626e-07
juvenile O 0 6.418339762603864e-05
- O 0 7.818660492375784e-07
onset O 0 0.00013747389311902225
) O 0 2.6094626903727658e-08
and O 0 6.611765712705164e-08
chronic O 1 0.9982890486717224
( O 0 2.5349791599182936e-07
adult O 0 2.117982376148575e-06
- O 0 2.5614332344048307e-07
onset O 0 4.712791451311205e-06
) O 0 1.8763688380829535e-09
variants O 0 1.9556127384134925e-08
are O 0 4.3029449448006574e-10
characterized O 0 1.0941736405811753e-09
by O 0 2.047434721763608e-10
a O 0 6.710579314450626e-10
broad O 0 1.2063311238819097e-08
spectrum O 0 4.044776602540878e-08
of O 0 3.0939573125721154e-09
clinical O 0 5.471455111205614e-08
manifestations O 0 1.1088115314805691e-07
and O 0 1.0554525031736262e-09
are O 0 4.5127518388810017e-10
associated O 0 1.8838242077379164e-09
with O 0 2.6941321396023454e-10
residual O 0 2.086461847738974e-07
levels O 0 1.731966534634921e-07
of O 0 3.5695987321560096e-07
Hex O 0 7.334414476645179e-06
A O 0 8.745478652372185e-08
enzyme O 0 3.417952854078976e-08
activity O 0 7.77488864400766e-08
. O 0 2.985459559567971e-07

We O 0 3.524498197293724e-06
identified O 0 9.203455988426867e-07
a O 0 2.0021383306811913e-07
1422 O 0 7.346856727963313e-05
G O 0 2.3590224373037927e-05
- O 0 1.262310252059251e-05
- O 0 1.5321809314627899e-06
> O 0 5.470442374644335e-07
C O 0 1.5069313121784944e-06
( O 0 4.969429312495777e-09
amino O 0 4.8771804372904626e-09
acid O 0 1.1517211628842006e-09
W474C O 0 1.9103328696701283e-08
) O 0 7.49756298712434e-11
substitution O 0 4.021095956208143e-10
in O 0 1.3451552371979147e-10
the O 0 3.1100724773303057e-10
first O 0 9.94862525693918e-10
position O 0 9.419462543291957e-09
of O 0 7.74752884069585e-09
exon O 0 4.123475250139563e-08
13 O 0 3.237769163888515e-08
of O 0 4.8643528316461015e-08
HEXA O 0 9.348273306386545e-05
of O 0 1.2131464188769314e-07
a O 0 6.738095947866896e-08
non O 0 3.6324747725302586e-06
- O 0 1.179175569632207e-06
Jewish O 0 5.472305133480404e-07
proband O 0 3.3549153158674017e-05
who O 0 4.196038716486328e-08
manifested O 0 4.907397510578448e-07
a O 0 7.582943339912163e-08
subacute O 0 5.523417257791152e-06
variant O 0 1.5943833204801194e-06
of O 0 4.5388010221358854e-06
G B-Disease 0 0.009422843344509602
( I-Disease 0 2.028805141662815e-07
M2 I-Disease 0 2.6320767574361525e-05
) I-Disease 0 1.9592087596720376e-07
gangliosidosis I-Disease 0 1.342394170933403e-05
. O 0 2.820493136823643e-06

On O 0 4.476772119232919e-06
the O 0 1.5383272966573713e-07
second O 0 2.2468694282906654e-07
maternally O 0 9.653051620261976e-07
inherited O 0 5.870999757462414e-07
allele O 0 2.99350517707353e-07
, O 0 6.895133353168603e-09
we O 0 5.4512545588636385e-09
identified O 0 1.889618950201566e-08
the O 0 3.0659375482855467e-08
common O 0 4.660301419789903e-05
infantile O 1 0.9999990463256836
disease O 1 0.999840259552002
- O 0 6.705443229293451e-05
causing O 0 1.384814277116675e-05
4 O 0 0.03430536389350891
- O 0 3.701053628901718e-06
bp O 0 1.3744103455337608e-07
insertion O 0 5.891404697422331e-08
, O 0 2.415527511345772e-08
+ O 0 4.356969327545812e-07
TATC O 0 1.523539140180219e-05
1278 O 0 1.114334099838743e-05
, O 0 2.087850603516017e-08
in O 0 1.5625206017944038e-08
exon O 0 8.986366424323933e-07
11 O 0 1.0813770359163755e-06
. O 0 1.3700515637538047e-06

Pulse O 0 0.0014123214641585946
- O 0 2.5948715119739063e-05
chase O 0 1.0772073437692598e-06
analysis O 0 5.243913037134007e-08
using O 0 1.2969775298188324e-07
proband O 0 3.8026523725420702e-06
fibroblasts O 0 8.96937081051874e-07
revealed O 0 1.6607970110271708e-07
that O 0 1.0197768185449263e-09
the O 0 5.702871508361795e-09
W474C O 0 6.604719970937367e-08
- O 0 8.246525240451774e-09
containing O 0 4.33890479101251e-09
alpha O 0 6.505561600533838e-08
- O 0 7.817145153410365e-09
subunit O 0 2.6293170307667424e-08
precursor O 0 2.7987280049046603e-08
was O 0 5.0418553776410135e-09
normally O 0 9.790072086346413e-10
synthesized O 0 2.137520604961196e-09
, O 0 1.4368703449285647e-10
but O 0 1.698228224711329e-10
not O 0 2.2105642316638807e-10
phosphorylated O 0 7.690874603838438e-09
or O 0 1.1514136311063794e-09
secreted O 0 1.2915651881328927e-09
, O 0 1.44305623006602e-09
and O 0 3.816237548193158e-09
the O 0 2.7412943026661196e-08
mature O 0 4.813434770767344e-07
lysosomal O 0 2.186654910474317e-06
alpha O 0 8.575194669901975e-07
- O 0 4.322857094507526e-08
subunit O 0 1.0297264196879041e-07
was O 0 2.0395011901541693e-08
not O 0 1.0978031816932798e-08
detected O 0 6.144358053461474e-07
. O 0 1.4063530215935316e-06

When O 0 7.577548899462272e-07
the O 0 6.188463430589763e-08
W474C O 0 5.553548589887214e-07
- O 0 2.8483320591021766e-08
containing O 0 4.31367119801962e-09
alpha O 0 1.1560490520423627e-07
- O 0 2.3844778596071592e-08
subunit O 0 1.3131709408753522e-07
was O 0 6.63268266976047e-08
transiently O 0 3.4666965120777604e-07
co O 0 1.3094805240143614e-07
- O 0 1.6001239444562998e-08
expressed O 0 6.758723025690472e-10
with O 0 3.270612114469884e-10
the O 0 3.130057768530037e-09
beta O 0 6.849181488632894e-08
- O 0 5.241270528699715e-09
subunit O 0 4.9857495909577665e-09
to O 0 4.5281162153187893e-10
produce O 0 1.4519885738195626e-08
Hex O 0 3.038592922166572e-06
A O 0 2.008349753168659e-07
( O 0 1.4349820887105125e-08
alphabeta O 0 4.1083751511905575e-07
) O 0 2.47869724745442e-09
in O 0 2.6443482958882214e-09
COS O 0 5.756367613685143e-07
- O 0 5.183491680327279e-08
7 O 0 2.8150836328677542e-08
cells O 0 4.402410436199489e-09
, O 0 6.994954615535676e-10
the O 0 1.6203069996834074e-09
mature O 0 2.081631578221277e-08
alpha O 0 4.800305219987422e-08
- O 0 2.83173329229669e-09
subunit O 0 6.138182406800752e-09
was O 0 7.749594299610862e-10
present O 0 2.1787929793681826e-10
, O 0 1.783363873242294e-10
but O 0 1.4414325288925056e-10
its O 0 9.001606404712703e-11
level O 0 2.3807150029142576e-08
was O 0 4.09357703290425e-09
much O 0 4.3592171539152957e-10
lower O 0 1.7945600561120045e-09
than O 0 1.2233046520204738e-10
that O 0 5.3628979729269943e-11
from O 0 2.147842875777073e-10
normal O 0 1.3737348147913053e-08
alpha O 0 1.7319301548468502e-07
- O 0 1.608594146773612e-08
subunit O 0 6.875935554262469e-08
transfections O 0 8.54910027214828e-08
, O 0 3.484697808087134e-10
although O 0 5.850470663482099e-10
higher O 0 1.0863318022913404e-09
than O 0 1.864018522867994e-10
in O 0 1.4442010087822865e-10
those O 0 2.713046731717128e-10
cells O 0 2.3415120953274027e-09
transfected O 0 2.1738721045494458e-08
with O 0 2.1552543083558362e-10
an O 0 4.1832326491686445e-10
alpha O 0 7.245984079418122e-08
- O 0 1.848096964351953e-08
subunit O 0 7.366805476749505e-08
associated O 0 6.589557699498982e-08
with O 0 4.808011411228108e-08
infantile O 0 0.0006918496219441295
TSD B-Disease 0 0.09771431237459183
. O 0 2.1198144168010913e-05

Furthermore O 0 1.2289393680475769e-06
, O 0 2.692973843920754e-08
the O 0 9.135456835451805e-09
precursor O 0 2.6221602666964827e-08
level O 0 5.873071984296985e-08
of O 0 4.638825323866058e-09
the O 0 3.72553898841943e-09
W474C O 0 8.506841453481684e-08
alpha O 0 1.6165655836175574e-07
- O 0 1.2672540350422423e-08
subunit O 0 4.2857653426153774e-08
was O 0 8.901768211444505e-09
found O 0 1.5270052999838413e-09
to O 0 7.382073285988611e-10
accumulate O 0 6.009593267464197e-09
in O 0 1.2670842153283957e-09
comparison O 0 4.828438537884949e-09
to O 0 1.8271191226659766e-09
the O 0 7.58121920796384e-09
normal O 0 5.06839263891834e-08
alpha O 0 4.1433273167967855e-07
- O 0 3.603019749220948e-08
subunit O 0 1.7414600961274118e-07
precursor O 0 1.8644050214788876e-07
levels O 0 2.824275497914641e-07
. O 0 3.173023515046225e-07

We O 0 8.219282108257175e-07
conclude O 0 9.57670749812678e-07
that O 0 4.008585463566305e-09
the O 0 2.7365979704541132e-08
1422 O 0 1.3907435459259432e-05
G O 0 4.245267518854234e-06
- O 0 9.389005413140694e-07
- O 0 1.5952305432165304e-07
> O 0 1.134097757926611e-07
C O 0 1.9785335325650522e-07
mutation O 0 4.163787536981545e-09
is O 0 1.0531755328946346e-10
the O 0 4.260705954717281e-10
cause O 0 5.2589546051251546e-09
of O 0 7.508177191084542e-08
Hex B-Disease 0 0.00042273267172276974
A I-Disease 0 6.12830845057033e-05
enzyme I-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999979734420776
in O 0 4.227190331107522e-08
the O 0 2.3809290894405422e-07
proband O 0 1.873076325864531e-05
. O 0 3.0511193926940905e-06

The O 0 6.247423129934759e-07
resulting O 0 3.4843594676203793e-07
W474C O 0 2.1157536593818804e-06
substitution O 0 3.516329343256075e-07
clearly O 0 8.66809060084961e-08
interferes O 0 4.27357811361162e-08
with O 0 2.981769942067558e-09
alpha O 0 2.627868695981306e-07
- O 0 1.3066459025878885e-08
subunit O 0 1.4000787196266629e-08
processing O 0 1.089708323576133e-09
, O 0 7.265085061325394e-11
but O 0 6.310341832405086e-11
because O 0 1.1919437659102528e-10
the O 0 2.494970063882107e-10
base O 0 1.7611495595204474e-09
substitution O 0 9.36516375560359e-09
falls O 0 4.0756294339416854e-08
at O 0 1.260922566359568e-08
the O 0 1.5300636313497762e-09
first O 0 1.6758977539055309e-09
position O 0 1.3640924834135149e-08
of O 0 2.108231278441508e-08
exon O 0 2.8385491646076844e-07
13 O 0 8.161140385709587e-08
, O 0 8.532366813085446e-09
aberrant O 0 8.303236853635099e-08
splicing O 0 1.1939295063712052e-07
may O 0 2.488817507639851e-08
also O 0 4.560944066867023e-09
contribute O 0 5.254222390504992e-09
to O 0 1.5416619092434303e-08
Hex B-Disease 0 0.002718997187912464
A I-Disease 0 4.383043233247008e-06
deficiency I-Disease 0 1.632488965697121e-05
in O 0 8.10593991928954e-09
this O 0 4.920113205741927e-09
proband O 0 9.264604727832193e-07
. O 0 6.0394711454137e-08
. O 0 7.373087669293454e-07

Two O 0 1.2800218200936797e-06
frequent O 0 4.888069611297396e-07
missense O 0 5.418219734565355e-05
mutations O 0 2.288859832333401e-05
in O 0 4.122360041947104e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.011243777349591255

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.0689897180782282e-06
an O 0 5.330255135049811e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 6.388284964486957e-05
by O 0 4.8610047542752e-08
early O 0 0.015090654604136944
childhood O 1 0.9999998807907104
deafness B-Disease 1 1.0
and O 1 0.9999960660934448
goiter B-Disease 1 1.0
. O 1 0.9965850114822388

A O 0 1.3880385267839301e-06
century O 0 2.6538697284195223e-07
after O 0 1.3892627492850806e-08
its O 0 3.4393601855420286e-10
recognition O 0 3.7030598587506347e-09
as O 0 5.933261437718329e-09
a O 0 8.305466536739914e-09
syndrome O 0 2.1256890647691762e-07
by O 0 2.9456825867413272e-09
Vaughan O 0 3.6826538689638255e-06
Pendred O 0 1.1457058462838177e-05
, O 0 4.932977137883654e-09
the O 0 7.809886959364576e-09
disease O 0 3.0578430454397676e-08
gene O 0 1.7277622887945654e-08
( O 0 4.386813401424661e-08
PDS O 0 1.8950468074763194e-05
) O 0 2.144676614079799e-08
was O 0 5.375543565833141e-08
mapped O 0 3.414460181261347e-08
to O 0 1.8079012065186362e-08
chromosome O 0 1.1591140491873375e-06
7q22 O 0 2.3038983272272162e-05
- O 0 1.7650567315286025e-05
q31 O 0 3.3686239476082847e-05
. O 0 7.1645554271526635e-06

1 O 0 7.214965535240481e-06
and O 0 6.491703175015573e-08
, O 0 9.434457659551754e-09
recently O 0 1.5616148374419936e-08
, O 0 1.730944276800983e-09
found O 0 1.1428454849138348e-09
to O 0 1.4591367003546907e-09
encode O 0 6.669993268815233e-08
a O 0 9.612560347704857e-08
putative O 0 4.377132427180186e-06
sulfate O 0 2.5153354727081023e-05
transporter O 0 0.00013944233069196343
. O 0 1.2543026969069615e-05

We O 0 2.877355029795581e-07
performed O 0 2.051200986841195e-08
mutation O 0 6.5889769196303405e-09
analysis O 0 9.977477510858535e-09
of O 0 1.38386244685762e-08
the O 0 1.5792091190292012e-08
PDS B-Disease 0 3.5652581118483795e-06
gene O 0 7.275603675083175e-09
in O 0 7.538548674190793e-10
patients O 0 8.796092187957072e-10
from O 0 2.0447701309933564e-09
14 O 0 7.729097717401601e-08
Pendred B-Disease 0 1.3480893130690674e-06
families O 0 7.466512963461014e-10
originating O 0 6.431456478495079e-10
from O 0 5.669053559920201e-10
seven O 0 1.5634796790564565e-09
countries O 0 2.3085794387256442e-10
and O 0 2.5953297289049715e-09
identified O 0 9.507111542461644e-09
all O 0 1.0263925709352861e-08
mutations O 0 3.891456685778394e-07
. O 0 8.522201824234799e-07

The O 0 4.964875301993743e-07
mutations O 0 1.5575238876408548e-07
include O 0 1.5223417193510613e-08
three O 0 9.599713024499579e-09
single O 0 5.944180703210122e-09
base O 0 2.6464185509667004e-08
deletions O 0 1.6130267965763778e-07
, O 0 1.1209488448571392e-08
one O 0 6.283301434706345e-09
splice O 0 1.8346163699334284e-07
site O 0 2.859185599390912e-08
mutation O 0 3.794617242647291e-08
and O 0 3.7665380148155236e-08
10 O 0 5.694275841960916e-07
missense O 0 3.2354844734072685e-05
mutations O 0 2.5581608497304842e-05
. O 0 3.161820495733991e-05

One O 0 1.168598487311101e-06
missense O 0 1.2119293387513608e-05
mutation O 0 5.002679586141312e-07
( O 0 5.5456631287142955e-08
L236P O 0 5.109309313411359e-07
) O 0 5.596654695239067e-09
was O 0 9.64949897763745e-09
found O 0 7.532511836494393e-10
in O 0 5.618792653372395e-10
a O 0 1.05507802494742e-09
homozygous O 0 1.1153504786420854e-08
state O 0 1.801800264544795e-09
in O 0 3.883787069725031e-09
two O 0 9.262095979067908e-09
consanguineous O 0 5.574891019932693e-07
families O 0 1.7908911020825258e-09
and O 0 1.741488286910453e-09
in O 0 1.3497434281362075e-09
a O 0 3.860758379659046e-09
heterozygous O 0 1.2257068249255099e-08
state O 0 2.415885491657832e-09
in O 0 3.563474182399773e-09
five O 0 1.6303333794098762e-08
additional O 0 3.07066621019203e-08
non O 0 3.734466190508101e-06
- O 0 5.095667802379467e-06
consanguineous O 0 1.4683102563139983e-05
families O 0 2.1733377764121542e-07
. O 0 2.252992089779582e-06

Another O 0 3.7550369142991258e-06
missense O 0 1.6512123693246394e-05
mutation O 0 5.642155542773253e-07
( O 0 9.929335931246897e-08
T416P O 0 7.966507382661803e-07
) O 0 8.58610960108308e-09
was O 0 1.6155862425648593e-08
found O 0 1.9671941853260932e-09
in O 0 9.704089753981293e-10
a O 0 1.6343987274680671e-09
homozygous O 0 9.365145992035195e-09
state O 0 5.985955064957693e-10
in O 0 1.1077895267774807e-09
one O 0 1.027477214421424e-09
family O 0 4.4895459572202867e-10
and O 0 7.333362805894694e-10
in O 0 1.069491939453826e-09
a O 0 1.8717005723090097e-09
heterozygous O 0 1.4130366210451939e-08
state O 0 2.592559056324717e-09
in O 0 9.667809663937987e-09
four O 0 6.607882596654235e-08
families O 0 9.757699359624894e-08
. O 0 1.5815971892152447e-06

Pendred B-Disease 0 0.0004215529770590365
patients O 0 4.225989300721267e-07
in O 0 2.465279891339378e-08
three O 0 5.325161822611335e-08
non O 0 2.3110901565814856e-06
- O 0 1.1798999821621692e-06
consanguineous O 0 6.320131546999619e-07
families O 0 1.2391659920396592e-09
were O 0 2.7227888832470626e-09
shown O 0 7.984893857226893e-10
to O 0 8.55357673579249e-10
be O 0 4.542998421896982e-09
compound O 0 1.4849925378257467e-07
heterozygotes O 0 2.886975210003584e-07
for O 0 1.7394576445894927e-08
L236P O 0 1.6479763189636287e-06
and O 0 1.4051771302092675e-07
T416P O 0 1.0992018360411748e-05
. O 0 2.474488383086282e-06

In O 0 9.00192773656272e-08
total O 0 1.9914622839678486e-08
, O 0 2.7826143611520138e-09
one O 0 5.396073032848392e-10
or O 0 3.2123365079073096e-10
both O 0 1.7205684099685925e-10
of O 0 4.920513996253817e-10
these O 0 9.456049138156786e-11
mutations O 0 1.0915096604335872e-09
were O 0 1.11117537393568e-09
found O 0 5.406292635790066e-10
in O 0 5.137353875639405e-10
nine O 0 5.9999041290836885e-09
of O 0 5.265016422839608e-09
the O 0 1.1925408216484357e-08
14 O 0 1.6053245133207383e-07
families O 0 1.3592047487520631e-08
analyzed O 0 4.293120525744598e-07
. O 0 1.3280097164170002e-06

The O 0 1.0694846963588134e-07
identification O 0 9.842035808560468e-08
of O 0 5.721614471099201e-08
two O 0 1.1589274429013585e-08
frequent O 0 2.6097813687897542e-08
PDS B-Disease 0 3.209072383469902e-05
mutations O 0 2.444584197291988e-07
will O 0 1.8196253392943618e-08
facilitate O 0 4.4316884384443256e-08
the O 0 1.746508715427808e-08
molecular O 0 2.8612478217837634e-06
diagnosis O 0 0.005994582083076239
of O 0 0.0015183737268671393
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0002953248913399875

Insertional O 0 0.0001266931794816628
mutation O 0 6.694872354273684e-07
by O 0 2.026778034291965e-08
transposable O 0 2.0677264274127083e-06
element O 0 3.446476171120594e-07
, O 0 4.7515072765236255e-08
L1 O 0 3.600681793614058e-06
, O 0 7.877944518952518e-09
in O 0 4.026024846837117e-09
the O 0 4.374096818082762e-08
DMD B-Disease 1 1.0
gene O 0 3.26667510819334e-08
results O 0 4.707333545184156e-08
in O 0 2.1845126596531372e-08
X B-Disease 1 0.9993187189102173
- I-Disease 1 0.990143895149231
linked I-Disease 0 0.000266255927272141
dilated I-Disease 0 0.0011130976490676403
cardiomyopathy I-Disease 1 1.0
. O 0 0.0029287110082805157

X B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999984502792358
linked I-Disease 0 0.3184732496738434
dilated I-Disease 1 0.9990171194076538
cardiomyopathy I-Disease 1 1.0
( O 0 0.11967018246650696
XLDCM B-Disease 1 0.9999992847442627
) O 0 3.722550090401455e-08
is O 0 1.634024693331071e-09
a O 0 2.574523705334286e-09
clinical O 0 1.9107672244444984e-07
phenotype O 0 6.978954729675024e-07
of O 0 2.19456310901478e-07
dystrophinopathy B-Disease 0 9.891595254885033e-06
which O 0 3.685542537823494e-09
is O 0 5.240258227345862e-10
characterized O 0 1.7130736829074067e-09
by O 0 9.663841948892582e-10
preferential O 0 1.1538087107965111e-07
myocardial B-Disease 0 0.00016356339619960636
involvement I-Disease 0 8.319565125702866e-08
without O 0 4.3482333289546204e-09
any O 0 1.1929293108892125e-09
overt O 0 1.3822321065504184e-08
clinical O 0 2.911594378929294e-07
signs O 0 1.1258383665335714e-06
of O 0 0.025034915655851364
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9743450284004211

To O 0 2.6514356932239025e-08
date O 0 1.2942925309289421e-07
, O 0 9.441005754950993e-10
several O 0 3.674555659749501e-10
mutations O 0 3.1886526752344935e-09
in O 0 3.1913178766274086e-09
the O 0 4.088012985903333e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.03296612203121185
, O 0 2.3341648557106964e-05
DMD O 1 1.0
, O 0 4.7972026351317254e-08
have O 0 1.315442310634296e-09
been O 0 1.7797696649779482e-09
identified O 0 3.409733828618755e-09
in O 0 7.12584713458142e-10
patients O 0 1.799725812823283e-09
with O 0 1.675571792425501e-09
XLDCM B-Disease 0 0.0036652267444878817
, O 0 7.669706647561725e-09
but O 0 1.7290437970274297e-09
a O 0 7.793841683145786e-10
pathogenic O 0 1.9402312645411257e-08
correlation O 0 4.845265966224588e-09
of O 0 3.038122198262272e-09
these O 0 9.86147608017518e-10
cardiospecific O 0 1.5276928877483442e-07
mutations O 0 2.8068429358540925e-08
in O 0 1.0524878746309696e-08
DMD O 1 1.0
with O 0 7.990077932618078e-09
the O 0 3.5646721130433434e-08
XLDCM B-Disease 0 0.00016888914979062974
phenotype O 0 1.740739463684804e-07
has O 0 9.66944635472089e-10
remained O 0 1.5799081154455052e-08
to O 0 2.0335650940950245e-09
be O 0 5.5319084424354514e-08
elucidated O 0 2.3826491087675095e-05
. O 0 4.380954123917036e-06

We O 0 1.7726038095133845e-06
report O 0 6.737954549862479e-08
here O 0 1.0159372898499441e-08
the O 0 1.485193634742643e-09
identification O 0 5.374649170164503e-09
of O 0 3.4622864575339918e-09
a O 0 2.7658935142227392e-09
unique O 0 1.6730306029444364e-08
de O 0 3.9821934478823096e-06
novo O 0 1.5969536661941675e-06
L1 O 0 4.5709193727816455e-06
insertion O 0 7.121097667095455e-08
in O 0 7.850270655751501e-09
the O 0 1.1540306488200258e-08
muscle O 0 7.68747483448351e-08
exon O 0 4.079651034771814e-07
1 O 0 2.025561371965523e-07
in O 0 1.5081857540621968e-08
DMD O 1 1.0
in O 0 1.2228952961379491e-08
three O 0 7.76482345088425e-09
XLDCM B-Disease 0 1.8247555999550968e-06
patients O 0 1.7526848861137978e-09
from O 0 6.833764110147911e-10
two O 0 1.9003745244106085e-09
unrelated O 0 3.8214984954265674e-08
Japanese O 0 2.2274670641309058e-07
families O 0 8.244720106631576e-08
. O 0 1.4165494803819456e-06

The O 0 7.214981110337249e-07
insertion O 0 5.703814736079948e-07
was O 0 1.555990110091443e-07
a O 0 1.404242855329585e-08
5 O 0 1.5733471059320436e-07
- O 0 2.345710647944088e-08
truncated O 0 1.3675729881867937e-08
form O 0 2.15378426204893e-09
of O 0 1.16916494263819e-08
human O 0 2.0233905217992287e-08
L1 O 0 8.769939086050726e-07
inversely O 0 9.089106356441334e-08
integrated O 0 2.750847905019782e-08
in O 0 6.998625012855086e-10
the O 0 1.5630979843805903e-09
5 O 0 2.980889846071477e-08
- O 0 2.6370415184828744e-08
untranslated O 0 5.097195412417932e-07
region O 0 5.312427386883201e-09
in O 0 7.944272462090396e-10
the O 0 2.1531763039206453e-09
muscle O 0 1.0439348052670994e-08
exon O 0 2.2096644514135733e-08
1 O 0 5.394305890860096e-09
, O 0 9.367422809658521e-11
which O 0 6.897783039194749e-11
affected O 0 3.531744063867137e-10
the O 0 2.5947097248568696e-10
transcription O 0 2.2749275796485335e-09
or O 0 8.16990142205043e-10
the O 0 1.0753665735663276e-09
stability O 0 3.1848735204675904e-08
of O 0 4.331256686640472e-09
the O 0 1.9559327490981104e-09
muscle O 0 7.67730323758542e-09
form O 0 1.9558999753144235e-08
of O 0 7.033518301113872e-08
dystrophin O 0 3.6066197139916767e-07
transcripts O 0 3.156950256766322e-08
but O 0 1.3638491724865531e-10
not O 0 5.2277866063876743e-11
that O 0 4.341955267550546e-11
of O 0 2.402261722878052e-09
the O 0 1.6716876771738498e-08
brain O 0 1.9868237359332852e-05
or O 0 1.9218933289266715e-07
Purkinje O 0 0.00026018026983365417
cell O 0 3.176961172357551e-06
form O 0 8.463177181283754e-08
, O 0 7.958533387864009e-09
probably O 0 1.593183540649079e-08
due O 0 2.5463855024554505e-08
to O 0 8.317590505235728e-10
its O 0 3.921494517999946e-10
unique O 0 2.8797519924239623e-09
site O 0 1.4171283702069104e-08
of O 0 3.348904087374649e-08
integration O 0 1.967466914720717e-06
. O 0 2.2524593532580184e-06

We O 0 3.2949856176855974e-07
speculate O 0 1.2124559134463198e-07
that O 0 3.614138710528181e-10
this O 0 2.2708643299118592e-10
insertion O 0 4.760621674648746e-09
of O 0 4.469350223246238e-09
an O 0 1.084801692918802e-09
L1 O 0 7.766016096866224e-07
sequence O 0 3.279285465396242e-08
in O 0 5.8719852091826397e-08
DMD O 1 1.0
is O 0 1.2251855530109879e-08
responsible O 0 8.946039464774458e-09
for O 0 3.6042052675711034e-10
some O 0 1.1840313451916273e-10
of O 0 1.0733297584053503e-09
the O 0 5.174526918061417e-10
population O 0 5.624505028389848e-11
of O 0 7.352943254268496e-10
Japanese O 0 3.195528464061681e-08
patients O 0 5.2686934814971664e-09
with O 0 4.949904486295509e-09
XLDCM B-Disease 0 3.1596475309925154e-05
. O 0 1.7958883802293713e-07
. O 0 1.4015784017828992e-06

Severe O 1 0.9745060205459595
early O 1 0.9980491399765015
- O 1 0.9999865293502808
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 2.8960943382116966e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9978359341621399
red O 1 0.9999855756759644
hair O 1 0.9997462630271912
pigmentation O 1 0.9790751338005066
caused O 0 2.594101943032001e-06
by O 0 1.208328086477195e-07
POMC O 0 0.0005586377810686827
mutations O 0 5.479872697833343e-07
in O 0 7.454282524577138e-08
humans O 0 1.146892259384913e-06
. O 0 2.013482799156918e-06

Sequential O 0 2.7193367714062333e-05
cleavage O 0 2.011425522141508e-06
of O 0 3.203786036465317e-07
the O 0 6.072946945323565e-08
precursor O 0 1.3679205324024224e-07
protein O 0 4.366911454667388e-08
pre O 0 1.151638002738764e-06
- O 0 4.6818092869216343e-07
pro O 0 1.254984726983821e-05
- O 0 2.9629943583131535e-06
opiomelanocortin O 0 5.647750185744371e-06
( O 0 6.555784182182833e-08
POMC O 0 9.08676338440273e-06
) O 0 6.8362839833469025e-09
generates O 0 1.3576526569636371e-08
the O 0 2.6750868187264132e-08
melanocortin O 0 8.51533332024701e-06
peptides O 0 2.4225897732321755e-07
adrenocorticotrophin O 0 9.674022294348106e-06
( O 0 1.4001621195802727e-07
ACTH O 0 7.812816875230055e-06
) O 0 6.613002057065387e-08
, O 0 9.458533156703197e-08
melanocyte O 0 0.00010620046668918803
- O 0 2.6979230824508704e-05
stimulating O 0 5.5899004109960515e-06
hormones O 0 2.726444563450059e-07
( O 0 4.18461745255172e-08
MSH O 0 8.066665031947196e-06
) O 0 4.982336765380069e-09
alpha O 0 5.829390659073397e-08
, O 0 1.0312349862928727e-09
beta O 0 2.9263139467161636e-08
and O 0 1.3509410257128707e-09
gamma O 0 3.738524512186814e-08
as O 0 4.620931692844721e-10
well O 0 1.877771410585538e-10
as O 0 2.575052671094369e-10
the O 0 1.3113115038265732e-09
opioid O 0 6.313565847904101e-08
- O 0 1.7595723988961254e-08
receptor O 0 4.086355431809352e-08
ligand O 0 1.724030056493575e-07
beta O 0 3.788925596381887e-06
- O 0 1.4696697689942084e-06
endorphin O 0 1.1515092410263605e-05
. O 0 1.605185161679401e-06

While O 0 4.901368697574071e-07
a O 0 1.75243837219341e-08
few O 0 8.548444618838857e-09
cases O 0 6.469069280257145e-09
of O 0 8.279388907794782e-08
isolated O 0 6.931602456461405e-06
ACTH B-Disease 1 0.8914498090744019
deficiency I-Disease 1 0.6447505354881287
have O 0 1.6667717872564936e-08
been O 0 2.8399238516385594e-08
reported O 0 5.576603712142969e-08
( O 0 8.89849616214633e-08
OMIM O 0 0.00010647545423125848
201400 O 0 4.424925009516301e-06
) O 0 2.11026289775873e-08
, O 0 6.359538229361306e-09
an O 0 7.413218039431513e-09
inherited O 0 0.01942855678498745
POMC O 1 1.0
defect O 0 0.08070868253707886
has O 0 3.329935793772165e-08
not O 0 1.4909277368246876e-08
been O 0 1.2766355084181669e-08
described O 0 1.4222082178605433e-08
so O 0 7.901194365445008e-09
far O 0 1.1678816491667021e-07
. O 0 1.4989249166319496e-06

Recent O 0 5.359092369872087e-07
studies O 0 7.988496264488276e-08
in O 0 7.356888431786501e-09
animal O 0 1.2092706391797492e-08
models O 0 4.679957044118055e-08
elucidated O 0 7.836030135877081e-07
a O 0 6.295597376748674e-09
central O 0 1.4462036901363717e-08
role O 0 2.2596589488443897e-08
of O 0 6.237321059643364e-08
alpha O 0 2.0627160211006412e-06
- O 0 4.520483969372435e-07
MSH O 0 8.8202496044687e-06
in O 0 1.9502555126393872e-09
the O 0 2.4828896716400095e-09
regulation O 0 6.555119558271372e-09
of O 0 1.5513924589427575e-09
food O 0 4.0152328684150973e-10
intake O 0 7.700455273429441e-10
by O 0 1.0030513225567361e-10
activation O 0 4.986871804391058e-09
of O 0 1.3647743379863186e-08
the O 0 2.2003781907642406e-08
brain O 0 7.008194984337024e-07
melanocortin O 0 4.2350734474894125e-06
- O 0 6.318227718793423e-08
4 O 0 8.149661567813382e-08
- O 0 2.6397136920763842e-08
receptor O 0 2.2506647212594544e-08
( O 0 8.168347775949769e-09
MC4 O 0 6.36120603303425e-06
- O 0 1.1722111281642356e-07
R O 0 8.040209564796896e-08
; O 0 3.0308526799416313e-09
refs O 0 1.312354669380511e-07
3 O 0 4.3412164529854635e-08
- O 0 5.699380967172374e-09
5 O 0 2.5656168300969284e-09
) O 0 1.256916098979488e-10
and O 0 3.1675442824230515e-10
the O 0 2.5103370493440025e-09
linkage O 0 5.6859526864627696e-08
of O 0 4.366594552607239e-08
human O 0 2.3666306958602945e-07
obesity B-Disease 1 0.8197467923164368
to O 0 2.2240354002889262e-09
chromosome O 0 1.141676175819839e-08
2 O 0 4.620566329549547e-08
in O 0 2.3019983697025737e-09
close O 0 1.3122753550476318e-08
proximity O 0 1.0600428090867808e-08
to O 0 2.025130951821552e-09
the O 0 1.6360369059498225e-08
POMC O 0 9.211136784870178e-06
locus O 0 1.1893406792751193e-07
, O 0 2.2529484944300293e-09
led O 0 2.15251105828429e-09
to O 0 4.5322207098408285e-10
the O 0 8.346768831657414e-10
proposal O 0 1.613300604219603e-09
of O 0 2.7985824768705925e-09
an O 0 1.3723304714829965e-09
association O 0 1.2731485199424242e-08
of O 0 2.3386148484405567e-07
POMC O 1 0.995388388633728
with O 0 1.0975257964673801e-06
human O 0 0.03394731134176254
obesity B-Disease 1 1.0
. O 0 3.687235584948212e-05

The O 0 2.048968781309668e-07
dual O 0 2.8881095204269513e-07
role O 0 6.002287022965902e-08
of O 0 2.870765740681236e-07
alpha O 0 2.6750041797640733e-05
- O 0 5.812929884996265e-06
MSH O 0 0.0002535646199248731
in O 0 2.9161173031866383e-08
regulating O 0 7.080818420490687e-08
food O 0 1.3536112675183176e-08
intake O 0 4.6166903189259756e-08
and O 0 1.988516906692439e-08
influencing O 0 7.574625669803936e-06
hair O 0 0.0002488179598003626
pigmentation O 0 6.287876749411225e-05
predicts O 0 5.5691529610157886e-08
that O 0 3.6780548051673634e-10
the O 0 1.758692413922347e-09
phenotype O 0 5.287128601594304e-08
associated O 0 6.109402317377999e-09
with O 0 9.162202663226537e-10
a O 0 5.751152443167484e-09
defect O 0 2.485564039034216e-07
in O 0 1.097363835356191e-07
POMC O 0 0.005419173277914524
function O 0 3.2489541013092094e-07
would O 0 9.389416355531921e-09
include O 0 6.907377780862589e-08
obesity B-Disease 1 1.0
, O 0 1.6327295071505432e-08
alteration O 0 8.684852446094737e-07
in O 0 8.146832897182321e-08
pigmentation O 1 0.9991948008537292
and O 0 1.804746534617152e-05
ACTH B-Disease 1 0.999863862991333
deficiency I-Disease 1 0.9997223019599915
. O 0 2.5070517949643545e-05

The O 0 3.850692849027837e-07
observation O 0 9.488144883107452e-07
of O 0 4.6051514601685994e-08
these O 0 7.210068098117972e-09
symptoms O 0 6.127248184384371e-07
in O 0 1.0609713108067353e-08
two O 0 1.9122358807521778e-08
probands O 0 1.3878400295652682e-06
prompted O 0 3.3397441256965976e-08
us O 0 1.6003093294969517e-09
to O 0 7.616899333484639e-10
search O 0 1.3983707525255795e-08
for O 0 1.3778592711233273e-09
mutations O 0 1.3886163330312229e-08
within O 0 2.9781054067257173e-08
their O 0 1.0512703596532447e-07
POMC O 0 7.844566425774246e-05
genes O 0 2.0299289644754026e-06
. O 0 2.9935388283774955e-06

Patient O 0 5.735184913646663e-06
1 O 0 2.1968153305351734e-06
was O 0 8.522871297600432e-08
found O 0 2.1630883750844987e-09
to O 0 9.762456398831887e-10
be O 0 1.112965608562888e-09
a O 0 1.989008957536953e-09
compound O 0 2.7579350359019372e-08
heterozygote O 0 9.146635449042151e-08
for O 0 7.146154223924839e-10
two O 0 4.805907338756299e-10
mutations O 0 1.145363803800592e-09
in O 0 1.498350443718266e-09
exon O 0 5.0498080383931665e-08
3 O 0 7.155298931138532e-08
( O 0 2.853137281988438e-09
G7013T O 0 5.141250980500445e-08
, O 0 2.117511277432982e-09
C7133delta O 0 3.084281843257486e-07
) O 0 9.296125536017996e-10
which O 0 4.467626546489356e-10
interfere O 0 2.5473898546124474e-09
with O 0 5.071075226403821e-10
appropriate O 0 1.3013531585670535e-08
synthesis O 0 8.62346780650114e-08
of O 0 6.675529817812276e-08
ACTH O 0 6.113745712355012e-06
and O 0 7.061584597067849e-07
alpha O 0 9.747929289005697e-05
- O 0 2.455092362652067e-05
MSH O 0 0.0007047054241411388
. O 0 3.0191990845196415e-06

Patient O 0 5.354971563065192e-06
2 O 0 2.9966809051984455e-06
was O 0 2.7415802605901263e-07
homozygous O 0 4.012243692841366e-08
for O 0 2.397190224101564e-09
a O 0 1.9225261382871395e-09
mutation O 0 8.296457743028895e-09
in O 0 6.462878232582625e-09
exon O 0 1.7486829051449604e-07
2 O 0 4.305502727675048e-07
( O 0 2.3140527716236647e-08
C3804A O 0 4.0130171896635147e-07
) O 0 6.350434844648589e-09
which O 0 2.3104716362354338e-08
abolishes O 0 5.535197942663217e-06
POMC O 0 0.00012683241220656782
translation O 0 1.0656617632776033e-05
. O 0 7.489463769161375e-06

These O 0 1.707093275626903e-07
findings O 0 4.355955240953335e-08
represent O 0 6.9972800886830555e-09
the O 0 2.6014106424554484e-09
first O 0 1.318982145726011e-09
examples O 0 2.2259960541504142e-09
of O 0 5.906050759563186e-09
a O 0 1.49173846608619e-08
genetic B-Disease 1 0.999933123588562
defect I-Disease 1 0.9608253836631775
within O 0 1.3014479804951407e-07
the O 0 3.8103554089730096e-08
POMC O 0 9.204840353049804e-06
gene O 0 1.3969126300139578e-08
and O 0 2.5091260180687414e-09
define O 0 2.715555247334578e-08
a O 0 7.828067083437418e-09
new O 0 2.397365790329786e-07
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 1.0
disorder I-Disease 0 0.00766302365809679
resulting O 0 1.593006402345054e-07
in O 0 1.5416382836974662e-08
early O 0 0.00043262692634016275
- O 1 0.9991148114204407
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0005175762926228344
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9988107681274414
red O 1 0.9992184638977051
hair O 1 0.9454783201217651
pigmentation O 0 0.05073536932468414
. O 0 1.0672599728422938e-06
. O 0 2.9581267426692648e-06

A O 0 4.0834838728187606e-06
European O 0 4.841655936616007e-06
multicenter O 0 0.00012179515033494681
study O 0 3.0276765983217047e-07
of O 0 4.5544606109615415e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.2036242935664632e-07
classification O 0 3.492206701594114e-08
of O 0 2.0056733163187346e-08
105 O 0 6.67584743041516e-08
mutations O 0 7.612895203124026e-09
and O 0 2.138972554632801e-09
a O 0 3.1250408927263607e-09
general O 0 5.683781445497971e-09
system O 0 1.3289120914805608e-08
for O 0 2.648815833339313e-09
genotype O 0 8.267601003808522e-08
- O 0 2.7010603531607558e-08
based O 0 1.7053473078121328e-09
prediction O 0 2.606709870178747e-07
of O 0 2.1154096430109348e-07
metabolic O 0 0.04527029022574425
phenotype O 0 1.718608291412238e-05
. O 0 2.8703216230496764e-06

Phenylketonuria B-Disease 1 0.9995805621147156
( O 0 8.225404599215835e-06
PKU B-Disease 0 0.00338749960064888
) O 0 1.9676497231557732e-07
and O 0 2.7858507678502065e-07
mild B-Disease 1 0.9995372295379639
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.46129369735717773
MHP B-Disease 1 1.0
) O 0 2.116860571277357e-07
are O 0 3.803210546493574e-08
allelic B-Disease 0 0.0003439286374486983
disorders I-Disease 0 2.951872556877788e-05
caused O 0 2.3414060024151695e-08
by O 0 5.887197396248212e-10
mutations O 0 1.7542935992764797e-09
in O 0 1.2927555692598958e-09
the O 0 7.991449280098095e-09
gene O 0 3.565120820780976e-08
encoding O 0 1.4719812497787643e-06
phenylalanine O 0 5.934452019573655e-06
hydroxylase O 0 3.8707734347553924e-05
( O 0 5.905935154260078e-07
PAH O 0 0.0002290679549332708
) O 0 1.9101440784652368e-07
. O 0 1.4325230495160213e-06

Previous O 0 1.8338324707656284e-06
studies O 0 6.416415487819904e-08
have O 0 1.2928911274912025e-09
suggested O 0 4.373952755543087e-09
that O 0 1.4919501745147556e-10
the O 0 1.1252775378167712e-09
highly O 0 1.5658320862144137e-08
variable O 0 8.519358516423381e-07
metabolic O 0 0.008848409168422222
phenotypes O 0 6.641577056143433e-05
of O 0 0.001459688413888216
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9977340698242188
correlate O 0 2.0165305159025593e-06
with O 0 1.0000112524721771e-06
PAH O 1 0.9999767541885376
genotypes O 0 0.00028908945387229323
. O 0 6.747368843207369e-06

We O 0 8.075318191913539e-07
identified O 0 1.4890326838212786e-07
both O 0 1.6148653969594307e-08
causative O 0 3.345192567394406e-07
mutations O 0 9.505011178134737e-08
in O 0 3.351575017518371e-08
686 O 0 1.8012293594438233e-06
patients O 0 2.7346933606509083e-08
from O 0 2.6177179535125106e-08
seven O 0 3.6205386777510284e-07
European O 0 3.6083472423342755e-06
centers O 0 8.262412620752002e-07
. O 0 1.63454819812614e-06

On O 0 1.4614807923862827e-06
the O 0 2.2570183944026212e-08
basis O 0 3.645970636512175e-08
of O 0 5.749924092413039e-09
the O 0 5.90500315311715e-09
phenotypic O 0 8.386134027205117e-07
characteristics O 0 1.2282768580007541e-07
of O 0 1.0912567205423329e-07
297 O 0 7.595332931487064e-07
functionally O 0 3.825429928383528e-07
hemizygous O 0 8.350405664714344e-07
patients O 0 8.74640804227056e-09
, O 0 3.0821889485110887e-09
105 O 0 2.4992115044142338e-08
of O 0 4.208001946892637e-09
the O 0 2.210388316825629e-09
mutations O 0 4.242009410404535e-09
were O 0 3.1937414934901653e-09
assigned O 0 1.148658612670772e-09
to O 0 3.4507541268880004e-10
one O 0 6.103318961336868e-10
of O 0 5.7286984045390454e-09
four O 0 1.680350791843921e-08
arbitrary O 0 7.526515588551774e-08
phenotype O 0 9.76682144937513e-07
categories O 0 7.360954441537615e-07
. O 0 2.4053590550465742e-06

We O 0 7.680087037442718e-07
proposed O 0 1.3047423408352188e-07
and O 0 1.4173798135175275e-08
tested O 0 1.6293945748202532e-08
a O 0 7.895525899748179e-10
simple O 0 2.696714407335321e-09
model O 0 3.923778635339659e-09
for O 0 4.674055587017278e-10
correlation O 0 8.89630236144967e-09
between O 0 4.696282474014879e-09
genotype O 0 6.772705063440299e-08
and O 0 1.2236675672738784e-08
phenotypic O 0 3.018778670593747e-06
outcome O 0 3.954007752327016e-06
. O 0 3.485822844595532e-06

The O 0 1.4034603736945428e-06
observed O 0 1.6930185893215821e-06
phenotype O 0 1.5457509334737551e-06
matched O 0 1.331500385504114e-07
the O 0 2.8632133108885682e-08
predicted O 0 1.9233308989896614e-07
phenotype O 0 5.3977874614474786e-08
in O 0 1.1688455758829264e-09
79 O 0 1.0143341278023854e-08
% O 0 2.705166646244095e-10
of O 0 6.993167156466029e-10
the O 0 5.078344966769066e-10
cases O 0 4.4331890936000207e-10
, O 0 1.420544792907208e-10
and O 0 1.2415359018635996e-10
in O 0 1.1870975036298859e-10
only O 0 1.2459197562542101e-10
5 O 0 4.5194297193518196e-09
of O 0 2.2261488208386027e-09
184 O 0 1.0719758414268199e-08
patients O 0 1.8162297221735457e-09
was O 0 1.0609955580775932e-08
the O 0 5.719898332756657e-09
observed O 0 2.7306381156222415e-08
phenotype O 0 1.550053418952757e-08
more O 0 1.9600435163802388e-10
than O 0 3.667036119203715e-10
one O 0 4.086102012301751e-10
category O 0 3.3058045190159646e-09
away O 0 1.8559062064937848e-09
from O 0 4.5999412612296453e-10
that O 0 1.0647210890724068e-09
expected O 0 1.1924684883979353e-07
. O 0 7.249508371387492e-07

Among O 0 6.990912311266584e-07
the O 0 1.0910360970228794e-07
seven O 0 2.6924293905494778e-08
contributing O 0 1.3795614428602221e-08
centers O 0 5.476223918776668e-09
, O 0 6.325456269884455e-10
the O 0 5.95811677772673e-10
proportion O 0 8.770961734683169e-10
of O 0 1.4283757510114015e-09
patients O 0 5.327696062096265e-10
for O 0 5.307371209184453e-10
whom O 0 6.631275972779349e-09
the O 0 6.343014113951995e-09
observed O 0 7.163120319120253e-09
phenotype O 0 1.5413796461416496e-08
did O 0 1.915348546432938e-09
not O 0 1.2026272200316157e-09
match O 0 1.209272255664473e-07
the O 0 1.188911546989857e-08
predicted O 0 5.9005021313396355e-08
phenotype O 0 7.966311699192374e-08
was O 0 2.0589386195979387e-08
4 O 0 2.341401561523071e-08
% O 0 1.4673280368526775e-09
- O 0 6.372894656436756e-09
23 O 0 9.002886436348945e-09
% O 0 1.7789074657770243e-09
( O 0 5.298836480704949e-09
P O 0 2.294238129252335e-06
< O 0 3.4457431752343837e-07
. O 0 1.6689956083837387e-08
0001 O 0 2.9022323360550217e-05
) O 0 3.0212023993669845e-09
, O 0 3.594909092630161e-10
suggesting O 0 1.7361421189576731e-09
that O 0 2.110868563276469e-10
differences O 0 4.009717002873003e-09
in O 0 3.7900205196450543e-10
methods O 0 3.921915681104338e-09
used O 0 7.282485725568222e-10
for O 0 5.680396708562796e-10
mutation O 0 2.753567152069536e-08
detection O 0 6.465630235652498e-07
or O 0 6.653462492067774e-08
phenotype O 0 7.993616009116522e-07
classification O 0 7.998178119805743e-08
may O 0 4.5501264978042855e-09
account O 0 7.44806494257233e-10
for O 0 2.1778208403322452e-10
a O 0 2.779144137043943e-10
considerable O 0 2.1052566356871694e-09
proportion O 0 5.6289968242140276e-09
of O 0 6.807478314385662e-08
genotype O 0 6.590263637917815e-06
- O 0 4.001737579528708e-06
phenotype O 0 4.154582256887807e-06
inconsistencies O 0 5.9473468354553916e-06
. O 0 2.2390734102373244e-06

Our O 0 3.280022610852029e-06
data O 0 2.4985450863823644e-07
indicate O 0 2.581650271338276e-08
that O 0 5.995705265604556e-09
the O 0 1.2863443998867297e-07
PAH O 1 0.6346946358680725
- O 0 1.4953097604575305e-07
mutation O 0 9.50232514895788e-09
genotype O 0 2.050543912446301e-08
is O 0 3.2291808116369225e-10
the O 0 1.1596211768605258e-09
main O 0 2.0221596841452083e-08
determinant O 0 4.2268882793905505e-07
of O 0 9.224177688338386e-08
metabolic O 0 5.18307278980501e-05
phenotype O 0 3.0555466423720645e-07
in O 0 9.233010800357988e-09
most O 0 1.1827459012181407e-08
patients O 0 2.8720526756842446e-07
with O 0 9.568843779561576e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0001172689298982732

In O 0 2.518232520287711e-07
the O 0 2.889822603435732e-08
present O 0 5.717433193552779e-09
study O 0 1.4181118501710444e-09
, O 0 3.036417228763355e-10
the O 0 4.680389409372765e-10
classification O 0 3.6225602517703237e-09
of O 0 1.3469049875425299e-08
105 O 0 6.169289008539636e-07
PAH O 0 0.00124633579980582
mutations O 0 1.2358716716676099e-08
may O 0 2.4222852612609813e-09
allow O 0 1.5927664742676484e-09
the O 0 2.97444824326476e-09
prediction O 0 3.7812082354093945e-08
of O 0 3.9631387060978795e-09
the O 0 3.6606646602876936e-09
biochemical O 0 5.551950010840301e-08
phenotype O 0 5.866522556630116e-08
in O 0 3.5570770773318827e-09
> O 0 1.43929028695311e-07
10 O 0 1.3884627669824567e-08
, O 0 2.580841540478218e-09
000 O 0 2.523708531043667e-08
genotypes O 0 1.398061897361913e-07
, O 0 1.8534829226979355e-09
which O 0 5.185642470983964e-10
may O 0 1.2640209989811524e-09
be O 0 5.568403516065246e-10
useful O 0 1.90198456984092e-09
for O 0 2.716609159847394e-10
the O 0 2.1917276882277292e-09
management O 0 2.1418642859316606e-08
of O 0 3.103616563748801e-08
hyperphenylalaninemia B-Disease 1 0.9999938011169434
in O 0 1.3479372285019053e-07
newborns O 0 7.25401775980572e-07
. O 0 1.332382339569449e-06

Somatic O 0 7.014536095084623e-05
instability O 0 5.10188692715019e-06
of O 0 6.334771001093031e-07
the O 0 2.500261189197772e-07
CTG O 0 5.489906106959097e-05
repeat O 0 5.316931037668837e-07
in O 0 2.3416337313619806e-08
mice O 0 7.06576201991993e-08
transgenic O 0 1.110625476030691e-07
for O 0 9.871567563379813e-09
the O 0 1.3011556802666746e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.771810386548168e-06
is O 0 1.872718424777986e-09
age O 0 2.7833255700215886e-09
dependent O 0 7.955341940757421e-10
but O 0 1.4308154661080152e-10
not O 0 2.5401303282990284e-10
correlated O 0 7.95424948130119e-10
to O 0 1.6154984294747265e-10
the O 0 2.2674073729689326e-09
relative O 0 1.7149388042980718e-07
intertissue O 0 1.8997503730133758e-06
transcription O 0 1.956187958285227e-07
levels O 0 2.7230612431594636e-07
and O 0 1.8920863453786296e-07
proliferative O 0 0.0011296354932710528
capacities O 0 6.692419265164062e-05
. O 0 4.852046913583763e-06

A O 0 2.004213456530124e-05
( O 0 1.3082589020996238e-06
CTG O 0 5.75299454794731e-05
) O 0 4.432821398836495e-08
nexpansion O 0 4.072156798429205e-07
in O 0 2.720489167273854e-09
the O 0 6.667739693710928e-09
3 O 0 1.1397315091699056e-07
- O 0 6.603875846167284e-08
untranslated O 0 2.278710326208966e-06
region O 0 3.450086438760991e-08
( O 0 1.2625422485257332e-08
UTR O 0 3.2270647807308706e-06
) O 0 3.3285754152956315e-09
of O 0 1.251799908175144e-08
the O 0 8.318993849343315e-08
DM O 1 0.9999988079071045
protein O 0 7.857629213958717e-08
kinase O 0 4.742389592138352e-08
gene O 0 6.266629437590154e-09
( O 0 2.331449255876805e-09
DMPK O 0 1.6450790099042933e-06
) O 0 1.840374963535396e-09
is O 0 3.1269056788296723e-10
responsible O 0 6.513107386751926e-09
for O 0 2.5891953470136286e-08
causing O 1 0.999920129776001
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999759197235107
DM B-Disease 1 1.0
) O 0 2.591883685454377e-06
. O 0 3.23653944178659e-06

Major O 0 8.982203326013405e-06
instability O 0 1.0738526725617703e-05
, O 0 3.0182373933484996e-08
with O 0 2.5923712065889504e-09
very O 0 2.937446286210843e-09
large O 0 2.5934938641114513e-09
expansions O 0 1.233836677272393e-08
between O 0 2.6856117329998597e-09
generations O 0 2.7505895339174913e-09
and O 0 5.732772589972512e-10
high O 0 4.731671499058621e-09
levels O 0 4.096310846080087e-09
of O 0 5.0063611034545374e-09
somatic O 0 8.923145742301131e-07
mosaicism O 0 2.3425641302310396e-06
, O 0 1.973711194480643e-09
is O 0 4.162451772149467e-10
observed O 0 7.267033197422279e-09
in O 0 4.555718913223927e-09
patients O 0 7.168973326088235e-08
. O 0 1.014171516544593e-06

There O 0 1.716674944418628e-07
is O 0 3.009837046263897e-09
a O 0 1.9685379992750995e-09
good O 0 1.04981525694825e-08
correlation O 0 1.1547836464842476e-08
between O 0 6.029364119086722e-09
repeat O 0 2.387923103697176e-08
size O 0 7.924271017145657e-09
( O 0 1.5281591547733342e-09
at O 0 3.934487846635193e-09
least O 0 6.139069252952822e-10
in O 0 4.455925350921319e-10
leucocytes O 0 1.559295412789652e-07
) O 0 8.615436142278554e-10
, O 0 3.462403697085392e-10
clinical O 0 1.1421836809688557e-08
severity O 0 3.423230765520202e-08
and O 0 2.782847952076395e-09
age O 0 4.6190685054625646e-08
of O 0 1.1237322183887954e-07
onset O 0 0.0001619470858713612
. O 0 2.3786940346326446e-06

The O 0 1.678275475569535e-05
trinucleotide O 0 0.0007157996878959239
repeat O 0 7.557943717984017e-06
instability O 0 8.773194167588372e-06
mechanisms O 0 0.00013748541823588312
involved O 0 1.2746735933433229e-07
in O 0 6.286096976282352e-08
DM B-Disease 1 1.0
and O 0 4.0336294659937266e-07
other O 0 2.152200018201711e-08
human O 0 9.012722330226097e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 3.5336999992807705e-09
unknown O 0 4.0007319057622226e-07
. O 0 9.210164080286631e-07

We O 0 1.0442911388963694e-06
studied O 0 1.0214066605840344e-06
somatic O 0 1.4901692111379816e-06
instability O 0 3.1745489081913547e-07
by O 0 1.1210109285286762e-08
measuring O 0 2.093610646625166e-06
the O 0 9.556566027413282e-08
CTG O 0 1.2038292879879009e-05
repeat O 0 1.1782476860844326e-07
length O 0 1.0554348506275346e-08
at O 0 9.36125310602165e-09
several O 0 2.745613736365726e-10
ages O 0 3.165939288507502e-09
in O 0 1.9509502346970464e-10
various O 0 2.8268426488509135e-10
tissues O 0 3.854562891092428e-09
of O 0 1.3236578944031407e-08
transgenic O 0 7.806435320389937e-08
mice O 0 2.2814118594283173e-08
carrying O 0 1.1400898003444127e-08
a O 0 1.231703894433167e-08
( O 0 3.2861859011745764e-08
CTG O 0 1.42125454658526e-05
) O 0 2.129277731910406e-08
55expansion O 0 5.991449825160089e-07
surrounded O 0 6.211617176177242e-08
by O 0 1.8744907848144976e-09
45 O 0 1.5024435029431515e-08
kb O 0 2.136583816536586e-06
of O 0 8.692179420677348e-08
the O 0 1.6395598834151315e-07
human O 0 3.009620286320569e-06
DM B-Disease 1 1.0
region O 0 1.386750909659895e-07
, O 0 7.116709443977243e-09
using O 0 9.48736644801329e-09
small O 0 4.7722608087497065e-08
- O 0 4.545873650840804e-07
pool O 0 6.789719009248074e-07
PCR O 0 2.2556557723873993e-06
. O 0 9.645791578805074e-07

These O 0 4.696034068274457e-07
mice O 0 3.5826130329041916e-07
have O 0 2.6483459869552917e-09
been O 0 1.7830382725847471e-09
shown O 0 8.723146649458613e-10
to O 0 6.999025248255464e-10
reproduce O 0 3.327243902617738e-08
the O 0 5.589848139919695e-09
intergenerational O 0 9.109221821290703e-08
and O 0 5.457017504539863e-09
somatic O 0 3.5361026107239013e-07
instability O 0 1.683196870772008e-07
of O 0 5.743197561969282e-08
the O 0 3.665487469106665e-08
55 O 0 2.665517229161196e-07
CTG O 0 7.673727850487921e-06
repeat O 0 1.2773764979101543e-07
suggesting O 0 8.576615861954906e-09
that O 0 4.385328489231455e-10
surrounding O 0 6.541343466892613e-09
sequences O 0 6.280366449118446e-09
and O 0 3.7995184776207225e-09
the O 0 5.211673759220048e-09
chromatin O 0 6.162702703704781e-08
environment O 0 3.061449760366486e-08
are O 0 7.071350172083157e-10
involved O 0 5.345787368327137e-09
in O 0 5.885471221489524e-09
instability O 0 1.760828354235855e-06
mechanisms O 0 0.0006731920875608921
. O 0 4.720168362837285e-06

As O 0 2.0438010039924848e-07
observed O 0 4.145334031591119e-08
in O 0 2.4749697846715435e-09
some O 0 7.187093697957891e-10
of O 0 3.5770937323320595e-09
the O 0 3.824391470175215e-09
tissues O 0 1.0948258477583295e-07
of O 0 1.4345832823892124e-06
DM B-Disease 1 1.0
patients O 0 6.624224369033982e-08
, O 0 1.0542392514523158e-09
there O 0 5.85850978840341e-10
is O 0 1.3620632399735655e-10
a O 0 2.0448161219821515e-10
tendency O 0 6.036920963126136e-10
for O 0 4.60727317408427e-10
repeat O 0 6.967860510798118e-09
length O 0 7.661855150331576e-09
and O 0 5.3827946544515726e-09
somatic O 0 2.7634436605694646e-07
mosaicism O 0 4.253889756000717e-07
to O 0 3.814627502762846e-10
increase O 0 2.5939478343062206e-10
with O 0 1.42356376686692e-10
the O 0 1.5305394729381305e-09
age O 0 1.7458992473962098e-08
of O 0 1.0454193066777862e-08
the O 0 3.18151016642787e-08
mouse O 0 7.840388320801139e-07
. O 0 4.876838488598878e-07

Furthermore O 0 3.435480493862997e-06
, O 0 2.2883805073092844e-08
we O 0 6.9664385371481785e-09
observed O 0 5.797100133264621e-09
no O 0 9.806743195284184e-10
correlation O 0 3.432519823931557e-09
between O 0 1.044776931635738e-09
the O 0 3.1139084644138393e-09
somatic O 0 2.863929466911941e-07
mutation O 0 5.25866674649933e-08
rate O 0 4.5445428753509987e-08
and O 0 2.2340699956657772e-08
tissue O 0 1.1275726592430146e-06
proliferation O 0 8.793675078777596e-06
capacity O 0 4.348092716099927e-06
. O 0 1.9253527625551214e-06

The O 0 2.0021930140501354e-06
somatic O 0 3.270273737143725e-05
mutation O 0 2.200471129754078e-07
rates O 0 1.0522368754095623e-08
in O 0 3.469668996558539e-10
different O 0 3.293637029777585e-10
tissues O 0 7.490823072942021e-09
were O 0 1.716170761056901e-09
also O 0 2.3267969495588403e-10
not O 0 8.724755640177051e-11
correlated O 0 9.310179294175214e-10
to O 0 1.670169003098465e-10
the O 0 1.8252171996024913e-09
relative O 0 1.979224180104211e-07
inter O 0 0.0026073073968291283
- O 0 6.532717833351853e-08
tissue O 0 5.576941575213823e-09
difference O 0 4.858137891972092e-09
in O 0 4.3097789226287375e-10
transcriptional O 0 6.932267204717846e-09
levels O 0 1.2387028069937855e-09
of O 0 5.228836252868518e-10
the O 0 3.336633469519512e-10
three O 0 3.4336578025317976e-10
genes O 0 2.0626125252221073e-09
( O 0 2.9210092122866627e-09
DMAHP O 0 1.9114575025014346e-06
, O 0 1.7790984685461808e-08
DMPK O 0 2.5809322323766537e-06
and O 0 2.3759019640579027e-08
59 O 0 1.104107454352743e-07
) O 0 6.034161614820732e-09
surrounding O 0 2.2053150416923017e-08
the O 0 1.5385129614742254e-08
repeat O 0 1.924022399180103e-07
. O 0 8.143865670717787e-08
. O 0 9.483684948463633e-07

A O 0 1.9446606529527344e-06
novel O 0 7.988326728991524e-07
missense O 0 5.160224645806011e-06
mutation O 0 1.5510995865497534e-07
in O 0 7.794604073296796e-09
patients O 0 1.2795461579173661e-08
from O 0 5.966375837829219e-09
a O 0 4.895412430983015e-08
retinoblastoma B-Disease 0 0.020725565031170845
pedigree O 0 1.7823253983806353e-06
showing O 0 1.8304307047856128e-07
only O 0 2.0415834356413143e-08
mild O 0 3.7410961795103503e-07
expression O 0 2.8995122747232926e-08
of O 0 2.676301491533195e-08
the O 0 2.2411207112327247e-08
tumor B-Disease 0 1.1064133786931052e-06
phenotype O 0 2.3253010112966876e-06
. O 0 2.1071734863653546e-06

We O 0 3.819335177013272e-07
have O 0 5.6737947673468625e-09
used O 0 6.1530456285652235e-09
single O 0 1.5749616721905113e-08
strand O 0 6.98193787229684e-08
conformation O 0 2.3256854220221612e-08
polymorphism O 0 1.3731454195919923e-08
analysis O 0 2.6127979779744237e-09
to O 0 3.261741154947373e-10
study O 0 8.11362421693218e-10
the O 0 1.8033611270951155e-09
27 O 0 5.262780433668013e-08
exons O 0 8.798046025049189e-08
of O 0 1.084471268342213e-08
the O 0 5.327871921423366e-09
RB1 O 0 9.84513235380291e-07
gene O 0 2.417858580017196e-09
in O 0 5.218036558396477e-10
individuals O 0 1.9050548638599452e-10
from O 0 7.778307997696743e-10
a O 0 2.443892421766236e-09
family O 0 2.7615603137576272e-09
showing O 0 4.223426941507569e-08
mild O 0 1.7607292193133617e-06
expression O 0 3.550965459453437e-07
of O 0 7.866601663408801e-07
the O 0 8.985911676973046e-07
retinoblastoma B-Disease 0 0.0012860995484516025
phenotype O 0 2.2419804736273363e-05
. O 0 2.6631366836227244e-06

In O 0 1.0942748218667475e-07
this O 0 6.035462352116383e-09
family O 0 6.010751008034276e-09
affected O 0 2.811867627627862e-09
individuals O 0 3.737494203015501e-10
developed O 0 3.323489039530614e-08
unilateral B-Disease 0 6.106974524300313e-06
tumors I-Disease 1 1.0
and O 0 3.7289071315171896e-06
, O 0 1.5282706655739275e-08
as O 0 1.562776019703449e-09
a O 0 5.767429867020724e-10
result O 0 2.7077697861699335e-09
of O 0 6.893910775573886e-09
linkage O 0 4.811121101511162e-08
analysis O 0 5.386923351835549e-09
, O 0 1.5442097600626425e-09
unaffected O 0 2.090412998256852e-08
mutation O 0 2.727846615258045e-09
carriers O 0 1.2674975513604636e-09
were O 0 4.824019850246941e-09
also O 0 2.209511684725385e-09
identified O 0 1.6386634271725598e-08
within O 0 2.1864552834927053e-08
the O 0 5.4059679399642846e-08
pedigree O 0 2.0998213585698977e-06
. O 0 3.485510433165473e-06

A O 0 7.753088766548899e-07
single O 0 4.502335926304113e-08
band O 0 7.625992282100924e-08
shift O 0 5.0418293540133163e-08
using O 0 2.224927442284752e-08
SSCP O 0 6.2428593992081005e-06
was O 0 5.9093437698720663e-08
identified O 0 1.1809020428188433e-08
in O 0 1.8990626848847114e-09
exon O 0 5.809776837395475e-08
21 O 0 1.4448526819421659e-08
which O 0 4.517410889803841e-10
resulted O 0 1.2606075294741004e-08
in O 0 1.4887444610423017e-09
a O 0 6.400327379196824e-09
missense O 0 4.385813667795446e-07
mutation O 0 6.724268786229004e-08
converting O 0 5.467568371386733e-07
a O 0 1.986074522619674e-07
cys O 0 0.00022222238476388156
- O 0 1.254848302778555e-05
- O 0 2.698352318475372e-06
> O 0 1.9310843981656944e-06
arg O 0 1.714534619168262e-06
at O 0 6.168912136672589e-08
nucleotide O 0 1.08745394911125e-08
position O 0 5.3218315088088275e-08
28 O 0 1.410913625932153e-07
in O 0 1.6112256417954995e-08
the O 0 1.4183551400037686e-07
exon O 0 5.718532520404551e-06
. O 0 2.3197592327051098e-06

The O 0 4.837497726839501e-07
mutation O 0 2.528402092139004e-07
destroyed O 0 1.49193817833293e-06
an O 0 1.3951684252333507e-08
NdeI O 0 3.466231191850966e-06
restriction O 0 1.1975490110671672e-07
enzyme O 0 3.6521379342957516e-07
site O 0 3.44074209124301e-07
. O 0 8.534035487173242e-07

Analysis O 0 6.565093713106762e-07
of O 0 2.0288361213260941e-07
all O 0 1.5820610599348583e-08
family O 0 2.1030051033932295e-09
members O 0 1.1073142403006386e-09
demonstrated O 0 6.632819182783578e-09
that O 0 5.095799893162223e-10
the O 0 1.740884769674267e-08
missense O 0 6.9417833401530515e-06
mutation O 0 4.291108780307695e-06
co O 0 6.0770835261791945e-05
- O 0 9.447468619327992e-05
segregated O 0 1.2133315863138705e-07
with O 0 2.7880013853121e-09
patients O 0 4.090387051292055e-08
with O 0 8.701153575429998e-08
tumors B-Disease 1 1.0
or O 1 0.9997829794883728
who O 0 1.0932811846942059e-06
, O 0 6.680545450166164e-09
as O 0 8.442709864553422e-10
a O 0 4.6040052326112857e-10
result O 0 4.194947944569094e-09
of O 0 1.5761937532943193e-08
linkage O 0 4.8731283897041067e-08
analysis O 0 5.928034951807604e-09
had O 0 5.668667313329934e-09
been O 0 2.6429920474413393e-09
predicted O 0 1.103092373000436e-08
to O 0 5.685339421468427e-10
carry O 0 3.4355918110406947e-09
the O 0 3.3266474019910675e-08
predisposing O 0 7.491307314921869e-06
mutation O 0 2.872052164093475e-06
. O 0 3.833416940324241e-06

These O 0 2.0615013340830046e-07
observations O 0 2.619611620957585e-07
point O 0 5.196886121439093e-08
to O 0 1.734169696732124e-09
another O 0 3.890519462146358e-09
region O 0 6.951492714790675e-09
of O 0 1.7539331764737653e-08
the O 0 1.9671050566216763e-08
RB1 O 0 1.289500232815044e-06
gene O 0 5.624692711592161e-09
where O 0 1.7449063305363666e-09
mutations O 0 4.4972785495644985e-09
only O 0 9.044360815835262e-10
modify O 0 1.508516511705693e-08
the O 0 1.5124196339755258e-09
function O 0 3.14349546393089e-09
of O 0 1.8877159835284374e-09
the O 0 2.0719419513426374e-09
gene O 0 2.401272292118506e-09
and O 0 1.1805231237005387e-09
raise O 0 3.112857527298729e-09
important O 0 3.6518084112202587e-09
questions O 0 4.403275077891067e-09
for O 0 5.181381435015453e-10
genetic O 0 1.1209445816007246e-08
counseling O 0 7.65515029144126e-09
in O 0 8.194074863077105e-10
families O 0 3.6431516137191977e-10
with O 0 4.187998559057604e-10
these O 0 3.692064654003957e-09
distinctive O 0 1.1279065859071125e-07
phenotypes O 0 5.385841745919606e-07
. O 0 1.525817481251579e-07
. O 0 1.7580547364559607e-06

Maternal B-Disease 0 0.0001326367346337065
disomy I-Disease 0 0.024214820936322212
and O 0 0.052226923406124115
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.7526294589042664
with O 0 9.369222908617303e-08
gamete O 0 1.8706614355323836e-06
complementation O 0 4.0535805965191685e-06
in O 0 3.3460292314657636e-09
a O 0 2.176729685388068e-09
case O 0 8.663690209687047e-09
of O 0 8.377219806732228e-09
familial O 0 6.66133459503726e-08
translocation O 0 6.58257306440646e-08
( O 0 6.353402692838017e-09
3 O 0 2.938344145775318e-08
; O 0 2.0380108711748335e-09
15 O 0 3.965764250324355e-08
) O 0 5.511547662706562e-09
( O 0 4.031511569024815e-09
p25 O 0 2.494782904705062e-07
; O 0 2.836057388933e-09
q11 O 0 1.300986411933991e-07
. O 0 5.092207544521443e-09
2 O 0 1.9589228372751677e-07
) O 0 5.255417789840067e-08
. O 0 9.6974247298931e-07

Maternal B-Disease 0 0.0010150775779038668
uniparental I-Disease 1 0.9992597699165344
disomy I-Disease 1 0.9981470108032227
( I-Disease 0 4.9330072215525433e-05
UPD I-Disease 1 1.0
) I-Disease 0 6.09059114253796e-08
for I-Disease 0 4.309452794615254e-09
chromosome I-Disease 0 4.5784744884258544e-08
15 I-Disease 0 3.217564170654441e-08
is O 0 8.116735616958692e-10
responsible O 0 3.4812848159759824e-09
for O 0 3.98899718812018e-10
an O 0 1.1046703829453719e-10
estimated O 0 5.439452777089571e-10
30 O 0 2.2163366697469655e-09
% O 0 3.20348275684168e-10
of O 0 2.1847366138416646e-09
cases O 0 5.3279123335414624e-09
of O 0 5.585146936937235e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.988528311252594
PWS B-Disease 1 1.0
) O 0 6.744286338289385e-07
. O 0 1.5841558251850074e-06

We O 0 1.3565858125730301e-06
report O 0 6.587358569731805e-08
on O 0 1.0210210454886237e-08
an O 0 3.629626876833214e-10
unusual O 0 4.197341141320976e-09
case O 0 1.6277793335461865e-08
of O 0 2.2475331817872757e-08
maternal B-Disease 0 2.453211607189587e-07
disomy I-Disease 0 4.7494686441496015e-06
15 I-Disease 0 3.4233883638989937e-07
in O 0 6.661691287490612e-08
PWS B-Disease 1 1.0
that O 0 4.221910376855931e-09
is O 0 4.14129175396738e-10
most O 0 1.2441482566405426e-10
consistent O 0 2.3594761699996525e-09
with O 0 3.0583416354978965e-10
adjacent O 0 1.633053337002366e-08
- O 0 1.5119242746663986e-08
1 O 0 1.654226799985281e-08
segregation O 0 1.1878258376896156e-08
of O 0 2.229276097054367e-09
a O 0 2.190766235088404e-09
paternal O 0 3.202160314685898e-08
t O 0 9.857291161097237e-08
( O 0 2.442764657217822e-09
3 O 0 1.3013382371696025e-08
; O 0 9.987048965598433e-10
15 O 0 8.71969074722756e-09
) O 0 1.2974117336028712e-09
( O 0 1.2006102778627792e-09
p25 O 0 4.106231799028137e-08
; O 0 4.804477371500582e-10
q11 O 0 1.3977921042851449e-08
. O 0 3.9448252997509314e-10
2 O 0 6.751356806944386e-09
) O 0 2.419490441329941e-10
with O 0 3.7217939841127645e-10
simultaneous O 0 3.2885431267004606e-08
maternal O 0 3.703704862800805e-07
meiotic O 0 9.913126632454805e-06
nondisjunction O 0 7.728249329375103e-06
for O 0 1.2058680454174464e-07
chromosome O 0 1.5883114201642456e-06
15 O 0 2.8557085443026153e-06
. O 0 3.1973199838830624e-06

The O 0 1.3221007293395814e-06
patient O 0 2.4833650513755856e-07
( O 0 1.8053031070053294e-08
J O 0 3.129773062937602e-07
. O 0 1.4988533747484212e-09
B O 0 2.407850097085884e-08
. O 0 4.360497796174201e-10
) O 0 3.8395334134300185e-10
, O 0 3.306048490525626e-10
a O 0 1.8312079630433686e-09
17 O 0 2.8347177050136452e-08
- O 0 2.0068519290816766e-08
year O 0 5.428386629091619e-09
- O 0 4.399063158189165e-08
old O 0 1.4371492795817176e-07
white O 0 4.872096681651783e-08
male O 0 3.990979280388274e-08
with O 0 2.0361547115044232e-08
PWS B-Disease 1 1.0
, O 0 7.947492974835768e-08
was O 0 4.835962030824703e-08
found O 0 1.2140076721678383e-09
to O 0 6.440994404499634e-10
have O 0 1.5601671066178824e-09
47 O 0 3.88014598229347e-08
chromosomes O 0 8.752766511577192e-09
with O 0 2.130519760612515e-09
a O 0 1.7670185314955233e-08
supernumerary O 0 1.9582462300604675e-06
, O 0 4.28298463361898e-09
paternal O 0 4.075038617656901e-08
der O 0 0.0002205443161074072
( O 0 8.447836208347326e-09
15 O 0 1.619751621717569e-08
) O 0 4.281887622248348e-10
consisting O 0 1.1887159034884576e-09
of O 0 6.0638707388704916e-09
the O 0 1.33615314368285e-08
short O 0 4.030867728488374e-08
arm O 0 6.974603365961229e-07
and O 0 3.611634014077936e-08
the O 0 1.6197647312310437e-07
proximal O 0 0.004405268467962742
long O 0 6.070602580621198e-07
arm O 0 1.3834568335369113e-06
of O 0 9.091409651773574e-07
chromosome O 0 9.749827540872502e-07
15 O 0 1.3041531019553076e-06
, O 0 8.109778804055168e-08
and O 0 1.4240561085898662e-06
distal O 1 0.7983466982841492
chromosome O 1 0.7922725081443787
arm O 1 0.9886906147003174
3p O 1 0.9999518394470215
. O 0 0.00030320341465994716

The O 0 3.026533022421063e-06
t O 0 1.1679545650622458e-06
( O 0 1.0474232148283136e-08
3 O 0 2.4177122526225503e-08
; O 0 7.639932020353513e-10
15 O 0 3.449505570074507e-09
) O 0 3.0123281646865507e-10
was O 0 1.2172352015227261e-09
present O 0 5.156448046328421e-10
in O 0 2.5557106431151055e-10
the O 0 4.646837359345568e-10
balanced O 0 1.5362132677054774e-09
state O 0 1.822172690513213e-10
in O 0 1.796518073193809e-10
the O 0 9.380408672043927e-10
patients O 0 1.37711053671552e-09
father O 0 1.0924662952049857e-08
and O 0 2.2334267768542304e-08
a O 0 8.415290153607202e-08
sister O 0 3.0769858767598635e-06
. O 0 7.657118658244144e-06

Fluorescent O 0 1.3684120858670212e-05
in O 0 5.808746195157255e-08
situ O 0 7.337621923397819e-07
hybridization O 0 3.865682174364338e-08
analysis O 0 1.1564014634757314e-08
demonstrated O 0 2.5837289641117422e-08
that O 0 2.470362137074744e-09
the O 0 3.4610405208468364e-08
PWS B-Disease 1 1.0
critical O 0 4.2454598769836593e-07
region O 0 2.7442029093549536e-08
resided O 0 2.5037678597072954e-08
on O 0 6.205812308479608e-09
the O 0 2.4649025043288475e-09
derivative O 0 1.492025702987121e-08
chromosome O 0 7.3327228733433e-09
3 O 0 1.2207745037073892e-08
and O 0 3.0563007680228793e-10
that O 0 7.282732750191201e-11
there O 0 5.364353405923339e-10
was O 0 3.964363504138646e-09
no O 0 1.3992504932502925e-09
deletion O 0 2.5994381758209784e-08
of O 0 1.3472234883238343e-08
the O 0 1.2184185038677242e-07
PWS B-Disease 1 1.0
region O 0 4.039927716803504e-07
on O 0 1.8463921946931805e-07
the O 0 4.85985509612874e-08
normal O 0 8.0550066172691e-08
pair O 0 9.286209490255715e-08
of O 0 6.387914908145831e-08
15s O 0 7.69706275605131e-06
present O 0 3.0503287007377367e-08
in O 0 5.295626692713995e-08
J O 0 3.534303687047213e-05
. O 0 4.346127752796747e-06

B O 0 0.0009834910742938519
. O 0 7.251706847455353e-05

Methylation O 0 6.91565583110787e-06
analysis O 0 9.87093812909734e-07
at O 0 7.141990181480651e-07
exon O 0 6.125991944827547e-07
alpha O 0 2.201677915536493e-07
of O 0 2.55533798565466e-08
the O 0 7.833682147406762e-09
small O 0 7.229580489820364e-09
nuclear O 0 8.50137382713001e-07
ribonucleoprotein O 0 1.559855809318833e-05
- O 0 6.892919941492437e-07
associated O 0 1.8503901344502083e-07
polypeptide O 0 1.0749261036835378e-06
N O 0 3.5014288641832536e-06
( O 0 2.783608543666105e-08
SNRPN O 0 3.032073891517939e-06
) O 0 5.161331362302235e-09
gene O 0 1.1060292237630165e-08
showed O 0 1.2263568827108884e-08
a O 0 3.4684535243911796e-09
pattern O 0 4.728877200932402e-08
characteristic O 0 9.281322377319157e-08
of O 0 2.325499259825392e-08
only O 0 3.219711386392987e-09
the O 0 3.5008613785691978e-09
maternal O 0 1.988816578091246e-08
chromosome O 0 6.243581651688146e-08
15 O 0 1.2208914768052637e-07
in O 0 1.0767960390012377e-07
J O 0 0.0002979627170134336
. O 0 1.7177953850477934e-05

B O 0 0.000978413736447692
. O 0 5.323921868694015e-05

Maternal B-Disease 0 4.0236522181658074e-05
disomy I-Disease 0 4.293736856197938e-05
was O 0 2.446949451950786e-07
confirmed O 0 4.485056948055899e-08
by O 0 2.8071038826738004e-09
polymerase O 0 3.825210370678178e-08
chain O 0 1.1843487079943316e-08
reaction O 0 5.097746669235903e-09
analysis O 0 1.2720270170518688e-08
of O 0 2.1640838454572986e-08
microsatellite O 0 1.182520236397977e-06
repeats O 0 2.1604510891393147e-07
at O 0 1.2636003532406903e-07
the O 0 2.6673323105796953e-08
gamma O 0 2.2010599423083477e-06
- O 0 3.697694808124652e-07
aminobutyric O 0 1.2756869409713545e-06
acid O 0 7.8804134773236e-08
receptor O 0 1.6950868086951232e-07
beta3 O 0 1.4947552244848339e-06
subunit O 0 8.985971930997039e-07
( O 0 4.090129479550342e-08
GABRB3 O 0 7.4968888839066494e-06
) O 0 7.850469074810462e-08
locus O 0 3.571223487597308e-06
. O 0 3.976046173193026e-06

A O 0 7.303480288101127e-06
niece O 0 7.3844071266648825e-06
( O 0 2.1742909694921764e-08
B O 0 1.0211655876446457e-07
. O 0 9.956542257327783e-10
B O 0 9.304396364484546e-09
. O 0 2.787643726964717e-10
) O 0 9.58546853002673e-11
with O 0 5.892587112699132e-11
45 O 0 1.4933232428404608e-09
chromosomes O 0 2.306701274434886e-09
and O 0 4.257066921198316e-10
the O 0 6.470484703591239e-10
derivative O 0 2.904231966027737e-09
3 O 0 2.8372584282010394e-09
but O 0 2.3274271399031932e-10
without O 0 9.77755099107469e-10
the O 0 1.6396911606264553e-09
der O 0 3.1164706797426334e-06
( O 0 3.155756544970245e-09
15 O 0 1.8623182995725074e-08
) O 0 1.4708277928932034e-09
demonstrated O 0 1.632004043017332e-08
a O 0 6.066322999487284e-09
phenotype O 0 1.3580417146386026e-07
consistent O 0 1.4361431155407445e-08
with O 0 7.034088866930688e-10
that O 0 6.931047957792202e-10
reported O 0 2.6265236652278645e-09
for O 0 1.8881984864549395e-09
haploinsufficiency O 0 3.3796732168411836e-07
of O 0 1.2062072585194983e-07
distal O 0 5.605526439467212e-06
3 O 0 8.416191121796146e-06
p O 0 2.5877201551338658e-05
. O 0 1.867748665063118e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999982118606567
associated O 0 3.2506047773495084e-06
with O 0 6.775676553161247e-08
unbalanced O 0 5.297104053170187e-06
segregation O 0 6.21027254510409e-07
of O 0 1.0697948482629727e-07
non O 0 1.601619806024246e-05
- O 0 4.684521172748646e-06
Robertsonian O 0 2.9338189051486552e-05
translocations O 0 2.900461140598054e-06
has O 0 6.787522544016156e-09
been O 0 7.550870151362687e-09
reported O 0 7.579989969030976e-09
previously O 0 5.582496687139837e-09
but O 0 9.219279784034029e-10
has O 0 2.1259155547070918e-10
not O 0 1.4840545459193777e-10
, O 0 1.6289733451024802e-10
to O 0 1.8545746882647762e-10
our O 0 1.5285147592081216e-09
knowledge O 0 1.4998438047086893e-08
, O 0 1.540314986669955e-09
been O 0 2.057273018607475e-09
observed O 0 9.379160559319644e-09
in O 0 1.3750475202911616e-09
a O 0 1.0305433839619127e-08
case O 0 2.4473368398503226e-07
of O 0 2.968065473396564e-06
PWS B-Disease 1 1.0
. O 0 0.00011479229578981176

Furthermore O 0 1.8475404431228526e-05
, O 0 3.117601181656937e-07
our O 0 7.949827818265476e-08
findings O 0 2.383468356015328e-08
are O 0 8.045970001369085e-10
best O 0 2.7385493872600364e-09
interpreted O 0 6.0499383280898655e-09
as O 0 3.6181684315295115e-09
true O 0 6.229462456985857e-08
gamete O 0 1.487010649725562e-06
complementation O 0 5.57288876734674e-06
resulting O 0 1.461228293919703e-07
in O 0 7.87085951969857e-08
maternal B-Disease 0 1.5617537428624928e-05
UPD I-Disease 1 1.0
15 I-Disease 0 0.00032241924782283604
and O 0 0.00023696872813161463
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9979286193847656
- I-Disease 1 0.9999192953109741
Jampel I-Disease 1 0.9999606609344482
syndrome I-Disease 0 0.2712946832180023
type I-Disease 0 7.153147180360975e-06
2 I-Disease 0 1.9210596292396076e-05
and O 0 4.699887199421937e-07
Stuve B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999996423721313
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999856948852539
: O 0 6.780754624458041e-09
a O 0 1.5778535145116734e-09
case O 0 2.289640921304681e-09
for O 0 1.0570339048499022e-09
" O 0 1.5669375130755725e-08
lumping O 0 1.5820164378510526e-07
" O 0 5.954833000032522e-07
. O 0 2.947201210190542e-06

Recent O 0 3.466174405275524e-07
studies O 0 5.316596229931747e-08
demonstrated O 0 3.5798663589048374e-08
the O 0 4.199599334953064e-09
existence O 0 6.2794920374642516e-09
of O 0 4.614892024079609e-09
a O 0 3.1249991483406347e-09
genetically O 0 1.0096899316636154e-08
distinct O 0 6.7328387309828486e-09
, O 0 1.4516223778571202e-09
usually O 0 7.830153192500688e-10
lethal O 0 1.2754526323988102e-08
form O 0 6.728756662965907e-09
of O 0 3.6488859933569984e-08
the O 0 4.0777909049438676e-08
Schwartz B-Disease 0 7.820084283594042e-05
- I-Disease 0 0.00016447690722998232
Jampel I-Disease 1 0.9974902868270874
syndrome I-Disease 1 0.982822597026825
( O 0 2.955246429792169e-07
SJS B-Disease 0 0.46000394225120544
) O 0 3.8447989680889805e-08
of O 0 4.6515506824107433e-07
myotonia B-Disease 1 0.9999719858169556
and O 0 3.9229144022101536e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999997615814209
, O 0 1.01495182036615e-07
which O 0 8.257558192781289e-09
we O 0 3.2656661375085605e-08
called O 0 1.0308701092753836e-07
SJS B-Disease 0 7.965735858306289e-05
type I-Disease 0 2.4644064069434535e-06
2 I-Disease 0 9.407592187926639e-06
. O 0 3.2754310268501285e-06

This O 0 6.760384962944954e-07
disorder O 0 0.48390790820121765
is O 0 1.2409950400638081e-08
reminiscent O 0 1.4707113393797044e-07
of O 0 1.9521468885841387e-08
another O 0 5.656570767342828e-09
rare O 0 1.4045670404527755e-08
condition O 0 1.3218847527696198e-07
, O 0 1.4348972676714311e-08
the O 0 6.977864330792727e-08
Stuve B-Disease 1 0.9810028076171875
- I-Disease 1 0.9999688863754272
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 1.1462741895229556e-05
SWS B-Disease 1 0.9624094367027283
) O 0 1.7777551875042263e-08
, O 0 4.262414865507935e-09
which O 0 4.143087206642804e-09
comprises O 0 3.8426875903496693e-08
campomelia B-Disease 0 8.8304068412981e-07
at O 0 9.517565047190146e-08
birth O 0 1.3100751061756455e-07
with O 0 7.260580048296106e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 5.003604201192502e-06
contractures B-Disease 1 0.9864245057106018
, O 0 6.605891655908636e-08
and O 0 1.6244698031187e-08
early B-Disease 0 1.0309856861567823e-06
death I-Disease 0 6.0914903770026285e-06
. O 0 2.3367138055618852e-06

To O 0 1.0635164215955228e-07
test O 0 1.1044338776855511e-07
for O 0 2.38030528620925e-09
possible O 0 2.6052155988054437e-08
nosologic O 0 1.0082717381010298e-06
identity O 0 1.464568999409721e-08
between O 0 1.565413931814419e-08
these O 0 9.176932991294962e-09
disorders O 0 5.853311222381308e-07
, O 0 6.563435905881931e-10
we O 0 1.3381469265993928e-09
reviewed O 0 3.6481739851268458e-09
the O 0 2.6171961819976275e-10
literature O 0 9.285741620068677e-10
and O 0 1.4384937685463228e-10
obtained O 0 2.6148421206073635e-09
a O 0 3.693161887419194e-10
follow O 0 2.287907863163241e-09
- O 0 3.896623468335747e-09
up O 0 4.181963941807254e-10
of O 0 3.6065020414532967e-10
the O 0 2.3720100883473094e-10
only O 0 1.3989615021969826e-10
two O 0 3.14204329221468e-10
surviving O 0 7.877103413989062e-09
patients O 0 8.536528706137858e-10
, O 0 7.728486184355177e-10
one O 0 1.2937247939603935e-09
with O 0 1.3686735078621837e-09
SJS B-Disease 0 1.1979621376667637e-05
type I-Disease 0 3.3548502642588574e-07
2 I-Disease 0 8.837550922180526e-07
at O 0 1.765165791312029e-08
age O 0 2.1632080571265533e-09
10 O 0 9.31486887623123e-10
years O 0 3.4590438846571203e-10
and O 0 3.1900379560134695e-10
another O 0 1.2328243981230003e-09
with O 0 1.8612803520667853e-09
SWS B-Disease 0 8.585918294556905e-06
at O 0 6.260538754077061e-08
age O 0 3.93858954339521e-08
7 O 0 2.3884499000814685e-07
years O 0 7.06925291638072e-08
. O 0 6.528912308567669e-07

Patients O 0 3.933308107662015e-06
reported O 0 6.574041577778189e-08
as O 0 4.46652981267448e-09
having O 0 1.997941545539561e-08
either O 0 3.6559293903337675e-07
neonatal O 1 0.9999914169311523
SJS B-Disease 1 1.0
or O 0 0.001678043627180159
SWS B-Disease 1 0.9254599809646606
presented O 0 1.0202719380458802e-07
a O 0 2.7538229474544096e-09
combination O 0 1.677100947006238e-08
of O 0 1.2340555244350071e-08
a O 0 4.834594502511891e-09
severe O 0 3.142375362585881e-06
, O 0 7.81094797730475e-08
prenatal O 0 0.00024653636501170695
- O 0 0.0018559286836534739
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 4.776286004926078e-06
with O 0 1.0798953553603496e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.9996930360794067
feeding O 0 0.09052920341491699
difficulties O 0 0.03625785931944847
, O 0 4.630589245380179e-08
tendency O 0 1.4750031418486742e-08
to O 0 4.384402174650859e-09
hyperthermia B-Disease 0 0.05692461505532265
, O 0 6.378196637513156e-09
and O 0 1.9173334031563627e-09
frequent O 0 1.3506911145100275e-09
death O 0 3.4905813350860626e-08
in O 0 1.7498656967873671e-09
infancy O 0 2.577449436103052e-07
) O 0 1.2257178605423746e-09
with O 0 2.0006279966011675e-10
a O 0 3.0933200445559805e-09
distinct O 0 1.526491359982174e-07
campomelic B-Disease 0 0.006087473593652248
- I-Disease 1 0.9641132950782776
metaphyseal I-Disease 1 0.5863755941390991
skeletal I-Disease 1 0.999995231628418
dysplasia I-Disease 1 0.9999995231628418
. O 0 0.0002220860042143613

The O 0 4.404184892337071e-07
similarity O 0 2.529596088152175e-07
of O 0 1.0550306939194343e-07
the O 0 3.169360596189108e-08
clinical O 0 6.816644031459873e-07
and O 0 1.1601350990986248e-08
radiographic O 0 1.8047156117972918e-05
findings O 0 1.889114855657681e-07
is O 0 1.4122921720982617e-09
so O 0 7.428585524493769e-10
extensive O 0 3.1822671164860594e-09
that O 0 5.562491023347604e-10
these O 0 2.1859339227603414e-08
disorders O 0 3.9299833588302135e-05
appear O 0 9.767360253931656e-09
to O 0 1.2164993457020046e-09
be O 0 2.273643495698252e-09
a O 0 3.860920472220641e-09
single O 0 1.720592912590746e-08
entity O 0 7.471434173567104e-07
. O 0 2.252729927931796e-06

The O 0 1.3811537655783468e-06
follow O 0 4.6767044636908395e-07
- O 0 3.5290750588501396e-07
up O 0 2.7532873758673304e-09
observation O 0 2.770218898717758e-08
of O 0 1.9288324271116153e-09
an O 0 1.0094405172855758e-10
identical O 0 2.094850293232753e-09
and O 0 8.63315252619401e-10
unique O 0 4.913782714055515e-09
pattern O 0 6.791253781557316e-07
of O 0 6.82812969898805e-05
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999997615814209
in O 0 4.183292645620895e-08
the O 0 2.0981662629537823e-08
two O 0 3.3437963509186375e-09
patients O 0 8.624199687723433e-10
( O 0 4.2168865621583507e-10
one O 0 4.5027870321234786e-10
with O 0 5.889275178638798e-10
SJS B-Disease 0 1.982107733056182e-06
type I-Disease 0 6.476899727658747e-08
2 I-Disease 0 1.0128188421276718e-07
, O 0 4.6564282984995486e-10
one O 0 2.3591598119487855e-10
with O 0 5.045537876391393e-10
SWS B-Disease 0 6.663299700448988e-06
) O 0 5.7668820829803735e-09
surviving O 0 6.544690478449411e-08
beyond O 0 7.865306628218605e-08
infancy O 0 2.093971147587581e-07
adds O 0 1.0694679808409546e-08
to O 0 7.613050745369776e-10
the O 0 1.8116629307840526e-09
evidence O 0 1.2511553570959677e-08
in O 0 1.574216090816094e-09
favor O 0 3.123695790918646e-08
of O 0 4.6014815069383985e-08
identity O 0 6.432584314097767e-07
. O 0 2.665647116373293e-06

The O 0 6.868037871754495e-07
hypothesis O 0 6.59025488403131e-07
that O 0 3.086432087684443e-08
SWS B-Disease 0 7.874643779359758e-05
and O 0 1.308067538730029e-07
SJS B-Disease 0 0.0017466405406594276
type I-Disease 0 4.264623385097366e-06
2 I-Disease 0 7.459568678314099e-06
are O 0 7.09132697007675e-10
the O 0 7.192853535009647e-10
same O 0 2.8087534520437885e-09
disorder O 0 1.8963351067213807e-07
should O 0 1.9676293927517463e-09
be O 0 1.235753055439659e-09
testable O 0 5.331096986083139e-08
by O 0 4.415433851878703e-10
molecular O 0 1.996516729718678e-08
methods O 0 2.5214520249505767e-08
. O 0 1.7146208008966823e-08
. O 0 3.440085833972262e-07

A O 0 9.37992717808811e-06
mouse O 0 1.9335318484081654e-06
model O 0 2.4942144705164537e-07
of O 0 3.930140053398645e-07
severe O 1 0.9998456239700317
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9872724413871765
defects O 1 0.9936327338218689
in O 0 6.223244781722315e-07
hemostasis O 1 0.5506641268730164
and O 0 1.8665821698959917e-05
thrombosis B-Disease 1 0.999250590801239
. O 0 0.0001742970198392868

von B-Disease 1 0.9527751803398132
Willebrand I-Disease 1 0.9998387098312378
factor I-Disease 0 0.0003290911845397204
( I-Disease 0 4.366134817246348e-06
vWf I-Disease 0 0.00834326259791851
) I-Disease 0 1.0654402103682514e-05
deficiency I-Disease 1 0.9998657703399658
causes O 0 0.36903050541877747
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0030940850265324116
humans O 0 2.636352292029187e-05
. O 0 1.5473970051971264e-06

We O 0 9.313594091509003e-07
generated O 0 7.565232351680606e-08
a O 0 2.1616294532122993e-08
mouse O 0 3.6062647978951645e-08
model O 0 1.0226133717594621e-08
for O 0 6.272725672218371e-10
this O 0 4.31964630731585e-10
disease O 0 1.89151450058489e-09
by O 0 1.537273641716297e-10
using O 0 2.0332393546595995e-09
gene O 0 1.6754318821199377e-08
targeting O 0 2.6480881842871895e-07
. O 0 8.796877182248863e-07

vWf B-Disease 0 0.013706084340810776
- I-Disease 1 0.9984544515609741
deficient I-Disease 0 0.0008137844852171838
mice O 0 1.2701598279818427e-06
appeared O 0 8.707096554871896e-08
normal O 0 4.7099558031504785e-08
at O 0 1.627804202541938e-08
birth O 0 8.627473735423052e-10
; O 0 2.1550077000664913e-10
they O 0 2.6257862550949085e-10
were O 0 4.4347303607139565e-09
viable O 0 1.260581683482087e-07
and O 0 4.3771432700623336e-08
fertile O 0 1.734132865749416e-06
. O 0 2.212265826528892e-06

Neither O 0 0.00011039800301659852
vWf O 0 0.0005344339879229665
nor O 0 3.495955388643779e-05
vWf O 0 0.00016798925935290754
propolypeptide O 0 7.791478128638119e-05
( O 0 4.3634480562104727e-07
von B-Disease 0 0.00017929259047377855
Willebrand I-Disease 0 0.00018171273404732347
antigen O 0 1.1823049135273322e-06
II O 0 0.1424810290336609
) O 0 1.1828316104356418e-08
were O 0 6.17663342694641e-09
detectable O 0 5.219754228846796e-08
in O 0 4.2151335200024675e-10
plasma O 0 2.1885872669713535e-08
, O 0 1.20017074056733e-09
platelets O 0 1.0180245091362394e-08
, O 0 6.014589937208825e-10
or O 0 4.970734934772736e-10
endothelial O 0 2.7249658085537476e-09
cells O 0 2.2931461174380274e-09
of O 0 5.224083832189308e-09
the O 0 1.3811780164019183e-08
homozygous O 0 2.896826458709256e-07
mutant O 0 4.797715064341901e-06
mice O 0 6.419747933250619e-06
. O 0 2.8746717362082563e-06

The O 0 4.017373612441588e-06
mutant O 0 8.958658872870728e-05
mice O 0 1.4536642083839979e-05
exhibited O 0 2.5052927412616555e-06
defects O 0 0.00018304357945453376
in O 0 9.586798199734403e-08
hemostasis O 0 0.0003405477909836918
with O 0 1.0272366068875272e-08
a O 0 2.520384612125781e-08
highly O 0 1.5802025927769137e-06
prolonged O 0 0.343697190284729
bleeding O 1 0.99637371301651
time O 0 5.356553174351575e-07
and O 0 3.304204909682085e-08
spontaneous O 0 2.3739140431189298e-07
bleeding O 0 1.0922266255875002e-06
events O 0 4.667919828449385e-09
in O 0 1.378824165954029e-09
approximately O 0 3.75175179812004e-09
10 O 0 4.559274291437987e-09
% O 0 2.799398934882902e-09
of O 0 5.513516398991669e-08
neonates O 0 4.177287792117568e-06
. O 0 4.826544227398699e-06

As O 0 1.7109496752709674e-07
in O 0 1.4469983433684774e-08
the O 0 3.5514386098611794e-08
human O 0 1.2669899263073603e-07
disease O 0 1.570969203612549e-07
, O 0 1.3838616919059632e-09
the O 0 2.7317779149882426e-09
factor O 0 1.2312859176688562e-08
VIII O 0 3.634720997069962e-05
level O 0 4.2556914081615105e-07
in O 0 9.044412441205907e-10
these O 0 1.1028437052473805e-09
mice O 0 1.644832181568745e-08
was O 0 3.0720415100660148e-09
reduced O 0 3.2373783653838473e-09
strongly O 0 9.472281847777708e-10
as O 0 2.735984494517396e-10
a O 0 1.7448255340557495e-10
result O 0 7.171414573292623e-10
of O 0 1.0298787378459906e-09
the O 0 7.983614880302525e-10
lack O 0 9.507365561489678e-09
of O 0 4.7519308488119805e-09
protection O 0 7.210644970001567e-09
provided O 0 5.729714480651182e-09
by O 0 1.7573587030028648e-08
vWf O 0 1.538703145342879e-05
. O 0 7.542973435192835e-06

Defective O 1 0.5008007884025574
thrombosis B-Disease 0 0.07299378514289856
in O 0 4.327402507442457e-07
mutant O 0 1.3785133887722623e-05
mice O 0 4.54705741503858e-07
was O 0 4.110894735731563e-08
also O 0 1.3478962390678362e-09
evident O 0 1.0476829181982339e-08
in O 0 6.797766793908977e-10
an O 0 2.634565343662132e-10
in O 0 6.071181335443043e-10
vivo O 0 6.074221658991519e-08
model O 0 4.283101162627645e-08
of O 0 1.441183258066303e-06
vascular B-Disease 1 0.9999998807907104
injury I-Disease 1 1.0
. O 0 0.0010997746139764786

In O 0 1.3176619972909975e-07
this O 0 4.435694922477751e-09
model O 0 4.874932102438834e-08
, O 0 7.449162620076777e-09
the O 0 2.3950892824586845e-08
exteriorized O 0 3.393096221770975e-06
mesentery O 0 7.059065865178127e-06
was O 0 2.936361909178231e-07
superfused O 0 2.7840710572490934e-06
with O 0 2.1444476416832003e-08
ferric O 0 2.6553937004791806e-06
chloride O 0 1.4926384039881668e-07
and O 0 9.399023781497817e-08
the O 0 4.1444089049491595e-08
accumulation O 0 1.7701059107366746e-07
of O 0 1.5487832172311755e-07
fluorescently O 0 2.113402388204122e-06
labeled O 0 8.476343538177389e-08
platelets O 0 4.0424288272333797e-07
was O 0 1.5450302726094378e-07
observed O 0 8.01465560584802e-08
by O 0 2.812078392366857e-08
intravital O 0 1.375771353195887e-05
microscopy O 0 5.7196535635739565e-05
. O 0 4.6549066610168666e-06

We O 0 6.549910267494852e-07
conclude O 0 6.050373713151203e-07
that O 0 2.046459668392231e-09
these O 0 3.4149274519279516e-09
mice O 0 6.665122498361598e-08
very O 0 1.199805144125321e-08
closely O 0 8.223769043524953e-08
mimic O 0 2.4061271687969565e-05
severe O 1 0.506595253944397
human O 1 0.6470701098442078
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.4595154880225891e-06
will O 0 6.115266515394069e-09
be O 0 6.909360861229175e-10
very O 0 1.3351708627595826e-10
useful O 0 7.46769535098224e-10
for O 0 8.79087080907226e-11
investigating O 0 2.2862896020825474e-09
the O 0 3.2270072725104626e-10
role O 0 1.8356246522799324e-09
of O 0 4.130250363942878e-09
vWf O 0 3.051918042729085e-07
in O 0 4.555536392558679e-09
normal O 0 2.736844066930644e-07
physiology O 0 2.1122496036696248e-06
and O 0 1.2730803966576332e-08
in O 0 1.3152924083215112e-08
disease O 0 1.3493198025571473e-07
models O 0 5.485447118758202e-08
. O 0 4.059019786950557e-08
. O 0 6.557360165970749e-07

Oral O 0 0.0004277662083040923
contraceptives O 0 7.588181324535981e-05
and O 0 9.678035439719679e-08
the O 0 4.54978135167039e-08
risk O 0 1.2332623100519413e-06
of O 0 0.004357771947979927
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9995468258857727

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.9791984558105469
Study O 0 2.1412060959846713e-06
Group O 0 8.385270575672621e-07
. O 0 3.7511570099013625e-06

BACKGROUND O 0 4.1498042264720425e-05
Women O 0 3.0265221084846416e-07
with O 0 3.388145541904919e-09
mutations O 0 8.338052914780292e-09
in O 0 1.2933498716449776e-09
either O 0 6.061823931702293e-09
the O 0 1.214510803038138e-08
BRCA1 O 0 9.511213505675187e-08
or O 0 5.441811445905387e-09
the O 0 6.54153042844996e-09
BRCA2 O 0 7.704591098445235e-08
gene O 0 6.482989700629105e-09
have O 0 1.5017836973996168e-09
a O 0 2.5105908463274318e-09
high O 0 9.329544781166987e-08
lifetime O 0 1.8322506889489887e-07
risk O 0 6.440566721721552e-06
of O 1 0.9928662776947021
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.09603061527013779

Oral O 0 0.0008753071306273341
contraceptives O 0 0.0014092386700212955
protect O 0 5.2329505706438795e-06
against O 1 0.999997615814209
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.7631062948785257e-07
general O 0 2.467053832333477e-07
, O 0 1.7351621250938365e-09
but O 0 2.9920346755751837e-10
it O 0 4.1629179270419314e-11
is O 0 2.0888554774778356e-11
not O 0 4.705584880082547e-11
known O 0 5.01353514259506e-10
whether O 0 2.171993473965017e-09
they O 0 1.4442402829217826e-09
also O 0 2.9194049400160793e-09
protect O 0 1.3286079791896555e-08
against O 0 2.658249229625653e-07
hereditary B-Disease 1 0.9997946619987488
forms I-Disease 0 0.49092793464660645
of I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.14580683410167694

METHODS O 0 4.832817467104178e-06
We O 0 3.2592231491435086e-07
enrolled O 0 2.2620139361606562e-07
207 O 0 2.0744741391354182e-07
women O 0 3.728569097916079e-08
with O 0 3.88014598229347e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.385943258166662e-07
161 O 0 8.131773654440622e-08
of O 0 3.0174259535442616e-08
their O 0 1.5298397215701698e-08
sisters O 0 3.997646444986458e-07
as O 0 9.206491569102582e-09
controls O 0 6.686310172199228e-08
in O 0 5.361584065610714e-09
a O 0 1.3533687059918975e-08
case O 0 1.1657618159688354e-07
- O 0 1.4415583393656561e-07
control O 0 7.981399363643504e-08
study O 0 8.240585458452188e-08
. O 0 5.075614808447426e-07

All O 0 2.566132764059148e-07
the O 0 2.753635364172169e-08
patients O 0 4.417179955140682e-09
carried O 0 6.4201346461345565e-09
a O 0 2.72174505155931e-09
pathogenic O 0 1.2982398800431838e-07
mutation O 0 1.4588954044825186e-08
in O 0 4.001740716574886e-09
either O 0 5.034180361462859e-08
BRCA1 O 0 9.92757236417674e-07
( O 0 1.813357819457906e-08
179 O 0 5.290245752576084e-08
women O 0 1.1751701833873085e-08
) O 0 1.9281445329255575e-09
or O 0 2.1717751153005338e-08
BRCA2 O 0 1.1221702607144834e-06
( O 0 3.893312339187105e-08
28 O 0 1.4097624898568029e-06
women O 0 1.875078794455476e-07
) O 0 9.499773767629449e-08
. O 0 1.8241448742628563e-06

The O 0 1.1603560778894462e-06
control O 0 3.90797958971234e-06
women O 0 5.343567721638465e-08
were O 0 1.2817935157727334e-08
enrolled O 0 7.753974351487614e-09
regardless O 0 3.0955746854743893e-09
of O 0 3.031789264085205e-09
whether O 0 9.326761585271015e-10
or O 0 1.2326082377001057e-09
not O 0 6.429420329467916e-10
they O 0 1.433397511796386e-09
had O 0 1.0334309408221998e-08
either O 0 6.187648438071847e-08
mutation O 0 1.0279970865667565e-06
. O 0 3.436977976889466e-06

Lifetime O 0 8.278935638372786e-06
histories O 0 6.706528665745282e-07
of O 0 3.8421643466790556e-07
oral O 0 2.7452401809568983e-06
- O 0 1.0174210984814636e-07
contraceptive O 0 2.7414250425294995e-08
use O 0 1.2201081256435486e-09
were O 0 2.1087127599628275e-09
obtained O 0 6.132565122385358e-09
by O 0 1.1067272653875193e-09
interview O 0 1.0644657599812035e-08
or O 0 7.717599892487215e-10
by O 0 4.336056513842834e-10
written O 0 4.594092883891676e-10
questionnaire O 0 1.0988709941983643e-09
and O 0 5.570294225876182e-10
were O 0 1.5519043827794121e-09
compared O 0 1.525765180865335e-09
between O 0 2.255132525164072e-09
patients O 0 2.0260888522471987e-09
and O 0 4.925239771580436e-09
control O 0 3.515776825224748e-06
women O 0 4.8639911653935997e-08
, O 0 3.139576598698568e-09
after O 0 1.1465360216789122e-08
adjustment O 0 9.778488241352079e-09
for O 0 2.1435088426446924e-10
year O 0 3.271473369981237e-10
of O 0 1.371265545557776e-09
birth O 0 1.6195569330079707e-08
and O 0 2.5626347266438643e-08
parity O 0 1.371386019854981e-06
. O 0 1.2379333611534094e-06

RESULTS O 0 5.01047215948347e-05
The O 0 8.731425396035775e-07
adjusted O 0 7.613876960022026e-07
odds O 0 5.962760383226851e-07
ratio O 0 3.644629202881333e-07
for O 0 3.278465101175243e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.317027624736511e-07
with O 0 5.873491693009214e-10
any O 0 1.0406282502373188e-09
past O 0 7.853636074806047e-10
use O 0 3.517894864302207e-10
of O 0 3.0918101412424903e-09
oral O 0 5.659411428382555e-08
contraceptives O 0 7.047053429687367e-08
was O 0 5.189130547478271e-08
0 O 0 3.273552238169941e-07
. O 0 5.157850182513357e-07

5 O 0 4.407093456393341e-06
( O 0 1.0426319363432413e-07
95 O 0 4.5220704691928404e-07
percent O 0 3.9190908296404814e-08
confidence O 0 1.808350020837679e-07
interval O 0 6.820292952625095e-08
, O 0 5.141294612265312e-10
0 O 0 1.6812476966165946e-09
. O 0 6.32036437075989e-11
3 O 0 4.375694806491026e-10
to O 0 7.4043639275434e-11
0 O 0 2.65086796957803e-09
. O 0 1.0167975350583447e-09
8 O 0 7.786286460031988e-08
) O 0 3.2597665011735444e-08
. O 0 8.07525623258698e-07

The O 0 2.2343272121361224e-06
risk O 0 6.085934955990524e-07
decreased O 0 9.344842766267902e-08
with O 0 9.629452790704818e-10
increasing O 0 2.8893800685381166e-09
duration O 0 1.328582577286852e-08
of O 0 3.06993852561277e-09
use O 0 2.7667270696696278e-09
( O 0 3.1510469788997852e-09
P O 0 1.5751757587167958e-07
for O 0 4.1520800686534187e-10
trend O 0 3.982977503369511e-09
, O 0 3.466626152803798e-10
< O 0 3.809045967528846e-09
0 O 0 1.6051606710476563e-09
. O 0 2.4356638927969243e-10
001 O 0 3.463047804075359e-08
) O 0 1.090917980950401e-10
; O 0 3.6734747188571504e-11
use O 0 1.1140461469993923e-10
for O 0 2.090809608779054e-10
six O 0 1.069086041916023e-09
or O 0 1.8158340109319937e-10
more O 0 2.4195445993968612e-11
years O 0 1.8834279968960033e-10
was O 0 8.668214479534697e-10
associated O 0 4.980576506774526e-10
with O 0 6.94161464420695e-11
a O 0 5.778815759249767e-10
60 O 0 3.191938713342779e-09
percent O 0 2.774918739234522e-09
reduction O 0 2.8326962109304077e-08
in O 0 3.3612803207461184e-08
risk O 0 2.0836216663155938e-06
. O 0 2.6134182462556055e-06

Oral O 0 0.0023107961751520634
- O 0 2.0970712284906767e-05
contraceptive O 0 2.892991005865042e-06
use O 0 7.869537910210056e-08
protected O 0 6.861105248390231e-06
against O 1 0.9999464750289917
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 6.19674267454684e-08
for O 0 4.345290349760944e-09
carriers O 0 2.259524123360279e-09
of O 0 8.621984015633188e-09
the O 0 2.7664754043144058e-08
BRCA1 O 0 7.905131838015222e-08
mutation O 0 1.184723785740971e-08
( O 0 1.8422081637936571e-09
odds O 0 3.410184135077543e-08
ratio O 0 5.560902405221668e-09
, O 0 6.509973671242619e-10
0 O 0 2.8720175127006087e-09
. O 0 3.12902953547578e-10
5 O 0 1.9971022613418654e-09
; O 0 3.241176216306485e-10
95 O 0 8.477730517597593e-09
percent O 0 2.3675408300505296e-09
confidence O 0 2.172500224162377e-08
interval O 0 1.772963642565628e-08
, O 0 2.642496499394298e-10
0 O 0 7.901537202315012e-10
. O 0 9.337490503025236e-11
3 O 0 3.192819897357424e-10
to O 0 4.683896673296495e-11
0 O 0 1.296501461744981e-09
. O 0 2.0779444831475757e-10
9 O 0 4.460706470865716e-09
) O 0 1.9169155152098938e-10
and O 0 1.4240633672280012e-10
for O 0 1.726334075691227e-10
carriers O 0 5.967681349083875e-10
of O 0 5.557159621361052e-09
the O 0 1.8089050257685813e-08
BRCA2 O 0 9.528824307381001e-07
mutation O 0 5.98424847453316e-08
( O 0 4.573061040957782e-09
odds O 0 4.339610271131278e-08
ratio O 0 6.4770078189724245e-09
, O 0 1.5112431306363305e-09
0 O 0 4.492537453160139e-09
. O 0 3.2443989161912157e-10
4 O 0 7.083233111160325e-09
; O 0 6.680376807288724e-10
95 O 0 1.4255106428606723e-08
percent O 0 3.3180025393875212e-09
confidence O 0 3.807943471656472e-08
interval O 0 2.0470384498594285e-08
, O 0 3.180390673040989e-10
0 O 0 1.6435519611945892e-09
. O 0 1.1363068819214561e-10
2 O 0 8.902935055843386e-10
to O 0 1.1631560298264176e-10
1 O 0 3.188153963051832e-09
. O 0 1.0710086151277665e-09
1 O 0 4.593922398044015e-08
) O 0 1.5874658032544176e-08
. O 0 1.9013130270195688e-07

CONCLUSIONS O 0 0.00013686568127013743
Oral O 0 0.0021594655700027943
- O 0 8.877092113834806e-06
contraceptive O 0 3.141112188131956e-07
use O 0 5.05889596880138e-09
may O 0 7.731438600444562e-09
reduce O 0 8.6299465351658e-09
the O 0 7.784620059680947e-09
risk O 0 4.004182585504168e-07
of O 0 0.004233034327626228
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.46983291782999e-08
women O 0 2.392102071979707e-09
with O 0 1.7944530583680063e-10
pathogenic O 0 3.938378867474057e-08
mutations O 0 6.1505933679484315e-09
in O 0 2.000415388891952e-09
the O 0 2.0355178875774982e-08
BRCA1 O 0 7.442220635311969e-07
or O 0 1.2916294735987321e-06
BRCA2 O 0 0.00011412217281758785
gene O 0 5.0669787015067413e-05

A O 0 4.166660346527351e-06
Japanese O 0 3.1506785944657167e-06
family O 0 1.0776322767469537e-07
with O 0 7.139103530562352e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 2.9531998180232222e-08
a O 0 4.915922602322098e-08
codon O 0 5.768408186668239e-07
291 O 0 1.8264114487465122e-07
deletion O 0 2.55193867815251e-07
: O 0 5.820899318109696e-09
a O 0 2.715419222809601e-09
clinical O 0 7.43576578088323e-08
, O 0 4.2124508325969146e-09
biochemical O 0 3.3459997439422295e-07
, O 0 2.4239781737378507e-08
pathological O 0 3.758397042474826e-06
, O 0 1.6675478775596275e-08
and O 0 5.165007266327848e-08
genetic O 0 1.6476745940963156e-06
report O 0 4.602697742939199e-07
. O 0 2.9625819024658995e-06

We O 0 1.0976209523505531e-06
report O 0 4.5151324457037845e-08
a O 0 9.485810359421976e-09
Japanese O 0 1.5040167511415348e-07
family O 0 7.277730418309147e-08
with O 0 4.85983662201761e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9953963160514832
ALD B-Disease 1 1.0
) O 0 1.9804886619567696e-08
with O 0 6.317872336403241e-10
a O 0 3.431079864668618e-09
three O 0 4.626208305325008e-09
base O 0 3.886997745894405e-08
pair O 0 1.792638784081646e-07
deletion O 0 1.2694841871052631e-06
( O 0 3.2612589961900085e-08
delGAG O 0 1.1423054502301966e-06
291 O 0 1.6527594937087997e-07
) O 0 6.544812691799962e-09
in O 0 8.778664906117228e-09
the O 0 5.446745490189642e-07
ALD B-Disease 1 1.0
gene O 0 1.107173284253804e-05
. O 0 9.081393727683462e-06

A O 0 9.119005994762119e-07
variety O 0 9.310825532793388e-08
of O 0 5.8726907781192494e-08
phenotypes O 0 7.685963510084548e-07
were O 0 1.884737876878262e-08
observed O 0 1.8150151603890663e-08
within O 0 1.102322677581924e-08
this O 0 3.3241975838649296e-09
family O 0 3.369920520412961e-08
. O 0 4.1171296061293106e-07

While O 0 1.0953799574053846e-06
the O 0 2.3749603883516102e-07
proband O 0 9.186949682771228e-06
( O 0 1.2871589127882999e-08
patient O 0 8.493267422693407e-09
1 O 0 8.710086518703974e-08
) O 0 3.476434251581395e-09
was O 0 9.704982595337697e-09
classified O 0 2.347867011920357e-09
as O 0 5.99132410350478e-10
having O 0 1.7330850088370653e-09
a O 0 9.732338268619856e-10
rare O 0 1.8569684678837461e-09
intermediate O 0 1.3776923424302367e-07
type O 0 9.392232414029422e-08
of O 0 7.273747826275212e-08
adult O 0 3.5275877507956466e-07
cerebral O 0 1.217118369822856e-05
and O 0 1.6207442854465626e-07
cerebello O 0 0.3720276355743408
- O 0 8.529409387847409e-05
brain O 0 5.92112701269798e-06
stem O 0 4.7885453824392243e-08
forms O 0 4.715436485724922e-09
, O 0 5.574205541591937e-10
his O 0 1.4399769154849196e-09
younger O 0 2.6432353195104952e-08
brother O 0 1.9903768588847015e-07
( O 0 4.122741259493523e-09
patient O 0 5.076032483231074e-09
2 O 0 1.0519824655830234e-07
) O 0 3.620681532368053e-09
and O 0 1.2672515481426672e-08
nephew O 0 3.8999041862552986e-06
( O 0 1.2842479968355747e-08
patient O 0 2.295457868228823e-08
3 O 0 8.253576879724278e-07
) O 0 1.3584038782710195e-08
had O 0 2.2399069266043625e-08
a O 0 6.316865608368971e-08
childhood O 0 7.736859697615728e-05
ALD B-Disease 1 1.0
type O 1 0.9340987801551819
. O 0 9.63805869105272e-05

Another O 0 4.647214609576622e-06
nephew O 0 5.7479337556287646e-05
( O 0 1.6155377124960069e-07
patient O 0 7.409276747694094e-08
4 O 0 5.693119646821287e-07
) O 0 6.62318644373272e-09
of O 0 7.382640276887287e-09
patient O 0 1.3873350468429635e-08
1 O 0 6.396174967449042e-07
was O 0 5.188170604242259e-08
classified O 0 8.535947060295257e-09
as O 0 9.823442059797571e-10
having O 0 4.497647587697884e-09
an O 0 2.1193700128208093e-09
adolescent O 0 1.7500309468232444e-07
form O 0 3.957823082600953e-07
. O 0 5.511431027116487e-06

The O 0 3.709201791934902e-06
tau O 0 9.284912266593892e-06
level O 0 5.409030450209684e-07
in O 0 5.238961708897705e-09
the O 0 9.828526437161145e-09
cerebrospinal O 0 6.869577191537246e-07
fluid O 0 8.226088539231569e-07
( O 0 7.173746752187071e-08
CSF O 0 5.393698302214034e-06
) O 0 1.3987487834654644e-09
in O 0 9.013809143532114e-10
patient O 0 3.4112037639033588e-09
1 O 0 3.4883985478018076e-08
was O 0 7.055469986028129e-09
as O 0 3.075774634986317e-10
high O 0 2.759591000156547e-09
as O 0 3.758896666150591e-11
that O 0 2.1786173559634747e-11
of O 0 8.732435330394139e-10
patients O 0 3.092305522756078e-09
with O 0 1.1683111367233323e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.39295119047164917
( O 0 3.1014863566269923e-08
AD B-Disease 0 2.925055468949722e-06
) O 0 5.194824481691285e-08
. O 0 3.8553815784325707e-07

His O 0 6.797125024604611e-06
brain O 0 1.534550028736703e-05
magnetic O 0 3.924532393284608e-06
resonance O 0 3.948879111703718e-06
image O 0 1.132604552367411e-06
( O 0 4.196494884922686e-08
MRI O 0 3.600147829274647e-05
) O 0 2.697250600647294e-08
showed O 0 1.468258830072955e-07
abnormalities B-Disease 0 1.0652755918272305e-05
in I-Disease 0 1.4087954802732838e-08
the I-Disease 0 4.521889351849495e-08
bilateral I-Disease 0 1.0984117579937447e-05
cerebellar I-Disease 1 0.9999983310699463
hemispheres I-Disease 1 0.9977007508277893
and O 0 6.706434305669973e-06
brain O 0 0.07566141337156296
stem O 0 1.4348512422657222e-07
, O 0 4.226001215634767e-10
but O 0 3.5674846410316263e-10
not O 0 4.5899500866752874e-10
in O 0 1.1540322031322603e-09
the O 0 1.1343439965116886e-08
cerebral O 0 3.6362256651045755e-05
white O 0 4.1416750917733225e-08
matter O 0 2.297551660035424e-08
, O 0 8.891463676441447e-10
where O 0 8.086988301236886e-10
marked O 0 2.7907358646217517e-09
reductions O 0 2.0549562051996872e-08
of O 0 1.7545723096645816e-08
the O 0 2.5192310459942746e-08
cerebral O 0 1.726235950627597e-06
blood O 0 2.4336879178576964e-08
flow O 0 2.0763220476283095e-08
and O 0 2.9254374922516035e-08
oxygen O 0 1.1959375001424633e-07
metabolism O 0 8.060968070822128e-07
were O 0 8.669376327929967e-09
clearly O 0 1.2712897401456758e-08
demonstrated O 0 1.2912283686716819e-08
by O 0 1.806562899275832e-09
positron O 0 5.4885443745433804e-08
emission O 0 6.711506728152017e-08
tomography O 0 5.511586778084165e-07
( O 0 2.1555894846869705e-08
PET O 0 1.8308986682313844e-07
) O 0 5.051975193737235e-08
. O 0 5.23233381954924e-07

In O 0 7.203362173413552e-08
patients O 0 9.426435632065022e-09
2 O 0 1.0250430193536886e-07
and O 0 3.457297559350536e-09
3 O 0 4.853259483184047e-08
, O 0 8.432554654547175e-10
the O 0 1.2107055358256957e-09
autopsy O 0 3.174357843249709e-08
findings O 0 9.264180533818944e-09
showed O 0 4.247152673997334e-08
massive O 0 4.190083473076811e-06
demyelination B-Disease 1 1.0
of I-Disease 0 0.1514863818883896
the I-Disease 0 2.8257725716684945e-05
cerebral I-Disease 1 0.9991443157196045
white I-Disease 0 4.626078009550838e-07
matter I-Disease 0 3.819873484189884e-08
with O 0 9.333185335691496e-10
sparing O 0 1.1341168004719293e-08
of O 0 3.1578053949488094e-08
the O 0 1.2859962339462072e-07
U O 1 0.5416824817657471
- O 0 0.0001107046555262059
fibers O 0 3.13080903424634e-07
, O 0 7.310462901699566e-09
compatible O 0 1.6691761572928954e-07
with O 0 1.1465266513965844e-09
the O 0 4.175247703130935e-09
findings O 0 2.1709963604621407e-08
of O 0 1.2967561247023696e-07
childhood O 0 4.3250805902061984e-05
ALD B-Disease 1 1.0
. O 0 5.4945252486504614e-05

Oleic O 0 0.0009824291337281466
and O 0 7.278504654095741e-06
erucic O 0 0.004845837131142616
acids O 0 2.1558419120992767e-06
( O 0 1.4864703246075806e-07
Lorenzos O 0 5.080731625639601e-06
Oil O 0 9.025981029253671e-08
) O 0 2.5753439381048793e-09
were O 0 1.7626886616994852e-09
administered O 0 5.692609716945185e-10
to O 0 1.545290284621359e-10
patients O 0 3.5608835324829613e-10
1 O 0 1.407790861662761e-08
and O 0 1.9138366447180033e-09
4 O 0 2.448214075911892e-08
, O 0 2.2751606154614024e-10
but O 0 1.271407285008408e-10
sufficient O 0 3.0918689830627955e-09
effectiveness O 0 1.8630998965818435e-08
was O 0 1.0870557787256985e-08
not O 0 2.1896382484953847e-09
obtained O 0 8.684109786827321e-08
. O 0 3.4310627938793914e-07

The O 0 8.637745736450597e-07
findings O 0 1.7724336487390246e-07
in O 0 4.363669869889009e-09
this O 0 1.1054803739085628e-09
family O 0 2.5736043851587453e-10
suggest O 0 7.259728374009455e-10
that O 0 1.3391623920888662e-10
delGAG291 O 0 3.180769780897208e-08
is O 0 2.6579444201146885e-10
part O 0 2.7960092574552675e-10
of O 0 2.0629076225020526e-09
the O 0 2.5350734844664657e-09
cause O 0 5.1798647149325916e-08
of O 0 2.507723593225819e-07
Japanese O 0 4.90069214720279e-05
ALD B-Disease 1 1.0
with O 0 2.214242584841486e-07
phenotypic O 0 9.406970639247447e-05
variations O 0 1.2576349945447873e-05
. O 0 7.366653335338924e-06

Moreover O 0 4.333130618761061e-07
, O 0 3.776470247629504e-09
although O 0 2.1320156751158947e-09
the O 0 1.5546537390775939e-09
scale O 0 8.190047751099883e-09
of O 0 1.4599105258028544e-09
the O 0 9.93410242955406e-10
study O 0 4.2451800408294105e-10
is O 0 5.5774461438229395e-11
limited O 0 5.316733164839604e-10
, O 0 3.9940523111070547e-10
there O 0 8.886614222269884e-10
is O 0 4.0884720609035696e-10
a O 0 1.93137994486392e-09
possibility O 0 1.0508674819220687e-07
that O 0 1.150369310920496e-08
PET O 0 4.1559275132385665e-07
can O 0 4.83360125258514e-08
detect O 0 3.590309233914013e-06
an O 0 2.135793764068694e-08
insidious B-Disease 0 3.145708978991024e-05
lesion I-Disease 0 0.0001553882466396317
which O 0 4.089394156636672e-09
is O 0 1.127266724409992e-09
undetectable O 0 2.4435209411421965e-08
by O 0 5.292914995180809e-10
computed O 0 2.8875085433810455e-08
tomogram O 0 1.1552735941222636e-06
( O 0 1.5684983978303535e-08
CT O 0 2.236065483884886e-05
) O 0 1.9263139972025556e-09
or O 0 1.1245737674414613e-09
MRI O 0 8.338279400277315e-08
analysis O 0 1.6938296321100665e-09
, O 0 2.6662613783479117e-10
and O 0 2.0170498604699105e-10
that O 0 5.882783149502302e-11
the O 0 4.53388937504684e-10
higher O 0 4.968993660980914e-09
level O 0 3.689701344455898e-08
of O 0 7.57035234499881e-09
tau O 0 5.246463885555386e-08
reflects O 0 3.9942046892171845e-10
the O 0 3.6691702454128006e-10
process O 0 4.174666390355242e-09
of O 0 1.6730338003867473e-08
neuronal B-Disease 0 1.1260798601142596e-05
degeneration I-Disease 1 0.9547547698020935
in O 0 2.7868734377989313e-06
ALD B-Disease 1 1.0
. O 0 8.513426291756332e-05

Lorenzos O 0 0.0004992661415599287
Oil O 0 1.0554689424679964e-06
should O 0 1.0630535562938803e-08
be O 0 1.58280277773315e-09
given O 0 1.4260973513202657e-09
in O 0 8.674267970576466e-10
the O 0 1.6660622881303766e-09
early O 0 1.2965318596513953e-08
stage O 0 3.3449271796826e-08
. O 0 2.7128530533104822e-08
. O 0 4.6606669457105454e-07

Nonsense O 0 1.213646919495659e-05
mutation O 0 1.7228630611043627e-07
in O 0 2.6755154536317605e-08
exon O 0 2.8052434686287597e-07
4 O 0 1.0643402958976367e-07
of O 0 1.8156004699676487e-08
human O 0 1.4845429774368313e-08
complement O 0 4.699941058561308e-08
C9 O 0 0.0095077995210886
gene O 0 1.6184113604822414e-08
is O 0 8.238518756087387e-10
the O 0 1.1360733465082262e-09
major O 0 4.643995410447133e-09
cause O 0 2.8662404005785902e-08
of O 0 6.954903852829375e-08
Japanese O 0 2.872964387279353e-06
complement B-Disease 0 0.0002648363879416138
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999208450317383
. O 0 3.03865599562414e-05

Deficiency B-Disease 1 0.9990683197975159
of I-Disease 0 1.4227151950763073e-05
the I-Disease 0 5.224036954132316e-07
ninth I-Disease 0 6.876499014651927e-07
component I-Disease 0 3.749586241497127e-08
of I-Disease 0 2.283841382677565e-08
human I-Disease 0 1.7013748632166426e-08
complement I-Disease 0 1.4291728689386218e-07
( O 0 1.2716516550881352e-07
C9 O 1 0.9994462132453918
) O 0 1.2668021298622989e-08
is O 0 9.067264161721766e-10
the O 0 1.3842654800200194e-09
most O 0 9.207382634102146e-10
common O 0 3.378693804734212e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.927098254536304e-09
Japan O 0 1.0246340664821219e-08
but O 0 1.6545700365355742e-09
is O 0 2.591638292859244e-10
rare O 0 1.0784311221812004e-09
in O 0 6.996609402953879e-10
other O 0 1.3180543323443317e-09
countries O 0 9.535514600145234e-09
. O 0 3.9944032437233545e-07

We O 0 6.404372356882959e-07
studied O 0 1.368542825730401e-07
the O 0 3.013950422570133e-09
molecular O 0 3.1624285412590325e-08
basis O 0 2.1472226663377114e-08
of O 0 1.9252135530223313e-07
C9 B-Disease 1 0.9999997615814209
deficiency I-Disease 0 0.0007395289139822125
in O 0 3.685776661654927e-08
four O 0 8.51700434623126e-08
Japanese O 0 3.325780198792927e-06
C9 B-Disease 1 1.0
- I-Disease 0 0.00021755210764240474
deficient I-Disease 0 3.700375827975222e-06
patients O 0 6.687904630098274e-08
who O 0 1.0677986495011282e-08
had O 0 1.9903237102880666e-07
suffered O 0 0.05664126202464104
from O 0 0.0002038537641055882
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0014923227718099952

Direct O 0 9.187722866954573e-07
sequencing O 0 7.873364324950671e-07
of O 0 3.3753701700334204e-07
amplified O 0 1.5004237639004714e-06
C9 O 0 5.9112691815244034e-05
cDNA O 0 2.0263011890619964e-07
and O 0 2.0725870797377866e-08
DNA O 0 8.064491652248762e-08
revealed O 0 5.9597596191451885e-08
a O 0 7.404950874700944e-09
nonsense O 0 1.9799453809810075e-07
substitution O 0 1.6572704453210463e-07
( O 0 3.3277515854024386e-08
CGA O 0 2.520207772249705e-06
- O 0 1.010682353808079e-06
- O 0 4.4742827753907477e-07
> O 0 3.1692522384219046e-07
TGA O 0 1.5945232689773547e-06
) O 0 7.3797830069111114e-09
at O 0 3.2752474510289176e-08
codon O 0 4.533444197818426e-08
95 O 0 3.120235803066862e-08
in O 0 2.5942952230906258e-09
exon O 0 4.800104136393202e-08
4 O 0 4.15326404379357e-08
in O 0 2.7548265890686707e-09
the O 0 1.3912276664029832e-08
four O 0 1.3373340834732517e-07
C9 B-Disease 1 0.9460067749023438
- I-Disease 0 5.955741016805405e-06
deficient I-Disease 0 1.2469431567296851e-06
individuals O 0 4.237135442508588e-08
. O 0 2.008086539717624e-06

An O 0 1.3836111065756995e-06
allele O 0 6.951528121135198e-06
- O 0 1.4846287967884564e-06
specific O 0 5.644427503170846e-08
polymerase O 0 2.3454829545244138e-07
chain O 0 1.856905562647171e-08
reaction O 0 5.215959220095101e-09
system O 0 1.5398047281678373e-08
designed O 0 9.412745249903764e-09
to O 0 9.399572231671982e-10
detect O 0 1.830035678551667e-08
exclusively O 0 1.046571940221952e-09
only O 0 3.087223809927764e-10
one O 0 2.215363448243579e-10
of O 0 3.332334130856651e-10
the O 0 3.503785594993758e-10
normal O 0 1.4265435499538626e-09
and O 0 2.208444399576237e-10
mutant O 0 4.0693977076955434e-09
alleles O 0 2.1276362893729583e-09
indicated O 0 1.0568304009694884e-09
that O 0 1.0499744129699451e-10
all O 0 1.247748571131524e-10
the O 0 1.929563731017936e-10
four O 0 2.217629413436839e-10
patients O 0 5.875237102381803e-11
were O 0 2.4352644900638154e-10
homozygous O 0 2.1504182878828715e-09
for O 0 2.3778173874333675e-10
the O 0 9.155476932143358e-10
mutation O 0 2.5891244703757366e-09
in O 0 2.228765838552249e-09
exon O 0 4.617438875698099e-08
4 O 0 4.309224266307865e-08
and O 0 9.035256987033335e-10
that O 0 1.9576334997495337e-10
the O 0 1.2063696708253246e-09
parents O 0 7.334705620642978e-10
of O 0 2.668292697904917e-09
patient O 0 1.2713382346873914e-08
2 O 0 2.7437303629085363e-07
were O 0 2.002921348775999e-07
heterozygous O 0 1.376817863274482e-06
. O 0 3.7641793824150227e-06

The O 0 1.1403287771827308e-06
common O 0 1.5375076145573985e-07
mutation O 0 1.1711930625324385e-07
at O 0 2.2077398398323567e-07
codon O 0 2.095573279348173e-07
95 O 0 1.0700029662302768e-07
in O 0 7.237444865637599e-09
exon O 0 7.452405981211996e-08
4 O 0 4.8579462230691206e-08
might O 0 2.790012221254301e-09
be O 0 3.491119393572717e-09
responsible O 0 1.1528645593728015e-08
for O 0 1.864001841767049e-09
most O 0 4.5072656718048165e-09
Japanese O 0 2.8024567200191086e-06
C9 B-Disease 1 0.9999997615814209
deficiency I-Disease 0 0.00448759226128459
. O 0 5.103426587993454e-07
. O 0 1.818208374970709e-06

BRCA1 O 0 9.949743798642885e-06
required O 0 5.485561587192933e-07
for O 0 9.239779075187471e-08
transcription O 0 2.2511148927151226e-06
- O 0 6.188982979438151e-07
coupled O 0 2.687614824026241e-07
repair O 0 8.364640393665468e-07
of O 0 2.416212225853087e-07
oxidative O 0 1.9231165424571373e-05
DNA O 0 5.507427886186633e-06
damage O 0 8.067669114097953e-05
. O 0 1.610544859431684e-05

The O 0 3.500632374198176e-05
breast B-Disease 1 0.9999421834945679
and I-Disease 1 0.8456133008003235
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.007070761639624834
gene O 0 4.917258593195584e-06
BRCA1 O 0 6.554330411745468e-06
encodes O 0 2.597676882487576e-07
a O 0 7.767862797436464e-08
zinc O 0 1.066969957719266e-06
finger O 0 6.141933113212872e-07
protein O 0 7.093443343819672e-08
of O 0 7.429669324210408e-08
unknown O 0 4.235014898767986e-07
function O 0 6.335447437777475e-07
. O 0 1.0113321877724957e-06

Association O 0 3.0378164410649333e-06
of O 0 2.693529381758708e-07
the O 0 1.1280722134188181e-07
BRCA1 O 0 1.085626522012717e-07
protein O 0 9.072873119464475e-09
with O 0 7.949138569607328e-10
the O 0 5.073390596521676e-09
DNA O 0 7.49791624343743e-08
repair O 0 1.6771416255778604e-07
protein O 0 5.136134362260236e-08
Rad51 O 0 1.442510097149352e-06
and O 0 1.4076074750235534e-09
changes O 0 1.911808267252013e-09
in O 0 2.8493507553406516e-10
the O 0 5.937061953176226e-10
phosphorylation O 0 3.738886089621474e-09
and O 0 1.1407026434540057e-09
cellular O 0 1.7688664755155514e-08
localization O 0 6.774332206305189e-08
of O 0 3.2494416046802144e-09
the O 0 2.119208364348424e-09
protein O 0 3.1584361792624804e-09
after O 0 8.173193677407653e-09
exposure O 0 1.5180965817762626e-08
to O 0 4.509286721798844e-09
DNA O 0 7.748107577754126e-07
- O 0 3.6269457837079244e-07
damaging O 0 1.1744182302209083e-06
agents O 0 2.7380480105421157e-09
are O 0 2.9489752306766093e-10
consistent O 0 2.249676445131854e-09
with O 0 7.944253588298977e-11
a O 0 6.773124838765909e-10
role O 0 4.0292973402245025e-09
for O 0 4.414552279285999e-09
BRCA1 O 0 2.49160649445912e-07
in O 0 3.6915739798359937e-08
DNA O 0 7.290789767466777e-07
repair O 0 1.1284588254056871e-05
. O 0 9.572567250870634e-06

Here O 0 1.0953203855024185e-06
, O 0 9.398859468490173e-09
it O 0 4.5435330497944904e-10
is O 0 2.7421387382986495e-10
shown O 0 2.269367360696606e-09
that O 0 2.069718174624313e-09
mouse O 0 1.0180171017282191e-07
embryonic O 0 9.490084096341889e-08
stem O 0 1.1439065161766848e-07
cells O 0 7.696880288676766e-08
deficient B-Disease 0 8.670290441159523e-08
in I-Disease 0 2.884237293443448e-09
BRCA1 I-Disease 0 6.208928482465126e-08
are O 0 7.461501971839368e-10
defective O 0 7.260773315920233e-08
in O 0 2.035862367577579e-09
the O 0 1.0413430118205724e-09
ability O 0 9.442230330947154e-10
to O 0 5.246919565493613e-10
carry O 0 3.87724430339631e-09
out O 0 3.1190621196941493e-09
transcription O 0 1.825250137699186e-07
- O 0 1.4986562746344134e-07
coupled O 0 9.39291311397028e-08
repair O 0 3.2568709684710484e-07
of O 0 8.366269810267113e-08
oxidative O 0 2.4231728730228497e-06
DNA O 0 3.388910556623159e-07
damage O 0 4.4915300350112375e-06
, O 0 2.3468025744932675e-08
and O 0 4.455861457586252e-08
are O 0 1.3979734703184477e-08
hypersensitive O 0 9.886302905215416e-07
to O 0 4.730121716534086e-08
ionizing O 0 2.1986699721310288e-05
radiation O 0 1.761699968483299e-05
and O 0 6.603221436307649e-08
hydrogen O 0 2.82330603340597e-07
peroxide O 0 1.3848195521859452e-05
. O 0 3.365121528986492e-06

These O 0 8.455997146938898e-08
results O 0 9.79467600359385e-08
suggest O 0 2.5170601603008436e-08
that O 0 2.550044175819721e-09
BRCA1 O 0 1.3205868754084804e-07
participates O 0 1.3930836928466306e-08
, O 0 1.919177483600265e-09
directly O 0 1.0052083609934925e-09
or O 0 2.065762227942969e-09
indirectly O 0 1.7048693568000317e-09
, O 0 8.520165128977908e-10
in O 0 1.6885007836364707e-09
transcription O 0 6.955765741167852e-08
- O 0 5.528237778662515e-08
coupled O 0 3.688083083375204e-08
repair O 0 3.2883428957575234e-07
of O 0 1.570554246654865e-07
oxidative O 0 3.311266254968359e-06
DNA O 0 4.4340475824355963e-07
damage O 0 1.638470280340698e-06
. O 0 2.5499099365333677e-07
. O 0 2.6959446586261038e-06

Truncation O 0 6.260754162212834e-05
mutations O 0 9.5832581337163e-07
in O 0 4.613890780547081e-08
the O 0 9.005448475818412e-08
transactivation O 0 1.15268367153476e-05
region O 0 1.5539571052158863e-07
of O 0 3.7463482271959947e-07
PAX6 O 0 0.00029539220849983394
result O 0 3.9981080135476077e-07
in O 0 6.327742596567987e-08
dominant O 0 1.2556647561723366e-05
- O 0 4.83906660520006e-07
negative O 0 1.4463188335867017e-07
mutants O 0 6.864645911264233e-06
. O 0 1.571153575241624e-06

PAX6 O 0 0.0014455856289714575
is O 0 1.0613359791022958e-07
a O 0 2.252730446627993e-08
transcription O 0 2.4478637783431623e-08
factor O 0 1.4831420536154383e-08
with O 0 8.129006356938362e-10
two O 0 1.7736696555914477e-09
DNA O 0 3.9313317046207885e-08
- O 0 2.9227829045908038e-08
binding O 0 3.980959561999953e-08
domains O 0 9.026066294381963e-08
( O 0 4.769401318327482e-09
paired O 0 9.550730872831537e-09
box O 0 2.487479200397047e-08
and O 0 6.833206889211851e-09
homeobox O 0 1.3472832449679117e-07
) O 0 4.28076329939131e-09
and O 0 9.40502786761499e-09
a O 0 7.466206852768664e-08
proline O 0 2.5176661893056007e-06
- O 0 2.5710442059789784e-06
serine O 0 3.2541342989134137e-06
- O 0 1.213787982123904e-06
threonine O 0 4.591155175148742e-06
( O 0 8.557811526088699e-08
PST O 0 0.0028074979782104492
) O 0 9.775919096455254e-08
- O 0 2.3783373137575836e-07
rich O 0 9.925019384127154e-08
transactivation O 0 2.4700990252313204e-05
domain O 0 3.987301170127466e-06
. O 0 3.6252313293516636e-06

PAX6 O 1 0.9999653100967407
regulates O 0 6.502748146886006e-05
eye O 0 0.04165588691830635
development O 0 6.235619594008313e-07
in O 0 1.0373173431332816e-08
animals O 0 2.9770985676691453e-09
ranging O 0 1.888819056716784e-08
from O 0 1.039212049747107e-09
jellyfish O 0 1.7652120876121558e-09
to O 0 1.1616245743084619e-09
Drosophila O 0 4.168748191091254e-08
to O 0 8.019330977049322e-09
humans O 0 3.962067864904384e-07
. O 0 1.613251129128912e-06

Heterozygous O 0 7.082356205501128e-06
mutations O 0 5.672157499247987e-07
in O 0 3.3249978770300004e-08
the O 0 5.286009496785482e-08
human O 0 9.379664334119298e-08
PAX6 O 0 1.2334526218182873e-05
gene O 0 1.7784978822987796e-08
result O 0 9.292105751512736e-09
in O 0 1.8785999422732402e-09
various O 0 4.141594178719288e-09
phenotypes O 0 1.3097552198360063e-07
, O 0 4.595076763536099e-09
including O 0 1.7840187993556356e-08
aniridia B-Disease 1 1.0
, O 0 1.49793891068839e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999997615814209
, O 0 5.9256187512346514e-08
autosomal B-Disease 0 0.0001671064383117482
dominant I-Disease 0 0.47532638907432556
keratitis I-Disease 1 0.9999980926513672
, O 0 6.518590680570924e-07
and O 0 2.6161289952142397e-06
familial B-Disease 1 0.9997112154960632
foveal I-Disease 1 0.9999996423721313
dysplasia I-Disease 1 1.0
. O 1 0.666327178478241

It O 0 6.506752470158972e-08
is O 0 3.162770711995222e-09
believed O 0 9.07306407782471e-09
that O 0 4.029364619739795e-10
the O 0 2.3951656213938577e-09
mutated O 0 2.092563100575262e-08
allele O 0 1.6041796868648817e-07
of O 0 1.1032317814851922e-07
PAX6 O 0 2.3411181246046908e-05
produces O 0 1.2466960797041793e-08
an O 0 1.8999866124858045e-09
inactive O 0 3.188326047620649e-08
protein O 0 4.480747506363514e-08
and O 0 7.690408665439463e-08
aniridia B-Disease 1 1.0
is O 0 6.413256148363189e-09
caused O 0 2.439129964670883e-08
due O 0 5.110619838433195e-08
to O 0 1.3863616032949722e-08
genetic O 0 1.4232197145247483e-06
haploinsufficiency O 0 1.6998532373690978e-05
. O 0 5.5381756283168215e-06

However O 0 3.6021407368025393e-07
, O 0 2.005512556024769e-08
several O 0 4.20209911311531e-09
truncation O 0 5.302237013893318e-07
mutations O 0 3.162325867833715e-08
have O 0 2.7658089152282628e-09
been O 0 1.982936925770673e-09
found O 0 1.1244278841360256e-09
to O 0 6.289521681246413e-10
occur O 0 2.29247265615129e-09
in O 0 1.7180638023361894e-09
the O 0 7.391672163237217e-09
C O 0 1.549824810354039e-05
- O 0 1.098197230930964e-07
terminal O 0 4.180030188649653e-08
half O 0 6.7126304514886215e-09
of O 0 8.743939794442213e-09
PAX6 O 0 5.929626240686048e-06
in O 0 5.456830542982516e-09
patients O 0 5.3884341433274585e-09
with O 0 3.5119900321234354e-09
Aniridia B-Disease 1 0.9999943971633911
resulting O 0 3.1016636370395645e-08
in O 0 2.5492077337929686e-09
mutant O 0 1.2797560344779413e-08
proteins O 0 3.288188610284237e-10
that O 0 5.568018615620396e-11
retain O 0 1.2628481371734779e-08
the O 0 3.835341377822488e-09
DNA O 0 1.5695608368559988e-08
- O 0 3.229533529491846e-09
binding O 0 2.7425797188840306e-09
domains O 0 4.429936861782835e-09
but O 0 8.417337382660151e-10
have O 0 5.468726582691374e-10
lost O 0 9.518542398723184e-09
most O 0 2.2704528535033575e-10
of O 0 1.5860757152097449e-09
the O 0 7.682957381405231e-09
transactivation O 0 2.195389015469118e-06
domain O 0 6.556272751367942e-07
. O 0 1.4293556205302593e-06

It O 0 4.273007547794805e-08
is O 0 2.392836817577404e-09
not O 0 7.098349685819016e-10
clear O 0 3.984056640149447e-09
whether O 0 1.989722386852577e-09
such O 0 1.5398509134456617e-09
mutants O 0 7.641716592843295e-07
really O 0 5.554544912911297e-08
behave O 0 1.0563089070103615e-08
as O 0 4.1380880944075216e-09
loss O 0 5.256600843495107e-08
- O 0 6.604329882975435e-08
of O 0 3.669299530884018e-08
- O 0 5.5278686517112874e-08
function O 0 2.3850963870586384e-08
mutants O 0 1.0633257119252448e-07
as O 0 5.234776168094868e-09
predicted O 0 7.245362354524332e-08
by O 0 3.076892696185496e-08
haploinsufficiency O 0 1.791568320186343e-05
. O 0 3.267098236392485e-06

Contrary O 0 9.76887918113789e-07
to O 0 1.1004740230191601e-08
this O 0 1.105353919506058e-09
theory O 0 2.8885001057687987e-08
, O 0 2.426678413769423e-09
our O 0 3.38969696755953e-09
data O 0 3.3393856568864067e-09
showed O 0 1.776303659717371e-09
that O 0 1.7936592489053993e-10
these O 0 4.106353035382426e-10
mutants O 0 3.2275707440021506e-08
are O 0 8.724710398588797e-10
dominant O 0 5.506191413928718e-08
- O 0 7.142914704161285e-09
negative O 0 2.794811049255941e-09
in O 0 1.3929368769538542e-09
transient O 0 5.0466301360074795e-08
transfection O 0 9.398737432775306e-08
assays O 0 2.04100345513325e-08
when O 0 2.434643153748084e-09
they O 0 1.0529892513488903e-09
are O 0 1.1084447804066144e-09
coexpressed O 0 1.9321848299114208e-07
with O 0 2.353965244950018e-09
wild O 0 5.664865554422249e-08
- O 0 1.9225092273700284e-07
type O 0 1.5039764775792719e-06
PAX6 O 0 0.020952068269252777
. O 0 7.84906751505332e-06

We O 0 2.5745725906745065e-07
found O 0 6.695381138399625e-09
that O 0 5.013564008393701e-10
the O 0 7.374463706355527e-09
dominant O 0 1.2675569678322063e-06
- O 0 2.4448354452033527e-08
negative O 0 2.4888542338175057e-09
effects O 0 2.2241890107466133e-08
result O 0 5.261964641789518e-09
from O 0 1.1583831671657663e-09
the O 0 1.1673372268816706e-09
enhanced O 0 9.128263478430654e-09
DNA O 0 3.090289135698754e-09
binding O 0 1.8459294093275957e-09
ability O 0 2.450562641698184e-09
of O 0 1.4623610766761885e-08
these O 0 9.875616768795226e-09
mutants O 0 2.66610732069239e-06
. O 0 9.290715752285905e-07

Kinetic O 0 1.9120783690596e-05
studies O 0 2.369083205167044e-07
of O 0 5.3634689578530015e-08
binding O 0 1.3746146976245655e-07
and O 0 1.724525766633178e-08
dissociation O 0 9.357756880490342e-08
revealed O 0 2.811660060331178e-08
that O 0 5.050553864016649e-10
various O 0 2.7481248388028234e-09
truncation O 0 2.1378036763053387e-07
mutants O 0 1.63778608452958e-07
have O 0 6.905254146261086e-09
3 O 0 1.0698396835095991e-07
- O 0 3.7747874159776984e-08
5 O 0 4.558450328318031e-08
- O 0 1.9352970781483236e-08
fold O 0 7.55654738782141e-09
higher O 0 4.570976930295956e-09
affinity O 0 9.14104625326928e-10
to O 0 1.919242265113752e-10
various O 0 3.410369486811504e-10
DNA O 0 4.100860540035001e-09
- O 0 1.986096564987605e-10
binding O 0 1.385619952110062e-10
sites O 0 2.34412961264141e-10
when O 0 1.5526971375301457e-10
compared O 0 1.144596709079515e-10
with O 0 5.398458763350433e-11
the O 0 1.951059092064611e-09
wild O 0 2.8536938145862223e-08
- O 0 8.517442751099225e-08
type O 0 6.278571618167916e-07
PAX6 O 0 0.000607551890425384
. O 0 6.9054149207659066e-06

These O 0 1.5004681586106017e-07
results O 0 8.372703064196685e-08
provide O 0 4.8246824313480374e-09
a O 0 1.6558360238505543e-09
new O 0 3.865746833753292e-09
insight O 0 1.1924225162829316e-08
into O 0 4.683345378175829e-10
the O 0 5.224400356773629e-10
role O 0 1.3277992039206765e-09
of O 0 4.7143036141505945e-09
mutant O 0 3.838348163753835e-07
PAX6 O 0 3.682371971081011e-05
in O 0 1.0274447248548313e-07
causing O 0 3.6668343454948626e-06
aniridia B-Disease 1 0.9999960660934448
. O 0 1.4457315273830318e-06
. O 0 5.3381754696602e-06

Reversal O 0 7.041235221549869e-05
of O 0 2.1127629224793054e-05
severe O 1 0.9999994039535522
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.9894499182701111
excellent O 0 0.12097980827093124
neuropsychologic O 0 0.001272748108021915
outcome O 0 1.242857615579851e-05
in O 0 3.730532327494984e-08
very B-Disease 0 1.7134888707914797e-07
- I-Disease 0 1.7521377912999014e-06
long I-Disease 0 3.7587736301247787e-07
- I-Disease 0 2.4940100047388114e-05
chain I-Disease 0 1.2319538654992357e-05
acyl I-Disease 0 4.063590313307941e-05
- I-Disease 1 0.9809751510620117
coenzyme I-Disease 0 0.26028159260749817
A I-Disease 0 0.0006490876548923552
dehydrogenase I-Disease 0 0.000503710878547281
deficiency I-Disease 0 0.0012103617191314697
. O 0 2.9795428417855874e-06

Very B-Disease 0 2.8440021196729504e-05
- I-Disease 0 3.850080247502774e-05
long I-Disease 0 1.8547500530985417e-06
- I-Disease 0 1.362597777188057e-05
chain I-Disease 0 3.0690437142766314e-06
acyl I-Disease 0 4.661352249968331e-06
- I-Disease 0 6.682725506834686e-05
coenzyme I-Disease 0 1.43642882903805e-05
A I-Disease 0 4.941840870742453e-06
dehydrogenase I-Disease 0 8.252049497059488e-07
( I-Disease 0 2.19644089582971e-08
VLCAD I-Disease 0 0.000397257215809077
) I-Disease 0 8.638942716743259e-08
deficiency I-Disease 0 4.3036002352891956e-06
is O 0 1.770671387291145e-09
a O 0 1.1168832969588038e-08
disorder O 0 4.420597178977914e-06
of O 0 6.800917731197842e-07
fatty O 0 8.906170023692539e-08
acid O 0 3.221850519707914e-08
beta O 0 6.37123207525292e-08
oxidation O 0 4.298574829419977e-09
that O 0 1.6875028041596352e-09
reportedly O 0 8.314584221125187e-08
has O 0 2.2341499761324712e-09
high O 0 4.8710376177041326e-08
rates O 0 1.0467401168057222e-08
of O 0 2.5138120918200002e-08
morbidity O 0 1.6036825627452345e-06
and O 0 5.264165636731377e-08
mortality O 0 1.2433072242856724e-06
. O 0 8.199880880965793e-07

We O 0 5.913876179874933e-07
describe O 0 1.2718855657567474e-07
the O 0 8.624812863899933e-09
outcome O 0 1.1220658535648909e-07
of O 0 1.0972170727541197e-08
a O 0 5.6668079118082915e-09
5 O 0 4.096742500792061e-08
- O 0 1.4473791942748448e-08
year O 0 1.8328644157961094e-09
- O 0 2.7891038811844737e-08
old O 0 1.1132383548329017e-07
girl O 0 9.292712377373391e-08
with O 0 7.542381297298562e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 9.830854708070547e-08
was O 0 5.4078657996115e-08
first O 0 5.452242213266345e-09
seen O 0 6.1230394088340745e-09
at O 0 1.7440852317918143e-08
5 O 0 8.591122480083868e-09
months O 0 6.409670016971347e-10
of O 0 1.3117041897103832e-09
age O 0 8.66392113607617e-09
with O 0 2.1467874145031374e-09
severe O 0 0.011496220715343952
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999997615814209
hepatomegaly B-Disease 1 1.0
, O 1 0.9999996423721313
encephalopathy B-Disease 1 0.9999903440475464
, O 0 1.0237041578875505e-06
and O 0 3.9432979974662885e-06
hypotonia B-Disease 1 0.8408151865005493
. O 0 6.154100265121087e-05

Biochemical O 0 3.557175296009518e-05
studies O 0 7.069211278576404e-06
indicated O 0 0.12154731154441833
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 4.645729131880216e-05
by O 0 9.539098400068724e-09
a O 0 1.1121385590229238e-08
stable O 0 1.4135359549527493e-07
yet O 0 8.934379280844951e-08
inactive O 0 6.570123218807566e-07
enzyme O 0 6.438556283683283e-07
. O 0 8.832748221720976e-07

Molecular O 0 7.59206932343659e-06
genetic O 0 1.8598942119751882e-07
analysis O 0 6.43162110236517e-08
of O 0 5.562209892673309e-08
her O 0 2.9097668274857824e-08
VLCAD O 0 0.0002510359918233007
gene O 0 3.6685867144115036e-07
revealed O 0 5.122726065565075e-07
a O 0 4.8416470832535197e-08
T1372C O 0 1.0124564369107247e-06
( O 0 3.562836781156875e-08
F458L O 0 9.901920066113234e-07
) O 0 3.21883462106598e-08
missense O 0 1.3676325352207641e-06
mutation O 0 1.3995132519539766e-07
and O 0 7.143203362147688e-08
a O 0 2.694628733479476e-07
1668 O 0 0.00019912405696231872
ACAG O 0 0.002767228288576007
1669 O 0 0.0003814209485426545
splice O 0 2.9160089979995973e-05
site O 0 2.765639692370314e-06
mutation O 0 2.297610080859158e-06
. O 0 5.467221853905357e-06

After O 0 8.490402478855685e-07
initial O 0 1.6143809489221894e-07
treatment O 0 6.350304460056577e-08
with O 0 4.649419516056241e-09
intravenous O 0 2.700041363823402e-07
glucose O 0 6.066637070034631e-06
and O 0 5.083631293700819e-08
carnitine O 0 3.4657020933082094e-06
, O 0 2.3142809890686067e-09
the O 0 2.363813811356863e-09
patient O 0 7.164295379169516e-09
has O 0 1.1623404461147402e-09
thrived O 0 2.5099694767050096e-08
on O 0 4.3823535911258205e-09
a O 0 2.7001936242498914e-09
low O 0 2.1001527272801468e-07
- O 0 1.2739067756228906e-07
fat O 0 2.612515359601275e-08
diet O 0 1.012223638241494e-08
supplemented O 0 4.513167173314514e-09
with O 0 5.193244168033573e-10
medium O 0 3.6231817830412183e-06
- O 0 2.0989833160456328e-07
chain O 0 1.86430124671233e-08
triglyceride O 0 1.0114636239677566e-07
oil O 0 2.9877604390549095e-08
and O 0 1.0697781327451139e-08
carnitine O 0 2.787668620385375e-07
and O 0 2.780365049304123e-09
avoidance O 0 1.840648309325843e-07
of O 0 6.631290716541116e-08
fasting O 0 2.6382119813206373e-06
. O 0 6.510476850962732e-07

Her O 0 1.477483965572901e-05
ventricular O 1 0.9996998310089111
hypertrophy O 1 0.9939723610877991
resolved O 0 3.0015060474397615e-05
significantly O 0 5.673429370744998e-08
over O 0 1.0039978626252832e-08
1 O 0 2.5737936226732927e-08
year O 0 7.723534589665348e-10
, O 0 2.944074706245914e-10
and O 0 1.3460490499994648e-09
cognitively O 0 5.051714992987399e-07
, O 0 1.3163558021389576e-09
she O 0 3.921704072595844e-10
is O 0 1.2919611214190496e-10
in O 0 3.4236258272812847e-10
the O 0 3.1720137627644363e-09
superior O 0 5.416200110630598e-07
range O 0 1.1441705538572933e-07
for O 0 1.5358567750922703e-08
age O 0 1.1787426501541631e-06
. O 0 9.847225328485365e-07

Clinical O 0 1.0969807590299752e-05
recognition O 0 2.33632636081893e-06
of O 1 0.9996150732040405
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.763954221052245e-08
important O 0 3.069961840296287e-09
because O 0 1.8054803485600956e-10
it O 0 9.797371247621811e-11
is O 0 8.615809454770584e-11
one O 0 1.1576316294448219e-10
of O 0 1.169175534165845e-09
the O 0 2.5919211221747673e-09
few O 0 7.787411604454064e-09
directly O 0 2.204150284512707e-08
treatable O 0 0.030676452443003654
causes O 0 4.4732803416991374e-07
of O 0 3.4426632282702485e-06
cardiomyopathy B-Disease 1 1.0
in O 0 1.9369608708075248e-06
children O 0 5.922183987649987e-08
. O 0 5.608091413478178e-08
. O 0 1.4527442999678897e-06

Cloning O 0 1.0673464885258e-06
of O 0 1.1190331861143932e-07
a O 0 1.387620862658423e-08
novel O 0 1.4878454912548023e-08
member O 0 1.8087531472588125e-08
of O 0 1.7920331885079577e-08
the O 0 2.8716575783960252e-08
low O 0 1.3653937003255123e-06
- O 0 2.137322496764682e-07
density O 0 6.976080868525969e-08
lipoprotein O 0 6.098814537836006e-06
receptor O 0 3.010269210790284e-06
family O 0 3.2836047125783807e-07
. O 0 1.2533321296359645e-06

A O 0 2.0415757262526313e-06
gene O 0 1.5288486565623316e-07
encoding O 0 2.9675143764507084e-07
a O 0 2.234219209640287e-08
novel O 0 9.170305759198527e-08
transmembrane O 0 4.024545603442675e-07
protein O 0 2.69417608222966e-08
was O 0 1.5319946200520462e-08
identified O 0 3.6144300885609937e-09
by O 0 2.6075494541366595e-10
DNA O 0 4.956498766972572e-09
sequence O 0 1.5322920710048038e-09
analysis O 0 2.9382025701352177e-09
within O 0 4.423781785334313e-09
the O 0 1.3348718574945906e-08
insulin B-Disease 0 6.704439329041634e-06
- I-Disease 0 7.886614912422374e-05
dependent I-Disease 0 1.612776395631954e-05
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 9.242560849997972e-07
IDDM B-Disease 0 2.130275242961943e-05
) O 0 7.086908837550254e-09
locus O 0 1.4869978315346088e-07
IDDM4 O 0 6.741528522979934e-06
on O 0 5.812104291180731e-07
chromosome O 0 2.2944307147554355e-06
11q13 O 0 2.1509262296603993e-05
. O 0 7.909542546258308e-06

Based O 0 5.396437927629449e-07
on O 0 1.1147511713716085e-07
its O 0 5.82364201306973e-09
chromosomal O 0 1.8982494509600656e-07
position O 0 2.4812203491819673e-07
, O 0 2.0047619120333593e-09
this O 0 2.1511063763579585e-10
gene O 0 2.185336800408777e-09
is O 0 2.5419524818381944e-10
a O 0 5.879286502086245e-10
candidate O 0 8.604289725155922e-09
for O 0 5.338013142619502e-09
conferring O 0 4.169202441062225e-07
susceptibility O 0 8.502512173436116e-06
to O 0 9.8942075510422e-07
diabetes B-Disease 1 0.9988704323768616
. O 0 4.375606295070611e-05

The O 0 2.1286173250700813e-06
gene O 0 3.540118314049323e-07
, O 0 4.1610899614852315e-08
termed O 0 2.8303369958848634e-07
low O 0 9.285303690376168e-07
- O 0 1.4158186445456522e-07
density O 0 1.937446469923998e-08
lipoprotein O 0 1.2856723685672478e-07
receptor O 0 2.6167993993908567e-08
related O 0 6.6355902994530425e-09
protein O 0 1.9774943904593556e-09
5 O 0 2.2928936971311487e-08
( O 0 7.779479838099235e-10
LRP5 O 0 3.218117399228504e-07
) O 0 6.162696464251383e-10
, O 0 4.5019024619286085e-10
encodes O 0 1.2749509226139821e-09
a O 0 7.284847725053112e-10
protein O 0 3.5991234437204866e-09
of O 0 2.4933218156775183e-08
1615 O 0 1.3622703590954188e-05
amino O 0 6.427978860301664e-08
acids O 0 6.561799548165936e-09
that O 0 5.28144861178248e-10
contains O 0 8.23220380752332e-10
conserved O 0 4.383850615852225e-09
modules O 0 5.8245195333483935e-09
which O 0 1.6213078102289558e-10
are O 0 9.83890677264121e-11
characteristic O 0 4.461012892420513e-09
of O 0 3.083117983138095e-09
the O 0 3.4347595878614356e-09
low O 0 9.711911275189777e-08
- O 0 2.2827046919360328e-08
density O 0 7.065084961510593e-09
lipoprotein O 0 5.973905672362889e-07
( O 0 1.515033254406717e-08
LDL O 0 1.0972630661854055e-06
) O 0 2.2113551878533144e-08
receptor O 0 1.7455337797400716e-07
family O 0 3.111950874767899e-08
. O 0 3.53335877889549e-07

These O 0 6.862440926624913e-08
modules O 0 3.1935212518874323e-07
include O 0 7.634983312243548e-09
a O 0 5.857608620374322e-09
putative O 0 1.2289483208860474e-07
signal O 0 1.0743096368059923e-07
peptide O 0 1.6957052650923288e-08
for O 0 8.290885755712907e-10
protein O 0 3.545744586830324e-09
export O 0 3.957080885186315e-09
, O 0 1.0446234988137348e-09
four O 0 3.4058469378095424e-09
epidermal O 0 1.7604047997110683e-08
growth O 0 1.0108108794426585e-09
factor O 0 4.704350686779435e-09
( O 0 2.4772415230245315e-09
EGF O 0 1.0750147794169607e-07
) O 0 9.391794009161458e-10
repeats O 0 7.411789848532635e-09
with O 0 4.92746399238797e-10
associated O 0 1.4317123486762284e-08
spacer O 0 8.823506192356945e-08
domains O 0 2.4299495748891786e-08
, O 0 4.682213283757619e-09
three O 0 5.7579137013874515e-09
LDL O 0 1.6391048518471507e-07
- O 0 8.223062764045608e-08
receptor O 0 2.1875354860867446e-08
( O 0 6.055479673250375e-09
LDLR O 0 1.2089429901607218e-06
) O 0 1.9378558757665587e-09
repeats O 0 1.8510037946839475e-08
, O 0 9.834972836131328e-10
a O 0 3.6007852255437456e-09
single O 0 2.388793340912798e-08
transmembrane O 0 4.454744555459911e-07
spanning O 0 1.5126316554869845e-07
domain O 0 2.9498783860049116e-08
, O 0 3.796714942438939e-09
and O 0 6.587091760934527e-09
a O 0 1.8459305195506204e-08
cytoplasmic O 0 1.313721327278472e-06
domain O 0 2.674707502592355e-06
. O 0 2.91430205834331e-06

The O 0 8.357463912034291e-07
encoded O 0 1.4028755401795934e-07
protein O 0 5.6113119484280105e-08
has O 0 8.692850883562642e-10
a O 0 6.848900335754138e-10
unique O 0 2.3853499175885418e-09
organization O 0 5.990436147129685e-09
of O 0 4.4750763095180446e-08
EGF O 0 1.8525685163695016e-06
and O 0 2.956852185320713e-08
LDLR O 0 6.073322765587363e-06
repeats O 0 4.159471700404538e-08
; O 0 1.1292509149996022e-09
therefore O 0 1.3464117820660704e-08
, O 0 6.852628242626224e-09
LRP5 O 0 4.204709512123372e-06
likely O 0 5.0443880184047885e-08
represents O 0 8.391981332067644e-09
a O 0 2.577486446497801e-09
new O 0 3.3480402894525696e-09
category O 0 2.166781065682244e-08
of O 0 2.8559806963812662e-08
the O 0 1.0343700296289171e-07
LDLR O 0 6.735700299032032e-05
family O 0 5.094347557133005e-07
. O 0 3.540071020324831e-06

Both O 0 1.8794967218127567e-06
human O 0 5.001463136977691e-07
and O 0 1.2501850221724453e-07
mouse O 0 7.431950734826387e-07
LRP5 O 0 3.9946262404555455e-05
cDNAs O 0 1.0124497293872992e-06
have O 0 2.2258557219601016e-09
been O 0 2.5455442198563105e-09
isolated O 0 6.223557669216007e-09
and O 0 1.7148619191331704e-09
the O 0 3.0060618438909614e-09
encoded O 0 3.5472800252733805e-09
mature O 0 2.598980586299149e-09
proteins O 0 1.771795626881456e-10
are O 0 1.8943516200131683e-10
95 O 0 3.3382456798847215e-09
% O 0 2.93166851905724e-10
identical O 0 3.74268926961463e-09
, O 0 6.38329278324079e-10
indicating O 0 4.490121607858555e-09
a O 0 1.1095064866850635e-09
high O 0 1.0010912987468146e-08
degree O 0 4.011539544990228e-08
of O 0 4.327152414163038e-09
evolutionary O 0 4.1625586533200476e-08
conservation O 0 6.252004247642162e-09
. O 0 8.421886299458947e-09
. O 0 2.2953929601499112e-07

The O 0 3.7874335703236284e-06
APC B-Disease 0 5.002540092391428e-06
variants O 0 7.360442282333679e-07
I1307K O 0 1.6935580333665712e-06
and O 0 3.064440790012668e-08
E1317Q O 0 5.905371267544979e-07
are O 0 8.627527137150537e-09
associated O 0 4.192670530756004e-07
with O 0 0.00015752395847812295
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.097379693732364e-06
but O 0 6.481531311663957e-09
not O 0 7.112023747701812e-10
always O 0 1.6891579246447463e-09
with O 0 3.4036307106077857e-10
a O 0 3.634554213149954e-09
family O 0 6.900870097581446e-09
history O 0 1.3320085656687297e-07
. O 0 1.1744393759727245e-06

Classical O 0 0.001506358734332025
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.049712926149368286
FAP B-Disease 0 0.0016550840809941292
) O 0 5.562422344951301e-08
is O 0 3.747889554261974e-09
a O 0 2.183633718289002e-08
high O 0 0.0002140574943041429
- O 1 0.9880878329277039
penetrance O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9667120575904846
that O 0 1.3989088776256153e-09
predisposes O 0 2.1229434210567888e-08
to O 0 2.660354825323452e-09
hundreds O 0 5.590093721252742e-09
or O 0 3.938617432197589e-09
thousands O 0 6.17906037447824e-09
of O 0 3.072211256949231e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.999996542930603
carcinoma I-Disease 1 1.0
and O 0 2.3078889910266298e-07
that O 0 1.4523202640503996e-09
results O 0 2.784782182629897e-08
from O 0 3.5619109883811007e-09
truncating O 0 1.2366230350835394e-07
mutations O 0 1.1230653740312846e-08
in O 0 3.7052994006359086e-09
the O 0 5.3932385668531424e-08
APC B-Disease 0 1.293622858611343e-06
gene O 0 8.682343377586221e-07
. O 0 3.383631565156975e-06

A O 0 2.5274862309743185e-06
variant O 0 3.2237092000286793e-06
of O 0 6.643241476922412e-07
FAP B-Disease 0 1.90189039130928e-05
is O 0 1.1286510925856419e-07
attenuated B-Disease 0 0.0011112240608781576
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 0.9999961853027344
, O 0 1.1729581217423402e-07
which O 0 4.529552288801142e-09
results O 0 3.5080152116506724e-08
from O 0 4.892068528050686e-09
germ O 0 1.1574898053368088e-05
- O 0 3.4397743320369045e-07
line O 0 1.8361998144200697e-08
mutations O 0 4.143885234952904e-09
in O 0 5.621825782675671e-10
the O 0 1.1452895298802446e-09
5 O 0 7.1862062966943085e-09
and O 0 5.066879693593762e-10
3 O 0 1.0633902647327886e-08
regions O 0 2.3448682995308445e-09
of O 0 1.0784851234291182e-08
the O 0 5.430709393294819e-08
APC B-Disease 0 8.310190651172888e-07
gene O 0 2.890057544391311e-07
. O 0 1.7074008837880683e-06

Attenuated B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
patients O 0 2.2276763047557324e-06
have O 0 1.803272553502211e-08
" O 0 1.4314862539777096e-07
multiple O 0 7.107675173756434e-06
" O 1 0.9999886751174927
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.1234339442344208e-07
typically O 0 4.835018163618088e-09
fewer O 0 1.557289186493449e-09
than O 0 5.823939108751119e-10
100 O 0 2.6252466867049407e-09
) O 0 2.692252254465899e-10
without O 0 1.9095087733234095e-09
the O 0 4.582919377327244e-09
florid O 0 2.694741851883009e-07
phenotype O 0 3.867769393650633e-08
of O 0 1.3447588820270084e-08
classical O 0 2.5965843519770715e-07
FAP B-Disease 0 2.9280863600433804e-06
. O 0 7.859905508666998e-07

Another O 0 3.152142198814545e-06
group O 0 6.898451232473235e-08
of O 0 7.695396675444499e-08
patients O 0 2.9079750163418794e-08
with O 0 3.3259925924511435e-09
multiple O 0 1.5061956446515978e-06
adenomas B-Disease 1 0.556381106376648
has O 0 5.470690567221936e-09
no O 0 3.7076961501014694e-09
mutations O 0 2.6276913978051653e-09
in O 0 9.220669228149347e-10
the O 0 3.522656832899429e-09
APC B-Disease 0 2.296885526220649e-08
gene O 0 3.3968809987072746e-09
, O 0 7.762508413833302e-10
and O 0 4.5006146032200434e-10
their O 0 1.1775478370168457e-09
phenotype O 0 3.357845912432822e-08
probably O 0 7.516097966231428e-09
results O 0 1.506817071117439e-08
from O 0 1.4223132671631333e-09
variation O 0 2.142321697817806e-08
at O 0 1.510364810997089e-08
a O 0 1.2870673415932288e-09
locus O 0 1.97409608659882e-08
, O 0 1.4718998242457815e-09
or O 0 2.6679363163140124e-09
loci O 0 6.662262563850163e-08
, O 0 2.965424128476002e-09
elsewhere O 0 1.5644110007428935e-08
in O 0 7.69163754910096e-09
the O 0 5.2435328967703754e-08
genome O 0 1.9965287378909125e-07
. O 0 8.469045269521303e-07

Recently O 0 1.7476937728133635e-06
, O 0 9.344840457004011e-09
however O 0 7.493653697565605e-09
, O 0 2.7370508082213973e-09
a O 0 3.5660780994817287e-09
missense O 0 1.565799863101347e-07
variant O 0 2.665293550307979e-07
of O 0 4.227428291869728e-07
APC B-Disease 0 2.468979573677643e-06
( O 0 3.212511145989083e-08
I1307K O 0 3.916520938673784e-07
) O 0 4.721115054451275e-09
was O 0 9.052269156484272e-09
described O 0 2.3454140851697503e-09
that O 0 1.729860837906827e-10
confers O 0 5.586938467416758e-09
an O 0 4.161792854784352e-10
increased O 0 6.820316311717534e-09
risk O 0 1.2724221960525028e-06
of O 1 0.9999971389770508
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.0571510908193886e-05
including O 0 5.418407411639237e-08
multiple O 0 1.3647739933730918e-06
adenomas B-Disease 0 0.00011010940215783194
, O 0 8.864175526923646e-08
in O 0 1.884396994000781e-07
Ashkenazim O 0 0.0004657086974475533
. O 0 6.331972144835163e-06

We O 0 4.61029316056738e-07
have O 0 8.407297080736953e-09
studied O 0 2.9430051284862202e-08
a O 0 1.2074308219922614e-09
set O 0 4.408830189817081e-09
of O 0 3.796302383562988e-09
164 O 0 2.610229188348967e-08
patients O 0 2.6314528334125953e-09
with O 0 5.820676829415561e-09
multiple O 1 0.9998815059661865
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999799728393555
/ I-Disease 1 1.0
or I-Disease 0 0.13702312111854553
carcinoma I-Disease 1 1.0
and O 0 1.3874057458451716e-07
analyzed O 0 9.857291161097237e-08
codons O 0 2.3075720889664808e-07
1263 O 0 4.598174655257026e-06
- O 0 6.277613806560112e-07
1377 O 0 9.021176083479077e-06
( O 0 5.304178429810236e-08
exon O 0 3.587477976907394e-07
15G O 0 1.2255662795723765e-06
) O 0 8.108925086958152e-09
of O 0 1.673866911744426e-08
the O 0 2.9689005032196292e-08
APC B-Disease 0 3.3508661090309033e-07
gene O 0 4.3327045062824254e-08
for O 0 2.8785123618035868e-08
germ O 0 0.00037965591764077544
- O 0 4.99957095598802e-05
line O 0 6.694133389828494e-06
variants O 0 1.3402338481682818e-05
. O 0 6.871654932183446e-06

Three O 0 1.739303797876346e-06
patients O 0 6.02479062195016e-08
with O 0 3.247043967036234e-09
the O 0 1.7605023217015514e-08
I1307K O 0 2.3581507946346392e-07
allele O 0 9.888003660307731e-08
were O 0 8.167552856264138e-09
detected O 0 6.936949681346505e-09
, O 0 1.3773916451853552e-09
each O 0 1.2160028539653922e-09
of O 0 3.406745108236464e-08
Ashkenazi O 0 9.803880857361946e-06
descent O 0 7.411873411911074e-06
. O 0 6.444818609452341e-06

Four O 0 6.049824150977656e-06
patients O 0 4.763108449878928e-07
had O 0 1.0779447023878674e-07
a O 0 7.971859616873189e-08
germ O 0 0.000247458548983559
- O 0 1.3110893632983789e-05
line O 0 7.762499194541306e-07
E1317Q O 0 1.8836616391126881e-06
missense O 0 7.884033834670845e-07
variant O 0 2.3281516803308477e-07
of O 0 7.901378040742202e-08
APC O 0 1.20073735843107e-07
that O 0 7.100286469885475e-10
was O 0 5.3192712456962e-09
not O 0 3.413004878716208e-10
present O 0 7.644903043946272e-10
in O 0 4.013250010093117e-10
controls O 0 7.575437166451593e-09
; O 0 1.187845599659454e-09
one O 0 2.7562913063050587e-10
of O 0 6.683958386766164e-10
these O 0 2.415769251307154e-10
individuals O 0 2.3374191471248196e-10
had O 0 6.299894494965486e-10
an O 0 1.3333818771332773e-10
unusually O 0 1.171532759691729e-09
large O 0 8.255081618280258e-10
number O 0 1.8556618464060648e-09
of O 0 4.690385679850806e-08
metaplastic B-Disease 0 3.5112464047415415e-06
polyps I-Disease 0 5.909168407924881e-07
of I-Disease 0 1.247785945679425e-07
the I-Disease 0 2.638018088418903e-07
colorectum I-Disease 0 1.9588849681895226e-05
. O 0 3.0729800073459046e-06

There O 0 3.619655046804837e-07
is O 0 3.872765219625762e-09
increasing O 0 1.6985400863589462e-09
evidence O 0 3.272835558121301e-09
that O 0 6.009748254598435e-11
there O 0 2.77127848447023e-10
exist O 0 4.023836819300186e-09
germ O 0 4.23142552108402e-07
- O 0 3.5854696989190415e-08
line O 0 4.569477685123502e-09
variants O 0 3.249807312144526e-09
of O 0 2.846104019127438e-09
the O 0 2.8510156457883795e-09
APC B-Disease 0 1.0268331074314574e-08
gene O 0 3.279507498898937e-10
that O 0 4.2350522394540846e-11
predispose O 0 3.6332996611321278e-09
to O 0 6.455371792668529e-10
the O 0 2.4704469581138255e-09
development O 0 8.412109231414888e-09
of O 0 3.0697584918470966e-08
multiple O 1 0.9999860525131226
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
, O 0 1.1438562808052666e-07
but O 0 2.9834084092073e-09
without O 0 7.702148252519692e-09
the O 0 7.70920305370737e-09
florid O 0 2.702318511182966e-07
phenotype O 0 2.6995975233035097e-08
of O 0 9.168028114459048e-09
classical O 0 5.3413767631127484e-08
FAP B-Disease 0 3.133826282919472e-07
, O 0 1.990709375121469e-09
and O 0 1.180784359178233e-09
possibly O 0 1.0413276463339116e-08
with O 0 4.0799263967272736e-10
importance O 0 1.4183214602780936e-07
for O 0 0.026555435732007027
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 5.957962798674998e-07
in O 0 2.830210288351509e-09
the O 0 1.8339973983927393e-09
general O 0 2.1716870524102205e-09
population O 0 9.872066358829201e-11
. O 0 5.7795679353489504e-09
. O 0 3.518348705711105e-07

Genomic O 0 3.4327424600633094e-06
structure O 0 1.4541442396875937e-06
of O 0 6.38944982256362e-07
the O 0 1.5682373941672267e-06
human O 1 0.9996453523635864
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999966621398926
CLD B-Disease 1 1.0
) O 0 1.4054159009901923e-06
gene O 0 1.4527428220389993e-06
. O 0 3.357095238243346e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999998807907104
CLD B-Disease 1 1.0
) O 0 7.720051087289903e-08
is O 0 9.679707035914475e-10
caused O 0 2.576262536635454e-09
by O 0 2.0486770613281635e-10
mutations O 0 1.085811995871211e-09
in O 0 6.202850455494513e-10
a O 0 1.971536489620007e-09
gene O 0 5.453479889894197e-09
which O 0 4.693264887833948e-09
encodes O 0 6.063780233489524e-08
an O 0 1.5287808352582033e-08
intestinal O 0 1.5392681234516203e-05
anion O 0 1.0008547178586014e-05
transporter O 0 0.00018843506404664367
. O 0 7.69588859839132e-06

We O 0 1.2351808891253313e-06
report O 0 3.964070316442303e-08
here O 0 3.781249091616701e-09
the O 0 7.971837634457302e-10
complete O 0 2.0576538251049215e-09
genomic O 0 9.687671997937741e-09
organization O 0 4.910681195013922e-09
of O 0 8.544074781013933e-09
the O 0 1.3828121758763245e-08
human O 0 5.899590860281023e-08
CLD B-Disease 0 3.792583447648212e-05
gene O 0 7.049863626207298e-08
which O 0 1.3832660350487913e-08
spans O 0 8.702846798769315e-08
approximately O 0 1.2030820784048046e-08
39kb O 0 2.7591565299189824e-07
, O 0 5.132518410277953e-09
and O 0 9.095623809685094e-09
comprises O 0 4.558337352023045e-08
21 O 0 4.776422315444506e-07
exons O 0 5.187604074308183e-06
. O 0 1.3319033769221278e-06

All O 0 6.611018307012273e-06
exon O 0 3.012118577316869e-05
/ O 0 5.406650871009333e-06
intron O 0 1.3723988558922429e-06
boundaries O 0 7.401410329066493e-08
conform O 0 7.567049919998681e-08
to O 0 1.265836058195191e-08
the O 0 1.3490200956312037e-07
GT O 0 0.003766946727409959
/ O 0 0.0001338776492048055
AG O 0 0.0002057255187537521
rule O 0 3.1301362923841225e-06
. O 0 3.400614787096856e-06

An O 0 6.664639329301281e-08
analysis O 0 3.409884996585788e-08
of O 0 2.6963043353589455e-08
the O 0 3.033080631098528e-08
putative O 0 4.3922725012635055e-07
promoter O 0 9.040260806614242e-07
region O 0 5.524285029423481e-08
sequence O 0 2.856656422522974e-08
shows O 0 1.8869751983174865e-08
a O 0 2.8608221569470516e-08
putative O 0 2.4490627765771933e-06
TATA O 0 5.488377792062238e-05
box O 0 5.904335580453335e-07
and O 0 4.0598482797804536e-08
predicts O 0 1.9372477311208058e-07
multiple O 0 3.386086433465607e-08
transcription O 0 8.59114237528047e-08
factor O 0 3.5544950094390515e-08
binding O 0 6.680318875851299e-08
sites O 0 2.452004537190078e-07
. O 0 1.5525232583968318e-06

The O 0 4.321884432556544e-07
genomic O 0 1.1611438566205834e-07
structure O 0 9.619292029583448e-08
was O 0 1.1910996633446302e-08
determined O 0 3.058039821368652e-09
using O 0 6.777673977609311e-10
DNA O 0 6.093598070577855e-09
from O 0 5.893174837012793e-10
several O 0 5.119980550638559e-10
sources O 0 5.604944508519338e-09
including O 0 1.08577047353009e-09
multiple O 0 8.198174583640139e-09
large O 0 5.204147157655825e-08
- O 0 1.0480285936864675e-06
insert O 0 1.1206948613562417e-07
libaries O 0 9.56372900873248e-07
and O 0 9.194786265709354e-09
genomic O 0 4.6536094089333346e-08
DNA O 0 7.142549662830788e-08
from O 0 1.815351069467397e-08
Finnish O 0 2.9588565666927025e-05
CLD B-Disease 1 0.9998716115951538
patients O 0 6.765047828594106e-07
and O 0 3.0465818667835265e-07
controls O 0 1.522619913885137e-05
. O 0 9.029309694597032e-06

Exon O 0 0.000178698988747783
- O 0 2.4042260520218406e-06
specific O 0 2.982431368536709e-08
primers O 0 3.176996301590407e-07
developed O 0 2.114078156978394e-08
in O 0 8.591806155422432e-10
this O 0 2.0399000544291113e-10
study O 0 2.54474663563542e-10
will O 0 1.271766303378996e-10
facilitate O 0 9.899601138840808e-10
mutation O 0 3.9258352124704743e-10
screening O 0 4.2623479745707016e-10
studies O 0 5.522878265828979e-10
of O 0 1.9586841037977365e-09
patients O 0 1.119108916647349e-09
with O 0 7.395871137738652e-10
the O 0 9.483534313403652e-08
disease O 0 2.632920404721517e-05
. O 0 5.81137783228769e-07

Genomic O 0 2.6984089345205575e-06
sequencing O 0 7.422912631227518e-07
of O 0 2.8959536280126486e-07
a O 0 5.044975068813073e-07
BAC O 0 0.0954202339053154
clone O 0 2.95731624646578e-05
H O 1 1.0
_ O 0 2.831360177424358e-07
RG364P16 O 0 4.968223947798833e-07
revealed O 0 4.3101529456635035e-08
the O 0 1.835537166705592e-09
presence O 0 1.4025208772139308e-09
of O 0 3.445021157233441e-09
another O 0 2.3023452033754666e-09
, O 0 9.861645944297948e-10
highly O 0 3.3516629471819215e-09
homologous O 0 2.4309125823407385e-09
gene O 0 5.682772918902401e-09
3 O 0 5.628612598229665e-08
of O 0 2.1799923644039154e-08
the O 0 4.585072232998755e-08
CLD B-Disease 0 0.00023041048552840948
gene O 0 3.5220537597524526e-08
, O 0 2.6499427097093076e-09
with O 0 3.7263683805299763e-10
a O 0 1.0328885524657494e-09
similar O 0 1.4031765749322744e-09
genomic O 0 2.2000046229209147e-08
structure O 0 1.6470180241867638e-07
, O 0 3.1712696912933325e-09
recently O 0 7.878335317457186e-09
identified O 0 6.698024801465863e-09
as O 0 4.417053389715875e-09
the O 0 1.2486037803682848e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.1349843589414377e-06
( O 0 1.20585539775675e-07
PDS B-Disease 0 1.4204510080162436e-05
) O 0 2.716591573914684e-08
. O 0 5.8139338676710395e-08
. O 0 9.072614943761437e-07

The O 0 4.562148660625098e-06
APCI1307K O 0 0.0007576239295303822
allele O 0 8.250827704614494e-06
and O 0 1.0218962387398278e-07
cancer B-Disease 0 3.4803485959855607e-06
risk O 0 4.8515016004557765e-08
in O 0 5.349387599551392e-09
a O 0 8.637653259313538e-09
community O 0 6.740227043167124e-09
- O 0 1.1241711561638112e-08
based O 0 1.2346104139027148e-09
study O 0 1.8417549707550052e-09
of O 0 1.1445651537655976e-08
Ashkenazi O 0 2.0084619336557807e-06
Jews O 0 1.4392081766345655e-06
. O 0 3.1707713787909597e-06

Mutations O 0 5.371697170630796e-06
in O 0 1.638918973867476e-07
APC O 0 1.2741076034217258e-06
are O 0 7.556979042533385e-09
classically O 0 3.282424358985736e-07
associated O 0 1.322037377349261e-07
with O 0 4.1014342855305586e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9998774528503418
FAP B-Disease 0 0.07176538556814194
) O 0 3.1945226908192126e-08
, O 0 8.390844463690428e-09
a O 0 2.10268140676817e-08
highly O 0 2.0021238015033305e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.9944782252423465e-05
by O 0 3.2948843653457516e-08
multiple O 0 6.462710643972969e-06
intestinal O 1 0.9039617776870728
polyps B-Disease 0 5.672943007084541e-05
and O 0 2.3512651381452088e-08
, O 0 2.5783224444353436e-09
without O 0 8.3381479498712e-09
surgical O 0 9.707500794320367e-07
intervention O 0 2.2507748553834972e-07
, O 0 7.076575325726253e-09
the O 0 6.4612510897177344e-09
development O 0 1.8795923040215712e-07
of O 0 0.003411486279219389
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.882669650716707e-05
CRC B-Disease 0 0.0003439286374486983
) O 0 1.2984824593331723e-07
. O 0 9.85726956059807e-07

APC B-Disease 0 5.7216337154386565e-05
is O 0 1.4778339618715108e-07
a O 0 2.402421728220361e-07
tumour O 1 1.0
- O 0 1.0642957022355404e-05
suppressor O 0 8.449256370113289e-07
gene O 0 2.034768797898323e-08
, O 0 6.318381817749241e-09
and O 0 2.24491980560515e-08
somatic O 0 6.023078185535269e-06
loss O 0 2.4484672849212075e-06
occurs O 0 8.386302283724945e-07
in O 0 1.0940364063571906e-06
tumours B-Disease 1 1.0
. O 0 0.00040962465573102236

The O 0 9.61867772275582e-06
germline O 0 0.0005056215450167656
T O 0 4.443203579285182e-05
- O 0 3.0486367563753447e-07
to O 0 9.434926617757355e-09
- O 0 6.741913693986135e-08
A O 0 4.095625172340078e-08
transversion O 0 1.038445702761237e-06
responsible O 0 3.62443515200539e-08
for O 0 3.2268920868716577e-09
the O 0 1.293772466937071e-08
APC O 0 1.6943950242875871e-07
I1307K O 0 3.162386406074802e-07
allele O 0 5.7206211323546086e-08
converts O 0 3.346771393353265e-08
the O 0 7.117537670353613e-09
wild O 0 1.745226718696813e-08
- O 0 8.001271645241559e-09
type O 0 2.566257872871347e-09
sequence O 0 1.612860622834944e-09
to O 0 6.879497527201295e-10
a O 0 1.1744710093353206e-08
homopolymer O 0 7.715169340372086e-05
tract O 0 1.069362315320177e-05
( O 0 1.3616781302516756e-07
A8 O 0 1.1092500244558323e-05
) O 0 3.3998497350751222e-09
that O 0 5.68141533818789e-10
is O 0 4.530597674801129e-09
genetically O 0 1.1114943276879785e-07
unstable O 0 3.7383929338830058e-06
and O 0 2.58632837812911e-07
prone O 0 5.265228537609801e-06
to O 0 8.255105399257445e-08
somatic O 0 0.00026038545183837414
mutation O 0 9.530691386316903e-06
. O 0 6.082243544369703e-06

The O 0 2.5576869120413903e-06
I1307K O 0 3.839241344394395e-06
allele O 0 5.674857561643876e-07
was O 0 1.0191360644284941e-07
found O 0 6.3175864539744e-09
in O 0 1.0992824428512904e-08
6 O 0 3.0448784400505247e-06
. O 0 3.236242946513812e-06

1 O 0 2.4971495804493316e-06
% O 0 5.1147644342108833e-08
of O 0 7.282798719643324e-08
unselected O 0 1.6246722225332633e-05
Ashkenazi O 0 1.737819729896728e-06
Jews O 0 9.987459037574808e-08
and O 0 6.554406795089562e-09
higher O 0 1.1079887229925589e-08
proportions O 0 4.05621065624473e-08
of O 0 4.899186123452637e-08
Ashkenazim O 0 2.7960231818724424e-05
with O 0 2.655098141346457e-09
family O 0 9.430206615590464e-10
or O 0 2.63057975402603e-09
personal O 0 9.777257226062375e-09
histories O 0 4.841878009642642e-08
of O 0 7.001701192166365e-07
CRC B-Disease 0 0.0003437300038058311
( O 0 1.265374294234789e-07
ref O 0 2.2029246338206576e-06
. O 0 1.9095351078135536e-08
2 O 0 4.498984083056712e-07
) O 0 1.0891233159782132e-07
. O 0 1.0501165661480627e-06

To O 0 4.6882746573828626e-07
evaluate O 0 6.240920811251272e-07
the O 0 2.478154748075667e-08
role O 0 3.991428698668642e-08
of O 0 3.2306008534987996e-08
I1307K O 0 4.6335307501976786e-07
in O 0 3.4882439159389378e-09
cancer B-Disease 0 4.2496157703908466e-08
, O 0 2.408303556578062e-09
we O 0 1.2020957562697276e-08
genotyped O 0 6.049225476090214e-07
5 O 0 2.4965632405837823e-07
, O 0 3.711752327717477e-08
081 O 0 9.694229447632097e-06
Ashkenazi O 0 1.998671223191195e-06
volunteers O 0 7.644020882935365e-08
in O 0 1.3660139686066941e-08
a O 0 5.2963741836720146e-08
community O 0 1.206688295951608e-07
survey O 0 4.6969390155027213e-07
. O 0 2.362761733820662e-06

Risk O 0 4.505370088736527e-05
of O 0 8.425297710346058e-05
developing O 1 0.9999995231628418
colorectal B-Disease 1 1.0
, I-Disease 1 0.5902268290519714
breast I-Disease 1 0.9856063723564148
and I-Disease 0 4.136701932111464e-07
other I-Disease 0 5.6831986228189635e-08
cancers I-Disease 1 0.6295595169067383
were O 0 4.505085016148769e-08
compared O 0 2.297753098901012e-08
between O 0 3.5982946400281435e-08
genotyped O 0 8.396145290134882e-07
I1307K O 0 1.1387167830889666e-07
carriers O 0 1.7020491682728789e-09
and O 0 2.679758193124826e-09
non O 0 7.133686352744917e-08
- O 0 6.306161370872587e-09
carriers O 0 4.778422657558679e-10
and O 0 4.797517938470719e-10
their O 0 1.067602561910519e-09
first O 0 4.7104387057572694e-09
- O 0 1.3626518580167613e-08
degree O 0 3.211611101505696e-07
relatives O 0 3.3044796055037295e-07
. O 0 6.402381131920265e-07

Sperm O 0 7.350313353526872e-07
DNA O 0 3.0525438887707423e-07
analysis O 0 5.327224172901879e-08
in O 0 3.304967677308923e-08
a O 0 2.6298670263713575e-07
Friedreich B-Disease 1 0.9973344802856445
ataxia I-Disease 1 0.9999996423721313
premutation O 0 0.3473415672779083
carrier O 0 5.460705665427668e-07
suggests O 0 1.467200689830861e-07
both O 0 5.684911386083513e-08
meiotic O 0 4.0167797124013305e-06
and O 0 3.486522714979401e-08
mitotic O 0 2.0279230739106424e-07
expansion O 0 2.8850477562514243e-08
in O 0 4.871090641955789e-09
the O 0 3.0463926492529936e-08
FRDA B-Disease 0 2.0257813957869075e-05
gene O 0 7.292354098353826e-07
. O 0 2.134860778824077e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.8307536038264516e-06
usually O 0 1.040268031715641e-07
caused O 0 5.6125646352711556e-08
by O 0 1.1941516664393248e-09
an O 0 2.3618521027835016e-10
expansion O 0 5.901501065608272e-09
of O 0 3.308095486431739e-08
a O 0 9.880217533009272e-08
GAA O 0 1.2246304322616197e-05
trinucleotide O 0 3.909854967787396e-06
repeat O 0 1.6695661031462805e-07
in O 0 1.0277442896722278e-08
intron O 0 1.6471091157654882e-07
1 O 0 9.611955675836725e-08
of O 0 3.5138612020091387e-08
the O 0 4.747294468643304e-08
FRDA B-Disease 0 2.4344404664589092e-05
gene O 0 1.0222232731393888e-06
. O 0 2.1825173917022767e-06

Occasionally O 0 3.747828031919198e-06
, O 0 6.362597559927963e-08
a O 0 1.9650576277285836e-08
fully O 0 4.0510069965193907e-08
expanded O 0 1.3730353742857915e-08
allele O 0 5.284658755044802e-08
has O 0 7.860034845208475e-10
been O 0 5.00784858026293e-10
found O 0 3.155399830312433e-10
to O 0 2.5133636838425844e-10
arise O 0 5.389523494159221e-09
from O 0 3.74367259414754e-10
a O 0 1.1295611113126824e-09
premutation O 0 6.75715625675366e-08
of O 0 1.3267542620098993e-08
100 O 0 2.2714559122505307e-08
or O 0 1.52657513297072e-08
less O 0 9.727947514193147e-08
triplet O 0 6.601473160117166e-06
repeats O 0 1.6093433714559069e-06
. O 0 1.039744802255882e-06

We O 0 1.2243513083376456e-06
have O 0 2.2701650337353385e-08
examined O 0 1.2432533935680112e-07
the O 0 2.595790027370981e-09
sperm O 0 4.183737356555639e-09
DNA O 0 9.03314134603761e-09
of O 0 9.113371390867542e-09
a O 0 3.144348426076249e-08
premutation O 0 6.589251825062092e-06
carrier O 0 2.1371627099142643e-06
. O 0 1.0061900866276119e-05

This O 0 5.631081876344979e-07
mans O 0 3.857436968246475e-05
leucocyte O 0 1.0119919352291618e-05
DNA O 0 2.625924651056266e-07
showed O 0 5.37770716846353e-08
one O 0 4.030504374696875e-09
normal O 0 1.900295742984781e-08
allele O 0 3.793560665599216e-08
and O 0 2.6815016873626973e-09
one O 0 1.2352369127555107e-09
allele O 0 2.2058365800603497e-08
of O 0 7.82903786245015e-09
approximately O 0 1.4316195340313698e-08
100 O 0 7.318376304965568e-08
repeats O 0 6.762396651538438e-07
. O 0 6.880080718474346e-07

His O 0 1.5126547623367514e-06
sperm O 0 2.7666845880958135e-07
showed O 0 7.253990474964667e-08
an O 0 3.0225626446167553e-09
expanded O 0 1.8950256475136484e-08
allele O 0 9.245543708402693e-08
in O 0 6.9461649765401035e-09
a O 0 1.9944119244996728e-08
tight O 0 3.430097592627135e-07
range O 0 2.876756752812071e-07
centering O 0 2.814931292505207e-07
on O 0 1.2448616359961306e-08
a O 0 1.2950630567942767e-09
size O 0 9.444179660533791e-09
of O 0 2.2825695111805544e-08
approximately O 0 5.41122915365122e-08
320 O 0 6.694834269183048e-07
trinucleotide O 0 3.78080403606873e-05
repeats O 0 6.842717994004488e-06
. O 0 7.2687935244175605e-06

His O 0 8.477783921989612e-06
affected O 0 2.230912059530965e-06
son O 0 4.677191554947058e-06
has O 0 1.56150150587564e-08
repeat O 0 8.993313116434365e-08
sizes O 0 2.6358151217209524e-07
of O 0 2.573465280875098e-07
1040 O 0 1.1889864254044369e-05
and O 0 1.134311915507169e-07
540 O 0 1.9473220618237974e-06
. O 0 8.856872568685503e-07

These O 0 1.9095065795227129e-07
data O 0 6.280440345562965e-08
suggest O 0 6.040322020339772e-09
that O 0 3.754441479930648e-10
expansion O 0 5.4434412533055365e-09
occurs O 0 1.1958976031678503e-09
in O 0 2.5293492300626497e-10
two O 0 1.5144682730117154e-10
stages O 0 3.722186558974272e-09
, O 0 2.148539401947147e-10
the O 0 4.2988762549711623e-10
first O 0 6.483604764184747e-10
during O 0 2.686984856836716e-09
meiosis O 0 3.907819845494487e-08
followed O 0 4.540927633911451e-09
by O 0 1.6125253354815072e-09
a O 0 7.0047851963295216e-09
second O 0 8.687588604061602e-08
mitotic O 0 2.845508561222232e-06
expansion O 0 3.2604682473902358e-06
. O 0 5.6857197705539875e-06

We O 0 5.594378080786555e-07
also O 0 7.448750949379246e-09
show O 0 1.7626282655669456e-09
that O 0 1.6532347713038575e-10
in O 0 5.246559298122122e-10
all O 0 9.446606830110227e-10
informative O 0 7.456412376427579e-09
carrier O 0 1.5960295307593242e-09
father O 0 5.215909926192808e-09
to O 0 2.6328887958726455e-09
affected O 0 2.3389688408315124e-08
child O 0 3.8477043773355035e-08
transmissions O 0 2.777266843168036e-07
, O 0 1.318101960912088e-09
with O 0 2.0988005777766716e-10
the O 0 1.3663755682458145e-09
notable O 0 2.328893744518723e-09
exception O 0 2.221266948154721e-09
of O 0 3.6876031117571983e-09
the O 0 1.037070163079079e-08
premutation O 0 4.0715198679208697e-07
carrier O 0 1.4632622225008163e-08
, O 0 6.482668624130383e-09
the O 0 1.1240082642416382e-08
expansion O 0 5.2576634601564365e-08
size O 0 1.3084514804972969e-08
decreases O 0 2.6788651297238175e-08
. O 0 5.13565439064223e-08
. O 0 1.0018450211646268e-06

The O 0 1.1920254792130436e-06
R496H O 0 5.392016646510456e-06
mutation O 0 1.4019137495324685e-07
of O 0 8.687770503001957e-08
arylsulfatase O 0 5.806386980111711e-06
A O 0 6.54174456826695e-08
does O 0 5.852024642649667e-09
not O 0 3.88621934632738e-08
cause O 0 0.00010128849680768326
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.8698465030174702e-05

Deficiency B-Disease 1 0.9403607249259949
of I-Disease 0 3.846226536552422e-05
arylsulfatase I-Disease 0 0.20012231171131134
A I-Disease 0 1.2897761735075619e-05
( O 0 2.469191144882643e-07
ARSA O 0 3.525850479491055e-05
) O 0 1.8653825151204728e-08
enzyme O 0 3.832601080944187e-08
activity O 0 1.8146816671560373e-07
causes O 0 6.119579211372184e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 9.629407941247337e-06
MLD B-Disease 1 0.9999998807907104
) O 0 5.494734409694502e-07
. O 0 1.576690806359693e-06

A O 0 3.2546014949730306e-07
number O 0 2.9031642867494156e-08
of O 0 1.3282587474350294e-07
ARSA O 0 3.8514055631821975e-05
gene O 0 8.73172751880702e-08
mutations O 0 5.770032274199366e-08
responsible O 0 5.2191570176773894e-08
for O 0 4.311082335561878e-08
MLD B-Disease 1 1.0
have O 0 4.84639635089934e-08
been O 0 4.4953857525342755e-08
identified O 0 3.563245343229937e-07
. O 0 2.029058123298455e-06

Recently O 0 1.7610600480111316e-06
, O 0 2.6653388829345204e-08
the O 0 1.7343293023941442e-08
R496H O 0 3.136005659598595e-07
mutation O 0 5.9029222398976344e-08
of O 0 1.796698683165232e-07
ARSA O 0 0.00017262586334254593
was O 0 1.0211635981249856e-07
proposed O 0 5.9050813128180835e-09
to O 0 5.526334945216149e-10
be O 0 1.1315018921820297e-09
a O 0 1.3151788547105525e-09
cause O 0 7.13648944383749e-08
of O 0 4.743335011880845e-06
MLD B-Disease 1 1.0
( O 0 4.7376525458275864e-07
Draghia O 0 1.1612313755904324e-05
et O 0 3.669237457870622e-06
al O 0 6.864508463877428e-07
. O 0 3.6160159311293683e-09
, O 0 2.6689899179643817e-09
1997 O 0 2.7759840648400314e-08
) O 0 3.66033177101599e-08
. O 0 9.372481599712046e-07

We O 0 1.3887072327634087e-06
have O 0 3.072271326232112e-08
investigated O 0 2.7316966111357033e-07
the O 0 8.074015234171839e-09
R496H O 0 1.47746476386601e-07
mutation O 0 1.2440949603842455e-08
and O 0 1.4544685456030493e-09
found O 0 1.5661001384614792e-09
this O 0 4.459615454699417e-10
mutation O 0 5.320286433629917e-09
at O 0 1.8130014822759222e-08
a O 0 9.42270927950517e-10
relatively O 0 2.417420486011679e-09
high O 0 6.7138978820935336e-09
frequency O 0 1.3403800736000449e-08
in O 0 1.9068799317345508e-10
an O 0 7.748378327843142e-11
African O 0 1.133670712860635e-09
American O 0 2.620112737883318e-10
population O 0 4.3062272497840226e-11
( O 0 1.4611523102558976e-10
f O 0 1.621720713274044e-08
= O 0 1.3861236602963345e-08
0 O 0 9.097741227037659e-09
. O 0 1.1226407581332865e-09
09 O 0 3.533694936663778e-08
, O 0 2.315853064871476e-09
n O 0 7.288316083986501e-08
= O 0 1.604225730034159e-07
61 O 0 9.448255866573163e-08
subjects O 0 1.7868052282210556e-07
) O 0 7.497745002638112e-08
. O 0 6.593573971258593e-07

The O 0 1.731573502183892e-05
ARSA O 0 0.0004355479031801224
enzyme O 0 1.9782713422955567e-07
activity O 0 2.4247642116392853e-08
in O 0 7.624137987605195e-10
subjects O 0 1.4897793221280153e-08
with O 0 3.2399710692132544e-10
and O 0 7.827092307621797e-10
without O 0 1.7585818357090943e-09
the O 0 2.391705056226101e-09
R496H O 0 5.847486406196367e-08
mutation O 0 4.636507622279851e-09
was O 0 3.322682795570131e-09
determined O 0 7.762231746255566e-09
and O 0 1.5310473999718965e-09
found O 0 1.422804318806925e-09
to O 0 1.9701231757096593e-09
be O 0 2.1205922351441586e-08
normal O 0 1.3829450153934886e-06
. O 0 2.3673853775108e-06

It O 0 8.122938055521445e-08
is O 0 4.84105378006916e-09
therefore O 0 1.4653848801060576e-08
concluded O 0 2.1636134661662254e-08
that O 0 3.610872989501246e-10
the O 0 3.2816303008331715e-09
R496H O 0 1.854237581255802e-07
mutation O 0 4.1514820026122834e-08
of O 0 4.625319149909046e-08
ARSA O 0 7.759407708363142e-06
does O 0 2.6009394638037975e-09
not O 0 2.084471484309347e-09
negatively O 0 2.820714772866495e-09
influence O 0 3.418883398609296e-09
the O 0 2.4174895418838105e-09
activity O 0 1.4079815535694706e-08
of O 0 2.2042257796783815e-08
ARSA O 0 2.1764044504379854e-05
and O 0 4.608330161914864e-09
is O 0 3.9041056498767546e-10
not O 0 7.917105859789331e-10
a O 0 1.3669731124821283e-08
cause O 0 1.7147112885140814e-06
of O 0 0.00016037536261137575
MLD B-Disease 1 1.0

Down O 0 5.198546568863094e-05
- O 0 3.5152102100255433e-06
regulation O 0 3.896176394846407e-07
of O 0 2.0751430440668628e-07
transmembrane O 0 1.0793198271130677e-05
carbonic O 0 0.0005289773107506335
anhydrases O 0 3.107001248281449e-05
in O 0 2.5358735911140684e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.6748678684234619
lines O 0 3.4964295991812833e-07
by O 0 1.2051674325164186e-08
wild O 0 9.482900509283354e-08
- O 0 1.8736952256404038e-07
type O 0 3.3007927413564175e-06
von B-Disease 1 0.9999992847442627
Hippel I-Disease 1 1.0
- I-Disease 1 0.999997615814209
Lindau I-Disease 1 0.9967336654663086
transgenes O 0 0.00047475198516622186
. O 0 1.09145830720081e-05

To O 0 6.414237532226252e-07
discover O 0 1.0289131751051173e-06
genes O 0 6.027124044294396e-08
involved O 0 6.852474143670406e-08
in O 0 4.090769323283894e-08
von B-Disease 1 0.99577796459198
Hippel I-Disease 1 0.9999994039535522
- I-Disease 1 0.999967098236084
Lindau I-Disease 1 0.9999706745147705
( O 0 1.94356312022137e-06
VHL B-Disease 1 0.9071013927459717
) O 0 6.806361056987953e-07
- O 0 2.960121946671279e-06
mediated O 0 4.115384854230797e-06
carcinogenesis O 0 0.00020978284010197967
, O 0 1.773511648650583e-08
we O 0 2.1637825753373363e-08
used O 0 1.736249686246083e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999924898147583
lines O 0 8.989830348582473e-06
stably O 0 1.3795983250020072e-05
transfected O 0 2.567014007581747e-06
with O 0 1.833648433091639e-08
wild O 0 2.2585068393254915e-07
- O 0 1.0415491260573617e-06
type O 0 2.7760252123698592e-05
VHL O 1 0.9999979734420776
- O 0 0.0004355485725682229
expressing O 0 7.542438424934517e-07
transgenes O 0 3.72782742488198e-05
. O 0 4.8171223170356825e-06

Large O 0 3.951976395910606e-06
- O 0 5.911761036259122e-06
scale O 0 1.8655803160072537e-06
RNA O 0 3.3811241451076057e-07
differential O 0 5.728023211304389e-07
display O 0 4.6446711365888405e-08
technology O 0 5.828901450399826e-08
applied O 0 7.357716658162872e-09
to O 0 2.732464254862066e-10
these O 0 3.0228147762656477e-10
cell O 0 1.2315513053806626e-08
lines O 0 1.119721759756942e-09
identified O 0 2.8630915416272273e-09
several O 0 6.922262207886831e-10
differentially O 0 4.206439641052384e-08
expressed O 0 1.5859547009000607e-09
genes O 0 1.9489314606602193e-09
, O 0 5.27845767095414e-10
including O 0 2.7960411763672255e-10
an O 0 1.2669850724122966e-09
alpha O 0 5.47355227809021e-07
carbonic O 0 5.573356247623451e-06
anhydrase O 0 6.52619382890407e-06
gene O 0 1.4555884320088808e-07
, O 0 4.940286402188576e-08
termed O 0 4.018745585199213e-06
CA12 O 0 0.00020689320808742195
. O 0 1.2351276382105425e-05

The O 0 1.439258994651027e-06
deduced O 0 8.098284638435871e-07
protein O 0 3.6581120355094754e-08
sequence O 0 2.0634832509358603e-08
was O 0 3.126860903535089e-08
classified O 0 4.3639780678006446e-09
as O 0 1.0450060816680207e-09
a O 0 2.08238915000436e-09
one O 0 7.2675736539906666e-09
- O 0 3.092868041676411e-07
pass O 0 2.8808199203922413e-07
transmembrane O 0 1.4522923265758436e-05
CA O 0 6.484930509031983e-06
possessing O 0 7.180851184784842e-07
an O 0 7.848908190055681e-09
apparently O 0 1.1186789095063432e-07
intact O 0 2.5747641529960674e-07
catalytic O 0 1.6758434639996267e-07
domain O 0 7.045910876968264e-08
in O 0 9.482842955321757e-09
the O 0 3.191222219811607e-08
extracellular O 0 1.0147781495106756e-06
CA O 0 5.9047906688647345e-06
module O 0 1.6124795365612954e-05
. O 0 4.4093849282944575e-06

Reintroduced O 0 0.00011628711217781529
wild O 0 6.776362624805188e-06
- O 0 3.2169557471206645e-06
type O 0 1.692921841822681e-06
VHL B-Disease 0 0.001148521201685071
strongly O 0 1.2909752911127725e-07
inhibited O 0 8.401465834140254e-08
the O 0 3.938797732416788e-09
overexpression O 0 3.6431067940156936e-08
of O 0 8.298483678004231e-09
the O 0 7.848623084782957e-09
CA12 O 0 1.2666905604419298e-06
gene O 0 5.253089963019875e-09
in O 0 2.1321377996486035e-09
the O 0 2.0089352403829253e-08
parental O 0 2.438840283502941e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999984502792358
lines O 0 0.00011394111788831651
. O 0 1.7932092305272818e-05

Similar O 0 2.3285200256850658e-07
results O 0 3.541283035701781e-07
were O 0 2.4365490958189184e-08
obtained O 0 2.2215266071157203e-08
with O 0 4.304942180510807e-09
CA9 O 0 0.00010187133011640981
, O 0 1.5946458375992734e-08
encoding O 0 1.192928067439425e-07
another O 0 2.1030261976306974e-08
transmembrane O 0 2.3179141805940162e-07
CA O 0 1.438152850141705e-07
with O 0 3.223016742381901e-09
an O 0 3.73575703704887e-09
intact O 0 4.262360562279355e-07
catalytic O 0 6.535022976095206e-07
domain O 0 1.727299832054996e-06
. O 0 2.134712076440337e-06

Although O 0 1.7540945407290565e-07
both O 0 1.4670181514020442e-08
domains O 0 4.1779660620022696e-08
of O 0 3.049863295245814e-08
the O 0 2.669134069321899e-08
VHL B-Disease 0 3.323941200505942e-06
protein O 0 1.5085827698158027e-08
contribute O 0 1.864215226632382e-09
to O 0 5.533232760868145e-10
regulation O 0 1.018546935682707e-08
of O 0 7.775390109543423e-09
CA12 O 0 5.400265763455536e-06
expression O 0 7.938263379969612e-09
, O 0 1.7164719645634818e-09
the O 0 3.016008998102393e-09
elongin O 0 1.3014280852985394e-07
binding O 0 1.3249006336479852e-08
domain O 0 2.3061657472567276e-08
alone O 0 5.466330943448838e-09
could O 0 1.2365624968424527e-08
effectively O 0 4.56849960528416e-07
regulate O 0 5.386272619034571e-07
CA9 O 0 0.000363628234481439
expression O 0 4.994964911020361e-06
. O 0 6.446312909247354e-06

We O 0 1.1969879778916948e-05
mapped O 0 6.9998645813029725e-06
CA12 O 0 7.789925439283252e-05
and O 0 7.488876008210354e-07
CA9 O 0 0.0003181717765983194
loci O 0 7.012660603322729e-07
to O 0 3.209008170301786e-08
chromosome O 0 3.8584568073929404e-07
bands O 0 8.309176564580412e-07
15q22 O 0 6.560089332197094e-06
and O 0 3.9019363384795724e-07
17q21 O 0 2.263601345475763e-05
. O 0 2.6091897780133877e-06

2 O 0 7.645946425327566e-06
respectively O 0 8.391006076635676e-07
, O 0 2.336271265335199e-08
regions O 0 4.450527413268901e-08
prone O 0 1.1176040004556853e-07
to O 0 5.11952435999774e-09
amplification O 0 1.5165373667969106e-07
in O 0 9.430985770109146e-09
some O 0 1.172879393607218e-08
human O 0 1.080492666005739e-06
cancers B-Disease 0 0.01776566356420517
. O 0 3.3031765269697644e-06

Additional O 0 5.070123734185472e-07
experiments O 0 1.2360064260974468e-07
are O 0 1.4817812532541552e-09
needed O 0 8.656257044492577e-09
to O 0 8.764740599964682e-10
define O 0 5.705177663628547e-09
the O 0 1.957261241969377e-09
role O 0 6.5919563141392246e-09
of O 0 9.865055439206571e-09
CA O 0 2.745863412201288e-07
IX O 0 7.251801889651688e-06
and O 0 4.485903914996925e-08
CA O 0 7.398995194307645e-07
XII O 0 2.2139385691843927e-05
enzymes O 0 3.8704776272879826e-08
in O 0 5.114810353035182e-09
the O 0 7.1365957587943285e-09
regulation O 0 2.8826988796026853e-08
of O 0 1.1242484276863252e-08
pH O 0 4.333585081894853e-07
in O 0 7.1814376667589386e-09
the O 0 1.565408069836849e-08
extracellular O 0 6.756357606718666e-08
microenvironment O 0 3.54237386090972e-07
and O 0 2.3304089769027314e-09
its O 0 4.884578852504262e-10
potential O 0 9.942313639044187e-09
impact O 0 1.9822729768748104e-07
on O 0 5.643780696118483e-07
cancer B-Disease 0 1.3098820090817753e-05
cell O 0 8.420944141107611e-06
growth O 0 4.777106141773402e-07
. O 0 1.1775550774473231e-06

A O 0 3.4316230994591024e-06
gene O 0 4.4224890416444396e-07
encoding O 0 1.6443779031760641e-06
a O 0 1.274013783358896e-07
transmembrane O 0 4.6996584046610224e-07
protein O 0 1.630774981720151e-08
is O 0 3.187915209590386e-10
mutated O 0 4.4087373751722225e-09
in O 0 8.447670341027447e-10
patients O 0 1.1447966130617715e-08
with O 0 2.0403383871325786e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9998875856399536
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 7.2818119178919e-07
. O 0 2.219891030108556e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0019613124895840883
WFS B-Disease 1 0.9999191761016846
; O 0 1.1720070460796705e-06
OMIM O 0 0.05914008617401123
222300 O 0 1.125421840697527e-05
) O 0 3.818016125478607e-08
is O 0 5.4101740865064585e-09
an O 0 2.5379826240623515e-08
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999996423721313
defined O 0 6.904360816406552e-07
by O 0 3.4759388256588863e-08
young O 0 1.535398951091338e-06
- O 0 1.1584009371290449e-05
onset O 1 0.9999877214431763
non O 1 0.9999984502792358
- O 1 0.9999867677688599
immune O 1 0.999911904335022
insulin B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
dependent I-Disease 1 0.9995570778846741
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999773502349854
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999985694885254
. O 0 0.00020642679010052234

Linkage O 0 1.3771521480521187e-05
to O 0 8.751252522642972e-08
markers O 0 3.3749000749594416e-07
on O 0 2.505849465705978e-07
chromosome O 0 1.4825673133600503e-06
4p O 0 0.00014715956058353186
was O 0 8.496712666783424e-07
confirmed O 0 1.6720518658530636e-07
in O 0 2.14963193911899e-08
five O 0 1.2020710471460916e-07
families O 0 4.5890534039472186e-08
. O 0 1.1627344065345824e-06

On O 0 6.53371444059303e-07
the O 0 1.5564614486152095e-08
basis O 0 4.661337982270197e-08
of O 0 4.9994362427696615e-08
meiotic O 0 4.718295895145275e-05
recombinants O 0 0.0005288744578137994
and O 0 1.4025906693859724e-06
disease O 0 0.0704166367650032
- O 0 7.872185392443498e-07
associated O 0 3.200585041440718e-08
haplotypes O 0 2.0698183789136237e-07
, O 0 5.305177630532398e-09
the O 0 3.985852004007029e-08
WFS B-Disease 0 9.294434130424634e-05
gene O 0 3.6421827331878376e-08
was O 0 2.8219215408853415e-08
localized O 0 5.330608843223672e-08
to O 0 1.2271524241214138e-08
a O 0 2.829737582032976e-07
BAC O 1 0.9240712523460388
/ O 0 0.0009379568509757519
P1 O 0 0.00017989192565437406
contig O 0 5.7195848057745025e-06
of O 0 5.310636908006927e-08
less O 0 2.0863101468648892e-08
than O 0 1.720163211871295e-08
250 O 0 2.579209876785171e-07
kb O 0 2.2542993974639103e-05
. O 0 1.3290562037582276e-06

Mutations O 0 6.696660648231045e-07
in O 0 1.3018769173811506e-08
a O 0 4.778980322583948e-09
novel O 0 1.5644021189586965e-08
gene O 0 2.280263267095961e-08
( O 0 2.2799589771693718e-08
WFS1 O 0 5.372168743633665e-06
) O 0 1.6198381302956477e-08
encoding O 0 1.0638511582783394e-07
a O 0 1.5940710085260434e-08
putative O 0 3.1657842214372067e-07
transmembrane O 0 1.9042201415686577e-07
protein O 0 1.559537032846947e-08
were O 0 3.5428850964080993e-09
found O 0 9.111089660507332e-10
in O 0 9.998886163486986e-10
all O 0 2.829843470664173e-09
affected O 0 3.871539533406576e-09
individuals O 0 5.877167086332236e-10
in O 0 5.527412749728455e-09
six O 0 2.9266414003359387e-07
WFS B-Disease 0 0.013224843889474869
families O 0 1.5125841690277753e-09
, O 0 4.965031163983724e-10
and O 0 1.4560444516753535e-10
these O 0 1.4535471437593372e-10
mutations O 0 4.451866431054441e-09
were O 0 6.970252819371581e-09
associated O 0 2.2989631531800114e-08
with O 0 7.304859828138888e-09
the O 0 6.826434741924459e-07
disease O 0 0.13379378616809845
phenotype O 0 2.5405130145372823e-05
. O 0 4.246295702614589e-06

WFS1 O 0 0.0003267072606831789
appears O 0 2.0936595035436767e-07
to O 0 5.795065760594298e-09
function O 0 2.7163116200767945e-08
in O 0 3.2087126289326307e-09
survival O 0 1.8689658531911846e-07
of O 0 6.689320741770644e-08
islet O 0 6.811894195379864e-07
beta O 0 1.2770758530677995e-06
- O 0 2.1182380294249015e-07
cells O 0 5.2506585745959455e-08
and O 0 3.46620652180718e-08
neurons O 0 5.243833243184781e-07
. O 0 7.296202397810703e-08
. O 0 5.961998681414116e-07

Stable O 0 0.00018542222096584737
interaction O 0 7.412775175907882e-07
between O 0 8.089725866966546e-08
the O 0 5.353552268161366e-09
products O 0 1.7282721920253152e-09
of O 0 5.3624025220244675e-09
the O 0 8.523436179075361e-09
BRCA1 O 0 1.0258840887900078e-07
and O 0 1.3629273709625522e-08
BRCA2 O 0 2.672415178039955e-07
tumor B-Disease 0 2.2774300134642544e-07
suppressor O 0 5.33844342953671e-07
genes O 0 1.665056004185317e-08
in O 0 1.405453975422688e-08
mitotic O 0 8.186597710846399e-07
and O 0 2.2046762637728534e-07
meiotic O 0 2.151629996660631e-05
cells O 0 5.8591422202880494e-06
. O 0 5.985401003272273e-06

BRCA1 O 0 0.00013209160533733666
and O 0 1.0105532055604272e-06
BRCA2 O 0 4.851094217883656e-06
account O 0 1.5161925048801095e-08
for O 0 2.2301394064783153e-09
most O 0 6.157809262496983e-10
cases O 0 6.879025127304317e-10
of O 0 2.014601818700612e-09
familial O 0 5.248595869034034e-08
, O 0 6.003773478369112e-09
early O 0 6.723716978740413e-07
onset O 1 0.990147054195404
breast B-Disease 1 0.9654520153999329
and I-Disease 1 0.7707788348197937
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.082249001337914e-06
encode O 0 6.705211319513182e-08
products O 0 1.2223635437180747e-08
that O 0 1.252776216098539e-09
each O 0 1.2972484197959488e-09
interact O 0 5.579292583490769e-09
with O 0 5.106330025483885e-09
hRAD51 O 0 2.3201996555144433e-06
. O 0 5.338301320989558e-07

Results O 0 9.648601917433552e-06
presented O 0 4.097364580957219e-07
here O 0 2.5278806603523662e-08
show O 0 4.397592956451035e-09
that O 0 1.5093333249893703e-09
BRCA1 O 0 1.403249996201339e-07
and O 0 4.5366792988943416e-08
BRCA2 O 0 2.484983724571066e-06
coexist O 0 2.917829249327042e-07
in O 0 7.525766676508283e-09
a O 0 1.2975312380092419e-08
biochemical O 0 2.883975582790299e-07
complex O 0 6.3730493593539e-07
and O 0 2.5161769556802938e-08
colocalize O 0 2.2877186438563513e-06
in O 0 1.4118081814729067e-08
subnuclear O 0 9.717115290186484e-07
foci O 0 1.0125868357135914e-06
in O 0 1.1754010209585886e-08
somatic O 0 1.8335266815938667e-07
cells O 0 1.7323852574691045e-08
and O 0 3.4024185691095e-09
on O 0 7.456540274120016e-09
the O 0 1.0042751075189926e-09
axial O 0 1.0859657173512005e-08
elements O 0 2.8522354256210747e-08
of O 0 7.528526424493975e-08
developing O 0 7.547604923274776e-07
synaptonemal O 0 6.041636879672296e-06
complexes O 0 1.8413225006952416e-06
. O 0 1.2113872571717366e-06

Like O 0 3.941252998629352e-06
BRCA1 O 0 1.7518957974971272e-05
and O 0 2.0022255284857238e-06
RAD51 O 0 0.0005031792097724974
, O 0 6.85852057813463e-07
BRCA2 O 0 4.871144483331591e-06
relocates O 0 1.1866344493682845e-06
to O 0 1.1750909578722712e-07
PCNA O 0 1.549280932522379e-05
+ O 0 1.9312396659643127e-07
replication O 0 3.4467909415525355e-08
sites O 0 3.1852609438942636e-09
following O 0 5.544877446084229e-09
exposure O 0 1.8854713346172502e-08
of O 0 1.842089680792469e-08
S O 0 6.779747536711511e-07
phase O 0 9.141636496678984e-07
cells O 0 2.7961508664020585e-08
to O 0 1.1959713219766854e-08
hydroxyurea O 0 2.2456279111793265e-06
or O 0 1.4470057863036345e-07
UV O 0 0.00018578341405373067
irradiation O 0 4.956386419507908e-06
. O 0 1.270758389182447e-06

Thus O 0 1.578950787006761e-06
, O 0 5.726046481413505e-08
BRCA1 O 0 2.8374284966048435e-07
and O 0 2.534359389017027e-08
BRCA2 O 0 1.4543978466008411e-07
participate O 0 8.650744121041498e-09
, O 0 1.0469353162179118e-09
together O 0 3.728238273659201e-10
, O 0 2.832931111917958e-10
in O 0 1.7721267508985505e-10
a O 0 6.873359659209655e-10
pathway O 0 3.908295020949026e-09
( O 0 1.4592674846269915e-09
s O 0 1.0451003618072718e-08
) O 0 9.253774413409133e-10
associated O 0 1.9456261046713053e-09
with O 0 1.4879092402608762e-10
the O 0 1.4042875751130168e-09
activation O 0 7.454194594913588e-09
of O 0 9.673159162559841e-09
double O 0 1.3576423540939686e-08
- O 0 1.0444590969882483e-07
strand O 0 3.215508925791255e-08
break O 0 7.168522131451027e-08
repair O 0 7.489797440030088e-07
and O 0 1.4288742988810554e-07
/ O 0 9.544709428155329e-06
or O 0 1.9457759492524929e-07
homologous O 0 1.1010639582309523e-06
recombination O 0 1.1721289183697081e-06
. O 0 2.7400874387240037e-06

Dysfunction O 0 0.020593322813510895
of O 0 3.777319363962306e-07
this O 0 4.082022275753161e-09
pathway O 0 2.553092137702606e-08
may O 0 3.1229969721380257e-09
be O 0 5.188679486067826e-10
a O 0 3.3728239645647307e-10
general O 0 2.451572278516778e-09
phenomenon O 0 6.736641466886795e-09
in O 0 3.854575825190665e-10
the O 0 6.464193624822201e-10
majority O 0 3.7395903040859935e-10
of O 0 1.81529125065083e-09
cases O 0 1.6223170584694913e-09
of O 0 3.3807364019367014e-08
hereditary B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999977350234985
and I-Disease 1 0.9999281167984009
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000271880766376853
. O 0 4.226615055813454e-05

A O 0 2.130676875822246e-06
novel O 0 7.784806825839041e-07
Arg362Ser O 0 4.346322384662926e-06
mutation O 0 3.065364495569156e-08
in O 0 3.0883091639566373e-09
the O 0 1.2598960985599206e-08
sterol O 0 4.6269161657619406e-07
27 O 0 8.290148230116756e-07
- O 0 1.072043232852593e-06
hydroxylase O 0 1.953381797648035e-06
gene O 0 4.867090552806985e-08
( O 0 2.1680996553641307e-08
CYP27 O 0 5.014620001020376e-06
) O 0 5.833970195823213e-09
: O 0 8.122991723702455e-10
its O 0 4.190028046746619e-10
effects O 0 1.2243376090737002e-08
on O 0 1.6319667395237047e-08
pre O 0 1.8818647617990791e-07
- O 0 1.5388415874895145e-08
mRNA O 0 2.77575136209407e-08
splicing O 0 2.2416893230570167e-08
and O 0 3.1877529504953372e-09
enzyme O 0 4.544014231555593e-08
activity O 0 2.1817317019667826e-07
. O 0 7.088073061822797e-07

A O 0 9.466201049690426e-07
novel O 0 1.0882470036222003e-07
C O 0 3.9053168165992247e-07
to O 0 1.018680473308109e-09
A O 0 6.743968938849321e-09
mutation O 0 4.827186206313172e-09
in O 0 1.8975130355869396e-09
the O 0 5.158162341700745e-09
sterol O 0 1.2953223915701528e-07
27 O 0 2.759756512205058e-07
- O 0 1.1811818012574804e-07
hydroxylase O 0 4.1387934857084474e-07
gene O 0 1.904021651455423e-08
( O 0 8.087424063774051e-09
CYP27 O 0 1.3007223742533824e-06
) O 0 3.731056796851817e-09
was O 0 1.1257569099143439e-08
identified O 0 7.544133318049262e-09
by O 0 2.457363423857828e-09
sequencing O 0 1.2056898412993178e-07
amplified O 0 4.0722730432207754e-07
CYP27 O 0 2.4400975235039368e-05
gene O 0 3.340655041483842e-08
products O 0 1.509529745646887e-08
from O 0 3.481404275973432e-09
a O 0 3.845809448677073e-09
patient O 0 2.2671319044320626e-08
with O 0 1.9320772537412267e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.75048704326764e-07
CTX B-Disease 0 0.00016693919315002859
) O 0 2.2835827451217483e-07
. O 0 8.790042897999228e-07

The O 0 1.6001627045625355e-06
mutation O 0 9.561831575410906e-07
changed O 0 2.851151066352031e-07
the O 0 1.0900210867248461e-07
adrenodoxin O 0 2.7667847461998463e-06
cofactor O 0 3.9542842955597735e-07
binding O 0 1.3088374828384985e-07
residue O 0 3.7720531054219464e-07
362Arg O 0 3.5939191889156064e-07
to O 0 1.2879545430166672e-08
362Ser O 0 3.757156719075283e-06
( O 0 1.8198549867065594e-07
CGT O 0 1.3488131116901059e-05
362Arg O 0 2.3061627416609554e-06
to O 0 2.992072012375502e-08
AGT O 0 4.036619793623686e-05
362Ser O 0 1.859936332948564e-06
) O 0 1.0999031907488188e-08
, O 0 3.7122034335368426e-09
and O 0 3.3961164991325177e-09
was O 0 3.938987447327236e-08
responsible O 0 4.0731890749157174e-08
for O 0 1.4435470596652067e-08
deficiency O 0 1.657614802752505e-06
in O 0 1.4130635328513108e-08
the O 0 3.763708633641727e-08
sterol O 0 8.470361763102119e-07
27 O 0 2.389042720096768e-06
- O 0 1.5257694485626416e-06
hydroxylase O 0 1.4107092738413485e-06
activity O 0 1.1745359351778006e-08
, O 0 5.180817996830456e-10
as O 0 1.3252077213365965e-10
confirmed O 0 7.595181705788434e-10
by O 0 9.949246981832971e-11
expression O 0 1.2161954776601647e-09
of O 0 5.007364300979589e-09
mutant O 0 2.7738828123347048e-08
cDNA O 0 5.6156803651674636e-08
into O 0 7.798934831271254e-08
COS O 0 5.996158961352194e-06
- O 0 8.359735943486157e-07
1 O 0 5.430164833342133e-07
cells O 0 9.959625231203972e-07
. O 0 1.4432848729484249e-06

Quantitative O 0 2.8886324798804708e-06
analysis O 0 6.471255886708605e-08
showed O 0 2.6863610003147187e-08
that O 0 3.310692830993389e-10
the O 0 9.188225180700726e-10
expression O 0 1.6102202904377805e-09
of O 0 7.140053881471431e-09
CYP27 O 0 4.0598916939416085e-07
gene O 0 1.0059832966646809e-09
mRNA O 0 6.157671261775022e-09
in O 0 1.5906714834201807e-09
the O 0 6.194790902469549e-09
patient O 0 4.695595023918031e-08
represented O 0 1.2634015433832246e-07
52 O 0 2.9271511721162824e-06
. O 0 5.231273917161161e-06

5 O 0 1.502508666817448e-06
% O 0 2.684440403299959e-08
of O 0 3.97595094625558e-08
the O 0 3.9255173334140636e-08
normal O 0 5.60526757453772e-07
level O 0 7.0656801653967705e-06
. O 0 1.2284448303034878e-06

As O 0 1.271634602062477e-07
the O 0 2.9274358936959288e-08
mutation O 0 3.3375027186366424e-08
occurred O 0 1.4023616756730917e-07
at O 0 2.4189992231526958e-08
the O 0 3.3401055254955736e-09
penultimate O 0 3.0748398671676114e-07
nucleotide O 0 1.1971694746648609e-08
of O 0 1.9598397571485293e-08
exon O 0 2.3099455859210138e-07
6 O 0 5.701046461581427e-07
( O 0 1.5896048921604233e-08
- O 0 1.4531383207838644e-08
2 O 0 2.8112204120134265e-08
position O 0 1.1920342046778387e-07
of O 0 5.991546458972152e-08
exon O 0 2.447194447086076e-07
6 O 0 6.432388204302697e-07
- O 0 7.401296642228772e-08
intron O 0 1.59688667622504e-07
6 O 0 2.80711162758962e-07
splice O 0 1.457027281048795e-07
site O 0 1.7622022951968574e-08
) O 0 6.035251742808612e-10
of O 0 1.4852361562844862e-09
the O 0 1.8603859563981473e-09
gene O 0 7.473811791669505e-09
, O 0 3.6343601461652497e-09
we O 0 5.719145601545961e-09
hypothesized O 0 2.4672507592526927e-08
that O 0 9.891221175450937e-10
the O 0 3.784799140760242e-09
mutation O 0 2.0360266361763024e-08
may O 0 2.77223790590142e-08
partially O 0 1.2124257864343235e-07
affect O 0 2.5950043891498353e-08
the O 0 1.2000477056517411e-08
normal O 0 4.922697272036203e-08
splicing O 0 5.4986351472052775e-08
efficiency O 0 2.5179820895004923e-08
in O 0 2.760154327319242e-09
exon O 0 4.1333727551773336e-08
6 O 0 1.8490279529714826e-08
and O 0 4.864366687229449e-10
cause O 0 1.951103723030201e-09
alternative O 0 6.224483151129334e-09
splicing O 0 1.7293876553026166e-08
elsewhere O 0 1.7609413927033302e-09
, O 0 1.9433107900646007e-10
which O 0 2.0124731048287714e-10
resulted O 0 5.733190810985889e-09
in O 0 1.626865975268288e-09
decreased O 0 4.497804440006803e-08
transcript O 0 1.3540029897285422e-07
in O 0 1.7090171500200313e-09
the O 0 1.946740546543424e-08
patient O 0 1.4736497178091668e-07
. O 0 1.1814605613835738e-06

Transfection O 0 0.00010718007251853123
of O 0 1.1739579122149735e-06
constructed O 0 4.519933554547606e-06
minigenes O 0 5.115855401527369e-06
, O 0 4.2002721301059864e-09
with O 0 4.815174370342845e-10
or O 0 2.6404978203942164e-09
without O 0 2.960507394789147e-09
the O 0 2.0384463006450915e-09
mutation O 0 2.8688968978229923e-09
, O 0 1.3826243483450185e-09
into O 0 6.121871898301379e-09
COS O 0 5.971854761810391e-07
- O 0 4.217477922452417e-08
1 O 0 1.7874997482181243e-08
cells O 0 1.4562506756021776e-09
confirmed O 0 1.979743702307246e-09
that O 0 1.0849707937632402e-10
the O 0 1.2654489678354253e-09
mutant O 0 1.1157254675708828e-07
minigene O 0 6.890441568430106e-07
was O 0 1.8811105562122066e-08
responsible O 0 4.641727890941638e-09
for O 0 6.35871022502954e-10
a O 0 1.4541579052007592e-09
mRNA O 0 2.3063503107323413e-08
species O 0 1.4760099809052463e-09
alternatively O 0 3.844198204205895e-08
spliced O 0 2.3063950038704206e-07
at O 0 1.198457368900563e-07
an O 0 4.552852317374345e-09
activated O 0 5.268500444799429e-07
cryptic O 0 7.434630333591485e-07
5 O 0 4.379064364457008e-07
splice O 0 1.1459225106591475e-06
site O 0 2.319413283657923e-07
88 O 0 9.086901968657912e-07
bp O 0 3.3901679330483603e-07
upstream O 0 2.1690800267037957e-08
from O 0 1.5331398373064076e-09
the O 0 3.3005560506893517e-09
3 O 0 4.049107005243968e-08
end O 0 3.318232089100093e-08
of O 0 3.8540868274594686e-08
exon O 0 9.731944601298892e-07
6 O 0 1.699016138445586e-06
. O 0 1.0462010777700925e-06

Our O 0 1.1058668860641774e-06
data O 0 6.02210263878078e-08
suggest O 0 5.33191801821431e-09
that O 0 2.3049540054387307e-10
the O 0 7.781616462310126e-10
C O 0 4.600428482604002e-08
to O 0 4.869286640563075e-10
A O 0 3.810499027423475e-09
mutation O 0 2.2608346306185467e-09
at O 0 8.822946817588218e-09
the O 0 2.4041502122429392e-09
penultimate O 0 9.710819171004914e-08
nucleotide O 0 3.586617225437294e-09
of O 0 2.960507394789147e-09
exon O 0 3.043616203513011e-08
6 O 0 2.51711771426244e-08
of O 0 4.060388469895315e-09
the O 0 4.758406557670014e-09
CYP27 O 0 9.84858729680127e-07
gene O 0 5.580867767918107e-09
not O 0 7.686353220570652e-10
only O 0 2.6491189242250357e-09
causes O 0 2.9665853773508388e-08
the O 0 3.992746044900741e-08
deficiency B-Disease 0 2.0293482521083206e-06
in I-Disease 0 1.0362218638704235e-08
the I-Disease 0 2.0810441370144872e-08
sterol I-Disease 0 5.233880528976442e-07
27 I-Disease 0 1.2457140883270768e-06
- I-Disease 0 3.8878843611200864e-07
hydroxylase I-Disease 0 3.9938817053553066e-07
activity I-Disease 0 6.775350946952585e-09
, O 0 3.8959083181744347e-10
but O 0 7.128280188339886e-10
also O 0 7.238628585426454e-10
partially O 0 9.503811959632458e-09
leads O 0 1.1074853256687334e-09
to O 0 4.196794856081709e-10
alternative O 0 2.2235189689467916e-08
pre O 0 2.6044162382277136e-07
- O 0 1.5659635366205293e-08
mRNA O 0 1.440172692213082e-08
splicing O 0 1.7466586399450534e-08
of O 0 6.3367382452383936e-09
the O 0 1.3680320876119367e-08
gene O 0 1.1290516255257899e-07
. O 0 8.976618346423493e-07

To O 0 2.020679801262304e-07
our O 0 7.813034130776941e-08
knowledge O 0 5.879068254444064e-08
, O 0 1.0649851001076627e-09
this O 0 1.780488395608515e-10
is O 0 1.244243180709148e-10
the O 0 5.674095082675024e-10
first O 0 1.5225671834429022e-09
report O 0 8.35933877674222e-10
regarding O 0 4.072410408895166e-09
effects O 0 2.0125325406183947e-08
on O 0 1.9592828692793773e-08
pre O 0 1.840808181441389e-07
- O 0 7.68701724496168e-09
mRNA O 0 3.468446863053032e-09
splicing O 0 3.818472649186333e-09
of O 0 1.457506670909936e-09
a O 0 9.090658781296668e-10
mutation O 0 5.121487678394487e-09
at O 0 2.43820874601397e-08
the O 0 3.446999574663323e-09
- O 0 1.5401100839085302e-08
2 O 0 1.9601351652909216e-08
position O 0 4.64869494010145e-08
of O 0 1.9341863222166467e-08
a O 0 1.3315558433646402e-08
5 O 0 2.361584989785115e-07
splice O 0 2.432723931633518e-06
site O 0 6.704354404973856e-07
. O 0 1.4532001841871534e-06

ATM O 0 0.00024149259843397886
germline O 0 4.976571653969586e-05
mutations O 0 3.1344868034466344e-07
in O 0 8.122674444166478e-08
classical O 1 0.9358148574829102
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00016005638462956995
in O 0 4.6782432150394015e-08
the O 0 6.104488647906692e-08
Dutch O 0 3.7286634324118495e-05
population O 0 8.223483227709494e-09
. O 0 4.1499038161418866e-07

Germline O 0 0.00013374074478633702
mutations O 0 3.877327969803446e-07
in O 0 1.826771622859269e-08
the O 0 1.7520138229087934e-08
ATM O 0 6.572348070221778e-07
gene O 0 8.817782060077661e-09
are O 0 6.497283822071154e-10
responsible O 0 5.315113238424374e-09
for O 0 2.1720019116600042e-09
the O 0 2.547883013903629e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7757984096533619e-06
. O 0 2.6918858111457666e-06

In O 0 1.3716984881284588e-07
our O 0 3.582366403520609e-08
study O 0 2.8323381418005056e-09
, O 0 5.839768113524713e-10
we O 0 4.1814696150055397e-10
have O 0 7.674776786315007e-11
determined O 0 4.685760224276692e-09
the O 0 3.3824505418778017e-09
ATM O 0 2.502054883279925e-07
mutation O 0 1.980386699074188e-08
spectrum O 0 3.116506874789593e-08
in O 0 2.1728303600809795e-09
19 O 0 2.7760634679907525e-08
classical O 0 3.2115070780491806e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 1.022036144604499e-08
, O 0 2.0543781953374918e-10
including O 0 6.017134013269754e-11
some O 0 6.152898329725431e-11
immigrant O 0 4.858506374993965e-10
populations O 0 1.1825597445724867e-10
, O 0 9.752625790282465e-11
as O 0 1.5890605498114496e-10
well O 0 2.2694614243423672e-10
as O 0 4.357671168353505e-10
12 O 0 4.205250370148406e-09
of O 0 2.1771613401000423e-09
Dutch O 0 2.6468129021850473e-07
ethnic O 0 1.216432732320527e-08
origin O 0 1.989780855637946e-07
. O 0 1.3840149222232867e-06

Both O 0 3.682108911107207e-07
the O 0 8.491943503941002e-08
protein O 0 3.386415770023632e-08
truncation O 0 5.264080868983001e-07
test O 0 2.1692420659746858e-07
( O 0 2.5960590122053873e-08
PTT O 0 6.112161372584524e-07
) O 0 9.082547491878756e-10
and O 0 2.9508206988992924e-10
the O 0 7.716466909890585e-10
restriction O 0 2.209819216503206e-09
endonuclease O 0 1.8307538596218365e-07
fingerprinting O 0 1.87316999245013e-07
( O 0 2.4119042763004472e-08
REF O 0 1.2184968909423333e-06
) O 0 9.105929899000387e-10
method O 0 5.4492170775688464e-09
were O 0 1.5662553476403218e-09
used O 0 1.0959866347803882e-09
and O 0 1.2486182088267128e-09
compared O 0 1.0672788208765382e-09
for O 0 1.9476076307256562e-10
their O 0 5.604407493642327e-10
detection O 0 2.0662637822965735e-08
efficiency O 0 1.4412718130074609e-08
, O 0 1.0721327159401994e-09
identifying O 0 1.0918017601113661e-08
76 O 0 7.304330473800746e-09
% O 0 1.5260670505057305e-10
and O 0 2.304123281060555e-10
60 O 0 9.424776514777022e-10
% O 0 1.45105136239998e-10
of O 0 1.1211513939457518e-09
the O 0 2.556764799876987e-09
mutations O 0 2.147730526758096e-08
, O 0 1.49509684632676e-08
respectively O 0 6.612717697862536e-07
. O 0 1.5965941884132917e-06

Most O 0 1.8639569532297173e-07
patients O 0 7.263183476879931e-08
were O 0 1.3361632689168346e-08
found O 0 2.3732420473265847e-09
to O 0 2.58790011642418e-09
be O 0 2.1282545503709116e-08
compound O 0 1.46727359151555e-06
heterozygote O 0 5.188201248529367e-05
. O 0 6.596526418434223e-06

Seventeen O 0 7.38411836209707e-06
mutations O 0 1.6279321357615117e-07
were O 0 1.5978731227050957e-08
distinct O 0 3.7228253813026413e-09
, O 0 8.830416953209408e-10
of O 0 1.6145750292295702e-09
which O 0 4.103894446494394e-10
10 O 0 3.1741744788149617e-09
were O 0 2.1903943103751544e-09
not O 0 4.374778761473408e-09
reported O 0 7.021588999123196e-08
previously O 0 2.977555482175376e-07
. O 0 1.9625538243417395e-06

Mutations O 0 4.841356258111773e-06
are O 0 2.1547961637224944e-08
small O 0 2.4070605064707706e-08
deletions O 0 2.3722891739907936e-07
or O 0 1.1145640854692829e-07
point O 0 6.065648676667479e-07
mutations O 0 3.9844925936449727e-07
frequently O 0 1.6228756294367486e-07
affecting O 0 4.262710433522443e-07
splice O 0 3.953857230953872e-06
sites O 0 1.060638396666036e-06
. O 0 3.91528419640963e-06

Moreover O 0 9.428770681552123e-06
, O 0 4.0407982737633574e-07
a O 0 2.767901037259435e-07
16 O 0 4.943061867379583e-06
. O 0 4.40231724496698e-06

7 O 0 5.590064392890781e-05
- O 0 6.010220204188954e-06
kb O 0 6.445501185226021e-06
genomic O 0 7.59900018465487e-08
deletion O 0 8.079949509465223e-08
of O 0 1.172514707548089e-08
the O 0 4.677902065708395e-09
3 O 0 3.793611114133455e-08
end O 0 1.2368525759143267e-08
of O 0 4.356060845367438e-09
the O 0 1.6476008335430947e-09
gene O 0 2.891949568706309e-09
, O 0 6.830727650175561e-10
most O 0 2.3807761317939935e-10
likely O 0 2.151308686748621e-09
a O 0 4.5938125525779583e-10
result O 0 4.041627921225199e-09
of O 0 7.886965747161412e-09
recombination O 0 2.0167094660905605e-08
between O 0 3.836051032379828e-09
two O 0 2.0276778034400422e-09
LINE O 0 4.430750522033122e-08
elements O 0 4.8110848638316384e-08
, O 0 8.303612908378e-09
was O 0 8.561093522985175e-08
identified O 0 4.5008206939201045e-07
. O 0 1.1871620699821506e-06

The O 0 6.635782483499497e-07
most O 0 8.586862776382986e-09
frequently O 0 3.5605527415327742e-09
found O 0 2.5237600898009305e-09
mutation O 0 5.395591973211822e-09
, O 0 1.4766435851853998e-09
identified O 0 4.54578907849168e-09
in O 0 2.1055497345656704e-09
three O 0 5.681960235648376e-09
unrelated O 0 6.981365174851817e-08
Turkish O 0 2.2470503608928993e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.6005664349449944e-08
, O 0 5.390953017325728e-09
was O 0 1.7325769263720758e-08
previously O 0 1.459587561924991e-09
described O 0 8.493943326470799e-10
to O 0 3.479610211076789e-10
be O 0 1.5315090307055357e-09
a O 0 4.9856638817402654e-09
Turkish O 0 1.4628486724177492e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
founder O 0 0.0003316834627185017
mutation O 0 3.3215801522601396e-06
. O 0 3.1821889479033416e-06

The O 0 2.0743615891660738e-07
presence O 0 3.273136428560974e-08
of O 0 7.932953849376645e-08
a O 0 2.482710748097361e-08
founder O 0 6.662300506832253e-07
mutation O 0 6.638757810151219e-08
among O 0 2.8418134512264714e-09
relatively O 0 2.4983857205285176e-09
small O 0 1.4748533505581918e-09
ethnic O 0 1.7251368111814713e-09
population O 0 2.2639619345898865e-10
groups O 0 1.7240898986248254e-10
in O 0 5.285136772670285e-10
Western O 0 2.1191890908767164e-08
Europe O 0 7.53780824425121e-08
could O 0 6.6248415642178315e-09
indicate O 0 5.294876537220716e-09
a O 0 2.183503378105911e-09
high O 0 2.643164798143971e-08
carrier O 0 4.225809480118414e-09
frequency O 0 4.140979825706381e-08
in O 0 1.2939790350330327e-09
such O 0 5.425788263124787e-09
communities O 0 8.598683365335091e-08
. O 0 8.702130571691669e-07

In O 0 2.481267529219622e-07
patients O 0 4.1421014174147786e-08
of O 0 5.1039858561807705e-08
Dutch O 0 2.2681306290905923e-05
ethnic O 0 5.961461990722228e-09
origin O 0 7.201271579049262e-09
, O 0 9.842797688008886e-10
however O 0 2.7618975995125084e-09
, O 0 1.2605083643535409e-09
no O 0 1.9941257534128454e-09
significant O 0 8.122035488611345e-09
founder O 0 1.4900200540068909e-07
effect O 0 6.094716553661783e-08
could O 0 1.9863712452661275e-08
be O 0 2.8300283005933125e-08
identified O 0 3.2522373771826096e-07
. O 0 1.3830951957061188e-06

The O 0 8.996707379083091e-07
observed O 0 3.5518391428013274e-07
genetic O 0 1.0085027213335707e-07
heterogeneity O 0 2.8123955075898266e-07
including O 0 1.0577363873665035e-08
the O 0 1.3058785164332676e-08
relative O 0 1.736887327297154e-07
high O 0 6.477628176071448e-07
percentage O 0 4.8409638964130863e-08
of O 0 7.539490098906754e-08
splice O 0 2.188154894611216e-06
- O 0 8.825340813700677e-08
site O 0 7.332555451711187e-09
mutations O 0 1.2490476208881773e-08
had O 0 7.621321351791721e-09
no O 0 8.839251997017072e-09
reflection O 0 1.071794244467128e-07
on O 0 9.277322732259563e-08
the O 0 8.869181300497075e-08
phenotype O 0 3.175331585225649e-06
. O 0 2.6992968287231633e-06

All O 0 2.066702080583127e-07
patients O 0 6.495071858125812e-08
manifested O 0 1.9784316407367442e-07
classical O 0 9.504972808827006e-07
A B-Disease 1 0.9999910593032837
- I-Disease 1 0.911611020565033
T I-Disease 1 0.9999974966049194
and O 0 3.878518128885844e-08
increased O 0 5.374785061462717e-08
cellular O 0 6.223281161510386e-07
radioresistant O 0 1.2429467233232572e-06
DNA O 0 4.447778394478519e-07
synthesis O 0 5.555635311793594e-07
. O 0 6.334498721116688e-07

Determination O 0 4.500199793255888e-06
of O 0 4.7283720050472766e-07
the O 0 2.0319957272363354e-08
genomic O 0 1.1941795996506244e-08
structure O 0 2.23063825188774e-08
of O 0 8.631263703762215e-09
the O 0 9.147033352974177e-09
COL4A4 O 0 1.4657701967735193e-06
gene O 0 6.10080830298898e-09
and O 0 1.4356356103917278e-09
of O 0 7.669223478501408e-09
novel O 0 8.772241955057325e-08
mutations O 0 6.380492413882166e-05
causing O 1 0.8165452480316162
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999823570251465

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.4764218475611415e-06
a O 0 9.222205221703916e-07
progressive O 1 0.9999896287918091
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0001217417448060587
by O 0 4.938086135553021e-07
glomerular B-Disease 1 0.9944570064544678
basement I-Disease 1 0.9999690055847168
membrane I-Disease 0 0.0012461749138310552
abnormalities I-Disease 1 0.9283372163772583
and O 0 4.210228254919457e-08
associated O 0 8.916130411762424e-08
with O 0 3.542898419084395e-09
mutations O 0 3.0326351208032065e-08
in O 0 4.177111101455466e-09
either O 0 1.4381606128210933e-08
the O 0 2.6140606124158694e-08
COL4A3 O 0 3.2301442843163386e-05
or O 0 4.124951935580157e-09
the O 0 4.357448624148219e-09
COL4A4 O 0 3.517204447689437e-07
gene O 0 1.750974143455153e-09
, O 0 6.313414790959371e-10
which O 0 4.0678746482392114e-10
encode O 0 2.4836475098766186e-09
the O 0 4.320414692671193e-09
alpha3 O 0 3.090031839292351e-07
and O 0 1.0365796221378787e-08
alpha4 O 0 9.969327265935135e-07
type O 0 4.281635312963772e-07
IV O 1 0.999850869178772
collagen O 0 1.7120972188422456e-05
chains O 0 4.930341219733236e-07
, O 0 6.978436317695014e-08
respectively O 0 5.488146257448534e-07
. O 0 1.2205542816445814e-06

To O 0 2.7792742329779685e-08
date O 0 1.6018559279018518e-07
, O 0 1.1217097251048358e-09
mutation O 0 1.2882093169963582e-09
screening O 0 1.1016347833958662e-09
in O 0 2.518018016317569e-10
the O 0 6.196760882204444e-10
two O 0 5.853919571308097e-10
genes O 0 1.599427479348492e-09
has O 0 1.50243914531778e-10
been O 0 3.447536978118393e-10
hampered O 0 1.3797929909742379e-08
by O 0 2.772621299218514e-10
the O 0 1.1195615545744886e-09
lack O 0 1.2112974623335049e-08
of O 0 2.0076674545066453e-08
genomic O 0 8.581888977232666e-08
structure O 0 4.937639346280775e-07
information O 0 1.3353790961900813e-07
. O 0 1.009221136882843e-06

We O 0 2.161080828955164e-06
report O 0 9.030767955664487e-08
here O 0 5.84644643808474e-09
the O 0 1.7753450931579096e-09
complete O 0 3.812520077417503e-09
characterization O 0 6.0489226960669384e-09
of O 0 4.7849728623816645e-09
the O 0 4.235614081693484e-09
48 O 0 3.688645833221926e-08
exons O 0 8.961104924765095e-08
of O 0 1.13492610864796e-08
the O 0 1.524131398866757e-08
COL4A4 O 0 2.6204386358585907e-06
gene O 0 8.75712569126108e-09
, O 0 1.2253484893420818e-09
a O 0 8.598921019675743e-10
comprehensive O 0 1.637451241265353e-08
gene O 0 1.9808767959261786e-09
screen O 0 1.6511565448240617e-08
, O 0 1.4143921589493402e-09
and O 0 1.1249750020425608e-09
the O 0 1.5571138822778607e-09
subsequent O 0 2.11175565922872e-09
detection O 0 1.2830263074192771e-08
of O 0 3.1407982881148655e-09
10 O 0 4.852951818179463e-09
novel O 0 2.4376913820844948e-09
mutations O 0 8.498258097233702e-09
in O 0 3.72394026726397e-09
eight O 0 7.209094121662929e-08
patients O 0 4.7291027271967323e-07
diagnosed O 0 0.04847798869013786
with O 0 3.692654354381375e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9997770190238953

Furthermore O 0 8.924720873437764e-07
, O 0 2.8133765539450906e-08
we O 0 1.0514183301779667e-08
identified O 0 1.2853972997106666e-08
a O 0 6.185475243114524e-09
glycine O 0 7.502866594677471e-08
to O 0 7.952857039583705e-09
alanine O 0 1.0495393354403859e-07
substitution O 0 8.80966624094981e-08
in O 0 1.1463654026044878e-08
the O 0 3.1617528151173246e-08
collagenous O 0 1.5478767636523116e-06
domain O 0 1.4471253528824946e-08
that O 0 1.4184302343789312e-10
is O 0 1.7760147519307878e-10
apparently O 0 5.243800060839021e-09
silent O 0 2.364441975544196e-08
in O 0 1.177011155206742e-09
the O 0 4.8686477072124035e-09
heterozygous O 0 2.6810120345999167e-08
carriers O 0 6.225076898402904e-09
, O 0 1.0225138957764557e-08
in O 0 2.482384253710279e-08
11 O 0 1.0355815902585164e-06
. O 0 2.4801988729450386e-06

5 O 0 9.655352641857462e-07
% O 0 8.396655815090526e-09
of O 0 6.958682963187357e-09
all O 0 7.768447551903535e-10
control O 0 7.799631163152299e-09
individuals O 0 1.5005117981470306e-10
, O 0 1.8707753401958627e-10
and O 0 4.143140552859137e-10
in O 0 2.2444637814977852e-10
one O 0 1.2839404539555233e-10
control O 0 1.470564114924855e-09
individual O 0 2.9024860292992116e-10
homozygous O 0 3.771453371825828e-09
for O 0 1.255237358499528e-09
this O 0 2.135255083857146e-09
glycine O 0 3.007853308645281e-07
substitution O 0 8.354204510396812e-07
. O 0 1.4264115861806204e-06

There O 0 2.9716153449044214e-07
has O 0 3.137349713355775e-09
been O 0 1.2333795096353128e-09
no O 0 7.051443873251628e-10
previous O 0 4.245360507582063e-09
finding O 0 5.9336007218746545e-09
of O 0 2.203001558953588e-09
a O 0 2.6062529911996535e-09
glycine O 0 1.0865790045500034e-08
substitution O 0 5.615913067913425e-09
that O 0 2.802426901649113e-10
is O 0 1.796518073193809e-10
not O 0 2.010650534955971e-10
associated O 0 2.539017440739144e-09
with O 0 2.100190160669868e-10
any O 0 1.3842919033280054e-09
obvious O 0 1.0550846418766469e-08
phenotype O 0 6.634504501334959e-08
in O 0 4.5232417811291725e-09
homozygous O 0 1.3764775985691813e-07
individuals O 0 3.427706474212755e-08
. O 0 1.5606507304255501e-06

Founder O 0 0.000253895326750353
BRCA1 O 0 9.48011893342482e-06
and O 0 3.3213919437002914e-07
BRCA2 O 0 1.218757120113878e-06
mutations O 0 9.327214200993694e-08
in O 0 3.1378363019030076e-08
French O 0 0.0015157797606661916
Canadian O 0 0.16347140073776245
breast B-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.387897545006126e-05
. O 0 7.056986214593053e-05

We O 0 2.0476561246596248e-07
have O 0 4.437294087722421e-09
identified O 0 1.32751623027616e-08
four O 0 3.0240101533962616e-09
mutations O 0 2.8068791735336163e-09
in O 0 8.774108106734957e-10
each O 0 6.144305064736955e-10
of O 0 1.9251469751679906e-08
the O 0 1.1577194669598612e-07
breast B-Disease 0 8.857320790411904e-05
cancer I-Disease 0 6.586086965398863e-05
- O 0 1.4213766007742379e-05
susceptibility O 0 2.1988076071011164e-07
genes O 0 4.2969787727997755e-08
, O 0 2.8442006083650995e-08
BRCA1 O 0 3.002568291776697e-07
and O 0 7.95985712898073e-08
BRCA2 O 0 3.5852275459546945e-07
, O 0 5.710610651021852e-09
in O 0 4.343061021927497e-09
French O 0 5.931800842517987e-05
Canadian O 0 3.48812245647423e-05
breast B-Disease 1 0.9888012409210205
cancer I-Disease 1 0.998190701007843
and O 1 0.9996600151062012
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.264638502922026e-07
from O 0 1.977026471422505e-07
Quebec O 0 1.4772810573049355e-05
. O 0 9.147923265118152e-06

To O 0 4.793672587766196e-07
identify O 0 1.6296032754326006e-06
founder O 0 1.715915641398169e-05
effects O 0 7.988837751327083e-06
, O 0 2.9819133828823396e-08
we O 0 1.816002104249037e-08
examined O 0 4.9075097763306985e-08
independently O 0 1.0048024634556896e-08
ascertained O 0 3.832923312074854e-07
French O 0 1.4661336535937153e-06
Canadian O 0 2.8404554086591816e-07
cancer B-Disease 0 3.7879252090533555e-07
families O 0 1.186667986097234e-09
for O 0 3.269159110086406e-10
the O 0 5.305599848348663e-10
distribution O 0 7.527987677669046e-10
of O 0 2.4898609840562358e-09
these O 0 2.4506983109517932e-09
eight O 0 8.138446361272145e-08
mutations O 0 4.688766637173103e-07
. O 0 1.1331792393320939e-06

Mutations O 0 2.5502727112325374e-06
were O 0 7.183741956851009e-08
found O 0 7.277976887820614e-09
in O 0 2.6236897099352063e-09
41 O 0 5.439998318479411e-08
of O 0 5.812137970906406e-08
97 O 0 1.4994310504334862e-06
families O 0 1.2060888820997206e-07
. O 0 2.2663982690573903e-06

Six O 0 9.182589906231442e-07
of O 0 5.763080679344057e-08
eight O 0 3.324326058873339e-08
mutations O 0 1.8133714974055692e-08
were O 0 1.1834657698273077e-08
observed O 0 3.354062982907635e-08
at O 0 1.5051000445964746e-07
least O 0 3.045794016998116e-08
twice O 0 4.7084290599741507e-07
. O 0 1.195131858366949e-06

The O 0 7.554167495982256e-06
BRCA1 O 0 1.6239535398199223e-05
C4446T O 0 9.810053597902879e-06
mutation O 0 2.295826391218725e-07
was O 0 5.113954770763485e-08
the O 0 3.5928067187995794e-09
most O 0 2.880145844041948e-10
common O 0 1.084160539122081e-09
mutation O 0 1.6254887436062404e-09
found O 0 7.469063145748578e-10
, O 0 5.073629849583483e-10
followed O 0 1.2938112803340118e-09
by O 0 1.5156423893714077e-09
the O 0 1.94827460830993e-08
BRCA2 O 0 2.122673777193995e-06
8765delAG O 0 7.1105837378127035e-06
mutation O 0 3.7045847420813516e-06
. O 0 7.708243174420204e-06

Together O 0 6.034681376831941e-08
, O 0 2.6896820326527404e-09
these O 0 3.072666843184635e-10
mutations O 0 1.3571781476429123e-09
were O 0 1.1293888046992606e-09
found O 0 2.791011310954161e-10
in O 0 4.769071249022261e-10
28 O 0 1.4308414897357125e-08
of O 0 8.75138095324246e-09
41 O 0 3.910757584435487e-08
families O 0 7.582010574935794e-10
identified O 0 2.6950484066645686e-09
to O 0 1.7530125129283647e-09
have O 0 6.20589535316185e-09
a O 0 5.386392132322726e-08
mutation O 0 1.477429577789735e-06
. O 0 6.767914328520419e-06

The O 0 3.962347534525179e-07
odds O 0 6.99909776358254e-07
of O 0 2.6486656423685417e-08
detection O 0 6.218671444457868e-08
of O 0 4.252167506990645e-09
any O 0 1.6492200938245105e-09
of O 0 5.882632159170953e-09
the O 0 7.3009598366979844e-09
four O 0 2.6414511467010016e-08
BRCA1 O 0 1.5693639454639197e-07
mutations O 0 1.598297387772618e-07
was O 0 6.265066190280777e-07
18 O 0 2.1754560748377116e-06
. O 0 6.454838967329124e-06

7x O 0 0.0015479265712201595
greater O 0 1.087746340999729e-06
if O 0 6.211511305309614e-08
one O 0 5.5169748769401394e-09
or O 0 1.1367344843193905e-09
more O 0 6.273212505014669e-11
cases O 0 8.25198076537248e-10
of O 0 1.8851662275665149e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.575296775830793e-07
also O 0 1.7278799502307152e-09
present O 0 2.536224785743002e-09
in O 0 3.0728208866293016e-09
the O 0 4.5918199020889006e-08
family O 0 7.617865804832036e-08
. O 0 8.096809551716433e-07

The O 0 6.610617901969817e-07
odds O 0 1.1487027222756296e-06
of O 0 3.4246479430066756e-08
detection O 0 1.9528438599536457e-07
of O 0 6.3978617959037365e-09
any O 0 2.5821118576629942e-09
of O 0 4.8491677340223305e-09
the O 0 7.0276153785187034e-09
four O 0 1.390914583510039e-08
BRCA2 O 0 1.8246392130549793e-07
mutations O 0 1.4732746933532326e-07
was O 0 5.804017177979404e-07
5 O 0 2.4889138785511022e-06
. O 0 3.730315938810236e-06

3x O 0 2.730161759245675e-05
greater O 0 1.210177913435473e-07
if O 0 1.3221263195362098e-08
there O 0 3.5595204561644778e-09
were O 0 3.981640794847863e-09
at O 0 5.577153849856131e-09
least O 0 5.954856052703406e-10
five O 0 1.0149199258790986e-09
cases O 0 9.218435459423802e-10
of O 0 1.0524536797618111e-08
breast B-Disease 0 1.5838053286643117e-06
cancer I-Disease 0 8.011382419681468e-07
in O 0 2.87527495146378e-08
the O 0 1.9937394313274126e-07
family O 0 1.4706284900967148e-07
. O 0 1.4784189943384263e-06

Interestingly O 0 3.156949560434441e-06
, O 0 4.4511388352930226e-08
the O 0 1.0525159410690321e-08
presence O 0 1.612643174553341e-08
of O 0 1.5266006414549338e-07
a O 0 1.8746568741789815e-07
breast B-Disease 0 1.7573409422766417e-05
cancer I-Disease 0 3.298429646747536e-06
case O 0 6.663469207524031e-07
< O 0 1.9942806375183864e-06
36 O 0 6.334771285310126e-08
years O 0 2.934120058029066e-09
of O 0 3.4950768945662958e-09
age O 0 1.3086262740102939e-08
was O 0 4.470671832734752e-09
strongly O 0 7.026124126952027e-10
predictive O 0 2.8065377577490835e-08
of O 0 2.1679706918575903e-09
the O 0 9.868080796948675e-10
presence O 0 5.988650686461483e-10
of O 0 2.0024844005206432e-09
any O 0 8.78588035657657e-10
of O 0 4.298378097900013e-09
the O 0 8.277837970638302e-09
eight O 0 4.6837254075171586e-08
mutations O 0 1.8378629818016634e-07
screened O 0 8.113622129712894e-07
. O 0 1.9651945422083372e-06

Carriers O 0 4.152132646595419e-07
of O 0 4.6878366077862665e-08
the O 0 3.9004457441649265e-09
same O 0 7.615141850436657e-10
mutation O 0 1.6228772770077171e-09
, O 0 3.6920347334934434e-10
from O 0 3.0773883441526095e-10
different O 0 4.969597511284007e-10
families O 0 1.475727734456811e-10
, O 0 2.4563734379867697e-10
shared O 0 6.448099276745722e-10
similar O 0 1.1516464448746433e-09
haplotypes O 0 1.7232993698712562e-08
, O 0 1.1921217346611002e-09
indicating O 0 4.634527428493129e-09
that O 0 4.945278075929593e-10
the O 0 1.8826027403662238e-09
mutant O 0 2.924121034197924e-08
alleles O 0 1.556987072603988e-08
were O 0 5.022160909362583e-09
likely O 0 2.955599098797279e-09
to O 0 4.354630267489057e-10
be O 0 5.574651851247836e-10
identical O 0 3.2524056781113586e-09
by O 0 5.382802537035047e-10
descent O 0 6.604830904421988e-09
for O 0 6.363077842408416e-10
a O 0 1.1910762376388107e-09
mutation O 0 5.661914048715744e-09
in O 0 5.100499134158554e-09
the O 0 3.5604184489557156e-08
founder O 0 1.2250369536559447e-06
population O 0 2.6496357108385382e-08
. O 0 9.853547453531064e-07

The O 0 1.943472653920253e-07
identification O 0 1.4411101290079387e-07
of O 0 1.0427670815715828e-07
common O 0 4.674559477280127e-07
BRCA1 O 0 1.8577400169306202e-06
and O 0 5.125726829646737e-07
BRCA2 O 0 2.6001355308835628e-06
mutations O 0 1.7551136011206836e-07
will O 0 2.0357742158694236e-08
facilitate O 0 3.516576541073846e-08
carrier O 0 7.79189868183039e-09
detection O 0 2.0136755551902752e-07
in O 0 9.829707714459346e-09
French O 0 0.26937228441238403
Canadian O 0 0.0046981642954051495
breast B-Disease 1 0.9999885559082031
cancer I-Disease 1 0.9999719858169556
and O 1 0.9997046589851379
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.6670593292219564e-06
. O 0 1.0789647603814956e-05

Are O 0 6.644482937190332e-07
Dp71 O 0 3.869226929964498e-05
and O 0 2.774391703042056e-07
Dp140 O 0 1.3159973605070263e-05
brain O 0 3.8821628550067544e-05
dystrophin O 0 1.0945292160613462e-05
isoforms O 0 2.1393302631622646e-06
related O 0 6.46728324227297e-08
to O 0 9.560281455378572e-09
cognitive B-Disease 0 0.0005743946530856192
impairment I-Disease 1 0.9733620285987854
in O 0 3.0515846447087824e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.999985933303833

Molecular O 0 1.1627306776063051e-05
study O 0 8.004343499123934e-08
and O 0 1.0991608512256335e-08
neuropsychological O 0 4.5688133809562714e-07
analysis O 0 7.244336241996052e-09
were O 0 3.3646205821469266e-09
performed O 0 1.2491470080533418e-09
concurrently O 0 5.173285799742189e-09
on O 0 3.7797778240644675e-09
49 O 0 1.9602810041874363e-08
patients O 0 6.9576744365917875e-09
with O 0 1.8226408826649276e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999986886978149
DMD B-Disease 1 1.0
) O 0 9.292460134702196e-09
in O 0 3.047534169464683e-10
order O 0 1.034892060935988e-09
to O 0 1.102044080991682e-10
find O 0 1.248608660908701e-09
a O 0 5.194283891896134e-10
molecular O 0 1.632433566101099e-08
explanation O 0 8.913167981461356e-09
for O 0 1.9086821012592736e-09
the O 0 1.4872298059742661e-08
cognitive B-Disease 0 0.00017111717897932976
impairment I-Disease 0 8.950086339609697e-06
observed O 0 5.5012055355518896e-08
in O 0 1.1767021135256073e-08
most O 0 9.216299190484278e-08
DMD B-Disease 1 1.0
patients O 0 2.779380565698375e-06
. O 0 2.4891012344596675e-06

Complete O 0 1.2839439023082377e-06
analysis O 0 5.9279702924186495e-08
of O 0 3.880101928643853e-08
the O 0 2.2044192249381922e-08
dystrophin O 0 6.389693680830533e-07
gene O 0 1.9564186715115284e-08
was O 0 1.4226287703422713e-08
performed O 0 9.820351198897015e-10
to O 0 4.380203977305541e-10
define O 0 1.087827339318892e-08
the O 0 7.231704568511077e-09
localization O 0 6.229925588741025e-07
of O 0 1.765307189316445e-08
deletions O 0 3.7911160433168334e-08
and O 0 8.018810504495377e-09
duplications O 0 2.984315301546303e-07
in O 0 3.0860125566078977e-09
relation O 0 2.5391253544171377e-08
to O 0 3.449360796992096e-09
the O 0 4.238161821490394e-08
different O 0 1.0590443935143412e-06
DMD B-Disease 1 1.0
promoters O 0 0.00014191532682161778
. O 0 8.705279469722882e-06

Qualitative O 0 2.904665507230675e-06
analysis O 0 1.3949880894870148e-07
of O 0 1.258287483096865e-07
the O 0 8.054284705849568e-08
Dp71 O 0 6.948247118998552e-06
transcript O 0 2.891394785820012e-07
and O 0 1.8543739876974996e-09
testing O 0 3.2849054587558157e-09
for O 0 3.691534855576606e-10
the O 0 5.947012882145941e-10
specific O 0 1.0402770866946298e-09
first O 0 4.020821897654514e-09
exon O 0 2.3242442637183558e-08
of O 0 5.425746962828271e-09
Dp140 O 0 1.5006999376510066e-07
were O 0 1.3731244585812874e-08
also O 0 7.771356891339565e-09
carried O 0 6.348196990302313e-08
out O 0 7.844690941283261e-08
. O 0 7.624420277352328e-07

Neuropsychological O 0 0.00013464463700074703
analysis O 0 8.110712883535598e-07
assessed O 0 8.358691161447496e-07
verbal O 0 1.6947374206210952e-06
and O 0 2.1069615740998415e-07
visuospatial O 0 4.0893370169214904e-05
intelligence O 0 7.876818699514843e-07
, O 0 3.916938595693864e-08
verbal O 0 1.543930011393968e-06
memory O 0 0.0003678140346892178
, O 0 1.0345042511517022e-07
and O 0 1.8826439429631137e-07
reading O 0 1.5755013009766117e-05
skills O 0 0.00016272073844447732
. O 0 1.1464699127827771e-05

Comparison O 0 1.098048187486711e-06
of O 0 3.676698270282941e-07
molecular O 0 1.5757693745399592e-06
and O 0 1.7072489200131713e-08
psychometric O 0 2.298092113051098e-06
findings O 0 3.092684508487764e-08
demonstrated O 0 1.729902265878991e-08
that O 0 1.9545265406151202e-09
deletions O 0 6.077176806229545e-08
and O 0 7.340167140768017e-09
duplications O 0 2.4353462890758237e-07
that O 0 1.683327033319415e-09
were O 0 1.0591515220426118e-08
localized O 0 7.431866322349379e-08
in O 0 1.1071120908923149e-08
the O 0 2.4087047023613195e-08
distal O 0 6.493629598480766e-07
part O 0 1.1320096859890327e-08
of O 0 5.083650833626052e-08
the O 0 9.255402666497048e-09
gene O 0 4.52689219443414e-09
seemed O 0 1.2001301286090893e-08
to O 0 7.969161441856443e-10
be O 0 2.9634676934620074e-09
preferentially O 0 2.4195161429929612e-08
associated O 0 1.4418085925171908e-07
with O 0 1.207484814358395e-07
cognitive B-Disease 1 0.9999961853027344
impairment I-Disease 1 0.9999696016311646
. O 0 1.6975529433693737e-05

Two O 0 8.109282134682871e-07
altered O 0 1.8147715081795468e-06
Dp71 O 0 1.5285660992958583e-05
transcripts O 0 1.0380624644312775e-06
and O 0 9.687412649839189e-09
two O 0 3.4660458947399775e-09
deleted O 0 1.3118974351300494e-08
Dp140 O 0 2.1843668207566225e-08
DNA O 0 3.089310807169454e-09
sequences O 0 8.089024450264048e-10
were O 0 1.0844665165876677e-09
found O 0 7.114031586041847e-10
in O 0 8.016192154514101e-10
four O 0 5.617177389893868e-09
patients O 0 1.3755151684335942e-08
with O 0 7.991316408606508e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.9751309752464294

These O 0 3.1361076935354504e-07
findings O 0 1.3880794824672193e-07
suggest O 0 1.3987228264511486e-08
that O 0 3.145581017882648e-10
some O 0 2.691574463309365e-10
sequences O 0 1.9838184428522254e-09
located O 0 2.220457817614374e-09
in O 0 8.494592251828692e-10
the O 0 3.539953441489274e-09
distal O 0 8.362711412246426e-08
part O 0 1.9751045243765475e-09
of O 0 4.433360345501569e-09
the O 0 2.5566089245643298e-09
gene O 0 1.8064836293518738e-09
and O 0 9.925920085862572e-10
, O 0 6.946134778473834e-10
in O 0 3.0507851800365415e-10
particular O 0 1.6380438117025165e-09
, O 0 1.4943404291756224e-09
some O 0 4.4429850909466495e-09
DMD B-Disease 1 0.9999997615814209
isoforms O 0 5.976492616355245e-07
expressed O 0 3.196642284208906e-09
in O 0 1.7150810771582314e-09
the O 0 5.80628478630274e-09
brain O 0 3.5569405554269906e-07
may O 0 2.4924362573841563e-09
be O 0 5.440189410066409e-10
related O 0 1.0189681320937893e-09
to O 0 4.6066758740970215e-10
the O 0 7.91934429145158e-09
cognitive B-Disease 0 0.025692015886306763
impairment I-Disease 0 0.0001805156352929771
associated O 0 2.0538402623060392e-07
with O 0 1.3221318795331172e-07
DMD B-Disease 1 1.0
. O 0 1.0761898465716513e-06
. O 0 1.7781709402697743e-06

I1307K O 0 7.536871271440759e-05
APC O 0 5.738790605391841e-06
and O 0 6.416733810965525e-08
hMLH1 O 0 8.141781222548161e-07
mutations O 0 2.2648842801231694e-08
in O 0 2.3121191627950566e-09
a O 0 5.6420024208136965e-09
non O 0 1.988680651265895e-07
- O 0 7.781905964066027e-08
Jewish O 0 4.270294695629673e-08
family O 0 2.511917562841859e-09
with O 0 3.3196483339992255e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999969005584717

We O 0 5.854259939042095e-07
describe O 0 7.928658618538975e-08
a O 0 1.6417542880731162e-08
French O 0 1.7389056665706448e-06
Canadian O 0 1.2828496664951672e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9803881645202637
HNPCC B-Disease 1 0.9999991655349731
) O 0 2.467599813371635e-07
kindred O 0 1.1862147175634163e-06
which O 0 5.22766230304228e-09
carries O 0 2.1475788258840112e-08
a O 0 7.2210228907465535e-09
novel O 0 5.6805326664743916e-08
truncating O 0 5.440288077807054e-07
mutation O 0 9.917374654833111e-08
in O 0 5.442011286049819e-08
hMLH1 O 0 8.36675098980777e-06
. O 0 4.8079982661874965e-06

Interestingly O 0 4.4418202378437854e-06
, O 0 6.094809634760168e-08
the O 0 3.3579098612790403e-08
I1307K O 0 5.97322753037588e-07
APC O 0 2.891138137783855e-07
polymorphism O 0 8.870230061575057e-08
, O 0 3.1468307959414688e-09
associated O 0 3.2307780895024507e-09
with O 0 3.7997191504324235e-10
an O 0 2.387278708049223e-10
increased O 0 3.775037615838528e-09
risk O 0 2.0334496184659656e-06
of O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.362391218317498e-07
is O 0 5.313285922348143e-10
also O 0 1.3118586772442598e-10
present O 0 3.177207663629389e-10
in O 0 7.363286091965904e-10
this O 0 1.9740349355146236e-09
family O 0 2.0841266490378985e-08
. O 0 4.220729294956982e-07

The O 0 1.4123272649158025e-06
I1307K O 0 6.876636689412408e-06
polymorphism O 0 4.87286399675213e-07
has O 0 1.1406003919134378e-09
previously O 0 2.8933728746238785e-09
only O 0 2.863658199458996e-10
been O 0 2.936475507198111e-10
identified O 0 7.781691402364288e-10
in O 0 1.6220562393254312e-10
individuals O 0 1.502476476566983e-10
of O 0 6.670639596251249e-09
self O 0 2.9490186648217787e-07
- O 0 1.8862609749703552e-06
reported O 0 1.6999581475829473e-07
Ashkenazi O 0 1.6226665593421785e-06
Jewish O 0 1.132076590693032e-06
origins O 0 5.3156200010562316e-06
. O 0 6.0014108385075815e-06

In O 0 1.0436027508831103e-07
addition O 0 2.6592097412958537e-08
, O 0 2.630775375322969e-09
in O 0 3.583797980599712e-10
this O 0 2.0681228951602293e-10
family O 0 1.964991780400993e-10
, O 0 2.1220344925687584e-10
there O 0 1.8009163604837397e-10
appears O 0 5.139166869838618e-10
to O 0 1.8753409936067555e-10
be O 0 6.023130882937267e-10
no O 0 1.4772858492051455e-09
relationship O 0 1.9073174151174044e-09
between O 0 4.38804148572558e-09
the O 0 6.442312461274469e-09
I1307K O 0 8.759868563856799e-08
polymorphism O 0 2.442663493695818e-08
and O 0 8.109740656792042e-10
the O 0 6.378996775247003e-10
presence O 0 1.728908460840728e-09
or O 0 4.749674431536732e-09
absence O 0 8.345551094635084e-08
of O 0 1.0936238226122441e-07
cancer B-Disease 0 4.719213393400423e-07
. O 0 1.1492217311115382e-07
. O 0 1.990207238122821e-06

Identification O 0 2.0603979464794975e-06
of O 0 1.6807507563498802e-07
a O 0 1.3408864241171159e-08
novel O 0 2.2892930218176843e-08
mutation O 0 2.209904792493944e-08
of O 0 2.293908352157814e-08
the O 0 4.252461849318934e-08
CPO O 0 1.9228077690058853e-06
gene O 0 3.104321422142675e-08
in O 0 7.686855596489295e-09
a O 0 2.7154102966164828e-08
Japanese O 0 2.80380140793568e-06
hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.7895136475563049
family O 0 8.723285986889096e-07
. O 0 4.0556069507147186e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999997615814209
( O 0 0.007999027147889137
HCP B-Disease 1 0.9999998807907104
) O 0 6.375182692863746e-08
is O 0 3.1464946204096123e-09
an O 0 5.539253944419897e-09
autosomal B-Disease 1 0.9999986886978149
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 7.111392505976255e-07
by O 0 1.6084776177649474e-08
a O 0 8.913393401144276e-08
deficiency B-Disease 0 0.00030282497755251825
of I-Disease 0 0.0005977705004625022
coproporphyrinogen I-Disease 1 0.9167170524597168
oxidase I-Disease 0 5.687303200829774e-06
( O 0 2.5467498332432115e-08
CPO O 0 6.097193363530096e-07
) O 0 1.1456915416374613e-09
caused O 0 3.3685310096842613e-09
by O 0 5.165750605051755e-10
a O 0 1.7040272526358535e-09
mutation O 0 5.790601775856885e-09
in O 0 4.66076688354633e-09
the O 0 4.780013540539585e-08
CPO O 0 6.562028829648625e-06
gene O 0 1.2050982149958145e-06
. O 0 4.177099981461652e-06

Only O 0 8.775455029308432e-08
11 O 0 1.1915510356175218e-07
mutations O 0 1.4870737530259248e-08
of O 0 5.76668446328199e-09
the O 0 1.5600420955053096e-09
gene O 0 3.703730877546718e-09
have O 0 1.4824964589266187e-09
been O 0 5.2161683861129404e-09
reported O 0 3.327732400748573e-08
in O 0 1.0184559329218246e-07
HCP B-Disease 1 0.9997536540031433
patients O 0 2.158191136913956e-06
. O 0 1.0372271390224341e-05

We O 0 1.689541250016191e-06
report O 0 5.15964089231602e-08
another O 0 1.2294061768614029e-08
mutation O 0 2.31846186693474e-08
in O 0 4.518024621091854e-09
a O 0 2.6553120591188417e-08
Japanese O 0 1.4895640561007895e-06
family O 0 5.772200211140444e-07
. O 0 3.7437159789988073e-06

Polymerase O 0 3.769050454138778e-05
chain O 0 9.835184755502269e-07
reaction O 0 2.1627373314458964e-07
- O 0 3.592795110307634e-07
single O 0 1.5655812646286904e-08
strand O 0 3.0561640329551665e-08
conformational O 0 1.3708269186452071e-08
polymorphism O 0 1.0440045272730458e-08
and O 0 9.819807189614949e-10
direct O 0 2.08212314056766e-09
sequence O 0 3.4861951103692945e-09
analyses O 0 4.32753211043746e-09
demonstrated O 0 5.394305890860096e-09
a O 0 2.9726843209232356e-09
C O 0 6.250444783972853e-08
to O 0 1.1354451823208933e-09
T O 0 2.172292923319219e-08
substitution O 0 2.7139177571910977e-09
in O 0 5.546641479448056e-10
exon O 0 7.19893700207308e-09
1 O 0 2.856807457263244e-09
of O 0 8.882818369748691e-10
the O 0 2.7173570060767815e-09
CPO O 0 1.212930129668166e-07
gene O 0 3.1875826422833597e-09
at O 0 1.5784834772603062e-08
nucleotide O 0 4.182572510558202e-09
position O 0 3.6251055490765793e-08
85 O 0 3.7489211734964556e-08
, O 0 3.277758064967884e-09
which O 0 1.1061046523153095e-09
lies O 0 1.9079806179433945e-08
in O 0 1.3624535943890237e-09
the O 0 6.992010082029765e-09
putative O 0 1.6500663946317218e-07
presequence O 0 4.966589699506585e-07
for O 0 5.964305049843688e-09
targeting O 0 6.770341087758425e-08
to O 0 8.268783346920827e-08
mitochondria O 0 6.318839950836264e-06
. O 0 5.179309937375365e-06

This O 0 2.700710055592026e-08
mutation O 0 4.8907459415659105e-08
changes O 0 1.3379714225436601e-08
the O 0 6.0407598923006844e-09
codon O 0 4.4616953687182104e-08
for O 0 2.29247265615129e-09
glutamine O 0 4.455130664382523e-08
to O 0 2.467649418136375e-09
a O 0 1.1771151164907678e-08
termination O 0 4.2922852117044386e-07
codon O 0 1.0265862329106312e-06
at O 0 6.328834842861397e-07
amino O 0 1.1521363063593526e-07
acid O 0 2.9110214683214508e-08
position O 0 8.508405358043092e-07
29 O 0 4.465162419364788e-06
. O 0 2.3619190869794693e-06

MaeI O 0 0.00015649096167180687
restriction O 0 5.89938792927569e-07
analysis O 0 1.455024971619423e-07
showed O 0 7.579920691114239e-08
two O 0 7.078195363163786e-09
other O 0 1.659437254275531e-09
carriers O 0 4.3579393427251034e-09
in O 0 4.056657232354155e-09
the O 0 3.0886756263726056e-08
family O 0 5.6571668238802886e-08
. O 0 7.570961315650493e-07

The O 0 5.834651801706059e-06
C O 0 0.06423207372426987
- O 0 0.00012212310684844851
T O 0 1.7709411395117058e-06
mutation O 0 2.171886848145732e-08
is O 0 1.2848426766964849e-09
located O 0 6.516064576800318e-09
within O 0 5.164432881343828e-09
a O 0 3.0604205836226583e-09
recently O 0 8.446321864141737e-09
proposed O 0 1.660251669477475e-08
putative O 0 7.788781886119978e-08
alternative O 0 4.241283235728588e-08
translation O 0 1.0884068046834727e-07
initiation O 0 1.315533779688849e-07
codon O 0 5.10374263740232e-07
( O 0 2.887409245033723e-08
TIC O 0 2.812390107465035e-07
- O 0 4.4655777742264036e-08
1 O 0 7.519671640920933e-08
) O 0 1.2437383345442754e-09
, O 0 6.833594801136655e-10
supporting O 0 3.1722555693391996e-09
that O 0 3.145168570029e-09
TIC O 0 4.382791018997523e-07
- O 0 7.324157991206448e-08
1 O 0 4.42164100888931e-08
is O 0 9.333470663008825e-10
the O 0 6.8945285036647874e-09
real O 0 3.06854730069972e-07
TIC O 0 7.175573273343616e-07
rather O 0 2.5368210643250677e-08
than O 0 2.196248161112635e-08
TIC O 0 6.326487778096634e-07
- O 0 1.256833996876594e-07
2 O 0 1.7100393279179116e-07
. O 0 6.101078753317779e-08
. O 0 8.547019092475239e-07

Human B-Disease 0 2.4922223929024767e-06
complement I-Disease 0 3.6980229651817353e-06
factor I-Disease 0 9.231973672285676e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
associated O 0 0.0247594453394413
with O 1 0.9249545335769653
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999946355819702

This O 0 8.711499077662666e-08
study O 0 2.5130352909741305e-08
reports O 0 1.1401072086414388e-08
on O 0 1.4548938942482437e-08
six O 0 1.2601748089480225e-08
cases O 0 8.34137736660523e-09
of O 0 3.668047199312241e-08
deficiency B-Disease 0 4.903266017208807e-06
in I-Disease 0 8.625980818521839e-09
the I-Disease 0 1.0642992265275097e-08
human I-Disease 0 8.765431047663697e-09
complement I-Disease 0 1.0764957814046738e-08
regulatory I-Disease 0 2.1441326936155747e-08
protein I-Disease 0 1.1876604588678674e-08
Factor I-Disease 0 1.3220284245107905e-07
H I-Disease 1 0.9999943971633911
( O 0 2.867049531118937e-08
FH O 0 1.1455651929281885e-06
) O 0 3.653980173989879e-10
in O 0 1.6182122308805447e-10
the O 0 6.183525358416375e-10
context O 0 4.720746016317889e-09
of O 0 1.1233610486272028e-08
an O 0 1.66384968025568e-08
acute B-Disease 1 0.9999997615814209
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.9824146628379822

Five O 0 6.560018164236681e-07
of O 0 4.410539844457162e-08
the O 0 5.02643482391818e-09
cases O 0 1.952548123185238e-09
were O 0 1.4031417139293012e-09
observed O 0 6.141695596539876e-09
in O 0 1.7026594578695153e-09
children O 0 6.304429422954172e-09
presenting O 0 1.8457988915088208e-07
with O 0 1.6894654208954307e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.0004927330301143229
. O 0 9.474244870943949e-05

Two O 0 1.533323938929243e-07
of O 0 5.8245671397116894e-08
the O 0 2.3164771434380782e-08
children O 0 5.444988460112654e-09
exhibited O 0 5.3856524573348e-08
a O 0 1.2851084818521485e-07
homozygous O 0 0.00032325860229320824
deficiency O 0 0.05109309032559395
characterized O 0 1.0753347368108734e-07
by O 0 4.935423625340718e-09
the O 0 1.3510139673655885e-08
absence O 0 1.7640492444570555e-07
of O 0 9.868070804941453e-08
the O 0 1.9739530898732482e-08
150 O 0 2.2325110649035196e-08
- O 0 3.627097555636283e-08
kD O 0 1.0064024280609374e-07
form O 0 2.1789976489827723e-09
of O 0 6.930521934123135e-09
Factor O 0 8.872091683542749e-08
H O 1 0.9999438524246216
and O 0 2.429605405751545e-09
the O 0 5.025473925890367e-10
presence O 0 2.634002460588647e-10
, O 0 3.0589716870643713e-10
upon O 0 2.9109921140246797e-09
immunoblotting O 0 5.6212961396795436e-08
, O 0 6.574987776453156e-10
of O 0 1.0674457984194419e-09
the O 0 2.4994579739257006e-09
42 O 0 2.4274573462435e-08
- O 0 3.8056345630366195e-08
kD O 0 2.295346916980634e-07
Factor O 0 1.0787695003955378e-07
H O 0 0.12378937005996704
- O 0 7.669607526850086e-08
like O 0 1.6259321666822757e-09
protein O 0 5.271076020108012e-09
1 O 0 5.2815448015053335e-08
( O 0 2.291091316664051e-09
FHL O 0 1.126005940932373e-06
- O 0 6.536478913687915e-09
1 O 0 5.696957572354222e-09
) O 0 2.74342548678419e-10
and O 0 7.58626328423162e-10
other O 0 3.2231337598886967e-09
FH O 0 5.6955209402076434e-06
- O 0 8.959618469361885e-08
related O 0 1.3761895623076725e-08
protein O 0 2.1922890169889797e-08
( O 0 5.907931921456111e-09
FHR O 0 4.903401986666722e-06
) O 0 1.7694771869969372e-08
bands O 0 1.2242497859915602e-06
. O 0 2.4610246782685863e-06

Southern O 0 6.686171673209174e-06
blot O 0 5.7326260503032245e-06
and O 0 3.039387053149767e-08
PCR O 0 1.4304177398116735e-07
analysis O 0 1.1703094493498156e-08
of O 0 4.988041535369803e-09
DNA O 0 1.630656853990331e-08
of O 0 7.558103476412725e-09
one O 0 3.146110705287697e-09
patient O 0 2.2731677873366607e-08
with O 0 1.0340697187416481e-08
homozygous O 0 6.676973134744912e-05
deficiency O 1 0.9075853228569031
ruled O 0 5.059563136455836e-06
out O 0 6.10854034022168e-09
the O 0 1.916671488189081e-09
presence O 0 8.069961920931235e-10
of O 0 3.4908993473692362e-09
a O 0 8.211378799138913e-10
large O 0 1.136944871582557e-09
deletion O 0 3.315713925644559e-08
of O 0 3.0665926686879175e-08
the O 0 1.2139786065290536e-07
FH O 0 9.160338231595233e-05
gene O 0 4.5502503098759917e-08
as O 0 1.2349903322217415e-08
the O 0 4.667067088348631e-08
underlying O 0 4.2043360735988244e-05
defect O 0 5.3924945859762374e-06
for O 0 2.487750521140697e-07
the O 0 8.934411198424641e-06
deficiency O 1 0.9999127388000488
. O 0 4.8535686801187694e-05

The O 0 4.0534968093197676e-07
other O 0 6.8472187919610406e-09
four O 0 1.0799631411373412e-08
children O 0 2.340578619808298e-09
presented O 0 2.53563587904182e-08
with O 0 1.0314303189318252e-08
heterozygous O 0 3.189778908563312e-06
deficiency O 0 0.0005866678548045456
and O 0 3.116239355449579e-08
exhibited O 0 1.2994884457384615e-07
a O 0 1.6480354858572355e-08
normal O 0 1.2325480724939553e-07
immunoblotting O 0 6.055424250916985e-07
pattern O 0 1.8863707040850386e-08
of O 0 6.338443103715008e-09
proteins O 0 1.0083576196251443e-09
of O 0 1.524593606916369e-08
the O 0 7.901694942802351e-08
FH O 0 7.229692710097879e-05
family O 0 3.595160364966432e-07
. O 0 2.3238824269355973e-06

Factor B-Disease 1 0.9918323755264282
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999946355819702
is O 0 1.7178287237129553e-08
the O 0 8.41225311631888e-09
only O 0 1.8476987051485594e-08
complement B-Disease 1 0.9999816417694092
deficiency I-Disease 1 1.0
associated O 0 1.0148701221623924e-06
with O 0 2.1022587759489397e-07
HUS B-Disease 1 1.0
. O 0 2.7224452423979528e-05

These O 0 1.8833046055988234e-07
observations O 0 3.936648624858208e-07
suggest O 0 4.0566440873135434e-08
a O 0 8.445049104466307e-09
role O 0 1.8590744943480786e-08
for O 0 1.1637119712304411e-08
FH O 0 3.817931064986624e-05
and O 0 1.4547336490977614e-07
/ O 0 4.365815402707085e-05
or O 0 1.9525423056165891e-07
FH O 0 9.359803698316682e-06
receptors O 0 2.0515608767368576e-08
in O 0 1.6482231135483971e-09
the O 0 6.9380878819913505e-09
pathogenesis O 0 2.089776671709842e-06
of O 0 8.43882119738737e-08
idiopathic O 0 0.000971631146967411
HUS B-Disease 1 0.9999991655349731
. O 0 1.7363570350426016e-06
. O 0 5.489604063768638e-06

Further O 0 7.05296315572923e-07
evidence O 0 2.0561586211442773e-07
for O 0 2.893599360120902e-09
a O 0 2.2606967409188883e-09
major O 0 5.2772826109048765e-09
ancient O 0 1.4006388937559677e-07
mutation O 0 4.820601134269964e-06
underlying O 1 0.9997170567512512
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.4258512237574905e-06
linkage O 0 5.805107775813667e-06
disequilibrium O 0 4.215087756165303e-06
studies O 0 2.6218353710305564e-08
in O 0 2.4603417081436874e-09
the O 0 4.224858685120125e-09
Japanese O 0 7.956077752169222e-08
population O 0 8.3909243997482e-09
. O 0 4.378947267014155e-07

The O 1 0.8012256026268005
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995723366737366
DM B-Disease 1 1.0
) O 0 7.851157590721414e-08
mutation O 0 3.632982981116584e-08
is O 0 1.347320588429568e-09
an O 0 1.577359909354925e-09
unstable O 0 6.930590075171494e-07
( O 0 1.3556193323438492e-07
CTG O 0 2.1315496269380674e-05
) O 0 1.6510149691839615e-08
n O 0 6.28734397878361e-08
repeat O 0 5.593989982344283e-08
, O 0 2.559839229476779e-09
present O 0 2.1066302036132356e-09
at O 0 1.1230160801289912e-08
a O 0 4.217666771388906e-10
copy O 0 1.927622284014774e-09
number O 0 7.850716188251283e-10
of O 0 3.1870051042659497e-09
5 O 0 6.356436443866187e-08
- O 0 3.6995391639038644e-08
37 O 0 1.564578155921481e-08
repeats O 0 9.002353529297125e-09
on O 0 4.330199310231819e-09
normal O 0 7.111864874786988e-09
chromosomes O 0 1.788863279728048e-09
but O 0 3.668988168836762e-10
amplified O 0 2.345091898448004e-09
to O 0 3.807990311965881e-10
50 O 0 4.580690937672216e-09
- O 0 7.869279450289923e-09
3000 O 0 1.8143506252954467e-08
copies O 0 1.2508476032735416e-08
on O 0 1.980194497264165e-07
DM B-Disease 1 0.9994631409645081
chromosomes O 0 1.8207625771538005e-06
. O 0 1.3499419537765789e-06

Previous O 0 2.9227578579593683e-06
findings O 0 2.5312829166068695e-07
in O 0 6.175643552097654e-09
Caucasian O 0 7.83906699552972e-08
populations O 0 1.1629420093584031e-08
of O 0 1.0263811844879456e-07
a O 0 1.7293698419962311e-06
DM B-Disease 1 1.0
founder O 1 0.9746395945549011
chromosome O 0 3.533928520482732e-06
raise O 0 3.8928220646994305e-08
a O 0 8.00420263402657e-09
question O 0 2.7246137790370994e-08
about O 0 6.281908326855046e-10
the O 0 1.1893509510585432e-09
molecular O 0 2.7876145836103206e-08
events O 0 2.598539383669163e-09
involved O 0 2.554824796163757e-09
in O 0 9.922929145034232e-10
the O 0 3.5605933756954755e-09
expansion O 0 5.0220293701386254e-08
mutation O 0 4.737055974146642e-07
. O 0 2.069922402370139e-06

To O 0 6.566766046489647e-07
investigate O 0 6.329191251097654e-07
whether O 0 4.697682598475694e-08
a O 0 6.459972468064734e-08
founder O 0 1.2504513051680988e-06
chromosome O 0 1.802238216441765e-07
for O 0 9.568162262496571e-09
the O 0 1.7556274656271853e-07
DM B-Disease 1 1.0
mutation O 0 5.64863817942296e-08
exists O 0 4.657914054462253e-09
in O 0 3.7512634665226585e-10
the O 0 5.463805519134723e-10
Japanese O 0 1.71589253916693e-09
population O 0 6.609651020950125e-11
, O 0 6.69233946037906e-10
we O 0 4.85281326234599e-09
genotyped O 0 2.46787749347277e-07
families O 0 1.6947119263477362e-09
using O 0 3.841176265950708e-09
polymorphic O 0 1.640337217168053e-07
markers O 0 6.511445604928667e-08
near O 0 2.871148865324358e-07
the O 0 8.384017036178193e-08
( O 0 5.168022454427046e-08
CTG O 0 8.536211680620909e-06
) O 0 1.3773948204232056e-08
n O 0 1.922624761618863e-07
repeat O 0 1.9985709798220341e-07
region O 0 3.522564639979464e-08
and O 0 3.8917676192795625e-08
constructed O 0 1.622822765057208e-06
haplotypes O 0 6.469265372288646e-06
. O 0 2.7983014661003835e-06

Six O 0 4.801839281753928e-07
different O 0 1.7090277637521467e-08
haplotypes O 0 2.520159227969998e-07
were O 0 1.7754915759837786e-08
found O 0 7.639425980698888e-09
and O 0 4.805307085575805e-08
DM B-Disease 1 1.0
alleles O 0 3.2222106938206707e-07
were O 0 7.893741127418252e-08
always O 0 1.087062386773141e-07
haplotype O 0 1.2829046909246244e-06
A O 0 5.561699936151854e-07
. O 0 2.358407527935924e-06

To O 0 6.878309477542643e-08
find O 0 2.2513431119364213e-08
an O 0 3.874019161020925e-10
origin O 0 3.067532894363012e-09
of O 0 1.7192054002634904e-08
the O 0 2.2380108433139867e-08
( O 0 2.613347760416218e-08
CTG O 0 2.275433416798478e-06
) O 0 5.919809531462761e-09
n O 0 4.333158898361944e-08
repeat O 0 2.7134946734008736e-08
mutation O 0 8.911808180300795e-09
and O 0 2.2889337092379947e-09
to O 0 1.3680366839352587e-09
investigate O 0 1.5565060351718785e-08
the O 0 1.9784602844907795e-09
mechanism O 0 3.111167501401724e-08
of O 0 5.6440905282784115e-09
the O 0 9.662864952630912e-10
expansion O 0 4.844804113446344e-09
mutation O 0 1.1244344344518709e-09
in O 0 1.3771386808691943e-10
the O 0 4.30252666827613e-10
Japanese O 0 4.573619261094564e-09
population O 0 1.0256986926471257e-10
we O 0 4.622633109629959e-10
have O 0 2.6037078049157003e-10
studied O 0 1.816185779546231e-08
90 O 0 3.132729275989732e-08
Japanese O 0 5.438005814539792e-07
DM B-Disease 1 1.0
families O 0 3.0370923553846296e-08
comprising O 0 3.359844669148515e-08
190 O 0 3.073959575772278e-08
affected O 0 7.040669824931456e-09
and O 0 5.993876062149184e-09
130 O 0 7.961086367913595e-08
unaffected O 0 4.0519896060686733e-07
members O 0 1.4092594824433036e-07
. O 0 2.271524408570258e-06

The O 0 1.8778109733830206e-06
results O 0 5.657333872477466e-07
suggest O 0 3.318409014241297e-08
that O 0 7.178558303344573e-10
a O 0 9.619246510439439e-10
few O 0 1.8535324386448337e-09
common O 0 2.983135294343242e-09
ancestral O 0 7.031517146316446e-09
mutations O 0 2.0194068639511897e-09
in O 0 3.313169461005572e-10
both O 0 9.534890654805395e-10
Caucasian O 0 2.115360686616441e-08
and O 0 3.510583823640445e-09
Japanese O 0 1.1840686653386001e-08
populations O 0 6.193050516856147e-10
have O 0 1.4691503569252973e-10
originated O 0 7.322125683550951e-10
by O 0 1.3200712745131682e-10
expansion O 0 2.4734596593134484e-09
of O 0 2.79630918420537e-09
an O 0 5.137452130377085e-10
ancestral O 0 1.70940257504526e-08
n O 0 5.218758758473996e-08
= O 0 1.0270234440667991e-07
5 O 0 3.431683737176172e-08
repeat O 0 1.8930530032434945e-08
to O 0 4.2159311597345095e-09
n O 0 1.6172856476259767e-07
= O 0 4.740585666240804e-07
19 O 0 4.784455427397916e-07
- O 0 1.0849558407244331e-07
37 O 0 4.228230565672675e-08
copies O 0 1.5509101558563998e-07
. O 0 6.664772058684321e-07

These O 0 1.3685233568594413e-07
data O 0 5.6836757522660264e-08
support O 0 1.622008483082027e-08
multistep O 0 5.47976810594264e-07
models O 0 3.2726188692322467e-07
of O 0 1.5975842870830093e-07
triplet O 0 5.124234576214803e-06
repeat O 0 1.4669431891434215e-07
expansion O 0 1.5712352308128175e-08
that O 0 2.445434688080894e-10
have O 0 2.9652189037499e-10
been O 0 5.709638317696886e-10
proposed O 0 1.7261637674792496e-09
for O 0 8.765476677830009e-10
both O 0 2.6904992012077855e-08
DM B-Disease 1 1.0
and O 0 7.533854500252346e-07
Friedreichs B-Disease 0 0.0003225576365366578
ataxia I-Disease 0 0.011778131127357483
. O 0 7.169396667450201e-07
. O 0 3.0656447052024305e-06

The O 0 1.9081740276760684e-07
molecular O 0 5.625655035146337e-07
basis O 0 4.691956121405383e-07
of O 0 2.840172419382725e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.7538087365996944e-08
the O 0 1.0577121400956457e-08
western O 0 8.037986276576703e-08
Cape O 0 2.388411758147413e-06
, O 0 1.4118889168912574e-08
South O 0 1.719284909995622e-07
Africa O 0 9.503849014436128e-07
. O 0 9.089052355193417e-07

Deficiency B-Disease 1 0.8363009691238403
of I-Disease 0 1.0637902960297652e-05
the I-Disease 0 4.198276144506963e-07
sixth I-Disease 0 3.916196078534995e-07
component I-Disease 0 1.6507282651900823e-08
of I-Disease 0 7.639557431105004e-09
human I-Disease 0 6.600121338351528e-09
complement I-Disease 0 2.3875816879126432e-08
( O 0 1.944584582247444e-08
C6 O 0 0.0023622550070285797
) O 0 3.2267322147561117e-09
has O 0 3.553867755634599e-10
been O 0 4.924879948298155e-10
reported O 0 7.127070045243045e-10
in O 0 7.70960656426567e-11
a O 0 1.266687171819214e-10
number O 0 2.031734086527237e-10
of O 0 8.78981942786794e-10
families O 0 1.142119315789003e-10
from O 0 2.2735903437709482e-10
the O 0 1.4945713555647444e-09
western O 0 3.649171276265406e-08
Cape O 0 2.2984536371950526e-06
, O 0 2.9188942818336727e-08
South O 0 2.6104416406269593e-07
Africa O 0 1.5667575326006045e-06
. O 0 2.800992888296605e-06

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999886751174927
is O 0 3.0215552726531314e-08
endemic O 0 8.068273160688477e-09
in O 0 1.5014686161052282e-09
the O 0 1.0292822594237805e-08
Cape O 0 5.795996571578144e-07
and O 0 1.8534723755792015e-09
almost O 0 1.6024442883733059e-09
all O 0 4.919613605380846e-10
pedigrees O 0 9.407647105774686e-09
of O 0 6.505459726469098e-09
total O 0 5.190576075619902e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.3291532613711752e-07
C6Q0 O 0 5.2209732530172914e-05
) O 0 3.6199565567329728e-09
have O 0 9.591674121622873e-10
been O 0 6.28462892837689e-10
ascertained O 0 6.252281536944793e-08
because O 0 3.069265064326032e-09
of O 0 7.766870169234608e-08
recurrent O 0 9.847035107668489e-05
disease O 0 0.1967402696609497
. O 0 7.299748176592402e-06

We O 0 2.6579502332424454e-07
have O 0 6.649767847477506e-09
sequenced O 0 1.687233286418177e-08
the O 0 3.588512820229539e-09
expressed O 0 7.652537270530502e-09
exons O 0 1.6651679857204726e-07
of O 0 2.794988418486355e-08
the O 0 2.0209682816130226e-08
C6 O 0 1.2325202987994999e-05
gene O 0 3.6718814655500864e-09
from O 0 6.580156974855811e-10
selected O 0 1.7267235419282656e-09
cases O 0 4.762508165612189e-10
and O 0 4.012392917918106e-10
have O 0 6.274017416707522e-10
found O 0 2.33103558677783e-09
three O 0 4.123378527509658e-09
molecular O 0 5.165206312085502e-05
defects O 0 0.00038266272167675197
leading O 0 6.880192131575313e-07
to O 0 1.5459345803492397e-08
total O 0 3.7486569226530264e-07
deficiency O 1 0.9957104921340942
879delG O 0 0.000162489726790227
, O 0 1.1301026781040946e-08
which O 0 1.2399768989368454e-09
is O 0 4.018328170207752e-10
the O 0 1.7097409044097844e-09
common O 0 1.2775172919532451e-08
defect O 0 4.465825043098448e-08
in O 0 3.050141028637654e-09
the O 0 2.6020671839432907e-08
Cape O 0 1.1212930530746235e-06
and O 0 5.025917459988705e-09
hitherto O 0 5.5221047290388015e-08
unreported O 0 1.1137837319097343e-08
, O 0 5.400160318913549e-10
and O 0 8.481251811964796e-10
1195delC O 0 5.027530747270248e-08
and O 0 2.7237552213676963e-09
1936delG O 0 1.038519457097209e-07
, O 0 8.97178664693854e-10
which O 0 1.3780636354265852e-10
have O 0 2.757495620731021e-10
been O 0 9.907421549826267e-10
previously O 0 7.083314379485728e-09
reported O 0 5.440099037912205e-09
in O 0 6.470685764980999e-09
African O 0 6.56756128591951e-07
- O 0 2.3970480356183543e-07
Americans O 0 1.642365816678648e-07
. O 0 1.8443540739099262e-06

We O 0 6.025940706422261e-07
also O 0 5.73558622818382e-09
show O 0 2.7592963469658116e-09
that O 0 2.7706442695674127e-10
the O 0 1.8106851573662652e-09
879delG O 0 1.2068619525962276e-07
and O 0 1.6383852496915097e-08
1195delC O 0 2.32729780691443e-06
defects O 0 1.1789225027314387e-06
are O 0 3.201291676191431e-09
associated O 0 3.824531802365527e-08
with O 0 2.938400278651443e-08
characteristic O 1 0.9999814033508301
C6 O 1 1.0
/ O 1 0.9999995231628418
C7 O 1 0.9893847107887268
region O 0 2.794328111122013e-07
DNA O 0 2.5915130663634045e-07
marker O 0 2.4962298539321637e-07
haplotypes O 0 9.696864111674586e-08
, O 0 1.3661384246077546e-09
although O 0 2.090164707979625e-09
small O 0 3.3338301008711824e-09
variations O 0 3.562470141105223e-08
were O 0 5.5110984220618775e-08
observed O 0 3.2730187626839324e-07
. O 0 9.90986450233322e-07

The O 0 2.933836185547989e-06
1936delG O 0 3.544855644577183e-05
defect O 0 3.365134261912317e-06
was O 0 1.3141684007678123e-07
observed O 0 1.3606054061199302e-08
only O 0 1.0821359364143746e-09
once O 0 4.466359282417898e-09
in O 0 7.398212598097587e-10
the O 0 4.393828412219136e-09
Cape O 0 4.842967769036477e-07
, O 0 4.679158172038456e-10
but O 0 5.41950762045218e-10
its O 0 4.3487621836924006e-10
associated O 0 6.3460032784234954e-09
haplotype O 0 6.986094547301036e-08
could O 0 1.6363989274736923e-08
be O 0 5.177128770128547e-08
deduced O 0 2.2825818177807378e-06
. O 0 1.886696395558829e-06

The O 0 1.1238098522881046e-06
data O 0 1.1118335407900304e-07
from O 0 4.045052293122353e-09
the O 0 3.6372520550997933e-09
haplotypes O 0 3.2908207714399396e-08
indicate O 0 3.775491030921785e-09
that O 0 3.1687286128345704e-10
these O 0 1.1161969126760596e-09
three O 0 4.783704543598333e-09
molecular O 0 1.2821982636523899e-05
defects O 0 4.501504463405581e-06
account O 0 5.811846559566902e-09
for O 0 5.008137460293938e-09
the O 0 5.367971667169513e-08
defects O 0 2.774383574433159e-06
in O 0 4.703399891781146e-09
all O 0 3.483835664397361e-09
the O 0 9.552152846481476e-09
38 O 0 5.37854845106267e-08
unrelated O 0 4.1572665310241064e-08
C6Q0 O 0 1.360922851745272e-06
individuals O 0 6.545133879320986e-10
we O 0 2.8137079333134807e-09
have O 0 9.021119407037759e-10
studied O 0 4.975568046461376e-08
from O 0 3.7087357629417284e-09
the O 0 3.9901120629792786e-08
Cape O 0 1.3933613445260562e-05
. O 0 2.9920004180894466e-06

We O 0 7.71699546930904e-07
have O 0 1.4522933078353617e-08
also O 0 4.814047382950548e-09
observed O 0 1.3455311531629377e-08
the O 0 7.495382980948762e-09
879delG O 0 5.645040346280439e-07
defect O 0 1.3701007617328287e-07
in O 0 1.6457924800761248e-08
two O 0 9.195755268365247e-08
Dutch O 1 0.9999955892562866
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 5.300315024214797e-05
, O 0 1.2831975482185953e-08
but O 0 8.721686484136626e-09
the O 0 3.405783743914981e-08
879delG O 0 1.5133862234506523e-06
defect O 0 2.4375492557737743e-07
in O 0 9.885341434312522e-09
the O 0 2.9848784777186665e-08
Cape O 0 1.7327027990177157e-06
probably O 0 3.6088589894234246e-08
did O 0 4.949837872914031e-09
not O 0 7.315927308404468e-10
come O 0 1.759980938764727e-09
from O 0 6.026463772457191e-10
The O 0 1.1318348036581938e-08
Netherlands O 0 4.842755174649938e-07
. O 0 6.244653150133672e-08
. O 0 9.757584393810248e-07

Complement B-Disease 1 0.9999998807907104
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.596713314545923e-07
seven O 0 7.519470557326713e-08
further O 0 1.9795557193447166e-08
molecular O 0 1.2118993254262023e-05
defects O 0 3.0780540782870958e-06
and O 0 1.2338060351169133e-08
their O 0 2.7503757493718695e-08
associated O 0 5.561482225857617e-07
marker O 0 2.750985004240647e-06
haplotypes O 0 2.2261672711465508e-05
. O 0 5.480664185597561e-06

Seven O 0 1.0583719358692179e-06
further O 0 2.185671377219478e-08
molecular O 0 3.3707055990817025e-07
bases O 0 1.0271057959698737e-07
of O 0 0.004758522845804691
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.868294129460992e-07
described O 0 9.333547836831713e-07
. O 0 1.2604436960828025e-06

All O 0 1.092506209943167e-07
these O 0 8.612664359475275e-09
new O 0 2.0762033869914376e-08
molecular O 0 1.2501246828833246e-06
defects O 0 7.615772688041034e-07
involve O 0 1.6952849790641267e-08
single O 0 1.3815573574049722e-08
- O 0 1.6058726259871037e-07
nucleotide O 0 1.2496814250084753e-08
events O 0 1.787713754808351e-09
, O 0 8.36554381322685e-10
deletions O 0 7.861103767936584e-09
and O 0 1.1299425839439436e-09
substitutions O 0 8.4792501908737e-09
, O 0 6.890107928647637e-10
some O 0 7.355618197868452e-11
of O 0 5.328671948134911e-10
which O 0 6.927280971069649e-10
alter O 0 3.384865721045571e-08
splice O 0 2.028662038355833e-07
sites O 0 2.4914726282077027e-08
, O 0 6.952036279983531e-09
and O 0 1.360579382492233e-08
others O 0 1.1691096091226427e-07
codons O 0 3.464747123871348e-06
. O 0 4.762776825373294e-06

They O 0 1.453622786584674e-07
are O 0 9.521048838223578e-09
distributed O 0 6.255678641764462e-09
along O 0 5.7260001184999965e-09
the O 0 2.42847626452658e-08
C7 O 0 1.6256270100711845e-05
gene O 0 1.494720436312491e-08
, O 0 1.0406123740480666e-09
but O 0 4.972138256675862e-10
predominantly O 0 7.672745772069334e-10
towards O 0 8.244653848521466e-09
the O 0 6.337245839205252e-09
3 O 0 1.1093107588067141e-07
end O 0 6.018095746185281e-07
. O 0 8.410570444539189e-07

All O 0 2.3493178957778582e-07
were O 0 4.332580871846403e-08
found O 0 4.574587819661247e-09
in O 0 3.0190940858432214e-09
compound O 0 1.5583023582621536e-07
heterozygous O 0 2.2016949685621512e-07
individuals O 0 6.634795113313885e-08
. O 0 2.65461881099327e-06

The O 0 3.947005461668596e-05
C6 O 1 1.0
/ O 1 0.9999579191207886
C7 O 1 0.9197195172309875
marker O 0 5.2131404117972124e-06
haplotypes O 0 1.5747988300063298e-06
associated O 0 1.6821216775042558e-07
with O 0 4.081790550003461e-08
most O 0 7.355453135460266e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9765803217887878
are O 0 1.1945503786137124e-07
tabulated O 0 1.0931769338640152e-06
. O 0 1.5490520866023871e-07
. O 0 1.5755692857055692e-06

A O 0 8.751435416343156e-06
genome O 0 4.0489030084245314e-07
- O 0 2.8009691277475213e-07
wide O 0 3.1809396006110546e-08
search O 0 2.3780918567695153e-08
for O 0 5.2924531424025645e-09
chromosomal O 0 6.555917934747413e-06
loci O 0 2.0151954231550917e-05
linked O 0 1.4857044334348757e-05
to O 0 1.6052219109496946e-07
mental O 1 0.9999089241027832
health O 0 5.663499450747622e-06
wellness O 0 5.266142125037732e-06
in O 0 1.8371773435887917e-08
relatives O 0 5.1294186675931996e-08
at O 0 2.065825128738652e-07
high O 0 8.799084412203229e-07
risk O 0 4.07338404784241e-07
for O 0 3.3310591334156925e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
among O 0 3.437305053921591e-07
the O 0 1.1962329438119923e-07
Old O 0 2.8812507935072063e-06
Order O 0 1.553973334011971e-06
Amish O 0 1.0632994417392183e-05
. O 0 2.56246016760997e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.8819150924682617
BPAD B-Disease 1 1.0
; O 1 0.9999618530273438
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.012584551877808e-07
is O 0 1.184964903977459e-09
characterized O 0 1.6281479497948226e-09
by O 0 4.740404735414927e-10
episodes O 0 8.885026048233158e-09
of O 0 3.0839899523016356e-08
mania B-Disease 0 5.847664397151675e-07
and O 0 8.890318525800467e-08
/ O 0 0.0223441943526268
or O 0 1.032479303830769e-06
hypomania B-Disease 0 0.001037206151522696
interspersed O 0 4.384028073900481e-08
with O 0 2.259394893400213e-09
periods O 0 2.2128682530819788e-07
of O 0 4.191607274606213e-07
depression B-Disease 0 0.00017965280858334154
. O 0 4.094726591574727e-06

Compelling O 0 7.491935321013443e-06
evidence O 0 5.777932869932556e-07
supports O 0 2.218435390943796e-08
a O 0 3.638674694883548e-09
significant O 0 3.2955425055547494e-09
genetic O 0 1.609852517958643e-08
component O 0 1.7170131982879866e-08
in O 0 2.405030841146072e-09
the O 0 6.898474680383515e-09
susceptibility O 0 1.0476073697418542e-07
to O 0 1.8977599935965372e-08
develop O 0 1.1215336598979775e-05
BPAD B-Disease 1 1.0
. O 0 7.923658995423466e-05

To O 0 5.865526730985948e-08
date O 0 2.5129307346105634e-07
, O 0 2.6124791219217514e-09
however O 0 7.081800923458559e-09
, O 0 2.0674848499879772e-09
linkage O 0 1.0890688351139488e-08
studies O 0 2.735662363306801e-09
have O 0 8.484439817380007e-10
attempted O 0 1.8452332994911558e-08
only O 0 1.4034547968222455e-09
to O 0 2.250440278572796e-09
identify O 0 8.269603313237894e-08
chromosomal O 0 3.749769120986457e-06
loci O 0 1.583270659466507e-06
that O 0 1.0306023590089808e-08
cause O 0 7.214623565232614e-07
or O 0 5.243223100137584e-08
increase O 0 5.9395568463571635e-09
the O 0 2.8781608207850695e-08
risk O 0 1.376207166003951e-07
of O 0 9.493883794675639e-07
developing O 0 0.0039008096791803837
BPAD B-Disease 1 1.0
. O 0 3.852467125398107e-05

To O 0 1.3285045952216024e-07
determine O 0 1.7822630127284356e-07
whether O 0 1.8562044346026596e-08
there O 0 2.277410926510015e-09
could O 0 2.3198936105472967e-09
be O 0 3.3036611224446233e-09
protective O 0 3.127290426618856e-08
alleles O 0 3.966695061308201e-08
that O 0 9.227512642873137e-10
prevent O 0 9.98187488221447e-09
or O 0 3.940856529993653e-09
reduce O 0 5.048562901066589e-09
the O 0 3.743845677917079e-09
risk O 0 1.1384210019116381e-08
of O 0 8.000557727427804e-08
developing O 0 0.0011572828516364098
BPAD B-Disease 1 1.0
, O 0 3.075541377128843e-09
similar O 0 2.0677520806700045e-10
to O 0 5.672057268313324e-11
what O 0 6.713174460770688e-11
is O 0 3.768372072721071e-11
observed O 0 5.33701305371892e-10
in O 0 2.704459989288921e-10
other O 0 7.964318093911515e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.906051482260864e-09
we O 0 2.3986674868581304e-09
used O 0 1.0755353052616101e-08
mental O 0 0.0021224680822342634
health O 0 2.8008432195747446e-07
wellness O 0 9.145446711045224e-07
( O 0 2.5706521356028134e-09
absence O 0 2.287904798947693e-08
of O 0 1.6771265265447255e-08
any O 0 3.815606319790277e-08
psychiatric B-Disease 0 0.001099310116842389
disorder I-Disease 0 3.6815607018070295e-05
) O 0 9.251838406498791e-09
as O 0 3.4963034689639017e-09
the O 0 1.0210190914961004e-08
phenotype O 0 5.942188607832577e-08
in O 0 7.309347793693632e-09
our O 0 1.0859599086643357e-07
genome O 0 8.513772797869024e-08
- O 0 3.31596112346233e-07
wide O 0 1.6414857384461357e-07
linkage O 0 2.709895738917112e-07
scan O 0 1.7132189213953097e-06
of O 0 6.954041253948162e-08
several O 0 4.689488797282593e-09
large O 0 2.2750285211259325e-08
multigeneration O 0 2.6857571810978698e-06
Old O 0 1.6809875660328544e-06
Order O 0 6.221720241228468e-07
Amish O 0 2.696854835448903e-06
pedigrees O 0 5.780159995083523e-07
exhibiting O 0 2.7252252721154946e-07
an O 0 1.2533575954876142e-08
extremely O 0 4.0838162362888397e-07
high O 0 2.3438702555722557e-05
incidence O 0 0.00021619003382511437
of O 0 9.686365228844807e-05
BPAD B-Disease 1 1.0
. O 0 7.29953681002371e-05

We O 0 5.230068609307637e-07
have O 0 2.6053135204762157e-09
found O 0 1.6769144961514826e-09
strong O 0 3.017021743545456e-09
evidence O 0 1.6089623855464197e-08
for O 0 1.6382313283713756e-09
a O 0 7.976129978715107e-09
locus O 0 1.8664205470031447e-07
on O 0 2.1717301024182234e-07
chromosome O 0 1.4638940228905994e-06
4p O 0 7.164869020925835e-05
at O 0 2.889772986236494e-06
D4S2949 O 0 3.833113169093849e-06
( O 0 3.730767161869153e-08
maximum O 0 1.0719522833824158e-06
GENEHUNTER O 0 1.6754640455474146e-05
- O 0 3.8890303244443203e-07
PLUS O 0 1.378884491032295e-07
nonparametric O 0 3.175757115059241e-07
linkage O 0 5.3724992454817766e-08
score O 0 2.8196620149856244e-08
= O 0 5.616023557308836e-08
4 O 0 2.2869972582384435e-08
. O 0 1.329448884312967e-09
05 O 0 1.60800894377644e-07
, O 0 3.7242882111598874e-09
P O 0 3.7523801665884093e-07
= O 0 2.0373356335312565e-08
5 O 0 4.813487386456927e-09
. O 0 5.724118956607072e-10
22 O 0 4.256898389343178e-09
x O 0 3.054439190464109e-08
10 O 0 2.1726741294969543e-08
( O 0 2.217013239658172e-09
- O 0 4.804580733264174e-09
4 O 0 1.2540581906250736e-08
) O 0 6.962794785181359e-10
; O 0 2.1816008999309133e-09
SIBPAL O 0 1.0723173318183399e-06
Pempirical O 0 6.181939511407109e-07
value O 0 2.1804041239192884e-08
< O 0 6.254141737827013e-08
3 O 0 1.5644589623775573e-08
x O 0 2.4982535151707452e-08
10 O 0 1.6163937743840506e-08
( O 0 1.7138220842483065e-09
- O 0 2.4845712154331068e-09
5 O 0 3.222039524075626e-09
) O 0 6.0518740019333e-10
) O 0 6.187666490298227e-10
and O 0 9.968247338676406e-10
suggestive O 0 3.624331412765969e-08
evidence O 0 1.1168682867435109e-08
for O 0 1.147708039717088e-09
a O 0 5.1349076102269464e-09
locus O 0 1.710355661543872e-07
on O 0 2.7497785026753263e-07
chromosome O 0 2.7347462037141668e-06
4q O 0 2.3263715775101446e-05
at O 0 1.2025702744722366e-06
D4S397 O 0 2.6261702714691637e-06
( O 0 5.987079987335164e-08
maximum O 0 1.2601960861502448e-06
GENEHUNTER O 0 4.188453021924943e-05
- O 0 5.615433451566787e-07
PLUS O 0 2.0303150449763052e-07
nonparametric O 0 5.785349230791326e-07
linkage O 0 8.977939103260724e-08
score O 0 3.3642240993003725e-08
= O 0 3.215968646941292e-08
3 O 0 9.974318260219661e-09
. O 0 8.941974938281305e-10
29 O 0 1.3284330968588165e-08
, O 0 1.9225150360568932e-09
P O 0 2.0653445176321839e-07
= O 0 2.453056424656097e-08
2 O 0 7.4871522315334e-09
. O 0 5.101109534777493e-10
57 O 0 4.53026949287505e-09
x O 0 2.6070647862752594e-08
10 O 0 1.2043448904819343e-08
( O 0 1.2110427105582744e-09
- O 0 3.7129967989102397e-09
3 O 0 9.737282091748511e-09
) O 0 5.527505120284104e-10
; O 0 1.882290545651699e-09
SIBPAL O 0 1.6856994307090645e-06
Pempirical O 0 8.827745432427037e-07
value O 0 1.3539056986644482e-08
< O 0 5.415689940946322e-08
1 O 0 3.1310623427316386e-08
x O 0 2.8170227039936435e-08
10 O 0 1.2659761239319778e-08
( O 0 1.0180627452172075e-09
- O 0 2.631713735823382e-09
3 O 0 6.835501498159147e-09
) O 0 2.9100635789980345e-10
) O 0 1.3082604444214496e-10
that O 0 2.3391361070324024e-10
are O 0 1.8481629560085366e-09
linked O 0 1.4089437172515318e-07
to O 0 5.323557417113989e-08
mental O 1 0.985789954662323
health O 0 2.4746210328885354e-05
wellness O 0 4.127989450353198e-05
. O 0 7.4796139415411744e-06

These O 0 3.3361570217493863e-07
findings O 0 1.872526951274267e-07
are O 0 2.1863331145510756e-09
consistent O 0 9.973025960618997e-09
with O 0 2.9714639082634164e-10
the O 0 7.86157972054724e-10
hypothesis O 0 1.8000002599549703e-09
that O 0 2.0834717631701416e-11
certain O 0 2.7473634478525355e-10
alleles O 0 7.1543402313523075e-09
could O 0 3.868616094138133e-09
prevent O 0 1.731281962236153e-08
or O 0 4.1067313993892185e-09
modify O 0 3.027329853466654e-08
the O 0 3.044868801538314e-09
clinical O 0 8.743793245002962e-08
manifestations O 0 8.131259505717026e-07
of O 0 4.6075592763372697e-07
BPAD B-Disease 1 1.0
and O 0 2.2941973654155845e-08
perhaps O 0 1.3633876250196408e-08
other O 0 5.5245776842127725e-09
related O 0 3.6581616313924314e-06
affective B-Disease 1 0.9784932732582092
disorders I-Disease 1 0.9994593262672424
. O 0 1.5940633602440357e-05

Segregation O 0 0.0009254898177459836
distortion O 1 0.5182141065597534
in O 0 8.544739102944732e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.004165340214967728

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 4.5691444938711356e-07
is O 0 1.6614165598838326e-09
an O 0 9.415164203829818e-10
autosomal B-Disease 0 0.0002990532957483083
dominant I-Disease 1 0.9999469518661499
disease I-Disease 0 0.1714445948600769
which O 0 4.229470551564418e-09
, O 0 1.4003904702519776e-09
in O 0 5.9413213238102e-10
the O 0 1.1686047685088852e-09
typical O 0 5.735651953386878e-09
pedigree O 0 1.0844630082829099e-08
, O 0 8.948833896127439e-10
shows O 0 1.7181260858478709e-09
a O 0 3.4275737803568518e-09
three O 0 6.3227822977296455e-09
generation O 0 2.654725506090472e-07
anticipation O 0 7.539719604210404e-07
cascade O 0 5.613095709122717e-06
. O 0 3.941388513339916e-06

This O 0 2.5422362881499794e-08
results O 0 1.2209332567181264e-07
in O 0 1.9651025695566204e-08
infertility B-Disease 0 0.0016800465527921915
and O 0 0.06871867179870605
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9993734955787659
CDM B-Disease 1 0.9566302299499512
) O 0 2.7409272629341785e-09
with O 0 3.597996067750131e-10
the O 0 5.890693710597361e-09
disappearance O 0 2.963781184917025e-07
of O 0 2.8873139967799943e-07
DM B-Disease 1 1.0
in O 0 6.075681824313506e-08
that O 0 3.7177745326744116e-08
pedigree O 0 3.029778781638015e-06
. O 0 4.392202754388563e-06

The O 0 3.310024396796507e-07
concept O 0 2.0892575491870957e-07
of O 0 1.2689524453435297e-07
segregation O 0 1.112795189328608e-06
distortion O 0 5.87679210184433e-07
, O 0 1.2343019939464739e-09
where O 0 6.391174811604117e-10
there O 0 3.0227398362114855e-10
is O 0 1.6802659263959185e-10
preferential O 0 6.519782047575973e-09
transmission O 0 2.0076100781807327e-08
of O 0 2.2562769430578555e-09
the O 0 1.772959445922595e-09
larger O 0 4.8436765709425345e-09
allele O 0 5.0605006407522524e-08
at O 0 4.0016125524289237e-08
the O 0 1.1211305661618098e-08
DM B-Disease 1 1.0
locus O 0 7.27050206705826e-08
, O 0 1.2026960538591425e-09
has O 0 3.3889840933554183e-10
been O 0 1.1632542706863092e-09
put O 0 4.0381147314860755e-09
forward O 0 4.388905594510106e-08
to O 0 4.376723428123341e-09
explain O 0 4.338344439247521e-08
partially O 0 8.368328963115346e-08
the O 0 1.3316142855046564e-08
maintenance O 0 1.5190443036772194e-07
of O 0 3.4061449127875676e-07
DM B-Disease 1 1.0
in O 0 3.80049129944382e-08
the O 0 3.6330661146166676e-08
population O 0 5.957119686428314e-09
. O 0 2.575793018877448e-07

In O 0 4.427160718023515e-07
a O 0 6.748449976612392e-08
survey O 0 6.446801847914685e-08
of O 0 1.4869722519961215e-07
DM B-Disease 1 1.0
in O 0 5.7431314814948564e-08
Northern O 0 1.5929350638543838e-07
Ireland O 0 3.3190744375133363e-07
, O 0 2.022252232336541e-08
59 O 0 1.903423054727682e-07
pedigrees O 0 3.801499985911505e-07
were O 0 2.3848582486607484e-07
ascertained O 0 2.2016574803274125e-05
. O 0 5.52627852812293e-06

Sibships O 0 6.920922169229016e-05
where O 0 9.391730770857976e-08
the O 0 7.0555778997061225e-09
status O 0 7.916868050017456e-09
of O 0 3.3750522376863046e-09
all O 0 1.056243870145579e-09
the O 0 1.5428673894035683e-09
members O 0 1.211643452236899e-09
had O 0 2.1863622023943208e-09
been O 0 1.5678993658951867e-09
identified O 0 1.1685897582935922e-08
were O 0 1.2352518119485012e-08
examined O 0 3.1481409479283684e-08
to O 0 1.4806738057870916e-09
determine O 0 3.607847176567702e-08
the O 0 3.31909895123772e-08
transmission O 0 5.9576327657850925e-06
of O 0 3.7938181662866555e-07
the O 0 1.0274756050421274e-06
DM B-Disease 1 1.0
expansion O 0 7.405772635138419e-07
from O 0 3.0919633520198886e-09
affected O 0 4.184599333711958e-09
parents O 0 8.393417627594602e-10
to O 0 1.2609002730812335e-09
their O 0 1.8479136443261268e-08
offspring O 0 2.939738124041469e-07
. O 0 1.0025761412180145e-06

Where O 0 6.104448857513489e-07
the O 0 1.3473653837081656e-07
transmitting O 0 5.1376518968027085e-06
parent O 0 9.303796844051249e-08
was O 0 8.183086919189009e-08
male O 0 7.145574443256919e-08
, O 0 7.165159132682675e-08
58 O 0 2.248591727038729e-06
. O 0 5.09600295117707e-06

3 O 0 2.371769369347021e-06
% O 0 2.0751107498995225e-08
of O 0 1.738591848265969e-08
the O 0 5.151800763769643e-09
offspring O 0 5.357249754922577e-09
were O 0 5.044789030961283e-09
affected O 0 2.971640933324693e-09
, O 0 9.309113480071574e-10
and O 0 6.742563729567053e-10
in O 0 4.254794017111152e-10
the O 0 1.1278001865733245e-09
case O 0 4.702664480049634e-09
of O 0 2.3543289540128853e-09
a O 0 3.289984507048871e-09
female O 0 2.341093363611435e-08
transmitting O 0 1.2813897001251462e-06
parent O 0 7.070143226428627e-08
, O 0 8.796938288924139e-08
68 O 0 3.360263008289621e-06
. O 0 5.806070930702845e-06

7 O 0 1.0587519682303537e-05
% O 0 4.184641397841915e-07
were O 0 9.705279353511287e-07
affected O 0 1.2204623089928646e-06
. O 0 3.966513304476393e-06

Studies O 0 2.1839643977727974e-06
on O 0 7.657736773580837e-07
meiotic O 0 8.972314390121028e-06
drive O 0 3.7445337852659577e-07
in O 0 1.2157141782154213e-07
DM B-Disease 1 1.0
have O 0 6.572483890465719e-09
shown O 0 2.5127036007432935e-09
increased O 0 3.374820423118763e-09
transmission O 0 1.519463843635549e-08
of O 0 1.3003846888182125e-09
the O 0 8.757037872619833e-10
larger O 0 1.0830278895923584e-09
allele O 0 1.6788003875944923e-08
at O 0 1.5092446403741633e-08
the O 0 9.220972430057373e-09
DM B-Disease 1 0.9993308782577515
locus O 0 1.5370764572253393e-07
in O 0 1.0598608213285843e-08
non O 0 3.825378826149972e-06
- O 0 2.757497895800043e-05
DM O 1 0.9999998807907104
heterozygotes O 0 8.965223059931304e-06
for O 0 1.6635600275094475e-07
CTGn O 0 0.0001054196254699491
. O 0 4.764802724821493e-06

This O 0 1.346336517826785e-07
study O 0 3.2379851688801864e-08
provides O 0 2.01334926508423e-09
further O 0 2.6146225184930927e-09
evidence O 0 1.4695048733415206e-08
that O 0 9.970091419120308e-10
the O 0 2.687867883821582e-08
DM B-Disease 1 1.0
expansion O 0 1.393256923165609e-07
tends O 0 2.1391777238477516e-08
to O 0 4.13370981888761e-09
be O 0 1.8982813543289012e-08
transmitted O 0 1.2684444072874612e-07
preferentially O 0 1.3185356806388882e-07
. O 0 4.819906962438836e-07

Diagnosis O 1 0.9999963045120239
of O 1 0.830562174320221
hemochromatosis B-Disease 1 1.0
. O 0 0.00789516232907772

If O 0 2.2907857783138752e-05
untreated O 1 0.9997889399528503
, O 0 1.0988591384375468e-05
hemochromatosis B-Disease 1 1.0
can O 0 3.4842175864469027e-06
cause O 0 0.013734735548496246
serious O 0 0.2944442629814148
illness O 0 0.0002489736652933061
and O 0 3.802374859418478e-09
early B-Disease 0 3.22569384536564e-08
death I-Disease 0 3.8565872273466084e-08
, O 0 7.350026698382806e-10
but O 0 8.82587114503508e-10
the O 0 7.365144050197614e-09
disease O 0 6.780950911888795e-07
is O 0 1.3751104699366579e-09
still O 0 7.381443456466741e-09
substantially O 0 8.646607341233903e-08
under O 0 7.777341579640051e-07
- O 0 0.0001941472291946411
diagnosed O 0 5.741375935031101e-05
. O 0 4.930279828840867e-06

The O 0 8.365677217625489e-07
cornerstone O 0 5.317668637871975e-06
of O 0 5.585258122664527e-08
screening O 0 2.2796546872427825e-08
and O 0 2.1677721839807873e-09
case O 0 5.593741470022451e-09
detection O 0 3.946394855347535e-08
is O 0 2.9568603121532533e-10
the O 0 5.989541640438745e-10
measurement O 0 2.802386944722457e-08
of O 0 1.8718514738225167e-08
serum O 0 4.5861568764848926e-08
transferrin O 0 2.5657021751612774e-07
saturation O 0 1.303059917745486e-07
and O 0 1.3409374943762487e-08
the O 0 1.5509524331491775e-08
serum O 0 9.582520732465127e-08
ferritin O 0 2.824878265528241e-06
level O 0 3.434805421420606e-06
. O 0 6.4747564465506e-07

Once O 0 1.4880945400363998e-06
the O 0 1.064013446239187e-07
diagnosis O 0 1.1225898560951464e-05
is O 0 7.1567156645357954e-09
suspected O 0 2.714095899136737e-07
, O 0 1.5591803403935955e-08
physicians O 0 4.045277890440957e-08
must O 0 2.0435900083271008e-08
use O 0 6.229284110759181e-08
serum O 0 1.1398960850783624e-06
ferritin O 0 0.00010621584806358442
levels O 0 2.99168150377227e-05
and O 0 2.765209728750051e-06
hepatic O 1 0.9999134540557861
iron O 0 0.0005750174750573933
stores O 0 3.051353587579797e-07
on O 0 1.7276509822750086e-07
liver O 0 4.568974532048742e-07
biopsy O 0 2.6124487817469344e-07
specimens O 0 9.951230950377976e-09
to O 0 1.5338769143724562e-09
assess O 0 3.535481596372847e-08
patients O 0 2.681793231928964e-09
for O 0 9.057359307007573e-10
the O 0 2.057971792979174e-09
presence O 0 1.2840887464449224e-08
of O 0 2.3771536916683544e-07
iron B-Disease 0 0.2781975567340851
overload I-Disease 0 0.0007936417823657393
. O 0 8.097295904008206e-06

Liver O 1 0.6064527034759521
biopsy O 1 0.7825899720191956
is O 0 1.9800278749926292e-08
also O 0 1.5335726022414065e-09
used O 0 5.426582516676604e-10
to O 0 4.282034726799111e-10
establish O 0 4.014101939731063e-09
the O 0 6.260700846638656e-10
presence O 0 1.4890512156640057e-09
or O 0 2.63293409297205e-09
absence O 0 4.184362012438214e-08
of O 0 5.054809193438814e-08
cirrhosis B-Disease 1 0.9737223982810974
, O 0 3.596865916222214e-09
which O 0 4.55860266201924e-10
can O 0 1.7513749339670426e-09
affect O 0 5.5627086936738124e-08
prognosis O 0 3.8759885683248285e-06
and O 0 1.587926732327105e-07
management O 0 3.6758535770786693e-06
. O 0 1.944994437508285e-06

A O 0 2.9545403776864987e-06
DNA O 0 9.176969228974485e-07
- O 0 1.0531006466862891e-07
based O 0 1.6112371437060347e-09
test O 0 9.611420104249646e-09
for O 0 1.8204159291101973e-09
the O 0 8.946584806324154e-09
HFE O 0 1.6490264897583984e-05
gene O 0 1.5902294592251565e-08
is O 0 3.6519595680850614e-10
commercially O 0 1.7473575919524365e-09
available O 0 9.626001107321258e-10
, O 0 1.8447388061559877e-10
but O 0 1.216774875301141e-10
its O 0 6.50525397438706e-11
place O 0 1.9860748601274736e-09
in O 0 1.7688106535018733e-10
the O 0 6.361342563820926e-10
diagnosis O 0 4.775502588927338e-07
of O 0 2.062476767150656e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.9736067002895652e-08
still O 0 4.6112077711768507e-08
being O 0 1.4615697807585093e-07
evaluated O 0 1.9642652659968007e-06
. O 0 2.2999272459856e-06

Currently O 0 1.1609472494455986e-06
, O 0 2.0605531503292696e-08
the O 0 7.017595837766066e-09
most O 0 4.958888855099985e-10
useful O 0 2.00921768112039e-09
role O 0 1.0402314565283177e-09
for O 0 9.05386668414998e-11
this O 0 2.4840903639633538e-11
test O 0 7.892830833355902e-10
is O 0 1.0054264365511045e-10
in O 0 1.2441103702798273e-10
the O 0 4.6127954234087554e-10
detection O 0 9.911776999160793e-08
of O 0 1.5640149797491176e-07
hemochromatosis B-Disease 1 1.0
in O 0 3.2939041716417705e-08
the O 0 2.3914694224913546e-08
family O 0 8.922484417972498e-10
members O 0 8.558767028432612e-10
of O 0 7.447926719805764e-09
patients O 0 4.6170667289402445e-09
with O 0 8.346195956576707e-10
a O 0 5.351826981581098e-09
proven O 0 8.797372288427141e-07
case O 0 1.1009531419858831e-07
of O 0 1.9219299929318368e-07
the O 0 9.60203919930791e-07
disease O 0 0.0002954045485239476
. O 0 2.948289193227538e-06

It O 0 5.9176901601176723e-08
is O 0 9.795214417351872e-09
crucial O 0 2.1265933014547045e-07
to O 0 8.52095283221388e-08
diagnose O 1 0.9999959468841553
hemochromatosis B-Disease 1 1.0
before O 1 0.9999244213104248
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 1.4137357538857032e-05
because O 0 1.3283386124385288e-07
phlebotomy O 1 0.6451748013496399
therapy O 0 3.2037365599535406e-05
can O 0 5.122027246784455e-08
avert O 0 0.0003548814565874636
serious O 1 0.999998927116394
chronic O 1 1.0
disease O 1 0.9999991655349731
and O 0 2.5697222127973873e-08
can O 0 3.6490162003133264e-09
even O 0 2.3298665219328996e-09
lead O 0 4.492211935769319e-09
to O 0 1.2253204006995588e-09
normal O 0 5.347003551037233e-08
life O 0 9.640171327873759e-09
expectancy O 0 1.590532860973326e-08
. O 0 1.3216094885137863e-08
. O 0 2.583739728834189e-07

Prevalence O 0 2.3939004677231424e-05
of O 0 3.6478357401392714e-07
the O 0 1.2660055404012382e-07
I1307K O 0 9.763858770384104e-07
APC B-Disease 0 1.3743932925081026e-07
gene O 0 4.855266411141201e-09
variant O 0 2.5061522634928224e-08
in O 0 1.3825900424535575e-09
Israeli O 0 3.095523126717126e-08
Jews O 0 5.624703369733197e-09
of O 0 1.236903801604683e-09
differing O 0 1.6397444513316373e-09
ethnic O 0 8.750325464212949e-10
origin O 0 8.505425697080682e-09
and O 0 2.937470000574649e-08
risk O 0 5.266754669719376e-06
for O 0 0.09288293868303299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.997591495513916

BACKGROUND O 0 2.663196028152015e-05
& O 0 8.839811016514432e-06
AIMS O 0 1.3783825352220447e-06
Israeli O 0 8.544337219973386e-07
Jews O 0 1.503391473534066e-07
of O 0 3.169989426510256e-08
European O 0 5.227984445355105e-08
birth O 0 2.0790288601801876e-08
, O 0 1.3540701893077767e-09
i O 0 7.48271222761332e-09
. O 0 1.3550003341578076e-09
e O 0 7.545255975571763e-09
. O 0 9.095081354715262e-10
, O 0 3.942661308542483e-09
Ashkenazim O 0 2.846800725819776e-06
, O 0 6.609052860540032e-09
have O 0 2.4208164361994022e-09
the O 0 3.281149929534877e-08
highest O 1 0.9900380373001099
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 9.844259693636559e-06
of O 0 4.6323204827558584e-08
any O 0 1.1917586029142058e-08
Israeli O 0 9.388960506839794e-07
ethnic O 0 8.150873753720589e-08
group O 0 2.1292193252975267e-07
. O 0 1.5873724805715028e-06

The O 0 3.52295205630071e-06
I1307K O 0 6.669142294413177e-06
APC B-Disease 0 2.2904648631083546e-06
gene O 0 6.371754324163703e-08
variant O 0 4.836663265450625e-07
was O 0 1.9304681586618244e-07
found O 0 1.4730773045812384e-08
in O 0 2.9009781243871657e-08
6 O 0 5.186085218156222e-06
. O 0 2.683990487639676e-06

1 O 0 8.66557570589066e-07
% O 0 4.659273411533604e-09
of O 0 5.0016750741121996e-09
American O 0 3.4675140536677418e-09
Jews O 0 8.772389037403627e-09
, O 0 7.807783308777516e-10
28 O 0 6.340934000093057e-09
% O 0 6.935491070336752e-10
of O 0 7.885942565621917e-09
their O 0 3.211390549040516e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 7.975168409757316e-05
, O 0 5.233099287238474e-09
but O 0 1.1586660519924408e-09
not O 0 8.123472450272118e-10
in O 0 1.9309562837577232e-09
non O 0 9.32091879235486e-08
- O 0 1.2762050971559802e-07
Jews O 0 2.923804345300596e-07
. O 0 1.5722147281849175e-06

We O 0 3.396256261112285e-06
assessed O 0 1.6621517033854616e-06
the O 0 5.4571245300394366e-08
I1307K O 0 5.992455385239737e-07
prevalence O 0 4.6693998001501313e-08
in O 0 3.4984429242435056e-10
Israeli O 0 1.174934816106088e-08
Jews O 0 4.108690276893867e-09
of O 0 6.697778998088211e-10
differing O 0 4.031794065273431e-10
ethnic O 0 5.656740631465595e-10
origin O 0 6.7664140956935626e-09
and O 0 2.294613032916004e-08
risk O 0 2.05133983399719e-06
for O 0 0.004505705554038286
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9865871071815491

METHODS O 0 3.286902256149915e-06
DNA O 0 1.795187927200459e-07
samples O 0 1.122303050493656e-08
from O 0 3.4428404571684723e-09
500 O 0 1.4350094446058392e-08
unrelated O 0 9.157734126574724e-09
Jews O 0 2.0627041408260993e-08
of O 0 1.3393041342624201e-08
European O 0 1.4089651756421517e-07
or O 0 5.218340604074001e-08
non O 0 4.080923474703013e-07
- O 0 1.6208456798949555e-08
European O 0 4.0662166966853874e-09
origin O 0 1.3823843181270945e-09
, O 0 1.5941090114601764e-10
with O 0 6.951883513295343e-11
or O 0 6.04827354866444e-10
without O 0 8.329942291496195e-10
a O 0 5.35148758640247e-10
personal O 0 7.824289660618433e-09
and O 0 3.3413879663157786e-08
/ O 0 1.5235639693855774e-05
or O 0 2.374411600669646e-08
family O 0 6.881623604293452e-10
history O 0 3.0355964408812497e-09
of O 0 9.820112722991325e-09
neoplasia B-Disease 0 2.0449353542062454e-05
, O 0 3.0190665967211316e-08
were O 0 5.5389186570664606e-08
examined O 0 1.4132231740404677e-07
for O 0 3.587787178460644e-09
the O 0 1.447467568027605e-08
I1307K O 0 2.40637717752179e-07
variant O 0 7.553135361604291e-08
by O 0 4.3774663893714205e-09
the O 0 9.032762982030818e-09
allele O 0 1.0834214236865591e-07
- O 0 3.803827297588214e-08
specific O 0 8.713572086094246e-09
oligonucleotide O 0 1.1295013564449619e-06
( O 0 5.349451726033294e-08
ASO O 0 1.0610009667288978e-05
) O 0 4.9384400568897036e-08
method O 0 9.005557899399719e-07
. O 0 1.664613705543161e-06

RESULTS O 0 1.0069177733385004e-05
In O 0 1.6123976820381358e-07
persons O 0 7.679092561829748e-08
at O 0 6.204975022683357e-08
average O 0 2.679477084654991e-09
risk O 0 3.5491634520212756e-08
for O 0 1.5870136849116534e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.7309889699390624e-07
I1307K O 0 1.7970567967040552e-07
was O 0 6.891859971602798e-09
found O 0 7.97174604105777e-10
in O 0 2.6174069578388526e-09
5 O 0 2.856003504803084e-07
. O 0 6.801689096391783e-07

0 O 0 9.120188906308613e-07
% O 0 9.842145765048826e-09
of O 0 1.1103475472395985e-08
120 O 0 2.968317502904938e-08
European O 0 4.915247586723126e-08
and O 0 3.1745695849849653e-08
1 O 0 8.387597745240782e-07
. O 0 5.60033015517547e-07

6 O 0 3.825612111540977e-06
% O 0 3.2919196257807926e-08
of O 0 7.985647698660614e-08
188 O 0 1.0690951057767961e-07
non O 0 2.5636353484514984e-07
- O 0 3.3736185400812246e-08
European O 0 1.9614851964888658e-08
Jews O 0 4.937987796438392e-08
( O 0 3.7280196707456525e-09
P O 0 3.6183502061248873e-07
= O 0 3.649136459671354e-08
0 O 0 1.671180882567569e-08
. O 0 3.021698002925177e-09
08 O 0 3.4807561632987927e-07
) O 0 4.1718266174939345e-08
. O 0 6.961605549804517e-07

It O 0 1.2016205630516197e-07
occurred O 0 5.869633241673e-07
in O 0 2.763980511133468e-08
15 O 0 6.064237254577165e-07
. O 0 1.6884506521819276e-06

4 O 0 2.0516411041171523e-06
% O 0 1.791756432112379e-08
of O 0 2.3835136531147327e-08
52 O 0 1.342419722050181e-07
Ashkenazi O 0 6.390644671228074e-07
Israelis O 0 2.3350200706317992e-07
with O 0 1.2031945217927387e-08
familial O 0 1.4742951179869124e-06
cancer B-Disease 0 7.152587841119384e-06
( O 0 1.2396978377182677e-07
P O 0 3.572609421098605e-05
= O 0 2.3947609406604897e-07
0 O 0 2.473984750395175e-08
. O 0 1.0660052840449907e-09
02 O 0 9.084703833650565e-08
) O 0 2.1649404491341784e-10
and O 0 2.0168153258559585e-10
was O 0 8.172924559346484e-10
not O 0 1.3229398132530434e-10
detected O 0 2.0216341933831927e-09
in O 0 9.065638240102203e-10
51 O 0 5.233191657794123e-08
non O 0 7.741083436485496e-07
- O 0 2.680353361483867e-07
European O 0 1.4175967066876183e-07
Jews O 0 3.1400668376591057e-07
at O 0 2.458434380514518e-07
increased O 0 1.0986582310579251e-07
cancer B-Disease 0 2.8522003958642017e-06
risk O 0 7.565245709884039e-07
. O 0 2.8178396860312205e-06

Colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999955892562866
occurred O 0 0.0019068487454205751
personally O 0 7.909669648142881e-07
or O 0 1.0594060739776978e-08
in O 0 3.228979306157953e-09
the O 0 2.4610313786865845e-09
families O 0 3.494694811312371e-10
of O 0 3.065620202136188e-09
13 O 0 2.5793763569481598e-08
of O 0 2.2645430419743207e-08
20 O 0 1.94085913562958e-07
Ashkenazi O 0 5.979462684990722e-07
I1307K O 0 1.6106257305636973e-07
carriers O 0 2.3703876639302734e-09
, O 0 2.9323297123795555e-09
8 O 0 6.503303495719592e-08
of O 0 1.4592543173819195e-08
whom O 0 7.561135362266214e-08
also O 0 9.561393454760037e-09
had O 0 1.4271320125658349e-08
a O 0 4.145427112689504e-09
personal O 0 4.203600312280287e-08
or O 0 3.528320746681857e-08
family O 0 5.3824456003326304e-09
history O 0 4.6842437484428956e-08
of O 0 6.25800794296083e-07
noncolonic O 0 0.0002337949408683926
neoplasia B-Disease 1 0.9724242687225342
. O 0 0.0001546677522128448

CONCLUSIONS O 0 1.3036759810347576e-05
The O 0 6.444459472731978e-07
I1307K O 0 3.1137196856434457e-06
APC O 0 9.420010655958322e-07
variant O 0 2.424422405056248e-07
may O 0 1.1524379672778196e-08
represent O 0 2.877149407609636e-09
a O 0 4.3247845304961174e-09
susceptibility O 0 8.982735266727104e-08
gene O 0 5.91875135569353e-08
for O 0 9.440113046821352e-08
colorectal B-Disease 1 1.0
, I-Disease 0 4.1747003365344426e-07
or I-Disease 0 8.063015144443852e-08
other I-Disease 0 1.9644270654595175e-09
, I-Disease 0 1.9205541601508003e-09
cancers I-Disease 0 1.4108961465808534e-07
in O 0 2.339052507238648e-09
Ashkenazi O 0 4.5374321189228795e-07
Jews O 0 9.553394875183585e-08
, O 0 4.248778662230279e-09
and O 0 5.238641520577403e-09
partially O 0 6.15611170928787e-08
explains O 0 1.3313095514888573e-08
the O 0 3.3660392251277926e-09
higher O 0 1.0993184673679934e-07
incidence O 0 1.157838778453879e-05
of O 1 0.9472969174385071
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.183057396607182e-07
European O 0 8.818962669465691e-06
Israelis O 0 9.50659978116164e-06
. O 0 1.3272385785967344e-06

Systematic O 0 1.3647974128616625e-06
analysis O 0 1.64764642818227e-07
of O 0 2.728007473251637e-07
coproporphyrinogen O 0 5.304446676746011e-05
oxidase O 0 8.510364750691224e-06
gene O 0 2.095164518323145e-06
defects O 0 1.1268672096775845e-05
in O 0 1.209996725037854e-07
hereditary B-Disease 1 0.9999972581863403
coproporphyria I-Disease 1 0.6857710480690002
and O 0 1.9822418835246935e-06
mutation O 0 3.1992781259759795e-06
update O 0 2.8894211936858483e-05
. O 0 7.235360499180388e-06

Hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9999781847000122
( O 0 8.129187335725874e-05
HC B-Disease 1 0.9999996423721313
) O 0 2.750919634308957e-07
is O 0 7.910528232457636e-09
an O 0 7.659370915291674e-09
acute O 1 0.9999984502792358
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.00277036358602345
autosomal O 1 0.9999997615814209
dominant O 1 0.9999961853027344
inheritance O 0 0.00017768971156328917
caused O 0 1.270284656129661e-06
by O 0 1.1453797021943046e-08
deficient B-Disease 0 8.630377834606406e-08
activity I-Disease 0 3.550476890268328e-08
of I-Disease 0 1.2340018429313204e-07
coproporphyrinogen I-Disease 0 8.466699000564404e-06
III I-Disease 1 0.8530710935592651
oxidase I-Disease 0 2.487594429112505e-06
( O 0 1.3537460574752913e-07
CPO O 0 6.473727353295544e-06
) O 0 2.189493812920773e-07
. O 0 1.6899134607228916e-06

Clinical O 0 0.0005455308128148317
manifestations O 0 0.01690021902322769
of O 0 5.735354534408543e-06
the O 0 2.339197635592427e-06
disease O 0 0.02001233771443367
are O 0 2.4792079500457476e-09
characterized O 0 9.447567173026528e-09
by O 0 1.7539825147849797e-09
acute O 0 0.0007772953249514103
attacks O 0 7.416572043439373e-05
of O 1 0.9999995231628418
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.542074639677594e-07
precipitated O 0 4.3909824398724595e-07
by O 0 1.6223355991940025e-09
drugs O 0 1.3315609947994744e-08
, O 0 1.4714794716041979e-08
fasting O 0 2.0205191049171844e-06
, O 0 6.227632809441275e-08
cyclical O 0 6.4205073613265995e-06
hormonal O 0 4.398712462716503e-06
changes O 0 4.5951188099024876e-07
, O 0 3.0097041303633887e-07
or O 0 4.808067387784831e-05
infectious B-Disease 1 0.9806295037269592
diseases I-Disease 0 0.3194371163845062
. O 0 5.492101990967058e-06

Skin O 1 1.0
photosensitivity O 1 0.9999982118606567
may O 0 9.743720147525892e-05
also O 0 4.879816017933081e-08
be O 0 1.623525136551507e-08
present O 0 6.280104969391687e-08
. O 0 6.080597358959494e-07

The O 0 1.2748101880788454e-06
seven O 0 6.023148557687819e-07
exons O 0 8.994322229227691e-07
, O 0 2.0429546054856473e-08
the O 0 3.4418242478295724e-08
exon O 0 7.116182132449467e-07
/ O 0 4.975312322130776e-07
intron O 0 1.467130630317115e-07
boundaries O 0 2.070797044950723e-08
and O 0 4.358221783462568e-09
part O 0 3.6125762381544746e-09
of O 0 9.526516464575252e-09
3 O 0 1.0590387944375834e-07
noncoding O 0 6.491109161288477e-08
sequence O 0 4.4766106377380765e-09
of O 0 1.0441000952710056e-08
the O 0 1.1079253070533923e-08
CPO O 0 3.019792984559899e-07
gene O 0 1.957486261972008e-08
were O 0 1.943227445622142e-08
systematically O 0 8.44287839640856e-08
analyzed O 0 1.6974333050256973e-08
by O 0 2.216023808898626e-09
an O 0 2.8539535179561426e-09
exon O 0 1.569753180774569e-07
- O 0 1.4290147021256416e-07
by O 0 2.727858472439948e-08
- O 0 3.5671796467795502e-06
exon O 0 4.897121016256278e-06
denaturing O 0 4.602848275681026e-05
gradient O 0 9.333091838925611e-06
gel O 0 5.367467565520201e-06
electrophoresis O 0 1.6451418787255534e-06
( O 0 8.907733217711211e-08
DGGE O 0 5.7360762184544e-06
) O 0 5.945178127575446e-09
strategy O 0 1.0411688400324692e-08
followed O 0 2.052961134424436e-09
by O 0 2.518114050609199e-10
direct O 0 1.15824627666683e-09
sequencing O 0 6.480974867884015e-09
in O 0 2.9576292526201087e-09
seven O 0 2.6421416166044764e-08
unrelated O 0 5.7057469859955745e-08
heterozygous O 0 7.820295166993674e-08
HC B-Disease 0 0.0003174824523739517
patients O 0 1.2242208136115096e-08
from O 0 3.6125966662581277e-09
France O 0 6.32756780305499e-07
, O 0 1.0513341308637791e-08
Holland O 0 5.690210400643991e-07
, O 0 3.1005735756650665e-09
and O 0 3.8825800352526585e-09
Czech O 0 4.933129957862548e-07
Republic O 0 2.3992008664208697e-06
. O 0 6.415647476387676e-06

Seven O 0 1.9098522443528054e-06
novel O 0 1.0918313364527421e-07
mutations O 0 3.893609346050653e-08
and O 0 2.500845974751087e-09
two O 0 2.4394635200764014e-09
new O 0 1.3334187975999612e-08
polymorphisms O 0 8.756611435956074e-08
were O 0 1.354039227408066e-07
detected O 0 9.445684554520994e-07
. O 0 3.5867981296178186e-06

Among O 0 9.458911875981357e-08
these O 0 3.382147450992079e-09
mutations O 0 1.2113760661236483e-08
two O 0 2.2258557219601016e-09
are O 0 1.7080721281814704e-09
missense O 0 3.024865975476132e-07
( O 0 1.568085572500877e-08
G197W O 0 1.6668552405008086e-07
, O 0 4.694741928545909e-09
W427R O 0 1.1087649909313768e-07
) O 0 1.1973309010926414e-09
, O 0 9.135050493824792e-10
two O 0 7.206901742051741e-10
are O 0 1.0593772525879785e-09
nonsense O 0 1.004002001536719e-07
( O 0 4.06209288428272e-09
Q306X O 0 8.19106702465433e-08
, O 0 2.3959010331253694e-09
Q385X O 0 4.317368862416515e-08
) O 0 1.404670713078815e-09
, O 0 6.84012735341355e-10
two O 0 4.677953580056737e-10
are O 0 2.634946982826847e-10
small O 0 2.408386379215699e-09
deletions O 0 1.2851110398059973e-07
( O 0 2.1102025016261905e-08
662de14bp O 0 3.5948241361438704e-07
; O 0 3.0800748618275975e-08
1168del3bp O 0 1.6480894373671617e-06
removing O 0 3.7204389968792384e-07
a O 0 4.937158948337128e-08
glycine O 0 1.2977272945136065e-07
at O 0 1.3368648410505557e-07
position O 0 9.643466825082214e-08
390 O 0 5.177118822530247e-08
) O 0 1.4225872702056108e-09
, O 0 6.478808045606854e-10
and O 0 8.422331165824914e-10
one O 0 1.1673394473277199e-09
is O 0 5.822406445865624e-10
a O 0 4.2257615184837505e-09
splicing O 0 1.1462893212410563e-07
mutation O 0 1.667411737571456e-07
( O 0 3.400668546760244e-08
IVS1 O 0 2.099266384902876e-05
- O 0 8.747470019443426e-07
15c O 0 2.146634415112203e-06
- O 0 2.2743240890577e-07
- O 0 6.370782301701183e-08
> O 0 1.0493312174730818e-07
g O 0 4.1239548664862014e-08
) O 0 9.249750965167891e-10
which O 0 3.6615568910214336e-10
creates O 0 2.0952177770539038e-09
a O 0 1.234843560737886e-09
new O 0 4.954892052211335e-09
acceptor O 0 3.725519093222829e-08
splice O 0 2.1250475583656225e-06
site O 0 3.683380498387123e-07
. O 0 7.338665000133915e-07

The O 0 7.450863108715566e-07
pathological O 0 1.8760246121019009e-06
significance O 0 1.5008687626050232e-07
of O 0 2.5223034327837013e-08
the O 0 6.812515440657307e-09
point O 0 3.278384852478666e-08
mutations O 0 3.866832543053533e-08
G197W O 0 2.0386384846915462e-07
, O 0 6.550470388333451e-09
W427R O 0 1.8133599155589764e-07
, O 0 4.353494897912924e-09
and O 0 3.833907857853092e-09
the O 0 7.697287252028673e-09
in O 0 1.1250763876091696e-08
- O 0 1.0045766885014018e-07
frame O 0 4.357551404154947e-07
deletion O 0 1.226036943080544e-07
390delGly O 0 3.105888026766479e-07
were O 0 1.1637363961369829e-08
assessed O 0 2.9608703044914364e-08
by O 0 6.434768828889048e-10
their O 0 1.5480966508718552e-09
respective O 0 8.577270449450225e-09
expression O 0 7.051851103057061e-09
in O 0 2.147135358399055e-09
a O 0 1.911272251575724e-09
prokaryotic O 0 1.2173634544865308e-08
system O 0 2.977700530593097e-09
using O 0 3.76528674905785e-09
site O 0 2.0623776464390176e-08
- O 0 4.378454221409811e-08
directed O 0 2.004774479757998e-08
mutagenesis O 0 8.45470822241623e-06
. O 0 3.874920366797596e-06

These O 0 4.980135059895474e-08
mutations O 0 8.696474651515018e-08
resulted O 0 2.5362501432368845e-08
in O 0 1.6377159628433446e-09
the O 0 2.5005120196652797e-09
absence O 0 3.409696347489444e-08
or O 0 5.480832232507282e-09
a O 0 1.962322526694038e-09
dramatic O 0 2.8639123073048722e-08
decrease O 0 3.34064864659922e-08
of O 0 5.974691816845734e-07
CPO O 0 1.868482468125876e-05
activity O 0 5.4376500884245615e-06
. O 0 4.279739187040832e-06

The O 0 2.868497119834501e-07
two O 0 2.0212883811154825e-08
polymorphisms O 0 4.6679396348281443e-08
were O 0 4.2301806502109685e-09
localized O 0 1.7242561156649572e-08
in O 0 2.2928225984486517e-09
noncoding O 0 1.8009282953812544e-08
part O 0 1.3289596090260147e-09
of O 0 3.6044820461711424e-09
the O 0 9.88469528451219e-10
gene O 0 8.610639423700661e-10
1 O 0 1.0417091189651728e-08
) O 0 1.0587026810782163e-09
a O 0 5.264705560392713e-09
C O 0 1.0757178188214311e-06
/ O 0 5.657155384142243e-07
G O 0 3.09402423681604e-07
polymorphism O 0 6.957318277045488e-08
in O 0 1.8147028324477787e-09
the O 0 8.733804790495014e-09
promotor O 0 2.08543065127742e-06
region O 0 3.0391841931987074e-08
, O 0 1.5592455326896015e-08
142 O 0 1.3882329596981435e-07
bp O 0 7.094634213444806e-08
upstream O 0 9.233415809717371e-09
from O 0 1.3178279578696106e-09
the O 0 5.611191511434299e-09
transcriptional O 0 5.671027736298129e-08
initiation O 0 3.5680461252241e-08
site O 0 1.470267552150517e-08
( O 0 4.274969711559606e-09
- O 0 3.51789140040637e-08
142C O 0 2.1717715981139918e-07
/ O 0 2.588168968031823e-07
G O 0 2.550420674651832e-07
) O 0 3.140690596481477e-09
, O 0 7.915837429983696e-10
and O 0 1.2251545333796798e-09
2 O 0 3.768535705717113e-08
) O 0 7.751633779307099e-10
a O 0 3.0820361818229003e-09
6 O 0 1.2740598265281733e-07
bp O 0 8.874697954297517e-08
deletion O 0 4.885133719767509e-08
polymorphism O 0 2.5012049320594087e-08
in O 0 1.0624287005711608e-09
the O 0 3.611446253160011e-09
3 O 0 3.8252178313769036e-08
noncoding O 0 5.446486994742372e-08
part O 0 2.9108533361466016e-09
of O 0 2.212848926319566e-08
the O 0 5.517198431448378e-08
CPO O 0 2.622476358737913e-06
gene O 0 8.121295991259103e-08
, O 0 7.056953421624712e-08
574 O 0 1.5547011571470648e-06
bp O 0 1.0541310757616884e-06
downstream O 0 1.3423326095107768e-07
of O 0 2.7831042359593994e-08
the O 0 1.2824243889042464e-08
last O 0 1.1807803623753443e-08
base O 0 9.115336041531918e-09
of O 0 7.089166587093132e-09
the O 0 5.1502975217943e-09
normal O 0 6.733740320896686e-08
termination O 0 1.725803286944938e-07
codon O 0 3.2502219937668997e-07
( O 0 5.10409314813387e-08
+ O 0 1.0030657904280815e-06
574 O 0 2.098542154271854e-06
delATTCTT O 0 4.544327566691209e-06
) O 0 1.925232027133461e-07
. O 0 2.0282996047171764e-06

Five O 0 1.3132166714058258e-05
intragenic O 0 6.186048995004967e-05
dimorphisms O 0 2.1719861251767725e-05
are O 0 7.89828646929891e-09
now O 0 4.13886169781108e-09
well O 0 1.168468877210671e-09
characterized O 0 2.144667332615313e-09
and O 0 6.441780442401068e-10
the O 0 1.0632315028402672e-09
high O 0 4.170384482193867e-09
degree O 0 2.7289825510479204e-08
of O 0 1.1086270568227974e-08
allelic O 0 5.608411584034911e-07
heterogeneity O 0 6.715694098602398e-07
in O 0 3.3239075492019765e-08
HC B-Disease 1 0.6609264612197876
is O 0 8.619286617772559e-09
demonstrated O 0 3.040825191646945e-08
with O 0 1.0814837914097097e-09
seven O 0 3.4717826391528206e-09
new O 0 4.529532859898211e-10
different O 0 1.5277065723573457e-10
mutations O 0 2.5390465285823893e-09
making O 0 4.32211877399169e-10
a O 0 1.89079946144588e-10
total O 0 3.691302818964459e-10
of O 0 9.018233271262943e-09
nineteen O 0 1.338693436991889e-06
CPO O 0 2.7364279958419502e-05
gene B-Disease 0 4.985413397662342e-06
defects I-Disease 0 1.1032734619220719e-05
reported O 0 4.6229818195797634e-08
so O 0 7.714263006164401e-09
far O 0 2.2462774751375036e-08
. O 0 7.890474762461963e-08
. O 0 1.2239801208124845e-06

Coincidence O 0 1.2120495739509352e-05
of O 0 4.722725464034738e-07
two O 0 1.6487584630908714e-08
novel O 0 6.386940043512368e-08
arylsulfatase O 0 8.804733511169616e-07
A O 0 6.836977917146214e-08
alleles O 0 7.340758401142011e-08
and O 0 1.8088117670345127e-08
mutation O 0 9.965690139779326e-08
459 O 0 3.250627855777566e-07
+ O 0 1.6636329291941365e-06
1G O 0 2.239734385511838e-05
> O 0 1.215771476381633e-06
A O 0 6.343984892964727e-08
within O 0 2.1177424258667088e-08
a O 0 7.90432963526655e-09
family O 0 6.209376124388655e-09
with O 0 2.0375106046799374e-08
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999990463256836
: O 0 1.6069748198788147e-08
molecular O 0 6.101672056502139e-08
basis O 0 2.4144174659568307e-08
of O 0 3.878029986026377e-08
phenotypic O 0 1.3363106518227141e-05
heterogeneity O 0 2.5024846763699315e-05
. O 0 1.5145821635087486e-05

In O 0 4.019662753762532e-07
a O 0 5.273350822676548e-08
family O 0 4.644898687899968e-09
with O 0 8.252798999741628e-10
three O 0 2.755951244992616e-09
siblings O 0 1.4524567326645865e-08
, O 0 8.740767554193951e-10
one O 0 3.8143654901290347e-10
developed O 0 4.38513803047158e-09
classical O 0 2.022287617364782e-07
late O 0 0.00017276089056394994
infantile O 1 0.9999181032180786
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 6.439981348194124e-07
MLD B-Disease 1 1.0
) O 0 2.371478657892112e-08
, O 0 1.034932051169335e-08
fatal O 0 4.971328166902822e-07
at O 0 1.0128034233503058e-07
age O 0 4.983746038078607e-08
5 O 0 5.7680406229110304e-08
years O 0 5.698076677163044e-09
, O 0 1.2679738370380278e-09
with O 0 1.5038762457564303e-09
deficient O 0 2.59341192077045e-07
arylsulfatase O 0 1.839100718825648e-06
A O 0 4.779165578838729e-07
( O 0 6.14210833305151e-08
ARSA O 0 8.597602572990581e-06
) O 0 2.5333093400803364e-09
activity O 0 5.88705439952264e-09
and O 0 3.859984776255487e-09
increased O 0 3.641752144289967e-08
galactosylsulfatide O 0 5.483738732436905e-06
( O 0 2.4143812993315805e-07
GS O 1 0.9999220371246338
) O 0 6.59914221046165e-08
excretion O 0 6.235988507796719e-07
. O 0 5.206306354921253e-07

The O 0 3.405381789889361e-07
two O 0 1.9385147709272132e-08
other O 0 3.816754468033423e-09
siblings O 0 3.7977379463427496e-08
, O 0 3.5969549561087888e-09
apparently O 0 2.6152925158839935e-08
healthy O 0 4.922509333482594e-08
at O 0 1.3312617852534459e-07
12 O 0 5.789246415588423e-08
( O 0 2.7294080329198778e-09
1 O 0 4.997815494789393e-08
/ O 0 3.939904047456366e-08
2 O 0 1.5150940058106244e-08
) O 0 3.3343433569754666e-10
and O 0 3.0997679423272473e-10
15 O 0 2.3505464241679874e-09
years O 0 7.409072244612958e-10
, O 0 4.342719239769366e-10
respectively O 0 2.529871201417677e-09
, O 0 3.125283920546451e-10
and O 0 1.4123049951741962e-10
their O 0 4.298343347919342e-10
father O 0 4.9487622888477745e-09
, O 0 2.6792827956256815e-09
apparently O 0 3.429367367857594e-08
healthy O 0 1.1695195922811763e-08
as O 0 2.710270674555204e-09
well O 0 5.9739257984858796e-09
, O 0 1.3475782267846625e-08
presented O 0 4.488069293984154e-07
ARSA O 0 0.00011688856466207653
and O 0 2.7378075628803344e-07
GS O 1 0.999901533126831
values O 0 4.77717883029527e-08
within O 0 1.3087160688485255e-08
the O 0 7.925691214438757e-09
range O 0 7.169725080302669e-08
of O 0 3.9583440525348124e-07
MLD B-Disease 1 1.0
patients O 0 3.150615611957619e-06
. O 0 2.986996832987643e-06

Mutation O 0 1.6590129234828055e-06
screening O 0 3.7970283983668196e-07
and O 0 2.317988645472724e-08
sequence O 0 2.630736517517107e-08
analysis O 0 2.6300842392856794e-08
disclosed O 0 9.131017719710144e-08
the O 0 6.548483533208582e-09
involvement O 0 5.259057900275366e-08
of O 0 1.5102237682640407e-08
three O 0 8.763808345690904e-09
different O 0 2.419608335912926e-08
ARSA O 0 1.811464608181268e-05
mutations O 0 6.987573186734153e-08
being O 0 8.302157183948111e-09
the O 0 1.8186875339054609e-09
molecular O 0 1.8012926261690154e-08
basis O 0 2.198469317704621e-08
of O 0 1.0327476474003561e-07
intrafamilial O 0 1.538097239972558e-05
phenotypic O 0 7.097444904502481e-05
heterogeneity O 0 9.720092202769592e-05
. O 0 2.4063221644610167e-05

The O 0 2.221523800471914e-06
late O 0 0.00017641547310631722
infantile O 0 0.00895707868039608
patient O 0 5.984077802168031e-07
inherited O 0 7.05299612491217e-07
from O 0 2.6516378426322262e-08
his O 0 3.330469411366721e-08
mother O 0 1.3871286341782252e-08
the O 0 1.1546052114397298e-08
frequent O 0 9.488651642186596e-09
0 O 0 6.951070758987044e-07
- O 0 2.0147301427186903e-07
type O 0 2.881116643038695e-07
mutation O 0 3.291401924343518e-07
459 O 0 2.8464268098105094e-07
+ O 0 2.7226741394770215e-07
1G O 0 1.764499643286399e-06
> O 0 8.41593248424033e-08
A O 0 7.926356460075112e-09
, O 0 3.031215278781474e-10
and O 0 2.1614168788097743e-10
from O 0 1.2276193950278014e-10
his O 0 8.424371755744176e-10
father O 0 3.6310761064584085e-09
a O 0 5.436051053742119e-10
novel O 0 2.194316728321155e-09
, O 0 1.6093053556431869e-09
single O 0 7.319685302320522e-09
basepair O 0 4.427160718023515e-07
microdeletion O 0 5.540106826629199e-07
of O 0 6.98352309314032e-08
guanine O 0 1.4667543268842564e-07
at O 0 1.8346391073009727e-07
nucleotide O 0 2.8003887209138156e-08
7 O 0 8.507798554546753e-08
in O 0 6.454611956030476e-09
exon O 0 1.456127165511134e-07
1 O 0 2.173887168055444e-07
( O 0 2.2215266071157203e-08
7delG O 0 1.622852209948178e-06
) O 0 6.303938704377288e-08
. O 0 1.0393295042376849e-06

The O 0 1.4574819715562626e-06
two O 0 2.981954025926825e-07
clinically O 0 3.113153070444241e-05
unaffected O 0 1.2873400692114956e-06
siblings O 0 1.7499607452009514e-07
carried O 0 2.8343011493348058e-08
the O 0 2.3456747655359322e-08
maternal O 0 2.4465924752803403e-07
mutation O 0 1.736415242703515e-07
459 O 0 4.3912964997616655e-07
+ O 0 1.9299357063573552e-06
1G O 0 1.595830690348521e-05
> O 0 5.895956860513252e-07
A O 0 3.69249626430701e-08
and O 0 3.144418725398168e-09
, O 0 1.1104042130227754e-09
on O 0 1.2604530752469145e-09
their O 0 5.222108856450802e-10
paternal O 0 1.1638983998807362e-08
allele O 0 3.6474730791269394e-08
, O 0 1.184840558998701e-09
a O 0 9.729295147309358e-10
novel O 0 5.435317973478959e-09
cytosine O 0 4.857037794181451e-08
to O 0 5.8793903079390475e-09
thymidine O 0 7.638495844730642e-07
transition O 0 3.437387192661845e-07
at O 0 3.7365748539741617e-07
nucleotide O 0 1.2568580132210627e-07
2435 O 0 5.3049743655719794e-06
in O 0 1.426195961329313e-08
exon O 0 1.4982460072587855e-07
8 O 0 6.818549991294276e-08
, O 0 1.1674641253733853e-09
resulting O 0 4.150672694436253e-09
in O 0 1.1044792858072583e-09
substitution O 0 1.634951374285265e-08
of O 0 5.162013039239355e-08
alanine O 0 6.001211545481056e-07
464 O 0 3.541475450674625e-07
by O 0 4.4555047651329005e-08
valine O 0 9.95198297459865e-06
( O 0 2.1921849224781909e-07
A464V O 0 9.12185714696534e-06
) O 0 3.132920767257019e-07
. O 0 3.391786094653071e-06

The O 0 2.9950920179544482e-06
fathers O 0 4.550854555418482e-06
genotype O 0 1.5980153875716496e-06
thus O 0 3.3441236269027286e-07
was O 0 1.3019846392126055e-06
7delG O 0 1.6290598068735562e-05
/ O 0 2.3131333364290185e-05
A464V O 0 5.5293690820690244e-05
. O 0 1.1544746485014912e-05

Mutation O 0 1.0769192158477381e-05
A464V O 0 4.783452368428698e-06
was O 0 5.005447079042824e-08
not O 0 7.928242506949346e-10
found O 0 9.141151169345108e-10
in O 0 2.5176349893740735e-09
18 O 0 4.226444900723436e-07
unrelated O 0 6.042818313289899e-06
MLD B-Disease 1 1.0
patients O 0 2.866082695618388e-07
and O 0 1.18157501560745e-07
50 O 0 3.2021853257901967e-07
controls O 0 3.7488537145691225e-06
. O 0 4.06085064241779e-06

A464V O 0 3.4380114811938256e-05
, O 0 8.607035084651216e-08
although O 0 9.681431833996612e-08
clearly O 0 2.507144927221816e-07
modifying O 0 2.1246321466605878e-06
ARSA O 0 0.0017564394511282444
and O 0 1.103778572542069e-06
GS O 1 1.0
levels O 0 2.2900991325514042e-07
, O 0 3.05047853643714e-09
apparently O 0 7.799570767019759e-09
bears O 0 1.091422863197522e-08
little O 0 1.8270285284671672e-09
significance O 0 8.931205996987046e-09
for O 0 5.705262373645326e-10
clinical O 0 1.9185122823728307e-08
manifestation O 0 2.119147097801033e-07
of O 0 3.16574812586623e-07
MLD B-Disease 1 1.0
, O 0 1.662058224383145e-07
mimicking O 0 6.436174544433015e-07
the O 0 1.3182867064642778e-07
frequent O 0 7.784264539623109e-07
ARSA O 0 0.0007171489996835589
pseudodeficiency O 0 0.00023447674175258726
allele O 0 8.963804430095479e-05
. O 0 1.782126128091477e-05

Our O 0 6.270798849072889e-07
results O 0 1.4091479272337892e-07
demonstrate O 0 8.557171859990831e-09
that O 0 3.664784586909775e-10
in O 0 3.833225958871367e-10
certain O 0 2.6600452951441866e-09
genetic O 0 6.622013870583032e-08
conditions O 0 2.1036014459241414e-06
MLD B-Disease 1 1.0
- O 0 0.21336251497268677
like O 0 1.7152545694898436e-07
ARSA O 0 0.28389766812324524
and O 0 3.4748126154227066e-07
GS O 1 0.9999997615814209
values O 0 7.722270822796418e-09
need O 0 1.317445930126837e-09
not O 0 1.2922002357029783e-10
be O 0 3.7431727162307027e-10
paralleled O 0 4.050217050632909e-09
by O 0 5.11738373898396e-10
clinical O 0 3.3549379168107407e-06
disease O 0 1.7100358036259422e-06
, O 0 2.3521429248773984e-09
a O 0 1.3766876527654404e-09
finding O 0 1.168596330813898e-08
with O 0 2.2615376238377394e-09
serious O 0 8.226684826695418e-07
diagnostic O 0 7.319734322663862e-06
and O 0 2.638279568145663e-07
prognostic O 0 0.061245739459991455
implications O 0 4.391294714878313e-05
. O 0 6.041636879672296e-06

Moreover O 0 7.260935944941593e-06
, O 0 2.490394876986102e-07
further O 0 9.983522204493056e-07
ARSA O 0 0.00040777772665023804
alleles O 0 1.7382523083142587e-06
functionally O 0 2.2581255620934826e-07
similar O 0 4.670671405193616e-09
to O 0 5.037337658109209e-09
A464V O 0 1.387056443036272e-07
might O 0 3.5399265740920782e-09
exist O 0 3.009205773452095e-09
which O 0 4.356225380419687e-10
, O 0 2.696101120136518e-10
together O 0 9.982912413386558e-11
with O 0 9.29823093520632e-11
0 O 0 2.990616820852665e-08
- O 0 4.673843978508785e-09
type O 0 5.90138871103818e-09
mutations O 0 7.059588913449488e-09
, O 0 6.152444109730482e-10
may O 0 1.3523880681987066e-08
cause O 0 1.5460841495951172e-06
pathological O 0 0.23779071867465973
ARSA O 1 0.9549771547317505
and O 0 9.96149651655287e-07
GS O 1 1.0
levels O 0 7.114770994576247e-08
, O 0 3.7176009493045115e-10
but O 0 5.2510815140571765e-11
not O 0 6.122612833392438e-11
clinical O 0 8.381999094808634e-09
outbreak O 0 3.481377630620841e-09
of O 0 6.938934316025325e-09
the O 0 2.6116337537018808e-08
disease O 0 2.2175223080012074e-07
. O 0 5.044291739864093e-08
. O 0 9.279637538384122e-07

Human O 1 0.9976915121078491
MLH1 O 1 1.0
deficiency O 1 0.9999996423721313
predisposes O 0 6.970791582716629e-05
to O 0 6.287673954830098e-07
hematological B-Disease 1 0.999991774559021
malignancy I-Disease 1 0.99998939037323
and O 0 7.71171380620217e-06
neurofibromatosis B-Disease 1 0.9989639520645142
type I-Disease 0 0.020102376118302345
1 I-Disease 0 0.014470766298472881
. O 0 3.886548711307114e-06

Heterozygous O 0 1.593570959812496e-05
germ O 0 0.0001732103555696085
- O 0 7.388203812297434e-06
line O 0 1.9358590463980363e-07
mutations O 0 4.117478269449748e-08
in O 0 3.2847424780158008e-09
the O 0 1.1145189660055621e-08
DNA O 0 2.711157094381633e-07
mismatch O 0 6.372791176545434e-06
repair O 0 8.286922934530594e-07
genes O 0 3.963457828604078e-08
lead O 0 2.1713634623665712e-07
to O 0 3.3548886335665884e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9990329742431641

The O 0 3.157434321110486e-06
disease O 0 5.2749819587916136e-05
susceptibility O 0 9.646131502449862e-07
of O 0 5.185039526622859e-07
individuals O 0 1.8040225313598057e-08
who O 0 5.6035901252471376e-08
constitutionally O 0 4.3106220459776523e-07
lack O 0 9.148133699454775e-07
both O 0 2.3837235119117395e-07
wild O 0 3.6722900631502853e-07
- O 0 1.5581819923227158e-07
type O 0 6.625147364047734e-08
alleles O 0 1.0333939570728035e-07
is O 0 7.788926836838073e-09
unknown O 0 6.140269306342816e-07
. O 0 1.561642307024158e-06

We O 0 4.3469796651152137e-07
have O 0 1.3937083487292057e-08
identified O 0 3.9030076948165515e-08
three O 0 1.9842232301670037e-09
offspring O 0 8.087532421541255e-09
in O 0 2.5581112783612525e-09
a O 0 4.74470596145693e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 7.397919489449123e-06
who O 0 1.1221344209388917e-07
developed O 0 1.771187635313254e-05
hematological B-Disease 1 0.9999998807907104
malignancy I-Disease 1 0.9999994039535522
at O 0 5.791432340629399e-05
a O 0 5.6603806086741315e-09
very O 0 1.3209309202011355e-09
early O 0 1.2521795156317239e-08
age O 0 1.5459434621334367e-08
, O 0 8.820686958621593e-10
and O 0 9.42556810379358e-10
at O 0 1.0023733842956517e-08
least O 0 8.010246355105721e-10
two O 0 1.9446085020025095e-10
of O 0 3.446031515697001e-10
them O 0 2.5742227793834616e-10
displayed O 0 7.285199110640406e-09
signs O 0 4.724621760487935e-08
of O 0 5.8796178592501747e-08
neurofibromatosis B-Disease 0 1.3548865354096051e-05
type I-Disease 0 1.7518220829515485e-06
1 I-Disease 0 5.635666639136616e-06
( O 0 4.101597994576878e-08
NF1 B-Disease 0 1.7091511836042628e-05
) O 0 8.784430605146554e-08
. O 0 9.448667128708621e-07

DNA O 0 1.2776021094396128e-06
sequence O 0 5.509227563038621e-08
analysis O 0 3.1869582528543106e-08
and O 0 1.37840672209677e-08
allele O 0 3.4853729857786675e-07
- O 0 4.340637005384451e-08
specific O 0 2.050096981065508e-09
amplification O 0 2.127032949772456e-08
in O 0 1.924209902526286e-09
two O 0 7.013595482163737e-09
siblings O 0 9.435397174684113e-08
revealed O 0 1.3684031330285507e-07
a O 0 6.677235830920836e-08
homozygous O 0 2.4283294806082267e-06
MLH1 O 0 0.0003433006349951029
mutation O 0 2.1667992768925615e-06
( O 0 3.326863691199833e-07
C676T O 0 9.498914550931659e-06
- O 0 1.1016774806194007e-05
- O 0 2.2065282792027574e-06
> O 0 1.4280026334745344e-06
Arg226Stop O 0 1.3840261999575887e-05
) O 0 8.11612324014277e-08
. O 0 7.801499464221706e-07

Thus O 0 2.080545982607873e-06
, O 0 8.63633999870217e-08
a O 0 4.7723702323310135e-08
homozygous O 0 8.69107509515743e-07
germ O 0 0.00021367595763877034
- O 0 5.8952362451236695e-05
line O 0 6.4958676375681534e-06
MLH1 O 1 0.84555983543396
mutation O 0 2.959910489153117e-06
and O 0 2.59523517343041e-07
consequent O 0 0.1398969143629074
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 0.003915439359843731
in O 0 2.1659552373876068e-07
a O 0 2.1026839647220186e-07
mutator O 0 0.0005882008117623627
phenotype O 0 9.672920668890583e-07
characterized O 0 1.4987627139362303e-08
by O 0 3.1320761539888053e-09
leukemia B-Disease 1 0.9996147155761719
and O 0 0.018938269466161728
/ O 1 1.0
or O 1 0.9999829530715942
lymphoma B-Disease 1 1.0
associated O 0 0.007650799583643675
with O 0 8.935197826076546e-08
neurofibromatosis B-Disease 0 0.07002070546150208
type I-Disease 0 2.1660534912371077e-05
1 I-Disease 0 2.155237780243624e-05
. O 0 7.804038659742218e-08
. O 0 4.4222068140697957e-07

Missense O 0 0.0001604397693881765
mutations O 0 1.1175789040862583e-06
in O 0 1.926836823429312e-08
the O 0 9.860372074399493e-09
most O 0 1.1036137559372605e-09
ancient O 0 7.357435549693037e-09
residues O 0 2.1969478680716747e-08
of O 0 1.355034662253729e-08
the O 0 4.2123087240497625e-08
PAX6 O 0 7.49434984754771e-05
paired O 0 3.2205579714172927e-07
domain O 0 1.7911931138314685e-07
underlie O 0 7.79320771471248e-07
a O 0 1.5198349245792997e-08
spectrum O 0 2.505871179891983e-06
of O 0 1.5079152035468724e-05
human O 1 0.9999990463256836
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.21657730638980865

Mutations O 0 1.4278706430559396e-06
of O 0 1.630242252304015e-07
the O 0 7.131237111934752e-08
human O 0 2.94095258368543e-07
PAX6 O 0 0.0002639339363668114
gene O 0 4.292639005143428e-06
underlie O 1 0.9990074038505554
aniridia B-Disease 1 1.0
( O 1 0.9570327997207642
congenital B-Disease 1 1.0
absence I-Disease 0 5.5949763918761164e-05
of I-Disease 0 7.193740020738915e-05
the I-Disease 0 2.702240635699127e-06
iris I-Disease 0 0.0038060774095356464
) O 0 2.8378391192518393e-08
, O 0 4.955496457625941e-09
a O 0 1.4220508326445724e-08
rare O 0 1.4913578070263611e-06
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.9808593392372131
the I-Disease 0 0.03852519765496254
eye I-Disease 1 0.9966482520103455
. O 0 1.7870597730507143e-05

The O 0 1.4194608866091585e-06
spectrum O 0 2.819393330355524e-06
of O 0 5.83162545808591e-07
PAX6 O 0 0.0008668007212691009
mutations O 0 2.9539094157371437e-06
in O 0 2.710042679154867e-07
aniridia B-Disease 1 1.0
patients O 0 1.2038078978093836e-07
is O 0 2.112517050179008e-09
highly O 0 7.394591161613562e-09
biased O 0 2.2329794902020694e-08
, O 0 6.738822277974066e-10
with O 0 2.0959523006069958e-10
92 O 0 1.505019042724598e-08
% O 0 6.362422255712374e-10
of O 0 3.825719296912666e-09
all O 0 3.000562909249993e-09
reported O 0 8.991577260530903e-09
mutations O 0 1.9451890764798918e-08
leading O 0 1.729842935560555e-08
to O 0 2.2740338501137103e-09
premature O 0 5.519745727156078e-08
truncation O 0 3.011630838045676e-07
of O 0 6.731480794996969e-08
the O 0 1.0425837082550515e-08
protein O 0 1.3162862799731556e-08
( O 0 1.3510904617319852e-09
nonsense O 0 1.85551058962119e-08
, O 0 7.88082599179063e-10
splicing O 0 8.958163100203365e-09
, O 0 1.1174878800090937e-09
insertions O 0 9.258616096019523e-09
and O 0 2.792535536144669e-09
deletions O 0 3.805707038395667e-08
) O 0 2.861852088642536e-09
and O 0 3.084782873585823e-09
just O 0 5.576728412393095e-09
2 O 0 4.744561010738835e-08
% O 0 1.0031111496999756e-09
leading O 0 1.6625640864020852e-09
to O 0 4.4107201224719006e-10
substitution O 0 1.064920684967774e-08
of O 0 1.3417306377050409e-08
one O 0 7.494339371305614e-09
amino O 0 6.642377758936391e-09
acid O 0 7.927319911615882e-10
by O 0 2.797812259647259e-10
another O 0 5.751394027697643e-09
( O 0 1.4980683360477087e-08
missense O 0 2.1020393887738464e-06
) O 0 2.259232871892891e-07
. O 0 2.3937841433507856e-06

The O 0 1.0827340020114207e-06
extraordinary O 0 2.866957231617562e-07
conservation O 0 2.3073800647921416e-08
of O 0 2.0246297083303944e-08
the O 0 5.4913929403710426e-08
PAX6 O 0 1.9969940694863908e-05
protein O 0 2.793166231640498e-07
at O 0 4.846276056014176e-07
the O 0 8.800463291436245e-08
amino O 0 3.2676354067007196e-07
acid O 0 1.6993874396575848e-07
level O 0 4.420428922458086e-06
amongst O 0 6.270709036471089e-07
vertebrates O 0 6.393399871740257e-07
predicts O 0 2.044685487589959e-08
that O 0 5.688636783851564e-10
pathological O 0 3.870386535709258e-07
missense O 0 6.983562457207881e-07
mutations O 0 4.589911029029281e-08
should O 0 4.660615449125771e-09
in O 0 5.872617947488834e-10
fact O 0 1.2226216705713e-09
be O 0 9.55243883993262e-10
common O 0 7.15238590576206e-10
even O 0 2.764953266343184e-10
though O 0 2.280539368459955e-10
they O 0 8.031970644140074e-10
are O 0 7.980326399703586e-10
hardly O 0 2.5685363169714037e-08
ever O 0 5.554576532063038e-08
seen O 0 1.3251020902771415e-07
in O 0 8.228994374803733e-08
aniridia B-Disease 1 0.9999929666519165
patients O 0 9.91949036688311e-07
. O 0 3.376977701918804e-06

This O 0 2.4618261207365322e-08
indicates O 0 2.317188574352258e-08
that O 0 5.843455719301005e-10
there O 0 1.921657055703463e-09
is O 0 4.849378121285497e-10
a O 0 1.0502713143623055e-09
heavy O 0 1.7089045911689027e-07
ascertainment O 0 0.0002487254678271711
bias O 0 4.2201335759273206e-07
in O 0 3.747489429883899e-09
the O 0 2.231624440796054e-09
selection O 0 9.73832214867798e-09
of O 0 4.9708512861457166e-09
patients O 0 1.911903080298316e-09
for O 0 3.320180352872626e-09
PAX6 O 0 3.2773214115877636e-06
mutation O 0 1.0411866036008632e-08
analysis O 0 3.6525464874870295e-09
and O 0 1.098850010983199e-09
that O 0 7.190535389334229e-10
the O 0 1.0610299305824356e-08
missing O 0 1.1163421049786848e-06
PAX6 O 0 0.000649155059363693
missense O 0 3.8591224438278005e-05
mutations O 0 2.1546682091866387e-06
frequently O 0 1.225738799348619e-07
may O 0 5.175312480787397e-07
underlie O 0 1.75169207068393e-05
phenotypes O 0 1.100433109968435e-05
distinct O 0 2.830749963322887e-07
from O 0 1.790281203284394e-07
textbook O 0 2.43448703258764e-05
aniridia B-Disease 1 0.9999953508377075
. O 0 2.320046041859314e-05

Here O 0 1.0395267509011319e-06
we O 0 5.0090765313370866e-08
present O 0 9.053806593328773e-09
four O 0 5.204749520260066e-09
novel O 0 5.145204085010846e-08
PAX6 O 0 2.9685112167499028e-05
missense O 0 3.4138008686568355e-06
mutations O 0 4.569227201045578e-07
, O 0 1.4950396476365313e-08
two O 0 7.1618631025671675e-09
in O 0 7.281240055334592e-09
association O 0 2.275657706718448e-08
with O 0 4.844951551064014e-09
atypical O 0 1.670967662903422e-06
phenotypes O 0 1.817077281884849e-05
ectopia B-Disease 0 6.702107202727348e-05
pupillae I-Disease 0 2.4823360945447348e-05
( O 0 1.4750425769705089e-08
displaced B-Disease 0 1.7809588470640847e-08
pupils I-Disease 0 1.0356216506579585e-07
) O 0 1.93415310434375e-08
and O 0 1.8187356545240618e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999995231628418
( O 0 6.922696229594294e-07
searching B-Disease 0 6.595328727598826e-07
gaze I-Disease 0 4.671841907111229e-06
) O 0 7.702677606857833e-09
, O 0 4.467458403212277e-09
and O 0 8.352267322209173e-09
two O 0 9.064865302832459e-09
in O 0 9.922308308318861e-09
association O 0 1.5243871942516307e-08
with O 0 5.804114522334203e-09
more O 0 1.529297044555733e-08
recognizable O 0 2.2863638150738552e-05
aniridia B-Disease 1 0.9999973773956299
phenotypes O 0 8.564081508666277e-05
. O 0 8.699228601471987e-06

Strikingly O 0 1.307815000473056e-05
, O 0 5.799292424057967e-08
all O 0 7.237651811209389e-09
four O 0 3.8232754739908614e-09
mutations O 0 6.4982916825329085e-09
are O 0 8.326320743989868e-10
located O 0 8.785197458394123e-09
within O 0 1.1762487872601923e-08
the O 0 3.851243235430957e-08
PAX6 O 0 4.633459684555419e-05
paired O 0 3.2909659353208554e-07
domain O 0 1.7544658703627647e-07
and O 0 4.5569205298079396e-08
affect O 0 1.5519739804403798e-07
amino O 0 6.709586841679993e-08
acids O 0 7.058956530414662e-09
which O 0 6.028395005408527e-10
are O 0 2.0601384487228813e-10
highly O 0 1.4031309447659623e-09
conserved O 0 3.2954734496826177e-09
in O 0 5.746401687822811e-10
all O 0 1.7038160882165698e-09
known O 0 3.8665652901670455e-09
paired O 0 3.710874452167445e-08
domain O 0 6.910909888802053e-08
proteins O 0 2.4360332417927566e-08
. O 0 4.1268000927630055e-07

Our O 0 1.3367746305448236e-06
results O 0 1.1456871362724996e-07
support O 0 1.1213359130124445e-08
the O 0 4.759768135187414e-09
hypothesis O 0 5.896168442376393e-09
that O 0 3.434611969832524e-11
the O 0 2.2538801380811435e-10
under O 0 1.9040968801675717e-09
- O 0 4.970017286609618e-09
representation O 0 3.4065485987611055e-09
of O 0 1.0512559711628455e-08
missense O 0 1.2575620758070727e-06
mutations O 0 2.762560882274556e-07
is O 0 4.478472703794978e-09
caused O 0 8.548008167963417e-08
by O 0 1.83440409529112e-08
ascertainment O 0 0.002114069415256381
bias O 0 2.566793455116567e-06
and O 0 2.1631224811358152e-08
suggest O 0 9.841976122970664e-09
that O 0 6.477078318134488e-10
a O 0 1.3642010854297837e-09
substantial O 0 2.8931426143685712e-08
burden O 0 4.363581069810607e-07
of O 0 2.9703433028771542e-05
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
related I-Disease 0 0.0007436978630721569
disease I-Disease 0 0.00011000613449141383
remains O 0 3.067236065135148e-08
to O 0 1.4316079433029927e-09
be O 0 4.299755662628968e-09
uncovered O 0 3.0032100539756357e-07
. O 0 3.588507624385784e-08
. O 0 6.751964178874914e-07

The O 0 4.2159098256888683e-07
chromosomal O 0 5.424083155958215e-07
order O 0 8.501634596314034e-08
of O 0 7.153087722144846e-08
genes O 0 4.631224825857316e-08
controlling O 0 3.746701793261309e-07
the O 0 1.2924300563099678e-07
major O 0 8.418522838837816e-07
histocompatibility O 0 0.007903520949184895
complex O 0 1.714925474516349e-06
, O 0 4.900594596790597e-09
properdin O 0 1.810705754223818e-07
factor O 0 1.6660820278957544e-08
B O 0 2.529038738430245e-07
, O 0 4.143103193854358e-09
and O 0 1.0890106594274584e-08
deficiency B-Disease 0 8.350851317118213e-07
of I-Disease 0 7.070669028053089e-08
the I-Disease 0 1.9892414826472304e-08
second I-Disease 0 2.701956880457601e-08
component I-Disease 0 3.557146754928908e-08
of I-Disease 0 3.6701816696904643e-08
complement I-Disease 0 4.881715653937135e-07
. O 0 2.427838580842945e-06

The O 0 2.333114821340132e-07
relationship O 0 1.575851271695683e-08
of O 0 2.2127643717340106e-08
the O 0 7.2169470399785496e-09
genes O 0 6.914242511868451e-09
coding O 0 3.7509593653339834e-08
for O 0 2.025578815789686e-09
HLA O 0 2.209458038748835e-08
to O 0 4.982885770665746e-10
those O 0 4.883693449642124e-10
coding O 0 1.0713279152696487e-08
for O 0 4.4099549012521777e-10
properdin O 0 4.4855703151824855e-08
Factor O 0 5.9789524442521724e-09
B O 0 1.0257784310852003e-07
allotypes O 0 1.877490802826287e-07
and O 0 2.2500754592869043e-09
for O 0 3.486454458467847e-09
deficiency B-Disease 0 5.979000405886836e-08
of I-Disease 0 7.895740949948049e-09
the I-Disease 0 1.4086843913574398e-09
second I-Disease 0 1.4813319459960894e-09
component I-Disease 0 1.0052236820712324e-09
of I-Disease 0 2.8404802954185016e-09
complement I-Disease 0 1.6178928419208205e-08
( O 0 7.104326904538993e-09
C2 O 0 1.6213516573770903e-06
) O 0 1.0968691510626627e-09
was O 0 3.31507377104856e-09
studied O 0 9.184322635746867e-09
in O 0 4.354115124005631e-10
families O 0 2.435185664229067e-10
of O 0 4.663861297160565e-09
patients O 0 3.327332720459708e-08
with O 0 4.6828142785670934e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.7993307113647461

Patients O 0 4.874039518654172e-07
were O 0 2.1519703352623765e-08
selected O 0 5.811070735717294e-09
because O 0 2.88639334655727e-10
they O 0 7.116556233199844e-10
were O 0 4.0515848453992476e-09
heterozygous O 0 2.4160206280043894e-08
or O 0 2.734380366575806e-08
homozygous O 0 3.428535137572908e-06
for O 0 6.009234311932232e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00011959527182625607

12 O 0 4.542620445135981e-06
families O 0 2.0266348599307094e-08
with O 0 1.388618997566482e-08
15 O 0 5.696090283890953e-07
matings O 0 1.7023821783368476e-05
informative O 0 9.260469596483745e-06
for O 0 5.57495604880387e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.243703420390375e-06
found O 0 2.8395888307386485e-07
. O 0 1.5894689795459271e-06

Of O 0 7.451149940607138e-06
57 O 0 5.569360837398563e-06
informative O 0 1.3112542092130752e-06
meioses O 0 1.8136640846933005e-06
, O 0 3.1881786100029785e-09
two O 0 1.0994914978468273e-09
crossovers O 0 1.2300488627658979e-08
were O 0 5.568214778151059e-09
noted O 0 8.533798556698002e-09
between O 0 4.1771372139010055e-08
the O 0 1.1125862329208758e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
gene O 0 1.4588035668339216e-08
and O 0 3.863697362049834e-09
the O 0 9.453642313417276e-09
HLA O 0 2.241967820282298e-07
- O 0 2.707590596173759e-08
B O 0 3.4204962418016294e-08
gene O 0 1.1730822979671984e-09
, O 0 1.2093616386099626e-10
with O 0 1.0135808165001592e-10
a O 0 4.711954715297395e-10
recombinant O 0 2.776565199980041e-09
fraction O 0 2.9634226184072077e-09
of O 0 2.214051875171208e-08
0 O 0 8.336559744748229e-07
. O 0 6.353272397063847e-07

035 O 0 0.045609187334775925
. O 0 0.0005072657950222492

A O 0 2.6935908863379154e-06
lod O 0 1.2167017302999739e-05
score O 0 1.7918661399107805e-07
of O 0 2.6293470511973283e-08
13 O 0 9.965461345018412e-08
was O 0 1.1752441686496695e-08
calculated O 0 6.470167512873104e-09
for O 0 2.6457811497238026e-09
linkage O 0 1.039194671648147e-06
between O 0 4.740155418403447e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 4.3617754386104934e-07
HLA O 0 2.774460426735459e-06
- O 0 1.0763853452999683e-07
B O 0 4.979365542112646e-08
at O 0 4.952057430784862e-09
a O 0 8.33147925649591e-11
maximum O 0 9.250862853527053e-10
likelihood O 0 1.213771416708198e-09
value O 0 6.909967598112132e-10
of O 0 9.80979297793283e-10
the O 0 7.806859603221028e-10
recombinant O 0 1.4673476878002134e-09
fraction O 0 1.71129388437663e-09
of O 0 8.48449133172835e-09
0 O 0 3.124792726794112e-07
. O 0 5.418695536718587e-07

04 O 0 0.008328709751367569
. O 0 0.0002062920102616772

18 O 0 4.8309007070201915e-06
families O 0 4.936725872539682e-08
with O 0 1.6558304949398917e-08
21 O 0 3.5692855249180866e-07
informative O 0 2.4587720304225513e-07
matings O 0 2.242615693148764e-07
for O 0 5.424205529180881e-09
both O 0 1.0306927755721063e-08
properdin O 0 8.199012881959789e-07
Factor O 0 1.0684631490676111e-07
B O 0 5.861858198841219e-07
allotype O 0 5.558444513553695e-07
and O 0 1.9081516811070287e-08
HLA O 0 6.23662515408796e-07
- O 0 4.239520023929799e-08
B O 0 1.0151841678407436e-07
were O 0 1.2252860948080979e-08
found O 0 2.9746653140705348e-08
. O 0 2.5632832034716557e-07

Of O 0 9.306844731327146e-06
72 O 0 7.830944014131092e-06
informative O 0 1.5413686469401e-06
meioses O 0 3.7210070331639145e-06
, O 0 1.2092083778725282e-08
three O 0 1.0253749849198357e-08
recombinants O 0 3.958736556342046e-07
were O 0 8.48221048954656e-09
found O 0 3.5097802442152215e-09
, O 0 7.580824856745494e-10
giving O 0 1.8841259663560095e-09
a O 0 1.5647714235456078e-09
recombinant O 0 4.436117695405528e-09
fraction O 0 6.595163082323552e-09
of O 0 5.1794003752547724e-08
0 O 0 1.5262729675669107e-06
. O 0 1.9793008050328353e-06

042 O 0 0.0051585654728114605
. O 0 0.0002139462885679677

A O 0 4.4372136471793056e-06
lod O 0 1.6615224012639374e-05
score O 0 3.959144123655278e-07
of O 0 1.0483130097327376e-07
16 O 0 3.667243504423823e-07
between O 0 8.216353108991825e-08
HLA O 0 6.777938210689172e-07
- O 0 2.923686004407955e-08
B O 0 2.461112735829829e-08
and O 0 4.3582612518910935e-10
Factor O 0 1.1714261560769046e-08
B O 0 8.145745056253872e-08
allotypes O 0 1.197244188233526e-07
was O 0 7.026060622195018e-09
calculated O 0 5.222629440027049e-09
at O 0 5.07293540508158e-09
a O 0 4.866139158288263e-10
maximum O 0 5.278601555858131e-09
likelihood O 0 2.5634254718909233e-09
value O 0 1.3681723531888679e-09
of O 0 1.702925800373123e-09
the O 0 9.264440881118219e-10
recombinant O 0 3.0557192332025807e-09
fraction O 0 1.2976369978545677e-09
of O 0 6.126204876721886e-09
0 O 0 3.4154544437114964e-07
. O 0 5.51666119008587e-07

04 O 0 0.008237904869019985
. O 0 0.00014644105976913124

A O 0 5.81570247959462e-07
crossover O 0 2.2527804333094537e-07
was O 0 3.5249236418621877e-08
shown O 0 1.2098330115506428e-09
to O 0 4.704079348272217e-10
have O 0 4.093458072507161e-10
occurred O 0 9.506567089090368e-09
between O 0 7.091678355664044e-10
genes O 0 1.6541369662892436e-10
for O 0 7.977780241974486e-11
Factor O 0 4.015013210789675e-09
B O 0 2.8979584953958692e-08
and O 0 5.808101111171027e-09
HLA O 0 2.0520018040315335e-07
- O 0 2.331245774200852e-08
D O 0 3.187596320231023e-08
, O 0 5.389716450920901e-10
in O 0 5.17630383001233e-10
which O 0 1.8183025085605209e-09
HLA O 0 2.648550321282528e-07
- O 0 7.362197607108101e-08
D O 0 1.934581774776234e-07
segregared O 0 4.058753688696015e-07
with O 0 6.6825975864048814e-09
HLA O 0 2.0856396076851524e-06
- O 0 1.4215035548659216e-07
A O 0 4.2712965608870945e-08
and O 0 8.314092525552041e-08
B O 0 1.22916544569307e-05
. O 0 2.183450078518945e-06

These O 0 1.0782819259702592e-07
studies O 0 2.7353715736921913e-08
suggest O 0 6.055202117494218e-09
that O 0 1.1094720975268757e-10
the O 0 4.425315114353623e-10
genes O 0 2.2589843884368577e-10
for O 0 1.3894892181287588e-10
Factor O 0 1.3883647120849218e-08
B O 0 7.1108479460235685e-06
and O 0 2.600393600005191e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.4389747171605904e-09
located O 0 1.2399178350719353e-09
outside O 0 1.2848867525505625e-09
those O 0 1.5315665402582113e-10
for O 0 6.305905242420806e-10
HLA O 0 3.6759896460125674e-08
, O 0 2.1409796158167183e-10
that O 0 3.533015893730784e-11
the O 0 1.643761099456853e-10
order O 0 1.6108254730085036e-09
of O 0 6.863419166336371e-09
genese O 0 5.100939688418293e-07
is O 0 5.60046720110563e-09
HLA O 0 2.6104839889740106e-07
- O 0 2.740970117542929e-08
A O 0 1.627686074812118e-08
, O 0 4.853627721956855e-09
- O 0 1.436855434633344e-08
B O 0 7.252081957176415e-08
, O 0 3.7754981363491424e-09
- O 0 6.356239534710539e-09
D O 0 1.497042845244323e-08
, O 0 7.942908553104644e-10
Factor O 0 3.436773354792422e-08
B O 0 7.249881832649407e-07
allotype O 0 8.896355211618356e-06
, O 0 8.582115924582467e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999978542327881
, O 0 3.401328552143923e-09
that O 0 3.1364869035321874e-10
the O 0 3.900683775981406e-09
genes O 0 2.5964798311406412e-08
coding O 0 7.93960452938336e-07
for O 0 3.5573339118855074e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
and O 0 1.004973082530114e-08
Factor O 0 2.3956099326483127e-08
B O 0 8.749499613713851e-08
allotypes O 0 5.255858681607606e-08
are O 0 2.051304542893817e-10
approximately O 0 8.190481071146394e-10
3 O 0 6.932690421734833e-09
- O 0 3.719588637096649e-09
- O 0 1.9459303057800525e-09
5 O 0 3.070512510916501e-09
centimorgans O 0 2.3235660506770728e-08
from O 0 7.705553417558519e-10
the O 0 3.7134146868567086e-09
HLA O 0 1.4005172488396056e-07
- O 0 5.298897320926699e-09
A O 0 5.356371346465494e-09
and O 0 7.95343435555651e-09
HLA O 0 6.692957867926452e-07
- O 0 5.4245596459168155e-08
B O 0 4.764775596299842e-08
loci O 0 8.738937573582461e-09
, O 0 2.880069238653249e-10
and O 0 1.285886397361935e-10
that O 0 4.332309511134724e-11
the O 0 4.19671464246818e-10
apparent O 0 6.939847807529986e-09
lack O 0 4.1231054126456e-08
of O 0 7.223890463592397e-08
recombinants O 0 5.75210947317828e-07
between O 0 6.2906284625796616e-09
the O 0 2.8054767398089098e-09
Factor O 0 2.685536415469869e-08
B O 0 1.5189327768894145e-06
gene O 0 7.643181447747338e-07
and O 0 3.3585067285457626e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.1439198860662145e-08
suggests O 0 1.70568892343681e-09
that O 0 7.655361761171875e-11
these O 0 9.388028548995564e-11
two O 0 2.5462323915981244e-10
genes O 0 6.017665254987037e-10
lie O 0 1.1992559834084204e-08
in O 0 8.263100204075613e-10
close O 0 1.4846137652568814e-08
proximity O 0 1.90083220275028e-08
to O 0 7.9209456771423e-09
one O 0 1.7954716824419847e-08
another O 0 1.607843387319008e-07
. O 0 2.4542462142562727e-06

Distribution O 0 4.866775498157949e-07
of O 0 4.7395772639902134e-07
emerin O 0 1.1113953405583743e-05
and O 0 4.516975948831714e-08
lamins O 0 7.348326107603498e-06
in O 0 1.611268807266697e-08
the O 0 3.601906328754012e-08
heart O 0 4.143935541378596e-07
and O 0 3.1877728901008595e-08
implications O 0 8.796064321359154e-07
for O 0 1.4814746407409984e-07
Emery B-Disease 1 0.999796450138092
- I-Disease 1 0.9999998807907104
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.028920471668243408

Emerin O 0 0.0012647235998883843
is O 0 1.825044648740004e-07
a O 0 5.2368065439623024e-08
nuclear O 0 5.421130708782584e-07
membrane O 0 1.3848635660451691e-07
protein O 0 2.835739643103352e-08
which O 0 1.254464199185179e-09
is O 0 8.171974208437405e-10
missing O 0 1.5773848005551372e-08
or O 0 4.6223447291993125e-09
defective O 0 2.740082436503144e-07
in O 0 3.1291520485865476e-08
Emery B-Disease 1 0.9999672174453735
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5311052203178406
EDMD B-Disease 1 1.0
) O 0 1.5864688975852914e-06
. O 0 2.906134341174038e-06

It O 0 5.07337318822465e-08
is O 0 2.7013165038169973e-09
one O 0 2.0603754258274876e-09
member O 0 6.133173524602853e-09
of O 0 7.5434858359813e-09
a O 0 6.1552758445770905e-09
family O 0 3.4928508974019223e-09
of O 0 5.7462436586774857e-08
lamina O 0 0.005892157554626465
- O 0 3.8246613257797435e-05
associated O 0 8.447872090755482e-08
proteins O 0 3.5252583074907307e-09
which O 0 3.2122646764776164e-09
includes O 0 5.973594952024541e-09
LAP1 O 0 4.334549885243177e-06
, O 0 3.653593694252777e-08
LAP2 O 0 6.954426226002397e-06
and O 0 6.80890650528454e-08
lamin O 0 5.847268766956404e-06
B O 0 1.6932156086113537e-06
receptor O 0 2.9800042966598994e-07
( O 0 4.714000212402425e-08
LBR O 0 3.4866870919358917e-06
) O 0 9.54769276972911e-08
. O 0 1.7437298538425239e-06

A O 0 6.260924692469416e-06
panel O 0 1.088465523935156e-06
of O 0 5.289347626558083e-08
16 O 0 8.614918556304474e-08
monoclonal O 0 1.1677274258659054e-08
antibodies O 0 8.487372582521857e-09
( O 0 1.59775428443254e-08
mAbs O 0 7.677341500311741e-07
) O 0 6.379401007450269e-09
has O 0 7.912470678661521e-10
been O 0 2.3865649456666915e-09
mapped O 0 5.066408625964414e-09
to O 0 8.826612218904017e-10
six O 0 2.3228203804848135e-09
specific O 0 7.927546952224418e-10
sites O 0 3.0353419777640056e-09
throughout O 0 2.5330870734308064e-09
the O 0 9.866447214790242e-09
emerin O 0 2.199869015839795e-07
molecule O 0 3.1933820032747917e-09
using O 0 5.383534062985973e-09
phage O 0 1.2486407285905443e-07
- O 0 2.1240287750856623e-08
displayed O 0 5.13504483379279e-09
peptide O 0 4.23672119609364e-09
libraries O 0 1.9988133370674177e-09
and O 0 6.96910584796484e-10
has O 0 1.1938663946331474e-10
been O 0 1.8106911803261738e-10
used O 0 4.541713671812886e-10
to O 0 3.51381257424066e-09
localize O 0 1.1851902854687069e-06
emerin O 0 5.450068329082569e-06
in O 0 2.5326150066007358e-08
human O 0 2.0671396327998082e-07
and O 0 2.492637918294349e-07
rabbit O 0 1.1495706075947965e-06
heart O 0 6.760521955584409e-06
. O 0 1.0536292393226177e-05

Several O 0 2.15259387914557e-06
mAbs O 0 1.5725770936114714e-05
against O 0 8.159107096616935e-07
different O 0 1.4474571230493893e-07
emerin O 0 6.301231678662589e-06
epitopes O 0 6.496255195997946e-07
did O 0 1.755074308107396e-08
not O 0 4.5552059901865505e-09
recognize O 0 2.177997515673269e-08
intercalated O 0 7.427423156514124e-07
discs O 0 3.2310359188159055e-07
in O 0 3.312861540649692e-09
the O 0 8.202710510829547e-09
heart O 0 2.958386602358587e-08
, O 0 9.302085213214184e-10
though O 0 3.265033798882655e-10
they O 0 5.857571649947602e-10
recognized O 0 7.836163717911404e-09
cardiomyocyte O 0 2.616934580146335e-07
nuclei O 0 1.4007898130330432e-07
strongly O 0 3.635790335465572e-08
, O 0 6.939874452882577e-09
both O 0 8.108445470611514e-09
at O 0 4.666270854158938e-07
the O 0 1.7683538189317005e-08
rim O 0 1.4179670415614964e-07
and O 0 3.353255229043839e-09
in O 0 6.277108610674986e-09
intranuclear O 0 7.743217338429531e-07
spots O 0 1.1686837808611017e-07
or O 0 5.341458120255993e-08
channels O 0 4.240762052631908e-07
. O 0 8.468593364341359e-07

A O 0 1.5707184502389282e-05
polyclonal O 0 9.870246867649257e-05
rabbit O 0 3.359554966664291e-06
antiserum O 0 5.5416785471607e-06
against O 0 8.825851978144783e-07
emerin O 0 7.936281690490432e-06
did O 0 3.9709640020646475e-08
recognize O 0 3.646478319296875e-08
both O 0 1.0576293618669297e-08
nuclear O 0 3.174933453919948e-07
membrane O 0 1.8611451935157675e-07
and O 0 4.709540313285743e-09
intercalated O 0 1.4245951263092138e-07
discs O 0 2.7120044876483007e-08
but O 0 7.973069426903123e-10
, O 0 3.6898242794514147e-10
after O 0 2.0545674050964635e-09
affinity O 0 2.381317809607708e-09
purification O 0 1.1428635815491361e-08
against O 0 1.3987815350446908e-08
a O 0 8.737504053613065e-09
pure O 0 1.9897656500234007e-07
- O 0 2.7102186095362413e-07
emerin O 0 9.387913451064378e-07
band O 0 3.1762837693349866e-08
on O 0 1.0303645048281851e-08
a O 0 2.286411726615256e-09
western O 0 1.1162315516344279e-08
blot O 0 8.158111768352683e-07
, O 0 9.91795712224075e-09
it O 0 2.227418693934169e-09
stained O 0 1.126953407037945e-06
only O 0 4.622256355446552e-09
the O 0 1.601678079055091e-08
nuclear O 0 7.43362363664346e-07
membrane O 0 5.002287252864335e-06
. O 0 2.3240509108291008e-06

These O 0 2.233299483123119e-07
results O 0 8.460917655384037e-08
would O 0 2.4529007713880446e-09
not O 0 5.936450220289657e-10
be O 0 6.981252242965752e-10
expected O 0 9.41103994733794e-09
if O 0 6.11176842468808e-09
immunostaining O 0 7.409884119624621e-07
at O 0 6.370551375312061e-08
intercalated O 0 3.6229980082680413e-07
discs O 0 1.6980024497570412e-07
were O 0 3.376700474788663e-09
due O 0 6.744921066115239e-09
to O 0 6.118378581554396e-10
a O 0 3.941215687142119e-10
product O 0 1.0206739897711259e-09
of O 0 3.0033340259194574e-09
the O 0 3.015531602201804e-09
emerin O 0 1.327128131833888e-07
gene O 0 2.1557076124167907e-09
and O 0 6.291753229525909e-10
, O 0 2.3291146789006234e-10
therefore O 0 1.2684189254486e-09
, O 0 3.8820965886365855e-10
cast O 0 1.1494607488060637e-09
some O 0 1.8789500511040558e-10
doubt O 0 4.8079269454603946e-09
upon O 0 7.836971072094912e-09
the O 0 3.0292055530622974e-09
hypothesis O 0 4.4129464527031814e-08
that O 0 6.1383462757191865e-09
cardiac B-Disease 0 0.0013068856205791235
defects I-Disease 0 0.00041550263995304704
in O 0 1.0809739023898146e-06
EDMD B-Disease 1 1.0
are O 0 2.6473726322251423e-08
caused O 0 3.9035885635030354e-08
by O 0 2.4550961263969384e-09
absence O 0 8.223675251883833e-08
of O 0 1.3400534726315527e-07
emerin O 0 3.7381362290034303e-06
from O 0 4.096656525121034e-08
intercalated O 0 4.949132289766567e-06
discs O 0 1.1926239494641777e-05
. O 0 3.3309954687865684e-06

Although O 0 1.1809187299149926e-06
emerin O 0 1.8538783479016274e-05
was O 0 1.2627135959064617e-07
abundant O 0 1.1688996437442256e-08
in O 0 9.145091905971015e-10
the O 0 2.8160809240063145e-09
membranes O 0 1.1459980520100999e-08
of O 0 8.173131504918274e-09
cardiomyocyte O 0 8.205702783925517e-08
nuclei O 0 5.991672225036382e-08
, O 0 2.2573618529975192e-09
it O 0 4.986498436387876e-10
was O 0 1.2266609950017937e-08
absent O 0 3.8348680675426294e-08
from O 0 2.39395969714451e-09
many O 0 1.3099640261415857e-09
non O 0 3.3779653563215106e-07
- O 0 1.5452040713626047e-07
myocyte O 0 1.0226854101347271e-06
cells O 0 1.8507883225993282e-08
in O 0 3.4093436962479018e-09
the O 0 2.019053368940149e-08
heart O 0 1.2782139720002306e-06
. O 0 1.9628046175057534e-06

This O 0 5.2710987574755563e-08
distribution O 0 4.712948253882132e-08
of O 0 7.629353149241069e-08
emerin O 0 2.329447170268395e-06
was O 0 2.3480069444303808e-08
similar O 0 5.081038367826807e-10
to O 0 3.393731962120228e-10
that O 0 2.7058533191848255e-10
of O 0 2.7907267607929498e-08
lamin O 0 4.91471246277797e-06
A O 0 2.8266567753121308e-08
, O 0 8.225863323829685e-10
a O 0 6.517440476194736e-10
candidate O 0 5.782941681076181e-09
gene O 0 9.583102311694347e-09
for O 0 1.5271102160596683e-09
an O 0 1.2994970655100246e-09
autosomal O 0 1.1722535475655604e-07
form O 0 7.246916311487439e-07
of O 0 0.0010491657303646207
EDMD B-Disease 1 1.0
. O 0 0.0002860085805878043

In O 0 6.246119141906092e-07
contrast O 0 7.34837840354885e-07
, O 0 2.4938458409451414e-07
lamin O 0 5.959202826488763e-05
B1 O 0 9.384581062477082e-05
was O 0 2.76421332046084e-07
absent O 0 2.1307896247435565e-07
from O 0 7.634590737382041e-09
cardiomyocyte O 0 4.1841903453132545e-07
nuclei O 0 2.175009115035209e-07
, O 0 1.0482466450412176e-08
showing O 0 2.252777697719921e-08
that O 0 1.1608698891052427e-08
lamin O 0 1.139767664426472e-05
B1 O 0 4.5491105993278325e-06
is O 0 1.2482086475529286e-09
not O 0 7.462341855557497e-10
essential O 0 7.623749631591181e-09
for O 0 1.1569876168238125e-09
localization O 0 4.843000169785228e-07
of O 0 5.857387819219184e-08
emerin O 0 1.0654873676685384e-06
to O 0 1.4994574470961197e-08
the O 0 1.0139901718275723e-07
nuclear O 0 8.253912710642908e-06
lamina O 1 0.9651007056236267
. O 0 2.936982491519302e-05

Lamin O 1 0.9943431615829468
B1 O 1 0.9407740831375122
is O 0 5.215564513605386e-08
also O 0 7.0652332873066825e-09
almost O 0 9.058884309354198e-09
completely O 0 1.1167686153612522e-07
absent O 0 3.809251438724459e-07
from O 0 5.158351612521983e-08
skeletal O 0 3.1908573873806745e-05
muscle O 0 1.1547995200089645e-05
nuclei O 0 0.002444067969918251
. O 0 5.791255898657255e-05

In O 0 2.82390033135016e-06
EDMD B-Disease 1 1.0
, O 0 2.817355770901031e-08
the O 0 2.6982320822099837e-09
additional O 0 1.7666739182686797e-09
absence O 0 1.9325895550537098e-08
of O 0 7.290484660416041e-08
lamin O 0 2.3518276066170074e-05
B1 O 0 5.918094393564388e-05
from O 0 5.429963678693639e-08
heart O 0 2.431584107398521e-05
and O 0 6.3839588619885035e-06
skeletal O 1 0.9999622106552124
muscle O 0 8.509148756274953e-05
nuclei O 1 0.9664695858955383
which O 0 6.040094717718603e-07
already O 0 1.055032754493368e-07
lack O 0 2.4783591925370274e-06
emerin O 0 4.6890188968973234e-05
may O 0 1.191058718319482e-08
offer O 0 2.690785150250008e-09
an O 0 1.5814198561781012e-10
alternative O 0 1.9820256547120607e-09
explanation O 0 5.337992714515849e-09
of O 0 1.6028447458182882e-09
why O 0 3.480634225283552e-09
these O 0 9.883414087141773e-10
tissues O 0 3.4909010793171547e-08
are O 0 2.577039248663482e-09
particularly O 0 1.0507367420586888e-08
affected O 0 1.987800146707741e-08
. O 0 4.330176395228591e-08
. O 0 9.062039225682383e-07

Genetic O 0 7.648769496881869e-06
mapping O 0 8.544614615857427e-07
of O 0 2.955094089429622e-07
the O 0 2.726868331137666e-07
copper B-Disease 0 1.498399524280103e-05
toxicosis I-Disease 0 0.0014916968066245317
locus O 0 3.90853847420658e-06
in O 0 4.1779981074796524e-07
Bedlington O 0 0.000149308965774253
terriers O 0 5.889881322218571e-06
to O 0 6.285569753572418e-08
dog O 0 9.267772327348212e-08
chromosome O 0 9.786813848222664e-08
10 O 0 3.6684600246417176e-08
, O 0 2.4695376854566575e-09
in O 0 1.2887795275418057e-09
a O 0 3.856291286297164e-09
region O 0 2.861640879814331e-08
syntenic O 0 8.331982144227368e-07
to O 0 8.60737614516438e-09
human O 0 5.181969342515913e-08
chromosome O 0 2.9743824825345655e-07
region O 0 3.3666961485323554e-07
2p13 O 0 1.907681507873349e-05
- O 0 5.692121703759767e-06
p16 O 0 8.528335456503555e-06
. O 0 3.2520092645427212e-06

Abnormal O 1 0.9999997615814209
hepatic B-Disease 1 1.0
copper I-Disease 0 0.013996661640703678
accumulation I-Disease 0 0.00013458020112011582
is O 0 1.3204856763593398e-08
recognized O 0 5.139434211542948e-09
as O 0 2.515604613506639e-09
an O 0 2.705028867566739e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.5461724817432696e-07
man O 0 6.986885637161322e-06
, O 0 3.6412384218920124e-08
mouse O 0 9.14418251340976e-07
, O 0 1.5428864230671024e-07
rat O 0 2.230099426014931e-06
and O 0 5.580608899435902e-07
dog O 0 5.379171852837317e-06
. O 0 8.670388524478767e-06

The O 0 5.731121177632303e-07
major O 0 2.3281181427137199e-07
cause O 0 4.4859989429824054e-06
of O 0 0.0001048254853230901
hepatic B-Disease 1 1.0
copper I-Disease 0 0.00010388252849224955
accumulation I-Disease 0 9.503553883405402e-05
in O 0 3.7405146713354043e-07
man O 0 2.7216328817303292e-06
is O 0 2.5639437239988183e-09
a O 0 7.786876921045405e-09
dysfunctional O 0 2.802914309540938e-07
ATP7B O 0 2.810073237924371e-05
gene O 0 1.0628999547179774e-07
, O 0 1.5729023417065946e-08
causing O 0 1.6670110198901966e-06
Wilson B-Disease 0 6.640594801865518e-05
disease I-Disease 0 0.06248323619365692
( O 0 5.090385002404219e-07
WD B-Disease 0 0.005126454867422581
) O 0 6.081751848796557e-07
. O 0 2.8310785182839027e-06

Mutations O 0 2.714085212573991e-06
in O 0 4.409597309518176e-08
the O 0 4.2905988095753855e-08
ATP7B O 0 9.356583177577704e-06
genes O 0 8.457558209329363e-09
have O 0 1.0813415718402553e-09
also O 0 6.30832330816844e-10
been O 0 9.54468060143654e-10
demonstrated O 0 2.0358051244784292e-08
in O 0 1.4731194042383322e-08
mouse O 0 3.0622211966147006e-07
and O 0 2.5007739168358967e-07
rat O 0 4.851246558246203e-06
. O 0 1.0635118314894498e-06

The O 0 1.6961361097855843e-06
ATP7B O 0 0.00012540063471533358
gene O 0 4.786025442626851e-08
has O 0 1.5598874414379793e-09
been O 0 1.395604187770516e-09
excluded O 0 7.588278450043617e-09
in O 0 6.587088652310058e-10
the O 0 1.738375443594009e-09
much O 0 8.02309507719201e-09
rarer O 0 4.977669959771447e-06
human O 0 2.8107594971515937e-06
copper B-Disease 0 0.00206081778742373
overload I-Disease 1 0.9940164089202881
disease O 1 0.9935508966445923
non B-Disease 0 0.0001816640724427998
- I-Disease 0 1.2115999652451137e-06
Indian I-Disease 0 1.0872009070794775e-08
childhood I-Disease 0 1.6754295018017729e-07
cirrhosis I-Disease 0 0.00015382954734377563
, O 0 6.57674714688028e-09
indicating O 0 1.5284228993550641e-07
genetic O 0 6.109020205258275e-07
heterogeneity O 0 1.7758489775587805e-05
. O 0 1.0205565558862872e-05

By O 0 5.527435860130936e-07
investigating O 0 1.7148420283774612e-06
the O 0 9.476753604076293e-08
common O 0 6.448975000239443e-06
autosomal O 1 0.999704897403717
recessive O 1 0.9996204376220703
copper B-Disease 1 0.7953401207923889
toxicosis I-Disease 1 0.9999983310699463
( O 0 3.2522448236704804e-06
CT B-Disease 1 0.9964842796325684
) O 0 3.2940548067017517e-08
in O 0 2.471286997263178e-08
Bedlington O 0 7.96366948634386e-05
terriers O 0 3.4628410503501073e-06
, O 0 3.5926901453819937e-09
we O 0 1.9664700978694327e-09
have O 0 2.9274999091555287e-10
identified O 0 1.2047853825691845e-09
a O 0 2.3226819079180672e-10
new O 0 7.880811003779797e-10
locus O 0 2.126375875377562e-08
involved O 0 9.854167259959468e-09
in O 0 5.361402699577411e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0013053269358351827

We O 0 1.082426365428546e-06
examined O 0 6.20569039710972e-07
whether O 0 1.0177837239666587e-08
the O 0 1.4409667237202939e-08
WD B-Disease 0 1.1682636795740109e-05
gene O 0 2.038537445514521e-07
ATP7B O 0 3.430720607866533e-05
was O 0 9.646814902453116e-08
also O 0 4.940076347992317e-09
causative O 0 3.441023466166371e-08
for O 0 4.918405682730054e-09
CT B-Disease 0 2.0368659534142353e-05
by O 0 6.2137246459315065e-09
investigating O 0 9.491659369587069e-08
the O 0 1.4168823447846535e-08
chromosomal O 0 4.652540610550204e-06
co O 0 6.996020147198578e-06
- O 0 6.340178060781909e-06
localization O 0 1.5782532500452362e-05
of O 0 6.595290642508189e-07
ATP7B O 0 0.0002319193590665236
and O 0 4.3656786630208444e-08
C04107 O 0 2.5464396458119154e-07
, O 0 2.6396869134970302e-09
using O 0 3.5743450421676926e-09
fluorescence O 0 4.601762171319024e-08
in O 0 2.853774105915363e-09
situ O 0 1.0872386724258831e-07
hybridization O 0 3.13828500964064e-08
( O 0 1.0490106561178436e-08
FISH O 0 5.2039388265257e-07
) O 0 7.730070450406856e-08
. O 0 5.087230761091632e-07

C04107 O 0 4.302660090615973e-05
is O 0 3.847132035161849e-08
an O 0 4.289197441664783e-09
anonymous O 0 1.1276979705598933e-07
microsatellite O 0 5.500483439391246e-06
marker O 0 5.086442797619384e-06
closely O 0 3.610615237903403e-07
linked O 0 1.7843747173174052e-06
to O 0 4.831379669667513e-07
CT B-Disease 1 0.9999620914459229
. O 0 4.579752203426324e-05

However O 0 3.1886931992630707e-06
, O 0 7.879584131842421e-07
BAC O 0 0.00010176666546612978
clones O 0 7.299137791960675e-07
containing O 0 9.328566363819846e-08
ATP7B O 0 8.70460644364357e-06
and O 0 3.4591266739880666e-08
C04107 O 0 3.539267368068977e-07
mapped O 0 2.0008169343554982e-08
to O 0 3.126286785004595e-09
the O 0 1.1038795655338163e-08
canine O 0 4.860652325078263e-07
chromosome O 0 1.712379571472411e-07
regions O 0 5.244042711183283e-08
CFA22q11 O 0 2.2293881556834094e-05
and O 0 4.449916346516147e-08
CFA10q26 O 0 1.1950307452934794e-05
, O 0 4.625467120433768e-09
respectively O 0 5.068022446153009e-09
, O 0 3.3533878451841304e-10
demonstrating O 0 1.7410898278669151e-09
that O 0 7.572847904313562e-10
WD B-Disease 0 4.1298119413113454e-07
cannot O 0 1.428967788541513e-08
be O 0 7.283073699682063e-09
homologous O 0 1.1235092500783139e-07
to O 0 1.402991927079711e-07
CT B-Disease 0 0.0032254327088594437
. O 0 1.5133953638724051e-05

The O 0 3.6949277273379266e-06
copper O 0 2.113003347403719e-06
transport O 0 3.5826877819999936e-07
genes O 0 8.168616005832519e-08
CTR1 O 0 1.5471076039830223e-05
and O 0 3.227133760219658e-08
CTR2 O 0 0.0001490060385549441
were O 0 2.3517404912354323e-08
also O 0 2.301111523550503e-09
excluded O 0 9.73204627996438e-09
as O 0 8.357283198812127e-10
candidate O 0 5.0134900675402605e-09
genes O 0 3.9261216500108276e-09
for O 0 2.9763662645621025e-09
CT B-Disease 0 1.1520726729941089e-05
since O 0 1.9910180171223146e-08
they O 0 1.6570871341770044e-09
both O 0 3.324083452937998e-09
mapped O 0 1.9695116648676958e-08
to O 0 6.17802342617324e-09
canine O 0 1.214027633977821e-06
chromosome O 0 2.9461866688507143e-06
region O 0 2.9349666874622926e-06
CFA11q22 O 0 0.0009983568452298641
. O 0 2.6871077352552675e-05

2 O 0 0.00010331055091228336
- O 0 2.9258280846988782e-05
22 O 0 5.817705186927924e-06
. O 0 4.569075827021152e-06

5 O 0 0.00019001177861355245
. O 0 4.1483483073534444e-05

A O 0 2.3967286324477755e-06
transcribed O 0 6.596561661353917e-07
sequence O 0 3.223719247102963e-08
identified O 0 3.195564701741205e-08
from O 0 3.0294831088184537e-09
the O 0 1.972748542300451e-08
C04107 O 0 7.22904530903179e-07
- O 0 7.155407644177103e-08
containing O 0 1.5439837852682103e-08
BAC O 0 2.897823833336588e-05
was O 0 1.3041312030281915e-08
found O 0 8.008306240370189e-10
to O 0 3.21541987480245e-10
be O 0 6.492477111486039e-10
homologous O 0 1.966984131129834e-09
to O 0 4.3266798477326063e-10
a O 0 2.121112840924866e-09
gene O 0 7.800910140076667e-09
expressed O 0 5.486856746728108e-09
from O 0 1.3078452099080096e-08
human O 0 1.4713482698880398e-07
chromosome O 0 4.55047143077536e-07
2p13 O 0 2.196630930484389e-06
- O 0 5.487649445967691e-07
p16 O 0 8.78855388464217e-08
, O 0 2.7336124475141332e-09
a O 0 1.530218396439409e-09
region O 0 4.832427791257032e-09
devoid O 0 2.0940051115303504e-07
of O 0 4.227937999701226e-09
any O 0 3.833622752580368e-09
positional O 0 4.2664640886869165e-07
candidate O 0 7.416480798383418e-07
genes O 0 1.2871314538642764e-06
. O 0 3.597036538849352e-06

Molecular O 0 3.3575433917576447e-06
analysis O 0 9.325187022568571e-08
of O 0 6.789946382923517e-08
the O 0 3.047543017942189e-08
APC B-Disease 0 1.095914399229514e-07
gene O 0 1.1913630970639133e-08
in O 0 9.466994299600628e-09
205 O 0 5.363949995285111e-08
families O 0 2.0765982267079153e-09
: O 0 6.536903018883322e-09
extended O 0 7.784860400761318e-08
genotype O 0 1.2181378679088084e-06
- O 0 6.218065777829906e-07
phenotype O 0 2.9965727321723534e-07
correlations O 0 1.4981131357671984e-07
in O 0 8.000127671436985e-09
FAP B-Disease 0 1.368351121300293e-07
and O 0 2.3796196124692415e-09
evidence O 0 8.759279523928853e-09
for O 0 7.646142607953266e-10
the O 0 1.1867676841248453e-09
role O 0 5.151162163485878e-09
of O 0 7.876685970131803e-08
APC B-Disease 0 8.003081575225224e-07
amino O 0 1.2931364778978605e-07
acid O 0 4.246075135938554e-08
changes O 0 6.197162747412222e-07
in O 0 0.001107869204133749
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9138095378875732
. O 0 7.628280582139269e-05

BACKGROUND O 0 0.0001687605254119262
/ O 0 0.00021135045972187072
AIMS O 0 7.534410997322993e-06
The O 0 2.6346643267061154e-07
development O 0 8.650193308312737e-07
of O 0 0.0016808784566819668
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.942517589119234e-08
a O 0 3.1408344813854683e-09
variable O 0 8.99413254984438e-09
range O 0 6.304742061757906e-09
of O 0 5.8001523584039205e-09
extracolonic O 0 8.720108439774776e-07
manifestations O 0 2.0468412458285457e-06
in O 0 1.701550900179427e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.0524602556834e-05
FAP B-Disease 0 1.275611066375859e-05
) O 0 1.5163140076879245e-08
is O 0 7.606708041230092e-10
the O 0 1.0151580687178807e-09
result O 0 3.802063108793163e-09
of O 0 1.1430903334996856e-08
the O 0 9.931946820529447e-09
dominant O 0 8.883196755959943e-07
inheritance O 0 8.781362907939183e-07
of O 0 1.0688259862945415e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999889135360718
coli I-Disease 1 0.9999990463256836
( O 0 2.274209919050918e-06
APC B-Disease 0 2.5641024876676966e-06
) O 0 1.0143383377680948e-07
gene O 0 4.368127974885283e-07
mutations O 0 2.0042923551955028e-06
. O 0 9.988703823182732e-06

In O 0 8.856706301685335e-08
this O 0 1.7691557108179268e-09
study O 0 8.582961008585244e-10
, O 0 1.9285556485115762e-10
direct O 0 4.785390417261226e-10
mutation O 0 1.3094219042386612e-09
analysis O 0 2.0630177566260954e-09
of O 0 4.500505301763269e-09
the O 0 5.55565460302887e-09
APC B-Disease 0 3.4949916738469256e-08
gene O 0 5.826708449063744e-09
was O 0 1.7464921953092016e-08
performed O 0 1.3814933641498328e-09
to O 0 1.620510947653031e-09
determine O 0 7.564351989231e-08
genotype O 0 3.1758313525642734e-06
- O 0 2.517102075216826e-06
phenotype O 0 2.9329137873901345e-07
correlations O 0 2.0406730527611217e-07
for O 0 6.992077139500452e-09
nine O 0 8.922969385594115e-08
extracolonic O 0 9.460054570809007e-07
manifestations O 0 9.151685276265198e-07
and O 0 2.7587281348218085e-09
to O 0 1.0781699977258086e-09
investigate O 0 2.0815880574787116e-08
the O 0 4.176011980661087e-09
incidence O 0 8.450322042108382e-08
of O 0 4.8124707774377384e-08
APC B-Disease 0 2.2095343865657924e-07
mutations O 0 8.84525945821224e-08
in O 0 7.833745740981612e-08
non O 1 0.9999339580535889
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000880578940268606

METHODS O 0 4.800314854946919e-06
The O 0 3.760293907362211e-07
APC B-Disease 0 7.655947911189287e-07
gene O 0 4.596744673790454e-08
was O 0 5.625296850553241e-08
analysed O 0 7.155407644177103e-08
in O 0 6.1263922823684425e-09
190 O 0 7.290832115813828e-08
unrelated O 0 7.190129736045492e-08
FAP B-Disease 0 4.5191950448497664e-07
and O 0 2.680960875522942e-08
15 O 0 1.1617967174970545e-06
non O 1 0.9789389371871948
- O 1 0.9999934434890747
FAP O 1 0.9999990463256836
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.0755213603915763e-07
using O 0 1.555373074779709e-07
denaturing O 0 1.0194223250437062e-05
gradient O 0 1.8359323803451844e-06
gel O 0 3.953665839162568e-07
electrophoresis O 0 5.981384276765311e-08
, O 0 2.8410707120229972e-09
the O 0 2.035136281719474e-09
protein O 0 2.68198241393236e-09
truncation O 0 5.477657794017432e-08
test O 0 1.2853481834440572e-08
, O 0 5.552177051448837e-10
and O 0 5.95811677772673e-10
direct O 0 9.315015425670481e-09
sequencing O 0 1.963705642538116e-07
. O 0 4.662205128624919e-07

RESULTS O 0 0.00014396880578715354
Chain O 0 3.743252136700903e-06
terminating O 0 6.680452315777075e-07
signals O 0 1.872648311973535e-07
were O 0 1.0950134132770017e-08
only O 0 1.4127717884448998e-09
identified O 0 5.591149765393766e-09
in O 0 7.012654901217275e-10
patients O 0 1.610183431033363e-09
belonging O 0 9.395794364763788e-09
to O 0 4.014124588280765e-09
the O 0 3.864620623517112e-08
FAP B-Disease 0 2.204727934440598e-06
group O 0 4.576178014303878e-08
( O 0 2.759603034974134e-08
105 O 0 4.1772094050429587e-07
patients O 0 5.483208198597822e-08
) O 0 6.346066072637768e-08
. O 0 1.1274393045823672e-06

Amino O 0 8.160040124494117e-06
acid O 0 1.33828322645968e-07
changes O 0 2.6359954219401516e-08
were O 0 9.995992478195603e-09
identified O 0 6.073060720979129e-09
in O 0 6.642703609394118e-10
four O 0 8.995140743373042e-10
patients O 0 1.547343086993891e-10
, O 0 2.1126973781537828e-10
three O 0 7.375726140956829e-10
of O 0 4.002198572550242e-09
whom O 0 1.027959939392531e-08
belonged O 0 2.5770603429009498e-08
to O 0 3.423092032051045e-09
the O 0 2.6175083434054613e-08
non O 0 3.095266583841294e-05
- O 0 1.542005338706076e-05
FAP O 0 5.665271146426676e-06
group O 0 2.6377361450613535e-07
of O 1 0.9998871088027954
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0027836875524371862
. O 0 2.8221800675964914e-05

Genotype O 0 0.054867543280124664
- O 0 0.0006707747816108167
phenotype O 0 7.68191421229858e-06
correlations O 0 9.855726830210187e-07
identified O 0 7.214389796672549e-08
significant O 0 1.2094321100164507e-08
differences O 0 6.009274500229367e-08
in O 0 3.1810232226092694e-09
the O 0 2.3573081264771645e-09
nature O 0 1.9704724518732064e-09
of O 0 3.121055858201771e-09
certain O 0 9.411794010816266e-09
extracolonic O 0 5.887068255105987e-07
manifestations O 0 2.3812741289930273e-07
in O 0 4.9803321466868056e-09
FAP B-Disease 0 1.8431708781463385e-07
patients O 0 7.573977889308026e-09
belonging O 0 2.461474046810963e-08
to O 0 1.866418308793527e-08
three O 0 9.146233992396446e-08
mutation O 0 2.0208024125167867e-06
subgroups O 0 8.74954912433168e-06
. O 0 1.561795397719834e-05

CONCLUSIONS O 0 3.849228232866153e-05
Extended O 0 8.575360880058724e-06
genotype O 0 3.568972533685155e-05
- O 0 3.398799208298442e-06
phenotype O 0 3.0902378966857214e-07
correlations O 0 1.7286166098529065e-07
made O 0 2.0346666573800576e-09
in O 0 2.9393054656878803e-10
this O 0 1.0154597301914592e-10
study O 0 2.416036259944576e-10
may O 0 5.338692266043665e-10
have O 0 1.800480042835062e-10
the O 0 2.536774956762855e-10
potential O 0 3.3928646003822394e-10
to O 0 1.5720699741983424e-10
determine O 0 5.192424268329887e-09
the O 0 1.142196226489034e-09
most O 0 2.0626902963449822e-10
appropriate O 0 2.812720500955379e-09
surveillance O 0 1.0972254216312649e-08
and O 0 4.914251228171906e-09
prophylactic O 0 3.4874021821451606e-06
treatment O 0 1.5179206513948884e-07
regimens O 0 9.812495704863977e-08
for O 0 1.4864774966483196e-09
those O 0 5.414754755683759e-10
patients O 0 4.02637617691326e-10
with O 0 2.0474620610055894e-10
mutations O 0 1.7926144124658094e-08
associated O 0 1.6615061326774594e-08
with O 0 3.797526293425335e-09
life O 0 9.23650134154741e-08
threatening O 0 3.0432850053330185e-06
conditions O 0 6.5856647779583e-06
. O 0 2.871723381758784e-06

This O 0 6.809088404224894e-08
study O 0 2.6950187859142716e-08
also O 0 1.2189357301295445e-09
provided O 0 8.254625316617137e-10
evidence O 0 4.804699749172414e-09
for O 0 6.360165727414824e-10
the O 0 2.55324650311195e-09
pathological O 0 1.4158766248328902e-07
nature O 0 1.3300581969133418e-08
of O 0 4.97375580721382e-08
amino O 0 3.500115042243124e-08
acid O 0 7.096715659571373e-09
changes O 0 1.324314524708825e-08
in O 0 8.377347704424665e-09
APC O 0 1.6277489578442328e-07
associated O 0 2.7477225827965412e-08
with O 0 1.3064581638744244e-09
both O 0 1.0028380792448388e-08
FAP B-Disease 0 2.4355979348911205e-06
and O 0 1.4343588361498405e-07
non O 1 0.9998242259025574
- O 1 0.9999997615814209
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.237606397808122e-06
. O 0 1.9552796004518314e-07
. O 0 2.6070233616337646e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.288402259349823
cancer B-Disease 1 0.9969960451126099
risk O 0 2.0479542399698403e-06
of O 0 1.0376149475632701e-05
the O 0 2.6437630822329083e-06
APC O 0 1.0926247341558337e-05
I1307K O 0 1.4971882592362817e-05
polymorphism O 0 8.183965292118955e-06
. O 0 5.171723387320526e-06

Germ O 0 0.3908435106277466
- O 0 0.00020580811542458832
line O 0 6.913730317137379e-07
and O 0 2.676337018669983e-08
somatic O 0 5.111360792398045e-07
truncating O 0 1.8547044078331965e-07
mutations O 0 5.513955514402369e-09
of O 0 5.808056702250042e-09
the O 0 5.209824571750232e-09
APC B-Disease 0 5.037993844325683e-08
gene O 0 3.995410224888474e-09
are O 0 6.234341931588006e-10
thought O 0 1.168048235911101e-08
to O 0 6.010407282985852e-09
initiate O 0 7.016092240519356e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00018082022143062204
formation O 0 6.532569386763498e-05
in O 0 2.1547610231209546e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999827146530151
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 9.396437235409394e-05
respectively O 0 6.832819781266153e-05
. O 0 2.0681365640484728e-05

Recently O 0 4.000105036539026e-06
, O 0 1.778741136604367e-07
an O 0 5.061997043753763e-08
isoleucine O 0 1.314415658271173e-05
- O 0 1.0325873518013395e-05
- O 0 1.0617217412800528e-05
> O 0 8.649923074699473e-06
lysine O 0 1.9146173144690692e-06
polymorphism O 0 1.776832334599021e-07
at O 0 1.743123334563279e-07
codon O 0 4.7370608058372454e-07
1307 O 0 1.2629328011826146e-05
( O 0 1.5836128852697584e-08
I1307K O 0 3.499855552036024e-07
) O 0 2.7640265631845296e-09
of O 0 5.455415230670724e-09
the O 0 1.0547626771995056e-08
APC B-Disease 0 1.0262774452485246e-07
gene O 0 9.917332732811701e-09
has O 0 1.6730042906587528e-09
been O 0 2.528154130487792e-09
identified O 0 2.9052844574550818e-09
in O 0 6.740596969478929e-10
6 O 0 4.1126043015538016e-08
% O 0 1.8888504094149994e-09
- O 0 1.4446791318789565e-08
7 O 0 4.1594553579216154e-08
% O 0 1.1930588739161863e-09
of O 0 5.3281259404514e-09
the O 0 1.2910190250181586e-08
Ashkenazi O 0 1.9977667875537009e-07
Jewish O 0 9.168766723632871e-08
population O 0 1.821413597724586e-08
. O 0 8.789598382463737e-07

To O 0 5.147511501490953e-07
assess O 0 8.93047626959742e-07
the O 0 2.5718208007674548e-08
risk O 0 1.3980400836999252e-08
of O 0 7.055981132708666e-09
this O 0 1.0751942669529058e-09
common O 0 3.536041504048626e-08
APC B-Disease 0 4.687568093686423e-07
allelic O 0 2.2672370505461004e-06
variant O 0 1.3316265722096432e-05
in O 0 5.886035410185286e-07
colorectal O 1 1.0
carcinogenesis O 1 0.9996242523193359
, O 0 3.5729083691649066e-08
we O 0 4.184032675880189e-09
have O 0 4.990075574973218e-10
analyzed O 0 4.224165905952759e-09
a O 0 4.681970366959831e-10
large O 0 1.813567740427402e-09
cohort O 0 5.704223582370105e-08
of O 0 4.710333101343167e-08
unselected O 0 1.1686470315908082e-05
Ashkenazi O 0 4.038447059429018e-06
Jewish O 0 4.991528044229199e-07
subjects O 0 1.4754133417227422e-06
with O 0 4.183165103199826e-08
adenomatous B-Disease 0 7.387166988337412e-05
polyps I-Disease 0 9.183761903841514e-06
and O 0 6.684014408619987e-08
. O 0 6.879345733068476e-07
or O 1 0.9999994039535522
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.455585897427227e-07
for O 0 1.729895515723001e-08
the O 0 1.0278112938522099e-07
APC O 0 1.2934439155287691e-06
I1307K O 0 2.599034814920742e-06
polymorphism O 0 4.805330263479846e-06
. O 0 3.4491372389311437e-06

The O 0 5.958706879027886e-06
APC O 0 1.0323599781258963e-05
I1307K O 0 2.694351451282273e-06
allele O 0 3.767850103031378e-07
was O 0 5.168653416376401e-08
identified O 0 6.094261095768161e-09
in O 0 9.605440887128225e-10
48 O 0 3.1222544549791564e-08
( O 0 2.4271273879605815e-09
10 O 0 2.6437281253066658e-09
. O 0 2.978892132965427e-10
1 O 0 5.061936203532014e-09
% O 0 2.7928218071515687e-10
) O 0 5.731602414904557e-10
of O 0 9.802876732578625e-09
476 O 0 2.3071143573361041e-07
patients O 0 1.3366022244554188e-07
. O 0 1.5209274124572403e-06

Compared O 0 2.0787976495739713e-07
with O 0 1.0823836271711684e-09
the O 0 1.140935568244572e-09
frequency O 0 9.83816583755015e-09
in O 0 1.555103823491777e-10
two O 0 7.957735859154269e-11
separate O 0 7.85477100029297e-11
population O 0 1.2044831278201773e-11
control O 0 8.205632284763453e-10
groups O 0 2.524577491502811e-10
, O 0 9.100720732568846e-10
the O 0 5.66799673862306e-09
APC O 0 1.6469142849473428e-07
I1307K O 0 2.0068696926500706e-07
allele O 0 1.515308554189687e-07
is O 0 9.083933605325001e-10
associated O 0 2.023061496103651e-09
with O 0 2.121811892852321e-10
an O 0 2.5568222539185115e-10
estimated O 0 8.605778867298852e-10
relative O 0 2.7413726400027372e-08
risk O 0 6.245654304848358e-08
of O 0 4.051293842621817e-07
1 O 0 2.056442463072017e-05
. O 0 3.51933545061911e-06

5 O 0 3.4310280170757324e-05
- O 0 1.3978213246446103e-05
1 O 0 4.947565685142763e-06
. O 0 2.7156129362992942e-06

7 O 0 5.4230637033469975e-05
for O 0 3.5298396596772363e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9988126754760742
( O 0 2.4664515763106465e-07
both O 0 1.1725431647846563e-07
P O 0 3.8078516809036955e-05
= O 0 2.8842094934589113e-07
. O 0 1.5787815499379576e-08
01 O 0 1.51164090311795e-06
) O 0 2.9668626666534692e-08
. O 0 6.089568955758295e-07

Furthermore O 0 3.735342716026935e-06
, O 0 8.280115082470729e-08
compared O 0 4.125040220515075e-08
with O 0 7.085314113197683e-09
noncarriers O 0 1.6679492773619131e-06
, O 0 1.4632846045969927e-08
APC O 0 2.3978643071131955e-07
I1307K O 0 1.6469614649849973e-07
carriers O 0 3.893303013313698e-09
had O 0 2.3508333057975506e-09
increased O 0 2.491951311967e-09
numbers O 0 6.6119900665739806e-09
of O 0 6.095122984106638e-08
adenomas B-Disease 0 0.12147640436887741
and O 0 5.2841860451735556e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999688863754272
per O 0 6.7546693571785e-08
patient O 0 5.999139318646485e-08
( O 0 1.502139745923614e-08
P O 0 5.282157417241251e-06
= O 0 5.15423117519731e-08
. O 0 8.166583520541337e-10
03 O 0 6.84202632328379e-08
) O 0 2.8769284177165844e-10
, O 0 1.17973464330845e-10
as O 0 3.29444110880317e-10
well O 0 4.057019165060183e-10
as O 0 8.651697136485836e-10
a O 0 1.5291388155702634e-09
younger O 0 3.57693146213478e-08
age O 0 1.9306062881696562e-07
at O 0 2.8818419650633587e-07
diagnosis O 0 4.036260179418605e-06
. O 0 1.1711132401615032e-06

We O 0 6.234739657884347e-07
conclude O 0 5.173299086891348e-07
that O 0 4.93476504104251e-09
the O 0 1.8163554216243938e-08
APC O 0 6.50503409360681e-07
I1307K O 0 7.636318173354084e-07
variant O 0 6.841137860646995e-07
leads O 0 4.287727506380179e-08
to O 0 1.123626702792535e-08
increased O 0 9.526970075057761e-07
adenoma B-Disease 1 1.0
formation O 0 8.63284913066309e-06
and O 0 1.6378885803192134e-08
directly O 0 1.2200662702355203e-09
contributes O 0 1.855094688973935e-10
to O 0 7.294382459166471e-11
3 O 0 4.2150309909061434e-09
% O 0 3.546263838138941e-10
- O 0 1.2616075961702222e-09
4 O 0 1.4993110086791717e-09
% O 0 8.600786055579235e-11
of O 0 6.139677655170317e-10
all O 0 2.596379333752452e-09
Ashkenazi O 0 2.1528730940190144e-06
Jewish O 0 5.2601037168642506e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1815307263750583e-05

The O 0 7.74688089677511e-07
estimated O 0 6.955898612659439e-08
relative O 0 1.8148287495023396e-07
risk O 0 6.431044852206469e-08
for O 0 3.864972786260523e-09
carriers O 0 5.607532216345135e-09
may O 0 1.3315837321670188e-08
justify O 0 2.6919261486568757e-08
specific O 0 1.4355616695382878e-09
clinical O 0 5.960972604412973e-09
screening O 0 1.0240611691969548e-09
for O 0 2.0709095549520384e-10
the O 0 5.926856228022359e-10
360 O 0 7.49162420987659e-09
, O 0 8.395050210552313e-10
000 O 0 3.886684751819303e-09
Americans O 0 2.950066579909816e-10
expected O 0 2.920652386606548e-09
to O 0 8.250281013921779e-10
harbor O 0 1.545554262349924e-08
this O 0 4.900994055034857e-10
allele O 0 4.080132853800933e-08
, O 0 1.6580039563507398e-09
and O 0 1.038835462097154e-09
genetic O 0 2.1673005612399265e-09
testing O 0 2.394640041814e-09
in O 0 5.485022991358335e-10
the O 0 1.4167925721508823e-09
setting O 0 8.98468588417245e-09
of O 0 9.226392094774383e-09
long O 0 6.989156808856478e-09
- O 0 1.8158774039989112e-08
term O 0 3.067189169314588e-08
- O 0 1.1803209964966754e-08
outcome O 0 3.019233574264035e-08
studies O 0 6.034092336903996e-09
may O 0 3.3264808685373737e-09
impact O 0 7.067298213314643e-08
significantly O 0 2.7417030423748656e-07
on O 0 0.33676260709762573
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.08770836959593e-05
in O 0 1.7334321755768656e-09
this O 0 9.301020509333568e-10
population O 0 1.06494846274785e-09
. O 0 1.6644948175326135e-07

Localization O 0 8.337486360687762e-05
of O 0 1.0896879985011765e-06
human O 0 1.736554509079724e-07
BRCA1 O 0 2.8506943294814846e-07
and O 0 1.2801223192582256e-08
its O 0 4.24892476758032e-09
loss O 0 1.6230241328685224e-07
in O 0 2.5005180148696127e-08
high O 0 2.268667049065698e-05
- O 0 2.066652086796239e-06
grade O 0 7.476247992599383e-05
, O 0 2.1966174301724095e-07
non B-Disease 1 0.874146580696106
- I-Disease 1 0.8989942669868469
inherited I-Disease 1 0.9999903440475464
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.004863432142883539

Although O 0 5.047838271821092e-07
the O 0 9.827405023088431e-08
link O 0 1.3738349480263423e-07
between O 0 4.2922930987288055e-08
the O 0 5.534768732218254e-08
BRCA1 O 0 1.8564506945040193e-06
tumour B-Disease 1 1.0
- O 0 3.910544819518691e-06
suppressor O 0 1.030489215736452e-06
gene O 0 6.273567976222694e-08
and O 0 1.1681444789246598e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 9.706843684398336e-07
established O 0 4.263864639142412e-08
, O 0 6.480031511379991e-10
the O 0 5.789969614866664e-10
role O 0 1.4788533730936138e-09
, O 0 1.4708381734784837e-10
if O 0 1.3036821622236516e-10
any O 0 5.49159662188714e-10
, O 0 7.563493720219583e-10
of O 0 6.44479536404674e-09
BRCA1 O 0 2.262853229240136e-07
in O 0 3.6845253958972535e-08
non B-Disease 0 0.18221300840377808
- I-Disease 0 0.2995467185974121
familial I-Disease 0 0.001724418718367815
cancers I-Disease 1 0.9997201561927795
is O 0 1.2436399288162647e-07
unclear O 0 3.553919668775052e-06
. O 0 6.8608960646088235e-06

BRCA1 O 0 3.192196527379565e-05
mutations O 0 8.743232342567353e-07
are O 0 5.597103225341016e-09
rare O 0 2.147451816369994e-08
in O 0 8.99706709134307e-09
sporadic B-Disease 0 5.8550645007926505e-06
cancers I-Disease 1 0.9909008741378784
, O 0 1.8433267356954275e-08
but O 0 6.866339496980345e-09
loss O 0 1.7147475261936052e-07
of O 0 7.014360647872309e-08
BRCA1 O 0 1.1334230265447331e-07
resulting O 0 2.1241140402139536e-08
from O 0 2.5126172253919776e-09
reduced O 0 6.536693319958431e-08
expression O 0 4.31433981873397e-08
or O 0 2.2637527408164715e-08
incorrect O 0 9.420472224519472e-08
subcellular O 0 1.3451164022626472e-06
localization O 0 1.6013503909562132e-06
is O 0 1.234141899786323e-09
postulated O 0 1.705416430297646e-08
to O 0 8.550184449340748e-10
be O 0 1.2998044862655433e-09
important O 0 6.641592609213376e-09
in O 0 6.470290969673442e-09
non B-Disease 0 1.2940353371959645e-05
- I-Disease 0 9.426644101040438e-05
familial I-Disease 0 0.38264963030815125
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9999983310699463

Epigenetic O 0 0.0008471927139908075
loss O 0 1.5812118363101035e-05
, O 0 5.828668037111129e-08
however O 0 3.283435034973081e-08
, O 0 2.8919275862904215e-09
has O 0 3.1429303604113557e-10
not O 0 2.4467175507858485e-10
received O 0 1.4563729111571888e-09
general O 0 4.281220267188246e-09
acceptance O 0 2.1766725311067603e-08
due O 0 3.503795653614361e-08
to O 0 4.31254409960502e-09
controversy O 0 4.180150270371996e-08
regarding O 0 2.048589209380225e-08
the O 0 1.0740838440881362e-08
subcellular O 0 5.989296028019453e-07
localization O 0 1.0222173614238272e-06
of O 0 7.957716263717884e-08
BRCA1 O 0 8.965277231709479e-08
proteins O 0 3.1474010064869162e-09
, O 0 3.22959503584741e-09
reports O 0 2.4637274442795842e-09
of O 0 7.20977899604236e-09
which O 0 2.234725515748437e-09
have O 0 4.354225424663127e-09
ranged O 0 7.582379879522705e-08
from O 0 1.3660966802220287e-09
exclusively O 0 2.0956096857815965e-09
nuclear O 0 4.06271460917651e-08
, O 0 1.580829689373786e-09
to O 0 7.615229002944091e-10
conditionally O 0 3.56599159090365e-08
nuclear O 0 1.8299799009469098e-08
, O 0 5.216643228500573e-10
to O 0 6.510247341218189e-10
the O 0 1.1449930781282092e-08
ER O 0 1.1186079063918442e-05
/ O 0 1.2158491244917968e-06
golgi O 0 1.0114633823832264e-06
, O 0 3.0479891943713255e-09
to O 0 1.5695870159149194e-09
cytoplasmic O 0 2.020830294213738e-07
invaginations O 0 8.430068305642635e-07
into O 0 3.000793213914221e-08
the O 0 3.989594432596277e-08
nucleus O 0 1.445224256713118e-06
. O 0 1.4148820355330827e-06

In O 0 1.5536504349711322e-07
an O 0 7.624782583093292e-09
attempt O 0 6.224794901754649e-08
to O 0 8.355263148018821e-09
resolve O 0 2.680432658053178e-07
this O 0 2.039869828607266e-09
issue O 0 1.3132267717708146e-08
, O 0 1.808038163630954e-09
we O 0 4.1410173068356926e-09
have O 0 5.730588892305377e-09
comprehensively O 0 1.1833618600576301e-06
characterized O 0 5.5457899605926286e-08
19 O 0 5.100317252981768e-07
anti O 0 6.742454388586339e-06
- O 0 7.731154255452566e-06
BRCA1 O 0 1.0677567843231373e-06
antibodies O 0 2.7919520562136313e-07
. O 0 2.406180328762275e-06

These O 0 6.740557410012116e-07
reagents O 0 2.781775265248143e-06
detect O 0 1.82207941179513e-06
a O 0 1.5253766605383134e-07
220 O 0 5.726870995204081e-07
- O 0 1.1069409993069712e-06
kD O 0 2.811424565152265e-06
protein O 0 2.6744897851926908e-08
localized O 0 8.21248278271014e-08
in O 0 1.9600108203121636e-09
discrete O 0 3.769937606534768e-08
nuclear O 0 7.41124139835847e-08
foci O 0 2.759477695235546e-07
in O 0 1.932592308406811e-09
all O 0 4.364835604064865e-09
epithelial O 0 1.3066288317986618e-07
cell O 0 3.008266560300399e-07
lines O 0 9.336057260611597e-09
, O 0 7.641739463437602e-10
including O 0 6.352564030365215e-10
those O 0 4.718312962559423e-10
derived O 0 6.576559297144513e-09
from O 0 4.4634745677285537e-08
breast B-Disease 0 9.194285667035729e-06
malignancies I-Disease 0 0.00011190718214493245
. O 0 1.612868618394714e-05

Immunohistochemical O 0 0.0014601271832361817
staining O 0 0.0004545966221485287
of O 0 2.4345334168174304e-05
human O 0 3.308359509901493e-06
breast O 0 6.618997758778278e-06
specimens O 0 4.867916914008674e-07
also O 0 1.0199898525797835e-07
revealed O 0 1.358577151222562e-06
BRCA1 O 0 1.6461777931908728e-06
nuclear O 0 4.149252617935417e-06
foci O 0 0.00021166888473089784
in O 0 2.5837962880359555e-07
benign O 1 0.9999605417251587
breast O 1 0.9999707937240601
, O 0 7.776809979986865e-06
invasive B-Disease 1 0.9999445676803589
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.0006837916444055736
low B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999985694885254
grade I-Disease 1 0.9999912977218628
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00025863939663395286

Conversely O 0 8.382485248148441e-06
, O 0 2.5363792133248353e-07
BRCA1 O 0 8.625850114185596e-07
expression O 0 1.8827192604931042e-07
was O 0 1.012457673255085e-07
reduced O 0 2.744030247470164e-08
or O 0 1.7981267586009153e-09
undetectable O 0 2.1008693451562976e-08
in O 0 2.0640282538675336e-10
the O 0 3.0444027854237277e-10
majority O 0 4.1162809272243805e-10
of O 0 3.5530494102431476e-09
high O 0 2.2602284843742382e-07
- O 0 7.755900810479943e-08
grade O 0 1.0401644203739124e-06
, O 0 1.0297186037178108e-07
ductal B-Disease 1 0.9997279047966003
carcinomas I-Disease 1 1.0
, O 0 1.500501944917687e-08
suggesting O 0 1.0071760314644962e-08
that O 0 6.834924293208644e-10
absence O 0 4.5674234172565775e-08
of O 0 1.0601341671190312e-07
BRCA1 O 0 3.579730218916666e-07
may O 0 2.0951111068256978e-08
contribute O 0 5.925039570087165e-09
to O 0 1.8540098345454226e-09
the O 0 9.388431365664474e-09
pathogenesis O 0 4.285906470613554e-06
of O 0 7.523800249487067e-09
a O 0 1.1926312160071006e-09
significant O 0 1.8793810951933665e-09
percentage O 0 1.1703116697958649e-08
of O 0 6.318468592780846e-08
sporadic B-Disease 0 0.0002639963640831411
breast I-Disease 1 0.756175696849823
cancers I-Disease 1 0.9550906419754028
. O 0 1.5045361578813754e-06
. O 0 6.965298325667391e-06

